diff --git "a/benchmark_data/benchmark_data/dev_sample.csv" "b/benchmark_data/benchmark_data/dev_sample.csv"
deleted file mode 100644--- "a/benchmark_data/benchmark_data/dev_sample.csv"
+++ /dev/null
@@ -1,2830 +0,0 @@
-uuid,template_uuid,question,answer,benchmark_query,execution_results,query_type,sql_category,bio_category
-Q25.1861,Q25,What is the effect size of rs11809116 in Parkinson's disease?,"The effect size, or beta, of rs11809116 is -0.0365 according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019). However, effect sizes may varry accross different populations.","SELECT UUID, SNP, b
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE SNP = ""rs11809116""
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_7246411', 'SNP': 'rs11809116', 'b': -0.0365}]",general,Select,Effect
-Q25.354,Q25,What is the effect size of rs10077515 in Parkinson's disease?,"The effect size, or beta, of rs10077515 is 0.0414 according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019). However, effect sizes may varry accross different populations.","SELECT UUID, SNP, b
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE SNP = ""rs10077515""
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_1284203', 'SNP': 'rs10077515', 'b': 0.0414}]",general,Select,Effect
-Q25.1334,Q25,What is the effect size of rs150430303 in Parkinson's disease?,"The effect size, or beta, of rs150430303 is -0.1387 according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019). However, effect sizes may varry accross different populations.","SELECT UUID, SNP, b
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE SNP = ""rs150430303""
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_5173230', 'SNP': 'rs150430303', 'b': -0.1387}]",general,Select,Effect
-Q25.906,Q25,What is the effect size of rs10948725 in Parkinson's disease?,"The effect size, or beta, of rs10948725 is 0.0359 according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019). However, effect sizes may varry accross different populations.","SELECT UUID, SNP, b
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE SNP = ""rs10948725""
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_3495017', 'SNP': 'rs10948725', 'b': 0.0359}]",general,Select,Effect
-Q25.1290,Q25,What is the effect size of rs79092434 in Parkinson's disease?,"The effect size, or beta, of rs79092434 is 0.0434 according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019). However, effect sizes may varry accross different populations.","SELECT UUID, SNP, b
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE SNP = ""rs79092434""
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_5050106', 'SNP': 'rs79092434', 'b': 0.0434}]",general,Select,Effect
-Q25.1274,Q25,What is the effect size of rs12402481 in Parkinson's disease?,"The effect size, or beta, of rs12402481 is 0.083 according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019). However, effect sizes may varry accross different populations.","SELECT UUID, SNP, b
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE SNP = ""rs12402481""
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_4978216', 'SNP': 'rs12402481', 'b': 0.083}]",general,Select,Effect
-Q25.939,Q25,What is the effect size of rs78531275 in Parkinson's disease?,"The effect size, or beta, of rs78531275 is 0.0699 according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019). However, effect sizes may varry accross different populations.","SELECT UUID, SNP, b
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE SNP = ""rs78531275""
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_3618636', 'SNP': 'rs78531275', 'b': 0.0699}]",general,Select,Effect
-Q25.1732,Q25,What is the effect size of rs141133136 in Parkinson's disease?,"The effect size, or beta, of rs141133136 is -0.0275 according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019). However, effect sizes may varry accross different populations.","SELECT UUID, SNP, b
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE SNP = ""rs141133136""
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_6756445', 'SNP': 'rs141133136', 'b': -0.0275}]",general,Select,Effect
-Q25.66,Q25,What is the effect size of rs28762375 in Parkinson's disease?,"The effect size, or beta, of rs28762375 is -0.4773 according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019). However, effect sizes may varry accross different populations.","SELECT UUID, SNP, b
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE SNP = ""rs28762375""
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_257420', 'SNP': 'rs28762375', 'b': -0.4773}]",general,Select,Effect
-Q25.1324,Q25,What is the effect size of rs12964064 in Parkinson's disease?,"The effect size, or beta, of rs12964064 is -0.0059 according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019). However, effect sizes may varry accross different populations.","SELECT UUID, SNP, b
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE SNP = ""rs12964064""
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_5152520', 'SNP': 'rs12964064', 'b': -0.0059}]",general,Select,Effect
-Q25.57,Q25,What is the effect size of rs66839605 in Parkinson's disease?,"The effect size, or beta, of rs66839605 is 0.0332 according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019). However, effect sizes may varry accross different populations.","SELECT UUID, SNP, b
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE SNP = ""rs66839605""
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_201998', 'SNP': 'rs66839605', 'b': 0.0332}]",general,Select,Effect
-Q25.1293,Q25,What is the effect size of rs78983879 in Parkinson's disease?,"The effect size, or beta, of rs78983879 is 0.0223 according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019). However, effect sizes may varry accross different populations.","SELECT UUID, SNP, b
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE SNP = ""rs78983879""
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_5056257', 'SNP': 'rs78983879', 'b': 0.0223}]",general,Select,Effect
-Q25.1119,Q25,What is the effect size of rs72731583 in Parkinson's disease?,"The effect size, or beta, of rs72731583 is 0.2221 according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019). However, effect sizes may varry accross different populations.","SELECT UUID, SNP, b
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE SNP = ""rs72731583""
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_4294323', 'SNP': 'rs72731583', 'b': 0.2221}]",general,Select,Effect
-Q25.585,Q25,What is the effect size of rs3098570 in Parkinson's disease?,"The effect size, or beta, of rs3098570 is 0.17 according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019). However, effect sizes may varry accross different populations.","SELECT UUID, SNP, b
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE SNP = ""rs3098570""
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_2201792', 'SNP': 'rs3098570', 'b': 0.17}]",general,Select,Effect
-Q25.375,Q25,What is the effect size of rs6141293 in Parkinson's disease?,"The effect size, or beta, of rs6141293 is -0.0121 according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019). However, effect sizes may varry accross different populations.","SELECT UUID, SNP, b
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE SNP = ""rs6141293""
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_1367045', 'SNP': 'rs6141293', 'b': -0.0121}]",general,Select,Effect
-Q25.276,Q25,What is the effect size of rs6538799 in Parkinson's disease?,"The effect size, or beta, of rs6538799 is -0.0163 according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019). However, effect sizes may varry accross different populations.","SELECT UUID, SNP, b
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE SNP = ""rs6538799""
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_1025478', 'SNP': 'rs6538799', 'b': -0.0163}]",general,Select,Effect
-Q11.1861,Q11,Are there any PPP4C SNPs that have a statistically significant adjusted SMR p-value in association with Alzheimer's Disease and what tissues are they significant in?,"Yes, the PPP4C gene has 3 SNPs that are statistically significant in Alzheimer's Disease. Here are the SNPs along with their adjusted SMR p-values:
-• rs12596543
-    • Whole Blood: Adjusted SMR multi-SNP P-value: 1.45e-08; HEIDI: 2.2026e-01
-    • Whole Brain: Adjusted SMR multi-SNP P-value: 9.70e-07; HEIDI: 1.1557e-03
-• rs7201518
-    • Multi Ancestry Whole Brain: Adjusted SMR multi-SNP P-value: 6.72e-07; HEIDI: 4.5794e-09
-• rs9783783
-    • Prefrontal Cortex: Adjusted SMR multi-SNP P-value: 2.47e-06; HEIDI: 7.3849e-02
-","SELECT UUID, Gene, topRSID, p_SMR_multi, Omic_tissue, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'AD' AND Gene = 'PPP4C' AND p_SMR_multi < 2.95e-6
- ORDER BY p_SMR_multi
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_1501442', 'Gene': 'PPP4C', 'topRSID': 'rs12596543', 'p_SMR_multi': 1.445689e-08, 'Omic_tissue': 'Whole Blood', 'p_HEIDI': 0.2202619}, {'UUID': 'NDD_SMR_genes_all_update_text_1396162', 'Gene': 'PPP4C', 'topRSID': 'rs7201518', 'p_SMR_multi': 6.718913e-07, 'Omic_tissue': 'Multi Ancestry Whole Brain', 'p_HEIDI': 4.579366e-09}, {'UUID': 'NDD_SMR_genes_all_update_text_1610395', 'Gene': 'PPP4C', 'topRSID': 'rs12596543', 'p_SMR_multi': 9.704975e-07, 'Omic_tissue': 'Whole Brain', 'p_HEIDI': 0.001155741}, {'UUID': 'NDD_SMR_genes_all_update_text_1202449', 'Gene': 'PPP4C', 'topRSID': 'rs9783783', 'p_SMR_multi': 2.467355e-06, 'Omic_tissue': 'Prefrontal Cortex', 'p_HEIDI': 0.07384892}]",refined,"Select, Order By, Multi-Filter, Threshold",SMR Significance
-Q11.354,Q11,Are there any FUCA2 SNPs that have a statistically significant adjusted SMR p-value in association with Amyotrophic Lateral Sclerosis and what tissues are they significant in?,"No, based on the Whole Brain, Multi Ancestry Whole Brain and Whole Blood samples tested there are no SNPs within the gene FUCA2 that are significantly associated with Amyotrophic Lateral Sclerosis.","SELECT UUID, Gene, topRSID, p_SMR_multi, Omic_tissue, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'ALS' AND Gene = 'FUCA2' AND p_SMR_multi < 2.95e-6
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold",SMR Significance
-Q11.1334,Q11,Are there any GRN SNPs that have a statistically significant adjusted SMR p-value in association with Alzheimer's Disease and what tissues are they significant in?,"Yes, the GRN gene has 1 SNP that is statistically significant in Alzheimer's Disease:
-• rs5848
-    • Multi Ancestry Whole Brain: Adjusted SMR multi-SNP P-value: 3.18e-07; HEIDI: 3.3180e-04","SELECT UUID, Gene, topRSID, p_SMR_multi, Omic_tissue, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'AD' AND Gene = 'GRN' AND p_SMR_multi < 2.95e-6
- ORDER BY p_SMR_multi
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_1396727', 'Gene': 'GRN', 'topRSID': 'rs5848', 'p_SMR_multi': 3.175137e-07, 'Omic_tissue': 'Multi Ancestry Whole Brain', 'p_HEIDI': 0.0003317978}, {'UUID': 'NDD_SMR_genes_all_update_text_1106816', 'Gene': 'GRN', 'topRSID': 'rs5848', 'p_SMR_multi': 4.468436e-07, 'Omic_tissue': 'Cortex', 'p_HEIDI': 0.4339071}, {'UUID': 'NDD_SMR_genes_all_update_text_1268104', 'Gene': 'GRN', 'topRSID': 'rs5848', 'p_SMR_multi': 6.684733e-07, 'Omic_tissue': 'Caudate Basal Ganglia', 'p_HEIDI': -9999.0}, {'UUID': 'NDD_SMR_genes_all_update_text_1291740', 'Gene': 'GRN', 'topRSID': 'rs5848', 'p_SMR_multi': 1.094655e-06, 'Omic_tissue': 'Tibial Nerve', 'p_HEIDI': 0.06459453}]",refined,"Select, Order By, Multi-Filter, Threshold",SMR Significance
-Q11.906,Q11,Are there any AC005822.1 SNPs that have a statistically significant adjusted SMR p-value in association with Parkinson's Disease and what tissues are they significant in?,"No, based on the Whole Brain and Prefrontal Cortex samples tested there are no SNPs within the gene AC005822.1 that are significantly associated with Parkinson's Disease.","SELECT UUID, Gene, topRSID, p_SMR_multi, Omic_tissue, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'PD' AND Gene = 'AC005822.1' AND p_SMR_multi < 2.95e-6
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold",SMR Significance
-Q11.1290,Q11,Are there any GTF2E1 SNPs that have a statistically significant adjusted SMR p-value in association with Parkinson's Disease and what tissues are they significant in?,"No, based on the Whole Brain, Skeletal Muscle and Whole Blood samples tested there are no SNPs within the gene GTF2E1 that are significantly associated with Parkinson's Disease.","SELECT UUID, Gene, topRSID, p_SMR_multi, Omic_tissue, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'PD' AND Gene = 'GTF2E1' AND p_SMR_multi < 2.95e-6
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold",SMR Significance
-Q11.1274,Q11,Are there any RP1-167G20.1 SNPs that have a statistically significant adjusted SMR p-value in association with Amyotrophic Lateral Sclerosis and what tissues are they significant in?,"No, based on the Whole Brain, Frontal Cortex, Cerebellar Hemisphere, Prefrontal Cortex, Cortex, Cerebellum and Nucleus Accumbens Basal samples tested there are no SNPs within the gene RP1-167G20.1 that are significantly associated with Amyotrophic Lateral Sclerosis.","SELECT UUID, Gene, topRSID, p_SMR_multi, Omic_tissue, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'ALS' AND Gene = 'RP1-167G20.1' AND p_SMR_multi < 2.95e-6
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold",SMR Significance
-Q11.939,Q11,Are there any CNOT4P1 SNPs that have a statistically significant adjusted SMR p-value in association with Progressive supranuclear palsy and what tissues are they significant in?,"No, based on the Whole Brain samples tested there are no SNPs within the gene CNOT4P1 that are significantly associated with Progressive supranuclear palsy.","SELECT UUID, Gene, topRSID, p_SMR_multi, Omic_tissue, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'PSP' AND Gene = 'CNOT4P1' AND p_SMR_multi < 2.95e-6
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold",SMR Significance
-Q11.1732,Q11,Are there any RP11-798G7.6 SNPs that have a statistically significant adjusted SMR p-value in association with Alzheimer's Disease and what tissues are they significant in?,"Yes, the RP11-798G7.6 gene has 1 SNP that is statistically significant in Alzheimer's Disease:
-• rs113564729
-    • Whole Blood: Adjusted SMR multi-SNP P-value: 5.26e-07; HEIDI: 6.8153e-05","SELECT UUID, Gene, topRSID, p_SMR_multi, Omic_tissue, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'AD' AND Gene = 'RP11-798G7.6' AND p_SMR_multi < 2.95e-6
- ORDER BY p_SMR_multi
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_1502443', 'Gene': 'RP11-798G7.6', 'topRSID': 'rs113564729', 'p_SMR_multi': 5.256e-07, 'Omic_tissue': 'Whole Blood', 'p_HEIDI': 6.815286e-05}]",refined,"Select, Order By, Multi-Filter, Threshold",SMR Significance
-Q11.66,Q11,Are there any CTB-171A8.1 SNPs that have a statistically significant adjusted SMR p-value in association with Alzheimer's Disease and what tissues are they significant in?,"Yes, the CTB-171A8.1 gene has 7 SNPs that are statistically significant in Alzheimer's Disease. Here are the SNPs along with their adjusted SMR p-values:
-• rs79638902
-    • Prefrontal Cortex: Adjusted SMR multi-SNP P-value: 4.04e-14; HEIDI: 1.1895e-10
-    • Tibial Nerve: Adjusted SMR multi-SNP P-value: 1.69e-11; HEIDI: 6.5064e-09
-    • Skeletal Muscle: Adjusted SMR multi-SNP P-value: 1.76e-11; HEIDI: 9.5389e-10
-    • Hippocampus: Adjusted SMR multi-SNP P-value: 1.15e-09; HEIDI: 2.4715e-07
-    • Frontal Cortex: Adjusted SMR multi-SNP P-value: 3.26e-09; HEIDI: 5.6797e-07
-    • Cerebellum: Adjusted SMR multi-SNP P-value: 1.54e-08; HEIDI: 3.5334e-07
-    • Cortex: Adjusted SMR multi-SNP P-value: 1.76e-08; HEIDI: 4.4821e-06
-    • Amygdala: Adjusted SMR multi-SNP P-value: 1.81e-08; HEIDI: 2.5324e-04
-    • Caudate Basal Ganglia: Adjusted SMR multi-SNP P-value: 1.85e-08; HEIDI: 2.6956e-06
-    • Nucleus Accumbens Basal: Adjusted SMR multi-SNP P-value: 3.67e-08; HEIDI: 1.2298e-05
-    • Putamen Basal Ganglia: Adjusted SMR multi-SNP P-value: 4.74e-08; HEIDI: 3.6912e-06
-    • Cerebellar Hemisphere: Adjusted SMR multi-SNP P-value: 7.19e-08; HEIDI: 1.1770e-07
-    • Substantia nigra: Adjusted SMR multi-SNP P-value: 8.95e-08; HEIDI: 6.4257e-04
-    • Hypothalamus: Adjusted SMR multi-SNP P-value: 8.16e-07; HEIDI: 1.2749e-04
-    • Anterior Cingulate Cortex BA24: Adjusted SMR multi-SNP P-value: 9.94e-07; HEIDI: 1.3958e-04
-• rs61744497
-    • Whole Brain: Adjusted SMR multi-SNP P-value: 1.42e-11; HEIDI: 5.8454e-08
-• rs10410915
-    • Whole Brain: Adjusted SMR multi-SNP P-value: 3.30e-08; HEIDI: 1.5421e-04
-• rs2301274
-    • Whole Blood: Adjusted SMR multi-SNP P-value: 4.08e-08; HEIDI: 4.5124e-02
-• rs12985368
-    • Whole Brain: Adjusted SMR multi-SNP P-value: 1.15e-06; HEIDI: 3.5951e-04
-• rs10426401
-    • Whole Brain: Adjusted SMR multi-SNP P-value: 2.20e-06; HEIDI: 4.6263e-03
-• rs2965164
-    • Whole Brain: Adjusted SMR multi-SNP P-value: 2.84e-06; HEIDI: 1.5203e-01
-","SELECT UUID, Gene, topRSID, p_SMR_multi, Omic_tissue, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'AD' AND Gene = 'CTB-171A8.1' AND p_SMR_multi < 2.95e-6
- ORDER BY p_SMR_multi
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_1203797', 'Gene': 'CTB-171A8.1', 'topRSID': 'rs79638902', 'p_SMR_multi': 4.039964e-14, 'Omic_tissue': 'Prefrontal Cortex', 'p_HEIDI': 1.189533e-10}, {'UUID': 'NDD_SMR_genes_all_update_text_1611533', 'Gene': 'CTB-171A8.1', 'topRSID': 'rs61744497', 'p_SMR_multi': 1.420057e-11, 'Omic_tissue': 'Whole Brain', 'p_HEIDI': 5.845447e-08}, {'UUID': 'NDD_SMR_genes_all_update_text_1292578', 'Gene': 'CTB-171A8.1', 'topRSID': 'rs79638902', 'p_SMR_multi': 1.692546e-11, 'Omic_tissue': 'Tibial Nerve', 'p_HEIDI': 6.506368e-09}, {'UUID': 'NDD_SMR_genes_all_update_text_1343791', 'Gene': 'CTB-171A8.1', 'topRSID': 'rs79638902', 'p_SMR_multi': 1.757301e-11, 'Omic_tissue': 'Skeletal Muscle', 'p_HEIDI': 9.538887e-10}, {'UUID': 'NDD_SMR_genes_all_update_text_1378750', 'Gene': 'CTB-171A8.1', 'topRSID': 'rs79638902', 'p_SMR_multi': 1.145628e-09, 'Omic_tissue': 'Hippocampus', 'p_HEIDI': 2.471456e-07}, {'UUID': 'NDD_SMR_genes_all_update_text_1157462', 'Gene': 'CTB-171A8.1', 'topRSID': 'rs79638902', 'p_SMR_multi': 3.256882e-09, 'Omic_tissue': 'Frontal Cortex', 'p_HEIDI': 5.679675e-07}, {'UUID': 'NDD_SMR_genes_all_update_text_1690529', 'Gene': 'CTB-171A8.1', 'topRSID': 'rs79638902', 'p_SMR_multi': 1.540107e-08, 'Omic_tissue': 'Cerebellum', 'p_HEIDI': 3.533378e-07}, {'UUID': 'NDD_SMR_genes_all_update_text_1247433', 'Gene': 'CTB-171A8.1', 'topRSID': 'rs79638902', 'p_SMR_multi': 1.755406e-08, 'Omic_tissue': 'Cortex', 'p_HEIDI': 4.4821e-06}, {'UUID': 'NDD_SMR_genes_all_update_text_1598391', 'Gene': 'CTB-171A8.1', 'topRSID': 'rs79638902', 'p_SMR_multi': 1.806946e-08, 'Omic_tissue': 'Amygdala', 'p_HEIDI': 0.0002532428}, {'UUID': 'NDD_SMR_genes_all_update_text_1268423', 'Gene': 'CTB-171A8.1', 'topRSID': 'rs79638902', 'p_SMR_multi': 1.846282e-08, 'Omic_tissue': 'Caudate Basal Ganglia', 'p_HEIDI': 2.695582e-06}, {'UUID': 'NDD_SMR_genes_all_update_text_122446', 'Gene': 'CTB-171A8.1', 'topRSID': 'rs10410915', 'p_SMR_multi': 3.296369e-08, 'Omic_tissue': 'Whole Brain', 'p_HEIDI': 0.0001542126}, {'UUID': 'NDD_SMR_genes_all_update_text_1717662', 'Gene': 'CTB-171A8.1', 'topRSID': 'rs79638902', 'p_SMR_multi': 3.671686e-08, 'Omic_tissue': 'Nucleus Accumbens Basal', 'p_HEIDI': 1.229775e-05}, {'UUID': 'NDD_SMR_genes_all_update_text_637412', 'Gene': 'CTB-171A8.1', 'topRSID': 'rs2301274', 'p_SMR_multi': 4.081727e-08, 'Omic_tissue': 'Whole Blood', 'p_HEIDI': 0.04512384}, {'UUID': 'NDD_SMR_genes_all_update_text_1584546', 'Gene': 'CTB-171A8.1', 'topRSID': 'rs79638902', 'p_SMR_multi': 4.741552e-08, 'Omic_tissue': 'Putamen Basal Ganglia', 'p_HEIDI': 3.691237e-06}, {'UUID': 'NDD_SMR_genes_all_update_text_1175008', 'Gene': 'CTB-171A8.1', 'topRSID': 'rs79638902', 'p_SMR_multi': 7.191394e-08, 'Omic_tissue': 'Cerebellar Hemisphere', 'p_HEIDI': 1.176971e-07}, {'UUID': 'NDD_SMR_genes_all_update_text_1446844', 'Gene': 'CTB-171A8.1', 'topRSID': 'rs79638902', 'p_SMR_multi': 8.953365e-08, 'Omic_tissue': 'Substantia nigra', 'p_HEIDI': 0.000642574}, {'UUID': 'NDD_SMR_genes_all_update_text_122447', 'Gene': 'CTB-171A8.1', 'topRSID': 'rs10410915', 'p_SMR_multi': 1.483343e-07, 'Omic_tissue': 'Whole Brain', 'p_HEIDI': 6.358048e-05}, {'UUID': 'NDD_SMR_genes_all_update_text_122448', 'Gene': 'CTB-171A8.1', 'topRSID': 'rs10410915', 'p_SMR_multi': 2.118067e-07, 'Omic_tissue': 'Whole Brain', 'p_HEIDI': 6.931851e-05}, {'UUID': 'NDD_SMR_genes_all_update_text_1454557', 'Gene': 'CTB-171A8.1', 'topRSID': 'rs79638902', 'p_SMR_multi': 8.161446e-07, 'Omic_tissue': 'Hypothalamus', 'p_HEIDI': 0.0001274934}, {'UUID': 'NDD_SMR_genes_all_update_text_1480338', 'Gene': 'CTB-171A8.1', 'topRSID': 'rs79638902', 'p_SMR_multi': 9.937833e-07, 'Omic_tissue': 'Anterior Cingulate Cortex BA24', 'p_HEIDI': 0.0001395768}, {'UUID': 'NDD_SMR_genes_all_update_text_122445', 'Gene': 'CTB-171A8.1', 'topRSID': 'rs12985368', 'p_SMR_multi': 1.151419e-06, 'Omic_tissue': 'Whole Brain', 'p_HEIDI': 0.000359511}, {'UUID': 'NDD_SMR_genes_all_update_text_122444', 'Gene': 'CTB-171A8.1', 'topRSID': 'rs10426401', 'p_SMR_multi': 2.199833e-06, 'Omic_tissue': 'Whole Brain', 'p_HEIDI': 0.004626335}, {'UUID': 'NDD_SMR_genes_all_update_text_122449', 'Gene': 'CTB-171A8.1', 'topRSID': 'rs2965164', 'p_SMR_multi': 2.837859e-06, 'Omic_tissue': 'Whole Brain', 'p_HEIDI': 0.1520308}]",refined,"Select, Order By, Multi-Filter, Threshold",SMR Significance
-Q11.1324,Q11,Are there any SERHL SNPs that have a statistically significant adjusted SMR p-value in association with Parkinson's Disease and what tissues are they significant in?,"No, based on the Whole Brain, Whole Blood, Frontal Cortex, Prefrontal Cortex, Cortex, Caudate Basal Ganglia, Tibial Nerve and Cerebellum samples tested there are no SNPs within the gene SERHL that are significantly associated with Parkinson's Disease.","SELECT UUID, Gene, topRSID, p_SMR_multi, Omic_tissue, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'PD' AND Gene = 'SERHL' AND p_SMR_multi < 2.95e-6
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold",SMR Significance
-Q11.57,Q11,Are there any IGSF6 SNPs that have a statistically significant adjusted SMR p-value in association with Parkinson's Disease and what tissues are they significant in?,"No, based on the Whole Blood samples tested there are no SNPs within the gene IGSF6 that are significantly associated with Parkinson's Disease.","SELECT UUID, Gene, topRSID, p_SMR_multi, Omic_tissue, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'PD' AND Gene = 'IGSF6' AND p_SMR_multi < 2.95e-6
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold",SMR Significance
-Q11.1293,Q11,Are there any FBXO31 SNPs that have a statistically significant adjusted SMR p-value in association with Frontotemporal Dementia and what tissues are they significant in?,"No, based on the Cerebellum, Whole Brain, Whole Blood, Cerebellar Hemisphere, Tibial Nerve and Multi Ancestry Whole Brain samples tested there are no SNPs within the gene FBXO31 that are significantly associated with Frontotemporal Dementia.","SELECT UUID, Gene, topRSID, p_SMR_multi, Omic_tissue, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'FTD' AND Gene = 'FBXO31' AND p_SMR_multi < 2.95e-6
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold",SMR Significance
-Q11.1119,Q11,Are there any UNG SNPs that have a statistically significant adjusted SMR p-value in association with Alzheimer's Disease and what tissues are they significant in?,"No, based on the Whole Brain, Cortex, Prefrontal Cortex, Multi Ancestry Whole Brain and Whole Blood samples tested there are no SNPs within the gene UNG that are significantly associated with Alzheimer's Disease.","SELECT UUID, Gene, topRSID, p_SMR_multi, Omic_tissue, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'AD' AND Gene = 'UNG' AND p_SMR_multi < 2.95e-6
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold",SMR Significance
-Q11.585,Q11,Are there any INO80E SNPs that have a statistically significant adjusted SMR p-value in association with Alzheimer's Disease and what tissues are they significant in?,"Yes, the INO80E gene has 8 SNPs that are statistically significant in Alzheimer's Disease. Here are the SNPs along with their adjusted SMR p-values:
-• rs9925915
-    • Whole Blood: Adjusted SMR multi-SNP P-value: 2.00e-11; HEIDI: 3.3713e-02
-    • Cortex: Adjusted SMR multi-SNP P-value: 7.15e-08; HEIDI: 2.7622e-01
-• rs10871451
-    • Whole Brain: Adjusted SMR multi-SNP P-value: 2.53e-08; HEIDI: 3.0811e-03
-• rs8054556
-    • Multi Ancestry Whole Brain: Adjusted SMR multi-SNP P-value: 3.44e-08; HEIDI: 9.6114e-09
-    • Cerebellum: Adjusted SMR multi-SNP P-value: 1.69e-06; HEIDI: 2.9176e-01
-    • Whole Blood: Adjusted SMR multi-SNP P-value: 2.35e-06; HEIDI: 3.8265e-01
-• rs4787491
-    • Tibial Nerve: Adjusted SMR multi-SNP P-value: 8.37e-08; HEIDI: 1.4418e-01
-• rs4788199
-    • Whole Blood: Adjusted SMR multi-SNP P-value: 1.03e-07; HEIDI: 9.6125e-02
-• rs9932196
-    • Cerebellum: Adjusted SMR multi-SNP P-value: 8.81e-07; HEIDI: 1.9887e-01
-• rs4788204
-    • Cerebellar Hemisphere: Adjusted SMR multi-SNP P-value: 1.12e-06; HEIDI: 7.3803e-01
-• rs12928610
-    • Whole Brain: Adjusted SMR multi-SNP P-value: 1.65e-06; HEIDI: 4.4705e-04
-","SELECT UUID, Gene, topRSID, p_SMR_multi, Omic_tissue, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'AD' AND Gene = 'INO80E' AND p_SMR_multi < 2.95e-6
- ORDER BY p_SMR_multi
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_1501441', 'Gene': 'INO80E', 'topRSID': 'rs9925915', 'p_SMR_multi': 1.99921e-11, 'Omic_tissue': 'Whole Blood', 'p_HEIDI': 0.03371315}, {'UUID': 'NDD_SMR_genes_all_update_text_109450', 'Gene': 'INO80E', 'topRSID': 'rs10871451', 'p_SMR_multi': 2.528427e-08, 'Omic_tissue': 'Whole Brain', 'p_HEIDI': 0.003081132}, {'UUID': 'NDD_SMR_genes_all_update_text_1396161', 'Gene': 'INO80E', 'topRSID': 'rs8054556', 'p_SMR_multi': 3.439942e-08, 'Omic_tissue': 'Multi Ancestry Whole Brain', 'p_HEIDI': 9.611447e-09}, {'UUID': 'NDD_SMR_genes_all_update_text_1610394', 'Gene': 'INO80E', 'topRSID': 'rs10871451', 'p_SMR_multi': 5.074467e-08, 'Omic_tissue': 'Whole Brain', 'p_HEIDI': 0.4675354}, {'UUID': 'NDD_SMR_genes_all_update_text_1111646', 'Gene': 'INO80E', 'topRSID': 'rs9925915', 'p_SMR_multi': 7.15089e-08, 'Omic_tissue': 'Cortex', 'p_HEIDI': 0.2762172}, {'UUID': 'NDD_SMR_genes_all_update_text_1291219', 'Gene': 'INO80E', 'topRSID': 'rs4787491', 'p_SMR_multi': 8.367231e-08, 'Omic_tissue': 'Tibial Nerve', 'p_HEIDI': 0.1441841}, {'UUID': 'NDD_SMR_genes_all_update_text_577415', 'Gene': 'INO80E', 'topRSID': 'rs4788199', 'p_SMR_multi': 1.03063e-07, 'Omic_tissue': 'Whole Blood', 'p_HEIDI': 0.09612456}, {'UUID': 'NDD_SMR_genes_all_update_text_2876', 'Gene': 'INO80E', 'topRSID': 'rs9932196', 'p_SMR_multi': 8.807658e-07, 'Omic_tissue': 'Cerebellum', 'p_HEIDI': 0.1988687}, {'UUID': 'NDD_SMR_genes_all_update_text_1174356', 'Gene': 'INO80E', 'topRSID': 'rs4788204', 'p_SMR_multi': 1.121733e-06, 'Omic_tissue': 'Cerebellar Hemisphere', 'p_HEIDI': 0.7380275}, {'UUID': 'NDD_SMR_genes_all_update_text_109451', 'Gene': 'INO80E', 'topRSID': 'rs12928610', 'p_SMR_multi': 1.645791e-06, 'Omic_tissue': 'Whole Brain', 'p_HEIDI': 0.0004470524}, {'UUID': 'NDD_SMR_genes_all_update_text_1689746', 'Gene': 'INO80E', 'topRSID': 'rs8054556', 'p_SMR_multi': 1.687546e-06, 'Omic_tissue': 'Cerebellum', 'p_HEIDI': 0.2917629}, {'UUID': 'NDD_SMR_genes_all_update_text_1652082', 'Gene': 'INO80E', 'topRSID': 'rs8054556', 'p_SMR_multi': 2.351872e-06, 'Omic_tissue': 'Whole Blood', 'p_HEIDI': 0.3826484}]",refined,"Select, Order By, Multi-Filter, Threshold",SMR Significance
-Q11.375,Q11,Are there any GREB1 SNPs that have a statistically significant adjusted SMR p-value in association with Frontotemporal Dementia and what tissues are they significant in?,"No, based on the Whole Brain, Whole Blood, Cortex, Frontal Cortex, Prefrontal Cortex, Caudate Basal Ganglia, Multi Ancestry Whole Brain, Putamen Basal Ganglia, Amygdala, Cerebellum and Nucleus Accumbens Basal samples tested there are no SNPs within the gene GREB1 that are significantly associated with Frontotemporal Dementia.","SELECT UUID, Gene, topRSID, p_SMR_multi, Omic_tissue, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'FTD' AND Gene = 'GREB1' AND p_SMR_multi < 2.95e-6
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold",SMR Significance
-Q11.276,Q11,Are there any LINC00652 SNPs that have a statistically significant adjusted SMR p-value in association with Alzheimer's Disease and what tissues are they significant in?,"No, based on the Whole Brain and Cerebellar Hemisphere samples tested there are no SNPs within the gene LINC00652 that are significantly associated with Alzheimer's Disease.","SELECT UUID, Gene, topRSID, p_SMR_multi, Omic_tissue, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'AD' AND Gene = 'LINC00652' AND p_SMR_multi < 2.95e-6
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold",SMR Significance
-Q14.1861,Q14,What mechanism type does the drug Meclofenamate Sodium use?,The drug Meclofenamate Sodium is an inhibitor.,"SELECT DISTINCT UUID, drugMechanismOfAction
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE(LOWER(drugName) LIKE ""%meclofenamate sodium%"" OR LOWER(tradeNames_string) LIKE ""%meclofenamate sodium%"" OR LOWER(drugSynonyms_string) LIKE ""%meclofenamate sodium%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3724', 'drugMechanismOfAction': 'Arachidonate 5-lipoxygenase inhibitor'}, {'UUID': 'DrugGeneTargets_v2_3725', 'drugMechanismOfAction': 'Cyclooxygenase inhibitor'}]",general,"Distinct, Similarity Search",Metadata
-Q14.354,Q14,What mechanism type does the drug Gemtuzumab use?,The drug Gemtuzumab is a binding agent.,"SELECT DISTINCT UUID, drugMechanismOfAction
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE(LOWER(drugName) LIKE ""%gemtuzumab%"" OR LOWER(tradeNames_string) LIKE ""%gemtuzumab%"" OR LOWER(drugSynonyms_string) LIKE ""%gemtuzumab%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3736', 'drugMechanismOfAction': 'Myeloid cell surface antigen CD33 binding agent'}, {'UUID': 'DrugGeneTargets_v2_6112', 'drugMechanismOfAction': 'Myeloid cell surface antigen CD33 binding agent'}]",general,"Distinct, Similarity Search",Metadata
-Q14.1334,Q14,What mechanism type does the drug Cotadutide use?,The drug Cotadutide is an agonist.,"SELECT DISTINCT UUID, drugMechanismOfAction
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE(LOWER(drugName) LIKE ""%cotadutide%"" OR LOWER(tradeNames_string) LIKE ""%cotadutide%"" OR LOWER(drugSynonyms_string) LIKE ""%cotadutide%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_5839', 'drugMechanismOfAction': 'Glucagon-like peptide 1 receptor agonist'}, {'UUID': 'DrugGeneTargets_v2_5840', 'drugMechanismOfAction': 'Glucagon receptor agonist'}]",general,"Distinct, Similarity Search",Metadata
-Q14.906,Q14,What mechanism type does the drug Fosnetupitant Chloride Hydrochloride use?,The drug Fosnetupitant Chloride Hydrochloride is an antagonist.,"SELECT DISTINCT UUID, drugMechanismOfAction
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE(LOWER(drugName) LIKE ""%fosnetupitant chloride hydrochloride%"" OR LOWER(tradeNames_string) LIKE ""%fosnetupitant chloride hydrochloride%"" OR LOWER(drugSynonyms_string) LIKE ""%fosnetupitant chloride hydrochloride%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_4376', 'drugMechanismOfAction': 'Neurokinin 1 receptor antagonist'}]",general,"Distinct, Similarity Search",Metadata
-Q14.1290,Q14,What mechanism type does the drug Am-461 use?,The drug Am-461 is an antagonist.,"SELECT DISTINCT UUID, drugMechanismOfAction
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE(LOWER(drugName) LIKE ""%am-461%"" OR LOWER(tradeNames_string) LIKE ""%am-461%"" OR LOWER(drugSynonyms_string) LIKE ""%am-461%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2988', 'drugMechanismOfAction': 'G protein-coupled receptor 44 antagonist'}]",general,"Distinct, Similarity Search",Metadata
-Q14.1274,Q14,What mechanism type does the drug Ji-101 use?,The drug Ji-101 is an inhibitor.,"SELECT DISTINCT UUID, drugMechanismOfAction
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE(LOWER(drugName) LIKE ""%ji-101%"" OR LOWER(tradeNames_string) LIKE ""%ji-101%"" OR LOWER(drugSynonyms_string) LIKE ""%ji-101%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_4147', 'drugMechanismOfAction': 'Ephrin type-B receptor 4 inhibitor'}, {'UUID': 'DrugGeneTargets_v2_4148', 'drugMechanismOfAction': 'Platelet-derived growth factor receptor beta inhibitor'}, {'UUID': 'DrugGeneTargets_v2_4149', 'drugMechanismOfAction': 'Vascular endothelial growth factor receptor 2 inhibitor'}]",general,"Distinct, Similarity Search",Metadata
-Q14.939,Q14,What mechanism type does the drug Amg553 use?,The drug Amg553 is a binding agent.,"SELECT DISTINCT UUID, drugMechanismOfAction
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE(LOWER(drugName) LIKE ""%amg553%"" OR LOWER(tradeNames_string) LIKE ""%amg553%"" OR LOWER(drugSynonyms_string) LIKE ""%amg553%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_5110', 'drugMechanismOfAction': 'Tyrosine-protein kinase receptor FLT3 binding agent'}]",general,"Distinct, Similarity Search",Metadata
-Q14.1732,Q14,What mechanism type does the drug Antrafenine use?,The drug Antrafenine is an inhibitor.,"SELECT DISTINCT UUID, drugMechanismOfAction
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE(LOWER(drugName) LIKE ""%antrafenine%"" OR LOWER(tradeNames_string) LIKE ""%antrafenine%"" OR LOWER(drugSynonyms_string) LIKE ""%antrafenine%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3195', 'drugMechanismOfAction': 'Prostaglandin-H2 D-isomerase inhibitor'}]",general,"Distinct, Similarity Search",Metadata
-Q14.66,Q14,What mechanism type does the drug Trimegestone use?,The drug Trimegestone is an agonist.,"SELECT DISTINCT UUID, drugMechanismOfAction
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE(LOWER(drugName) LIKE ""%trimegestone%"" OR LOWER(tradeNames_string) LIKE ""%trimegestone%"" OR LOWER(drugSynonyms_string) LIKE ""%trimegestone%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3154', 'drugMechanismOfAction': 'Progesterone receptor agonist'}]",general,"Distinct, Similarity Search",Metadata
-Q14.1324,Q14,What mechanism type does the drug Telmisartan use?,The drug Telmisartan is an antagonist.,"SELECT DISTINCT UUID, drugMechanismOfAction
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE(LOWER(drugName) LIKE ""%telmisartan%"" OR LOWER(tradeNames_string) LIKE ""%telmisartan%"" OR LOWER(drugSynonyms_string) LIKE ""%telmisartan%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3908', 'drugMechanismOfAction': 'Type-1 angiotensin II receptor antagonist'}]",general,"Distinct, Similarity Search",Metadata
-Q14.57,Q14,What mechanism type does the drug Lby-135 use?,The drug Lby-135 is an agonist.,"SELECT DISTINCT UUID, drugMechanismOfAction
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE(LOWER(drugName) LIKE ""%lby-135%"" OR LOWER(tradeNames_string) LIKE ""%lby-135%"" OR LOWER(drugSynonyms_string) LIKE ""%lby-135%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3373', 'drugMechanismOfAction': 'Tumor necrosis factor receptor superfamily member 10B agonist'}]",general,"Distinct, Similarity Search",Metadata
-Q14.1293,Q14,What mechanism type does the drug Mk-2201 use?,The drug Mk-2201 is an inhibitor.,"SELECT DISTINCT UUID, drugMechanismOfAction
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE(LOWER(drugName) LIKE ""%mk-2201%"" OR LOWER(tradeNames_string) LIKE ""%mk-2201%"" OR LOWER(drugSynonyms_string) LIKE ""%mk-2201%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_1380', 'drugMechanismOfAction': 'Serine/threonine-protein kinase AKT inhibitor'}]",general,"Distinct, Similarity Search",Metadata
-Q14.1119,Q14,What mechanism type does the drug Insulin Zinc Susp Extended Recombinant Human use?,The drug Insulin Zinc Susp Extended Recombinant Human is an agonist.,"SELECT DISTINCT UUID, drugMechanismOfAction
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE(LOWER(drugName) LIKE ""%insulin zinc susp extended recombinant human%"" OR LOWER(tradeNames_string) LIKE ""%insulin zinc susp extended recombinant human%"" OR LOWER(drugSynonyms_string) LIKE ""%insulin zinc susp extended recombinant human%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_4713', 'drugMechanismOfAction': 'Insulin receptor agonist'}]",general,"Distinct, Similarity Search",Metadata
-Q14.585,Q14,What mechanism type does the drug Emvododstat use?,The drug Emvododstat is an inhibitor.,"SELECT DISTINCT UUID, drugMechanismOfAction
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE(LOWER(drugName) LIKE ""%emvododstat%"" OR LOWER(tradeNames_string) LIKE ""%emvododstat%"" OR LOWER(drugSynonyms_string) LIKE ""%emvododstat%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_1774', 'drugMechanismOfAction': 'Dihydroorotate dehydrogenase inhibitor'}]",general,"Distinct, Similarity Search",Metadata
-Q14.375,Q14,What mechanism type does the drug Alosetron use?,The drug Alosetron is an antagonist.,"SELECT DISTINCT UUID, drugMechanismOfAction
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE(LOWER(drugName) LIKE ""%alosetron%"" OR LOWER(tradeNames_string) LIKE ""%alosetron%"" OR LOWER(drugSynonyms_string) LIKE ""%alosetron%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_4889', 'drugMechanismOfAction': 'Serotonin 3a (5-HT3a) receptor antagonist'}, {'UUID': 'DrugGeneTargets_v2_5986', 'drugMechanismOfAction': 'Serotonin 3a (5-HT3a) receptor antagonist'}]",general,"Distinct, Similarity Search",Metadata
-Q14.276,Q14,What mechanism type does the drug Almotriptan use?,The drug Almotriptan is an agonist.,"SELECT DISTINCT UUID, drugMechanismOfAction
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE(LOWER(drugName) LIKE ""%almotriptan%"" OR LOWER(tradeNames_string) LIKE ""%almotriptan%"" OR LOWER(drugSynonyms_string) LIKE ""%almotriptan%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2780', 'drugMechanismOfAction': 'Serotonin 1f (5-HT1f) receptor agonist'}, {'UUID': 'DrugGeneTargets_v2_2781', 'drugMechanismOfAction': 'Serotonin 1d (5-HT1d) receptor agonist'}, {'UUID': 'DrugGeneTargets_v2_2782', 'drugMechanismOfAction': 'Serotonin 1b (5-HT1b) receptor agonist'}, {'UUID': 'DrugGeneTargets_v2_3458', 'drugMechanismOfAction': 'Serotonin 1f (5-HT1f) receptor agonist'}, {'UUID': 'DrugGeneTargets_v2_3459', 'drugMechanismOfAction': 'Serotonin 1d (5-HT1d) receptor agonist'}, {'UUID': 'DrugGeneTargets_v2_3460', 'drugMechanismOfAction': 'Serotonin 1b (5-HT1b) receptor agonist'}]",general,"Distinct, Similarity Search",Metadata
-Q42.1861,Q42,What is the genomic location of rs11237534 in the GRCh38/hg38 build of the human genome and what gene is it located on or near?,The SNP rs11237534 is located on or closest to the gene SHANK2 on chromosome 11 at base pair position 70798734 in the GRCh38/hg38 build of the human genome.,"SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, SNP, chr_38, bp_38, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs11237534'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, SNP, chr_38, bp_38, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs11237534'
- LIMIT 100","[{'source_table': 'ParkinsonDisease_CompleteGeneData_No23andMe', 'UUID': 'PDno23andme_full_gene_notext_675079', 'SNP': 'rs11237534', 'chr_38': 11, 'bp_38': 70798734, 'nearestGene': 'SHANK2'}, {'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_14218619', 'SNP': 'rs11237534', 'chr_38': 11, 'bp_38': 70798734, 'nearestGene': 'SHANK2'}]",general,"Select, Join",Metadata
-Q42.354,Q42,What is the genomic location of rs6791338 in the GRCh38/hg38 build of the human genome and what gene is it located on or near?,"According to the largest European genome-wide meta-analysis of Alzheimer's disease from Bellenguez (2022), the SNP rs6791338 is located on or closest to the genes MB21D2 and PLAAT1 on chromosome 3 at base pair position 193149461 in the GRCh38/hg38 build of the human genome.","SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, SNP, chr_38, bp_38, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs6791338'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, SNP, chr_38, bp_38, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs6791338'
- LIMIT 100","[{'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_4995200', 'SNP': 'rs6791338', 'chr_38': 3, 'bp_38': 193149461, 'nearestGene': 'MB21D2;PLAAT1'}]",general,"Select, Join",Metadata
-Q42.1334,Q42,What is the genomic location of rs12255438 in the GRCh38/hg38 build of the human genome and what gene is it located on or near?,The SNP rs12255438 is located on or closest to the gene CTNNA3 on chromosome 10 at base pair position 66465707 in the GRCh38/hg38 build of the human genome.,"SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, SNP, chr_38, bp_38, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs12255438'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, SNP, chr_38, bp_38, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs12255438'
- LIMIT 100","[{'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_13150432', 'SNP': 'rs12255438', 'chr_38': 10, 'bp_38': 66465707, 'nearestGene': 'CTNNA3'}, {'source_table': 'ParkinsonDisease_CompleteGeneData_No23andMe', 'UUID': 'PDno23andme_full_gene_notext_2550126', 'SNP': 'rs12255438', 'chr_38': 10, 'bp_38': 66465707, 'nearestGene': 'CTNNA3'}]",general,"Select, Join",Metadata
-Q42.906,Q42,What is the genomic location of rs947377866 in the GRCh38/hg38 build of the human genome and what gene is it located on or near?,"According to the largest European genome-wide meta-analysis of Alzheimer's disease from Bellenguez (2022), the SNP rs947377866 is located on or closest to the genes HCN1 and NONE on chromosome 5 at base pair position 46009429 in the GRCh38/hg38 build of the human genome.","SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, SNP, chr_38, bp_38, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs947377866'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, SNP, chr_38, bp_38, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs947377866'
- LIMIT 100","[{'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_6930672', 'SNP': 'rs947377866', 'chr_38': 5, 'bp_38': 46009429, 'nearestGene': 'HCN1;NONE'}]",general,"Select, Join",Metadata
-Q42.1290,Q42,What is the genomic location of rs116245373 in the GRCh38/hg38 build of the human genome and what gene is it located on or near?,The SNP rs116245373 is located on or closest to the gene FYB1 on chromosome 5 at base pair position 39220724 in the GRCh38/hg38 build of the human genome.,"SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, SNP, chr_38, bp_38, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs116245373'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, SNP, chr_38, bp_38, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs116245373'
- LIMIT 100","[{'source_table': 'ParkinsonDisease_CompleteGeneData_No23andMe', 'UUID': 'PDno23andme_full_gene_notext_2789116', 'SNP': 'rs116245373', 'chr_38': 5, 'bp_38': 39220724, 'nearestGene': 'FYB1'}, {'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_6877480', 'SNP': 'rs116245373', 'chr_38': 5, 'bp_38': 39220724, 'nearestGene': 'FYB1'}]",general,"Select, Join",Metadata
-Q42.1274,Q42,What is the genomic location of rs72764958 in the GRCh38/hg38 build of the human genome and what gene is it located on or near?,The SNP rs72764958 is located on or closest to the gene BHMT on chromosome 5 at base pair position 79121952 in the GRCh38/hg38 build of the human genome.,"SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, SNP, chr_38, bp_38, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs72764958'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, SNP, chr_38, bp_38, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs72764958'
- LIMIT 100","[{'source_table': 'ParkinsonDisease_CompleteGeneData_No23andMe', 'UUID': 'PDno23andme_full_gene_notext_75108', 'SNP': 'rs72764958', 'chr_38': 5, 'bp_38': 79121952, 'nearestGene': 'BHMT'}, {'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_7141255', 'SNP': 'rs72764958', 'chr_38': 5, 'bp_38': 79121952, 'nearestGene': 'BHMT'}]",general,"Select, Join",Metadata
-Q42.939,Q42,What is the genomic location of rs56308926 in the GRCh38/hg38 build of the human genome and what gene is it located on or near?,"According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), the SNP rs56308926 is located on or closest to the gene HCAR3 on chromosome 0 at base pair position 0 in the GRCh38/hg38 build of the human genome.","SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, SNP, chr_38, bp_38, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs56308926'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, SNP, chr_38, bp_38, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs56308926'
- LIMIT 100","[{'source_table': 'ParkinsonDisease_CompleteGeneData_No23andMe', 'UUID': 'PDno23andme_full_gene_notext_2460884', 'SNP': 'rs56308926', 'chr_38': 0, 'bp_38': 0, 'nearestGene': 'HCAR3'}]",general,"Select, Join",Metadata
-Q42.1732,Q42,What is the genomic location of rs11923648 in the GRCh38/hg38 build of the human genome and what gene is it located on or near?,The SNP rs11923648 is located on or closest to the gene MUC4 on chromosome 3 at base pair position 195790109 in the GRCh38/hg38 build of the human genome.,"SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, SNP, chr_38, bp_38, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs11923648'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, SNP, chr_38, bp_38, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs11923648'
- LIMIT 100","[{'source_table': 'ParkinsonDisease_CompleteGeneData_No23andMe', 'UUID': 'PDno23andme_full_gene_notext_6462536', 'SNP': 'rs11923648', 'chr_38': 3, 'bp_38': 195790109, 'nearestGene': 'MUC4'}, {'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_5017259', 'SNP': 'rs11923648', 'chr_38': 3, 'bp_38': 195790109, 'nearestGene': 'MUC4'}]",general,"Select, Join",Metadata
-Q42.66,Q42,What is the genomic location of rs60921995 in the GRCh38/hg38 build of the human genome and what gene is it located on or near?,"According to the largest European genome-wide meta-analysis of Alzheimer's disease from Bellenguez (2022), the SNP rs60921995 is located on or closest to the gene LINC01359 on chromosome 1 at base pair position 64979672 in the GRCh38/hg38 build of the human genome.","SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, SNP, chr_38, bp_38, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs60921995'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, SNP, chr_38, bp_38, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs60921995'
- LIMIT 100","[{'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_481082', 'SNP': 'rs60921995', 'chr_38': 1, 'bp_38': 64979672, 'nearestGene': 'LINC01359'}]",general,"Select, Join",Metadata
-Q42.1324,Q42,What is the genomic location of rs5852461 in the GRCh38/hg38 build of the human genome and what gene is it located on or near?,"According to the largest European genome-wide meta-analysis of Alzheimer's disease from Bellenguez (2022), the SNP rs5852461 is located on chromosome 3 at base pair position 126051448 in the GRCh38/hg38 build of the human genome.","SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, SNP, chr_38, bp_38, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs5852461'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, SNP, chr_38, bp_38, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs5852461'
- LIMIT 100","[{'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_4486930', 'SNP': 'rs5852461', 'chr_38': 3, 'bp_38': 126051448, 'nearestGene': '.'}]",general,"Select, Join",Metadata
-Q42.57,Q42,What is the genomic location of rs37403 in the GRCh38/hg38 build of the human genome and what gene is it located on or near?,The SNP rs37403 is located on or closest to the genes ZNF813 and ZNF331 on chromosome 19 at base pair position 53511584 in the GRCh38/hg38 build of the human genome.,"SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, SNP, chr_38, bp_38, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs37403'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, SNP, chr_38, bp_38, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs37403'
- LIMIT 100","[{'source_table': 'ParkinsonDisease_CompleteGeneData_No23andMe', 'UUID': 'PDno23andme_full_gene_notext_5180026', 'SNP': 'rs37403', 'chr_38': 19, 'bp_38': 53511584, 'nearestGene': 'ZNF813;ZNF331'}, {'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_20046728', 'SNP': 'rs37403', 'chr_38': 19, 'bp_38': 53511584, 'nearestGene': 'ZNF813;ZNF331'}]",general,"Select, Join",Metadata
-Q42.1293,Q42,What is the genomic location of rs1570544 in the GRCh38/hg38 build of the human genome and what gene is it located on or near?,The SNP rs1570544 is located on or closest to the genes BIVM and BIVM-ERCC5 on chromosome 13 at base pair position 102819722 in the GRCh38/hg38 build of the human genome.,"SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, SNP, chr_38, bp_38, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs1570544'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, SNP, chr_38, bp_38, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs1570544'
- LIMIT 100","[{'source_table': 'ParkinsonDisease_CompleteGeneData_No23andMe', 'UUID': 'PDno23andme_full_gene_notext_3063079', 'SNP': 'rs1570544', 'chr_38': 13, 'bp_38': 102819722, 'nearestGene': 'BIVM;BIVM-ERCC5'}, {'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_16407094', 'SNP': 'rs1570544', 'chr_38': 13, 'bp_38': 102819722, 'nearestGene': 'BIVM;BIVM-ERCC5'}]",general,"Select, Join",Metadata
-Q42.1119,Q42,What is the genomic location of rs7266763 in the GRCh38/hg38 build of the human genome and what gene is it located on or near?,"According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), the SNP rs7266763 is located on or closest to the genes RASSF2 and SLC23A2 on chromosome 20 at base pair position 4831200 in the GRCh38/hg38 build of the human genome.","SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, SNP, chr_38, bp_38, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs7266763'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, SNP, chr_38, bp_38, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs7266763'
- LIMIT 100","[{'source_table': 'ParkinsonDisease_CompleteGeneData_No23andMe', 'UUID': 'PDno23andme_full_gene_notext_3248983', 'SNP': 'rs7266763', 'chr_38': 20, 'bp_38': 4831200, 'nearestGene': 'RASSF2;SLC23A2'}]",general,"Select, Join",Metadata
-Q42.585,Q42,What is the genomic location of rs17255297 in the GRCh38/hg38 build of the human genome and what gene is it located on or near?,The SNP rs17255297 is located on or closest to the genes LINC01500 and DAAM1 on chromosome 14 at base pair position 59130234 in the GRCh38/hg38 build of the human genome.,"SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, SNP, chr_38, bp_38, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs17255297'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, SNP, chr_38, bp_38, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs17255297'
- LIMIT 100","[{'source_table': 'ParkinsonDisease_CompleteGeneData_No23andMe', 'UUID': 'PDno23andme_full_gene_notext_7349685', 'SNP': 'rs17255297', 'chr_38': 14, 'bp_38': 59130234, 'nearestGene': 'LINC01500;DAAM1'}, {'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_16815444', 'SNP': 'rs17255297', 'chr_38': 14, 'bp_38': 59130234, 'nearestGene': 'LINC01500;DAAM1'}]",general,"Select, Join",Metadata
-Q42.375,Q42,What is the genomic location of rs62129063 in the GRCh38/hg38 build of the human genome and what gene is it located on or near?,"According to the largest European genome-wide meta-analysis of Alzheimer's disease from Bellenguez (2022), the SNP rs62129063 is located on or closest to the gene SMARCA4 on chromosome 19 at base pair position 11025330 in the GRCh38/hg38 build of the human genome.","SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, SNP, chr_38, bp_38, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs62129063'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, SNP, chr_38, bp_38, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs62129063'
- LIMIT 100","[{'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_19721866', 'SNP': 'rs62129063', 'chr_38': 19, 'bp_38': 11025330, 'nearestGene': 'SMARCA4'}, {'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_19721865', 'SNP': 'rs62129063', 'chr_38': 19, 'bp_38': 11025330, 'nearestGene': 'SMARCA4'}, {'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_19721868', 'SNP': 'rs62129063', 'chr_38': 19, 'bp_38': 11025330, 'nearestGene': 'SMARCA4'}, {'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_19721867', 'SNP': 'rs62129063', 'chr_38': 19, 'bp_38': 11025330, 'nearestGene': 'SMARCA4'}]",general,"Select, Join",Metadata
-Q42.276,Q42,What is the genomic location of rs2769073 in the GRCh38/hg38 build of the human genome and what gene is it located on or near?,The SNP rs2769073 is located on or closest to the gene ADAMTS13 on chromosome 9 at base pair position 133448783 in the GRCh38/hg38 build of the human genome.,"SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, SNP, chr_38, bp_38, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs2769073'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, SNP, chr_38, bp_38, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs2769073'
- LIMIT 100","[{'source_table': 'ParkinsonDisease_CompleteGeneData_No23andMe', 'UUID': 'PDno23andme_full_gene_notext_2339674', 'SNP': 'rs2769073', 'chr_38': 9, 'bp_38': 133448783, 'nearestGene': 'ADAMTS13'}, {'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_12574082', 'SNP': 'rs2769073', 'chr_38': 9, 'bp_38': 133448783, 'nearestGene': 'ADAMTS13'}]",general,"Select, Join",Metadata
-Q9.1861,Q9,Is Amp579 approved by the FDA and if so when was it?,"No, the drug Amp579 has not been approved by the FDA.","SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%amp579%"" OR LOWER(tradeNames_string) LIKE ""%amp579%"" OR LOWER(drugSynonyms_string) LIKE ""%amp579%"")
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_727', 'drugName': 'Amp579', 'tradeNames_string': '', 'drugSynonyms_string': 'Amp579, RPR-100579', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False}, {'UUID': 'DrugGeneTargets_v2_728', 'drugName': 'Amp579', 'tradeNames_string': '', 'drugSynonyms_string': 'Amp579, RPR-100579', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False}]",general,"Distinct, Similarity Search, Order By",Approval Status
-Q9.354,Q9,Is Drozitumab approved by the FDA and if so when was it?,"No, the drug Drozitumab has not been approved by the FDA.","SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%drozitumab%"" OR LOWER(tradeNames_string) LIKE ""%drozitumab%"" OR LOWER(drugSynonyms_string) LIKE ""%drozitumab%"")
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_5207', 'drugName': 'Drozitumab', 'tradeNames_string': '', 'drugSynonyms_string': 'ANTI-DR5, ANTI-DR5 RHUMAB-DR5, Drozitumab, PRO-95780, RHUMAB DR5, RHUMAB-DR5, Usp mab 003, monoclonal igg1', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False}]",general,"Distinct, Similarity Search, Order By",Approval Status
-Q9.1334,Q9,Is Estrone approved by the FDA and if so when was it?,"Yes, the drug Estrone was first FDA approved for use in 1979.","SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%estrone%"" OR LOWER(tradeNames_string) LIKE ""%estrone%"" OR LOWER(drugSynonyms_string) LIKE ""%estrone%"")
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2018', 'drugName': 'Estrone Sulfuric Acid', 'tradeNames_string': '', 'drugSynonyms_string': 'Estrone Sulphate', 'yearOfFirstApproval': 1977, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4799', 'drugName': 'Progesterone', 'tradeNames_string': 'Crinone, Cyclogest, Endometrin, Gesterol, Lutigest, Milprosa, Prochieve, Progesta-care, Progestasert, Progesterone, Progestin, Prometrium, Regumate, Serenity for women, Syngestrone, Utrogestan', 'drugSynonyms_string': 'NSC-64377, NSC-9704, Progesterone, Progesterone, micronized, Progesteronum, U 3672', 'yearOfFirstApproval': 1976, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3573', 'drugName': 'Estrone', 'tradeNames_string': 'Estrogenic substance, Estrone, Natural estrogenic substance-estrone, Oestrone, Theelin', 'drugSynonyms_string': '1,3,5-estratrien-3-ol-17-one, Estradiol metabolite e1, Estrone, Follicular hormone, Follicular-hormone, Folliculin, Folliculinum, Ketohydroxyestrin, NSC-9699, Oestrone, Theelin, Thelykinin, Tokokin, WAY 164397', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2257', 'drugName': 'Estropipate', 'tradeNames_string': 'Estropipate, Harmogen, Ogen, Ogen .625, Ogen 1.25, Ogen 2.5, Ogen 5, Ortho-est', 'drugSynonyms_string': 'Estrone sulfate piperazine salt, Estropipate, NSC-758912, Piperazine estrone sulfate, Piperazine estrone sulphate, Sulestrex piperazine', 'yearOfFirstApproval': 1977, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}]",general,"Distinct, Similarity Search, Order By",Approval Status
-Q9.906,Q9,Is Gestodene approved by the FDA and if so when was it?,"No, the drug Gestodene has not been approved by the FDA.","SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%gestodene%"" OR LOWER(tradeNames_string) LIKE ""%gestodene%"" OR LOWER(drugSynonyms_string) LIKE ""%gestodene%"")
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_925', 'drugName': 'Gestodene', 'tradeNames_string': '', 'drugSynonyms_string': 'Gestodene, SH B 331, SH-B-331', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False}]",general,"Distinct, Similarity Search, Order By",Approval Status
-Q9.1290,Q9,Is Phenelzine Sulfate approved by the FDA and if so when was it?,"Yes, the drug Phenelzine Sulfate was first FDA approved for use in 1961.","SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%phenelzine sulfate%"" OR LOWER(tradeNames_string) LIKE ""%phenelzine sulfate%"" OR LOWER(drugSynonyms_string) LIKE ""%phenelzine sulfate%"")
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_351', 'drugName': 'Phenelzine Sulfate', 'tradeNames_string': 'Nardil, Phenelzine sulfate', 'drugSynonyms_string': 'NSC-170957, Phenelzine acid sulfate, Phenelzine sulfate, Phenelzine sulphate', 'yearOfFirstApproval': 1961, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}]",general,"Distinct, Similarity Search, Order By",Approval Status
-Q9.1274,Q9,Is Bevenopran approved by the FDA and if so when was it?,"No, the drug Bevenopran has not been approved by the FDA.","SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%bevenopran%"" OR LOWER(tradeNames_string) LIKE ""%bevenopran%"" OR LOWER(drugSynonyms_string) LIKE ""%bevenopran%"")
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3338', 'drugName': 'Bevenopran', 'tradeNames_string': '', 'drugSynonyms_string': 'ADL-5945, ADL5945, Bevenopran, CB-5945, CB5-945, CB5945', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False}]",general,"Distinct, Similarity Search, Order By",Approval Status
-Q9.939,Q9,Is Ripretinib approved by the FDA and if so when was it?,"Yes, the drug Ripretinib was first FDA approved for use in 2020.","SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%ripretinib%"" OR LOWER(tradeNames_string) LIKE ""%ripretinib%"" OR LOWER(drugSynonyms_string) LIKE ""%ripretinib%"")
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3036', 'drugName': 'Ripretinib', 'tradeNames_string': 'Qinlock', 'drugSynonyms_string': 'DCC-2618, Dcc-2618, Ripretinib', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3037', 'drugName': 'Ripretinib', 'tradeNames_string': 'Qinlock', 'drugSynonyms_string': 'DCC-2618, Dcc-2618, Ripretinib', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}]",general,"Distinct, Similarity Search, Order By",Approval Status
-Q9.1732,Q9,Is Selinexor approved by the FDA and if so when was it?,"Yes, the drug Selinexor was first FDA approved for use in 2019.","SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%selinexor%"" OR LOWER(tradeNames_string) LIKE ""%selinexor%"" OR LOWER(drugSynonyms_string) LIKE ""%selinexor%"")
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_58', 'drugName': 'Selinexor', 'tradeNames_string': 'Xpovio', 'drugSynonyms_string': 'KPT-330, Selinexor', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}]",general,"Distinct, Similarity Search, Order By",Approval Status
-Q9.66,Q9,Is Baminercept approved by the FDA and if so when was it?,"No, the drug Baminercept has not been approved by the FDA.","SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%baminercept%"" OR LOWER(tradeNames_string) LIKE ""%baminercept%"" OR LOWER(drugSynonyms_string) LIKE ""%baminercept%"")
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_5474', 'drugName': 'Baminercept', 'tradeNames_string': '', 'drugSynonyms_string': 'BG 9924, BG-9924, BG9924, Baminercept, Baminercept alfa, TT-47', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False}, {'UUID': 'DrugGeneTargets_v2_5475', 'drugName': 'Baminercept', 'tradeNames_string': '', 'drugSynonyms_string': 'BG 9924, BG-9924, BG9924, Baminercept, Baminercept alfa, TT-47', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False}]",general,"Distinct, Similarity Search, Order By",Approval Status
-Q9.1324,Q9,Is Ilepatril approved by the FDA and if so when was it?,"No, the drug Ilepatril has not been approved by the FDA.","SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%ilepatril%"" OR LOWER(tradeNames_string) LIKE ""%ilepatril%"" OR LOWER(drugSynonyms_string) LIKE ""%ilepatril%"")
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_1768', 'drugName': 'Ilepatril', 'tradeNames_string': '', 'drugSynonyms_string': 'AVE-7688, AVE7688, Ave7688, Ilepatril', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False}, {'UUID': 'DrugGeneTargets_v2_1769', 'drugName': 'Ilepatril', 'tradeNames_string': '', 'drugSynonyms_string': 'AVE-7688, AVE7688, Ave7688, Ilepatril', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False}]",general,"Distinct, Similarity Search, Order By",Approval Status
-Q9.57,Q9,Is Anisotropine approved by the FDA and if so when was it?,"Yes, the drug Anisotropine was first FDA approved for use in 1962.","SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%anisotropine%"" OR LOWER(tradeNames_string) LIKE ""%anisotropine%"" OR LOWER(drugSynonyms_string) LIKE ""%anisotropine%"")
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_6146', 'drugName': 'Anisotropine Methylbromide', 'tradeNames_string': 'Anisotropine methylbromide, Valpin, Valpin 50', 'drugSynonyms_string': 'Anisotropine methylbromide, Methyloctatropine bromide, Octatropine methylbromide, Octatropone bromide, Octotropine methylbromide', 'yearOfFirstApproval': 1962, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6145', 'drugName': 'Anisotropine Methylbromide', 'tradeNames_string': 'Anisotropine methylbromide, Valpin, Valpin 50', 'drugSynonyms_string': 'Anisotropine methylbromide, Methyloctatropine bromide, Octatropine methylbromide, Octatropone bromide, Octotropine methylbromide', 'yearOfFirstApproval': 1962, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6239', 'drugName': 'Anisotropine', 'tradeNames_string': '', 'drugSynonyms_string': 'Anisotropine, Octatropine', 'yearOfFirstApproval': 1962, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6238', 'drugName': 'Anisotropine', 'tradeNames_string': '', 'drugSynonyms_string': 'Anisotropine, Octatropine', 'yearOfFirstApproval': 1962, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}]",general,"Distinct, Similarity Search, Order By",Approval Status
-Q9.1293,Q9,Is Valproate Sodium approved by the FDA and if so when was it?,"Yes, the drug Valproate Sodium was first FDA approved for use in 1996.","SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%valproate sodium%"" OR LOWER(tradeNames_string) LIKE ""%valproate sodium%"" OR LOWER(drugSynonyms_string) LIKE ""%valproate sodium%"")
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_1604', 'drugName': 'Valproate Sodium', 'tradeNames_string': 'Delepsine, Depacon, Depakine, Depakote, Depakote CP, Depakote ER, Epilim, Epilim 200, Epilim 500, Epilim chrono 200, Epilim chrono 300, Epilim chrono 500, Epilim chronosphere, Epilim iv, Episenta, Kentilim, Orfiril, Orlept, Valproate sodium', 'drugSynonyms_string': 'A-44090, ABBOTT 44090, ABBOTT-44090, KW-6066N, NSC-732626, NSC-757376, Natrii valproas, Selenica, Sodium 2-propylpentanoate, Sodium valproate, Valproate sodium, Valproic acid sodium salt (1:1), Valproic acid, sodium, Valproic acid, sodium salt', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}]",general,"Distinct, Similarity Search, Order By",Approval Status
-Q9.1119,Q9,Is Meclofenamic Acid approved by the FDA and if so when was it?,"Yes, the drug Meclofenamic Acid was first FDA approved for use in 1980.","SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%meclofenamic acid%"" OR LOWER(tradeNames_string) LIKE ""%meclofenamic acid%"" OR LOWER(drugSynonyms_string) LIKE ""%meclofenamic acid%"")
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3725', 'drugName': 'Meclofenamate Sodium', 'tradeNames_string': 'Meclodium, Meclofenamate sodium, Meclomen', 'drugSynonyms_string': 'CL-583.NA SALT, Meclofenamate sodium, Meclofenamate sodium anhydrous, Meclofenamate sodium hydrate, Meclofenamic acid sodium, NSC-757088, Sodium meclofenamate, Sodium meclofenamate monohydrate', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3724', 'drugName': 'Meclofenamate Sodium', 'tradeNames_string': 'Meclodium, Meclofenamate sodium, Meclomen', 'drugSynonyms_string': 'CL-583.NA SALT, Meclofenamate sodium, Meclofenamate sodium anhydrous, Meclofenamate sodium hydrate, Meclofenamic acid sodium, NSC-757088, Sodium meclofenamate, Sodium meclofenamate monohydrate', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5035', 'drugName': 'Meclofenamic Acid', 'tradeNames_string': '', 'drugSynonyms_string': 'CI-583, CL-583, INF 4668, INF-4668, Meclodium, Meclofenamate, Meclofenamic acid, Meclomen, NSC-95309', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5034', 'drugName': 'Meclofenamic Acid', 'tradeNames_string': '', 'drugSynonyms_string': 'CI-583, CL-583, INF 4668, INF-4668, Meclodium, Meclofenamate, Meclofenamic acid, Meclomen, NSC-95309', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}]",general,"Distinct, Similarity Search, Order By",Approval Status
-Q9.585,Q9,Is Carbinoxamine approved by the FDA and if so when was it?,"Yes, the drug Carbinoxamine was first FDA approved for use in 2003.","SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%carbinoxamine%"" OR LOWER(tradeNames_string) LIKE ""%carbinoxamine%"" OR LOWER(drugSynonyms_string) LIKE ""%carbinoxamine%"")
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_4593', 'drugName': 'Carbinoxamine Maleate', 'tradeNames_string': 'Carbinoxamine maleate, Clistin, Davenol, Karbinal er', 'drugSynonyms_string': 'Carbinoxamine maleate, NSC-62362', 'yearOfFirstApproval': 2003, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1625', 'drugName': 'Carbinoxamine', 'tradeNames_string': '', 'drugSynonyms_string': 'Carbinoxamine, Clistin, Palgic', 'yearOfFirstApproval': 2003, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}]",general,"Distinct, Similarity Search, Order By",Approval Status
-Q9.375,Q9,Is Lecanemab approved by the FDA and if so when was it?,"No, the drug Lecanemab has not been approved by the FDA.","SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%lecanemab%"" OR LOWER(tradeNames_string) LIKE ""%lecanemab%"" OR LOWER(drugSynonyms_string) LIKE ""%lecanemab%"")
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2736', 'drugName': 'Lecanemab', 'tradeNames_string': '', 'drugSynonyms_string': 'BAN-2401, BAN2401, Ban 2401, Ban2401, Lecanemab', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False}]",general,"Distinct, Similarity Search, Order By",Approval Status
-Q9.276,Q9,Is Vercirnon approved by the FDA and if so when was it?,"No, the drug Vercirnon has not been approved by the FDA.","SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%vercirnon%"" OR LOWER(tradeNames_string) LIKE ""%vercirnon%"" OR LOWER(drugSynonyms_string) LIKE ""%vercirnon%"")
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_1403', 'drugName': 'Vercirnon', 'tradeNames_string': '', 'drugSynonyms_string': 'CCX-282-B, CCX282, GSK-1605786, GSK1605786, Vercirnon, Verecimon', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False}]",general,"Distinct, Similarity Search, Order By",Approval Status
-Q10.1861,Q10,Are there any DGKQ SNPs that have a statistically significant association with Parkinson's Disease?,"Yes, according to the largest European genome-wide meta-analysis of Parkinson's Disease (Nalls et al., 2019), there is at least 12 DGKQ SNP that are significantly associatied with Parkinson's Disease:
-• rs3733345 (GWAS p-value: 2.13e-11; b-value: 0.1172)
-• rs4690326 (GWAS p-value: 2.13e-11; b-value: 0.1172)
-• rs73211813 (GWAS p-value: 6.97e-10; b-value: 0.1406)
-• rs2290402 (GWAS p-value: 9.42e-10; b-value: 0.1389)
-• rs748483 (GWAS p-value: 1.72e-09; b-value: -0.165)
-• rs3733349 (GWAS p-value: 5.53e-09; b-value: -0.1032)
-• rs4690196 (GWAS p-value: 9.46e-09; b-value: -0.1016)
-• rs1377586 (GWAS p-value: 1.12e-08; b-value: -0.1011)
-• rs4690229 (GWAS p-value: 2.62e-08; b-value: -0.0985)
-• rs11724804 (GWAS p-value: 3.34e-08; b-value: -0.0983)","SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'PD' AND Gene = 'DGKQ' AND p_GWAS < 5e-8
- ORDER BY p_GWAS
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_996295', 'Gene': 'DGKQ', 'topRSID': 'rs4690326', 'p_GWAS': 2.125338e-11, 'b_GWAS': 0.1172}, {'UUID': 'NDD_SMR_genes_all_update_text_19050', 'Gene': 'DGKQ', 'topRSID': 'rs3733345', 'p_GWAS': 2.125338e-11, 'b_GWAS': 0.1172}, {'UUID': 'NDD_SMR_genes_all_update_text_1167096', 'Gene': 'DGKQ', 'topRSID': 'rs73211813', 'p_GWAS': 6.974456e-10, 'b_GWAS': 0.1406}, {'UUID': 'NDD_SMR_genes_all_update_text_996294', 'Gene': 'DGKQ', 'topRSID': 'rs2290402', 'p_GWAS': 9.419825e-10, 'b_GWAS': 0.1389}, {'UUID': 'NDD_SMR_genes_all_update_text_429852', 'Gene': 'DGKQ', 'topRSID': 'rs748483', 'p_GWAS': 1.723837e-09, 'b_GWAS': -0.165}, {'UUID': 'NDD_SMR_genes_all_update_text_996297', 'Gene': 'DGKQ', 'topRSID': 'rs3733349', 'p_GWAS': 5.525873e-09, 'b_GWAS': -0.1032}, {'UUID': 'NDD_SMR_genes_all_update_text_1474953', 'Gene': 'DGKQ', 'topRSID': 'rs4690196', 'p_GWAS': 9.46134e-09, 'b_GWAS': -0.1016}, {'UUID': 'NDD_SMR_genes_all_update_text_1675610', 'Gene': 'DGKQ', 'topRSID': 'rs4690196', 'p_GWAS': 9.46134e-09, 'b_GWAS': -0.1016}, {'UUID': 'NDD_SMR_genes_all_update_text_1555640', 'Gene': 'DGKQ', 'topRSID': 'rs1377586', 'p_GWAS': 1.117451e-08, 'b_GWAS': -0.1011}, {'UUID': 'NDD_SMR_genes_all_update_text_996304', 'Gene': 'DGKQ', 'topRSID': 'rs1377586', 'p_GWAS': 1.117451e-08, 'b_GWAS': -0.1011}, {'UUID': 'NDD_SMR_genes_all_update_text_996300', 'Gene': 'DGKQ', 'topRSID': 'rs1377586', 'p_GWAS': 1.117451e-08, 'b_GWAS': -0.1011}, {'UUID': 'NDD_SMR_genes_all_update_text_1323351', 'Gene': 'DGKQ', 'topRSID': 'rs4690229', 'p_GWAS': 2.621949e-08, 'b_GWAS': -0.0985}, {'UUID': 'NDD_SMR_genes_all_update_text_429854', 'Gene': 'DGKQ', 'topRSID': 'rs11724804', 'p_GWAS': 3.342633e-08, 'b_GWAS': -0.0983}, {'UUID': 'NDD_SMR_genes_all_update_text_996307', 'Gene': 'DGKQ', 'topRSID': 'rs11248061', 'p_GWAS': 4.169534e-08, 'b_GWAS': -0.0998}, {'UUID': 'NDD_SMR_genes_all_update_text_996306', 'Gene': 'DGKQ', 'topRSID': 'rs11248061', 'p_GWAS': 4.169534e-08, 'b_GWAS': -0.0998}, {'UUID': 'NDD_SMR_genes_all_update_text_1385727', 'Gene': 'DGKQ', 'topRSID': 'rs17783233', 'p_GWAS': 4.881996e-08, 'b_GWAS': 0.1473}]",refined,"Distinct, Multi-Filter, Order By",GWAS Significance
-Q10.354,Q10,Are there any CELA1 SNPs that have a statistically significant association with Amyotrophic Lateral Sclerosis?,"No, according to genome-wide analysis of Amyotrophic Lateral Sclerosis (Nicolas et al., 2018), there are no SNPs within CELA1 that are significantly associated with Amyotrophic Lateral Sclerosis.","SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'ALS' AND Gene = 'CELA1' AND p_GWAS < 5e-8
- ORDER BY p_GWAS
- LIMIT 100",[],refined,"Distinct, Multi-Filter, Order By",GWAS Significance
-Q10.1334,Q10,Are there any SMLR1 SNPs that have a statistically significant association with Progressive supranuclear palsy?,"No, according to genome-wide analysis of Progressive supranuclear palsy (Höglinger et al., 2011), there are no SNPs within SMLR1 that are significantly associated with Progressive supranuclear palsy.","SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'PSP' AND Gene = 'SMLR1' AND p_GWAS < 5e-8
- ORDER BY p_GWAS
- LIMIT 100",[],refined,"Distinct, Multi-Filter, Order By",GWAS Significance
-Q10.906,Q10,Are there any JAZF1 SNPs that have a statistically significant association with Alzheimer's Disease?,"No, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there are no SNPs within JAZF1 that are significantly associated with Alzheimer's Disease.","SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'AD' AND Gene = 'JAZF1' AND p_GWAS < 5e-8
- ORDER BY p_GWAS
- LIMIT 100",[],refined,"Distinct, Multi-Filter, Order By",GWAS Significance
-Q10.1290,Q10,Are there any WDR62 SNPs that have a statistically significant association with Alzheimer's Disease?,"No, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there are no SNPs within WDR62 that are significantly associated with Alzheimer's Disease.","SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'AD' AND Gene = 'WDR62' AND p_GWAS < 5e-8
- ORDER BY p_GWAS
- LIMIT 100",[],refined,"Distinct, Multi-Filter, Order By",GWAS Significance
-Q10.1274,Q10,Are there any RP11-867G2.8 SNPs that have a statistically significant association with Parkinson's Disease?,"No, according to the largest European genome-wide meta-analysis of Parkinson's Disease (Nalls et al., 2019), there are no SNPs within RP11-867G2.8 that are significantly associated with Parkinson's Disease.","SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'PD' AND Gene = 'RP11-867G2.8' AND p_GWAS < 5e-8
- ORDER BY p_GWAS
- LIMIT 100",[],refined,"Distinct, Multi-Filter, Order By",GWAS Significance
-Q10.939,Q10,Are there any YJEFN3 SNPs that have a statistically significant association with Progressive supranuclear palsy?,"No, according to genome-wide analysis of Progressive supranuclear palsy (Höglinger et al., 2011), there are no SNPs within YJEFN3 that are significantly associated with Progressive supranuclear palsy.","SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'PSP' AND Gene = 'YJEFN3' AND p_GWAS < 5e-8
- ORDER BY p_GWAS
- LIMIT 100",[],refined,"Distinct, Multi-Filter, Order By",GWAS Significance
-Q10.1732,Q10,Are there any CRHR1-IT1 SNPs that have a statistically significant association with Alzheimer's Disease?,"Yes, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there is at least 15 CRHR1-IT1 SNP that are significantly associatied with Alzheimer's Disease:
-• rs17652520 (GWAS p-value: 1.24e-08; b-value: -0.0558)
-• rs9468 (GWAS p-value: 2.00e-08; b-value: -0.055)
-• rs34739559 (GWAS p-value: 2.25e-08; b-value: -0.0548)
-• rs17573907 (GWAS p-value: 2.25e-08; b-value: -0.0548)
-• rs112560196 (GWAS p-value: 2.33e-08; b-value: -0.0553)
-• rs3087534 (GWAS p-value: 2.77e-08; b-value: -0.055)
-• rs17650860 (GWAS p-value: 3.19e-08; b-value: -0.0542)
-• rs62061822 (GWAS p-value: 3.29e-08; b-value: -0.0547)
-• rs62056905 (GWAS p-value: 3.38e-08; b-value: -0.0541)
-• rs62055932 (GWAS p-value: 3.80e-08; b-value: -0.0539)","SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'AD' AND Gene = 'CRHR1-IT1' AND p_GWAS < 5e-8
- ORDER BY p_GWAS
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_1174595', 'Gene': 'CRHR1-IT1', 'topRSID': 'rs17652520', 'p_GWAS': 1.241862e-08, 'b_GWAS': -0.0558}, {'UUID': 'NDD_SMR_genes_all_update_text_1717375', 'Gene': 'CRHR1-IT1', 'topRSID': 'rs9468', 'p_GWAS': 1.997185e-08, 'b_GWAS': -0.055}, {'UUID': 'NDD_SMR_genes_all_update_text_1454354', 'Gene': 'CRHR1-IT1', 'topRSID': 'rs17573907', 'p_GWAS': 2.2468e-08, 'b_GWAS': -0.0548}, {'UUID': 'NDD_SMR_genes_all_update_text_1157199', 'Gene': 'CRHR1-IT1', 'topRSID': 'rs34739559', 'p_GWAS': 2.2468e-08, 'b_GWAS': -0.0548}, {'UUID': 'NDD_SMR_genes_all_update_text_1480157', 'Gene': 'CRHR1-IT1', 'topRSID': 'rs112560196', 'p_GWAS': 2.325484e-08, 'b_GWAS': -0.0553}, {'UUID': 'NDD_SMR_genes_all_update_text_1502446', 'Gene': 'CRHR1-IT1', 'topRSID': 'rs112560196', 'p_GWAS': 2.325484e-08, 'b_GWAS': -0.0553}, {'UUID': 'NDD_SMR_genes_all_update_text_1203004', 'Gene': 'CRHR1-IT1', 'topRSID': 'rs3087534', 'p_GWAS': 2.767302e-08, 'b_GWAS': -0.055}, {'UUID': 'NDD_SMR_genes_all_update_text_1598268', 'Gene': 'CRHR1-IT1', 'topRSID': 'rs17650860', 'p_GWAS': 3.19115e-08, 'b_GWAS': -0.0542}, {'UUID': 'NDD_SMR_genes_all_update_text_1446735', 'Gene': 'CRHR1-IT1', 'topRSID': 'rs62061822', 'p_GWAS': 3.29012e-08, 'b_GWAS': -0.0547}, {'UUID': 'NDD_SMR_genes_all_update_text_1268113', 'Gene': 'CRHR1-IT1', 'topRSID': 'rs62056905', 'p_GWAS': 3.382131e-08, 'b_GWAS': -0.0541}, {'UUID': 'NDD_SMR_genes_all_update_text_1690043', 'Gene': 'CRHR1-IT1', 'topRSID': 'rs62055932', 'p_GWAS': 3.797912e-08, 'b_GWAS': -0.0539}, {'UUID': 'NDD_SMR_genes_all_update_text_1247082', 'Gene': 'CRHR1-IT1', 'topRSID': 'rs77692262', 'p_GWAS': 4.023984e-08, 'b_GWAS': -0.0538}, {'UUID': 'NDD_SMR_genes_all_update_text_1291757', 'Gene': 'CRHR1-IT1', 'topRSID': 'rs4564621', 'p_GWAS': 4.145559e-08, 'b_GWAS': -0.0532}, {'UUID': 'NDD_SMR_genes_all_update_text_1652497', 'Gene': 'CRHR1-IT1', 'topRSID': 'rs2696532', 'p_GWAS': 4.500356e-08, 'b_GWAS': -0.0547}, {'UUID': 'NDD_SMR_genes_all_update_text_1396747', 'Gene': 'CRHR1-IT1', 'topRSID': 'rs62056913', 'p_GWAS': 4.515928e-08, 'b_GWAS': -0.0536}, {'UUID': 'NDD_SMR_genes_all_update_text_1343151', 'Gene': 'CRHR1-IT1', 'topRSID': 'rs62055888', 'p_GWAS': 4.783287e-08, 'b_GWAS': -0.0535}]",refined,"Distinct, Multi-Filter, Order By",GWAS Significance
-Q10.66,Q10,Are there any DCHS2 SNPs that have a statistically significant association with Alzheimer's Disease?,"No, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there are no SNPs within DCHS2 that are significantly associated with Alzheimer's Disease.","SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'AD' AND Gene = 'DCHS2' AND p_GWAS < 5e-8
- ORDER BY p_GWAS
- LIMIT 100",[],refined,"Distinct, Multi-Filter, Order By",GWAS Significance
-Q10.1324,Q10,Are there any SLC25A39P2 SNPs that have a statistically significant association with Alzheimer's Disease?,"No, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there are no SNPs within SLC25A39P2 that are significantly associated with Alzheimer's Disease.","SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'AD' AND Gene = 'SLC25A39P2' AND p_GWAS < 5e-8
- ORDER BY p_GWAS
- LIMIT 100",[],refined,"Distinct, Multi-Filter, Order By",GWAS Significance
-Q10.57,Q10,Are there any OR2M2 SNPs that have a statistically significant association with Parkinson's Disease?,"No, according to the largest European genome-wide meta-analysis of Parkinson's Disease (Nalls et al., 2019), there are no SNPs within OR2M2 that are significantly associated with Parkinson's Disease.","SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'PD' AND Gene = 'OR2M2' AND p_GWAS < 5e-8
- ORDER BY p_GWAS
- LIMIT 100",[],refined,"Distinct, Multi-Filter, Order By",GWAS Significance
-Q10.1293,Q10,Are there any DYDC2 SNPs that have a statistically significant association with Alzheimer's Disease?,"Yes, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there is at least 1 DYDC2 SNP that are significantly associatied with Alzheimer's Disease:
-• rs2185425 (GWAS p-value: 1.72e-09; b-value: -0.0536)","SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'AD' AND Gene = 'DYDC2' AND p_GWAS < 5e-8
- ORDER BY p_GWAS
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_572628', 'Gene': 'DYDC2', 'topRSID': 'rs2185425', 'p_GWAS': 1.717732e-09, 'b_GWAS': -0.0536}, {'UUID': 'NDD_SMR_genes_all_update_text_572629', 'Gene': 'DYDC2', 'topRSID': 'rs2185425', 'p_GWAS': 1.717732e-09, 'b_GWAS': -0.0536}]",refined,"Distinct, Multi-Filter, Order By",GWAS Significance
-Q10.1119,Q10,Are there any TMCO3 SNPs that have a statistically significant association with Alzheimer's Disease?,"No, according to the largest European genome-wide meta-analysis of Alzheimer's Disease (Bellenguez, 2022), there are no SNPs within TMCO3 that are significantly associated with Alzheimer's Disease.","SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'AD' AND Gene = 'TMCO3' AND p_GWAS < 5e-8
- ORDER BY p_GWAS
- LIMIT 100",[],refined,"Distinct, Multi-Filter, Order By",GWAS Significance
-Q10.585,Q10,Are there any ARL17A SNPs that have a statistically significant association with Progressive supranuclear palsy?,"Yes, according to genome-wide analysis of Progressive supranuclear palsy (Höglinger et al., 2011), there are at least 7 ARL17A SNPs that are significantly associatied with Progressive supranuclear palsy:
-• rs393152 (GWAS p-value: 8.30e-51; b-value: -1.652)
-• rs242557 (GWAS p-value: 2.00e-37; b-value: 0.7415)
-• rs17692129 (GWAS p-value: 5.79e-22; b-value: -0.5568)
-• rs1981997 (GWAS p-value: 1.79e-51; b-value: -1.715)
-• rs169201 (GWAS p-value: 8.55e-46; b-value: 1.588)
-• rs12373139 (GWAS p-value: 4.65e-51; b-value: 1.688)
-• rs11012 (GWAS p-value: 2.11e-42; b-value: 1.608)","SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'PSP' AND Gene = 'ARL17A' AND p_GWAS < 5e-8
- ORDER BY p_GWAS
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_1714164', 'Gene': 'ARL17A', 'topRSID': 'rs1981997', 'p_GWAS': 1.792216e-51, 'b_GWAS': 1.7146}, {'UUID': 'NDD_SMR_genes_all_update_text_1154401', 'Gene': 'ARL17A', 'topRSID': 'rs1981997', 'p_GWAS': 1.792216e-51, 'b_GWAS': -1.7146}, {'UUID': 'NDD_SMR_genes_all_update_text_1732403', 'Gene': 'ARL17A', 'topRSID': 'rs1981997', 'p_GWAS': 1.792216e-51, 'b_GWAS': 1.7146}, {'UUID': 'NDD_SMR_genes_all_update_text_1264990', 'Gene': 'ARL17A', 'topRSID': 'rs1981997', 'p_GWAS': 1.792216e-51, 'b_GWAS': 1.7146}, {'UUID': 'NDD_SMR_genes_all_update_text_1283711', 'Gene': 'ARL17A', 'topRSID': 'rs1981997', 'p_GWAS': 1.792216e-51, 'b_GWAS': 1.7146}, {'UUID': 'NDD_SMR_genes_all_update_text_1170880', 'Gene': 'ARL17A', 'topRSID': 'rs1981997', 'p_GWAS': 1.792216e-51, 'b_GWAS': 1.7146}, {'UUID': 'NDD_SMR_genes_all_update_text_1444276', 'Gene': 'ARL17A', 'topRSID': 'rs12373139', 'p_GWAS': 4.6506369999999996e-51, 'b_GWAS': 1.6879}, {'UUID': 'NDD_SMR_genes_all_update_text_1375937', 'Gene': 'ARL17A', 'topRSID': 'rs12373139', 'p_GWAS': 4.650637e-51, 'b_GWAS': 1.6879}, {'UUID': 'NDD_SMR_genes_all_update_text_1604720', 'Gene': 'ARL17A', 'topRSID': 'rs393152', 'p_GWAS': 8.302968999999999e-51, 'b_GWAS': 1.6521}, {'UUID': 'NDD_SMR_genes_all_update_text_1489545', 'Gene': 'ARL17A', 'topRSID': 'rs393152', 'p_GWAS': 8.302968999999999e-51, 'b_GWAS': 1.6521}, {'UUID': 'NDD_SMR_genes_all_update_text_22221', 'Gene': 'ARL17A', 'topRSID': 'rs393152', 'p_GWAS': 8.302968999999999e-51, 'b_GWAS': -1.6521}, {'UUID': 'NDD_SMR_genes_all_update_text_33475', 'Gene': 'ARL17A', 'topRSID': 'rs393152', 'p_GWAS': 8.302968999999999e-51, 'b_GWAS': 1.6521}, {'UUID': 'NDD_SMR_genes_all_update_text_27916', 'Gene': 'ARL17A', 'topRSID': 'rs393152', 'p_GWAS': 8.302968999999999e-51, 'b_GWAS': 1.6521}, {'UUID': 'NDD_SMR_genes_all_update_text_1388488', 'Gene': 'ARL17A', 'topRSID': 'rs393152', 'p_GWAS': 8.302968999999999e-51, 'b_GWAS': 1.6521}, {'UUID': 'NDD_SMR_genes_all_update_text_1194224', 'Gene': 'ARL17A', 'topRSID': 'rs169201', 'p_GWAS': 8.550985e-46, 'b_GWAS': 1.5881}, {'UUID': 'NDD_SMR_genes_all_update_text_1596830', 'Gene': 'ARL17A', 'topRSID': 'rs169201', 'p_GWAS': 8.550985e-46, 'b_GWAS': 1.5881}, {'UUID': 'NDD_SMR_genes_all_update_text_1464425', 'Gene': 'ARL17A', 'topRSID': 'rs169201', 'p_GWAS': 8.550985e-46, 'b_GWAS': 1.5881}, {'UUID': 'NDD_SMR_genes_all_update_text_1646051', 'Gene': 'ARL17A', 'topRSID': 'rs11012', 'p_GWAS': 2.10769e-42, 'b_GWAS': 1.6076}, {'UUID': 'NDD_SMR_genes_all_update_text_30485', 'Gene': 'ARL17A', 'topRSID': 'rs242557', 'p_GWAS': 2.001902e-37, 'b_GWAS': 0.7415}, {'UUID': 'NDD_SMR_genes_all_update_text_1041774', 'Gene': 'ARL17A', 'topRSID': 'rs17692129', 'p_GWAS': 5.788764e-22, 'b_GWAS': -0.5568}, {'UUID': 'NDD_SMR_genes_all_update_text_1336299', 'Gene': 'ARL17A', 'topRSID': 'rs17692129', 'p_GWAS': 5.788764e-22, 'b_GWAS': -0.5568}, {'UUID': 'NDD_SMR_genes_all_update_text_1478194', 'Gene': 'ARL17A', 'topRSID': 'rs17692129', 'p_GWAS': 5.788764e-22, 'b_GWAS': -0.5568}, {'UUID': 'NDD_SMR_genes_all_update_text_1579430', 'Gene': 'ARL17A', 'topRSID': 'rs17692129', 'p_GWAS': 5.788764e-22, 'b_GWAS': -0.5568}, {'UUID': 'NDD_SMR_genes_all_update_text_1684942', 'Gene': 'ARL17A', 'topRSID': 'rs17692129', 'p_GWAS': 5.788764e-22, 'b_GWAS': -0.5568}]",refined,"Distinct, Multi-Filter, Order By",GWAS Significance
-Q10.375,Q10,Are there any RP11-346I3.2 SNPs that have a statistically significant association with Parkinson's Disease?,"No, according to the largest European genome-wide meta-analysis of Parkinson's Disease (Nalls et al., 2019), there are no SNPs within RP11-346I3.2 that are significantly associated with Parkinson's Disease.","SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'PD' AND Gene = 'RP11-346I3.2' AND p_GWAS < 5e-8
- ORDER BY p_GWAS
- LIMIT 100",[],refined,"Distinct, Multi-Filter, Order By",GWAS Significance
-Q10.276,Q10,Are there any GLYCAM1 SNPs that have a statistically significant association with Parkinson's Disease?,"No, according to the largest European genome-wide meta-analysis of Parkinson's Disease (Nalls et al., 2019), there are no SNPs within GLYCAM1 that are significantly associated with Parkinson's Disease.","SELECT DISTINCT UUID, Gene, topRSID, p_GWAS, b_GWAS
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'PD' AND Gene = 'GLYCAM1' AND p_GWAS < 5e-8
- ORDER BY p_GWAS
- LIMIT 100",[],refined,"Distinct, Multi-Filter, Order By",GWAS Significance
-Q38.1861,Q38,How many mechanisms of action does the drug Vupanorsen have?,The drug Vupanorsen has 2 mechanisms of action: Angiopoietin like 3 (ANGPTL3) mRNA antisense inhibitor and Asialoglycoprotein receptor 1 binding agent.,"SELECT UUID, drugName, tradeNames_string, drugMechanismOfAction
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%vupanorsen%"" OR LOWER(tradeNames_string) LIKE ""%vupanorsen%"" OR LOWER(drugSynonyms_string) LIKE ""%vupanorsen%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2325', 'drugName': 'Vupanorsen', 'tradeNames_string': '', 'drugMechanismOfAction': 'Angiopoietin like 3 (ANGPTL3) mRNA antisense inhibitor'}, {'UUID': 'DrugGeneTargets_v2_2326', 'drugName': 'Vupanorsen', 'tradeNames_string': '', 'drugMechanismOfAction': 'Asialoglycoprotein receptor 1 binding agent'}, {'UUID': 'DrugGeneTargets_v2_1745', 'drugName': 'Vupanorsen Sodium', 'tradeNames_string': '', 'drugMechanismOfAction': 'Asialoglycoprotein receptor 1 binding agent'}, {'UUID': 'DrugGeneTargets_v2_1746', 'drugName': 'Vupanorsen Sodium', 'tradeNames_string': '', 'drugMechanismOfAction': 'Angiopoietin like 3 (ANGPTL3) mRNA antisense inhibitor'}]",general,"Select, Similarity Search",Metadata
-Q38.354,Q38,How many mechanisms of action does the drug Bosutinib have?,"The drug Bosutinib has 5 mechanisms of action: Bcr/Abl fusion protein, Tyrosine-protein kinase HCK inhibitor, Tyrosine-protein kinase SRC inhibitor, Tyrosine-protein kinase Lyn inhibitor, and Tyrosine-protein kinase ABL inhibitor.","SELECT UUID, drugName, tradeNames_string, drugMechanismOfAction
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%bosutinib%"" OR LOWER(tradeNames_string) LIKE ""%bosutinib%"" OR LOWER(drugSynonyms_string) LIKE ""%bosutinib%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3955', 'drugName': 'Bosutinib', 'tradeNames_string': 'Bosulif', 'drugMechanismOfAction': 'Bcr/Abl fusion protein'}, {'UUID': 'DrugGeneTargets_v2_3956', 'drugName': 'Bosutinib', 'tradeNames_string': 'Bosulif', 'drugMechanismOfAction': 'Tyrosine-protein kinase HCK inhibitor'}, {'UUID': 'DrugGeneTargets_v2_3957', 'drugName': 'Bosutinib', 'tradeNames_string': 'Bosulif', 'drugMechanismOfAction': 'Tyrosine-protein kinase SRC inhibitor'}, {'UUID': 'DrugGeneTargets_v2_3958', 'drugName': 'Bosutinib', 'tradeNames_string': 'Bosulif', 'drugMechanismOfAction': 'Tyrosine-protein kinase Lyn inhibitor'}, {'UUID': 'DrugGeneTargets_v2_3959', 'drugName': 'Bosutinib', 'tradeNames_string': 'Bosulif', 'drugMechanismOfAction': 'Tyrosine-protein kinase ABL inhibitor'}]",general,"Select, Similarity Search",Metadata
-Q38.1334,Q38,How many mechanisms of action does the drug Vicriviroc have?,"The drug Vicriviroc has 1 mechanism of action, C-C chemokine receptor type 5 antagonist.","SELECT UUID, drugName, tradeNames_string, drugMechanismOfAction
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%vicriviroc%"" OR LOWER(tradeNames_string) LIKE ""%vicriviroc%"" OR LOWER(drugSynonyms_string) LIKE ""%vicriviroc%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_428', 'drugName': 'Vicriviroc', 'tradeNames_string': '', 'drugMechanismOfAction': 'C-C chemokine receptor type 5 antagonist'}, {'UUID': 'DrugGeneTargets_v2_1086', 'drugName': 'Vicriviroc Maleate', 'tradeNames_string': '', 'drugMechanismOfAction': 'C-C chemokine receptor type 5 antagonist'}]",general,"Select, Similarity Search",Metadata
-Q38.906,Q38,How many mechanisms of action does the drug Golvatinib have?,The drug Golvatinib has 2 mechanisms of action: Vascular endothelial growth factor receptor 2 inhibitor and Hepatocyte growth factor receptor inhibitor.,"SELECT UUID, drugName, tradeNames_string, drugMechanismOfAction
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%golvatinib%"" OR LOWER(tradeNames_string) LIKE ""%golvatinib%"" OR LOWER(drugSynonyms_string) LIKE ""%golvatinib%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2108', 'drugName': 'Golvatinib', 'tradeNames_string': '', 'drugMechanismOfAction': 'Vascular endothelial growth factor receptor 2 inhibitor'}, {'UUID': 'DrugGeneTargets_v2_2109', 'drugName': 'Golvatinib', 'tradeNames_string': '', 'drugMechanismOfAction': 'Hepatocyte growth factor receptor inhibitor'}]",general,"Select, Similarity Search",Metadata
-Q38.1290,Q38,How many mechanisms of action does the drug Osi-7904 have?,"The drug Osi-7904 has 1 mechanism of action, Thymidylate synthase inhibitor.","SELECT UUID, drugName, tradeNames_string, drugMechanismOfAction
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%osi-7904%"" OR LOWER(tradeNames_string) LIKE ""%osi-7904%"" OR LOWER(drugSynonyms_string) LIKE ""%osi-7904%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_5813', 'drugName': 'Osi-7904', 'tradeNames_string': '', 'drugMechanismOfAction': 'Thymidylate synthase inhibitor'}]",general,"Select, Similarity Search",Metadata
-Q38.1274,Q38,How many mechanisms of action does the drug Diazoxide have?,"The drug Diazoxide has 2 mechanisms of action: Potassium channel,  inwardly rectifying,  subfamily J,  member 11 opener, Potassium channel,  inwardly rectifying,  subfamily J, and  member 8 opener.","SELECT UUID, drugName, tradeNames_string, drugMechanismOfAction
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%diazoxide%"" OR LOWER(tradeNames_string) LIKE ""%diazoxide%"" OR LOWER(drugSynonyms_string) LIKE ""%diazoxide%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_1171', 'drugName': 'Diazoxide', 'tradeNames_string': 'Diazoxide, Eudemine, Eudimine, Hyperstat, Mutabase, Proglycem', 'drugMechanismOfAction': 'Potassium channel, inwardly rectifying, subfamily J, member 11 opener'}, {'UUID': 'DrugGeneTargets_v2_1172', 'drugName': 'Diazoxide', 'tradeNames_string': 'Diazoxide, Eudemine, Eudimine, Hyperstat, Mutabase, Proglycem', 'drugMechanismOfAction': 'Potassium channel, inwardly rectifying, subfamily J, member 8 opener'}]",general,"Select, Similarity Search",Metadata
-Q38.939,Q38,How many mechanisms of action does the drug Paroxetine have?,"The drug Paroxetine has 1 mechanism of action, Serotonin transporter inhibitor.","SELECT UUID, drugName, tradeNames_string, drugMechanismOfAction
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%paroxetine%"" OR LOWER(tradeNames_string) LIKE ""%paroxetine%"" OR LOWER(drugSynonyms_string) LIKE ""%paroxetine%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_4720', 'drugName': 'Paroxetine Hydrochloride', 'tradeNames_string': 'Paroxetine hydrochloride, Paxil, Paxil cr, Seroxat', 'drugMechanismOfAction': 'Serotonin transporter inhibitor'}, {'UUID': 'DrugGeneTargets_v2_5200', 'drugName': 'Paroxetine', 'tradeNames_string': 'Paxil [as hydrochloride]', 'drugMechanismOfAction': 'Serotonin transporter inhibitor'}, {'UUID': 'DrugGeneTargets_v2_5494', 'drugName': 'Paroxetine Mesylate', 'tradeNames_string': 'Brisdelle, Pexeva', 'drugMechanismOfAction': 'Serotonin transporter inhibitor'}, {'UUID': 'DrugGeneTargets_v2_3442', 'drugName': 'Paroxetine Hydrochloride Hemihydrate', 'tradeNames_string': '', 'drugMechanismOfAction': 'Serotonin transporter inhibitor'}]",general,"Select, Similarity Search",Metadata
-Q38.1732,Q38,How many mechanisms of action does the drug Dwp05195 have?,"The drug Dwp05195 has 1 mechanism of action, Vanilloid receptor antagonist.","SELECT UUID, drugName, tradeNames_string, drugMechanismOfAction
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%dwp05195%"" OR LOWER(tradeNames_string) LIKE ""%dwp05195%"" OR LOWER(drugSynonyms_string) LIKE ""%dwp05195%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_195', 'drugName': 'Dwp05195', 'tradeNames_string': '', 'drugMechanismOfAction': 'Vanilloid receptor antagonist'}]",general,"Select, Similarity Search",Metadata
-Q38.66,Q38,How many mechanisms of action does the drug Pf-06263507 have?,The drug Pf-06263507 has 2 mechanisms of action: Trophoblast glycoprotein binding agent and Tubulin inhibitor.,"SELECT UUID, drugName, tradeNames_string, drugMechanismOfAction
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%pf-06263507%"" OR LOWER(tradeNames_string) LIKE ""%pf-06263507%"" OR LOWER(drugSynonyms_string) LIKE ""%pf-06263507%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_1355', 'drugName': 'Pf-06263507', 'tradeNames_string': '', 'drugMechanismOfAction': 'Trophoblast glycoprotein binding agent'}, {'UUID': 'DrugGeneTargets_v2_1356', 'drugName': 'Pf-06263507', 'tradeNames_string': '', 'drugMechanismOfAction': 'Tubulin inhibitor'}]",general,"Select, Similarity Search",Metadata
-Q38.1324,Q38,How many mechanisms of action does the drug Adoprazine have?,"The drug Adoprazine has 3 mechanisms of action: Dopamine D3 receptor antagonist, Serotonin 1a (5-HT1a) receptor agonist, and Dopamine D2 receptor antagonist.","SELECT UUID, drugName, tradeNames_string, drugMechanismOfAction
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%adoprazine%"" OR LOWER(tradeNames_string) LIKE ""%adoprazine%"" OR LOWER(drugSynonyms_string) LIKE ""%adoprazine%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_1854', 'drugName': 'Adoprazine', 'tradeNames_string': '', 'drugMechanismOfAction': 'Dopamine D3 receptor antagonist'}, {'UUID': 'DrugGeneTargets_v2_1855', 'drugName': 'Adoprazine', 'tradeNames_string': '', 'drugMechanismOfAction': 'Serotonin 1a (5-HT1a) receptor agonist'}, {'UUID': 'DrugGeneTargets_v2_1856', 'drugName': 'Adoprazine', 'tradeNames_string': '', 'drugMechanismOfAction': 'Dopamine D2 receptor antagonist'}]",general,"Select, Similarity Search",Metadata
-Q38.57,Q38,How many mechanisms of action does the drug Tas-115 have?,The drug Tas-115 has 2 mechanisms of action: Vascular endothelial growth factor receptor 2 inhibitor and Hepatocyte growth factor receptor inhibitor.,"SELECT UUID, drugName, tradeNames_string, drugMechanismOfAction
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%tas-115%"" OR LOWER(tradeNames_string) LIKE ""%tas-115%"" OR LOWER(drugSynonyms_string) LIKE ""%tas-115%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_532', 'drugName': 'Tas-115', 'tradeNames_string': '', 'drugMechanismOfAction': 'Vascular endothelial growth factor receptor 2 inhibitor'}, {'UUID': 'DrugGeneTargets_v2_533', 'drugName': 'Tas-115', 'tradeNames_string': '', 'drugMechanismOfAction': 'Hepatocyte growth factor receptor inhibitor'}]",general,"Select, Similarity Search",Metadata
-Q38.1293,Q38,How many mechanisms of action does the drug Amrubicin Hydrochloride have?,"The drug Amrubicin Hydrochloride has 1 mechanism of action, DNA topoisomerase II alpha inhibitor.","SELECT UUID, drugName, tradeNames_string, drugMechanismOfAction
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%amrubicin hydrochloride%"" OR LOWER(tradeNames_string) LIKE ""%amrubicin hydrochloride%"" OR LOWER(drugSynonyms_string) LIKE ""%amrubicin hydrochloride%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3383', 'drugName': 'Amrubicin Hydrochloride', 'tradeNames_string': '', 'drugMechanismOfAction': 'DNA topoisomerase II alpha inhibitor'}]",general,"Select, Similarity Search",Metadata
-Q38.1119,Q38,How many mechanisms of action does the drug Bismuth Subgallate have?,"The drug Bismuth Subgallate has 1 mechanism of action, Coagulation factor XII activator.","SELECT UUID, drugName, tradeNames_string, drugMechanismOfAction
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%bismuth subgallate%"" OR LOWER(tradeNames_string) LIKE ""%bismuth subgallate%"" OR LOWER(drugSynonyms_string) LIKE ""%bismuth subgallate%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_5123', 'drugName': 'Bismuth Subgallate', 'tradeNames_string': '', 'drugMechanismOfAction': 'Coagulation factor XII activator'}]",general,"Select, Similarity Search",Metadata
-Q38.585,Q38,How many mechanisms of action does the drug Gsk-461364 have?,"The drug Gsk-461364 has 1 mechanism of action, Serine/threonine-protein kinase PLK1 inhibitor.","SELECT UUID, drugName, tradeNames_string, drugMechanismOfAction
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%gsk-461364%"" OR LOWER(tradeNames_string) LIKE ""%gsk-461364%"" OR LOWER(drugSynonyms_string) LIKE ""%gsk-461364%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2668', 'drugName': 'Gsk-461364', 'tradeNames_string': '', 'drugMechanismOfAction': 'Serine/threonine-protein kinase PLK1 inhibitor'}]",general,"Select, Similarity Search",Metadata
-Q38.375,Q38,How many mechanisms of action does the drug Amitriptyline have?,The drug Amitriptyline has 2 mechanisms of action: Norepinephrine transporter inhibitor and Serotonin transporter inhibitor.,"SELECT UUID, drugName, tradeNames_string, drugMechanismOfAction
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%amitriptyline%"" OR LOWER(tradeNames_string) LIKE ""%amitriptyline%"" OR LOWER(drugSynonyms_string) LIKE ""%amitriptyline%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_1623', 'drugName': 'Amitriptyline', 'tradeNames_string': '', 'drugMechanismOfAction': 'Norepinephrine transporter inhibitor'}, {'UUID': 'DrugGeneTargets_v2_1624', 'drugName': 'Amitriptyline', 'tradeNames_string': '', 'drugMechanismOfAction': 'Serotonin transporter inhibitor'}, {'UUID': 'DrugGeneTargets_v2_3357', 'drugName': 'Amitriptyline Hydrochloride', 'tradeNames_string': 'Amitid, Amitril, Amitriptyline hydrochloride, Cytriptyline, Domical, Elavil, Endep, Lentizol, Limbitrol 5, Saroten, Saroten retard, Triptafen, Triptafen-m, Tryptizol, Tryptizol-75', 'drugMechanismOfAction': 'Norepinephrine transporter inhibitor'}, {'UUID': 'DrugGeneTargets_v2_3358', 'drugName': 'Amitriptyline Hydrochloride', 'tradeNames_string': 'Amitid, Amitril, Amitriptyline hydrochloride, Cytriptyline, Domical, Elavil, Endep, Lentizol, Limbitrol 5, Saroten, Saroten retard, Triptafen, Triptafen-m, Tryptizol, Tryptizol-75', 'drugMechanismOfAction': 'Serotonin transporter inhibitor'}, {'UUID': 'DrugGeneTargets_v2_597', 'drugName': 'Nortriptyline', 'tradeNames_string': 'Allegron, Aventyl, Motipress, Motival', 'drugMechanismOfAction': 'Serotonin transporter inhibitor'}, {'UUID': 'DrugGeneTargets_v2_598', 'drugName': 'Nortriptyline', 'tradeNames_string': 'Allegron, Aventyl, Motipress, Motival', 'drugMechanismOfAction': 'Norepinephrine transporter inhibitor'}]",general,"Select, Similarity Search",Metadata
-Q38.276,Q38,How many mechanisms of action does the drug Nefazodone have?,"The drug Nefazodone has 4 mechanisms of action: Serotonin 2c (5-HT2c) receptor antagonist, Serotonin transporter inhibitor, Norepinephrine transporter inhibitor, and Serotonin 2a (5-HT2a) receptor antagonist.","SELECT UUID, drugName, tradeNames_string, drugMechanismOfAction
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%nefazodone%"" OR LOWER(tradeNames_string) LIKE ""%nefazodone%"" OR LOWER(drugSynonyms_string) LIKE ""%nefazodone%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_5045', 'drugName': 'Nefazodone Hydrochloride', 'tradeNames_string': 'Dutonin, Nefazodone hydrochloride, Serzone', 'drugMechanismOfAction': 'Serotonin 2c (5-HT2c) receptor antagonist'}, {'UUID': 'DrugGeneTargets_v2_5046', 'drugName': 'Nefazodone Hydrochloride', 'tradeNames_string': 'Dutonin, Nefazodone hydrochloride, Serzone', 'drugMechanismOfAction': 'Serotonin transporter inhibitor'}, {'UUID': 'DrugGeneTargets_v2_5047', 'drugName': 'Nefazodone Hydrochloride', 'tradeNames_string': 'Dutonin, Nefazodone hydrochloride, Serzone', 'drugMechanismOfAction': 'Norepinephrine transporter inhibitor'}, {'UUID': 'DrugGeneTargets_v2_5048', 'drugName': 'Nefazodone Hydrochloride', 'tradeNames_string': 'Dutonin, Nefazodone hydrochloride, Serzone', 'drugMechanismOfAction': 'Serotonin 2a (5-HT2a) receptor antagonist'}, {'UUID': 'DrugGeneTargets_v2_4081', 'drugName': 'Nefazodone', 'tradeNames_string': '', 'drugMechanismOfAction': 'Serotonin 2c (5-HT2c) receptor antagonist'}, {'UUID': 'DrugGeneTargets_v2_4082', 'drugName': 'Nefazodone', 'tradeNames_string': '', 'drugMechanismOfAction': 'Serotonin transporter inhibitor'}, {'UUID': 'DrugGeneTargets_v2_4083', 'drugName': 'Nefazodone', 'tradeNames_string': '', 'drugMechanismOfAction': 'Norepinephrine transporter inhibitor'}, {'UUID': 'DrugGeneTargets_v2_4084', 'drugName': 'Nefazodone', 'tradeNames_string': '', 'drugMechanismOfAction': 'Serotonin 2a (5-HT2a) receptor antagonist'}]",general,"Select, Similarity Search",Metadata
-Q15.1861,Q15,When was Amp579 approved by the FDA?,The drug Amp579 has not been approved by the FDA.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%amp579%"" OR LOWER(tradeNames_string) LIKE ""%amp579%"" OR LOWER(drugSynonyms_string) LIKE ""%amp579%"") AND drugIsApproved = True
- LIMIT 100",[],refined,"Distinct, Similarity Search, Multi-Filter",Approval Status
-Q15.354,Q15,When was Drozitumab approved by the FDA?,The drug Drozitumab has not been approved by the FDA.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%drozitumab%"" OR LOWER(tradeNames_string) LIKE ""%drozitumab%"" OR LOWER(drugSynonyms_string) LIKE ""%drozitumab%"") AND drugIsApproved = True
- LIMIT 100",[],refined,"Distinct, Similarity Search, Multi-Filter",Approval Status
-Q15.1334,Q15,When was Estrone approved by the FDA?,The drug Estrone was first FDA approved for use in 1979.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%estrone%"" OR LOWER(tradeNames_string) LIKE ""%estrone%"" OR LOWER(drugSynonyms_string) LIKE ""%estrone%"") AND drugIsApproved = True
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_4799', 'drugName': 'Progesterone', 'tradeNames_string': 'Crinone, Cyclogest, Endometrin, Gesterol, Lutigest, Milprosa, Prochieve, Progesta-care, Progestasert, Progesterone, Progestin, Prometrium, Regumate, Serenity for women, Syngestrone, Utrogestan', 'drugSynonyms_string': 'NSC-64377, NSC-9704, Progesterone, Progesterone, micronized, Progesteronum, U 3672', 'yearOfFirstApproval': 1976, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2018', 'drugName': 'Estrone Sulfuric Acid', 'tradeNames_string': '', 'drugSynonyms_string': 'Estrone Sulphate', 'yearOfFirstApproval': 1977, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2257', 'drugName': 'Estropipate', 'tradeNames_string': 'Estropipate, Harmogen, Ogen, Ogen .625, Ogen 1.25, Ogen 2.5, Ogen 5, Ortho-est', 'drugSynonyms_string': 'Estrone sulfate piperazine salt, Estropipate, NSC-758912, Piperazine estrone sulfate, Piperazine estrone sulphate, Sulestrex piperazine', 'yearOfFirstApproval': 1977, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3573', 'drugName': 'Estrone', 'tradeNames_string': 'Estrogenic substance, Estrone, Natural estrogenic substance-estrone, Oestrone, Theelin', 'drugSynonyms_string': '1,3,5-estratrien-3-ol-17-one, Estradiol metabolite e1, Estrone, Follicular hormone, Follicular-hormone, Folliculin, Folliculinum, Ketohydroxyestrin, NSC-9699, Oestrone, Theelin, Thelykinin, Tokokin, WAY 164397', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}]",refined,"Distinct, Similarity Search, Multi-Filter",Approval Status
-Q15.906,Q15,When was Gestodene approved by the FDA?,The drug Gestodene has not been approved by the FDA.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%gestodene%"" OR LOWER(tradeNames_string) LIKE ""%gestodene%"" OR LOWER(drugSynonyms_string) LIKE ""%gestodene%"") AND drugIsApproved = True
- LIMIT 100",[],refined,"Distinct, Similarity Search, Multi-Filter",Approval Status
-Q15.1290,Q15,When was Phenelzine Sulfate approved by the FDA?,The drug Phenelzine Sulfate was first FDA approved for use in 1961.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%phenelzine sulfate%"" OR LOWER(tradeNames_string) LIKE ""%phenelzine sulfate%"" OR LOWER(drugSynonyms_string) LIKE ""%phenelzine sulfate%"") AND drugIsApproved = True
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_351', 'drugName': 'Phenelzine Sulfate', 'tradeNames_string': 'Nardil, Phenelzine sulfate', 'drugSynonyms_string': 'NSC-170957, Phenelzine acid sulfate, Phenelzine sulfate, Phenelzine sulphate', 'yearOfFirstApproval': 1961, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}]",refined,"Distinct, Similarity Search, Multi-Filter",Approval Status
-Q15.1274,Q15,When was Bevenopran approved by the FDA?,The drug Bevenopran has not been approved by the FDA.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%bevenopran%"" OR LOWER(tradeNames_string) LIKE ""%bevenopran%"" OR LOWER(drugSynonyms_string) LIKE ""%bevenopran%"") AND drugIsApproved = True
- LIMIT 100",[],refined,"Distinct, Similarity Search, Multi-Filter",Approval Status
-Q15.939,Q15,When was Ripretinib approved by the FDA?,The drug Ripretinib was first FDA approved for use in 2020.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%ripretinib%"" OR LOWER(tradeNames_string) LIKE ""%ripretinib%"" OR LOWER(drugSynonyms_string) LIKE ""%ripretinib%"") AND drugIsApproved = True
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3036', 'drugName': 'Ripretinib', 'tradeNames_string': 'Qinlock', 'drugSynonyms_string': 'DCC-2618, Dcc-2618, Ripretinib', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3037', 'drugName': 'Ripretinib', 'tradeNames_string': 'Qinlock', 'drugSynonyms_string': 'DCC-2618, Dcc-2618, Ripretinib', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}]",refined,"Distinct, Similarity Search, Multi-Filter",Approval Status
-Q15.1732,Q15,When was Selinexor approved by the FDA?,The drug Selinexor was first FDA approved for use in 2019.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%selinexor%"" OR LOWER(tradeNames_string) LIKE ""%selinexor%"" OR LOWER(drugSynonyms_string) LIKE ""%selinexor%"") AND drugIsApproved = True
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_58', 'drugName': 'Selinexor', 'tradeNames_string': 'Xpovio', 'drugSynonyms_string': 'KPT-330, Selinexor', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}]",refined,"Distinct, Similarity Search, Multi-Filter",Approval Status
-Q15.66,Q15,When was Baminercept approved by the FDA?,The drug Baminercept has not been approved by the FDA.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%baminercept%"" OR LOWER(tradeNames_string) LIKE ""%baminercept%"" OR LOWER(drugSynonyms_string) LIKE ""%baminercept%"") AND drugIsApproved = True
- LIMIT 100",[],refined,"Distinct, Similarity Search, Multi-Filter",Approval Status
-Q15.1324,Q15,When was Ilepatril approved by the FDA?,The drug Ilepatril has not been approved by the FDA.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%ilepatril%"" OR LOWER(tradeNames_string) LIKE ""%ilepatril%"" OR LOWER(drugSynonyms_string) LIKE ""%ilepatril%"") AND drugIsApproved = True
- LIMIT 100",[],refined,"Distinct, Similarity Search, Multi-Filter",Approval Status
-Q15.57,Q15,When was Anisotropine approved by the FDA?,The drug Anisotropine was first FDA approved for use in 1962.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%anisotropine%"" OR LOWER(tradeNames_string) LIKE ""%anisotropine%"" OR LOWER(drugSynonyms_string) LIKE ""%anisotropine%"") AND drugIsApproved = True
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_6145', 'drugName': 'Anisotropine Methylbromide', 'tradeNames_string': 'Anisotropine methylbromide, Valpin, Valpin 50', 'drugSynonyms_string': 'Anisotropine methylbromide, Methyloctatropine bromide, Octatropine methylbromide, Octatropone bromide, Octotropine methylbromide', 'yearOfFirstApproval': 1962, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6146', 'drugName': 'Anisotropine Methylbromide', 'tradeNames_string': 'Anisotropine methylbromide, Valpin, Valpin 50', 'drugSynonyms_string': 'Anisotropine methylbromide, Methyloctatropine bromide, Octatropine methylbromide, Octatropone bromide, Octotropine methylbromide', 'yearOfFirstApproval': 1962, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6238', 'drugName': 'Anisotropine', 'tradeNames_string': '', 'drugSynonyms_string': 'Anisotropine, Octatropine', 'yearOfFirstApproval': 1962, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6239', 'drugName': 'Anisotropine', 'tradeNames_string': '', 'drugSynonyms_string': 'Anisotropine, Octatropine', 'yearOfFirstApproval': 1962, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}]",refined,"Distinct, Similarity Search, Multi-Filter",Approval Status
-Q15.1293,Q15,When was Valproate Sodium approved by the FDA?,The drug Valproate Sodium was first FDA approved for use in 1996.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%valproate sodium%"" OR LOWER(tradeNames_string) LIKE ""%valproate sodium%"" OR LOWER(drugSynonyms_string) LIKE ""%valproate sodium%"") AND drugIsApproved = True
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_1604', 'drugName': 'Valproate Sodium', 'tradeNames_string': 'Delepsine, Depacon, Depakine, Depakote, Depakote CP, Depakote ER, Epilim, Epilim 200, Epilim 500, Epilim chrono 200, Epilim chrono 300, Epilim chrono 500, Epilim chronosphere, Epilim iv, Episenta, Kentilim, Orfiril, Orlept, Valproate sodium', 'drugSynonyms_string': 'A-44090, ABBOTT 44090, ABBOTT-44090, KW-6066N, NSC-732626, NSC-757376, Natrii valproas, Selenica, Sodium 2-propylpentanoate, Sodium valproate, Valproate sodium, Valproic acid sodium salt (1:1), Valproic acid, sodium, Valproic acid, sodium salt', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}]",refined,"Distinct, Similarity Search, Multi-Filter",Approval Status
-Q15.1119,Q15,When was Meclofenamic Acid approved by the FDA?,The drug Meclofenamic Acid was first FDA approved for use in 1980.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%meclofenamic acid%"" OR LOWER(tradeNames_string) LIKE ""%meclofenamic acid%"" OR LOWER(drugSynonyms_string) LIKE ""%meclofenamic acid%"") AND drugIsApproved = True
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3724', 'drugName': 'Meclofenamate Sodium', 'tradeNames_string': 'Meclodium, Meclofenamate sodium, Meclomen', 'drugSynonyms_string': 'CL-583.NA SALT, Meclofenamate sodium, Meclofenamate sodium anhydrous, Meclofenamate sodium hydrate, Meclofenamic acid sodium, NSC-757088, Sodium meclofenamate, Sodium meclofenamate monohydrate', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3725', 'drugName': 'Meclofenamate Sodium', 'tradeNames_string': 'Meclodium, Meclofenamate sodium, Meclomen', 'drugSynonyms_string': 'CL-583.NA SALT, Meclofenamate sodium, Meclofenamate sodium anhydrous, Meclofenamate sodium hydrate, Meclofenamic acid sodium, NSC-757088, Sodium meclofenamate, Sodium meclofenamate monohydrate', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5034', 'drugName': 'Meclofenamic Acid', 'tradeNames_string': '', 'drugSynonyms_string': 'CI-583, CL-583, INF 4668, INF-4668, Meclodium, Meclofenamate, Meclofenamic acid, Meclomen, NSC-95309', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5035', 'drugName': 'Meclofenamic Acid', 'tradeNames_string': '', 'drugSynonyms_string': 'CI-583, CL-583, INF 4668, INF-4668, Meclodium, Meclofenamate, Meclofenamic acid, Meclomen, NSC-95309', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}]",refined,"Distinct, Similarity Search, Multi-Filter",Approval Status
-Q15.585,Q15,When was Carbinoxamine approved by the FDA?,The drug Carbinoxamine was first FDA approved for use in 2003.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%carbinoxamine%"" OR LOWER(tradeNames_string) LIKE ""%carbinoxamine%"" OR LOWER(drugSynonyms_string) LIKE ""%carbinoxamine%"") AND drugIsApproved = True
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_4593', 'drugName': 'Carbinoxamine Maleate', 'tradeNames_string': 'Carbinoxamine maleate, Clistin, Davenol, Karbinal er', 'drugSynonyms_string': 'Carbinoxamine maleate, NSC-62362', 'yearOfFirstApproval': 2003, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1625', 'drugName': 'Carbinoxamine', 'tradeNames_string': '', 'drugSynonyms_string': 'Carbinoxamine, Clistin, Palgic', 'yearOfFirstApproval': 2003, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}]",refined,"Distinct, Similarity Search, Multi-Filter",Approval Status
-Q15.375,Q15,When was Lecanemab approved by the FDA?,The drug Lecanemab has not been approved by the FDA.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%lecanemab%"" OR LOWER(tradeNames_string) LIKE ""%lecanemab%"" OR LOWER(drugSynonyms_string) LIKE ""%lecanemab%"") AND drugIsApproved = True
- LIMIT 100",[],refined,"Distinct, Similarity Search, Multi-Filter",Approval Status
-Q15.276,Q15,When was Vercirnon approved by the FDA?,The drug Vercirnon has not been approved by the FDA.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%vercirnon%"" OR LOWER(tradeNames_string) LIKE ""%vercirnon%"" OR LOWER(drugSynonyms_string) LIKE ""%vercirnon%"") AND drugIsApproved = True
- LIMIT 100",[],refined,"Distinct, Similarity Search, Multi-Filter",Approval Status
-Q69.1861,Q69,What is the nearest gene to SNP rs74698907?,The SNP rs74698907 is located on or closest to the genes GADL1 and MIR466.,"SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs74698907'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs74698907'
- LIMIT 100","[{'source_table': 'ParkinsonDisease_CompleteGeneData_No23andMe', 'UUID': 'PDno23andme_full_gene_notext_4791305', 'nearestGene': 'GADL1;MIR466'}, {'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_3775285', 'nearestGene': 'GADL1;MIR466'}]",general,"Select, Join",Metadata
-Q69.354,Q69,What is the nearest gene to SNP rs571476918?,"According to the largest European genome-wide meta-analysis of Alzheimer's disease from Bellenguez (2022), the SNP rs571476918 is located on or closest to the genes LOC284898 and LOC105372977.","SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs571476918'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs571476918'
- LIMIT 100","[{'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_20932210', 'nearestGene': 'LOC284898;LOC105372977'}]",general,"Select, Join",Metadata
-Q69.1334,Q69,What is the nearest gene to SNP rs112451470?,The nearest gene to SNP rs112451470 is LINC00670.,"SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs112451470'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs112451470'
- LIMIT 100","[{'source_table': 'ParkinsonDisease_CompleteGeneData_No23andMe', 'UUID': 'PDno23andme_full_gene_notext_2040206', 'nearestGene': 'LINC00670'}, {'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_18549116', 'nearestGene': 'LINC00670'}]",general,"Select, Join",Metadata
-Q69.906,Q69,What is the nearest gene to SNP rs6805627?,The SNP rs6805627 is located on or closest to the genes ZNF717 and ROBO2.,"SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs6805627'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs6805627'
- LIMIT 100","[{'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_4119696', 'nearestGene': 'ZNF717;ROBO2'}, {'source_table': 'ParkinsonDisease_CompleteGeneData_No23andMe', 'UUID': 'PDno23andme_full_gene_notext_6652410', 'nearestGene': 'ZNF717;ROBO2'}]",general,"Select, Join",Metadata
-Q69.1290,Q69,What is the nearest gene to SNP rs9968437?,The SNP rs9968437 is located on or closest to the genes LINC02382 and LINC02431.,"SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs9968437'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs9968437'
- LIMIT 100","[{'source_table': 'ParkinsonDisease_CompleteGeneData_No23andMe', 'UUID': 'PDno23andme_full_gene_notext_2109545', 'nearestGene': 'LINC02382;LINC02431'}, {'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_6388698', 'nearestGene': 'LINC02382;LINC02431'}]",general,"Select, Join",Metadata
-Q69.1274,Q69,What is the nearest gene to SNP rs11655511?,The nearest gene to SNP rs11655511 is BCAS3.,"SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs11655511'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs11655511'
- LIMIT 100","[{'source_table': 'ParkinsonDisease_CompleteGeneData_No23andMe', 'UUID': 'PDno23andme_full_gene_notext_462266', 'nearestGene': 'BCAS3'}, {'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_18848066', 'nearestGene': 'BCAS3'}]",general,"Select, Join",Metadata
-Q69.939,Q69,What is the nearest gene to SNP rs145500479?,The nearest gene to SNP rs145500479 is NEUROG1.,"SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs145500479'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs145500479'
- LIMIT 100","[{'source_table': 'ParkinsonDisease_CompleteGeneData_No23andMe', 'UUID': 'PDno23andme_full_gene_notext_3610194', 'nearestGene': 'NEUROG1'}, {'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_7590479', 'nearestGene': 'NEUROG1'}]",general,"Select, Join",Metadata
-Q69.1732,Q69,What is the nearest gene to SNP rs35972757?,The nearest gene to SNP rs35972757 is SNTG2.,"SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs35972757'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs35972757'
- LIMIT 100","[{'source_table': 'ParkinsonDisease_CompleteGeneData_No23andMe', 'UUID': 'PDno23andme_full_gene_notext_2802065', 'nearestGene': 'SNTG2'}, {'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_1698099', 'nearestGene': 'SNTG2'}]",general,"Select, Join",Metadata
-Q69.66,Q69,What is the nearest gene to SNP rs573530492?,"According to the largest European genome-wide meta-analysis of Alzheimer's disease from Bellenguez (2022), the SNP rs573530492 is located on or closest to the genes FIGN and GRB14.","SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs573530492'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs573530492'
- LIMIT 100","[{'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_2901564', 'nearestGene': 'FIGN;GRB14'}]",general,"Select, Join",Metadata
-Q69.1324,Q69,What is the nearest gene to SNP rs73130538?,"According to the largest European genome-wide meta-analysis of Alzheimer's disease from Bellenguez (2022), the SNP rs73130538 is located on or closest to the genes CNTN1 and PDZRN4.","SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs73130538'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs73130538'
- LIMIT 100","[{'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_15039573', 'nearestGene': 'CNTN1;PDZRN4'}]",general,"Select, Join",Metadata
-Q69.57,Q69,What is the nearest gene to SNP rs12949979?,The nearest gene to SNP rs12949979 is PITPNC1.,"SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs12949979'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs12949979'
- LIMIT 100","[{'source_table': 'ParkinsonDisease_CompleteGeneData_No23andMe', 'UUID': 'PDno23andme_full_gene_notext_414143', 'nearestGene': 'PITPNC1'}, {'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_18890688', 'nearestGene': 'PITPNC1'}]",general,"Select, Join",Metadata
-Q69.1293,Q69,What is the nearest gene to SNP rs2396464?,The nearest gene to SNP rs2396464 is COL4A3.,"SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs2396464'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs2396464'
- LIMIT 100","[{'source_table': 'ParkinsonDisease_CompleteGeneData_No23andMe', 'UUID': 'PDno23andme_full_gene_notext_3018374', 'nearestGene': 'COL4A3'}, {'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_3370119', 'nearestGene': 'COL4A3'}]",general,"Select, Join",Metadata
-Q69.1119,Q69,What is the nearest gene to SNP rs189288031?,"According to the largest European genome-wide meta-analysis of Alzheimer's disease from Bellenguez (2022), the SNP rs189288031 is located on or closest to the genes C21orf62 and LINC01690.","SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs189288031'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs189288031'
- LIMIT 100","[{'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_20736198', 'nearestGene': 'C21orf62;LINC01690'}]",general,"Select, Join",Metadata
-Q69.585,Q69,What is the nearest gene to SNP rs75815079?,"According to the largest European genome-wide meta-analysis of Alzheimer's disease from Bellenguez (2022), the SNP rs75815079 is located on or closest to the genes LINC02639 and MIR6078.","SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs75815079'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs75815079'
- LIMIT 100","[{'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_12654818', 'nearestGene': 'LINC02639;MIR6078'}]",general,"Select, Join",Metadata
-Q69.375,Q69,What is the nearest gene to SNP rs1448586?,The SNP rs1448586 is located on or closest to the genes CYLC2 and LINC01492.,"SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs1448586'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs1448586'
- LIMIT 100","[{'source_table': 'ParkinsonDisease_CompleteGeneData_No23andMe', 'UUID': 'PDno23andme_full_gene_notext_2103303', 'nearestGene': 'CYLC2;LINC01492'}, {'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_12336899', 'nearestGene': 'CYLC2;LINC01492'}]",general,"Select, Join",Metadata
-Q69.276,Q69,What is the nearest gene to SNP rs1322694?,The nearest gene to SNP rs1322694 is FGF14.,"SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs1322694'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, nearestGene
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs1322694'
- LIMIT 100","[{'source_table': 'ParkinsonDisease_CompleteGeneData_No23andMe', 'UUID': 'PDno23andme_full_gene_notext_831754', 'nearestGene': 'FGF14'}, {'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_16398933', 'nearestGene': 'FGF14'}]",general,"Select, Join",Metadata
-Q22.479,Q22,What is Ongentys?,"Ongentys, also known generically as Opicapone, was approved by the FDA in 2020 to treat Parkinson disease. It is a small molecule therapy that acts as a(n) inhibitor.","SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%ongentys%"" OR LOWER(tradeNames_string) LIKE ""%ongentys%"" OR LOWER(drugSynonyms_string) LIKE ""%ongentys%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2548', 'tradeNames_string': 'Ongentys', 'drugName': 'Opicapone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Catechol O-methyltransferase inhibitor', 'linkedDiseasesDrug_string': 'Parkinson Disease (MONDO_0005180)', 'newLinkedTargets_string': 'COMT (ENSG00000093010)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}]",general,"Similarity Search, Select",Metadata
-Q22.82,Q22,What is Orladeyo?,"Orladeyo, also known generically as Berotralstat Hydrochloride, was approved by the FDA in 2020 to treat hereditary angioedema. It is a small molecule therapy that acts as a(n) inhibitor.","SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%orladeyo%"" OR LOWER(tradeNames_string) LIKE ""%orladeyo%"" OR LOWER(drugSynonyms_string) LIKE ""%orladeyo%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_4296', 'tradeNames_string': 'Orladeyo', 'drugName': 'Berotralstat Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Plasma kallikrein inhibitor', 'linkedDiseasesDrug_string': 'Hereditary Angioedema (MONDO_0019623)', 'newLinkedTargets_string': 'KLKB1 (ENSG00000164344)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}]",general,"Similarity Search, Select",Metadata
-Q22.78,Q22,What is Rezurock?,"Rezurock, also known generically as Belumosudil Mesylate, was approved by the FDA in 2021 to treat graft versus host disease. It is a small molecule therapy that acts as a(n) inhibitor.","SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%rezurock%"" OR LOWER(tradeNames_string) LIKE ""%rezurock%"" OR LOWER(drugSynonyms_string) LIKE ""%rezurock%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_6300', 'tradeNames_string': 'Rezurock', 'drugName': 'Belumosudil Mesylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Rho-associated protein kinase inhibitor', 'linkedDiseasesDrug_string': 'Graft Versus Host Disease (MONDO_0013730)', 'newLinkedTargets_string': 'ROCK2 (ENSG00000134318), ROCK1 (ENSG00000067900)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}]",general,"Similarity Search, Select",Metadata
-Q22.209,Q22,What is Drizalma Sprinkle?,"Drizalma Sprinkle, also known generically as Duloxetine Hydrochloride, was approved by the FDA in 2004 to treat Chronic pain, muscular disease, unipolar depression, fibromyalgia, neuropathic pain, anxiety disorder, and major depressive disorder. It is a small molecule therapy that acts as a(n) inhibitor.","SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%drizalma sprinkle%"" OR LOWER(tradeNames_string) LIKE ""%drizalma sprinkle%"" OR LOWER(drugSynonyms_string) LIKE ""%drizalma sprinkle%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_5702', 'tradeNames_string': 'Ariclaim, Cymbalta, Drizalma sprinkle, Duciltia, Duloxetine hydrochloride, Yentreve', 'drugName': 'Duloxetine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Norepinephrine transporter inhibitor', 'linkedDiseasesDrug_string': 'Post-Traumatic Stress Disorder (EFO_0001358), Unipolar Depression (EFO_0003761), Osteoarthritis (MONDO_0005178), Anxiety Disorder (EFO_0006788), Diabetic Neuropathy (EFO_1000783), Multiple Sclerosis (MONDO_0005301), Muscular Disease (EFO_0002970), Pain (EFO_0003843), Chronic Pain (HP_0012532), Neuropathic Pain (EFO_0005762), Anxiety (EFO_0005230), Fibromyalgia (EFO_0005687), Major Depressive Disorder (MONDO_0002009), Depressive Disorder (MONDO_0002050), Colorectal Carcinoma (EFO_1001951), Urinary Incontinence (HP_0000020)', 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2004, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5703', 'tradeNames_string': 'Ariclaim, Cymbalta, Drizalma sprinkle, Duciltia, Duloxetine hydrochloride, Yentreve', 'drugName': 'Duloxetine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Serotonin transporter inhibitor', 'linkedDiseasesDrug_string': 'Post-Traumatic Stress Disorder (EFO_0001358), Unipolar Depression (EFO_0003761), Osteoarthritis (MONDO_0005178), Anxiety Disorder (EFO_0006788), Diabetic Neuropathy (EFO_1000783), Multiple Sclerosis (MONDO_0005301), Muscular Disease (EFO_0002970), Pain (EFO_0003843), Chronic Pain (HP_0012532), Neuropathic Pain (EFO_0005762), Anxiety (EFO_0005230), Fibromyalgia (EFO_0005687), Major Depressive Disorder (MONDO_0002009), Depressive Disorder (MONDO_0002050), Colorectal Carcinoma (EFO_1001951), Urinary Incontinence (HP_0000020)', 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2004, 'drugIsApproved': True}]",general,"Similarity Search, Select",Metadata
-Q22.320,Q22,What is Arcapta Neohaler?,"Arcapta Neohaler, also known generically as Indacaterol Maleate, was approved by the FDA in 2011 to treat chronic obstructive pulmonary disease, emphysema, and chronic bronchitis. It is a small molecule therapy that acts as a(n) agonist.","SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%arcapta neohaler%"" OR LOWER(tradeNames_string) LIKE ""%arcapta neohaler%"" OR LOWER(drugSynonyms_string) LIKE ""%arcapta neohaler%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3427', 'tradeNames_string': 'Arcapta neohaler, Onbrez breezhaler', 'drugName': 'Indacaterol Maleate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Beta-2 adrenergic receptor agonist', 'linkedDiseasesDrug_string': 'Emphysema (EFO_0000464), Chronic Bronchitis (EFO_0006505), Chronic Obstructive Pulmonary Disease (EFO_0000341), Asthma (MONDO_0004979)', 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2011, 'drugIsApproved': True}]",general,"Similarity Search, Select",Metadata
-Q22.327,Q22,What is Corlanor?,"Corlanor, also known generically as Ivabradine, was approved by the FDA in 2015 to treat cardiovascular disease. It is a small molecule therapy that acts as a(n) blocker.","SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%corlanor%"" OR LOWER(tradeNames_string) LIKE ""%corlanor%"" OR LOWER(drugSynonyms_string) LIKE ""%corlanor%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_32', 'tradeNames_string': 'Corlanor, Procoralan', 'drugName': 'Ivabradine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Orthostatic Hypotension (EFO_0005252), Coronary Artery Disease (EFO_0001645), Non-St Elevation Myocardial Infarction (EFO_0008586), Hypotension (EFO_0005251), Aging (GO_0007568), Atrial Fibrillation (EFO_0000275), Congestive Heart Failure (EFO_0000373), Angina Pectoris (EFO_0003913), Septic Shock (EFO_0006834), Cardiovascular Disease (EFO_0000319), Lymphoma (EFO_0000574), Multiple Organ Failure (EFO_1001373), Tachycardia (HP_0001649), Diastolic Heart Failure (EFO_1000899), Systolic Heart Failure (EFO_1001207), Diabetic Nephropathy (EFO_0000401), Heart Failure (EFO_0003144), Mitral Valve Stenosis (EFO_0007372)', 'newLinkedTargets_string': 'HCN4 (ENSG00000138622)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1183', 'tradeNames_string': 'Corlanor, Procoralan', 'drugName': 'Ivabradine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker', 'linkedDiseasesDrug_string': 'Heart Failure (EFO_0003144), Congestive Heart Failure (EFO_0000373)', 'newLinkedTargets_string': 'HCN4 (ENSG00000138622)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}]",general,"Similarity Search, Select",Metadata
-Q58.1861,Q58,How many genes does the drug Amp579 target and what are they?,"The drug Amp579 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: ADORA2A and ADORA1.","SELECT DISTINCT UUID, drugName, drugMolecularType, newLinkedTargets_string, numberLinkedTargets, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%amp579%"" OR LOWER(tradeNames_string) LIKE ""%amp579%"" OR LOWER(drugSynonyms_string) LIKE ""%amp579%"")
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_727', 'drugName': 'Amp579', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'ADORA2A (ENSG00000128271), ADORA1 (ENSG00000163485)', 'numberLinkedTargets': 2, 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False}, {'UUID': 'DrugGeneTargets_v2_728', 'drugName': 'Amp579', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'ADORA2A (ENSG00000128271), ADORA1 (ENSG00000163485)', 'numberLinkedTargets': 2, 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False}]",general,"Distinct, Order By, Similarity Search",Genetic Target
-Q58.354,Q58,How many genes does the drug Drozitumab target and what are they?,"The drug Drozitumab is not approved by the FDA. However, it is currently undergoing clinical trials and indecated to target the gene TNFRSF10B.","SELECT DISTINCT UUID, drugName, drugMolecularType, newLinkedTargets_string, numberLinkedTargets, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%drozitumab%"" OR LOWER(tradeNames_string) LIKE ""%drozitumab%"" OR LOWER(drugSynonyms_string) LIKE ""%drozitumab%"")
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_5207', 'drugName': 'Drozitumab', 'drugMolecularType': 'Antibody', 'newLinkedTargets_string': 'TNFRSF10B (ENSG00000120889)', 'numberLinkedTargets': 1, 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False}]",general,"Distinct, Order By, Similarity Search",Genetic Target
-Q58.1334,Q58,How many genes does the drug Fingolimod Lauryl Sulfate target and what are they?,"There are 5 gene targets for the drug Fingolimod Lauryl Sulfate: S1PR5, S1PR2, S1PR4, S1PR3, and S1PR1.","SELECT DISTINCT UUID, drugName, drugMolecularType, newLinkedTargets_string, numberLinkedTargets, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%fingolimod lauryl sulfate%"" OR LOWER(tradeNames_string) LIKE ""%fingolimod lauryl sulfate%"" OR LOWER(drugSynonyms_string) LIKE ""%fingolimod lauryl sulfate%"")
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_5906', 'drugName': 'Fingolimod Lauryl Sulfate', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'S1PR5 (ENSG00000180739), S1PR2 (ENSG00000267534), S1PR4 (ENSG00000125910), S1PR3 (ENSG00000213694), S1PR1 (ENSG00000170989)', 'numberLinkedTargets': 5, 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}]",general,"Distinct, Order By, Similarity Search",Genetic Target
-Q58.906,Q58,How many genes does the drug Gestodene target and what are they?,"The drug Gestodene is not approved by the FDA. However, it is currently undergoing clinical trials and indecated to target the gene PGR.","SELECT DISTINCT UUID, drugName, drugMolecularType, newLinkedTargets_string, numberLinkedTargets, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%gestodene%"" OR LOWER(tradeNames_string) LIKE ""%gestodene%"" OR LOWER(drugSynonyms_string) LIKE ""%gestodene%"")
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_925', 'drugName': 'Gestodene', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'PGR (ENSG00000082175)', 'numberLinkedTargets': 1, 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False}]",general,"Distinct, Order By, Similarity Search",Genetic Target
-Q58.1290,Q58,How many genes does the drug Erdafitinib target and what are they?,"There are 4 gene targets for the drug Erdafitinib: FGFR3, FGFR1, FGFR4, and FGFR2.","SELECT DISTINCT UUID, drugName, drugMolecularType, newLinkedTargets_string, numberLinkedTargets, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%erdafitinib%"" OR LOWER(tradeNames_string) LIKE ""%erdafitinib%"" OR LOWER(drugSynonyms_string) LIKE ""%erdafitinib%"")
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_5765', 'drugName': 'Erdafitinib', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 4, 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}]",general,"Distinct, Order By, Similarity Search",Genetic Target
-Q58.1274,Q58,How many genes does the drug Bevenopran target and what are they?,"The drug Bevenopran is not approved by the FDA. However, it is currently undergoing clinical trials and indecated to target the gene OPRM1.","SELECT DISTINCT UUID, drugName, drugMolecularType, newLinkedTargets_string, numberLinkedTargets, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%bevenopran%"" OR LOWER(tradeNames_string) LIKE ""%bevenopran%"" OR LOWER(drugSynonyms_string) LIKE ""%bevenopran%"")
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3338', 'drugName': 'Bevenopran', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1, 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False}]",general,"Distinct, Order By, Similarity Search",Genetic Target
-Q58.939,Q58,How many genes does the drug Atosiban target and what are they?,OXTR is the only gene target of drug Atosiban.,"SELECT DISTINCT UUID, drugName, drugMolecularType, newLinkedTargets_string, numberLinkedTargets, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%atosiban%"" OR LOWER(tradeNames_string) LIKE ""%atosiban%"" OR LOWER(drugSynonyms_string) LIKE ""%atosiban%"")
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_4904', 'drugName': 'Atosiban', 'drugMolecularType': 'Protein', 'newLinkedTargets_string': 'OXTR (ENSG00000180914)', 'numberLinkedTargets': 1, 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}]",general,"Distinct, Order By, Similarity Search",Genetic Target
-Q58.1732,Q58,How many genes does the drug Allylestrenol target and what are they?,"There are 3 gene targets for the drug Allylestrenol: ESR2, ESR1, and PGR.","SELECT DISTINCT UUID, drugName, drugMolecularType, newLinkedTargets_string, numberLinkedTargets, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%allylestrenol%"" OR LOWER(tradeNames_string) LIKE ""%allylestrenol%"" OR LOWER(drugSynonyms_string) LIKE ""%allylestrenol%"")
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_1120', 'drugName': 'Allylestrenol', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'ESR2 (ENSG00000140009), ESR1 (ENSG00000091831), PGR (ENSG00000082175)', 'numberLinkedTargets': 3, 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1121', 'drugName': 'Allylestrenol', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'ESR2 (ENSG00000140009), ESR1 (ENSG00000091831), PGR (ENSG00000082175)', 'numberLinkedTargets': 3, 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}]",general,"Distinct, Order By, Similarity Search",Genetic Target
-Q58.66,Q58,How many genes does the drug Baminercept target and what are they?,"The drug Baminercept is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 3 genes: LTA, LTB, and TNFSF14.","SELECT DISTINCT UUID, drugName, drugMolecularType, newLinkedTargets_string, numberLinkedTargets, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%baminercept%"" OR LOWER(tradeNames_string) LIKE ""%baminercept%"" OR LOWER(drugSynonyms_string) LIKE ""%baminercept%"")
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_5474', 'drugName': 'Baminercept', 'drugMolecularType': 'Protein', 'newLinkedTargets_string': 'LTA (ENSG00000226979), LTB (ENSG00000227507), TNFSF14 (ENSG00000125735)', 'numberLinkedTargets': 3, 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False}, {'UUID': 'DrugGeneTargets_v2_5475', 'drugName': 'Baminercept', 'drugMolecularType': 'Protein', 'newLinkedTargets_string': 'LTA (ENSG00000226979), LTB (ENSG00000227507), TNFSF14 (ENSG00000125735)', 'numberLinkedTargets': 3, 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False}]",general,"Distinct, Order By, Similarity Search",Genetic Target
-Q58.1324,Q58,How many genes does the drug Ilepatril target and what are they?,"The drug Ilepatril is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: MME and ACE.","SELECT DISTINCT UUID, drugName, drugMolecularType, newLinkedTargets_string, numberLinkedTargets, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%ilepatril%"" OR LOWER(tradeNames_string) LIKE ""%ilepatril%"" OR LOWER(drugSynonyms_string) LIKE ""%ilepatril%"")
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_1768', 'drugName': 'Ilepatril', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'MME (ENSG00000196549), ACE (ENSG00000159640)', 'numberLinkedTargets': 2, 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False}, {'UUID': 'DrugGeneTargets_v2_1769', 'drugName': 'Ilepatril', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'MME (ENSG00000196549), ACE (ENSG00000159640)', 'numberLinkedTargets': 2, 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False}]",general,"Distinct, Order By, Similarity Search",Genetic Target
-Q58.57,Q58,"How many genes does the drug Gonadotropin, Chorionic target and what are they?","LHCGR is the only gene target of drug Gonadotropin, Chorionic.","SELECT DISTINCT UUID, drugName, drugMolecularType, newLinkedTargets_string, numberLinkedTargets, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%gonadotropin, chorionic%"" OR LOWER(tradeNames_string) LIKE ""%gonadotropin, chorionic%"" OR LOWER(drugSynonyms_string) LIKE ""%gonadotropin, chorionic%"")
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3636', 'drugName': 'Gonadotropin, Chorionic', 'drugMolecularType': 'Protein', 'newLinkedTargets_string': 'LHCGR (ENSG00000138039)', 'numberLinkedTargets': 1, 'yearOfFirstApproval': 1973, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}]",general,"Distinct, Order By, Similarity Search",Genetic Target
-Q58.1293,Q58,How many genes does the drug Tipiracil target and what are they?,TYMP is the only gene target of drug Tipiracil.,"SELECT DISTINCT UUID, drugName, drugMolecularType, newLinkedTargets_string, numberLinkedTargets, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%tipiracil%"" OR LOWER(tradeNames_string) LIKE ""%tipiracil%"" OR LOWER(drugSynonyms_string) LIKE ""%tipiracil%"")
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_4740', 'drugName': 'Tipiracil Hydrochloride', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'TYMP (ENSG00000025708)', 'numberLinkedTargets': 1, 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1091', 'drugName': 'Tipiracil', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'TYMP (ENSG00000025708)', 'numberLinkedTargets': 1, 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}]",general,"Distinct, Order By, Similarity Search",Genetic Target
-Q58.1119,Q58,How many genes does the drug Tafasitamab target and what are they?,CD19 is the only gene target of drug Tafasitamab.,"SELECT DISTINCT UUID, drugName, drugMolecularType, newLinkedTargets_string, numberLinkedTargets, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%tafasitamab%"" OR LOWER(tradeNames_string) LIKE ""%tafasitamab%"" OR LOWER(drugSynonyms_string) LIKE ""%tafasitamab%"")
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3753', 'drugName': 'Tafasitamab', 'drugMolecularType': 'Antibody', 'newLinkedTargets_string': 'CD19 (ENSG00000177455)', 'numberLinkedTargets': 1, 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}]",general,"Distinct, Order By, Similarity Search",Genetic Target
-Q58.585,Q58,How many genes does the drug Apomorphine target and what are they?,"There are 3 gene targets for the drug Apomorphine: DRD2, DRD3, and DRD4.","SELECT DISTINCT UUID, drugName, drugMolecularType, newLinkedTargets_string, numberLinkedTargets, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%apomorphine%"" OR LOWER(tradeNames_string) LIKE ""%apomorphine%"" OR LOWER(drugSynonyms_string) LIKE ""%apomorphine%"")
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3259', 'drugName': 'Apomorphine', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 3, 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3300', 'drugName': 'Apomorphine Hydrochloride', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 3, 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}]",general,"Distinct, Order By, Similarity Search",Genetic Target
-Q58.375,Q58,How many genes does the drug Lecanemab target and what are they?,"The drug Lecanemab is not approved by the FDA. However, it is currently undergoing clinical trials and indecated to target the gene APP.","SELECT DISTINCT UUID, drugName, drugMolecularType, newLinkedTargets_string, numberLinkedTargets, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%lecanemab%"" OR LOWER(tradeNames_string) LIKE ""%lecanemab%"" OR LOWER(drugSynonyms_string) LIKE ""%lecanemab%"")
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2736', 'drugName': 'Lecanemab', 'drugMolecularType': 'Antibody', 'newLinkedTargets_string': 'APP (ENSG00000142192)', 'numberLinkedTargets': 1, 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False}]",general,"Distinct, Order By, Similarity Search",Genetic Target
-Q58.276,Q58,How many genes does the drug Vercirnon target and what are they?,"The drug Vercirnon is not approved by the FDA. However, it is currently undergoing clinical trials and indecated to target the gene CCR9.","SELECT DISTINCT UUID, drugName, drugMolecularType, newLinkedTargets_string, numberLinkedTargets, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%vercirnon%"" OR LOWER(tradeNames_string) LIKE ""%vercirnon%"" OR LOWER(drugSynonyms_string) LIKE ""%vercirnon%"")
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_1403', 'drugName': 'Vercirnon', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'CCR9 (ENSG00000173585)', 'numberLinkedTargets': 1, 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False}]",general,"Distinct, Order By, Similarity Search",Genetic Target
-Q16.1316,Q16,What Small molecule therapies have been approved by the FDA to treat metastatic melanoma?,"There are 6 Small molecule therapy drugs that are approved to treat metastatic melanoma which are as follows: Vemurafenib, Encorafenib, Dabrafenib Mesylate, Binimetinib, Cobimetinib Fumarate, and Trametinib Dimethyl Sulfoxide.","SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses`
- WHERE (LOWER(efo_term) = ""metastatic melanoma"" OR LOWER(mesh_heading) = ""metastatic melanoma"") AND LOWER(drugType) = ""small molecule"" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_752098', 'drugName': 'Vemurafenib', 'tradeNames_list': ""['Zelboraf']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752119', 'drugName': 'Vemurafenib', 'tradeNames_list': ""['Zelboraf']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752140', 'drugName': 'Vemurafenib', 'tradeNames_list': ""['Zelboraf']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752161', 'drugName': 'Vemurafenib', 'tradeNames_list': ""['Zelboraf']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752182', 'drugName': 'Vemurafenib', 'tradeNames_list': ""['Zelboraf']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752203', 'drugName': 'Vemurafenib', 'tradeNames_list': ""['Zelboraf']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752224', 'drugName': 'Vemurafenib', 'tradeNames_list': ""['Zelboraf']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752239', 'drugName': 'Encorafenib', 'tradeNames_list': ""['Braftovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752253', 'drugName': 'Encorafenib', 'tradeNames_list': ""['Braftovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752267', 'drugName': 'Encorafenib', 'tradeNames_list': ""['Braftovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752281', 'drugName': 'Encorafenib', 'tradeNames_list': ""['Braftovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752295', 'drugName': 'Encorafenib', 'tradeNames_list': ""['Braftovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752309', 'drugName': 'Encorafenib', 'tradeNames_list': ""['Braftovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752323', 'drugName': 'Encorafenib', 'tradeNames_list': ""['Braftovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752337', 'drugName': 'Encorafenib', 'tradeNames_list': ""['Braftovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752351', 'drugName': 'Encorafenib', 'tradeNames_list': ""['Braftovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752365', 'drugName': 'Encorafenib', 'tradeNames_list': ""['Braftovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752379', 'drugName': 'Encorafenib', 'tradeNames_list': ""['Braftovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752393', 'drugName': 'Encorafenib', 'tradeNames_list': ""['Braftovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752407', 'drugName': 'Encorafenib', 'tradeNames_list': ""['Braftovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752421', 'drugName': 'Encorafenib', 'tradeNames_list': ""['Braftovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752435', 'drugName': 'Encorafenib', 'tradeNames_list': ""['Braftovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752449', 'drugName': 'Encorafenib', 'tradeNames_list': ""['Braftovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752463', 'drugName': 'Encorafenib', 'tradeNames_list': ""['Braftovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752477', 'drugName': 'Encorafenib', 'tradeNames_list': ""['Braftovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752491', 'drugName': 'Encorafenib', 'tradeNames_list': ""['Braftovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752505', 'drugName': 'Encorafenib', 'tradeNames_list': ""['Braftovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752519', 'drugName': 'Encorafenib', 'tradeNames_list': ""['Braftovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752533', 'drugName': 'Encorafenib', 'tradeNames_list': ""['Braftovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752547', 'drugName': 'Encorafenib', 'tradeNames_list': ""['Braftovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752561', 'drugName': 'Encorafenib', 'tradeNames_list': ""['Braftovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752575', 'drugName': 'Encorafenib', 'tradeNames_list': ""['Braftovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752589', 'drugName': 'Encorafenib', 'tradeNames_list': ""['Braftovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752603', 'drugName': 'Encorafenib', 'tradeNames_list': ""['Braftovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752617', 'drugName': 'Encorafenib', 'tradeNames_list': ""['Braftovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752631', 'drugName': 'Encorafenib', 'tradeNames_list': ""['Braftovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752645', 'drugName': 'Encorafenib', 'tradeNames_list': ""['Braftovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752659', 'drugName': 'Encorafenib', 'tradeNames_list': ""['Braftovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752673', 'drugName': 'Encorafenib', 'tradeNames_list': ""['Braftovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752678', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752685', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752692', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752699', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752706', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752713', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752720', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752727', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752734', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752741', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752748', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752755', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752762', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752769', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752776', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752783', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752790', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752797', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752804', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752811', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752818', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752825', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752832', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752839', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752846', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752853', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752860', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752867', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752874', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752881', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752888', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752895', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752902', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752909', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752916', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752923', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752930', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752937', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752944', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752951', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752958', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752965', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752972', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_752979', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_list': ""['Tafinlar']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_926655', 'drugName': 'Binimetinib', 'tradeNames_list': ""['Mektovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_926681', 'drugName': 'Binimetinib', 'tradeNames_list': ""['Mektovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_926707', 'drugName': 'Binimetinib', 'tradeNames_list': ""['Mektovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_926733', 'drugName': 'Binimetinib', 'tradeNames_list': ""['Mektovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_926759', 'drugName': 'Binimetinib', 'tradeNames_list': ""['Mektovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_926785', 'drugName': 'Binimetinib', 'tradeNames_list': ""['Mektovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_926811', 'drugName': 'Binimetinib', 'tradeNames_list': ""['Mektovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_926837', 'drugName': 'Binimetinib', 'tradeNames_list': ""['Mektovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_926863', 'drugName': 'Binimetinib', 'tradeNames_list': ""['Mektovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_926889', 'drugName': 'Binimetinib', 'tradeNames_list': ""['Mektovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_926915', 'drugName': 'Binimetinib', 'tradeNames_list': ""['Mektovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_926941', 'drugName': 'Binimetinib', 'tradeNames_list': ""['Mektovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_926967', 'drugName': 'Binimetinib', 'tradeNames_list': ""['Mektovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_926993', 'drugName': 'Binimetinib', 'tradeNames_list': ""['Mektovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_927019', 'drugName': 'Binimetinib', 'tradeNames_list': ""['Mektovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_927045', 'drugName': 'Binimetinib', 'tradeNames_list': ""['Mektovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}, {'UUID': 'DrugTargetsIndication121923_text_927071', 'drugName': 'Binimetinib', 'tradeNames_list': ""['Mektovi']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma'}]",refined,"Distinct, Multi-Filter, Similarity Search",Approval Status
-Q16.213,Q16,What Protein therapies have been approved by the FDA to treat mast-cell leukemia?,There are no drug Protein therapies approved to treat mast-cell leukemia.,"SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses`
- WHERE (LOWER(efo_term) = ""mast-cell leukemia"" OR LOWER(mesh_heading) = ""mast-cell leukemia"") AND LOWER(drugType) = ""protein"" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
- LIMIT 100",[],refined,"Distinct, Multi-Filter, Similarity Search",Approval Status
-Q16.417,Q16,What Small molecule therapies have been approved by the FDA to treat Dupuytren Contracture?,There are no drug Small molecule therapies approved to treat Dupuytren Contracture.,"SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses`
- WHERE (LOWER(efo_term) = ""dupuytren contracture"" OR LOWER(mesh_heading) = ""dupuytren contracture"") AND LOWER(drugType) = ""small molecule"" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
- LIMIT 100",[],refined,"Distinct, Multi-Filter, Similarity Search",Approval Status
-Q16.678,Q16,What Small molecule therapies have been approved by the FDA to treat Vogt-Koyanagi-Harada disease?,There are no drug Small molecule therapies approved to treat Vogt-Koyanagi-Harada disease.,"SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses`
- WHERE (LOWER(efo_term) = ""vogt-koyanagi-harada disease"" OR LOWER(mesh_heading) = ""vogt-koyanagi-harada disease"") AND LOWER(drugType) = ""small molecule"" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
- LIMIT 100",[],refined,"Distinct, Multi-Filter, Similarity Search",Approval Status
-Q16.1549,Q16,What Small molecule therapies have been approved by the FDA to treat pulmonary fibrosis?,There are no drug Small molecule therapies approved to treat pulmonary fibrosis.,"SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses`
- WHERE (LOWER(efo_term) = ""pulmonary fibrosis"" OR LOWER(mesh_heading) = ""pulmonary fibrosis"") AND LOWER(drugType) = ""small molecule"" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
- LIMIT 100",[],refined,"Distinct, Multi-Filter, Similarity Search",Approval Status
-Q16.765,Q16,What Small molecule therapies have been approved by the FDA to treat angioimmunoblastic T-cell lymphoma?,There are no drug Small molecule therapies approved to treat angioimmunoblastic T-cell lymphoma.,"SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses`
- WHERE (LOWER(efo_term) = ""angioimmunoblastic t-cell lymphoma"" OR LOWER(mesh_heading) = ""angioimmunoblastic t-cell lymphoma"") AND LOWER(drugType) = ""small molecule"" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
- LIMIT 100",[],refined,"Distinct, Multi-Filter, Similarity Search",Approval Status
-Q16.1317,Q16,What Small molecule therapies have been approved by the FDA to treat metastatic neoplasm?,There are no drug Small molecule therapies approved to treat metastatic neoplasm.,"SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses`
- WHERE (LOWER(efo_term) = ""metastatic neoplasm"" OR LOWER(mesh_heading) = ""metastatic neoplasm"") AND LOWER(drugType) = ""small molecule"" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
- LIMIT 100",[],refined,"Distinct, Multi-Filter, Similarity Search",Approval Status
-Q16.340,Q16,What Small molecule therapies have been approved by the FDA to treat Anorexia?,"There are 3 Small molecule therapy drugs that are approved to treat Anorexia which are as follows: Metoclopramide Hydrochloride, Megestrol Acetate, and Dronabinol.","SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses`
- WHERE (LOWER(efo_term) = ""anorexia"" OR LOWER(mesh_heading) = ""anorexia"") AND LOWER(drugType) = ""small molecule"" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_199661', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'""clopra-""""yellow""""""\', \'Clopra\', \'Clopra-""Yellow""\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anorexia', 'efo_term': 'Anorexia'}, {'UUID': 'DrugTargetsIndication121923_text_199669', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'""clopra-""""yellow""""""\', \'Clopra\', \'Clopra-""Yellow""\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anorexia', 'efo_term': 'Anorexia'}, {'UUID': 'DrugTargetsIndication121923_text_199677', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'""clopra-""""yellow""""""\', \'Clopra\', \'Clopra-""Yellow""\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anorexia', 'efo_term': 'Anorexia'}, {'UUID': 'DrugTargetsIndication121923_text_199685', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'""clopra-""""yellow""""""\', \'Clopra\', \'Clopra-""Yellow""\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000166736', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A', 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anorexia', 'efo_term': 'Anorexia'}, {'UUID': 'DrugTargetsIndication121923_text_199693', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'""clopra-""""yellow""""""\', \'Clopra\', \'Clopra-""Yellow""\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000164270', 'approvedSymbol': 'HTR4', 'approvedName': '5-hydroxytryptamine receptor 4', 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anorexia', 'efo_term': 'Anorexia'}, {'UUID': 'DrugTargetsIndication121923_text_199701', 'drugName': 'Metoclopramide Hydrochloride', 'tradeNames_list': '[\'""clopra-""""yellow""""""\', \'Clopra\', \'Clopra-""Yellow""\', \'Gastrese l.a.Gastrobid continus\', \'Gastroflux\', \'Gastromax\', \'Gimoti\', \'MaxolonMaxolon sr\', \'Metoclomex\', \'Metoclopramide hydrochlorideMetoclopramide intensol\', \'Metox\', \'Metozolv odt\', \'Metramid\', \'MygdalonParmid\', \'Primperan\', \'Reglan\', \'Reglan odt\']', 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000164270', 'approvedSymbol': 'HTR4', 'approvedName': '5-hydroxytryptamine receptor 4', 'yearOfFirstApproval': 1979, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anorexia', 'efo_term': 'Anorexia'}, {'UUID': 'DrugTargetsIndication121923_text_940511', 'drugName': 'Megestrol Acetate', 'tradeNames_list': ""['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']"", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anorexia', 'efo_term': 'Anorexia'}, {'UUID': 'DrugTargetsIndication121923_text_940532', 'drugName': 'Megestrol Acetate', 'tradeNames_list': ""['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']"", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anorexia', 'efo_term': 'Anorexia'}, {'UUID': 'DrugTargetsIndication121923_text_940553', 'drugName': 'Megestrol Acetate', 'tradeNames_list': ""['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']"", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anorexia', 'efo_term': 'Anorexia'}, {'UUID': 'DrugTargetsIndication121923_text_940574', 'drugName': 'Megestrol Acetate', 'tradeNames_list': ""['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']"", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anorexia', 'efo_term': 'Anorexia'}, {'UUID': 'DrugTargetsIndication121923_text_940595', 'drugName': 'Megestrol Acetate', 'tradeNames_list': ""['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']"", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anorexia', 'efo_term': 'Anorexia'}, {'UUID': 'DrugTargetsIndication121923_text_1073218', 'drugName': 'Dronabinol', 'tradeNames_list': ""['Dronabinol', 'Marinol', 'Syndros']"", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anorexia', 'efo_term': 'Anorexia'}, {'UUID': 'DrugTargetsIndication121923_text_1073254', 'drugName': 'Dronabinol', 'tradeNames_list': ""['Dronabinol', 'Marinol', 'Syndros']"", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anorexia', 'efo_term': 'Anorexia'}, {'UUID': 'DrugTargetsIndication121923_text_1073290', 'drugName': 'Dronabinol', 'tradeNames_list': ""['Dronabinol', 'Marinol', 'Syndros']"", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anorexia', 'efo_term': 'Anorexia'}, {'UUID': 'DrugTargetsIndication121923_text_1073326', 'drugName': 'Dronabinol', 'tradeNames_list': ""['Dronabinol', 'Marinol', 'Syndros']"", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anorexia', 'efo_term': 'Anorexia'}]",refined,"Distinct, Multi-Filter, Similarity Search",Approval Status
-Q16.1048,Q16,What Small molecule therapies have been approved by the FDA to treat exocrine pancreatic insufficiency?,There are no drug Small molecule therapies approved to treat exocrine pancreatic insufficiency.,"SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses`
- WHERE (LOWER(efo_term) = ""exocrine pancreatic insufficiency"" OR LOWER(mesh_heading) = ""exocrine pancreatic insufficiency"") AND LOWER(drugType) = ""small molecule"" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
- LIMIT 100",[],refined,"Distinct, Multi-Filter, Similarity Search",Approval Status
-Q16.1245,Q16,What Small molecule therapies have been approved by the FDA to treat leiomyoma?,There are no drug Small molecule therapies approved to treat leiomyoma.,"SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses`
- WHERE (LOWER(efo_term) = ""leiomyoma"" OR LOWER(mesh_heading) = ""leiomyoma"") AND LOWER(drugType) = ""small molecule"" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
- LIMIT 100",[],refined,"Distinct, Multi-Filter, Similarity Search",Approval Status
-Q16.1637,Q16,What Small molecule therapies have been approved by the FDA to treat soft tissue sarcoma?,Pazopanib Hydrochloride is the only Small molecule therapy approved by the FDA to treat soft tissue sarcoma.,"SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses`
- WHERE (LOWER(efo_term) = ""soft tissue sarcoma"" OR LOWER(mesh_heading) = ""soft tissue sarcoma"") AND LOWER(drugType) = ""small molecule"" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_667828', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': ""['Votrient']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma'}, {'UUID': 'DrugTargetsIndication121923_text_667856', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': ""['Votrient']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma'}, {'UUID': 'DrugTargetsIndication121923_text_667884', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': ""['Votrient']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma'}, {'UUID': 'DrugTargetsIndication121923_text_667912', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': ""['Votrient']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma'}, {'UUID': 'DrugTargetsIndication121923_text_667940', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': ""['Votrient']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma'}, {'UUID': 'DrugTargetsIndication121923_text_667968', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': ""['Votrient']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma'}, {'UUID': 'DrugTargetsIndication121923_text_667996', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': ""['Votrient']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma'}, {'UUID': 'DrugTargetsIndication121923_text_668024', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': ""['Votrient']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma'}, {'UUID': 'DrugTargetsIndication121923_text_668052', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': ""['Votrient']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma'}, {'UUID': 'DrugTargetsIndication121923_text_668080', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': ""['Votrient']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma'}, {'UUID': 'DrugTargetsIndication121923_text_668108', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': ""['Votrient']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma'}, {'UUID': 'DrugTargetsIndication121923_text_668136', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': ""['Votrient']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma'}, {'UUID': 'DrugTargetsIndication121923_text_668164', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': ""['Votrient']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma'}, {'UUID': 'DrugTargetsIndication121923_text_668192', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': ""['Votrient']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma'}, {'UUID': 'DrugTargetsIndication121923_text_668220', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': ""['Votrient']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma'}, {'UUID': 'DrugTargetsIndication121923_text_668248', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': ""['Votrient']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma'}, {'UUID': 'DrugTargetsIndication121923_text_668276', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': ""['Votrient']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000182866', 'approvedSymbol': 'LCK', 'approvedName': 'LCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma'}, {'UUID': 'DrugTargetsIndication121923_text_668304', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': ""['Votrient']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000182866', 'approvedSymbol': 'LCK', 'approvedName': 'LCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma'}, {'UUID': 'DrugTargetsIndication121923_text_668332', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': ""['Votrient']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000182578', 'approvedSymbol': 'CSF1R', 'approvedName': 'colony stimulating factor 1 receptor', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma'}, {'UUID': 'DrugTargetsIndication121923_text_668360', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': ""['Votrient']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000182578', 'approvedSymbol': 'CSF1R', 'approvedName': 'colony stimulating factor 1 receptor', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma'}, {'UUID': 'DrugTargetsIndication121923_text_668388', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': ""['Votrient']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113263', 'approvedSymbol': 'ITK', 'approvedName': 'IL2 inducible T cell kinase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma'}, {'UUID': 'DrugTargetsIndication121923_text_668416', 'drugName': 'Pazopanib Hydrochloride', 'tradeNames_list': ""['Votrient']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113263', 'approvedSymbol': 'ITK', 'approvedName': 'IL2 inducible T cell kinase', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'soft tissue sarcoma'}]",refined,"Distinct, Multi-Filter, Similarity Search",Approval Status
-Q16.1334,Q16,What Small molecule therapies have been approved by the FDA to treat movement disorder?,Valbenazine Tosylate is the only Small molecule therapy approved by the FDA to treat movement disorder.,"SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses`
- WHERE (LOWER(efo_term) = ""movement disorder"" OR LOWER(mesh_heading) = ""movement disorder"") AND LOWER(drugType) = ""small molecule"" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_938924', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938925', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938926', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938927', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938928', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938929', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938930', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938931', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938932', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938933', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938934', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938935', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938936', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938937', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938938', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938939', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938940', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938941', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938942', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938943', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938944', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938945', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938946', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938947', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938948', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938949', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938950', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938951', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938952', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938953', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938954', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938955', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938956', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938957', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938958', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938959', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938960', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938961', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938962', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938963', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938964', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938965', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938966', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938967', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938968', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938969', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938970', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938971', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938972', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938973', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938974', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938975', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938976', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938977', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938978', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938979', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938980', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938981', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938982', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938983', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938984', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938985', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938986', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938987', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938988', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}, {'UUID': 'DrugTargetsIndication121923_text_938989', 'drugName': 'Valbenazine Tosylate', 'tradeNames_list': ""['Ingrezza']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165646', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tardive Dyskinesia', 'efo_term': 'movement disorder'}]",refined,"Distinct, Multi-Filter, Similarity Search",Approval Status
-Q16.716,Q16,What Small molecule therapies have been approved by the FDA to treat adenoid cystic carcinoma?,There are no drug Small molecule therapies approved to treat adenoid cystic carcinoma.,"SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses`
- WHERE (LOWER(efo_term) = ""adenoid cystic carcinoma"" OR LOWER(mesh_heading) = ""adenoid cystic carcinoma"") AND LOWER(drugType) = ""small molecule"" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
- LIMIT 100",[],refined,"Distinct, Multi-Filter, Similarity Search",Approval Status
-Q16.756,Q16,What Small molecule therapies have been approved by the FDA to treat anaplastic astrocytoma?,Everolimus is the only Small molecule therapy approved by the FDA to treat anaplastic astrocytoma.,"SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses`
- WHERE (LOWER(efo_term) = ""anaplastic astrocytoma"" OR LOWER(mesh_heading) = ""anaplastic astrocytoma"") AND LOWER(drugType) = ""small molecule"" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_1084960', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085095', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085230', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085365', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085500', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085635', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085770', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085905', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086040', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086175', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086310', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086445', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086580', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086715', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086850', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086985', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087120', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087255', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087390', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087525', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087660', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087795', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087930', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088065', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088200', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088335', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088470', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088605', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088740', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088875', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089010', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089145', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089280', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089415', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089550', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089685', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089820', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089955', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1090090', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1090225', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1090360', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1090495', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}, {'UUID': 'DrugTargetsIndication121923_text_1090630', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Astrocytoma', 'efo_term': 'anaplastic astrocytoma'}]",refined,"Distinct, Multi-Filter, Similarity Search",Approval Status
-Q40.1861,Q40,"Are there any specific alleles within the gene RNF222 associated with increased susceptibility to developing Progressive supranuclear palsy, as determined by significant SMR analysis?","No, based on the Whole Brain and Whole Blood samples tested, there are no alleles within the gene RNF222 that are significantly associated with an increased susceptibility to developing Progressive supranuclear palsy.","SELECT UUID, Gene, Omic_tissue, topSNP, A1, A2, Freq, p_SMR_multi, Disease, b_SMR, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Gene = 'RNF222' AND Disease = 'PSP' AND p_SMR_multi < 2.95e-6 AND b_SMR > 0
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold","SMR Significance, Effect"
-Q40.354,Q40,"Are there any specific alleles within the gene RP11-395G23.3 associated with increased susceptibility to developing Frontotemporal Dementia, as determined by significant SMR analysis?","No, based on the Tibial Nerve, Multi Ancestry Whole Brain and Whole Blood samples tested, there are no alleles within the gene RP11-395G23.3 that are significantly associated with an increased susceptibility to developing Frontotemporal Dementia.","SELECT UUID, Gene, Omic_tissue, topSNP, A1, A2, Freq, p_SMR_multi, Disease, b_SMR, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Gene = 'RP11-395G23.3' AND Disease = 'FTD' AND p_SMR_multi < 2.95e-6 AND b_SMR > 0
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold","SMR Significance, Effect"
-Q40.1334,Q40,"Are there any specific alleles within the gene MINK1 associated with increased susceptibility to developing Alzheimer's Disease, as determined by significant SMR analysis?","Yes, there is 1 allele within the gene MINK1 that is significantly associated with an increased susceptibility to developing Alzheimer's Disease:
-• rs3966782
-    • Whole Blood: Adjusted SMR multi-SNP P-value: 1.47e-06; b: 9.7087e-03","SELECT UUID, Gene, Omic_tissue, topSNP, A1, A2, Freq, p_SMR_multi, Disease, b_SMR, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Gene = 'MINK1' AND Disease = 'AD' AND p_SMR_multi < 2.95e-6 AND b_SMR > 0
- ORDER BY p_SMR_multi
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_1501910', 'Gene': 'MINK1', 'Omic_tissue': 'Whole Blood', 'topSNP': 'rs3966782', 'A1': 'C', 'A2': 'T', 'Freq': 0.371166, 'p_SMR_multi': 1.46809e-06, 'Disease': 'AD', 'b_SMR': 0.00970866, 'p_HEIDI': 0.01444606}]",refined,"Select, Order By, Multi-Filter, Threshold","SMR Significance, Effect"
-Q40.906,Q40,"Are there any specific alleles within the gene LACTB associated with increased susceptibility to developing Alzheimer's Disease, as determined by significant SMR analysis?","Yes, there are 4 alleles within the gene LACTB that are significantly associated with an increased susceptibility to developing Alzheimer's Disease:
-• rs2729779
-    • Whole Blood: Adjusted SMR multi-SNP P-value: 7.14e-08; b: 1.0206e-01
-• rs2652823
-    • Multi Ancestry Whole Brain: Adjusted SMR multi-SNP P-value: 8.32e-08; b: 6.8851e-02
-• rs1472631
-    • Skeletal Muscle: Adjusted SMR multi-SNP P-value: 3.18e-07; b: 1.2652e-01
-• rs4775633
-    • Cortex: Adjusted SMR multi-SNP P-value: 4.60e-07; b: 8.6554e-02
-","SELECT UUID, Gene, Omic_tissue, topSNP, A1, A2, Freq, p_SMR_multi, Disease, b_SMR, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Gene = 'LACTB' AND Disease = 'AD' AND p_SMR_multi < 2.95e-6 AND b_SMR > 0
- ORDER BY p_SMR_multi
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_1500801', 'Gene': 'LACTB', 'Omic_tissue': 'Whole Blood', 'topSNP': 'rs2729779', 'A1': 'T', 'A2': 'C', 'Freq': 0.269939, 'p_SMR_multi': 7.143396e-08, 'Disease': 'AD', 'b_SMR': 0.102055, 'p_HEIDI': 1.512549e-08}, {'UUID': 'NDD_SMR_genes_all_update_text_1395768', 'Gene': 'LACTB', 'Omic_tissue': 'Multi Ancestry Whole Brain', 'topSNP': 'rs2652823', 'A1': 'A', 'A2': 'T', 'Freq': 0.49591, 'p_SMR_multi': 8.319234e-08, 'Disease': 'AD', 'b_SMR': 0.0688515, 'p_HEIDI': 5.97761e-07}, {'UUID': 'NDD_SMR_genes_all_update_text_1342449', 'Gene': 'LACTB', 'Omic_tissue': 'Skeletal Muscle', 'topSNP': 'rs1472631', 'A1': 'G', 'A2': 'A', 'Freq': 0.493865, 'p_SMR_multi': 3.176604e-07, 'Disease': 'AD', 'b_SMR': 0.126524, 'p_HEIDI': 0.03690984}, {'UUID': 'NDD_SMR_genes_all_update_text_1110001', 'Gene': 'LACTB', 'Omic_tissue': 'Cortex', 'topSNP': '15:63145547:rs4775633:G_A', 'A1': 'G', 'A2': 'A', 'Freq': 0.50818, 'p_SMR_multi': 4.595053e-07, 'Disease': 'AD', 'b_SMR': 0.0865541, 'p_HEIDI': 0.001610107}]",refined,"Select, Order By, Multi-Filter, Threshold","SMR Significance, Effect"
-Q40.1290,Q40,"Are there any specific alleles within the gene PTH1R associated with increased susceptibility to developing Lewy Body Dementia, as determined by significant SMR analysis?","No, based on the Whole Brain, Whole Blood, Cortex, Frontal Cortex, Cerebellar Hemisphere, Prefrontal Cortex, Multi Ancestry Whole Brain, Hypothalamus and Cerebellum samples tested, there are no alleles within the gene PTH1R that are significantly associated with an increased susceptibility to developing Lewy Body Dementia.","SELECT UUID, Gene, Omic_tissue, topSNP, A1, A2, Freq, p_SMR_multi, Disease, b_SMR, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Gene = 'PTH1R' AND Disease = 'LBD' AND p_SMR_multi < 2.95e-6 AND b_SMR > 0
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold","SMR Significance, Effect"
-Q40.1274,Q40,"Are there any specific alleles within the gene RP11-21G15.1 associated with increased susceptibility to developing Progressive supranuclear palsy, as determined by significant SMR analysis?","No, based on the Nucleus Accumbens Basal samples tested, there are no alleles within the gene RP11-21G15.1 that are significantly associated with an increased susceptibility to developing Progressive supranuclear palsy.","SELECT UUID, Gene, Omic_tissue, topSNP, A1, A2, Freq, p_SMR_multi, Disease, b_SMR, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Gene = 'RP11-21G15.1' AND Disease = 'PSP' AND p_SMR_multi < 2.95e-6 AND b_SMR > 0
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold","SMR Significance, Effect"
-Q40.939,Q40,"Are there any specific alleles within the gene FAM118B associated with increased susceptibility to developing Frontotemporal Dementia, as determined by significant SMR analysis?","No, based on the Whole Blood samples tested, there are no alleles within the gene FAM118B that are significantly associated with an increased susceptibility to developing Frontotemporal Dementia.","SELECT UUID, Gene, Omic_tissue, topSNP, A1, A2, Freq, p_SMR_multi, Disease, b_SMR, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Gene = 'FAM118B' AND Disease = 'FTD' AND p_SMR_multi < 2.95e-6 AND b_SMR > 0
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold","SMR Significance, Effect"
-Q40.1732,Q40,"Are there any specific alleles within the gene DIPK1A associated with increased susceptibility to developing Parkinson's Disease, as determined by significant SMR analysis?","No, based on the Cerebellum and Cortex samples tested, there are no alleles within the gene DIPK1A that are significantly associated with an increased susceptibility to developing Parkinson's Disease.","SELECT UUID, Gene, Omic_tissue, topSNP, A1, A2, Freq, p_SMR_multi, Disease, b_SMR, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Gene = 'DIPK1A' AND Disease = 'PD' AND p_SMR_multi < 2.95e-6 AND b_SMR > 0
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold","SMR Significance, Effect"
-Q40.66,Q40,"Are there any specific alleles within the gene CDK5R2 associated with increased susceptibility to developing Amyotrophic Lateral Sclerosis, as determined by significant SMR analysis?","No, based on the Whole Brain samples tested, there are no alleles within the gene CDK5R2 that are significantly associated with an increased susceptibility to developing Amyotrophic Lateral Sclerosis.","SELECT UUID, Gene, Omic_tissue, topSNP, A1, A2, Freq, p_SMR_multi, Disease, b_SMR, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Gene = 'CDK5R2' AND Disease = 'ALS' AND p_SMR_multi < 2.95e-6 AND b_SMR > 0
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold","SMR Significance, Effect"
-Q40.1324,Q40,"Are there any specific alleles within the gene PRR14 associated with increased susceptibility to developing Parkinson's Disease, as determined by significant SMR analysis?","Yes, there is 1 allele within the gene PRR14 that is significantly associated with an increased susceptibility to developing Parkinson's Disease:
-• rs4616297
-    • Whole Blood: Adjusted SMR multi-SNP P-value: 1.76e-07; b: 8.1880e-01","SELECT UUID, Gene, Omic_tissue, topSNP, A1, A2, Freq, p_SMR_multi, Disease, b_SMR, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Gene = 'PRR14' AND Disease = 'PD' AND p_SMR_multi < 2.95e-6 AND b_SMR > 0
- ORDER BY p_SMR_multi
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_1563800', 'Gene': 'PRR14', 'Omic_tissue': 'Whole Blood', 'topSNP': 'rs4616297', 'A1': 'A', 'A2': 'G', 'Freq': 0.276074, 'p_SMR_multi': 1.759651e-07, 'Disease': 'PD', 'b_SMR': 0.818804, 'p_HEIDI': 0.002092658}]",refined,"Select, Order By, Multi-Filter, Threshold","SMR Significance, Effect"
-Q40.57,Q40,"Are there any specific alleles within the gene CTD-2330K9.3 associated with increased susceptibility to developing Lewy Body Dementia, as determined by significant SMR analysis?","No, based on the Whole Brain and Whole Blood samples tested, there are no alleles within the gene CTD-2330K9.3 that are significantly associated with an increased susceptibility to developing Lewy Body Dementia.","SELECT UUID, Gene, Omic_tissue, topSNP, A1, A2, Freq, p_SMR_multi, Disease, b_SMR, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Gene = 'CTD-2330K9.3' AND Disease = 'LBD' AND p_SMR_multi < 2.95e-6 AND b_SMR > 0
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold","SMR Significance, Effect"
-Q40.1293,Q40,"Are there any specific alleles within the gene OR4N5 associated with increased susceptibility to developing Frontotemporal Dementia, as determined by significant SMR analysis?","No, based on the Whole Brain and Whole Blood samples tested, there are no alleles within the gene OR4N5 that are significantly associated with an increased susceptibility to developing Frontotemporal Dementia.","SELECT UUID, Gene, Omic_tissue, topSNP, A1, A2, Freq, p_SMR_multi, Disease, b_SMR, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Gene = 'OR4N5' AND Disease = 'FTD' AND p_SMR_multi < 2.95e-6 AND b_SMR > 0
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold","SMR Significance, Effect"
-Q40.1119,Q40,"Are there any specific alleles within the gene NAA40 associated with increased susceptibility to developing Alzheimer's Disease, as determined by significant SMR analysis?","No, based on the Whole Brain and Whole Blood samples tested, there are no alleles within the gene NAA40 that are significantly associated with an increased susceptibility to developing Alzheimer's Disease.","SELECT UUID, Gene, Omic_tissue, topSNP, A1, A2, Freq, p_SMR_multi, Disease, b_SMR, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Gene = 'NAA40' AND Disease = 'AD' AND p_SMR_multi < 2.95e-6 AND b_SMR > 0
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold","SMR Significance, Effect"
-Q40.585,Q40,"Are there any specific alleles within the gene RP11-707O23.5 associated with increased susceptibility to developing Parkinson's Disease, as determined by significant SMR analysis?","Yes, there is 1 allele within the gene RP11-707O23.5 that is significantly associated with an increased susceptibility to developing Parkinson's Disease:
-• rs440778
-    • Whole Brain: Adjusted SMR multi-SNP P-value: 6.02e-12; b: 3.3142e-01","SELECT UUID, Gene, Omic_tissue, topSNP, A1, A2, Freq, p_SMR_multi, Disease, b_SMR, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Gene = 'RP11-707O23.5' AND Disease = 'PD' AND p_SMR_multi < 2.95e-6 AND b_SMR > 0
- ORDER BY p_SMR_multi
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_491082', 'Gene': 'RP11-707O23.5', 'Omic_tissue': 'Whole Brain', 'topSNP': 'rs440778', 'A1': 'G', 'A2': 'A', 'Freq': 0.236196, 'p_SMR_multi': 6.018701e-12, 'Disease': 'PD', 'b_SMR': 0.331419, 'p_HEIDI': -9999.0}]",refined,"Select, Order By, Multi-Filter, Threshold","SMR Significance, Effect"
-Q40.375,Q40,"Are there any specific alleles within the gene SERTAD2 associated with increased susceptibility to developing Alzheimer's Disease, as determined by significant SMR analysis?","No, based on the Whole Brain, Whole Blood, Tibial Nerve, Skeletal Muscle and Multi Ancestry Whole Brain samples tested, there are no alleles within the gene SERTAD2 that are significantly associated with an increased susceptibility to developing Alzheimer's Disease.","SELECT UUID, Gene, Omic_tissue, topSNP, A1, A2, Freq, p_SMR_multi, Disease, b_SMR, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Gene = 'SERTAD2' AND Disease = 'AD' AND p_SMR_multi < 2.95e-6 AND b_SMR > 0
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold","SMR Significance, Effect"
-Q40.276,Q40,"Are there any specific alleles within the gene CNMD associated with increased susceptibility to developing Parkinson's Disease, as determined by significant SMR analysis?","No, based on the Cortex samples tested, there are no alleles within the gene CNMD that are significantly associated with an increased susceptibility to developing Parkinson's Disease.","SELECT UUID, Gene, Omic_tissue, topSNP, A1, A2, Freq, p_SMR_multi, Disease, b_SMR, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Gene = 'CNMD' AND Disease = 'PD' AND p_SMR_multi < 2.95e-6 AND b_SMR > 0
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold","SMR Significance, Effect"
-Q12.1861,Q12,What other names are there for the drug Vanucizumab?,"Some additional names for Vanucizumab are RO5520985, RO-5520985, C0u97738ae, RG7221, and RG-7221.","SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%vanucizumab%"" OR LOWER(tradeNames_string) LIKE ""%vanucizumab%"" OR LOWER(drugSynonyms_string) LIKE ""%vanucizumab%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2714', 'drugName': 'Vanucizumab', 'tradeNames_string': '', 'drugSynonyms_string': 'C0u97738ae, RG-7221, RG7221, RO-5520985, RO5520985, Vanucizumab'}, {'UUID': 'DrugGeneTargets_v2_2715', 'drugName': 'Vanucizumab', 'tradeNames_string': '', 'drugSynonyms_string': 'C0u97738ae, RG-7221, RG7221, RO-5520985, RO5520985, Vanucizumab'}]",general,"Distinct, Similarity Search",Metadata
-Q12.354,Q12,What other names are there for the drug Encainide Hydrochloride?,"Some additional names for Encainide Hydrochloride are Encainide hcl, MJ-9067-1, Encainide hydrochloride, Enkaid, MJ-9067, and MJ 9067-1.","SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%encainide hydrochloride%"" OR LOWER(tradeNames_string) LIKE ""%encainide hydrochloride%"" OR LOWER(drugSynonyms_string) LIKE ""%encainide hydrochloride%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_6219', 'drugName': 'Encainide Hydrochloride', 'tradeNames_string': 'Enkaid', 'drugSynonyms_string': 'Encainide hcl, Encainide hydrochloride, MJ 9067-1, MJ-9067, MJ-9067-1'}]",general,"Distinct, Similarity Search",Metadata
-Q12.1334,Q12,What other names are there for the drug Solabegron?,The drug Solabegron has one aditional name: Gw427353.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%solabegron%"" OR LOWER(tradeNames_string) LIKE ""%solabegron%"" OR LOWER(drugSynonyms_string) LIKE ""%solabegron%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_5295', 'drugName': 'Solabegron', 'tradeNames_string': '', 'drugSynonyms_string': 'Gw427353, Solabegron'}]",general,"Distinct, Similarity Search",Metadata
-Q12.906,Q12,What other names are there for the drug Ar9281?,There are no additional names for the drug Ar9281.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%ar9281%"" OR LOWER(tradeNames_string) LIKE ""%ar9281%"" OR LOWER(drugSynonyms_string) LIKE ""%ar9281%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_572', 'drugName': 'Ar9281', 'tradeNames_string': '', 'drugSynonyms_string': 'Ar9281'}]",general,"Distinct, Similarity Search",Metadata
-Q12.1290,Q12,What other names are there for the drug Oxycodone Terephthalate?,The drug Oxycodone Terephthalate has one aditional name: Oxycodone terephthalate.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%oxycodone terephthalate%"" OR LOWER(tradeNames_string) LIKE ""%oxycodone terephthalate%"" OR LOWER(drugSynonyms_string) LIKE ""%oxycodone terephthalate%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_754', 'drugName': 'Oxycodone Terephthalate', 'tradeNames_string': '', 'drugSynonyms_string': 'Oxycodone terephthalate'}]",general,"Distinct, Similarity Search",Metadata
-Q12.1274,Q12,What other names are there for the drug Guanidine?,There are no additional names for the drug Guanidine.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%guanidine%"" OR LOWER(tradeNames_string) LIKE ""%guanidine%"" OR LOWER(drugSynonyms_string) LIKE ""%guanidine%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_5267', 'drugName': 'Iobenguane I 131', 'tradeNames_string': 'Azedra', 'drugSynonyms_string': '(131i)-mibg, 131 i-mibg, 131i-mibg, 3-iodobenzylguanidine (131i), 3-iodobenzylguanidine, i-131, I-131 metaiodobenzylguanidine, Iobenguane (131 i), Iobenguane (131i), Iobenguane i 131, Iobenguane i-131, Iobenguane, i-131, Iodine (131i) iobenguane, M131ibg, Metaiodobenzylguanidine i-131, Mibg i-131'}, {'UUID': 'DrugGeneTargets_v2_2190', 'drugName': 'Guanidine', 'tradeNames_string': '', 'drugSynonyms_string': 'Guanidine'}, {'UUID': 'DrugGeneTargets_v2_5118', 'drugName': 'Guanidine Hydrochloride', 'tradeNames_string': 'Guanidine hydrochloride', 'drugSynonyms_string': 'Guanidine HCl, Guanidine hydrochloride'}]",general,"Distinct, Similarity Search",Metadata
-Q12.939,Q12,What other names are there for the drug Eltrombopag?,Some additional names for Eltrombopag are Revolade and SB497115.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%eltrombopag%"" OR LOWER(tradeNames_string) LIKE ""%eltrombopag%"" OR LOWER(drugSynonyms_string) LIKE ""%eltrombopag%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2769', 'drugName': 'Eltrombopag Olamine', 'tradeNames_string': 'Promacta, Promacta kit', 'drugSynonyms_string': 'Eltrombopag (as olamine), Eltrombopag compd with 2-aminoethanol (1:2), Eltrombopag olamine, SB-497115-GR'}, {'UUID': 'DrugGeneTargets_v2_1104', 'drugName': 'Eltrombopag', 'tradeNames_string': 'Revolade', 'drugSynonyms_string': 'Eltrombopag, SB497115'}]",general,"Distinct, Similarity Search",Metadata
-Q12.1732,Q12,What other names are there for the drug Veltuzumab?,Some additional names for Veltuzumab are IMMU-106 and HA20.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%veltuzumab%"" OR LOWER(tradeNames_string) LIKE ""%veltuzumab%"" OR LOWER(drugSynonyms_string) LIKE ""%veltuzumab%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_4242', 'drugName': 'Veltuzumab', 'tradeNames_string': '', 'drugSynonyms_string': 'HA20, IMMU-106, Veltuzumab'}]",general,"Distinct, Similarity Search",Metadata
-Q12.66,Q12,What other names are there for the drug Pf-06263507?,There are no additional names for the drug Pf-06263507.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%pf-06263507%"" OR LOWER(tradeNames_string) LIKE ""%pf-06263507%"" OR LOWER(drugSynonyms_string) LIKE ""%pf-06263507%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_1355', 'drugName': 'Pf-06263507', 'tradeNames_string': '', 'drugSynonyms_string': 'Pf-06263507'}, {'UUID': 'DrugGeneTargets_v2_1356', 'drugName': 'Pf-06263507', 'tradeNames_string': '', 'drugSynonyms_string': 'Pf-06263507'}]",general,"Distinct, Similarity Search",Metadata
-Q12.1324,Q12,What other names are there for the drug Bms-779788?,"Some additional names for Bms-779788 are XL-014, XL-652, EXEL 04286652, BMS 788, EXEL-04286652, and XL 652.","SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%bms-779788%"" OR LOWER(tradeNames_string) LIKE ""%bms-779788%"" OR LOWER(drugSynonyms_string) LIKE ""%bms-779788%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2568', 'drugName': 'Bms-779788', 'tradeNames_string': '', 'drugSynonyms_string': 'BMS 788, Bms-779788, EXEL 04286652, EXEL-04286652, XL 652, XL-014, XL-652'}]",general,"Distinct, Similarity Search",Metadata
-Q12.57,Q12,What other names are there for the drug Abituzumab?,"Some additional names for Abituzumab are EMD 525797, DI 17E6, EMD-525797, DI17E6, ALD403, and DI-17E6.","SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%abituzumab%"" OR LOWER(tradeNames_string) LIKE ""%abituzumab%"" OR LOWER(drugSynonyms_string) LIKE ""%abituzumab%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_1965', 'drugName': 'Abituzumab', 'tradeNames_string': '', 'drugSynonyms_string': 'ALD403, Abituzumab, DI 17E6, DI-17E6, DI17E6, EMD 525797, EMD-525797'}, {'UUID': 'DrugGeneTargets_v2_1966', 'drugName': 'Abituzumab', 'tradeNames_string': '', 'drugSynonyms_string': 'ALD403, Abituzumab, DI 17E6, DI-17E6, DI17E6, EMD 525797, EMD-525797'}, {'UUID': 'DrugGeneTargets_v2_1967', 'drugName': 'Abituzumab', 'tradeNames_string': '', 'drugSynonyms_string': 'ALD403, Abituzumab, DI 17E6, DI-17E6, DI17E6, EMD 525797, EMD-525797'}, {'UUID': 'DrugGeneTargets_v2_1968', 'drugName': 'Abituzumab', 'tradeNames_string': '', 'drugSynonyms_string': 'ALD403, Abituzumab, DI 17E6, DI-17E6, DI17E6, EMD 525797, EMD-525797'}, {'UUID': 'DrugGeneTargets_v2_1969', 'drugName': 'Abituzumab', 'tradeNames_string': '', 'drugSynonyms_string': 'ALD403, Abituzumab, DI 17E6, DI-17E6, DI17E6, EMD 525797, EMD-525797'}]",general,"Distinct, Similarity Search",Metadata
-Q12.1293,Q12,What other names are there for the drug Dopamine?,"Some additional names for Dopamine are Dobutamine a, Medopa, Sinemet, A-dopamine, Parcopa, Intropin, Oxytyramine, Carbilev, and NSC-173182.","SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%dopamine%"" OR LOWER(tradeNames_string) LIKE ""%dopamine%"" OR LOWER(drugSynonyms_string) LIKE ""%dopamine%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3237', 'drugName': 'Dopamine', 'tradeNames_string': '', 'drugSynonyms_string': 'A-dopamine, Carbilev, Dobutamine a, Dopamine, Intropin, Medopa, NSC-173182, Oxytyramine, Parcopa, Sinemet'}, {'UUID': 'DrugGeneTargets_v2_4778', 'drugName': 'Dopamine Hydrochloride', 'tradeNames_string': 'Dopamin-Natterman, Dopamine hydrochloride, Dopmin, Dynatra, Intropin, Sabax Dopamin, Selectajet', 'drugSynonyms_string': 'ASL-279, Cardiosteril, Dopamine hcl, Dopamine hydrochloride, Dopamini hydrochloridum, Inotropin, NSC-169105, Tensamin'}]",general,"Distinct, Similarity Search",Metadata
-Q12.1119,Q12,What other names are there for the drug Bethanidine?,The drug Bethanidine has one aditional name: Betanidine.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%bethanidine%"" OR LOWER(tradeNames_string) LIKE ""%bethanidine%"" OR LOWER(drugSynonyms_string) LIKE ""%bethanidine%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2133', 'drugName': 'Bethanidine', 'tradeNames_string': '', 'drugSynonyms_string': 'Betanidine, Bethanidine'}, {'UUID': 'DrugGeneTargets_v2_4786', 'drugName': 'Bethanidine Sulfate', 'tradeNames_string': 'Bendogen, Esbatal, Tenathan', 'drugSynonyms_string': 'BW-467-C-60, Betanidine sulfate, Betanidine sulphate, Bethanidine sulfate, Bethanidine sulphate, NSC-106563'}]",general,"Distinct, Similarity Search",Metadata
-Q12.585,Q12,What other names are there for the drug Conbercept?,The drug Conbercept has one aditional name: KH-902.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%conbercept%"" OR LOWER(tradeNames_string) LIKE ""%conbercept%"" OR LOWER(drugSynonyms_string) LIKE ""%conbercept%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_4610', 'drugName': 'Conbercept', 'tradeNames_string': '', 'drugSynonyms_string': 'Conbercept, KH-902'}, {'UUID': 'DrugGeneTargets_v2_4611', 'drugName': 'Conbercept', 'tradeNames_string': '', 'drugSynonyms_string': 'Conbercept, KH-902'}, {'UUID': 'DrugGeneTargets_v2_4612', 'drugName': 'Conbercept', 'tradeNames_string': '', 'drugSynonyms_string': 'Conbercept, KH-902'}, {'UUID': 'DrugGeneTargets_v2_4613', 'drugName': 'Conbercept', 'tradeNames_string': '', 'drugSynonyms_string': 'Conbercept, KH-902'}]",general,"Distinct, Similarity Search",Metadata
-Q12.375,Q12,What other names are there for the drug Rosmantuzumab?,The drug Rosmantuzumab has one aditional name: OMP-131R10.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%rosmantuzumab%"" OR LOWER(tradeNames_string) LIKE ""%rosmantuzumab%"" OR LOWER(drugSynonyms_string) LIKE ""%rosmantuzumab%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_5619', 'drugName': 'Rosmantuzumab', 'tradeNames_string': '', 'drugSynonyms_string': 'OMP-131R10, Rosmantuzumab'}]",general,"Distinct, Similarity Search",Metadata
-Q12.276,Q12,What other names are there for the drug Cafusertib?,There are no additional names for the drug Cafusertib.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%cafusertib%"" OR LOWER(tradeNames_string) LIKE ""%cafusertib%"" OR LOWER(drugSynonyms_string) LIKE ""%cafusertib%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2649', 'drugName': 'Cafusertib', 'tradeNames_string': '', 'drugSynonyms_string': 'Cafusertib'}]",general,"Distinct, Similarity Search",Metadata
-Q23.1861,Q23,Is there a black box warning for the drug Pranlukast?,"No, the drug Pranlukast does not have a black box warning from the FDA.","SELECT DISTINCT UUID, drugName, blackBoxWarning
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%pranlukast%"" OR LOWER(tradeNames_string) LIKE ""%pranlukast%"" OR LOWER(drugSynonyms_string) LIKE ""%pranlukast%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2311', 'drugName': 'Pranlukast', 'blackBoxWarning': False}]",general,"Distinct, Similarity Search",Metadata
-Q23.354,Q23,Is there a black box warning for the drug Ozoralizumab?,"No, the drug Ozoralizumab does not have a black box warning from the FDA.","SELECT DISTINCT UUID, drugName, blackBoxWarning
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%ozoralizumab%"" OR LOWER(tradeNames_string) LIKE ""%ozoralizumab%"" OR LOWER(drugSynonyms_string) LIKE ""%ozoralizumab%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_5268', 'drugName': 'Ozoralizumab', 'blackBoxWarning': False}]",general,"Distinct, Similarity Search",Metadata
-Q23.1334,Q23,Is there a black box warning for the drug Vinorelbine?,"Yes, the drug Vinorelbine has a black box warning from the FDA.","SELECT DISTINCT UUID, drugName, blackBoxWarning
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%vinorelbine%"" OR LOWER(tradeNames_string) LIKE ""%vinorelbine%"" OR LOWER(drugSynonyms_string) LIKE ""%vinorelbine%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_6364', 'drugName': 'Vinorelbine Tartrate', 'blackBoxWarning': True}, {'UUID': 'DrugGeneTargets_v2_2330', 'drugName': 'Vinorelbine', 'blackBoxWarning': True}]",general,"Distinct, Similarity Search",Metadata
-Q23.906,Q23,Is there a black box warning for the drug Carotuximab?,"No, the drug Carotuximab does not have a black box warning from the FDA.","SELECT DISTINCT UUID, drugName, blackBoxWarning
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%carotuximab%"" OR LOWER(tradeNames_string) LIKE ""%carotuximab%"" OR LOWER(drugSynonyms_string) LIKE ""%carotuximab%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_330', 'drugName': 'Carotuximab', 'blackBoxWarning': False}]",general,"Distinct, Similarity Search",Metadata
-Q23.1290,Q23,Is there a black box warning for the drug Lomitapide?,"Yes, the drug Lomitapide has a black box warning from the FDA.","SELECT DISTINCT UUID, drugName, blackBoxWarning
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%lomitapide%"" OR LOWER(tradeNames_string) LIKE ""%lomitapide%"" OR LOWER(drugSynonyms_string) LIKE ""%lomitapide%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3058', 'drugName': 'Lomitapide Mesylate', 'blackBoxWarning': True}, {'UUID': 'DrugGeneTargets_v2_476', 'drugName': 'Lomitapide', 'blackBoxWarning': True}]",general,"Distinct, Similarity Search",Metadata
-Q23.1274,Q23,Is there a black box warning for the drug Azd2066?,"No, the drug Azd2066 does not have a black box warning from the FDA.","SELECT DISTINCT UUID, drugName, blackBoxWarning
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%azd2066%"" OR LOWER(tradeNames_string) LIKE ""%azd2066%"" OR LOWER(drugSynonyms_string) LIKE ""%azd2066%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2800', 'drugName': 'Azd2066', 'blackBoxWarning': False}]",general,"Distinct, Similarity Search",Metadata
-Q23.939,Q23,Is there a black box warning for the drug Pentazocine Lactate?,"Yes, the drug Pentazocine Lactate has a black box warning from the FDA.","SELECT DISTINCT UUID, drugName, blackBoxWarning
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%pentazocine lactate%"" OR LOWER(tradeNames_string) LIKE ""%pentazocine lactate%"" OR LOWER(drugSynonyms_string) LIKE ""%pentazocine lactate%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_652', 'drugName': 'Pentazocine Lactate', 'blackBoxWarning': True}]",general,"Distinct, Similarity Search",Metadata
-Q23.1732,Q23,Is there a black box warning for the drug Meperidine Hydrochloride?,"Yes, the drug Meperidine Hydrochloride has a black box warning from the FDA.","SELECT DISTINCT UUID, drugName, blackBoxWarning
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%meperidine hydrochloride%"" OR LOWER(tradeNames_string) LIKE ""%meperidine hydrochloride%"" OR LOWER(drugSynonyms_string) LIKE ""%meperidine hydrochloride%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_497', 'drugName': 'Meperidine Hydrochloride', 'blackBoxWarning': True}]",general,"Distinct, Similarity Search",Metadata
-Q23.66,Q23,Is there a black box warning for the drug Cyclopentolate?,"No, the drug Cyclopentolate does not have a black box warning from the FDA.","SELECT DISTINCT UUID, drugName, blackBoxWarning
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%cyclopentolate%"" OR LOWER(tradeNames_string) LIKE ""%cyclopentolate%"" OR LOWER(drugSynonyms_string) LIKE ""%cyclopentolate%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_5172', 'drugName': 'Cyclopentolate', 'blackBoxWarning': False}, {'UUID': 'DrugGeneTargets_v2_6338', 'drugName': 'Cyclopentolate Hydrochloride', 'blackBoxWarning': False}]",general,"Distinct, Similarity Search",Metadata
-Q23.1324,Q23,Is there a black box warning for the drug Temanogrel?,"No, the drug Temanogrel does not have a black box warning from the FDA.","SELECT DISTINCT UUID, drugName, blackBoxWarning
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%temanogrel%"" OR LOWER(tradeNames_string) LIKE ""%temanogrel%"" OR LOWER(drugSynonyms_string) LIKE ""%temanogrel%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_1195', 'drugName': 'Temanogrel', 'blackBoxWarning': False}]",general,"Distinct, Similarity Search",Metadata
-Q23.57,Q23,Is there a black box warning for the drug Ieramilimab?,"No, the drug Ieramilimab does not have a black box warning from the FDA.","SELECT DISTINCT UUID, drugName, blackBoxWarning
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%ieramilimab%"" OR LOWER(tradeNames_string) LIKE ""%ieramilimab%"" OR LOWER(drugSynonyms_string) LIKE ""%ieramilimab%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_1744', 'drugName': 'Ieramilimab', 'blackBoxWarning': False}]",general,"Distinct, Similarity Search",Metadata
-Q23.1293,Q23,Is there a black box warning for the drug Cobitolimod?,"No, the drug Cobitolimod does not have a black box warning from the FDA.","SELECT DISTINCT UUID, drugName, blackBoxWarning
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%cobitolimod%"" OR LOWER(tradeNames_string) LIKE ""%cobitolimod%"" OR LOWER(drugSynonyms_string) LIKE ""%cobitolimod%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2420', 'drugName': 'Cobitolimod', 'blackBoxWarning': False}]",general,"Distinct, Similarity Search",Metadata
-Q23.1119,Q23,Is there a black box warning for the drug Ketorolac Tromethamine?,"Yes, the drug Ketorolac Tromethamine has a black box warning from the FDA.","SELECT DISTINCT UUID, drugName, blackBoxWarning
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%ketorolac tromethamine%"" OR LOWER(tradeNames_string) LIKE ""%ketorolac tromethamine%"" OR LOWER(drugSynonyms_string) LIKE ""%ketorolac tromethamine%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2258', 'drugName': 'Ketorolac Tromethamine', 'blackBoxWarning': True}]",general,"Distinct, Similarity Search",Metadata
-Q23.585,Q23,Is there a black box warning for the drug Thyrotropin Alfa?,"No, the drug Thyrotropin Alfa does not have a black box warning from the FDA.","SELECT DISTINCT UUID, drugName, blackBoxWarning
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%thyrotropin alfa%"" OR LOWER(tradeNames_string) LIKE ""%thyrotropin alfa%"" OR LOWER(drugSynonyms_string) LIKE ""%thyrotropin alfa%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2659', 'drugName': 'Thyrotropin Alfa', 'blackBoxWarning': False}]",general,"Distinct, Similarity Search",Metadata
-Q23.375,Q23,Is there a black box warning for the drug Nly-01?,"No, the drug Nly-01 does not have a black box warning from the FDA.","SELECT DISTINCT UUID, drugName, blackBoxWarning
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%nly-01%"" OR LOWER(tradeNames_string) LIKE ""%nly-01%"" OR LOWER(drugSynonyms_string) LIKE ""%nly-01%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_1361', 'drugName': 'Nly-01', 'blackBoxWarning': False}]",general,"Distinct, Similarity Search",Metadata
-Q23.276,Q23,Is there a black box warning for the drug Diltiazem Malate?,"No, the drug Diltiazem Malate does not have a black box warning from the FDA.","SELECT DISTINCT UUID, drugName, blackBoxWarning
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%diltiazem malate%"" OR LOWER(tradeNames_string) LIKE ""%diltiazem malate%"" OR LOWER(drugSynonyms_string) LIKE ""%diltiazem malate%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3324', 'drugName': 'Diltiazem Malate', 'blackBoxWarning': False}]",general,"Distinct, Similarity Search",Metadata
-Q45.1861,Q45,Is there an association between LINC02605 and Parkinson's disease?,"No, there is no significant association between LINC02605 and PD according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019).","SELECT UUID, SNP, p, b, nearestGene 
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE nearestGene LIKE '%LINC02605%' AND p<5e-8
- ORDER BY p
- LIMIT 100",[],refined,"Select, Similarity Search, Threshold, Order By",GWAS Significance
-Q45.354,Q45,Is there an association between PCYOX1L and Parkinson's disease?,"No, there is no significant association between PCYOX1L and PD according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019).","SELECT UUID, SNP, p, b, nearestGene 
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE nearestGene LIKE '%PCYOX1L%' AND p<5e-8
- ORDER BY p
- LIMIT 100",[],refined,"Select, Similarity Search, Threshold, Order By",GWAS Significance
-Q45.1334,Q45,Is there an association between MINAR2 and Parkinson's disease?,"No, there is no significant association between MINAR2 and PD according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019).","SELECT UUID, SNP, p, b, nearestGene 
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE nearestGene LIKE '%MINAR2%' AND p<5e-8
- ORDER BY p
- LIMIT 100",[],refined,"Select, Similarity Search, Threshold, Order By",GWAS Significance
-Q45.906,Q45,Is there an association between STATH and Parkinson's disease?,"No, there is no significant association between STATH and PD according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019).","SELECT UUID, SNP, p, b, nearestGene 
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE nearestGene LIKE '%STATH%' AND p<5e-8
- ORDER BY p
- LIMIT 100",[],refined,"Select, Similarity Search, Threshold, Order By",GWAS Significance
-Q45.1290,Q45,Is there an association between SPATA46 and Parkinson's disease?,"No, there is no significant association between SPATA46 and PD according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019).","SELECT UUID, SNP, p, b, nearestGene 
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE nearestGene LIKE '%SPATA46%' AND p<5e-8
- ORDER BY p
- LIMIT 100",[],refined,"Select, Similarity Search, Threshold, Order By",GWAS Significance
-Q45.1274,Q45,Is there an association between LINC01039 and Parkinson's disease?,"No, there is no significant association between LINC01039 and PD according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019).","SELECT UUID, SNP, p, b, nearestGene 
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE nearestGene LIKE '%LINC01039%' AND p<5e-8
- ORDER BY p
- LIMIT 100",[],refined,"Select, Similarity Search, Threshold, Order By",GWAS Significance
-Q45.939,Q45,Is there an association between ADGRL3-AS1 and Parkinson's disease?,"No, there is no significant association between ADGRL3-AS1 and PD according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019).","SELECT UUID, SNP, p, b, nearestGene 
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE nearestGene LIKE '%ADGRL3-AS1%' AND p<5e-8
- ORDER BY p
- LIMIT 100",[],refined,"Select, Similarity Search, Threshold, Order By",GWAS Significance
-Q45.1732,Q45,Is there an association between GSN and Parkinson's disease?,"No, there is no significant association between GSN and PD according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019).","SELECT UUID, SNP, p, b, nearestGene 
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE nearestGene LIKE '%GSN%' AND p<5e-8
- ORDER BY p
- LIMIT 100",[],refined,"Select, Similarity Search, Threshold, Order By",GWAS Significance
-Q45.66,Q45,Is there an association between SLC45A3 and Parkinson's disease?,"Yes, there are 9 significant SNP associations between SLC45A3 and PD, according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019): rs823106: (GWAS P-value: 4.10e-10; b value: 1.4920e-01), rs2153904: (GWAS P-value: 4.45e-10; b value: 1.4590e-01), rs4951254: (GWAS P-value: 8.47e-10; b value: 1.4110e-01), rs12132270: (GWAS P-value: 1.37e-09; b value: 1.4330e-01), rs12118655: (GWAS P-value: 1.42e-09; b value: 1.4280e-01), rs3747972: (GWAS P-value: 2.58e-09; b value: 1.4300e-01), rs1418549: (GWAS P-value: 3.27e-09; b value: 1.3500e-01), rs12748961: (GWAS P-value: 4.82e-09; b value: 1.3970e-01), rs1891091: (GWAS P-value: 6.42e-09; b value: 1.4900e-01).","SELECT UUID, SNP, p, b, nearestGene 
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE nearestGene LIKE '%SLC45A3%' AND p<5e-8
- ORDER BY p
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_4684582', 'SNP': 'rs823106', 'p': 4.1e-10, 'b': 0.1492, 'nearestGene': 'SLC45A3;NUCKS1'}, {'UUID': 'PDno23andme_full_gene_notext_6050237', 'SNP': 'rs2153904', 'p': 4.453e-10, 'b': 0.1459, 'nearestGene': 'SLC45A3'}, {'UUID': 'PDno23andme_full_gene_notext_6369585', 'SNP': 'rs4951254', 'p': 8.468e-10, 'b': 0.1411, 'nearestGene': 'SLC45A3'}, {'UUID': 'PDno23andme_full_gene_notext_2032677', 'SNP': 'rs12132270', 'p': 1.373e-09, 'b': 0.1433, 'nearestGene': 'SLC45A3;NUCKS1'}, {'UUID': 'PDno23andme_full_gene_notext_1802666', 'SNP': 'rs12118655', 'p': 1.416e-09, 'b': 0.1428, 'nearestGene': 'SLC45A3;NUCKS1'}, {'UUID': 'PDno23andme_full_gene_notext_818212', 'SNP': 'rs3747972', 'p': 2.581e-09, 'b': 0.143, 'nearestGene': 'SLC45A3;NUCKS1'}, {'UUID': 'PDno23andme_full_gene_notext_200936', 'SNP': 'rs1418549', 'p': 3.273e-09, 'b': 0.135, 'nearestGene': 'SLC45A3'}, {'UUID': 'PDno23andme_full_gene_notext_2904209', 'SNP': 'rs12748961', 'p': 4.818e-09, 'b': 0.1397, 'nearestGene': 'SLC45A3;NUCKS1'}, {'UUID': 'PDno23andme_full_gene_notext_841341', 'SNP': 'rs1891091', 'p': 6.417e-09, 'b': 0.149, 'nearestGene': 'SLC45A3;NUCKS1'}]",refined,"Select, Similarity Search, Threshold, Order By",GWAS Significance
-Q45.1324,Q45,Is there an association between RESF1 and Parkinson's disease?,"No, there is no significant association between RESF1 and PD according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019).","SELECT UUID, SNP, p, b, nearestGene 
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE nearestGene LIKE '%RESF1%' AND p<5e-8
- ORDER BY p
- LIMIT 100",[],refined,"Select, Similarity Search, Threshold, Order By",GWAS Significance
-Q45.57,Q45,Is there an association between RAB25 and Parkinson's disease?,"Yes, there is 1 significant association between RAB25 and PD, according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019): rs34372695: (GWAS P-value: 2.53e-12; b value: 3.9990e-01).","SELECT UUID, SNP, p, b, nearestGene 
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE nearestGene LIKE '%RAB25%' AND p<5e-8
- ORDER BY p
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_6820677', 'SNP': 'rs34372695', 'p': 2.533e-12, 'b': 0.3999, 'nearestGene': 'RAB25'}]",refined,"Select, Similarity Search, Threshold, Order By",GWAS Significance
-Q45.1293,Q45,Is there an association between H3C1 and Parkinson's disease?,"No, there is no significant association between H3C1 and PD according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019).","SELECT UUID, SNP, p, b, nearestGene 
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE nearestGene LIKE '%H3C1%' AND p<5e-8
- ORDER BY p
- LIMIT 100",[],refined,"Select, Similarity Search, Threshold, Order By",GWAS Significance
-Q45.1119,Q45,Is there an association between LINC02014 and Parkinson's disease?,"No, there is no significant association between LINC02014 and PD according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019).","SELECT UUID, SNP, p, b, nearestGene 
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE nearestGene LIKE '%LINC02014%' AND p<5e-8
- ORDER BY p
- LIMIT 100",[],refined,"Select, Similarity Search, Threshold, Order By",GWAS Significance
-Q45.585,Q45,Is there an association between NSMAF and Parkinson's disease?,"No, there is no significant association between NSMAF and PD according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019).","SELECT UUID, SNP, p, b, nearestGene 
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE nearestGene LIKE '%NSMAF%' AND p<5e-8
- ORDER BY p
- LIMIT 100",[],refined,"Select, Similarity Search, Threshold, Order By",GWAS Significance
-Q45.375,Q45,Is there an association between KLHL9 and Parkinson's disease?,"No, there is no significant association between KLHL9 and PD according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019).","SELECT UUID, SNP, p, b, nearestGene 
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE nearestGene LIKE '%KLHL9%' AND p<5e-8
- ORDER BY p
- LIMIT 100",[],refined,"Select, Similarity Search, Threshold, Order By",GWAS Significance
-Q45.276,Q45,Is there an association between NKILA and Parkinson's disease?,"No, there is no significant association between NKILA and PD according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019).","SELECT UUID, SNP, p, b, nearestGene 
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE nearestGene LIKE '%NKILA%' AND p<5e-8
- ORDER BY p
- LIMIT 100",[],refined,"Select, Similarity Search, Threshold, Order By",GWAS Significance
-Q17.1861,Q17,What gene does the drug F19 131I target?,"The drug F19 131I is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene FAP.","SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%f19 131i%"" OR LOWER(tradeNames_string) LIKE ""%f19 131i%"" OR LOWER(drugSynonyms_string) LIKE ""%f19 131i%"")
- ORDER  BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_331', 'drugName': 'F19 131I', 'tradeNames_string': '', 'drugSynonyms_string': 'BIBH-1, F19, F19 131i', 'linkedDiseasesDrug_string': 'Colorectal Carcinoma (EFO_1001951)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'FAP (ENSG00000078098)', 'numberLinkedTargets': 1}]",general,"Distinct, Similarity Search, Order By","Genetic Target, Approval Status"
-Q17.354,Q17,What gene does the drug Epitumomab target?,"The drug Epitumomab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene MUC1.","SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%epitumomab%"" OR LOWER(tradeNames_string) LIKE ""%epitumomab%"" OR LOWER(drugSynonyms_string) LIKE ""%epitumomab%"")
- ORDER  BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_781', 'drugName': 'Epitumomab Cituxetan', 'tradeNames_string': '', 'drugSynonyms_string': 'Epitumomab cituxetan, Hmfg 1', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'MUC1 (ENSG00000185499)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1824', 'drugName': 'Epitumomab', 'tradeNames_string': '', 'drugSynonyms_string': 'Epitumomab', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'MUC1 (ENSG00000185499)', 'numberLinkedTargets': 1}]",general,"Distinct, Similarity Search, Order By","Genetic Target, Approval Status"
-Q17.1334,Q17,What gene does the drug Cevimeline target?,The drug Cevimeline targets 2 genes: CHRM1 and CHRM3.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%cevimeline%"" OR LOWER(tradeNames_string) LIKE ""%cevimeline%"" OR LOWER(drugSynonyms_string) LIKE ""%cevimeline%"")
- ORDER  BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2497', 'drugName': 'Cevimeline', 'tradeNames_string': '', 'drugSynonyms_string': 'Cevimeline', 'linkedDiseasesDrug_string': 'Xerostomia (EFO_0009869)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2496', 'drugName': 'Cevimeline', 'tradeNames_string': '', 'drugSynonyms_string': 'Cevimeline', 'linkedDiseasesDrug_string': 'Xerostomia (EFO_0009869)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3774', 'drugName': 'Cevimeline Hydrochloride', 'tradeNames_string': 'Cevimeline, Cevimeline hydrochloride, Evoxac', 'drugSynonyms_string': 'AF-102B, AF102B, Cevimeline hcl, Cevimeline hydrochloride, Cevimeline hydrochloride hemihydrate, Cevimeline hydrochloride hydrate, FKS-508, SND-5008, SNI-2011, SNK-508, Saligren', 'linkedDiseasesDrug_string': 'Xerostomia (EFO_0009869)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3773', 'drugName': 'Cevimeline Hydrochloride', 'tradeNames_string': 'Cevimeline, Cevimeline hydrochloride, Evoxac', 'drugSynonyms_string': 'AF-102B, AF102B, Cevimeline hcl, Cevimeline hydrochloride, Cevimeline hydrochloride hemihydrate, Cevimeline hydrochloride hydrate, FKS-508, SND-5008, SNI-2011, SNK-508, Saligren', 'linkedDiseasesDrug_string': 'Xerostomia (EFO_0009869)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}]",general,"Distinct, Similarity Search, Order By","Genetic Target, Approval Status"
-Q17.906,Q17,What gene does the drug Pf-04531083 target?,"The drug Pf-04531083 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene SCN10A.","SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%pf-04531083%"" OR LOWER(tradeNames_string) LIKE ""%pf-04531083%"" OR LOWER(drugSynonyms_string) LIKE ""%pf-04531083%"")
- ORDER  BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2440', 'drugName': 'Pf-04531083', 'tradeNames_string': '', 'drugSynonyms_string': 'PF-4531083, Pf-04531083', 'linkedDiseasesDrug_string': 'Toothache (EFO_0010072), Chronic Pain (HP_0012532)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'SCN10A (ENSG00000185313)', 'numberLinkedTargets': 1}]",general,"Distinct, Similarity Search, Order By","Genetic Target, Approval Status"
-Q17.1290,Q17,What gene does the drug Oprelvekin target?,The drug Oprelvekin targets the gene IL11RA.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%oprelvekin%"" OR LOWER(tradeNames_string) LIKE ""%oprelvekin%"" OR LOWER(drugSynonyms_string) LIKE ""%oprelvekin%"")
- ORDER  BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2215', 'drugName': 'Oprelvekin', 'tradeNames_string': 'Neumega', 'drugSynonyms_string': 'Interleukin-11 (2-178), Oprelvekin', 'linkedDiseasesDrug_string': 'Thrombocytopenia (HP_0001873), Follicular Lymphoma (MONDO_0018906), Chronic Lymphocytic Leukemia (EFO_0000095), Neoplasm (EFO_0000616), Hemophilia A (MONDO_0010602), Von Willebrand Disease (Orphanet_903), Waldenstrom Macroglobulinemia (EFO_0009441), Malt Lymphoma (EFO_0000191), Chronic Myelogenous Leukemia (EFO_0000339)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IL11RA (ENSG00000137070)', 'numberLinkedTargets': 1}]",general,"Distinct, Similarity Search, Order By","Genetic Target, Approval Status"
-Q17.1274,Q17,What gene does the drug Dersimelagon target?,"The drug Dersimelagon is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene MC1R.","SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%dersimelagon%"" OR LOWER(tradeNames_string) LIKE ""%dersimelagon%"" OR LOWER(drugSynonyms_string) LIKE ""%dersimelagon%"")
- ORDER  BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_935', 'drugName': 'Dersimelagon', 'tradeNames_string': '', 'drugSynonyms_string': 'Dersimelagon, MT-7117, Mt-7117', 'linkedDiseasesDrug_string': 'Kidney Disease (EFO_0003086), Liver Disease (EFO_0001421), Erythropoietic Protoporphyria (MONDO_0001676), Diffuse Scleroderma (EFO_0000404)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'MC1R (ENSG00000258839)', 'numberLinkedTargets': 1}]",general,"Distinct, Similarity Search, Order By","Genetic Target, Approval Status"
-Q17.939,Q17,What gene does the drug Rivastigmine target?,The drug Rivastigmine targets 2 genes: ACHE and BCHE.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%rivastigmine%"" OR LOWER(tradeNames_string) LIKE ""%rivastigmine%"" OR LOWER(drugSynonyms_string) LIKE ""%rivastigmine%"")
- ORDER  BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_486', 'drugName': 'Rivastigmine', 'tradeNames_string': 'Alzest, Eluden, Erastig, Exelon, Kerstipon, Nimvastid, Prometax, Rivastigmine, Somniton, Voleze', 'drugSynonyms_string': 'ENA-713, ENA-713D, ONO-2540, Rivastigmine, Rivastigmine hexal, Rivastigmine sandoz, Rivastigmine teva, SDZ-212-713, SDZ-212713, SDZ-ENA-713', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Methamphetamine Dependence (EFO_0004701), Orthostatic Hypotension (EFO_0005252), Drug Dependence (EFO_0003890), Substance Abuse (MONDO_0002491), Cognitive Impairment (HP_0100543), Neurobehavioral Manifestations (EFO_0004364), Down Syndrome (EFO_0001064), Delirium (EFO_0009267), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Progressive Supranuclear Palsy (MONDO_0019037), Cocaine Dependence (EFO_0002610), Brain Injury (MONDO_0043510), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090), Vascular Dementia (EFO_0004718)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'BCHE (ENSG00000114200), ACHE (ENSG00000087085)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1705', 'drugName': 'Rivastigmine Tartrate', 'tradeNames_string': 'Exelon, Rivastigmine tartrate', 'drugSynonyms_string': 'ENA 713, Rivastigmine Tartrate, Rivastigmine actavis, Rivastigmine bitartrate, Rivastigmine hydrogen tartrate, Rivastigmine hydrogentartrate, Rivastigmine tartrate, Sdz-ena 713', 'linkedDiseasesDrug_string': 'Orthostatic Hypotension (EFO_0005252), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'BCHE (ENSG00000114200), ACHE (ENSG00000087085)', 'numberLinkedTargets': 2}]",general,"Distinct, Similarity Search, Order By","Genetic Target, Approval Status"
-Q17.1732,Q17,What gene does the drug Icatibant Acetate target?,The drug Icatibant Acetate targets the gene BDKRB2.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%icatibant acetate%"" OR LOWER(tradeNames_string) LIKE ""%icatibant acetate%"" OR LOWER(drugSynonyms_string) LIKE ""%icatibant acetate%"")
- ORDER  BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_226', 'drugName': 'Icatibant Acetate', 'tradeNames_string': 'Firazyr', 'drugSynonyms_string': 'HOE 140, HOE-140, Icatibant acetate', 'linkedDiseasesDrug_string': 'Angioedema (EFO_0005532), Hereditary Angioedema (MONDO_0019623), Inflammation (MP_0001845), Covid-19 (MONDO_0100096)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'BDKRB2 (ENSG00000168398)', 'numberLinkedTargets': 1}]",general,"Distinct, Similarity Search, Order By","Genetic Target, Approval Status"
-Q17.66,Q17,What gene does the drug Azd-1080 target?,"The drug Azd-1080 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: GSK3B and GSK3A","SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%azd-1080%"" OR LOWER(tradeNames_string) LIKE ""%azd-1080%"" OR LOWER(drugSynonyms_string) LIKE ""%azd-1080%"")
- ORDER  BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_815', 'drugName': 'Azd-1080', 'tradeNames_string': '', 'drugSynonyms_string': 'AZ-11548415, AZD-1080, Azd-1080', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'GSK3A (ENSG00000105723), GSK3B (ENSG00000082701)', 'numberLinkedTargets': 2}]",general,"Distinct, Similarity Search, Order By","Genetic Target, Approval Status"
-Q17.1324,Q17,What gene does the drug Avutometinib target?,"The drug Avutometinib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: MAP2K2 and MAP2K1","SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%avutometinib%"" OR LOWER(tradeNames_string) LIKE ""%avutometinib%"" OR LOWER(drugSynonyms_string) LIKE ""%avutometinib%"")
- ORDER  BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2766', 'drugName': 'Avutometinib', 'tradeNames_string': '', 'drugSynonyms_string': 'Avutometinib, CH-5126766, CH5126766, CKI-27, R-7304, RG-7304, Rg-7304, Ro 5126766, Ro-5126766, VS-6766', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'MAP2K1 (ENSG00000169032), MAP2K2 (ENSG00000126934)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2767', 'drugName': 'Avutometinib', 'tradeNames_string': '', 'drugSynonyms_string': 'Avutometinib, CH-5126766, CH5126766, CKI-27, R-7304, RG-7304, Rg-7304, Ro 5126766, Ro-5126766, VS-6766', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'MAP2K1 (ENSG00000169032), MAP2K2 (ENSG00000126934)', 'numberLinkedTargets': 2}]",general,"Distinct, Similarity Search, Order By","Genetic Target, Approval Status"
-Q17.57,Q17,What gene does the drug Spirapril target?,The drug Spirapril targets the gene ACE.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%spirapril%"" OR LOWER(tradeNames_string) LIKE ""%spirapril%"" OR LOWER(drugSynonyms_string) LIKE ""%spirapril%"")
- ORDER  BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2773', 'drugName': 'Spirapril', 'tradeNames_string': '', 'drugSynonyms_string': 'Spirapril', 'linkedDiseasesDrug_string': 'Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 1994, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACE (ENSG00000159640)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4466', 'drugName': 'Spirapril Hydrochloride', 'tradeNames_string': 'Renormax', 'drugSynonyms_string': 'SCH 33844, SCH-33844, Spirapril hcl, Spirapril hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1994, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACE (ENSG00000159640)', 'numberLinkedTargets': 1}]",general,"Distinct, Similarity Search, Order By","Genetic Target, Approval Status"
-Q17.1293,Q17,What gene does the drug Crizotinib target?,"The drug Crizotinib targets 4 genes: NPM1, EML4, MET and ALK.","SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%crizotinib%"" OR LOWER(tradeNames_string) LIKE ""%crizotinib%"" OR LOWER(drugSynonyms_string) LIKE ""%crizotinib%"")
- ORDER  BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_5879', 'drugName': 'Crizotinib', 'tradeNames_string': 'Xalkori', 'drugSynonyms_string': 'Crizotinib, NSC-756645, PF-02341066, PF-2341066, Pf-2341066', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Anaplastic Large Cell Lymphoma (EFO_0003032), Colorectal Carcinoma (EFO_1001951), Endometrial Cancer (MONDO_0011962), Gastric Cancer (MONDO_0001056), Papillary Renal Cell Carcinoma (EFO_0000640), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Lung Adenocarcinoma (EFO_0000571), Inflammatory Myofibroblastic Tumor (MONDO_0015798), Neurofibromatosis Type 2 (MONDO_0007039), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Adenocarcinoma (EFO_0000228), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Disease (EFO_0003086), Glioblastoma Multiforme (EFO_0000519)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MET (ENSG00000105976), ALK (ENSG00000171094), NPM1 (ENSG00000181163), EML4 (ENSG00000143924)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_5878', 'drugName': 'Crizotinib', 'tradeNames_string': 'Xalkori', 'drugSynonyms_string': 'Crizotinib, NSC-756645, PF-02341066, PF-2341066, Pf-2341066', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Anaplastic Large Cell Lymphoma (EFO_0003032), Colorectal Carcinoma (EFO_1001951), Endometrial Cancer (MONDO_0011962), Gastric Cancer (MONDO_0001056), Papillary Renal Cell Carcinoma (EFO_0000640), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Lung Adenocarcinoma (EFO_0000571), Inflammatory Myofibroblastic Tumor (MONDO_0015798), Neurofibromatosis Type 2 (MONDO_0007039), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Adenocarcinoma (EFO_0000228), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Disease (EFO_0003086), Glioblastoma Multiforme (EFO_0000519)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MET (ENSG00000105976), ALK (ENSG00000171094), NPM1 (ENSG00000181163), EML4 (ENSG00000143924)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_5881', 'drugName': 'Crizotinib', 'tradeNames_string': 'Xalkori', 'drugSynonyms_string': 'Crizotinib, NSC-756645, PF-02341066, PF-2341066, Pf-2341066', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Anaplastic Large Cell Lymphoma (EFO_0003032), Colorectal Carcinoma (EFO_1001951), Endometrial Cancer (MONDO_0011962), Gastric Cancer (MONDO_0001056), Papillary Renal Cell Carcinoma (EFO_0000640), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Lung Adenocarcinoma (EFO_0000571), Inflammatory Myofibroblastic Tumor (MONDO_0015798), Neurofibromatosis Type 2 (MONDO_0007039), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Adenocarcinoma (EFO_0000228), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Disease (EFO_0003086), Glioblastoma Multiforme (EFO_0000519)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MET (ENSG00000105976), ALK (ENSG00000171094), NPM1 (ENSG00000181163), EML4 (ENSG00000143924)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_5880', 'drugName': 'Crizotinib', 'tradeNames_string': 'Xalkori', 'drugSynonyms_string': 'Crizotinib, NSC-756645, PF-02341066, PF-2341066, Pf-2341066', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Anaplastic Large Cell Lymphoma (EFO_0003032), Colorectal Carcinoma (EFO_1001951), Endometrial Cancer (MONDO_0011962), Gastric Cancer (MONDO_0001056), Papillary Renal Cell Carcinoma (EFO_0000640), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Lung Adenocarcinoma (EFO_0000571), Inflammatory Myofibroblastic Tumor (MONDO_0015798), Neurofibromatosis Type 2 (MONDO_0007039), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Adenocarcinoma (EFO_0000228), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Disease (EFO_0003086), Glioblastoma Multiforme (EFO_0000519)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MET (ENSG00000105976), ALK (ENSG00000171094), NPM1 (ENSG00000181163), EML4 (ENSG00000143924)', 'numberLinkedTargets': 4}]",general,"Distinct, Similarity Search, Order By","Genetic Target, Approval Status"
-Q17.1119,Q17,What gene does the drug Peginesatide Acetate target?,The drug Peginesatide Acetate targets the gene EPOR.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%peginesatide acetate%"" OR LOWER(tradeNames_string) LIKE ""%peginesatide acetate%"" OR LOWER(drugSynonyms_string) LIKE ""%peginesatide acetate%"")
- ORDER  BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_5606', 'drugName': 'Peginesatide Acetate', 'tradeNames_string': 'Omontys, Omontys preservative free', 'drugSynonyms_string': 'AF37702, Hematide acetate, Peginesatide acetate', 'linkedDiseasesDrug_string': 'Anemia (Phenotype) (EFO_0004272)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EPOR (ENSG00000187266)', 'numberLinkedTargets': 1}]",general,"Distinct, Similarity Search, Order By","Genetic Target, Approval Status"
-Q17.585,Q17,What gene does the drug Golimumab target?,The drug Golimumab targets the gene TNF.,"SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%golimumab%"" OR LOWER(tradeNames_string) LIKE ""%golimumab%"" OR LOWER(drugSynonyms_string) LIKE ""%golimumab%"")
- ORDER  BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_393', 'drugName': 'Golimumab', 'tradeNames_string': 'Simponi', 'drugSynonyms_string': 'CNTO 148, CNTO-148, Golimumab', 'linkedDiseasesDrug_string': ""Sarcoidosis (MONDO_0019338), Spondyloarthropathy (EFO_0000706), Asthma (MONDO_0004979), Crohn'S Disease (EFO_0000384), Osteoarthritis (MONDO_0005178), Juvenile Idiopathic Arthritis (EFO_0002609), Ankylosing Spondylitis (EFO_0003898), Inner Ear Disease (EFO_0009672), Psoriatic Arthritis (EFO_0003778), Type 1 Diabetes Mellitus (MONDO_0005147), Rheumatoid Arthritis (EFO_0000685), Ulcerative Colitis (EFO_0000729), Immune System Disease (EFO_0000540), Spondylitis (MONDO_0003937)"", 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TNF (ENSG00000232810)', 'numberLinkedTargets': 1}]",general,"Distinct, Similarity Search, Order By","Genetic Target, Approval Status"
-Q17.375,Q17,What gene does the drug M4344 target?,"The drug M4344 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene ATR.","SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%m4344%"" OR LOWER(tradeNames_string) LIKE ""%m4344%"" OR LOWER(drugSynonyms_string) LIKE ""%m4344%"")
- ORDER  BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3112', 'drugName': 'M4344', 'tradeNames_string': '', 'drugSynonyms_string': 'Gartisertib, M 4344, M-4344, M4344, VX-803', 'linkedDiseasesDrug_string': 'Ovarian Cancer (MONDO_0008170), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'ATR (ENSG00000175054)', 'numberLinkedTargets': 1}]",general,"Distinct, Similarity Search, Order By","Genetic Target, Approval Status"
-Q17.276,Q17,What gene does the drug Runcaciguat target?,"The drug Runcaciguat is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 4 genes: GUCY1A1, GUCY1B2, GUCY1A2 and GUCY1B1","SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%runcaciguat%"" OR LOWER(tradeNames_string) LIKE ""%runcaciguat%"" OR LOWER(drugSynonyms_string) LIKE ""%runcaciguat%"")
- ORDER  BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_6133', 'drugName': 'Runcaciguat', 'tradeNames_string': '', 'drugSynonyms_string': 'Runcaciguat', 'linkedDiseasesDrug_string': 'Chronic Kidney Disease (EFO_0003884), Diabetic Retinopathy (EFO_0003770)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'GUCY1B1 (ENSG00000061918), GUCY1B2 (ENSG00000123201), GUCY1A2 (ENSG00000152402), GUCY1A1 (ENSG00000164116)', 'numberLinkedTargets': 4}]",general,"Distinct, Similarity Search, Order By","Genetic Target, Approval Status"
-Q59.1861,Q59,"What is the genetic target of the antibody drug Toralizumab, and what is its status in clinical trials and FDA approval?",The genetic target of the antibody drug Toralizumab is CD40LG. Toralizumab reached phase 2 clinical trials but is not approved by the FDA for treatment of any disease.,"SELECT DISTINCT UUID, drugName, drugMolecularType, newLinkedTargets_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved 
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%toralizumab%"" OR LOWER(tradeNames_string) LIKE ""%toralizumab%"" OR LOWER(drugSynonyms_string) LIKE ""%toralizumab%"") 
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_6191', 'drugName': 'Toralizumab', 'drugMolecularType': 'Antibody', 'newLinkedTargets_string': 'CD40LG (ENSG00000102245)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False}]",general,"Distinct, Similarity Search, Order By","Approval Status, Trial Phase, Genetic Target"
-Q59.354,Q59,"What is the genetic target of the small molecule drug Naveglitazar, and what is its status in clinical trials and FDA approval?",There are 2 genetic targets of the small molecule drug Naveglitazar: PPARA and PPARG. Naveglitazar reached phase 2 clinical trials but is not approved by the FDA for treatment of any disease.,"SELECT DISTINCT UUID, drugName, drugMolecularType, newLinkedTargets_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved 
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%naveglitazar%"" OR LOWER(tradeNames_string) LIKE ""%naveglitazar%"" OR LOWER(drugSynonyms_string) LIKE ""%naveglitazar%"") 
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_1633', 'drugName': 'Naveglitazar', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'PPARA (ENSG00000186951), PPARG (ENSG00000132170)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False}, {'UUID': 'DrugGeneTargets_v2_1634', 'drugName': 'Naveglitazar', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'PPARA (ENSG00000186951), PPARG (ENSG00000132170)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False}]",general,"Distinct, Similarity Search, Order By","Approval Status, Trial Phase, Genetic Target"
-Q59.1334,Q59,"What is the genetic target of the small molecule drug Amiodarone Hydrochloride, and what is its status in clinical trials and FDA approval?",The genetic target of the small molecule drug Amiodarone Hydrochloride is KCNH2. Amiodarone Hydrochloride reached phase 4 clinical trials meaning it has been approved by the FDA.,"SELECT DISTINCT UUID, drugName, drugMolecularType, newLinkedTargets_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved 
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%amiodarone hydrochloride%"" OR LOWER(tradeNames_string) LIKE ""%amiodarone hydrochloride%"" OR LOWER(drugSynonyms_string) LIKE ""%amiodarone hydrochloride%"") 
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3146', 'drugName': 'Amiodarone Hydrochloride', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'KCNH2 (ENSG00000055118)', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}]",general,"Distinct, Similarity Search, Order By","Approval Status, Trial Phase, Genetic Target"
-Q59.906,Q59,"What is the genetic target of the small molecule drug Gandotinib, and what is its status in clinical trials and FDA approval?",The genetic target of the small molecule drug Gandotinib is JAK2. Gandotinib reached phase 2 clinical trials but is not approved by the FDA for treatment of any disease.,"SELECT DISTINCT UUID, drugName, drugMolecularType, newLinkedTargets_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved 
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%gandotinib%"" OR LOWER(tradeNames_string) LIKE ""%gandotinib%"" OR LOWER(drugSynonyms_string) LIKE ""%gandotinib%"") 
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2644', 'drugName': 'Gandotinib', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'JAK2 (ENSG00000096968)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False}]",general,"Distinct, Similarity Search, Order By","Approval Status, Trial Phase, Genetic Target"
-Q59.1290,Q59,"What is the genetic target of the small molecule drug Amoxapine, and what is its status in clinical trials and FDA approval?","There are 7 genetic targets of the small molecule drug Amoxapine: DRD2, DRD3, DRD5, DRD4, DRD1, SLC6A4, and SLC6A2. Amoxapine reached phase 4 clinical trials meaning it has been approved by the FDA.","SELECT DISTINCT UUID, drugName, drugMolecularType, newLinkedTargets_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved 
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%amoxapine%"" OR LOWER(tradeNames_string) LIKE ""%amoxapine%"" OR LOWER(drugSynonyms_string) LIKE ""%amoxapine%"") 
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2376', 'drugName': 'Amoxapine', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD5 (ENSG00000169676), DRD4 (ENSG00000069696), DRD1 (ENSG00000184845), SLC6A4 (ENSG00000108576), SLC6A2 (ENSG00000103546)', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2377', 'drugName': 'Amoxapine', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD5 (ENSG00000169676), DRD4 (ENSG00000069696), DRD1 (ENSG00000184845), SLC6A4 (ENSG00000108576), SLC6A2 (ENSG00000103546)', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2378', 'drugName': 'Amoxapine', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD5 (ENSG00000169676), DRD4 (ENSG00000069696), DRD1 (ENSG00000184845), SLC6A4 (ENSG00000108576), SLC6A2 (ENSG00000103546)', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}]",general,"Distinct, Similarity Search, Order By","Approval Status, Trial Phase, Genetic Target"
-Q59.1274,Q59,"What is the genetic target of the small molecule drug Aslan-003, and what is its status in clinical trials and FDA approval?",The genetic target of the small molecule drug Aslan-003 is DHODH. Aslan-003 reached phase 2 clinical trials but is not approved by the FDA for treatment of any disease.,"SELECT DISTINCT UUID, drugName, drugMolecularType, newLinkedTargets_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved 
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%aslan-003%"" OR LOWER(tradeNames_string) LIKE ""%aslan-003%"" OR LOWER(drugSynonyms_string) LIKE ""%aslan-003%"") 
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_4399', 'drugName': 'Aslan-003', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'DHODH (ENSG00000102967)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False}]",general,"Distinct, Similarity Search, Order By","Approval Status, Trial Phase, Genetic Target"
-Q59.939,Q59,"What is the genetic target of the small molecule drug Lurasidone, and what is its status in clinical trials and FDA approval?",There are 2 genetic targets of the small molecule drug Lurasidone: DRD2 and HTR2A. Lurasidone reached phase 4 clinical trials meaning it has been approved by the FDA.,"SELECT DISTINCT UUID, drugName, drugMolecularType, newLinkedTargets_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved 
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%lurasidone%"" OR LOWER(tradeNames_string) LIKE ""%lurasidone%"" OR LOWER(drugSynonyms_string) LIKE ""%lurasidone%"") 
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3925', 'drugName': 'Lurasidone Hydrochloride', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'yearOfFirstApproval': 2010, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3924', 'drugName': 'Lurasidone Hydrochloride', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'yearOfFirstApproval': 2010, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5709', 'drugName': 'Lurasidone', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'yearOfFirstApproval': 2010, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5708', 'drugName': 'Lurasidone', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'yearOfFirstApproval': 2010, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}]",general,"Distinct, Similarity Search, Order By","Approval Status, Trial Phase, Genetic Target"
-Q59.1732,Q59,"What is the genetic target of the small molecule drug Valbenazine Tosylate, and what is its status in clinical trials and FDA approval?",The genetic target of the small molecule drug Valbenazine Tosylate is SLC18A2. Valbenazine Tosylate reached phase 4 clinical trials meaning it has been approved by the FDA.,"SELECT DISTINCT UUID, drugName, drugMolecularType, newLinkedTargets_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved 
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%valbenazine tosylate%"" OR LOWER(tradeNames_string) LIKE ""%valbenazine tosylate%"" OR LOWER(drugSynonyms_string) LIKE ""%valbenazine tosylate%"") 
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_5423', 'drugName': 'Valbenazine Tosylate', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'SLC18A2 (ENSG00000165646)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}]",general,"Distinct, Similarity Search, Order By","Approval Status, Trial Phase, Genetic Target"
-Q59.66,Q59,"What is the genetic target of the small molecule drug Burapitant, and what is its status in clinical trials and FDA approval?",The genetic target of the small molecule drug Burapitant is TACR1. Burapitant reached phase 2 clinical trials but is not approved by the FDA for treatment of any disease.,"SELECT DISTINCT UUID, drugName, drugMolecularType, newLinkedTargets_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved 
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%burapitant%"" OR LOWER(tradeNames_string) LIKE ""%burapitant%"" OR LOWER(drugSynonyms_string) LIKE ""%burapitant%"") 
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_4526', 'drugName': 'Burapitant', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'TACR1 (ENSG00000115353)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False}]",general,"Distinct, Similarity Search, Order By","Approval Status, Trial Phase, Genetic Target"
-Q59.1324,Q59,"What is the genetic target of the small molecule drug Vofopitant, and what is its status in clinical trials and FDA approval?",The genetic target of the small molecule drug Vofopitant is TACR1. Vofopitant reached phase 2 clinical trials but is not approved by the FDA for treatment of any disease.,"SELECT DISTINCT UUID, drugName, drugMolecularType, newLinkedTargets_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved 
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%vofopitant%"" OR LOWER(tradeNames_string) LIKE ""%vofopitant%"" OR LOWER(drugSynonyms_string) LIKE ""%vofopitant%"") 
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_4385', 'drugName': 'Vofopitant', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'TACR1 (ENSG00000115353)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False}]",general,"Distinct, Similarity Search, Order By","Approval Status, Trial Phase, Genetic Target"
-Q59.57,Q59,"What is the genetic target of the protein drug Setmelanotide Acetate, and what is its status in clinical trials and FDA approval?",The genetic target of the protein drug Setmelanotide Acetate is MC4R. Setmelanotide Acetate reached phase 4 clinical trials meaning it has been approved by the FDA.,"SELECT DISTINCT UUID, drugName, drugMolecularType, newLinkedTargets_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved 
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%setmelanotide acetate%"" OR LOWER(tradeNames_string) LIKE ""%setmelanotide acetate%"" OR LOWER(drugSynonyms_string) LIKE ""%setmelanotide acetate%"") 
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2878', 'drugName': 'Setmelanotide Acetate', 'drugMolecularType': 'Protein', 'newLinkedTargets_string': 'MC4R (ENSG00000166603)', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}]",general,"Distinct, Similarity Search, Order By","Approval Status, Trial Phase, Genetic Target"
-Q59.1293,Q59,"What is the genetic target of the small molecule drug Benserazide, and what is its status in clinical trials and FDA approval?",The genetic target of the small molecule drug Benserazide is DDC. Benserazide reached phase 4 clinical trials meaning it has been approved by the FDA.,"SELECT DISTINCT UUID, drugName, drugMolecularType, newLinkedTargets_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved 
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%benserazide%"" OR LOWER(tradeNames_string) LIKE ""%benserazide%"" OR LOWER(drugSynonyms_string) LIKE ""%benserazide%"") 
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2020', 'drugName': 'Benserazide', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'DDC (ENSG00000132437)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}]",general,"Distinct, Similarity Search, Order By","Approval Status, Trial Phase, Genetic Target"
-Q59.1119,Q59,"What is the genetic target of the small molecule drug Tegafur, and what is its status in clinical trials and FDA approval?",The genetic target of the small molecule drug Tegafur is TYMS. Tegafur reached phase 4 clinical trials meaning it has been approved by the FDA.,"SELECT DISTINCT UUID, drugName, drugMolecularType, newLinkedTargets_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved 
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%tegafur%"" OR LOWER(tradeNames_string) LIKE ""%tegafur%"" OR LOWER(drugSynonyms_string) LIKE ""%tegafur%"") 
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3988', 'drugName': 'Tegafur', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'TYMS (ENSG00000176890)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}]",general,"Distinct, Similarity Search, Order By","Approval Status, Trial Phase, Genetic Target"
-Q59.585,Q59,"What is the genetic target of the enzyme drug Tenecteplase, and what is its status in clinical trials and FDA approval?",The genetic target of the enzyme drug Tenecteplase is PLG. Tenecteplase reached phase 4 clinical trials meaning it has been approved by the FDA.,"SELECT DISTINCT UUID, drugName, drugMolecularType, newLinkedTargets_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved 
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%tenecteplase%"" OR LOWER(tradeNames_string) LIKE ""%tenecteplase%"" OR LOWER(drugSynonyms_string) LIKE ""%tenecteplase%"") 
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_5412', 'drugName': 'Tenecteplase', 'drugMolecularType': 'Enzyme', 'newLinkedTargets_string': 'PLG (ENSG00000122194)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True}]",general,"Distinct, Similarity Search, Order By","Approval Status, Trial Phase, Genetic Target"
-Q59.375,Q59,"What is the genetic target of the antibody drug Stx-100, and what is its status in clinical trials and FDA approval?",There are 2 genetic targets of the antibody drug Stx-100: ITGAV and ITGB6. Stx-100 reached phase 2 clinical trials but is not approved by the FDA for treatment of any disease.,"SELECT DISTINCT UUID, drugName, drugMolecularType, newLinkedTargets_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved 
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%stx-100%"" OR LOWER(tradeNames_string) LIKE ""%stx-100%"" OR LOWER(drugSynonyms_string) LIKE ""%stx-100%"") 
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_625', 'drugName': 'Stx-100', 'drugMolecularType': 'Antibody', 'newLinkedTargets_string': 'ITGAV (ENSG00000138448), ITGB6 (ENSG00000115221)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False}]",general,"Distinct, Similarity Search, Order By","Approval Status, Trial Phase, Genetic Target"
-Q59.276,Q59,"What is the genetic target of the small molecule drug Capromorelin, and what is its status in clinical trials and FDA approval?",The genetic target of the small molecule drug Capromorelin is GHSR. Capromorelin reached phase 2 clinical trials but is not approved by the FDA for treatment of any disease.,"SELECT DISTINCT UUID, drugName, drugMolecularType, newLinkedTargets_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved 
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%capromorelin%"" OR LOWER(tradeNames_string) LIKE ""%capromorelin%"" OR LOWER(drugSynonyms_string) LIKE ""%capromorelin%"") 
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_1109', 'drugName': 'Capromorelin', 'drugMolecularType': 'Small molecule', 'newLinkedTargets_string': 'GHSR (ENSG00000121853)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False}]",general,"Distinct, Similarity Search, Order By","Approval Status, Trial Phase, Genetic Target"
-Q7.539,Q7,What are the approved uses for Upadacitinib?,Upadacitinib has been approved by the FDA to treat 2 diseases: immune system disease and rheumatoid arthritis.,"SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind 
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%upadacitinib%"" OR LOWER(tradeNames_list) LIKE ""%upadacitinib%"" OR LOWER(syns_list) LIKE ""%upadacitinib%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_846868', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846833', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847072', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846772', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846892', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847300', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846821', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846941', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846977', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847001', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847085', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847133', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846784', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847240', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847217', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847252', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847253', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847313', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847301', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847324', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846904', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846917', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846953', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846796', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847000', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846988', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847024', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847121', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847073', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847096', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847097', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847157', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847144', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847169', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846808', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847277', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846785', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847229', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847228', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847276', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847241', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847265', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847264', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847348', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847289', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847312', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846820', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847337', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846905', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847336', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847325', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846880', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846929', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846928', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846965', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846952', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846964', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847048', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846797', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846989', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846869', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847037', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847012', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847036', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847025', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847193', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847061', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847084', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846844', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847120', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846881', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847109', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847108', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847192', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847132', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847156', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847145', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847181', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847168', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847180', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846856', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847349', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846809', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847205', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846893', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847361', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847360', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847204', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847049', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846976', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846940', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846916', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846773', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846832', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847013', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846845', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847216', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847288', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_847060', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_846857', 'drugName': 'Upadacitinib', 'tradeNames_list': ""['Rinvoq']"", 'syns_list': ""['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']"", 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0}]",general,"Distinct, Similarity Search, Order By",Approval Status
-Q7.524,Q7,What are the approved uses for Trametinib Dimethyl Sulfoxide?,"Trametinib Dimethyl Sulfoxide has been approved by the FDA to treat 4 diseases: cutaneous melanoma, metastatic melanoma, thyroid cancer, and lung cancer.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind 
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%trametinib dimethyl sulfoxide%"" OR LOWER(tradeNames_list) LIKE ""%trametinib dimethyl sulfoxide%"" OR LOWER(syns_list) LIKE ""%trametinib dimethyl sulfoxide%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_927821', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927743', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927765', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927736', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927738', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927837', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927732', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927759', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927844', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927744', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927830', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927813', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927771', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927884', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927879', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927751', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927752', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927891', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927739', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927785', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927787', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927758', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927793', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927795', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927849', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927799', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927764', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927863', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927766', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927809', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927746', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927865', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927815', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927870', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927772', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927886', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927737', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927883', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927731', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927885', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927778', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927779', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927780', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927897', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927753', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927890', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927836', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927893', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927786', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927892', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927788', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927729', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927834', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927792', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927842', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927794', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927750', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927856', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927827', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927848', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927800', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927855', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927802', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927851', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927850', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927877', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927806', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927807', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927808', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927862', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927767', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927858', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927829', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927876', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927814', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927864', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927816', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927872', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927869', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927871', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927820', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927898', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927822', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927823', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927774', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927900', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927899', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927878', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927857', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927843', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927841', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927828', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927757', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'cutaneous melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927760', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927801', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927730', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927835', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Melanoma', 'efo_term': 'metastatic melanoma', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927781', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927745', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_927773', 'drugName': 'Trametinib Dimethyl Sulfoxide', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212B', 'GSK1120212B', 'Trametinib dimethyl sulfoxide']"", 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0}]",general,"Distinct, Similarity Search, Order By",Approval Status
-Q7.235,Q7,What are the approved uses for Guanfacine?,Guanfacine has been approved by the FDA to treat 1 disease: hypertension.,"SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind 
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%guanfacine%"" OR LOWER(tradeNames_list) LIKE ""%guanfacine%"" OR LOWER(syns_list) LIKE ""%guanfacine%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_1025329', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025323', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025375', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025306', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025315', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025342', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025325', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025316', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025331', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025333', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025320', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025339', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025341', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025307', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025647', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025615', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025503', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025439', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025321', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025535', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025326', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025299', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025298', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025330', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025631', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025332', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025334', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025343', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025300', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025297', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025302', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025519', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025340', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025301', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025318', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025305', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025319', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025455', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025322', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025308', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025304', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025338', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025391', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025336', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025309', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025471', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025335', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025679', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025310', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025314', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025663', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025327', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025328', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025303', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025567', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025312', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025551', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025695', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025313', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025317', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025711', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025583', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025359', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025311', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025324', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025727', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025599', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025487', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025407', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025423', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025337', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Attention Deficit Disorder with Hyperactivity', 'efo_term': 'attention deficit hyperactivity disorder', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025296', 'drugName': 'Guanfacine Hydrochloride', 'tradeNames_list': ""['Akfen', 'Estulic', 'Guanfacine hydrochloride', 'Intuniv', 'Tenex']"", 'syns_list': ""['BS 100-141', 'BS-100-141', 'Guafacine hydrochloride', 'Guanfacine hclGuanfacine hydrochloride', 'SPD503']"", 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1025373', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Delirium', 'efo_term': 'delirium', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1025374', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1025438', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1025453', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Delirium', 'efo_term': 'delirium', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1025454', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1025452', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1025468', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1025469', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Delirium', 'efo_term': 'delirium', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1025470', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1025390', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1025389', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Delirium', 'efo_term': 'delirium', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1025388', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1025486', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1025502', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1025500', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1025501', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Delirium', 'efo_term': 'delirium', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1025484', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1025549', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Delirium', 'efo_term': 'delirium', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1025516', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1025517', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Delirium', 'efo_term': 'delirium', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1025518', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1025532', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1025533', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Delirium', 'efo_term': 'delirium', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1025534', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1025548', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1025356', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Tourette Syndrome', 'efo_term': 'Tourette syndrome', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1025357', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Delirium', 'efo_term': 'delirium', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1025358', 'drugName': 'Guanfacine', 'tradeNames_list': ""['Intuniv']"", 'syns_list': ""['Guanfacine', 'NSC-759121', 'Tenex']"", 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}]",general,"Distinct, Similarity Search, Order By",Approval Status
-Q7.525,Q7,What are the approved uses for Tranexamic Acid?,"Tranexamic Acid has been approved by the FDA to treat 3 diseases: Menorrhagia, hemorrhage, and hemophilia A.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind 
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%tranexamic acid%"" OR LOWER(tradeNames_list) LIKE ""%tranexamic acid%"" OR LOWER(syns_list) LIKE ""%tranexamic acid%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_993619', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Hemophilia A', 'efo_term': 'hemophilia A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_993443', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_993444', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_993617', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_993327', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_993502', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_993387', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Hemophilia A', 'efo_term': 'hemophilia A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_993559', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_993618', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_993733', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_993501', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_993386', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_993734', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_993677', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Hemophilia A', 'efo_term': 'hemophilia A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_993561', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Hemophilia A', 'efo_term': 'hemophilia A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_993329', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Hemophilia A', 'efo_term': 'hemophilia A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_993328', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_993735', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Hemophilia A', 'efo_term': 'hemophilia A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_993503', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Hemophilia A', 'efo_term': 'hemophilia A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_993676', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_993675', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_993445', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Hemophilia A', 'efo_term': 'hemophilia A', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_993560', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_993385', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Menorrhagia', 'efo_term': 'Menorrhagia', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_993374', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Femoral Neck Fractures', 'efo_term': 'femoral neck fracture', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993315', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Shoulder Impingement Syndrome', 'efo_term': 'shoulder impingement syndrome', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993302', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Aortic Aneurysm, Abdominal', 'efo_term': 'Abdominal Aortic Aneurysm', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993316', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Femoral Neck Fractures', 'efo_term': 'femoral neck fracture', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993289', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993383', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993303', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993382', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Brain Injuries', 'efo_term': 'brain injury', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993288', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993398', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993296', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Coronary Disease', 'efo_term': 'coronary artery disease', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993318', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Ileus', 'efo_term': 'ileus', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993319', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993305', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'upper aerodigestive tract neoplasm', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993384', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Severe Acute Respiratory Syndrome', 'efo_term': 'COVID-19', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993325', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993373', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Shoulder Impingement Syndrome', 'efo_term': 'shoulder impingement syndrome', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993326', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Severe Acute Respiratory Syndrome', 'efo_term': 'COVID-19', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993346', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Sepsis', 'efo_term': 'Sepsis', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993292', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Glioma', 'efo_term': 'central nervous system cancer', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993345', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Shock', 'efo_term': 'Shock', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993285', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Joint Diseases', 'efo_term': 'Arthropathy', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993371', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993369', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993324', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Brain Injuries', 'efo_term': 'brain injury', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993323', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Genital Neoplasms, Female', 'efo_term': 'female reproductive system neoplasm', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993381', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Genital Neoplasms, Female', 'efo_term': 'female reproductive system neoplasm', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993317', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Hematoma, Subdural, Intracranial', 'efo_term': 'intracranial subdural hematoma', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993295', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'lymphoid neoplasm', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993375', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Hematoma, Subdural, Intracranial', 'efo_term': 'intracranial subdural hematoma', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993354', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Coronary Disease', 'efo_term': 'coronary artery disease', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993314', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Joint Diseases', 'efo_term': 'joint disease', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993294', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Leiomyoma', 'efo_term': 'uterine fibroid', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993365', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Placenta Accreta', 'efo_term': 'placenta accreta', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993321', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Telangiectasia, Hereditary Hemorrhagic', 'efo_term': 'hereditary hemorrhagic telangiectasia', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993363', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'upper aerodigestive tract neoplasm', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993362', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Scoliosis', 'efo_term': 'scoliosis', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993361', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993320', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Meningioma', 'efo_term': 'meningioma', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993297', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993286', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Shoulder Pain', 'efo_term': 'Shoulder pain', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993357', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Fractures, Bone', 'efo_term': 'bone fracture', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993298', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993355', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993356', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993358', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Melanosis', 'efo_term': 'freckles', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993359', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Hip Fractures', 'efo_term': 'hip fracture', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993360', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Aortic Aneurysm, Abdominal', 'efo_term': 'Abdominal Aortic Aneurysm', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993379', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Telangiectasia, Hereditary Hemorrhagic', 'efo_term': 'hereditary hemorrhagic telangiectasia', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993353', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'lymphoid neoplasm', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993322', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Angioedemas, Hereditary', 'efo_term': 'hereditary angioedema', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993370', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Bone Neoplasms', 'efo_term': 'Malignant Bone Neoplasm', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993364', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Pelvic Organ Prolapse', 'efo_term': 'pelvic organ prolapse', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993366', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Placenta Previa', 'efo_term': 'placenta praevia', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993367', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Blood Coagulation Disorders', 'efo_term': 'blood coagulation disease', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993368', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Postpartum Hemorrhage', 'efo_term': 'postpartum hemorrhage', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993352', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Leiomyoma', 'efo_term': 'uterine fibroid', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993351', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993399', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Hemoptysis', 'efo_term': 'Hemoptysis', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993372', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Joint Diseases', 'efo_term': 'joint disease', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993350', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Glioma', 'efo_term': 'central nervous system cancer', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993349', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993299', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Fractures, Bone', 'efo_term': 'bone fracture', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993348', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Astrocytoma', 'efo_term': 'astrocytoma', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993311', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Hematoma', 'efo_term': 'hematoma', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993347', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993310', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Postpartum Hemorrhage', 'efo_term': 'postpartum hemorrhage', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993283', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Hemoptysis', 'efo_term': 'Hemoptysis', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993293', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Wounds and Injuries', 'efo_term': 'injury', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993312', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Bone Neoplasms', 'efo_term': 'Malignant Bone Neoplasm', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993313', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal Cavity Polyp', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993284', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Gastrointestinal Hemorrhage', 'efo_term': 'Gastrointestinal hemorrhage', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993287', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Shock', 'efo_term': 'Shock', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993300', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Melanosis', 'efo_term': 'freckles', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993301', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Hip Fractures', 'efo_term': 'hip fracture', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_993304', 'drugName': 'Tranexamic Acid', 'tradeNames_list': ""['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']"", 'syns_list': ""['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']"", 'mesh_heading': 'Scoliosis', 'efo_term': 'scoliosis', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 3.0}]",general,"Distinct, Similarity Search, Order By",Approval Status
-Q7.487,Q7,What are the approved uses for Tafluprost?,"Tafluprost has been approved by the FDA to treat 3 diseases: glaucoma, open-angle glaucoma, and ocular hypertension.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind 
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%tafluprost%"" OR LOWER(tradeNames_list) LIKE ""%tafluprost%"" OR LOWER(syns_list) LIKE ""%tafluprost%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_1149438', 'drugName': 'Tafluprost', 'tradeNames_list': ""['Saflutan', 'Zioptan']"", 'syns_list': ""['AFP-168', 'MK-2452', 'Tafluprost']"", 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1149441', 'drugName': 'Tafluprost', 'tradeNames_list': ""['Saflutan', 'Zioptan']"", 'syns_list': ""['AFP-168', 'MK-2452', 'Tafluprost']"", 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1149440', 'drugName': 'Tafluprost', 'tradeNames_list': ""['Saflutan', 'Zioptan']"", 'syns_list': ""['AFP-168', 'MK-2452', 'Tafluprost']"", 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1149436', 'drugName': 'Tafluprost', 'tradeNames_list': ""['Saflutan', 'Zioptan']"", 'syns_list': ""['AFP-168', 'MK-2452', 'Tafluprost']"", 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1149433', 'drugName': 'Tafluprost', 'tradeNames_list': ""['Saflutan', 'Zioptan']"", 'syns_list': ""['AFP-168', 'MK-2452', 'Tafluprost']"", 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1149434', 'drugName': 'Tafluprost', 'tradeNames_list': ""['Saflutan', 'Zioptan']"", 'syns_list': ""['AFP-168', 'MK-2452', 'Tafluprost']"", 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1149439', 'drugName': 'Tafluprost', 'tradeNames_list': ""['Saflutan', 'Zioptan']"", 'syns_list': ""['AFP-168', 'MK-2452', 'Tafluprost']"", 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1149437', 'drugName': 'Tafluprost', 'tradeNames_list': ""['Saflutan', 'Zioptan']"", 'syns_list': ""['AFP-168', 'MK-2452', 'Tafluprost']"", 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1149435', 'drugName': 'Tafluprost', 'tradeNames_list': ""['Saflutan', 'Zioptan']"", 'syns_list': ""['AFP-168', 'MK-2452', 'Tafluprost']"", 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0}]",general,"Distinct, Similarity Search, Order By",Approval Status
-Q36.1861,Q36,What is the genomic location of SNP rs144253917?,"The SNP rs144253917 is located on chromosome 4. Genomic Build GrCh37/HG19: base pair position 171941295, Genomic Build GrCh38/HG38: base pair position 171020144.","SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, SNP, chr_38, bp_38, chr_37, bp_37
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs144253917'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, SNP, chr_38, bp_38, chr_37, bp_37
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs144253917'
- LIMIT 100","[{'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_6388743', 'SNP': 'rs144253917', 'chr_38': 4, 'bp_38': 171020144, 'chr_37': 4, 'bp_37': 171941295}]",general,"Select, Join",Metadata
-Q36.354,Q36,What is the genomic location of SNP rs943543?,"The SNP rs943543 is located on chromosome 10. Genomic Build GrCh37/HG19: base pair position 97148729, Genomic Build GrCh38/HG38: base pair position 95388972.","SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, SNP, chr_38, bp_38, chr_37, bp_37
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs943543'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, SNP, chr_38, bp_38, chr_37, bp_37
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs943543'
- LIMIT 100","[{'source_table': 'ParkinsonDisease_CompleteGeneData_No23andMe', 'UUID': 'PDno23andme_full_gene_notext_6552983', 'SNP': 'rs943543', 'chr_38': 10, 'bp_38': 95388972, 'chr_37': 10, 'bp_37': 97148729}, {'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_13372429', 'SNP': 'rs943543', 'chr_38': 10, 'bp_38': 95388972, 'chr_37': 10, 'bp_37': 97148729}]",general,"Select, Join",Metadata
-Q36.1334,Q36,What is the genomic location of SNP rs73531423?,"The SNP rs73531423 is located on chromosome 13. Genomic Build GrCh37/HG19: base pair position 74062874, Genomic Build GrCh38/HG38: base pair position 73488737.","SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, SNP, chr_38, bp_38, chr_37, bp_37
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs73531423'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, SNP, chr_38, bp_38, chr_37, bp_37
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs73531423'
- LIMIT 100","[{'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_16170734', 'SNP': 'rs73531423', 'chr_38': 13, 'bp_38': 73488737, 'chr_37': 13, 'bp_37': 74062874}]",general,"Select, Join",Metadata
-Q36.906,Q36,What is the genomic location of SNP rs117648554?,"The SNP rs117648554 is located on chromosome 15. Genomic Build GrCh37/HG19: base pair position 58644464, Genomic Build GrCh38/HG38: base pair position 58352265.","SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, SNP, chr_38, bp_38, chr_37, bp_37
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs117648554'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, SNP, chr_38, bp_38, chr_37, bp_37
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs117648554'
- LIMIT 100","[{'source_table': 'ParkinsonDisease_CompleteGeneData_No23andMe', 'UUID': 'PDno23andme_full_gene_notext_2341377', 'SNP': 'rs117648554', 'chr_38': 15, 'bp_38': 58352265, 'chr_37': 15, 'bp_37': 58644464}, {'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_17444170', 'SNP': 'rs117648554', 'chr_38': 15, 'bp_38': 58352265, 'chr_37': 15, 'bp_37': 58644464}]",general,"Select, Join",Metadata
-Q36.1290,Q36,What is the genomic location of SNP rs147347202?,"The SNP rs147347202 is located on chromosome 18. Genomic Build GrCh37/HG19: base pair position 45029954, Genomic Build GrCh38/HG38: base pair position 47503583.","SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, SNP, chr_38, bp_38, chr_37, bp_37
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs147347202'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, SNP, chr_38, bp_38, chr_37, bp_37
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs147347202'
- LIMIT 100","[{'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_19344673', 'SNP': 'rs147347202', 'chr_38': 18, 'bp_38': 47503583, 'chr_37': 18, 'bp_37': 45029954}]",general,"Select, Join",Metadata
-Q36.1274,Q36,What is the genomic location of SNP rs574795786?,"The SNP rs574795786 is located on chromosome 2. Genomic Build GrCh37/HG19: base pair position 112840922, Genomic Build GrCh38/HG38: base pair position 112083345.","SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, SNP, chr_38, bp_38, chr_37, bp_37
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs574795786'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, SNP, chr_38, bp_38, chr_37, bp_37
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs574795786'
- LIMIT 100","[{'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_2526455', 'SNP': 'rs574795786', 'chr_38': 2, 'bp_38': 112083345, 'chr_37': 2, 'bp_37': 112840922}]",general,"Select, Join",Metadata
-Q36.939,Q36,What is the genomic location of SNP rs9829928?,"The SNP rs9829928 is located on chromosome 3. Genomic Build GrCh37/HG19: base pair position 69678772, Genomic Build GrCh38/HG38: base pair position 69629621.","SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, SNP, chr_38, bp_38, chr_37, bp_37
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs9829928'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, SNP, chr_38, bp_38, chr_37, bp_37
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs9829928'
- LIMIT 100","[{'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_4070697', 'SNP': 'rs9829928', 'chr_38': 3, 'bp_38': 69629621, 'chr_37': 3, 'bp_37': 69678772}]",general,"Select, Join",Metadata
-Q36.1732,Q36,What is the genomic location of SNP rs919278277?,"The SNP rs919278277 is located on chromosome 22. Genomic Build GrCh37/HG19: base pair position 28414975, Genomic Build GrCh38/HG38: base pair position 28018987.","SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, SNP, chr_38, bp_38, chr_37, bp_37
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs919278277'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, SNP, chr_38, bp_38, chr_37, bp_37
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs919278277'
- LIMIT 100","[{'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_20940952', 'SNP': 'rs919278277', 'chr_38': 22, 'bp_38': 28018987, 'chr_37': 22, 'bp_37': 28414975}]",general,"Select, Join",Metadata
-Q36.66,Q36,What is the genomic location of SNP rs560513081?,"The SNP rs560513081 is located on chromosome 7. Genomic Build GrCh37/HG19: base pair position 27592937, Genomic Build GrCh38/HG38: base pair position 27553318.","SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, SNP, chr_38, bp_38, chr_37, bp_37
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs560513081'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, SNP, chr_38, bp_38, chr_37, bp_37
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs560513081'
- LIMIT 100","[{'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_9564073', 'SNP': 'rs560513081', 'chr_38': 7, 'bp_38': 27553318, 'chr_37': 7, 'bp_37': 27592937}]",general,"Select, Join",Metadata
-Q36.1324,Q36,What is the genomic location of SNP rs76463349?,"The SNP rs76463349 is located on chromosome 11. Genomic Build GrCh37/HG19: base pair position 85307167, Genomic Build GrCh38/HG38: base pair position 85596123.","SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, SNP, chr_38, bp_38, chr_37, bp_37
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs76463349'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, SNP, chr_38, bp_38, chr_37, bp_37
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs76463349'
- LIMIT 100","[{'source_table': 'ParkinsonDisease_CompleteGeneData_No23andMe', 'UUID': 'PDno23andme_full_gene_notext_644613', 'SNP': 'rs76463349', 'chr_38': 11, 'bp_38': 85596123, 'chr_37': 11, 'bp_37': 85307167}, {'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_14333203', 'SNP': 'rs76463349', 'chr_38': 11, 'bp_38': 85596123, 'chr_37': 11, 'bp_37': 85307167}]",general,"Select, Join",Metadata
-Q36.57,Q36,What is the genomic location of SNP rs73243060?,"The SNP rs73243060 is located on chromosome 8. Genomic Build GrCh37/HG19: base pair position 59760145, Genomic Build GrCh38/HG38: base pair position 58847586.","SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, SNP, chr_38, bp_38, chr_37, bp_37
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs73243060'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, SNP, chr_38, bp_38, chr_37, bp_37
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs73243060'
- LIMIT 100","[{'source_table': 'ParkinsonDisease_CompleteGeneData_No23andMe', 'UUID': 'PDno23andme_full_gene_notext_4976937', 'SNP': 'rs73243060', 'chr_38': 8, 'bp_38': 58847586, 'chr_37': 8, 'bp_37': 59760145}, {'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_11043901', 'SNP': 'rs73243060', 'chr_38': 8, 'bp_38': 58847586, 'chr_37': 8, 'bp_37': 59760145}]",general,"Select, Join",Metadata
-Q36.1293,Q36,What is the genomic location of SNP rs9514499?,"The SNP rs9514499 is located on chromosome 13. Genomic Build GrCh37/HG19: base pair position 106794817, Genomic Build GrCh38/HG38: base pair position 106142468.","SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, SNP, chr_38, bp_38, chr_37, bp_37
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs9514499'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, SNP, chr_38, bp_38, chr_37, bp_37
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs9514499'
- LIMIT 100","[{'source_table': 'ParkinsonDisease_CompleteGeneData_No23andMe', 'UUID': 'PDno23andme_full_gene_notext_2666527', 'SNP': 'rs9514499', 'chr_38': 13, 'bp_38': 106142468, 'chr_37': 13, 'bp_37': 106794817}, {'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_16436747', 'SNP': 'rs9514499', 'chr_38': 13, 'bp_38': 106142468, 'chr_37': 13, 'bp_37': 106794817}]",general,"Select, Join",Metadata
-Q36.1119,Q36,What is the genomic location of SNP rs72779183?,"The SNP rs72779183 is located on chromosome 16. Genomic Build GrCh37/HG19: base pair position 11675175, Genomic Build GrCh38/HG38: base pair position 11581319.","SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, SNP, chr_38, bp_38, chr_37, bp_37
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs72779183'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, SNP, chr_38, bp_38, chr_37, bp_37
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs72779183'
- LIMIT 100","[{'source_table': 'ParkinsonDisease_CompleteGeneData_No23andMe', 'UUID': 'PDno23andme_full_gene_notext_286720', 'SNP': 'rs72779183', 'chr_38': 16, 'bp_38': 11581319, 'chr_37': 16, 'bp_37': 11675175}, {'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_17916730', 'SNP': 'rs72779183', 'chr_38': 16, 'bp_38': 11581319, 'chr_37': 16, 'bp_37': 11675175}]",general,"Select, Join",Metadata
-Q36.585,Q36,What is the genomic location of SNP rs59872153?,"The SNP rs59872153 is located on chromosome 1. Genomic Build GrCh37/HG19: base pair position 191691180, Genomic Build GrCh38/HG38: base pair position 191722050.","SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, SNP, chr_38, bp_38, chr_37, bp_37
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs59872153'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, SNP, chr_38, bp_38, chr_37, bp_37
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs59872153'
- LIMIT 100","[{'source_table': 'ParkinsonDisease_CompleteGeneData_No23andMe', 'UUID': 'PDno23andme_full_gene_notext_2610287', 'SNP': 'rs59872153', 'chr_38': 1, 'bp_38': 191722050, 'chr_37': 1, 'bp_37': 191691180}, {'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_1230561', 'SNP': 'rs59872153', 'chr_38': 1, 'bp_38': 191722050, 'chr_37': 1, 'bp_37': 191691180}]",general,"Select, Join",Metadata
-Q36.375,Q36,What is the genomic location of SNP rs12747360?,"The SNP rs12747360 is located on chromosome 1. Genomic Build GrCh37/HG19: base pair position 117665577, Genomic Build GrCh38/HG38: base pair position 117122955.","SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, SNP, chr_38, bp_38, chr_37, bp_37
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs12747360'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, SNP, chr_38, bp_38, chr_37, bp_37
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs12747360'
- LIMIT 100","[{'source_table': 'ParkinsonDisease_CompleteGeneData_No23andMe', 'UUID': 'PDno23andme_full_gene_notext_5952405', 'SNP': 'rs12747360', 'chr_38': 1, 'bp_38': 117122955, 'chr_37': 1, 'bp_37': 117665577}, {'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_876699', 'SNP': 'rs12747360', 'chr_38': 1, 'bp_38': 117122955, 'chr_37': 1, 'bp_37': 117665577}]",general,"Select, Join",Metadata
-Q36.276,Q36,What is the genomic location of SNP rs548528835?,"The SNP rs548528835 is located on chromosome 14. Genomic Build GrCh37/HG19: base pair position 52377037, Genomic Build GrCh38/HG38: base pair position 51910319.","SELECT 'AlzheimerDisease_CombinedGeneData_UUID' AS source_table, UUID, SNP, chr_38, bp_38, chr_37, bp_37
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs548528835'
- UNION ALL
- SELECT 'ParkinsonDisease_CompleteGeneData_No23andMe' AS source_table, UUID, SNP, chr_38, bp_38, chr_37, bp_37
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe`
- WHERE SNP = 'rs548528835'
- LIMIT 100","[{'source_table': 'AlzheimerDisease_CombinedGeneData_UUID', 'UUID': 'AD_combo_gene_notext_UUID_16758992', 'SNP': 'rs548528835', 'chr_38': 14, 'bp_38': 51910319, 'chr_37': 14, 'bp_37': 52377037}]",general,"Select, Join",Metadata
-Q50.1861,Q50,Do FBXO44 gene mutations increase the risk of Parkinson's disease?,"No, there are no significant mutations in the FBXO44 gene associated with an increased risk of Parkinson's disease according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019).","SELECT UUID, SNP, p, b 
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE nearestGene LIKE ""%FBXO44%""
- ORDER BY p
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_461003', 'SNP': 'rs78988331', 'p': 0.04226, 'b': -0.5765}, {'UUID': 'PDno23andme_full_gene_notext_236913', 'SNP': 'rs3125816', 'p': 0.09636, 'b': 0.0478}, {'UUID': 'PDno23andme_full_gene_notext_5363937', 'SNP': 'rs3117063', 'p': 0.1571, 'b': 0.0347}, {'UUID': 'PDno23andme_full_gene_notext_7037397', 'SNP': 'rs3125815', 'p': 0.1588, 'b': 0.0395}, {'UUID': 'PDno23andme_full_gene_notext_3452370', 'SNP': 'rs12140970', 'p': 0.2653, 'b': -0.0326}, {'UUID': 'PDno23andme_full_gene_notext_2780366', 'SNP': 'rs4478814', 'p': 0.2657, 'b': -0.0324}, {'UUID': 'PDno23andme_full_gene_notext_2124678', 'SNP': 'rs111931059', 'p': 0.2947, 'b': -0.0645}, {'UUID': 'PDno23andme_full_gene_notext_546025', 'SNP': 'rs145818193', 'p': 0.3261, 'b': 0.0528}, {'UUID': 'PDno23andme_full_gene_notext_4011418', 'SNP': 'rs41274542', 'p': 0.337, 'b': 0.0517}, {'UUID': 'PDno23andme_full_gene_notext_5313991', 'SNP': 'rs56052340', 'p': 0.3395, 'b': -0.0435}, {'UUID': 'PDno23andme_full_gene_notext_331773', 'SNP': 'rs72638619', 'p': 0.384, 'b': -0.0393}, {'UUID': 'PDno23andme_full_gene_notext_5505931', 'SNP': 'rs2294640', 'p': 0.4212, 'b': -0.0363}, {'UUID': 'PDno23andme_full_gene_notext_2239578', 'SNP': 'rs145432128', 'p': 0.4334, 'b': -0.0686}, {'UUID': 'PDno23andme_full_gene_notext_5081728', 'SNP': 'rs150648343', 'p': 0.4384, 'b': -0.0679}, {'UUID': 'PDno23andme_full_gene_notext_6541119', 'SNP': 'rs3820340', 'p': 0.4497, 'b': -0.0341}, {'UUID': 'PDno23andme_full_gene_notext_5577389', 'SNP': 'rs2294642', 'p': 0.4677, 'b': -0.0327}, {'UUID': 'PDno23andme_full_gene_notext_230214', 'SNP': 'rs3125814', 'p': 0.504, 'b': 0.0155}, {'UUID': 'PDno23andme_full_gene_notext_941885', 'SNP': 'rs113706416', 'p': 0.5242, 'b': 0.0339}, {'UUID': 'PDno23andme_full_gene_notext_765226', 'SNP': 'rs12139487', 'p': 0.5622, 'b': -0.0172}, {'UUID': 'PDno23andme_full_gene_notext_5152231', 'SNP': 'rs112882368', 'p': 0.5662, 'b': 0.0307}, {'UUID': 'PDno23andme_full_gene_notext_7076421', 'SNP': 'rs190371744', 'p': 0.5927, 'b': 0.0316}, {'UUID': 'PDno23andme_full_gene_notext_4450285', 'SNP': 'rs58092895', 'p': 0.597, 'b': 0.0275}, {'UUID': 'PDno23andme_full_gene_notext_7625612', 'SNP': 'rs144533111', 'p': 0.6908, 'b': 0.0231}, {'UUID': 'PDno23andme_full_gene_notext_5899783', 'SNP': 'rs2294641', 'p': 0.729, 'b': 0.0078}, {'UUID': 'PDno23andme_full_gene_notext_477374', 'SNP': 'rs150816569', 'p': 0.7588, 'b': -0.0415}, {'UUID': 'PDno23andme_full_gene_notext_5593463', 'SNP': 'rs3125813', 'p': 0.8091, 'b': 0.0054}, {'UUID': 'PDno23andme_full_gene_notext_5883788', 'SNP': 'rs12403639', 'p': 0.8944, 'b': 0.009}]",general,"Select, Order By, Similarity Search, Multi-Filter","Effect, GWAS Significance"
-Q50.354,Q50,Do ARSI gene mutations increase the risk of Parkinson's disease?,"No, there are no significant mutations in the ARSI gene associated with an increased risk of Parkinson's disease according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019).","SELECT UUID, SNP, p, b 
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE nearestGene LIKE ""%ARSI%""
- ORDER BY p
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_2136933', 'SNP': 'rs78918451', 'p': 0.00273, 'b': 0.1327}, {'UUID': 'PDno23andme_full_gene_notext_755452', 'SNP': 'rs13185909', 'p': 0.003074, 'b': 0.1011}, {'UUID': 'PDno23andme_full_gene_notext_6628725', 'SNP': 'rs11167498', 'p': 0.003355, 'b': 0.1001}, {'UUID': 'PDno23andme_full_gene_notext_1505322', 'SNP': 'rs11750343', 'p': 0.003702, 'b': 0.0989}, {'UUID': 'PDno23andme_full_gene_notext_3845277', 'SNP': 'rs12657958', 'p': 0.003781, 'b': 0.0988}, {'UUID': 'PDno23andme_full_gene_notext_7492522', 'SNP': 'rs11745092', 'p': 0.005028, 'b': 0.125}, {'UUID': 'PDno23andme_full_gene_notext_5143862', 'SNP': 'rs76673582', 'p': 0.006257, 'b': 0.1235}, {'UUID': 'PDno23andme_full_gene_notext_6311086', 'SNP': 'rs891945', 'p': 0.008472, 'b': -0.2468}, {'UUID': 'PDno23andme_full_gene_notext_7496440', 'SNP': 'rs80063012', 'p': 0.01615, 'b': 0.106}, {'UUID': 'PDno23andme_full_gene_notext_4311839', 'SNP': 'rs57666488', 'p': 0.02347, 'b': 0.062}, {'UUID': 'PDno23andme_full_gene_notext_4702484', 'SNP': 'rs72805927', 'p': 0.03342, 'b': 0.0822}, {'UUID': 'PDno23andme_full_gene_notext_3331351', 'SNP': 'rs11745823', 'p': 0.03488, 'b': 0.0392}, {'UUID': 'PDno23andme_full_gene_notext_1452128', 'SNP': 'rs10039050', 'p': 0.03607, 'b': -0.0519}, {'UUID': 'PDno23andme_full_gene_notext_6221323', 'SNP': 'rs6881772', 'p': 0.04116, 'b': -0.0504}, {'UUID': 'PDno23andme_full_gene_notext_2462451', 'SNP': 'rs10055648', 'p': 0.04399, 'b': -0.0669}, {'UUID': 'PDno23andme_full_gene_notext_979774', 'SNP': 'rs11739460', 'p': 0.05032, 'b': 0.0382}, {'UUID': 'PDno23andme_full_gene_notext_7416915', 'SNP': 'rs4286653', 'p': 0.05145, 'b': 0.0835}, {'UUID': 'PDno23andme_full_gene_notext_7749607', 'SNP': 'rs12657774', 'p': 0.05563, 'b': -0.0633}, {'UUID': 'PDno23andme_full_gene_notext_1814220', 'SNP': 'rs59913498', 'p': 0.05659, 'b': -0.0631}, {'UUID': 'PDno23andme_full_gene_notext_3304756', 'SNP': 'rs112026546', 'p': 0.05788, 'b': 0.4445}, {'UUID': 'PDno23andme_full_gene_notext_409039', 'SNP': 'rs59853353', 'p': 0.05906, 'b': -0.0459}, {'UUID': 'PDno23andme_full_gene_notext_4243506', 'SNP': 'rs13161248', 'p': 0.06142, 'b': -0.0378}, {'UUID': 'PDno23andme_full_gene_notext_2154790', 'SNP': 'rs10515640', 'p': 0.06735, 'b': -0.035}, {'UUID': 'PDno23andme_full_gene_notext_1529260', 'SNP': 'rs79273852', 'p': 0.06811, 'b': -0.0448}, {'UUID': 'PDno23andme_full_gene_notext_1159900', 'SNP': 'rs75049558', 'p': 0.06882, 'b': -0.0447}, {'UUID': 'PDno23andme_full_gene_notext_4157686', 'SNP': 'rs4958811', 'p': 0.06931, 'b': -0.0348}, {'UUID': 'PDno23andme_full_gene_notext_7367174', 'SNP': 'rs79849171', 'p': 0.07002, 'b': -0.0606}, {'UUID': 'PDno23andme_full_gene_notext_6712574', 'SNP': 'rs76203067', 'p': 0.07327, 'b': -0.0599}, {'UUID': 'PDno23andme_full_gene_notext_3890611', 'SNP': 'rs113402031', 'p': 0.07381, 'b': -0.0598}, {'UUID': 'PDno23andme_full_gene_notext_1932243', 'SNP': 'rs76049260', 'p': 0.07384, 'b': -0.0597}, {'UUID': 'PDno23andme_full_gene_notext_684559', 'SNP': 'rs6865726', 'p': 0.09619, 'b': -0.0319}, {'UUID': 'PDno23andme_full_gene_notext_6279697', 'SNP': 'rs112720032', 'p': 0.09677, 'b': 0.1534}, {'UUID': 'PDno23andme_full_gene_notext_7745857', 'SNP': 'rs17656654', 'p': 0.09982, 'b': -0.0325}, {'UUID': 'PDno23andme_full_gene_notext_1403403', 'SNP': 'rs7705113', 'p': 0.1078, 'b': -0.0318}, {'UUID': 'PDno23andme_full_gene_notext_1636176', 'SNP': 'rs891942', 'p': 0.1085, 'b': 0.0373}, {'UUID': 'PDno23andme_full_gene_notext_3484534', 'SNP': 'rs9688182', 'p': 0.109, 'b': -0.0308}, {'UUID': 'PDno23andme_full_gene_notext_3919511', 'SNP': 'rs12651800', 'p': 0.1153, 'b': 0.0401}, {'UUID': 'PDno23andme_full_gene_notext_7187097', 'SNP': 'rs10434720', 'p': 0.1334, 'b': 0.0382}, {'UUID': 'PDno23andme_full_gene_notext_582110', 'SNP': 'rs57179351', 'p': 0.1335, 'b': -0.0298}, {'UUID': 'PDno23andme_full_gene_notext_2639897', 'SNP': 'rs12656742', 'p': 0.1409, 'b': -0.0292}, {'UUID': 'PDno23andme_full_gene_notext_2953284', 'SNP': 'rs4958407', 'p': 0.1472, 'b': -0.0289}, {'UUID': 'PDno23andme_full_gene_notext_6742318', 'SNP': 'rs12652122', 'p': 0.1533, 'b': -0.0286}, {'UUID': 'PDno23andme_full_gene_notext_4655890', 'SNP': 'rs6888551', 'p': 0.1649, 'b': -0.0276}, {'UUID': 'PDno23andme_full_gene_notext_3312853', 'SNP': 'rs11740704', 'p': 0.1777, 'b': -0.0281}, {'UUID': 'PDno23andme_full_gene_notext_6039778', 'SNP': 'rs3806947', 'p': 0.1779, 'b': -0.0645}, {'UUID': 'PDno23andme_full_gene_notext_6533051', 'SNP': 'rs10037049', 'p': 0.1781, 'b': 0.0502}, {'UUID': 'PDno23andme_full_gene_notext_4220278', 'SNP': 'rs72805921', 'p': 0.1783, 'b': 0.0502}, {'UUID': 'PDno23andme_full_gene_notext_5669140', 'SNP': 'rs72805922', 'p': 0.1804, 'b': 0.05}, {'UUID': 'PDno23andme_full_gene_notext_7570099', 'SNP': 'rs10045518', 'p': 0.1821, 'b': 0.0497}, {'UUID': 'PDno23andme_full_gene_notext_2926700', 'SNP': 'rs10068584', 'p': 0.2316, 'b': 0.0461}, {'UUID': 'PDno23andme_full_gene_notext_1420445', 'SNP': 'rs3806948', 'p': 0.2344, 'b': -0.0421}, {'UUID': 'PDno23andme_full_gene_notext_1580543', 'SNP': 'rs150094057', 'p': 0.2406, 'b': 0.2883}, {'UUID': 'PDno23andme_full_gene_notext_1023156', 'SNP': 'rs2880537', 'p': 0.2679, 'b': -0.0383}, {'UUID': 'PDno23andme_full_gene_notext_237167', 'SNP': 'rs17111118', 'p': 0.2716, 'b': 0.042}, {'UUID': 'PDno23andme_full_gene_notext_5517031', 'SNP': 'rs72805915', 'p': 0.2792, 'b': 0.0414}, {'UUID': 'PDno23andme_full_gene_notext_6214663', 'SNP': 'rs72805916', 'p': 0.2828, 'b': 0.0411}, {'UUID': 'PDno23andme_full_gene_notext_5351051', 'SNP': 'rs4958849', 'p': 0.2875, 'b': -0.0358}, {'UUID': 'PDno23andme_full_gene_notext_1064475', 'SNP': 'rs115726682', 'p': 0.3129, 'b': 0.4583}, {'UUID': 'PDno23andme_full_gene_notext_1560056', 'SNP': 'rs891940', 'p': 0.3166, 'b': -0.0448}, {'UUID': 'PDno23andme_full_gene_notext_339072', 'SNP': 'rs891939', 'p': 0.3199, 'b': -0.0445}, {'UUID': 'PDno23andme_full_gene_notext_7016059', 'SNP': 'rs77429758', 'p': 0.3203, 'b': -0.0517}, {'UUID': 'PDno23andme_full_gene_notext_2251739', 'SNP': 'rs10044860', 'p': 0.3446, 'b': -0.0176}, {'UUID': 'PDno23andme_full_gene_notext_7604437', 'SNP': 'rs56950939', 'p': 0.3472, 'b': -0.0349}, {'UUID': 'PDno23andme_full_gene_notext_1417684', 'SNP': 'rs6579786', 'p': 0.3494, 'b': -0.0423}, {'UUID': 'PDno23andme_full_gene_notext_4406557', 'SNP': 'rs59857791', 'p': 0.3836, 'b': -0.0323}, {'UUID': 'PDno23andme_full_gene_notext_5049137', 'SNP': 'rs73796401', 'p': 0.3866, 'b': -0.0459}, {'UUID': 'PDno23andme_full_gene_notext_4876596', 'SNP': 'rs10434711', 'p': 0.3968, 'b': -0.0292}, {'UUID': 'PDno23andme_full_gene_notext_282289', 'SNP': 'rs75044862', 'p': 0.3973, 'b': -0.0313}, {'UUID': 'PDno23andme_full_gene_notext_6930463', 'SNP': 'rs113994618', 'p': 0.4008, 'b': -0.0312}, {'UUID': 'PDno23andme_full_gene_notext_6924226', 'SNP': 'rs72805924', 'p': 0.4125, 'b': -0.0749}, {'UUID': 'PDno23andme_full_gene_notext_7322876', 'SNP': 'rs78824631', 'p': 0.42, 'b': -0.0275}, {'UUID': 'PDno23andme_full_gene_notext_3608986', 'SNP': 'rs77346270', 'p': 0.429, 'b': -0.0269}, {'UUID': 'PDno23andme_full_gene_notext_2593471', 'SNP': 'rs78612648', 'p': 0.4292, 'b': -0.0269}, {'UUID': 'PDno23andme_full_gene_notext_3537136', 'SNP': 'rs75569013', 'p': 0.4306, 'b': -0.0268}, {'UUID': 'PDno23andme_full_gene_notext_6908739', 'SNP': 'rs77018379', 'p': 0.4307, 'b': -0.0268}, {'UUID': 'PDno23andme_full_gene_notext_4611253', 'SNP': 'rs77312446', 'p': 0.4314, 'b': -0.0268}, {'UUID': 'PDno23andme_full_gene_notext_4309742', 'SNP': 'rs76179877', 'p': 0.4331, 'b': -0.0267}, {'UUID': 'PDno23andme_full_gene_notext_1525620', 'SNP': 'rs13184396', 'p': 0.4337, 'b': -0.0173}, {'UUID': 'PDno23andme_full_gene_notext_3133427', 'SNP': 'rs78817570', 'p': 0.4348, 'b': -0.0267}, {'UUID': 'PDno23andme_full_gene_notext_950740', 'SNP': 'rs76931427', 'p': 0.4354, 'b': -0.0267}, {'UUID': 'PDno23andme_full_gene_notext_6095627', 'SNP': 'rs10434712', 'p': 0.436, 'b': -0.0268}, {'UUID': 'PDno23andme_full_gene_notext_5670885', 'SNP': 'rs1017373', 'p': 0.4375, 'b': -0.0285}, {'UUID': 'PDno23andme_full_gene_notext_7691754', 'SNP': 'rs74441919', 'p': 0.4391, 'b': -0.0264}, {'UUID': 'PDno23andme_full_gene_notext_7353230', 'SNP': 'rs6884015', 'p': 0.4394, 'b': -0.0264}, {'UUID': 'PDno23andme_full_gene_notext_1425489', 'SNP': 'rs76058864', 'p': 0.4414, 'b': -0.0267}, {'UUID': 'PDno23andme_full_gene_notext_3883576', 'SNP': 'rs77764041', 'p': 0.442, 'b': -0.0263}, {'UUID': 'PDno23andme_full_gene_notext_1435528', 'SNP': 'rs112943546', 'p': 0.4431, 'b': -0.0262}, {'UUID': 'PDno23andme_full_gene_notext_3579122', 'SNP': 'rs114654603', 'p': 0.4455, 'b': -0.0259}, {'UUID': 'PDno23andme_full_gene_notext_3136993', 'SNP': 'rs6862123', 'p': 0.4464, 'b': -0.028}, {'UUID': 'PDno23andme_full_gene_notext_3813563', 'SNP': 'rs6579787', 'p': 0.449, 'b': -0.0258}, {'UUID': 'PDno23andme_full_gene_notext_1982926', 'SNP': 'rs13185389', 'p': 0.464, 'b': -0.0159}, {'UUID': 'PDno23andme_full_gene_notext_6058628', 'SNP': 'rs4552576', 'p': 0.4859, 'b': -0.013}, {'UUID': 'PDno23andme_full_gene_notext_4754569', 'SNP': 'rs72805928', 'p': 0.4996, 'b': -0.0288}, {'UUID': 'PDno23andme_full_gene_notext_1445947', 'SNP': 'rs6881714', 'p': 0.5152, 'b': -0.0217}, {'UUID': 'PDno23andme_full_gene_notext_2162560', 'SNP': 'rs76918897', 'p': 0.5181, 'b': -0.0215}, {'UUID': 'PDno23andme_full_gene_notext_925690', 'SNP': 'rs79485659', 'p': 0.5195, 'b': -0.0216}, {'UUID': 'PDno23andme_full_gene_notext_5968632', 'SNP': 'rs66657421', 'p': 0.5228, 'b': 0.0128}, {'UUID': 'PDno23andme_full_gene_notext_4278611', 'SNP': 'rs891943', 'p': 0.5274, 'b': -0.0147}, {'UUID': 'PDno23andme_full_gene_notext_4766861', 'SNP': 'rs12522210', 'p': 0.5293, 'b': -0.0288}, {'UUID': 'PDno23andme_full_gene_notext_2722129', 'SNP': 'rs79240588', 'p': 0.5307, 'b': -0.021}]",general,"Select, Order By, Similarity Search, Multi-Filter","Effect, GWAS Significance"
-Q50.1334,Q50,Do PPARG gene mutations increase the risk of Parkinson's disease?,"No, there are no significant mutations in the PPARG gene associated with an increased risk of Parkinson's disease according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019).","SELECT UUID, SNP, p, b 
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE nearestGene LIKE ""%PPARG%""
- ORDER BY p
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_6262030', 'SNP': 'rs13110224', 'p': 0.0005046, 'b': -0.0947}, {'UUID': 'PDno23andme_full_gene_notext_7741404', 'SNP': 'rs2191597', 'p': 0.00145, 'b': 0.0682}, {'UUID': 'PDno23andme_full_gene_notext_1171145', 'SNP': 'rs2655259', 'p': 0.001611, 'b': 0.2416}, {'UUID': 'PDno23andme_full_gene_notext_5114589', 'SNP': 'rs640050', 'p': 0.001821, 'b': 0.0643}, {'UUID': 'PDno23andme_full_gene_notext_3915226', 'SNP': 'rs614747', 'p': 0.001863, 'b': 0.0718}, {'UUID': 'PDno23andme_full_gene_notext_1749193', 'SNP': 'rs7676049', 'p': 0.001984, 'b': 0.0726}, {'UUID': 'PDno23andme_full_gene_notext_4502050', 'SNP': 'rs34197556', 'p': 0.002032, 'b': -0.1013}, {'UUID': 'PDno23andme_full_gene_notext_2870464', 'SNP': 'rs6448237', 'p': 0.002175, 'b': -0.0967}, {'UUID': 'PDno23andme_full_gene_notext_3362834', 'SNP': 'rs6847910', 'p': 0.002209, 'b': 0.0688}, {'UUID': 'PDno23andme_full_gene_notext_147131', 'SNP': 'rs61799325', 'p': 0.002225, 'b': 0.0709}, {'UUID': 'PDno23andme_full_gene_notext_313340', 'SNP': 'rs10025406', 'p': 0.002283, 'b': 0.0623}, {'UUID': 'PDno23andme_full_gene_notext_3359038', 'SNP': 'rs114591387', 'p': 0.002488, 'b': 0.3713}, {'UUID': 'PDno23andme_full_gene_notext_1155738', 'SNP': 'rs609501', 'p': 0.002612, 'b': 0.0699}, {'UUID': 'PDno23andme_full_gene_notext_1471862', 'SNP': 'rs6834383', 'p': 0.002716, 'b': 0.0616}, {'UUID': 'PDno23andme_full_gene_notext_3840675', 'SNP': 'rs148743887', 'p': 0.002936, 'b': -0.2338}, {'UUID': 'PDno23andme_full_gene_notext_3702682', 'SNP': 'rs142946354', 'p': 0.002949, 'b': 0.253}, {'UUID': 'PDno23andme_full_gene_notext_5209720', 'SNP': 'rs682087', 'p': 0.002956, 'b': 0.0699}, {'UUID': 'PDno23andme_full_gene_notext_2544712', 'SNP': 'rs150754975', 'p': 0.002963, 'b': 0.2385}, {'UUID': 'PDno23andme_full_gene_notext_213108', 'SNP': 'rs4697435', 'p': 0.00314, 'b': 0.0634}, {'UUID': 'PDno23andme_full_gene_notext_1825069', 'SNP': 'rs2324233', 'p': 0.003188, 'b': 0.0712}, {'UUID': 'PDno23andme_full_gene_notext_2149060', 'SNP': 'rs16874420', 'p': 0.003199, 'b': -0.0933}, {'UUID': 'PDno23andme_full_gene_notext_7403911', 'SNP': 'rs6857250', 'p': 0.003228, 'b': 0.0605}, {'UUID': 'PDno23andme_full_gene_notext_4185213', 'SNP': 'rs71609001', 'p': 0.003294, 'b': -0.0842}, {'UUID': 'PDno23andme_full_gene_notext_5963467', 'SNP': 'rs605532', 'p': 0.003298, 'b': 0.0627}, {'UUID': 'PDno23andme_full_gene_notext_175182', 'SNP': 'rs6838942', 'p': 0.00343, 'b': -0.0841}, {'UUID': 'PDno23andme_full_gene_notext_4312803', 'SNP': 'rs4463056', 'p': 0.003453, 'b': 0.0624}, {'UUID': 'PDno23andme_full_gene_notext_1507362', 'SNP': 'rs140506952', 'p': 0.003573, 'b': -1.0193}, {'UUID': 'PDno23andme_full_gene_notext_3567629', 'SNP': 'rs116433705', 'p': 0.003579, 'b': -0.2672}, {'UUID': 'PDno23andme_full_gene_notext_7144968', 'SNP': 'rs114857705', 'p': 0.003631, 'b': 0.2259}, {'UUID': 'PDno23andme_full_gene_notext_1439102', 'SNP': 'rs10517031', 'p': 0.003681, 'b': -0.0913}, {'UUID': 'PDno23andme_full_gene_notext_213177', 'SNP': 'rs13143473', 'p': 0.003748, 'b': -0.079}, {'UUID': 'PDno23andme_full_gene_notext_452737', 'SNP': 'rs76062007', 'p': 0.00385, 'b': -0.2511}, {'UUID': 'PDno23andme_full_gene_notext_912043', 'SNP': 'rs9324630', 'p': 0.004084, 'b': -0.0614}, {'UUID': 'PDno23andme_full_gene_notext_5353096', 'SNP': 'rs9324629', 'p': 0.004102, 'b': -0.0614}, {'UUID': 'PDno23andme_full_gene_notext_2557710', 'SNP': 'rs16874564', 'p': 0.004245, 'b': -0.082}, {'UUID': 'PDno23andme_full_gene_notext_260466', 'SNP': 'rs12717846', 'p': 0.004272, 'b': -0.0609}, {'UUID': 'PDno23andme_full_gene_notext_5111765', 'SNP': 'rs17653473', 'p': 0.004301, 'b': -0.0609}, {'UUID': 'PDno23andme_full_gene_notext_4689110', 'SNP': 'rs11167482', 'p': 0.004449, 'b': -0.0608}, {'UUID': 'PDno23andme_full_gene_notext_2270844', 'SNP': 'rs624456', 'p': 0.004482, 'b': 0.0664}, {'UUID': 'PDno23andme_full_gene_notext_6312724', 'SNP': 'rs10517026', 'p': 0.004592, 'b': -0.0895}, {'UUID': 'PDno23andme_full_gene_notext_270572', 'SNP': 'rs594629', 'p': 0.004714, 'b': 0.0626}, {'UUID': 'PDno23andme_full_gene_notext_1882746', 'SNP': 'rs117991638', 'p': 0.004724, 'b': 0.2362}, {'UUID': 'PDno23andme_full_gene_notext_7250000', 'SNP': 'rs6858027', 'p': 0.00475, 'b': -0.089}, {'UUID': 'PDno23andme_full_gene_notext_2003212', 'SNP': 'rs2946405', 'p': 0.004798, 'b': 0.0848}, {'UUID': 'PDno23andme_full_gene_notext_1367677', 'SNP': 'rs16874778', 'p': 0.004963, 'b': 0.0603}, {'UUID': 'PDno23andme_full_gene_notext_4613333', 'SNP': 'rs139495991', 'p': 0.005049, 'b': 0.2242}, {'UUID': 'PDno23andme_full_gene_notext_5397354', 'SNP': 'rs4697048', 'p': 0.005133, 'b': 0.0667}, {'UUID': 'PDno23andme_full_gene_notext_3843956', 'SNP': 'rs16874396', 'p': 0.005507, 'b': -0.088}, {'UUID': 'PDno23andme_full_gene_notext_1001740', 'SNP': 'rs145925010', 'p': 0.005524, 'b': 0.222}, {'UUID': 'PDno23andme_full_gene_notext_1870103', 'SNP': 'rs56098241', 'p': 0.005767, 'b': 0.0592}, {'UUID': 'PDno23andme_full_gene_notext_769300', 'SNP': 'rs17029002', 'p': 0.005804, 'b': 0.2251}, {'UUID': 'PDno23andme_full_gene_notext_5476541', 'SNP': 'rs2109596', 'p': 0.0059, 'b': 0.059}, {'UUID': 'PDno23andme_full_gene_notext_1241190', 'SNP': 'rs146975611', 'p': 0.006, 'b': 0.2106}, {'UUID': 'PDno23andme_full_gene_notext_4636273', 'SNP': 'rs626610', 'p': 0.006239, 'b': 0.0623}, {'UUID': 'PDno23andme_full_gene_notext_7587617', 'SNP': 'rs588634', 'p': 0.006567, 'b': 0.0613}, {'UUID': 'PDno23andme_full_gene_notext_3292062', 'SNP': 'rs10938978', 'p': 0.006694, 'b': 0.0608}, {'UUID': 'PDno23andme_full_gene_notext_936742', 'SNP': 'rs694917', 'p': 0.006833, 'b': 0.0617}, {'UUID': 'PDno23andme_full_gene_notext_4677683', 'SNP': 'rs16874194', 'p': 0.006974, 'b': 0.09}, {'UUID': 'PDno23andme_full_gene_notext_704449', 'SNP': 'rs12502003', 'p': 0.006988, 'b': 0.0606}, {'UUID': 'PDno23andme_full_gene_notext_1178763', 'SNP': 'rs6448238', 'p': 0.007349, 'b': 0.0601}, {'UUID': 'PDno23andme_full_gene_notext_7373342', 'SNP': 'rs13119232', 'p': 0.007398, 'b': -0.0782}, {'UUID': 'PDno23andme_full_gene_notext_2012114', 'SNP': 'rs667716', 'p': 0.00742, 'b': 0.0596}, {'UUID': 'PDno23andme_full_gene_notext_218935', 'SNP': 'rs16874726', 'p': 0.007432, 'b': 0.0596}, {'UUID': 'PDno23andme_full_gene_notext_6099433', 'SNP': 'rs796289', 'p': 0.007568, 'b': 0.2096}, {'UUID': 'PDno23andme_full_gene_notext_3942503', 'SNP': 'rs16874774', 'p': 0.007636, 'b': 0.0583}, {'UUID': 'PDno23andme_full_gene_notext_1659352', 'SNP': 'rs614457', 'p': 0.007727, 'b': 0.0608}, {'UUID': 'PDno23andme_full_gene_notext_164294', 'SNP': 'rs1910456', 'p': 0.007797, 'b': -0.0561}, {'UUID': 'PDno23andme_full_gene_notext_3034727', 'SNP': 'rs651046', 'p': 0.007832, 'b': 0.0606}, {'UUID': 'PDno23andme_full_gene_notext_1155251', 'SNP': 'rs6858012', 'p': 0.008356, 'b': -0.0556}, {'UUID': 'PDno23andme_full_gene_notext_2042908', 'SNP': 'rs35847952', 'p': 0.008365, 'b': -0.0553}, {'UUID': 'PDno23andme_full_gene_notext_7224976', 'SNP': 'rs10489098', 'p': 0.008405, 'b': 0.0687}, {'UUID': 'PDno23andme_full_gene_notext_1987902', 'SNP': 'rs4544700', 'p': 0.008486, 'b': -0.0555}, {'UUID': 'PDno23andme_full_gene_notext_3703529', 'SNP': 'rs534369488', 'p': 0.00891, 'b': -1.057}, {'UUID': 'PDno23andme_full_gene_notext_613274', 'SNP': 'rs114869325', 'p': 0.009006, 'b': 0.2081}, {'UUID': 'PDno23andme_full_gene_notext_4536352', 'SNP': 'rs12646780', 'p': 0.009528, 'b': 0.0651}, {'UUID': 'PDno23andme_full_gene_notext_3404031', 'SNP': 'rs16874363', 'p': 0.009596, 'b': 0.0659}, {'UUID': 'PDno23andme_full_gene_notext_2476904', 'SNP': 'rs7675816', 'p': 0.009825, 'b': 0.0577}, {'UUID': 'PDno23andme_full_gene_notext_238975', 'SNP': 'rs4301098', 'p': 0.009835, 'b': -0.0566}, {'UUID': 'PDno23andme_full_gene_notext_6208733', 'SNP': 'rs16874921', 'p': 0.009903, 'b': 0.0581}, {'UUID': 'PDno23andme_full_gene_notext_92225', 'SNP': 'rs16874922', 'p': 0.009909, 'b': 0.058}, {'UUID': 'PDno23andme_full_gene_notext_3640729', 'SNP': 'rs984591', 'p': 0.009917, 'b': 0.0648}, {'UUID': 'PDno23andme_full_gene_notext_2265031', 'SNP': 'rs12509527', 'p': 0.01009, 'b': 0.0576}, {'UUID': 'PDno23andme_full_gene_notext_6066979', 'SNP': 'rs2089067', 'p': 0.01026, 'b': -0.0554}, {'UUID': 'PDno23andme_full_gene_notext_5000711', 'SNP': 'rs16874919', 'p': 0.0106, 'b': 0.0577}, {'UUID': 'PDno23andme_full_gene_notext_7687382', 'SNP': 'rs59744082', 'p': 0.01061, 'b': 0.0575}, {'UUID': 'PDno23andme_full_gene_notext_5729301', 'SNP': 'rs12648710', 'p': 0.01062, 'b': 0.0668}, {'UUID': 'PDno23andme_full_gene_notext_524521', 'SNP': 'rs16874917', 'p': 0.01064, 'b': 0.0577}, {'UUID': 'PDno23andme_full_gene_notext_7711293', 'SNP': 'rs67717089', 'p': 0.01077, 'b': -0.073}, {'UUID': 'PDno23andme_full_gene_notext_3330184', 'SNP': 'rs6851904', 'p': 0.01098, 'b': 0.0665}, {'UUID': 'PDno23andme_full_gene_notext_3226952', 'SNP': 'rs12648568', 'p': 0.01111, 'b': 0.0663}, {'UUID': 'PDno23andme_full_gene_notext_6453167', 'SNP': 'rs16874509', 'p': 0.01148, 'b': 0.0631}, {'UUID': 'PDno23andme_full_gene_notext_3259633', 'SNP': 'rs13109150', 'p': 0.01149, 'b': 0.0575}, {'UUID': 'PDno23andme_full_gene_notext_6511926', 'SNP': 'rs13109835', 'p': 0.01151, 'b': 0.0574}, {'UUID': 'PDno23andme_full_gene_notext_4003543', 'SNP': 'rs593180', 'p': 0.01178, 'b': 0.0591}, {'UUID': 'PDno23andme_full_gene_notext_868448', 'SNP': 'rs16874536', 'p': 0.01215, 'b': 0.0625}, {'UUID': 'PDno23andme_full_gene_notext_2172113', 'SNP': 'rs3774908', 'p': 0.01217, 'b': 0.0833}, {'UUID': 'PDno23andme_full_gene_notext_1001547', 'SNP': 'rs59717986', 'p': 0.01232, 'b': 0.0633}, {'UUID': 'PDno23andme_full_gene_notext_3391903', 'SNP': 'rs4697434', 'p': 0.0124, 'b': 0.0528}, {'UUID': 'PDno23andme_full_gene_notext_3293414', 'SNP': 'rs1878951', 'p': 0.01251, 'b': 0.0558}, {'UUID': 'PDno23andme_full_gene_notext_2681215', 'SNP': 'rs78664543', 'p': 0.01257, 'b': -0.6364}]",general,"Select, Order By, Similarity Search, Multi-Filter","Effect, GWAS Significance"
-Q50.906,Q50,Do LINC02549 gene mutations increase the risk of Parkinson's disease?,"No, there are no significant mutations in the LINC02549 gene associated with an increased risk of Parkinson's disease according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019).","SELECT UUID, SNP, p, b 
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE nearestGene LIKE ""%LINC02549%""
- ORDER BY p
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_3390029', 'SNP': 'rs150112065', 'p': 0.005011, 'b': -0.201}, {'UUID': 'PDno23andme_full_gene_notext_676366', 'SNP': 'rs190078315', 'p': 0.005727, 'b': -0.4796}, {'UUID': 'PDno23andme_full_gene_notext_7695450', 'SNP': 'rs79549211', 'p': 0.007213, 'b': 0.2042}, {'UUID': 'PDno23andme_full_gene_notext_1290657', 'SNP': 'rs2932673', 'p': 0.00735, 'b': 0.0693}, {'UUID': 'PDno23andme_full_gene_notext_6031370', 'SNP': 'rs111985921', 'p': 0.007668, 'b': 0.233}, {'UUID': 'PDno23andme_full_gene_notext_5803516', 'SNP': 'rs148951961', 'p': 0.00788, 'b': 0.2023}, {'UUID': 'PDno23andme_full_gene_notext_579349', 'SNP': 'rs62415519', 'p': 0.008614, 'b': -0.1051}, {'UUID': 'PDno23andme_full_gene_notext_4579453', 'SNP': 'rs17576708', 'p': 0.008715, 'b': -0.1044}, {'UUID': 'PDno23andme_full_gene_notext_2494157', 'SNP': 'rs17576666', 'p': 0.008827, 'b': -0.1043}, {'UUID': 'PDno23andme_full_gene_notext_4057705', 'SNP': 'rs62415520', 'p': 0.00887, 'b': -0.1046}, {'UUID': 'PDno23andme_full_gene_notext_872717', 'SNP': 'rs17576652', 'p': 0.009008, 'b': -0.104}, {'UUID': 'PDno23andme_full_gene_notext_688524', 'SNP': 'rs62415525', 'p': 0.009024, 'b': -0.1039}, {'UUID': 'PDno23andme_full_gene_notext_5862794', 'SNP': 'rs62415524', 'p': 0.009025, 'b': -0.104}, {'UUID': 'PDno23andme_full_gene_notext_1862504', 'SNP': 'rs62415521', 'p': 0.009163, 'b': -0.1039}, {'UUID': 'PDno23andme_full_gene_notext_5594455', 'SNP': 'rs72909457', 'p': 0.009194, 'b': -0.1035}, {'UUID': 'PDno23andme_full_gene_notext_6976938', 'SNP': 'rs62415523', 'p': 0.009248, 'b': -0.1037}, {'UUID': 'PDno23andme_full_gene_notext_3061488', 'SNP': 'rs78597926', 'p': 0.009308, 'b': 0.1981}, {'UUID': 'PDno23andme_full_gene_notext_6083532', 'SNP': 'rs72909451', 'p': 0.01009, 'b': -0.1025}, {'UUID': 'PDno23andme_full_gene_notext_7280526', 'SNP': 'rs117888972', 'p': 0.01021, 'b': -0.1491}, {'UUID': 'PDno23andme_full_gene_notext_3279216', 'SNP': 'rs72909458', 'p': 0.01027, 'b': -0.1019}, {'UUID': 'PDno23andme_full_gene_notext_5132987', 'SNP': 'rs56697349', 'p': 0.01033, 'b': 0.1924}, {'UUID': 'PDno23andme_full_gene_notext_5133329', 'SNP': 'rs56677785', 'p': 0.01038, 'b': 0.1946}, {'UUID': 'PDno23andme_full_gene_notext_3582654', 'SNP': 'rs62415527', 'p': 0.01062, 'b': -0.1013}, {'UUID': 'PDno23andme_full_gene_notext_4922154', 'SNP': 'rs73451406', 'p': 0.01092, 'b': 0.1913}, {'UUID': 'PDno23andme_full_gene_notext_2615396', 'SNP': 'rs34253746', 'p': 0.01164, 'b': 0.1211}, {'UUID': 'PDno23andme_full_gene_notext_2928911', 'SNP': 'rs79473449', 'p': 0.01247, 'b': 0.1887}, {'UUID': 'PDno23andme_full_gene_notext_1355', 'SNP': 'rs147146647', 'p': 0.01409, 'b': -0.1734}, {'UUID': 'PDno23andme_full_gene_notext_7590424', 'SNP': 'rs62415518', 'p': 0.01452, 'b': -0.0995}, {'UUID': 'PDno23andme_full_gene_notext_6108551', 'SNP': 'rs62415517', 'p': 0.01555, 'b': -0.0985}, {'UUID': 'PDno23andme_full_gene_notext_149811', 'SNP': 'rs72909442', 'p': 0.016, 'b': -0.098}, {'UUID': 'PDno23andme_full_gene_notext_5781534', 'SNP': 'rs62415529', 'p': 0.01603, 'b': -0.0957}, {'UUID': 'PDno23andme_full_gene_notext_2830523', 'SNP': 'rs62415516', 'p': 0.01687, 'b': -0.0973}, {'UUID': 'PDno23andme_full_gene_notext_7006280', 'SNP': 'rs62415522', 'p': 0.01785, 'b': -0.0956}, {'UUID': 'PDno23andme_full_gene_notext_3739988', 'SNP': 'rs72893521', 'p': 0.01828, 'b': -0.0944}, {'UUID': 'PDno23andme_full_gene_notext_339536', 'SNP': 'rs62415515', 'p': 0.01845, 'b': -0.096}, {'UUID': 'PDno23andme_full_gene_notext_2532570', 'SNP': 'rs151242376', 'p': 0.0185, 'b': 0.1811}, {'UUID': 'PDno23andme_full_gene_notext_805976', 'SNP': 'rs62417081', 'p': 0.01855, 'b': -0.0939}, {'UUID': 'PDno23andme_full_gene_notext_538948', 'SNP': 'rs62417078', 'p': 0.01858, 'b': -0.0948}, {'UUID': 'PDno23andme_full_gene_notext_7408583', 'SNP': 'rs62417080', 'p': 0.01864, 'b': -0.0947}, {'UUID': 'PDno23andme_full_gene_notext_1140131', 'SNP': 'rs62415536', 'p': 0.01886, 'b': -0.094}, {'UUID': 'PDno23andme_full_gene_notext_3444759', 'SNP': 'rs62415535', 'p': 0.01888, 'b': -0.094}, {'UUID': 'PDno23andme_full_gene_notext_5273767', 'SNP': 'rs62415547', 'p': 0.0189, 'b': -0.0938}, {'UUID': 'PDno23andme_full_gene_notext_5440340', 'SNP': 'rs62415543', 'p': 0.0189, 'b': -0.0939}, {'UUID': 'PDno23andme_full_gene_notext_652301', 'SNP': 'rs62415544', 'p': 0.01891, 'b': -0.0939}, {'UUID': 'PDno23andme_full_gene_notext_2688977', 'SNP': 'rs62415546', 'p': 0.01891, 'b': -0.0938}, {'UUID': 'PDno23andme_full_gene_notext_4778383', 'SNP': 'rs62417069', 'p': 0.01891, 'b': -0.0938}, {'UUID': 'PDno23andme_full_gene_notext_437309', 'SNP': 'rs72893509', 'p': 0.01892, 'b': -0.094}, {'UUID': 'PDno23andme_full_gene_notext_860207', 'SNP': 'rs62417070', 'p': 0.01892, 'b': -0.0938}, {'UUID': 'PDno23andme_full_gene_notext_119750', 'SNP': 'rs62417071', 'p': 0.01894, 'b': -0.0937}, {'UUID': 'PDno23andme_full_gene_notext_6220362', 'SNP': 'rs72893523', 'p': 0.01894, 'b': -0.0938}, {'UUID': 'PDno23andme_full_gene_notext_5434118', 'SNP': 'rs62417075', 'p': 0.01897, 'b': -0.0937}, {'UUID': 'PDno23andme_full_gene_notext_3333568', 'SNP': 'rs62417076', 'p': 0.01897, 'b': -0.0937}, {'UUID': 'PDno23andme_full_gene_notext_5415750', 'SNP': 'rs72893527', 'p': 0.01898, 'b': -0.0937}, {'UUID': 'PDno23andme_full_gene_notext_127032', 'SNP': 'rs62415542', 'p': 0.01902, 'b': -0.0938}, {'UUID': 'PDno23andme_full_gene_notext_4502856', 'SNP': 'rs62415541', 'p': 0.01902, 'b': -0.0938}, {'UUID': 'PDno23andme_full_gene_notext_3318786', 'SNP': 'rs62415534', 'p': 0.01904, 'b': -0.094}, {'UUID': 'PDno23andme_full_gene_notext_2552753', 'SNP': 'rs62417077', 'p': 0.01905, 'b': -0.0935}, {'UUID': 'PDno23andme_full_gene_notext_2881376', 'SNP': 'rs62415540', 'p': 0.01915, 'b': -0.0937}, {'UUID': 'PDno23andme_full_gene_notext_2141128', 'SNP': 'rs62415528', 'p': 0.01932, 'b': -0.0939}, {'UUID': 'PDno23andme_full_gene_notext_34593', 'SNP': 'rs17576854', 'p': 0.01946, 'b': -0.0939}, {'UUID': 'PDno23andme_full_gene_notext_5800979', 'SNP': 'rs17576827', 'p': 0.01968, 'b': -0.0938}, {'UUID': 'PDno23andme_full_gene_notext_2826347', 'SNP': 'rs17492325', 'p': 0.0198, 'b': -0.0937}, {'UUID': 'PDno23andme_full_gene_notext_7137140', 'SNP': 'rs62415526', 'p': 0.01996, 'b': -0.0936}, {'UUID': 'PDno23andme_full_gene_notext_769755', 'SNP': 'rs146537195', 'p': 0.0208, 'b': -0.1084}, {'UUID': 'PDno23andme_full_gene_notext_2749205', 'SNP': 'rs62417079', 'p': 0.02104, 'b': -0.0927}, {'UUID': 'PDno23andme_full_gene_notext_1873991', 'SNP': 'rs62415531', 'p': 0.02147, 'b': -0.0919}, {'UUID': 'PDno23andme_full_gene_notext_4543077', 'SNP': 'rs72911085', 'p': 0.02159, 'b': -0.0918}, {'UUID': 'PDno23andme_full_gene_notext_6265041', 'SNP': 'rs112770473', 'p': 0.0219, 'b': 0.1351}, {'UUID': 'PDno23andme_full_gene_notext_4833953', 'SNP': 'rs62415532', 'p': 0.02213, 'b': -0.0914}, {'UUID': 'PDno23andme_full_gene_notext_2310142', 'SNP': 'rs62415512', 'p': 0.02222, 'b': -0.0931}, {'UUID': 'PDno23andme_full_gene_notext_6857777', 'SNP': 'rs62415533', 'p': 0.02228, 'b': -0.0913}, {'UUID': 'PDno23andme_full_gene_notext_5928806', 'SNP': 'rs9454429', 'p': 0.02282, 'b': -0.0805}, {'UUID': 'PDno23andme_full_gene_notext_7696522', 'SNP': 'rs62415513', 'p': 0.02308, 'b': -0.0926}, {'UUID': 'PDno23andme_full_gene_notext_510036', 'SNP': 'rs72908245', 'p': 0.02412, 'b': -0.126}, {'UUID': 'PDno23andme_full_gene_notext_1448704', 'SNP': 'rs143591361', 'p': 0.02423, 'b': 0.1801}, {'UUID': 'PDno23andme_full_gene_notext_327530', 'SNP': 'rs73451405', 'p': 0.02431, 'b': 0.1831}, {'UUID': 'PDno23andme_full_gene_notext_6176833', 'SNP': 'rs10945061', 'p': 0.02483, 'b': 0.065}, {'UUID': 'PDno23andme_full_gene_notext_7744315', 'SNP': 'rs117406823', 'p': 0.02499, 'b': 0.1994}, {'UUID': 'PDno23andme_full_gene_notext_144390', 'SNP': 'rs10455650', 'p': 0.02501, 'b': 0.065}, {'UUID': 'PDno23andme_full_gene_notext_1308517', 'SNP': 'rs10455651', 'p': 0.02554, 'b': 0.0647}, {'UUID': 'PDno23andme_full_gene_notext_7278565', 'SNP': 'rs117182159', 'p': 0.0261, 'b': 0.1981}, {'UUID': 'PDno23andme_full_gene_notext_1032356', 'SNP': 'rs7746319', 'p': 0.02681, 'b': 0.0958}, {'UUID': 'PDno23andme_full_gene_notext_4838724', 'SNP': 'rs1083444', 'p': 0.02807, 'b': 0.103}, {'UUID': 'PDno23andme_full_gene_notext_5532761', 'SNP': 'rs35725083', 'p': 0.02809, 'b': 0.103}, {'UUID': 'PDno23andme_full_gene_notext_3142489', 'SNP': 'rs2932674', 'p': 0.02937, 'b': 0.1304}, {'UUID': 'PDno23andme_full_gene_notext_5917935', 'SNP': 'rs778023', 'p': 0.03007, 'b': 0.1017}, {'UUID': 'PDno23andme_full_gene_notext_5793217', 'SNP': 'rs116881946', 'p': 0.03047, 'b': -0.1616}, {'UUID': 'PDno23andme_full_gene_notext_4122211', 'SNP': 'rs12198069', 'p': 0.03067, 'b': 0.09}, {'UUID': 'PDno23andme_full_gene_notext_5502170', 'SNP': 'rs778010', 'p': 0.03073, 'b': 0.1016}, {'UUID': 'PDno23andme_full_gene_notext_7324331', 'SNP': 'rs62417106', 'p': 0.03111, 'b': -0.0876}, {'UUID': 'PDno23andme_full_gene_notext_4321597', 'SNP': 'rs10945056', 'p': 0.03164, 'b': 0.0894}, {'UUID': 'PDno23andme_full_gene_notext_2303418', 'SNP': 'rs62417107', 'p': 0.0318, 'b': -0.0872}, {'UUID': 'PDno23andme_full_gene_notext_6738207', 'SNP': 'rs10945057', 'p': 0.03187, 'b': 0.0891}, {'UUID': 'PDno23andme_full_gene_notext_6999339', 'SNP': 'rs12213014', 'p': 0.03251, 'b': 0.0887}, {'UUID': 'PDno23andme_full_gene_notext_6987545', 'SNP': 'rs12202268', 'p': 0.03306, 'b': 0.0886}, {'UUID': 'PDno23andme_full_gene_notext_4857247', 'SNP': 'rs12210367', 'p': 0.03313, 'b': 0.0884}, {'UUID': 'PDno23andme_full_gene_notext_433762', 'SNP': 'rs12198159', 'p': 0.03328, 'b': 0.0886}, {'UUID': 'PDno23andme_full_gene_notext_4368979', 'SNP': 'rs13206586', 'p': 0.03348, 'b': 0.0883}, {'UUID': 'PDno23andme_full_gene_notext_3748508', 'SNP': 'rs28408162', 'p': 0.03379, 'b': 0.0881}, {'UUID': 'PDno23andme_full_gene_notext_7564606', 'SNP': 'rs57112373', 'p': 0.03412, 'b': 0.0881}]",general,"Select, Order By, Similarity Search, Multi-Filter","Effect, GWAS Significance"
-Q50.1290,Q50,Do CADM4 gene mutations increase the risk of Parkinson's disease?,"No, there are no significant mutations in the CADM4 gene associated with an increased risk of Parkinson's disease according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019).","SELECT UUID, SNP, p, b 
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE nearestGene LIKE ""%CADM4%""
- ORDER BY p
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_1374433', 'SNP': 'rs433226', 'p': 0.05457, 'b': -0.035}, {'UUID': 'PDno23andme_full_gene_notext_1161261', 'SNP': 'rs7251275', 'p': 0.05487, 'b': 0.0373}, {'UUID': 'PDno23andme_full_gene_notext_3052946', 'SNP': 'rs79700174', 'p': 0.06382, 'b': -0.4789}, {'UUID': 'PDno23andme_full_gene_notext_1745276', 'SNP': 'rs10402946', 'p': 0.09202, 'b': 0.0324}, {'UUID': 'PDno23andme_full_gene_notext_4729277', 'SNP': 'rs4803647', 'p': 0.1005, 'b': 0.0299}, {'UUID': 'PDno23andme_full_gene_notext_4350211', 'SNP': 'rs13345377', 'p': 0.1009, 'b': 0.0278}, {'UUID': 'PDno23andme_full_gene_notext_1182468', 'SNP': 'rs3803910', 'p': 0.102, 'b': 0.0299}, {'UUID': 'PDno23andme_full_gene_notext_5915178', 'SNP': 'rs139421078', 'p': 0.1027, 'b': -0.2573}, {'UUID': 'PDno23andme_full_gene_notext_4252576', 'SNP': 'rs4803646', 'p': 0.1045, 'b': 0.0315}, {'UUID': 'PDno23andme_full_gene_notext_3711960', 'SNP': 'rs2270075', 'p': 0.1122, 'b': 0.0308}, {'UUID': 'PDno23andme_full_gene_notext_3310750', 'SNP': 'rs8101721', 'p': 0.1137, 'b': 0.027}, {'UUID': 'PDno23andme_full_gene_notext_4415107', 'SNP': 'rs34637472', 'p': 0.1142, 'b': 0.0289}, {'UUID': 'PDno23andme_full_gene_notext_1295467', 'SNP': 'rs4802188', 'p': 0.1147, 'b': 0.027}, {'UUID': 'PDno23andme_full_gene_notext_6885452', 'SNP': 'rs2240633', 'p': 0.1199, 'b': 0.0284}, {'UUID': 'PDno23andme_full_gene_notext_1669837', 'SNP': 'rs17655646', 'p': 0.1248, 'b': 0.0299}, {'UUID': 'PDno23andme_full_gene_notext_4073097', 'SNP': 'rs7245651', 'p': 0.1274, 'b': 0.0278}, {'UUID': 'PDno23andme_full_gene_notext_802934', 'SNP': 'rs8101956', 'p': 0.1329, 'b': 0.0275}, {'UUID': 'PDno23andme_full_gene_notext_6035189', 'SNP': 'rs7257640', 'p': 0.2502, 'b': -0.0372}, {'UUID': 'PDno23andme_full_gene_notext_5846502', 'SNP': 'rs73038875', 'p': 0.2837, 'b': 0.0274}, {'UUID': 'PDno23andme_full_gene_notext_6308209', 'SNP': 'rs16976597', 'p': 0.3092, 'b': -0.034}, {'UUID': 'PDno23andme_full_gene_notext_7090024', 'SNP': 'rs144007933', 'p': 0.3621, 'b': 0.0767}, {'UUID': 'PDno23andme_full_gene_notext_2505240', 'SNP': 'rs4802189', 'p': 0.3645, 'b': 0.0204}, {'UUID': 'PDno23andme_full_gene_notext_1983781', 'SNP': 'rs62114101', 'p': 0.4105, 'b': 0.0348}, {'UUID': 'PDno23andme_full_gene_notext_4412581', 'SNP': 'rs73935020', 'p': 0.466, 'b': 0.1956}, {'UUID': 'PDno23andme_full_gene_notext_5657298', 'SNP': 'rs76416090', 'p': 0.5615, 'b': 0.0364}, {'UUID': 'PDno23andme_full_gene_notext_5982012', 'SNP': 'rs76003987', 'p': 0.6, 'b': -0.0423}, {'UUID': 'PDno23andme_full_gene_notext_1781588', 'SNP': 'rs400058', 'p': 0.6057, 'b': 0.0105}, {'UUID': 'PDno23andme_full_gene_notext_4011345', 'SNP': 'rs73038867', 'p': 0.7028, 'b': 0.0091}, {'UUID': 'PDno23andme_full_gene_notext_807227', 'SNP': 'rs112870666', 'p': 0.7068, 'b': 0.009}, {'UUID': 'PDno23andme_full_gene_notext_5170687', 'SNP': 'rs4803648', 'p': 0.7091, 'b': 0.0081}, {'UUID': 'PDno23andme_full_gene_notext_7181565', 'SNP': 'rs12461175', 'p': 0.7192, 'b': 0.0086}, {'UUID': 'PDno23andme_full_gene_notext_6068431', 'SNP': 'rs2079646', 'p': 0.7296, 'b': 0.0083}, {'UUID': 'PDno23andme_full_gene_notext_3405536', 'SNP': 'rs11083712', 'p': 0.7437, 'b': 0.0078}, {'UUID': 'PDno23andme_full_gene_notext_7180222', 'SNP': 'rs112855625', 'p': 0.7482, 'b': 0.0407}, {'UUID': 'PDno23andme_full_gene_notext_7084983', 'SNP': 'rs3746003', 'p': 0.7809, 'b': 0.0069}, {'UUID': 'PDno23andme_full_gene_notext_3438040', 'SNP': 'rs10408322', 'p': 0.8174, 'b': 0.005}, {'UUID': 'PDno23andme_full_gene_notext_4290011', 'SNP': 'rs7252391', 'p': 0.9234, 'b': 0.0021}, {'UUID': 'PDno23andme_full_gene_notext_686977', 'SNP': 'rs1879387', 'p': 0.9747, 'b': 0.0008}]",general,"Select, Order By, Similarity Search, Multi-Filter","Effect, GWAS Significance"
-Q50.1274,Q50,Do GPR156 gene mutations increase the risk of Parkinson's disease?,"No, there are no significant mutations in the GPR156 gene associated with an increased risk of Parkinson's disease according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019).","SELECT UUID, SNP, p, b 
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE nearestGene LIKE ""%GPR156%""
- ORDER BY p
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_2798861', 'SNP': 'rs62264965', 'p': 0.008706, 'b': 0.256}, {'UUID': 'PDno23andme_full_gene_notext_6710363', 'SNP': 'rs78918837', 'p': 0.00963, 'b': 0.2086}, {'UUID': 'PDno23andme_full_gene_notext_2561715', 'SNP': 'rs75440544', 'p': 0.01907, 'b': 0.2414}, {'UUID': 'PDno23andme_full_gene_notext_5897167', 'SNP': 'rs62264989', 'p': 0.03221, 'b': 0.2038}, {'UUID': 'PDno23andme_full_gene_notext_2490620', 'SNP': 'rs115665588', 'p': 0.03466, 'b': 0.2608}, {'UUID': 'PDno23andme_full_gene_notext_3688959', 'SNP': 'rs77642108', 'p': 0.03842, 'b': -0.2948}, {'UUID': 'PDno23andme_full_gene_notext_713621', 'SNP': 'rs115813388', 'p': 0.04111, 'b': 0.2239}, {'UUID': 'PDno23andme_full_gene_notext_6321045', 'SNP': 'rs74886437', 'p': 0.04175, 'b': -0.2484}, {'UUID': 'PDno23andme_full_gene_notext_5669167', 'SNP': 'rs75140918', 'p': 0.05417, 'b': 0.2035}, {'UUID': 'PDno23andme_full_gene_notext_2893301', 'SNP': 'rs76030347', 'p': 0.05572, 'b': -0.2328}, {'UUID': 'PDno23andme_full_gene_notext_466347', 'SNP': 'rs140363797', 'p': 0.057, 'b': -0.1138}, {'UUID': 'PDno23andme_full_gene_notext_4110056', 'SNP': 'rs192958568', 'p': 0.0636, 'b': -0.1799}, {'UUID': 'PDno23andme_full_gene_notext_2525198', 'SNP': 'rs62266289', 'p': 0.06583, 'b': 0.1721}, {'UUID': 'PDno23andme_full_gene_notext_4994013', 'SNP': 'rs58159117', 'p': 0.0681, 'b': -0.061}, {'UUID': 'PDno23andme_full_gene_notext_4082398', 'SNP': 'rs74395262', 'p': 0.07584, 'b': -0.1644}, {'UUID': 'PDno23andme_full_gene_notext_2077268', 'SNP': 'rs78782005', 'p': 0.0787, 'b': -0.2669}, {'UUID': 'PDno23andme_full_gene_notext_1029246', 'SNP': 'rs12635508', 'p': 0.08199, 'b': -0.0582}, {'UUID': 'PDno23andme_full_gene_notext_1859772', 'SNP': 'rs11716696', 'p': 0.09797, 'b': 0.0764}, {'UUID': 'PDno23andme_full_gene_notext_7164634', 'SNP': 'rs6780433', 'p': 0.09802, 'b': -0.0835}, {'UUID': 'PDno23andme_full_gene_notext_6353626', 'SNP': 'rs1602613', 'p': 0.09845, 'b': 0.0772}, {'UUID': 'PDno23andme_full_gene_notext_5123576', 'SNP': 'rs12492422', 'p': 0.09982, 'b': 0.077}, {'UUID': 'PDno23andme_full_gene_notext_1035426', 'SNP': 'rs9852150', 'p': 0.1002, 'b': 0.0769}, {'UUID': 'PDno23andme_full_gene_notext_3046061', 'SNP': 'rs12635156', 'p': 0.1012, 'b': 0.0767}, {'UUID': 'PDno23andme_full_gene_notext_5673289', 'SNP': 'rs7633690', 'p': 0.1021, 'b': 0.0765}, {'UUID': 'PDno23andme_full_gene_notext_2973167', 'SNP': 'rs9858897', 'p': 0.1025, 'b': 0.0765}, {'UUID': 'PDno23andme_full_gene_notext_5759752', 'SNP': 'rs2319544', 'p': 0.1025, 'b': 0.0765}, {'UUID': 'PDno23andme_full_gene_notext_4426451', 'SNP': 'rs10804551', 'p': 0.103, 'b': 0.0791}, {'UUID': 'PDno23andme_full_gene_notext_7742549', 'SNP': 'rs9833127', 'p': 0.1035, 'b': 0.0762}, {'UUID': 'PDno23andme_full_gene_notext_5270807', 'SNP': 'rs13078387', 'p': 0.1036, 'b': -0.0332}, {'UUID': 'PDno23andme_full_gene_notext_7029331', 'SNP': 'rs55861253', 'p': 0.1061, 'b': 0.0322}, {'UUID': 'PDno23andme_full_gene_notext_2647588', 'SNP': 'rs182471086', 'p': 0.1081, 'b': 0.1517}, {'UUID': 'PDno23andme_full_gene_notext_6636704', 'SNP': 'rs2319672', 'p': 0.1089, 'b': 0.0734}, {'UUID': 'PDno23andme_full_gene_notext_2054290', 'SNP': 'rs12491165', 'p': 0.1096, 'b': 0.0751}, {'UUID': 'PDno23andme_full_gene_notext_7311464', 'SNP': 'rs150770159', 'p': 0.1099, 'b': -0.098}, {'UUID': 'PDno23andme_full_gene_notext_2032868', 'SNP': 'rs16830894', 'p': 0.1107, 'b': 0.0748}, {'UUID': 'PDno23andme_full_gene_notext_1594194', 'SNP': 'rs72625409', 'p': 0.1111, 'b': -0.0328}, {'UUID': 'PDno23andme_full_gene_notext_7625335', 'SNP': 'rs13075809', 'p': 0.1121, 'b': -0.0329}, {'UUID': 'PDno23andme_full_gene_notext_1779877', 'SNP': 'rs17811061', 'p': 0.1122, 'b': 0.044}, {'UUID': 'PDno23andme_full_gene_notext_6167159', 'SNP': 'rs67984114', 'p': 0.1132, 'b': -0.0327}, {'UUID': 'PDno23andme_full_gene_notext_4550626', 'SNP': 'rs72956841', 'p': 0.1169, 'b': -0.1919}, {'UUID': 'PDno23andme_full_gene_notext_7365589', 'SNP': 'rs114417310', 'p': 0.1181, 'b': -0.1087}, {'UUID': 'PDno23andme_full_gene_notext_7409804', 'SNP': 'rs11927947', 'p': 0.1184, 'b': -0.0322}, {'UUID': 'PDno23andme_full_gene_notext_3199183', 'SNP': 'rs35450153', 'p': 0.1185, 'b': -0.0322}, {'UUID': 'PDno23andme_full_gene_notext_2735523', 'SNP': 'rs144980988', 'p': 0.1193, 'b': -0.1875}, {'UUID': 'PDno23andme_full_gene_notext_841591', 'SNP': 'rs73177923', 'p': 0.1197, 'b': -0.0321}, {'UUID': 'PDno23andme_full_gene_notext_5157915', 'SNP': 'rs9826773', 'p': 0.1197, 'b': 0.0725}, {'UUID': 'PDno23andme_full_gene_notext_6155115', 'SNP': 'rs3755557', 'p': 0.1206, 'b': 0.0429}, {'UUID': 'PDno23andme_full_gene_notext_7090149', 'SNP': 'rs112872798', 'p': 0.1208, 'b': -0.1654}, {'UUID': 'PDno23andme_full_gene_notext_5807549', 'SNP': 'rs2319669', 'p': 0.1211, 'b': 0.0717}, {'UUID': 'PDno23andme_full_gene_notext_6698035', 'SNP': 'rs10934526', 'p': 0.1212, 'b': 0.0717}, {'UUID': 'PDno23andme_full_gene_notext_6838681', 'SNP': 'rs9851018', 'p': 0.1215, 'b': 0.0721}, {'UUID': 'PDno23andme_full_gene_notext_6924113', 'SNP': 'rs1844972', 'p': 0.1218, 'b': 0.0721}, {'UUID': 'PDno23andme_full_gene_notext_5652894', 'SNP': 'rs2319671', 'p': 0.1225, 'b': 0.0715}, {'UUID': 'PDno23andme_full_gene_notext_7716646', 'SNP': 'rs11705695', 'p': 0.1234, 'b': -0.0317}, {'UUID': 'PDno23andme_full_gene_notext_7351277', 'SNP': 'rs9824334', 'p': 0.124, 'b': 0.0712}, {'UUID': 'PDno23andme_full_gene_notext_6017007', 'SNP': 'rs35605064', 'p': 0.1242, 'b': -0.0321}, {'UUID': 'PDno23andme_full_gene_notext_1338863', 'SNP': 'rs13319879', 'p': 0.125, 'b': 0.0711}, {'UUID': 'PDno23andme_full_gene_notext_3793717', 'SNP': 'rs12638442', 'p': 0.1253, 'b': 0.0715}, {'UUID': 'PDno23andme_full_gene_notext_1437856', 'SNP': 'rs1118199', 'p': 0.1254, 'b': 0.0715}, {'UUID': 'PDno23andme_full_gene_notext_6073016', 'SNP': 'rs1388754', 'p': 0.1256, 'b': 0.0715}, {'UUID': 'PDno23andme_full_gene_notext_6920127', 'SNP': 'rs6771865', 'p': 0.1256, 'b': 0.0714}, {'UUID': 'PDno23andme_full_gene_notext_1424575', 'SNP': 'rs13088757', 'p': 0.1261, 'b': -0.0317}, {'UUID': 'PDno23andme_full_gene_notext_1831615', 'SNP': 'rs9856618', 'p': 0.1267, 'b': 0.0707}, {'UUID': 'PDno23andme_full_gene_notext_4531223', 'SNP': 'rs114798987', 'p': 0.1269, 'b': 0.0907}, {'UUID': 'PDno23andme_full_gene_notext_6233174', 'SNP': 'rs139597165', 'p': 0.1272, 'b': -0.1406}, {'UUID': 'PDno23andme_full_gene_notext_568897', 'SNP': 'rs13090279', 'p': 0.1282, 'b': -0.0315}, {'UUID': 'PDno23andme_full_gene_notext_4863780', 'SNP': 'rs9856288', 'p': 0.1283, 'b': 0.0704}, {'UUID': 'PDno23andme_full_gene_notext_7096983', 'SNP': 'rs13086387', 'p': 0.1285, 'b': -0.0419}, {'UUID': 'PDno23andme_full_gene_notext_3387075', 'SNP': 'rs58693617', 'p': 0.1308, 'b': 0.0722}, {'UUID': 'PDno23andme_full_gene_notext_7347451', 'SNP': 'rs9848714', 'p': 0.1309, 'b': 0.0701}, {'UUID': 'PDno23andme_full_gene_notext_7310604', 'SNP': 'rs2035669', 'p': 0.1313, 'b': -0.0312}, {'UUID': 'PDno23andme_full_gene_notext_6815610', 'SNP': 'rs72954789', 'p': 0.1318, 'b': 0.0698}, {'UUID': 'PDno23andme_full_gene_notext_4628067', 'SNP': 'rs1873652', 'p': 0.1323, 'b': 0.0697}, {'UUID': 'PDno23andme_full_gene_notext_6378261', 'SNP': 'rs1074053', 'p': 0.1346, 'b': -0.031}, {'UUID': 'PDno23andme_full_gene_notext_5516127', 'SNP': 'rs73177910', 'p': 0.135, 'b': 0.1623}, {'UUID': 'PDno23andme_full_gene_notext_2474669', 'SNP': 'rs9849695', 'p': 0.1356, 'b': 0.0693}, {'UUID': 'PDno23andme_full_gene_notext_970343', 'SNP': 'rs787198', 'p': 0.143, 'b': 0.0389}, {'UUID': 'PDno23andme_full_gene_notext_3666919', 'SNP': 'rs334548', 'p': 0.1431, 'b': -0.0303}, {'UUID': 'PDno23andme_full_gene_notext_2813553', 'SNP': 'rs1085619', 'p': 0.1432, 'b': -0.0255}, {'UUID': 'PDno23andme_full_gene_notext_252332', 'SNP': 'rs334550', 'p': 0.1447, 'b': -0.0302}, {'UUID': 'PDno23andme_full_gene_notext_2998944', 'SNP': 'rs17811013', 'p': 0.1457, 'b': 0.0471}, {'UUID': 'PDno23andme_full_gene_notext_3029741', 'SNP': 'rs80050568', 'p': 0.1461, 'b': 0.047}, {'UUID': 'PDno23andme_full_gene_notext_2745963', 'SNP': 'rs73177909', 'p': 0.1481, 'b': 0.0467}, {'UUID': 'PDno23andme_full_gene_notext_92418', 'SNP': 'rs1085623', 'p': 0.1485, 'b': -0.0252}, {'UUID': 'PDno23andme_full_gene_notext_1742081', 'SNP': 'rs1085621', 'p': 0.1487, 'b': -0.0251}, {'UUID': 'PDno23andme_full_gene_notext_3203558', 'SNP': 'rs143676003', 'p': 0.1493, 'b': -0.169}, {'UUID': 'PDno23andme_full_gene_notext_3750250', 'SNP': 'rs115722733', 'p': 0.1544, 'b': 0.0486}, {'UUID': 'PDno23andme_full_gene_notext_1518466', 'SNP': 'rs6778180', 'p': 0.1545, 'b': -0.0275}, {'UUID': 'PDno23andme_full_gene_notext_7524046', 'SNP': 'rs6806460', 'p': 0.156, 'b': 0.0345}, {'UUID': 'PDno23andme_full_gene_notext_2878035', 'SNP': 'rs35049714', 'p': 0.1583, 'b': -0.0271}, {'UUID': 'PDno23andme_full_gene_notext_6507475', 'SNP': 'rs111661335', 'p': 0.1584, 'b': 0.0469}, {'UUID': 'PDno23andme_full_gene_notext_7707495', 'SNP': 'rs112321186', 'p': 0.1591, 'b': 0.0479}, {'UUID': 'PDno23andme_full_gene_notext_1313253', 'SNP': 'rs56259926', 'p': 0.1599, 'b': -0.0296}, {'UUID': 'PDno23andme_full_gene_notext_7545915', 'SNP': 'rs9816153', 'p': 0.1609, 'b': -0.0244}, {'UUID': 'PDno23andme_full_gene_notext_5048606', 'SNP': 'rs11927974', 'p': 0.1636, 'b': 0.0463}, {'UUID': 'PDno23andme_full_gene_notext_4887672', 'SNP': 'rs75684688', 'p': 0.1653, 'b': 0.0855}, {'UUID': 'PDno23andme_full_gene_notext_5127415', 'SNP': 'rs2673712', 'p': 0.1693, 'b': 0.0236}, {'UUID': 'PDno23andme_full_gene_notext_4046618', 'SNP': 'rs17811405', 'p': 0.1728, 'b': -0.0284}, {'UUID': 'PDno23andme_full_gene_notext_6812657', 'SNP': 'rs9843220', 'p': 0.1729, 'b': 0.023}, {'UUID': 'PDno23andme_full_gene_notext_7715898', 'SNP': 'rs115559988', 'p': 0.1733, 'b': -0.1516}]",general,"Select, Order By, Similarity Search, Multi-Filter","Effect, GWAS Significance"
-Q50.939,Q50,Do TSEN34 gene mutations increase the risk of Parkinson's disease?,"No, there are no significant mutations in the TSEN34 gene associated with an increased risk of Parkinson's disease according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019).","SELECT UUID, SNP, p, b 
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE nearestGene LIKE ""%TSEN34%""
- ORDER BY p
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_4583270', 'SNP': 'rs79447697', 'p': 0.06963, 'b': 0.2558}, {'UUID': 'PDno23andme_full_gene_notext_1869634', 'SNP': 'rs550726413', 'p': 0.1874, 'b': -0.4661}, {'UUID': 'PDno23andme_full_gene_notext_5935138', 'SNP': 'rs36618', 'p': 0.1914, 'b': -0.0667}, {'UUID': 'PDno23andme_full_gene_notext_1337502', 'SNP': 'rs190430', 'p': 0.2217, 'b': -0.0481}, {'UUID': 'PDno23andme_full_gene_notext_4610400', 'SNP': 'rs150681063', 'p': 0.2459, 'b': 0.2119}, {'UUID': 'PDno23andme_full_gene_notext_7287047', 'SNP': 'rs3810233', 'p': 0.2652, 'b': 0.0374}, {'UUID': 'PDno23andme_full_gene_notext_7195683', 'SNP': 'rs34172242', 'p': 0.2721, 'b': -0.0343}, {'UUID': 'PDno23andme_full_gene_notext_3813816', 'SNP': 'rs538968348', 'p': 0.2859, 'b': -0.4524}, {'UUID': 'PDno23andme_full_gene_notext_902911', 'SNP': 'rs79970109', 'p': 0.337, 'b': -0.1055}, {'UUID': 'PDno23andme_full_gene_notext_3854431', 'SNP': 'rs429347', 'p': 0.3641, 'b': 0.0342}, {'UUID': 'PDno23andme_full_gene_notext_6592767', 'SNP': 'rs34629529', 'p': 0.3663, 'b': -0.0277}, {'UUID': 'PDno23andme_full_gene_notext_1958436', 'SNP': 'rs150365314', 'p': 0.3925, 'b': -0.0705}, {'UUID': 'PDno23andme_full_gene_notext_2021367', 'SNP': 'rs12983976', 'p': 0.4455, 'b': 0.0286}, {'UUID': 'PDno23andme_full_gene_notext_4097256', 'SNP': 'rs148442614', 'p': 0.4469, 'b': -0.1433}, {'UUID': 'PDno23andme_full_gene_notext_448281', 'SNP': 'rs548828249', 'p': 0.4889, 'b': -0.2524}, {'UUID': 'PDno23andme_full_gene_notext_3540793', 'SNP': 'rs28513', 'p': 0.5374, 'b': 0.0215}, {'UUID': 'PDno23andme_full_gene_notext_3889932', 'SNP': 'rs16985457', 'p': 0.546, 'b': -0.0171}, {'UUID': 'PDno23andme_full_gene_notext_5349942', 'SNP': 'rs7595', 'p': 0.5537, 'b': -0.0186}, {'UUID': 'PDno23andme_full_gene_notext_66665', 'SNP': 'rs635608', 'p': 0.5671, 'b': -0.018}, {'UUID': 'PDno23andme_full_gene_notext_4987852', 'SNP': 'rs527337424', 'p': 0.5804, 'b': -0.1063}, {'UUID': 'PDno23andme_full_gene_notext_6984011', 'SNP': 'rs144441443', 'p': 0.5814, 'b': -0.0375}, {'UUID': 'PDno23andme_full_gene_notext_4883403', 'SNP': 'rs8105385', 'p': 0.5915, 'b': -0.0132}, {'UUID': 'PDno23andme_full_gene_notext_5560370', 'SNP': 'rs36621', 'p': 0.6319, 'b': -0.0151}, {'UUID': 'PDno23andme_full_gene_notext_3043344', 'SNP': 'rs593073', 'p': 0.6471, 'b': -0.0146}, {'UUID': 'PDno23andme_full_gene_notext_520965', 'SNP': 'rs36624', 'p': 0.7025, 'b': 0.0116}, {'UUID': 'PDno23andme_full_gene_notext_4519599', 'SNP': 'rs36623', 'p': 0.7072, 'b': -0.0117}, {'UUID': 'PDno23andme_full_gene_notext_5769877', 'SNP': 'rs62133062', 'p': 0.82, 'b': -0.0159}, {'UUID': 'PDno23andme_full_gene_notext_607688', 'SNP': 'rs78260145', 'p': 0.9296, 'b': 0.0069}, {'UUID': 'PDno23andme_full_gene_notext_1399568', 'SNP': 'rs158365', 'p': 0.9331, 'b': 0.0035}, {'UUID': 'PDno23andme_full_gene_notext_1032818', 'SNP': 'rs4042', 'p': 0.9512, 'b': 0.0098}, {'UUID': 'PDno23andme_full_gene_notext_2348423', 'SNP': 'rs78510537', 'p': 0.9693, 'b': 0.0061}]",general,"Select, Order By, Similarity Search, Multi-Filter","Effect, GWAS Significance"
-Q50.1732,Q50,Do MIMT1 gene mutations increase the risk of Parkinson's disease?,"No, there are no significant mutations in the MIMT1 gene associated with an increased risk of Parkinson's disease according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019).","SELECT UUID, SNP, p, b 
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE nearestGene LIKE ""%MIMT1%""
- ORDER BY p
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_1789207', 'SNP': 'rs78884690', 'p': 0.001406, 'b': 0.2859}, {'UUID': 'PDno23andme_full_gene_notext_5106075', 'SNP': 'rs144642449', 'p': 0.002583, 'b': 0.2992}, {'UUID': 'PDno23andme_full_gene_notext_312802', 'SNP': 'rs72629164', 'p': 0.003109, 'b': 0.1436}, {'UUID': 'PDno23andme_full_gene_notext_3330133', 'SNP': 'rs56928374', 'p': 0.003602, 'b': 0.1422}, {'UUID': 'PDno23andme_full_gene_notext_904623', 'SNP': 'rs34593206', 'p': 0.004713, 'b': 0.1387}, {'UUID': 'PDno23andme_full_gene_notext_3976476', 'SNP': 'rs145097436', 'p': 0.005265, 'b': 0.2122}, {'UUID': 'PDno23andme_full_gene_notext_6867919', 'SNP': 'rs11879078', 'p': 0.005475, 'b': 0.1344}, {'UUID': 'PDno23andme_full_gene_notext_7380160', 'SNP': 'rs12461163', 'p': 0.005628, 'b': 0.1349}, {'UUID': 'PDno23andme_full_gene_notext_4375266', 'SNP': 'rs12461308', 'p': 0.006495, 'b': 0.1326}, {'UUID': 'PDno23andme_full_gene_notext_3310114', 'SNP': 'rs11670532', 'p': 0.006913, 'b': 0.0608}, {'UUID': 'PDno23andme_full_gene_notext_7774173', 'SNP': 'rs12461944', 'p': 0.007034, 'b': 0.132}, {'UUID': 'PDno23andme_full_gene_notext_6583448', 'SNP': 'rs12609660', 'p': 0.007403, 'b': 0.1315}, {'UUID': 'PDno23andme_full_gene_notext_708263', 'SNP': 'rs10418013', 'p': 0.009214, 'b': 0.1159}, {'UUID': 'PDno23andme_full_gene_notext_3434755', 'SNP': 'rs11878196', 'p': 0.01049, 'b': 0.1102}, {'UUID': 'PDno23andme_full_gene_notext_731478', 'SNP': 'rs11878195', 'p': 0.01056, 'b': 0.1102}, {'UUID': 'PDno23andme_full_gene_notext_3185410', 'SNP': 'rs2116931', 'p': 0.01132, 'b': 0.1092}, {'UUID': 'PDno23andme_full_gene_notext_600040', 'SNP': 'rs11878192', 'p': 0.0114, 'b': 0.109}, {'UUID': 'PDno23andme_full_gene_notext_2547330', 'SNP': 'rs11665956', 'p': 0.01149, 'b': 0.0569}, {'UUID': 'PDno23andme_full_gene_notext_7701855', 'SNP': 'rs2163848', 'p': 0.01162, 'b': 0.1087}, {'UUID': 'PDno23andme_full_gene_notext_5971813', 'SNP': 'rs11880915', 'p': 0.01219, 'b': 0.1078}, {'UUID': 'PDno23andme_full_gene_notext_6967269', 'SNP': 'rs5027754', 'p': 0.01421, 'b': 0.0736}, {'UUID': 'PDno23andme_full_gene_notext_122076', 'SNP': 'rs5027755', 'p': 0.01449, 'b': 0.0754}, {'UUID': 'PDno23andme_full_gene_notext_4683065', 'SNP': 'rs1567518', 'p': 0.01506, 'b': 0.0551}, {'UUID': 'PDno23andme_full_gene_notext_2561436', 'SNP': 'rs11880457', 'p': 0.01525, 'b': 0.1229}, {'UUID': 'PDno23andme_full_gene_notext_3366856', 'SNP': 'rs1007799', 'p': 0.01866, 'b': 0.0531}, {'UUID': 'PDno23andme_full_gene_notext_6224278', 'SNP': 'rs12462228', 'p': 0.02016, 'b': -0.06}, {'UUID': 'PDno23andme_full_gene_notext_686434', 'SNP': 'rs138457672', 'p': 0.0218, 'b': -0.3902}, {'UUID': 'PDno23andme_full_gene_notext_5512923', 'SNP': 'rs8101034', 'p': 0.02217, 'b': -0.0581}, {'UUID': 'PDno23andme_full_gene_notext_4998531', 'SNP': 'rs7260649', 'p': 0.02341, 'b': 0.0507}, {'UUID': 'PDno23andme_full_gene_notext_1536974', 'SNP': 'rs8105520', 'p': 0.02512, 'b': 0.0527}, {'UUID': 'PDno23andme_full_gene_notext_6003539', 'SNP': 'rs148485861', 'p': 0.02616, 'b': -0.3732}, {'UUID': 'PDno23andme_full_gene_notext_4253286', 'SNP': 'rs75086077', 'p': 0.02644, 'b': -0.1506}, {'UUID': 'PDno23andme_full_gene_notext_2909234', 'SNP': 'rs12978189', 'p': 0.02667, 'b': 0.0496}, {'UUID': 'PDno23andme_full_gene_notext_478113', 'SNP': 'rs11670474', 'p': 0.02699, 'b': 0.0495}, {'UUID': 'PDno23andme_full_gene_notext_2704546', 'SNP': 'rs57861035', 'p': 0.02803, 'b': 0.1118}, {'UUID': 'PDno23andme_full_gene_notext_596661', 'SNP': 'rs73622139', 'p': 0.02811, 'b': 0.1118}, {'UUID': 'PDno23andme_full_gene_notext_978253', 'SNP': 'rs12462837', 'p': 0.02827, 'b': 0.0611}, {'UUID': 'PDno23andme_full_gene_notext_6901117', 'SNP': 'rs75489545', 'p': 0.03313, 'b': -0.2004}, {'UUID': 'PDno23andme_full_gene_notext_6655408', 'SNP': 'rs112445632', 'p': 0.03926, 'b': -0.2531}, {'UUID': 'PDno23andme_full_gene_notext_2477070', 'SNP': 'rs117345721', 'p': 0.03954, 'b': -0.275}, {'UUID': 'PDno23andme_full_gene_notext_5841351', 'SNP': 'rs10410780', 'p': 0.04022, 'b': 0.0471}, {'UUID': 'PDno23andme_full_gene_notext_3728745', 'SNP': 'rs142743813', 'p': 0.04441, 'b': 0.4391}, {'UUID': 'PDno23andme_full_gene_notext_2691584', 'SNP': 'rs34716639', 'p': 0.04568, 'b': -0.0531}, {'UUID': 'PDno23andme_full_gene_notext_3311725', 'SNP': 'rs73056962', 'p': 0.04959, 'b': 0.1275}, {'UUID': 'PDno23andme_full_gene_notext_6291323', 'SNP': 'rs4801404', 'p': 0.05667, 'b': -0.0429}, {'UUID': 'PDno23andme_full_gene_notext_2934038', 'SNP': 'rs10407612', 'p': 0.05733, 'b': 0.1266}, {'UUID': 'PDno23andme_full_gene_notext_6875971', 'SNP': 'rs35010362', 'p': 0.05734, 'b': -0.0425}, {'UUID': 'PDno23andme_full_gene_notext_4523818', 'SNP': 'rs1036239', 'p': 0.05735, 'b': 0.0462}, {'UUID': 'PDno23andme_full_gene_notext_3033018', 'SNP': 'rs4801415', 'p': 0.05834, 'b': -0.043}, {'UUID': 'PDno23andme_full_gene_notext_4420184', 'SNP': 'rs12974085', 'p': 0.05849, 'b': -0.0423}, {'UUID': 'PDno23andme_full_gene_notext_3907358', 'SNP': 'rs1976625', 'p': 0.06085, 'b': -0.0425}, {'UUID': 'PDno23andme_full_gene_notext_1841894', 'SNP': 'rs12976013', 'p': 0.06155, 'b': -0.0419}, {'UUID': 'PDno23andme_full_gene_notext_1220455', 'SNP': 'rs148169134', 'p': 0.06301, 'b': 0.3843}, {'UUID': 'PDno23andme_full_gene_notext_2160427', 'SNP': 'rs11672915', 'p': 0.06529, 'b': 0.0451}, {'UUID': 'PDno23andme_full_gene_notext_7535962', 'SNP': 'rs8110582', 'p': 0.06553, 'b': 0.0446}, {'UUID': 'PDno23andme_full_gene_notext_1672372', 'SNP': 'rs75596483', 'p': 0.06583, 'b': 0.2717}, {'UUID': 'PDno23andme_full_gene_notext_3934661', 'SNP': 'rs113984367', 'p': 0.06615, 'b': -0.2469}, {'UUID': 'PDno23andme_full_gene_notext_2629981', 'SNP': 'rs17273547', 'p': 0.06677, 'b': 0.0448}, {'UUID': 'PDno23andme_full_gene_notext_7563956', 'SNP': 'rs8102873', 'p': 0.06715, 'b': 0.0415}, {'UUID': 'PDno23andme_full_gene_notext_6825504', 'SNP': 'rs35757728', 'p': 0.06933, 'b': -0.0479}, {'UUID': 'PDno23andme_full_gene_notext_4275868', 'SNP': 'rs187934611', 'p': 0.07055, 'b': -0.1669}, {'UUID': 'PDno23andme_full_gene_notext_1769291', 'SNP': 'rs4435360', 'p': 0.07057, 'b': 0.0441}, {'UUID': 'PDno23andme_full_gene_notext_7680277', 'SNP': 'rs11669548', 'p': 0.07191, 'b': 0.0439}, {'UUID': 'PDno23andme_full_gene_notext_6912345', 'SNP': 'rs13343495', 'p': 0.07212, 'b': 0.0596}, {'UUID': 'PDno23andme_full_gene_notext_5917463', 'SNP': 'rs1036238', 'p': 0.07227, 'b': 0.0437}, {'UUID': 'PDno23andme_full_gene_notext_5095794', 'SNP': 'rs12460059', 'p': 0.07268, 'b': 0.0601}, {'UUID': 'PDno23andme_full_gene_notext_6468752', 'SNP': 'rs12985819', 'p': 0.0729, 'b': 0.0438}, {'UUID': 'PDno23andme_full_gene_notext_1174691', 'SNP': 'rs11084485', 'p': 0.07402, 'b': 0.0437}, {'UUID': 'PDno23andme_full_gene_notext_1320648', 'SNP': 'rs12976734', 'p': 0.07442, 'b': 0.0436}, {'UUID': 'PDno23andme_full_gene_notext_2487161', 'SNP': 'rs183742550', 'p': 0.07508, 'b': 0.147}, {'UUID': 'PDno23andme_full_gene_notext_3530751', 'SNP': 'rs111804409', 'p': 0.07645, 'b': 0.0588}, {'UUID': 'PDno23andme_full_gene_notext_2543857', 'SNP': 'rs12459720', 'p': 0.07715, 'b': 0.0593}, {'UUID': 'PDno23andme_full_gene_notext_6611753', 'SNP': 'rs74483586', 'p': 0.07821, 'b': 0.0763}, {'UUID': 'PDno23andme_full_gene_notext_225856', 'SNP': 'rs59715627', 'p': 0.08662, 'b': 0.0572}, {'UUID': 'PDno23andme_full_gene_notext_1392606', 'SNP': 'rs11084483', 'p': 0.08811, 'b': 0.0569}, {'UUID': 'PDno23andme_full_gene_notext_3274373', 'SNP': 'rs62132573', 'p': 0.08846, 'b': 0.0418}, {'UUID': 'PDno23andme_full_gene_notext_6722126', 'SNP': 'rs28584887', 'p': 0.08928, 'b': 0.1063}, {'UUID': 'PDno23andme_full_gene_notext_4347902', 'SNP': 'rs11671095', 'p': 0.09115, 'b': 0.0414}, {'UUID': 'PDno23andme_full_gene_notext_5679115', 'SNP': 'rs117267255', 'p': 0.09255, 'b': 0.1199}, {'UUID': 'PDno23andme_full_gene_notext_4121374', 'SNP': 'rs141303871', 'p': 0.09282, 'b': 0.1712}, {'UUID': 'PDno23andme_full_gene_notext_3246696', 'SNP': 'rs12610857', 'p': 0.09346, 'b': 0.0559}, {'UUID': 'PDno23andme_full_gene_notext_507451', 'SNP': 'rs34510494', 'p': 0.09391, 'b': -0.0382}, {'UUID': 'PDno23andme_full_gene_notext_2300220', 'SNP': 'rs61556872', 'p': 0.09397, 'b': 0.0559}, {'UUID': 'PDno23andme_full_gene_notext_5813376', 'SNP': 'rs4801194', 'p': 0.09399, 'b': -0.0487}, {'UUID': 'PDno23andme_full_gene_notext_311538', 'SNP': 'rs7256852', 'p': 0.09419, 'b': -0.0805}, {'UUID': 'PDno23andme_full_gene_notext_7064035', 'SNP': 'rs12052055', 'p': 0.0943, 'b': 0.0558}, {'UUID': 'PDno23andme_full_gene_notext_812115', 'SNP': 'rs11084482', 'p': 0.09478, 'b': 0.0557}, {'UUID': 'PDno23andme_full_gene_notext_5002507', 'SNP': 'rs11671363', 'p': 0.09917, 'b': 0.039}, {'UUID': 'PDno23andme_full_gene_notext_3451370', 'SNP': 'rs10402304', 'p': 0.1005, 'b': -0.0396}, {'UUID': 'PDno23andme_full_gene_notext_6724173', 'SNP': 'rs60943018', 'p': 0.1008, 'b': 0.0546}, {'UUID': 'PDno23andme_full_gene_notext_3411094', 'SNP': 'rs79443177', 'p': 0.1017, 'b': -0.0817}, {'UUID': 'PDno23andme_full_gene_notext_4903452', 'SNP': 'rs10411213', 'p': 0.1019, 'b': 0.0544}, {'UUID': 'PDno23andme_full_gene_notext_6390569', 'SNP': 'rs145045170', 'p': 0.1066, 'b': 0.1652}, {'UUID': 'PDno23andme_full_gene_notext_976171', 'SNP': 'rs72490756', 'p': 0.1079, 'b': 0.0538}, {'UUID': 'PDno23andme_full_gene_notext_22273', 'SNP': 'rs8100664', 'p': 0.1089, 'b': -0.0386}, {'UUID': 'PDno23andme_full_gene_notext_3864712', 'SNP': 'rs8112090', 'p': 0.1103, 'b': -0.0386}, {'UUID': 'PDno23andme_full_gene_notext_2201481', 'SNP': 'rs12461283', 'p': 0.1107, 'b': 0.0421}, {'UUID': 'PDno23andme_full_gene_notext_4557789', 'SNP': 'rs3848522', 'p': 0.1111, 'b': 0.0378}, {'UUID': 'PDno23andme_full_gene_notext_2778525', 'SNP': 'rs147625998', 'p': 0.1122, 'b': -0.3223}, {'UUID': 'PDno23andme_full_gene_notext_3693087', 'SNP': 'rs10420571', 'p': 0.1145, 'b': -0.06}]",general,"Select, Order By, Similarity Search, Multi-Filter","Effect, GWAS Significance"
-Q50.66,Q50,Do XDH gene mutations increase the risk of Parkinson's disease?,"No, there are no significant mutations in the XDH gene associated with an increased risk of Parkinson's disease according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019).","SELECT UUID, SNP, p, b 
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE nearestGene LIKE ""%XDH%""
- ORDER BY p
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_2762311', 'SNP': 'rs13394691', 'p': 0.00413, 'b': -0.1203}, {'UUID': 'PDno23andme_full_gene_notext_6507117', 'SNP': 'rs55994653', 'p': 0.004138, 'b': -0.1221}, {'UUID': 'PDno23andme_full_gene_notext_2994501', 'SNP': 'rs72786972', 'p': 0.004186, 'b': -0.1193}, {'UUID': 'PDno23andme_full_gene_notext_3959854', 'SNP': 'rs13422633', 'p': 0.00447, 'b': -0.1175}, {'UUID': 'PDno23andme_full_gene_notext_2871565', 'SNP': 'rs72786996', 'p': 0.004724, 'b': -0.1192}, {'UUID': 'PDno23andme_full_gene_notext_1485997', 'SNP': 'rs17011230', 'p': 0.005875, 'b': -0.1156}, {'UUID': 'PDno23andme_full_gene_notext_4716468', 'SNP': 'rs72786999', 'p': 0.006016, 'b': -0.116}, {'UUID': 'PDno23andme_full_gene_notext_3750454', 'SNP': 'rs62140757', 'p': 0.00646, 'b': -0.1148}, {'UUID': 'PDno23andme_full_gene_notext_5974934', 'SNP': 'rs72786990', 'p': 0.006525, 'b': -0.1146}, {'UUID': 'PDno23andme_full_gene_notext_6047187', 'SNP': 'rs17011265', 'p': 0.00665, 'b': -0.1143}, {'UUID': 'PDno23andme_full_gene_notext_2030544', 'SNP': 'rs17011262', 'p': 0.006957, 'b': -0.1136}, {'UUID': 'PDno23andme_full_gene_notext_1883346', 'SNP': 'rs55844041', 'p': 0.007012, 'b': -0.1133}, {'UUID': 'PDno23andme_full_gene_notext_6332277', 'SNP': 'rs55847034', 'p': 0.009014, 'b': -0.1093}, {'UUID': 'PDno23andme_full_gene_notext_5858799', 'SNP': 'rs111648202', 'p': 0.01057, 'b': 0.218}, {'UUID': 'PDno23andme_full_gene_notext_7516906', 'SNP': 'rs12478111', 'p': 0.01445, 'b': -0.0852}, {'UUID': 'PDno23andme_full_gene_notext_2847583', 'SNP': 'rs113848211', 'p': 0.01573, 'b': 0.2133}, {'UUID': 'PDno23andme_full_gene_notext_6061828', 'SNP': 'rs112898119', 'p': 0.01789, 'b': 0.203}, {'UUID': 'PDno23andme_full_gene_notext_1275338', 'SNP': 'rs17011237', 'p': 0.02299, 'b': -0.0744}, {'UUID': 'PDno23andme_full_gene_notext_1891731', 'SNP': 'rs115339728', 'p': 0.02418, 'b': -0.5312}, {'UUID': 'PDno23andme_full_gene_notext_1983607', 'SNP': 'rs606089', 'p': 0.03618, 'b': -0.0684}, {'UUID': 'PDno23andme_full_gene_notext_7461402', 'SNP': 'rs60852132', 'p': 0.03673, 'b': -0.096}, {'UUID': 'PDno23andme_full_gene_notext_840340', 'SNP': 'rs4951978', 'p': 0.04119, 'b': -0.0484}, {'UUID': 'PDno23andme_full_gene_notext_627147', 'SNP': 'rs45514500', 'p': 0.04575, 'b': -0.2222}, {'UUID': 'PDno23andme_full_gene_notext_1982386', 'SNP': 'rs12468456', 'p': 0.04906, 'b': -0.0923}, {'UUID': 'PDno23andme_full_gene_notext_6497904', 'SNP': 'rs13420414', 'p': 0.04922, 'b': -0.0914}, {'UUID': 'PDno23andme_full_gene_notext_5586732', 'SNP': 'rs146470381', 'p': 0.05086, 'b': -0.2452}, {'UUID': 'PDno23andme_full_gene_notext_4811933', 'SNP': 'rs79210670', 'p': 0.05169, 'b': -0.4641}, {'UUID': 'PDno23andme_full_gene_notext_1810277', 'SNP': 'rs45601433', 'p': 0.05966, 'b': -0.141}, {'UUID': 'PDno23andme_full_gene_notext_166334', 'SNP': 'rs115789905', 'p': 0.06025, 'b': -0.1152}, {'UUID': 'PDno23andme_full_gene_notext_5846555', 'SNP': 'rs206823', 'p': 0.0608, 'b': -0.0364}, {'UUID': 'PDno23andme_full_gene_notext_3509677', 'SNP': 'rs206837', 'p': 0.06375, 'b': -0.0351}, {'UUID': 'PDno23andme_full_gene_notext_3998586', 'SNP': 'rs148756340', 'p': 0.06483, 'b': -0.1403}, {'UUID': 'PDno23andme_full_gene_notext_4271742', 'SNP': 'rs206800', 'p': 0.06549, 'b': 0.0425}, {'UUID': 'PDno23andme_full_gene_notext_5527944', 'SNP': 'rs6758752', 'p': 0.06747, 'b': -0.0355}, {'UUID': 'PDno23andme_full_gene_notext_1137482', 'SNP': 'rs72790679', 'p': 0.06854, 'b': -0.1616}, {'UUID': 'PDno23andme_full_gene_notext_6371675', 'SNP': 'rs75380923', 'p': 0.06903, 'b': -0.1113}, {'UUID': 'PDno23andme_full_gene_notext_2986584', 'SNP': 'rs206839', 'p': 0.07171, 'b': -0.0341}, {'UUID': 'PDno23andme_full_gene_notext_2286167', 'SNP': 'rs206835', 'p': 0.07225, 'b': -0.034}, {'UUID': 'PDno23andme_full_gene_notext_4405456', 'SNP': 'rs206826', 'p': 0.07288, 'b': -0.0346}, {'UUID': 'PDno23andme_full_gene_notext_6349262', 'SNP': 'rs206821', 'p': 0.07491, 'b': -0.0353}, {'UUID': 'PDno23andme_full_gene_notext_4577913', 'SNP': 'rs1346644', 'p': 0.07638, 'b': 0.0481}, {'UUID': 'PDno23andme_full_gene_notext_3154485', 'SNP': 'rs206843', 'p': 0.07717, 'b': -0.0339}, {'UUID': 'PDno23andme_full_gene_notext_1523529', 'SNP': 'rs206840', 'p': 0.08459, 'b': -0.033}, {'UUID': 'PDno23andme_full_gene_notext_2963858', 'SNP': 'rs45461698', 'p': 0.08748, 'b': 0.2412}, {'UUID': 'PDno23andme_full_gene_notext_5712323', 'SNP': 'rs206790', 'p': 0.08752, 'b': -0.0336}, {'UUID': 'PDno23andme_full_gene_notext_5994153', 'SNP': 'rs961316', 'p': 0.08835, 'b': -0.0584}, {'UUID': 'PDno23andme_full_gene_notext_391671', 'SNP': 'rs10865088', 'p': 0.1012, 'b': -0.0411}, {'UUID': 'PDno23andme_full_gene_notext_4646812', 'SNP': 'rs17011356', 'p': 0.1016, 'b': 0.0403}, {'UUID': 'PDno23andme_full_gene_notext_5138751', 'SNP': 'rs2281550', 'p': 0.1037, 'b': 0.0401}, {'UUID': 'PDno23andme_full_gene_notext_5491639', 'SNP': 'rs11684698', 'p': 0.1042, 'b': -0.0316}, {'UUID': 'PDno23andme_full_gene_notext_4507844', 'SNP': 'rs206798', 'p': 0.1066, 'b': 0.0402}, {'UUID': 'PDno23andme_full_gene_notext_4710669', 'SNP': 'rs72790675', 'p': 0.1084, 'b': 0.0506}, {'UUID': 'PDno23andme_full_gene_notext_39812', 'SNP': 'rs494852', 'p': 0.1143, 'b': 0.0393}, {'UUID': 'PDno23andme_full_gene_notext_6303749', 'SNP': 'rs4549138', 'p': 0.1147, 'b': 0.0335}, {'UUID': 'PDno23andme_full_gene_notext_5845672', 'SNP': 'rs62141164', 'p': 0.1154, 'b': 0.0489}, {'UUID': 'PDno23andme_full_gene_notext_7017389', 'SNP': 'rs206827', 'p': 0.1162, 'b': -0.0287}, {'UUID': 'PDno23andme_full_gene_notext_4432225', 'SNP': 'rs62141174', 'p': 0.1164, 'b': 0.0489}, {'UUID': 'PDno23andme_full_gene_notext_6088349', 'SNP': 'rs114263200', 'p': 0.1185, 'b': -0.1253}, {'UUID': 'PDno23andme_full_gene_notext_1095288', 'SNP': 'rs77558957', 'p': 0.119, 'b': 0.0492}, {'UUID': 'PDno23andme_full_gene_notext_6495661', 'SNP': 'rs17011422', 'p': 0.1197, 'b': 0.049}, {'UUID': 'PDno23andme_full_gene_notext_3812513', 'SNP': 'rs206838', 'p': 0.1206, 'b': 0.0354}, {'UUID': 'PDno23andme_full_gene_notext_1394748', 'SNP': 'rs2018410', 'p': 0.1207, 'b': 0.0356}, {'UUID': 'PDno23andme_full_gene_notext_744212', 'SNP': 'rs115714598', 'p': 0.1213, 'b': -0.151}, {'UUID': 'PDno23andme_full_gene_notext_798717', 'SNP': 'rs206822', 'p': 0.1219, 'b': -0.0283}, {'UUID': 'PDno23andme_full_gene_notext_5121465', 'SNP': 'rs4952218', 'p': 0.1261, 'b': -0.0293}, {'UUID': 'PDno23andme_full_gene_notext_153477', 'SNP': 'rs62144962', 'p': 0.1261, 'b': 0.0481}, {'UUID': 'PDno23andme_full_gene_notext_5929199', 'SNP': 'rs206836', 'p': 0.1276, 'b': 0.0348}, {'UUID': 'PDno23andme_full_gene_notext_2116445', 'SNP': 'rs56225825', 'p': 0.1277, 'b': -0.0596}, {'UUID': 'PDno23andme_full_gene_notext_1069686', 'SNP': 'rs151204187', 'p': 0.1286, 'b': -0.121}, {'UUID': 'PDno23andme_full_gene_notext_1678124', 'SNP': 'rs62141163', 'p': 0.13, 'b': 0.0471}, {'UUID': 'PDno23andme_full_gene_notext_4814519', 'SNP': 'rs207440', 'p': 0.1332, 'b': -0.0725}, {'UUID': 'PDno23andme_full_gene_notext_3201615', 'SNP': 'rs13387204', 'p': 0.1368, 'b': 0.0341}, {'UUID': 'PDno23andme_full_gene_notext_6004281', 'SNP': 'rs6759319', 'p': 0.1372, 'b': 0.0452}, {'UUID': 'PDno23andme_full_gene_notext_527361', 'SNP': 'rs62141162', 'p': 0.1375, 'b': 0.0466}, {'UUID': 'PDno23andme_full_gene_notext_6110503', 'SNP': 'rs141818141', 'p': 0.138, 'b': -0.1664}, {'UUID': 'PDno23andme_full_gene_notext_532387', 'SNP': 'rs2281549', 'p': 0.1383, 'b': 0.034}, {'UUID': 'PDno23andme_full_gene_notext_5356925', 'SNP': 'rs628362', 'p': 0.1396, 'b': -0.0495}, {'UUID': 'PDno23andme_full_gene_notext_4263709', 'SNP': 'rs62142957', 'p': 0.1413, 'b': 0.0464}, {'UUID': 'PDno23andme_full_gene_notext_5771551', 'SNP': 'rs6713694', 'p': 0.1417, 'b': 0.042}, {'UUID': 'PDno23andme_full_gene_notext_6375027', 'SNP': 'rs111766801', 'p': 0.1418, 'b': 0.0462}, {'UUID': 'PDno23andme_full_gene_notext_3840268', 'SNP': 'rs743163', 'p': 0.1452, 'b': 0.0334}, {'UUID': 'PDno23andme_full_gene_notext_3296275', 'SNP': 'rs113374803', 'p': 0.1457, 'b': -0.1137}, {'UUID': 'PDno23andme_full_gene_notext_283805', 'SNP': 'rs207445', 'p': 0.1488, 'b': -0.0701}, {'UUID': 'PDno23andme_full_gene_notext_6674648', 'SNP': 'rs55732422', 'p': 0.1539, 'b': -0.1196}, {'UUID': 'PDno23andme_full_gene_notext_4652014', 'SNP': 'rs2145036', 'p': 0.156, 'b': -0.0384}, {'UUID': 'PDno23andme_full_gene_notext_5257362', 'SNP': 'rs72862636', 'p': 0.1592, 'b': 0.0661}, {'UUID': 'PDno23andme_full_gene_notext_4404556', 'SNP': 'rs2281548', 'p': 0.1593, 'b': 0.0323}, {'UUID': 'PDno23andme_full_gene_notext_2141817', 'SNP': 'rs111731674', 'p': 0.1604, 'b': 0.0923}, {'UUID': 'PDno23andme_full_gene_notext_1168296', 'SNP': 'rs17011439', 'p': 0.1655, 'b': 0.0432}, {'UUID': 'PDno23andme_full_gene_notext_6177821', 'SNP': 'rs78070886', 'p': 0.1659, 'b': 0.0768}, {'UUID': 'PDno23andme_full_gene_notext_3135542', 'SNP': 'rs115177404', 'p': 0.1677, 'b': -0.1759}, {'UUID': 'PDno23andme_full_gene_notext_5215255', 'SNP': 'rs144313077', 'p': 0.168, 'b': 0.0996}, {'UUID': 'PDno23andme_full_gene_notext_6294794', 'SNP': 'rs62141166', 'p': 0.169, 'b': 0.043}, {'UUID': 'PDno23andme_full_gene_notext_7332614', 'SNP': 'rs113995021', 'p': 0.1708, 'b': -0.0842}, {'UUID': 'PDno23andme_full_gene_notext_3809430', 'SNP': 'rs12988379', 'p': 0.1719, 'b': -0.034}, {'UUID': 'PDno23andme_full_gene_notext_6853738', 'SNP': 'rs62144965', 'p': 0.1734, 'b': 0.0431}, {'UUID': 'PDno23andme_full_gene_notext_2593815', 'SNP': 'rs206833', 'p': 0.1744, 'b': 0.0343}, {'UUID': 'PDno23andme_full_gene_notext_6973882', 'SNP': 'rs55855978', 'p': 0.176, 'b': 0.0422}, {'UUID': 'PDno23andme_full_gene_notext_978636', 'SNP': 'rs72790646', 'p': 0.1761, 'b': 0.0871}, {'UUID': 'PDno23andme_full_gene_notext_5213083', 'SNP': 'rs206860', 'p': 0.1764, 'b': -0.0286}]",general,"Select, Order By, Similarity Search, Multi-Filter","Effect, GWAS Significance"
-Q50.1324,Q50,Do MARK2P9 gene mutations increase the risk of Parkinson's disease?,"No, there are no significant mutations in the MARK2P9 gene associated with an increased risk of Parkinson's disease according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019).","SELECT UUID, SNP, p, b 
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE nearestGene LIKE ""%MARK2P9%""
- ORDER BY p
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_1620304', 'SNP': 'rs34037673', 'p': 0.00333, 'b': 0.1883}, {'UUID': 'PDno23andme_full_gene_notext_3955676', 'SNP': 'rs148513036', 'p': 0.004121, 'b': 0.1422}, {'UUID': 'PDno23andme_full_gene_notext_3655493', 'SNP': 'rs144713530', 'p': 0.01892, 'b': 0.1129}, {'UUID': 'PDno23andme_full_gene_notext_1332016', 'SNP': 'rs146016606', 'p': 0.02188, 'b': 0.1427}, {'UUID': 'PDno23andme_full_gene_notext_279234', 'SNP': 'rs2901587', 'p': 0.03477, 'b': -0.0478}, {'UUID': 'PDno23andme_full_gene_notext_3584378', 'SNP': 'rs78410704', 'p': 0.03873, 'b': -0.1604}, {'UUID': 'PDno23andme_full_gene_notext_3244568', 'SNP': 'rs2798253', 'p': 0.03988, 'b': -0.0407}, {'UUID': 'PDno23andme_full_gene_notext_894451', 'SNP': 'rs113629157', 'p': 0.04507, 'b': -0.1579}, {'UUID': 'PDno23andme_full_gene_notext_702529', 'SNP': 'rs4933726', 'p': 0.04829, 'b': 0.0567}, {'UUID': 'PDno23andme_full_gene_notext_6650385', 'SNP': 'rs75631171', 'p': 0.04879, 'b': 0.0565}, {'UUID': 'PDno23andme_full_gene_notext_2105444', 'SNP': 'rs11187000', 'p': 0.04886, 'b': 0.0566}, {'UUID': 'PDno23andme_full_gene_notext_5130818', 'SNP': 'rs4933725', 'p': 0.04915, 'b': 0.0565}, {'UUID': 'PDno23andme_full_gene_notext_2550730', 'SNP': 'rs11187003', 'p': 0.04933, 'b': 0.0564}, {'UUID': 'PDno23andme_full_gene_notext_6999151', 'SNP': 'rs4933231', 'p': 0.04938, 'b': 0.0565}, {'UUID': 'PDno23andme_full_gene_notext_4292854', 'SNP': 'rs11187004', 'p': 0.04956, 'b': 0.0563}, {'UUID': 'PDno23andme_full_gene_notext_1950166', 'SNP': 'rs7910977', 'p': 0.04981, 'b': 0.0562}, {'UUID': 'PDno23andme_full_gene_notext_5328857', 'SNP': 'rs10786047', 'p': 0.04984, 'b': 0.0563}, {'UUID': 'PDno23andme_full_gene_notext_5394033', 'SNP': 'rs11814555', 'p': 0.05048, 'b': 0.0561}, {'UUID': 'PDno23andme_full_gene_notext_2193619', 'SNP': 'rs10882064', 'p': 0.05355, 'b': -0.0459}, {'UUID': 'PDno23andme_full_gene_notext_3887486', 'SNP': 'rs7894946', 'p': 0.05539, 'b': -0.0374}, {'UUID': 'PDno23andme_full_gene_notext_5286436', 'SNP': 'rs12778730', 'p': 0.05774, 'b': -0.0798}, {'UUID': 'PDno23andme_full_gene_notext_976881', 'SNP': 'rs7086285', 'p': 0.05841, 'b': -0.0365}, {'UUID': 'PDno23andme_full_gene_notext_7699208', 'SNP': 'rs10882060', 'p': 0.05992, 'b': -0.0393}, {'UUID': 'PDno23andme_full_gene_notext_3557739', 'SNP': 'rs2209972', 'p': 0.06242, 'b': -0.039}, {'UUID': 'PDno23andme_full_gene_notext_5663055', 'SNP': 'rs884526', 'p': 0.06381, 'b': -0.0388}, {'UUID': 'PDno23andme_full_gene_notext_7092642', 'SNP': 'rs967878', 'p': 0.065, 'b': -0.0356}, {'UUID': 'PDno23andme_full_gene_notext_2988385', 'SNP': 'rs6583813', 'p': 0.06974, 'b': -0.0358}, {'UUID': 'PDno23andme_full_gene_notext_5769183', 'SNP': 'rs7911558', 'p': 0.07066, 'b': 0.0494}, {'UUID': 'PDno23andme_full_gene_notext_5626908', 'SNP': 'rs61875362', 'p': 0.07285, 'b': -0.0354}, {'UUID': 'PDno23andme_full_gene_notext_6529723', 'SNP': 'rs11186967', 'p': 0.0778, 'b': -0.0319}, {'UUID': 'PDno23andme_full_gene_notext_5091136', 'SNP': 'rs11186965', 'p': 0.07824, 'b': -0.0319}, {'UUID': 'PDno23andme_full_gene_notext_204398', 'SNP': 'rs11186966', 'p': 0.07946, 'b': -0.0318}, {'UUID': 'PDno23andme_full_gene_notext_7015482', 'SNP': 'rs11186968', 'p': 0.08152, 'b': -0.0315}, {'UUID': 'PDno23andme_full_gene_notext_3926805', 'SNP': 'rs7909013', 'p': 0.08349, 'b': -0.0357}, {'UUID': 'PDno23andme_full_gene_notext_7079588', 'SNP': 'rs1810809', 'p': 0.08664, 'b': -0.0311}, {'UUID': 'PDno23andme_full_gene_notext_1238182', 'SNP': 'rs2265200', 'p': 0.08937, 'b': -0.0309}, {'UUID': 'PDno23andme_full_gene_notext_6368524', 'SNP': 'rs2019640', 'p': 0.0898, 'b': -0.0308}, {'UUID': 'PDno23andme_full_gene_notext_4924117', 'SNP': 'rs913645', 'p': 0.0915, 'b': -0.0306}, {'UUID': 'PDno23andme_full_gene_notext_1371345', 'SNP': 'rs2257636', 'p': 0.09267, 'b': -0.0305}, {'UUID': 'PDno23andme_full_gene_notext_656008', 'SNP': 'rs2257628', 'p': 0.09297, 'b': -0.0305}, {'UUID': 'PDno23andme_full_gene_notext_3253927', 'SNP': 'rs2257625', 'p': 0.09319, 'b': -0.0304}, {'UUID': 'PDno23andme_full_gene_notext_2536928', 'SNP': 'rs2265199', 'p': 0.09405, 'b': -0.0304}, {'UUID': 'PDno23andme_full_gene_notext_3755573', 'SNP': 'rs2259430', 'p': 0.09444, 'b': -0.0303}, {'UUID': 'PDno23andme_full_gene_notext_2197954', 'SNP': 'rs2259433', 'p': 0.0949, 'b': -0.0303}, {'UUID': 'PDno23andme_full_gene_notext_5911603', 'SNP': 'rs2259373', 'p': 0.09494, 'b': -0.0303}, {'UUID': 'PDno23andme_full_gene_notext_5197882', 'SNP': 'rs2771266', 'p': 0.09569, 'b': -0.0302}, {'UUID': 'PDno23andme_full_gene_notext_5605294', 'SNP': 'rs3121424', 'p': 0.09689, 'b': -0.0302}, {'UUID': 'PDno23andme_full_gene_notext_7513042', 'SNP': 'rs7075928', 'p': 0.1064, 'b': -0.0312}, {'UUID': 'PDno23andme_full_gene_notext_5059455', 'SNP': 'rs35183660', 'p': 0.1109, 'b': -0.0332}, {'UUID': 'PDno23andme_full_gene_notext_7583821', 'SNP': 'rs10786044', 'p': 0.111, 'b': -0.0332}, {'UUID': 'PDno23andme_full_gene_notext_4182224', 'SNP': 'rs11186973', 'p': 0.1112, 'b': -0.0291}, {'UUID': 'PDno23andme_full_gene_notext_5356901', 'SNP': 'rs2480307', 'p': 0.1166, 'b': -0.0286}, {'UUID': 'PDno23andme_full_gene_notext_4454039', 'SNP': 'rs2488794', 'p': 0.1177, 'b': 0.0403}, {'UUID': 'PDno23andme_full_gene_notext_1505642', 'SNP': 'rs2480308', 'p': 0.1178, 'b': -0.0285}, {'UUID': 'PDno23andme_full_gene_notext_3690455', 'SNP': 'rs2480306', 'p': 0.1178, 'b': -0.0285}, {'UUID': 'PDno23andme_full_gene_notext_6321686', 'SNP': 'rs35909985', 'p': 0.1187, 'b': -0.0326}, {'UUID': 'PDno23andme_full_gene_notext_7695820', 'SNP': 'rs3121426', 'p': 0.1192, 'b': -0.0284}, {'UUID': 'PDno23andme_full_gene_notext_4953597', 'SNP': 'rs11186994', 'p': 0.1221, 'b': -0.0323}, {'UUID': 'PDno23andme_full_gene_notext_6308505', 'SNP': 'rs2259053', 'p': 0.1224, 'b': -0.0282}, {'UUID': 'PDno23andme_full_gene_notext_7143098', 'SNP': 'rs11186969', 'p': 0.1225, 'b': -0.0281}, {'UUID': 'PDno23andme_full_gene_notext_345784', 'SNP': 'rs2771268', 'p': 0.1235, 'b': -0.0281}, {'UUID': 'PDno23andme_full_gene_notext_6633261', 'SNP': 'rs11186993', 'p': 0.1253, 'b': -0.032}, {'UUID': 'PDno23andme_full_gene_notext_4468023', 'SNP': 'rs1810810', 'p': 0.1281, 'b': -0.0289}, {'UUID': 'PDno23andme_full_gene_notext_3371293', 'SNP': 'rs2987829', 'p': 0.1282, 'b': -0.0277}, {'UUID': 'PDno23andme_full_gene_notext_2536597', 'SNP': 'rs2995786', 'p': 0.1301, 'b': -0.0276}, {'UUID': 'PDno23andme_full_gene_notext_5333709', 'SNP': 'rs2259090', 'p': 0.1315, 'b': -0.0275}, {'UUID': 'PDno23andme_full_gene_notext_5760488', 'SNP': 'rs10786045', 'p': 0.1321, 'b': -0.0327}, {'UUID': 'PDno23andme_full_gene_notext_5922844', 'SNP': 'rs2480302', 'p': 0.1342, 'b': -0.0273}, {'UUID': 'PDno23andme_full_gene_notext_1446293', 'SNP': 'rs10786046', 'p': 0.1362, 'b': -0.0324}, {'UUID': 'PDno23andme_full_gene_notext_487', 'SNP': 'rs3121427', 'p': 0.1377, 'b': -0.0271}, {'UUID': 'PDno23andme_full_gene_notext_3024905', 'SNP': 'rs12255071', 'p': 0.1519, 'b': -0.0295}, {'UUID': 'PDno23andme_full_gene_notext_3517121', 'SNP': 'rs2771260', 'p': 0.1746, 'b': -0.0263}, {'UUID': 'PDno23andme_full_gene_notext_5188114', 'SNP': 'rs2259376', 'p': 0.1755, 'b': -0.0262}, {'UUID': 'PDno23andme_full_gene_notext_7428255', 'SNP': 'rs2259471', 'p': 0.1791, 'b': -0.026}, {'UUID': 'PDno23andme_full_gene_notext_4025571', 'SNP': 'rs2480305', 'p': 0.1843, 'b': -0.0258}, {'UUID': 'PDno23andme_full_gene_notext_7063187', 'SNP': 'rs10882063', 'p': 0.1918, 'b': -0.0287}, {'UUID': 'PDno23andme_full_gene_notext_5873725', 'SNP': 'rs2798249', 'p': 0.1926, 'b': -0.0253}, {'UUID': 'PDno23andme_full_gene_notext_5529012', 'SNP': 'rs2259049', 'p': 0.208, 'b': -0.0244}, {'UUID': 'PDno23andme_full_gene_notext_7368494', 'SNP': 'rs2259052', 'p': 0.2083, 'b': -0.0244}, {'UUID': 'PDno23andme_full_gene_notext_669751', 'SNP': 'rs1810811', 'p': 0.2112, 'b': -0.0256}, {'UUID': 'PDno23andme_full_gene_notext_7049577', 'SNP': 'rs2259087', 'p': 0.2223, 'b': -0.0237}, {'UUID': 'PDno23andme_full_gene_notext_1639674', 'SNP': 'rs66503910', 'p': 0.2253, 'b': -0.0297}, {'UUID': 'PDno23andme_full_gene_notext_3564715', 'SNP': 'rs2995787', 'p': 0.2357, 'b': -0.0231}, {'UUID': 'PDno23andme_full_gene_notext_4431637', 'SNP': 'rs61875360', 'p': 0.2406, 'b': 0.1683}, {'UUID': 'PDno23andme_full_gene_notext_5633631', 'SNP': 'rs77064819', 'p': 0.2457, 'b': 0.1241}, {'UUID': 'PDno23andme_full_gene_notext_4730233', 'SNP': 'rs2260125', 'p': 0.2534, 'b': 0.0235}, {'UUID': 'PDno23andme_full_gene_notext_919725', 'SNP': 'rs2257635', 'p': 0.2603, 'b': -0.0228}, {'UUID': 'PDno23andme_full_gene_notext_772752', 'SNP': 'rs11186958', 'p': 0.2754, 'b': -0.0195}, {'UUID': 'PDno23andme_full_gene_notext_7223774', 'SNP': 'rs35472331', 'p': 0.2767, 'b': -0.1048}, {'UUID': 'PDno23andme_full_gene_notext_4062482', 'SNP': 'rs884525', 'p': 0.2843, 'b': 0.1155}, {'UUID': 'PDno23andme_full_gene_notext_6490432', 'SNP': 'rs117064900', 'p': 0.2853, 'b': -0.0722}, {'UUID': 'PDno23andme_full_gene_notext_679524', 'SNP': 'rs2263638', 'p': 0.2926, 'b': 0.0216}, {'UUID': 'PDno23andme_full_gene_notext_7154318', 'SNP': 'rs140600352', 'p': 0.2955, 'b': -0.0886}, {'UUID': 'PDno23andme_full_gene_notext_794448', 'SNP': 'rs75132975', 'p': 0.2996, 'b': 0.113}, {'UUID': 'PDno23andme_full_gene_notext_405464', 'SNP': 'rs180712011', 'p': 0.2999, 'b': 0.113}, {'UUID': 'PDno23andme_full_gene_notext_1921802', 'SNP': 'rs7911784', 'p': 0.3028, 'b': -0.0184}, {'UUID': 'PDno23andme_full_gene_notext_5353502', 'SNP': 'rs11511268', 'p': 0.306, 'b': 0.0176}, {'UUID': 'PDno23andme_full_gene_notext_2411565', 'SNP': 'rs7912223', 'p': 0.3079, 'b': -0.0182}, {'UUID': 'PDno23andme_full_gene_notext_6948965', 'SNP': 'rs11186959', 'p': 0.309, 'b': -0.0182}, {'UUID': 'PDno23andme_full_gene_notext_7664326', 'SNP': 'rs75411125', 'p': 0.3134, 'b': 0.1089}]",general,"Select, Order By, Similarity Search, Multi-Filter","Effect, GWAS Significance"
-Q50.57,Q50,Do CD200R1 gene mutations increase the risk of Parkinson's disease?,"No, there are no significant mutations in the CD200R1 gene associated with an increased risk of Parkinson's disease according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019).","SELECT UUID, SNP, p, b 
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE nearestGene LIKE ""%CD200R1%""
- ORDER BY p
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_844137', 'SNP': 'rs62263757', 'p': 0.0164, 'b': -0.1893}, {'UUID': 'PDno23andme_full_gene_notext_1703912', 'SNP': 'rs114316866', 'p': 0.01874, 'b': 0.0754}, {'UUID': 'PDno23andme_full_gene_notext_3894422', 'SNP': 'rs76677551', 'p': 0.01899, 'b': 0.0736}, {'UUID': 'PDno23andme_full_gene_notext_368339', 'SNP': 'rs140507562', 'p': 0.02048, 'b': 0.0727}, {'UUID': 'PDno23andme_full_gene_notext_5481008', 'SNP': 'rs77593899', 'p': 0.02052, 'b': 0.073}, {'UUID': 'PDno23andme_full_gene_notext_5030619', 'SNP': 'rs112530882', 'p': 0.02082, 'b': 0.073}, {'UUID': 'PDno23andme_full_gene_notext_2283263', 'SNP': 'rs114486595', 'p': 0.02207, 'b': 0.0723}, {'UUID': 'PDno23andme_full_gene_notext_7240962', 'SNP': 'rs77077729', 'p': 0.02255, 'b': 0.0719}, {'UUID': 'PDno23andme_full_gene_notext_3486799', 'SNP': 'rs80353124', 'p': 0.02276, 'b': 0.0719}, {'UUID': 'PDno23andme_full_gene_notext_7319822', 'SNP': 'rs35595668', 'p': 0.02426, 'b': -0.3778}, {'UUID': 'PDno23andme_full_gene_notext_1030419', 'SNP': 'rs16860242', 'p': 0.02574, 'b': 0.0694}, {'UUID': 'PDno23andme_full_gene_notext_7678959', 'SNP': 'rs6775807', 'p': 0.02775, 'b': 0.0706}, {'UUID': 'PDno23andme_full_gene_notext_5498582', 'SNP': 'rs6438107', 'p': 0.02805, 'b': 0.0695}, {'UUID': 'PDno23andme_full_gene_notext_3539879', 'SNP': 'rs72950395', 'p': 0.02952, 'b': 0.0682}, {'UUID': 'PDno23andme_full_gene_notext_5778148', 'SNP': 'rs6438108', 'p': 0.02988, 'b': 0.0683}, {'UUID': 'PDno23andme_full_gene_notext_2564879', 'SNP': 'rs1352425', 'p': 0.0304, 'b': 0.0544}, {'UUID': 'PDno23andme_full_gene_notext_4296243', 'SNP': 'rs72952147', 'p': 0.03057, 'b': 0.0675}, {'UUID': 'PDno23andme_full_gene_notext_3061047', 'SNP': 'rs72952134', 'p': 0.03082, 'b': 0.0673}, {'UUID': 'PDno23andme_full_gene_notext_5287177', 'SNP': 'rs72952145', 'p': 0.03095, 'b': 0.0673}, {'UUID': 'PDno23andme_full_gene_notext_1487054', 'SNP': 'rs58910474', 'p': 0.03131, 'b': 0.067}, {'UUID': 'PDno23andme_full_gene_notext_3731659', 'SNP': 'rs75252809', 'p': 0.03165, 'b': 0.0688}, {'UUID': 'PDno23andme_full_gene_notext_326792', 'SNP': 'rs72948479', 'p': 0.03218, 'b': 0.0681}, {'UUID': 'PDno23andme_full_gene_notext_135059', 'SNP': 'rs6770507', 'p': 0.03397, 'b': 0.0661}, {'UUID': 'PDno23andme_full_gene_notext_1886885', 'SNP': 'rs76908881', 'p': 0.03417, 'b': 0.0669}, {'UUID': 'PDno23andme_full_gene_notext_4480048', 'SNP': 'rs9847757', 'p': 0.0342, 'b': 0.0659}, {'UUID': 'PDno23andme_full_gene_notext_1832590', 'SNP': 'rs12631307', 'p': 0.03486, 'b': 0.0662}, {'UUID': 'PDno23andme_full_gene_notext_6187629', 'SNP': 'rs75350327', 'p': 0.03548, 'b': 0.066}, {'UUID': 'PDno23andme_full_gene_notext_4688197', 'SNP': 'rs72952148', 'p': 0.03569, 'b': 0.0654}, {'UUID': 'PDno23andme_full_gene_notext_1890808', 'SNP': 'rs78661547', 'p': 0.03639, 'b': 0.0653}, {'UUID': 'PDno23andme_full_gene_notext_1334658', 'SNP': 'rs62263753', 'p': 0.03654, 'b': -0.1782}, {'UUID': 'PDno23andme_full_gene_notext_1928401', 'SNP': 'rs72952157', 'p': 0.03674, 'b': 0.0652}, {'UUID': 'PDno23andme_full_gene_notext_4889769', 'SNP': 'rs72950393', 'p': 0.03714, 'b': 0.0654}, {'UUID': 'PDno23andme_full_gene_notext_3088262', 'SNP': 'rs72952155', 'p': 0.0394, 'b': 0.0642}, {'UUID': 'PDno23andme_full_gene_notext_5816263', 'SNP': 'rs111382914', 'p': 0.04543, 'b': 0.0632}, {'UUID': 'PDno23andme_full_gene_notext_6150818', 'SNP': 'rs6768154', 'p': 0.04785, 'b': 0.0755}, {'UUID': 'PDno23andme_full_gene_notext_3328239', 'SNP': 'rs6803891', 'p': 0.05391, 'b': 0.0736}, {'UUID': 'PDno23andme_full_gene_notext_2518227', 'SNP': 'rs72952158', 'p': 0.05998, 'b': 0.0587}, {'UUID': 'PDno23andme_full_gene_notext_5223717', 'SNP': 'rs7642984', 'p': 0.07118, 'b': 0.0433}, {'UUID': 'PDno23andme_full_gene_notext_4643830', 'SNP': 'rs59168637', 'p': 0.07541, 'b': -0.037}, {'UUID': 'PDno23andme_full_gene_notext_256137', 'SNP': 'rs62263670', 'p': 0.08132, 'b': 0.0654}, {'UUID': 'PDno23andme_full_gene_notext_2203499', 'SNP': 'rs62263673', 'p': 0.08656, 'b': 0.063}, {'UUID': 'PDno23andme_full_gene_notext_6616163', 'SNP': 'rs62263672', 'p': 0.08699, 'b': 0.0639}, {'UUID': 'PDno23andme_full_gene_notext_2059972', 'SNP': 'rs1994509', 'p': 0.08802, 'b': 0.0407}, {'UUID': 'PDno23andme_full_gene_notext_3725186', 'SNP': 'rs57650262', 'p': 0.089, 'b': -0.9951}, {'UUID': 'PDno23andme_full_gene_notext_7350667', 'SNP': 'rs62263675', 'p': 0.09169, 'b': -0.0635}, {'UUID': 'PDno23andme_full_gene_notext_1777895', 'SNP': 'rs62263674', 'p': 0.09177, 'b': 0.062}, {'UUID': 'PDno23andme_full_gene_notext_2919652', 'SNP': 'rs820555', 'p': 0.09196, 'b': -0.0358}, {'UUID': 'PDno23andme_full_gene_notext_6081975', 'SNP': 'rs112653127', 'p': 0.09449, 'b': 0.0809}, {'UUID': 'PDno23andme_full_gene_notext_2296427', 'SNP': 'rs75594059', 'p': 0.0951, 'b': 0.079}, {'UUID': 'PDno23andme_full_gene_notext_914227', 'SNP': 'rs77757195', 'p': 0.09661, 'b': 0.0787}, {'UUID': 'PDno23andme_full_gene_notext_144404', 'SNP': 'rs6438103', 'p': 0.09875, 'b': 0.0609}, {'UUID': 'PDno23andme_full_gene_notext_5268691', 'SNP': 'rs55843927', 'p': 0.1072, 'b': -0.0329}, {'UUID': 'PDno23andme_full_gene_notext_224010', 'SNP': 'rs62263720', 'p': 0.1122, 'b': -0.0324}, {'UUID': 'PDno23andme_full_gene_notext_7084147', 'SNP': 'rs7632570', 'p': 0.1141, 'b': 0.0748}, {'UUID': 'PDno23andme_full_gene_notext_4582063', 'SNP': 'rs34843017', 'p': 0.1194, 'b': -0.0865}, {'UUID': 'PDno23andme_full_gene_notext_4799578', 'SNP': 'rs62263666', 'p': 0.1216, 'b': 0.0609}, {'UUID': 'PDno23andme_full_gene_notext_5857014', 'SNP': 'rs7628337', 'p': 0.1267, 'b': 0.034}, {'UUID': 'PDno23andme_full_gene_notext_6481759', 'SNP': 'rs57349641', 'p': 0.1334, 'b': 0.046}, {'UUID': 'PDno23andme_full_gene_notext_4643831', 'SNP': 'rs59842034', 'p': 0.1339, 'b': 0.0459}, {'UUID': 'PDno23andme_full_gene_notext_3810619', 'SNP': 'rs59048040', 'p': 0.1365, 'b': 0.0456}, {'UUID': 'PDno23andme_full_gene_notext_6858411', 'SNP': 'rs77484679', 'p': 0.1392, 'b': 0.0328}, {'UUID': 'PDno23andme_full_gene_notext_7705756', 'SNP': 'rs72950327', 'p': 0.1399, 'b': 0.0328}, {'UUID': 'PDno23andme_full_gene_notext_3754651', 'SNP': 'rs73220346', 'p': 0.142, 'b': 0.048}, {'UUID': 'PDno23andme_full_gene_notext_706561', 'SNP': 'rs72950326', 'p': 0.1447, 'b': 0.0326}, {'UUID': 'PDno23andme_full_gene_notext_1678742', 'SNP': 'rs9968081', 'p': 0.1459, 'b': 0.0568}, {'UUID': 'PDno23andme_full_gene_notext_1389357', 'SNP': 'rs56370936', 'p': 0.1464, 'b': -0.0568}, {'UUID': 'PDno23andme_full_gene_notext_3120780', 'SNP': 'rs73225774', 'p': 0.1485, 'b': -0.0564}, {'UUID': 'PDno23andme_full_gene_notext_3002899', 'SNP': 'rs142695426', 'p': 0.1485, 'b': -0.0565}, {'UUID': 'PDno23andme_full_gene_notext_1952861', 'SNP': 'rs4682443', 'p': 0.1493, 'b': -0.0564}, {'UUID': 'PDno23andme_full_gene_notext_825179', 'SNP': 'rs7433444', 'p': 0.1493, 'b': -0.0563}, {'UUID': 'PDno23andme_full_gene_notext_4760660', 'SNP': 'rs73225789', 'p': 0.1537, 'b': -0.0558}, {'UUID': 'PDno23andme_full_gene_notext_1338423', 'SNP': 'rs6797920', 'p': 0.1542, 'b': -0.0267}, {'UUID': 'PDno23andme_full_gene_notext_4731131', 'SNP': 'rs73227782', 'p': 0.1548, 'b': -0.0557}, {'UUID': 'PDno23andme_full_gene_notext_5723059', 'SNP': 'rs62263665', 'p': 0.157, 'b': 0.0555}, {'UUID': 'PDno23andme_full_gene_notext_4158227', 'SNP': 'rs116074663', 'p': 0.159, 'b': -0.0551}, {'UUID': 'PDno23andme_full_gene_notext_7273630', 'SNP': 'rs73225772', 'p': 0.163, 'b': -0.0543}, {'UUID': 'PDno23andme_full_gene_notext_5597307', 'SNP': 'rs72950324', 'p': 0.1634, 'b': 0.0311}, {'UUID': 'PDno23andme_full_gene_notext_6368623', 'SNP': 'rs4682117', 'p': 0.1664, 'b': 0.0311}, {'UUID': 'PDno23andme_full_gene_notext_1113218', 'SNP': 'rs73223880', 'p': 0.1687, 'b': -0.0539}, {'UUID': 'PDno23andme_full_gene_notext_2628290', 'SNP': 'rs11918522', 'p': 0.1699, 'b': 0.0309}, {'UUID': 'PDno23andme_full_gene_notext_6900588', 'SNP': 'rs4682436', 'p': 0.1729, 'b': -0.053}, {'UUID': 'PDno23andme_full_gene_notext_751392', 'SNP': 'rs1586534', 'p': 0.1744, 'b': -0.0531}, {'UUID': 'PDno23andme_full_gene_notext_1917841', 'SNP': 'rs6438105', 'p': 0.1791, 'b': -0.0241}, {'UUID': 'PDno23andme_full_gene_notext_4411619', 'SNP': 'rs150862225', 'p': 0.1833, 'b': 0.0727}, {'UUID': 'PDno23andme_full_gene_notext_1848821', 'SNP': 'rs73225770', 'p': 0.1841, 'b': -0.0516}, {'UUID': 'PDno23andme_full_gene_notext_5520608', 'SNP': 'rs73225763', 'p': 0.185, 'b': -0.0515}, {'UUID': 'PDno23andme_full_gene_notext_6378564', 'SNP': 'rs1948165', 'p': 0.1872, 'b': 0.0299}, {'UUID': 'PDno23andme_full_gene_notext_61050', 'SNP': 'rs73225764', 'p': 0.1874, 'b': -0.0512}, {'UUID': 'PDno23andme_full_gene_notext_4786678', 'SNP': 'rs1387015', 'p': 0.1881, 'b': 0.028}, {'UUID': 'PDno23andme_full_gene_notext_1582219', 'SNP': 'rs7648520', 'p': 0.1896, 'b': 0.0465}, {'UUID': 'PDno23andme_full_gene_notext_2268050', 'SNP': 'rs73229413', 'p': 0.1912, 'b': -0.0685}, {'UUID': 'PDno23andme_full_gene_notext_3182536', 'SNP': 'rs73225761', 'p': 0.1917, 'b': -0.051}, {'UUID': 'PDno23andme_full_gene_notext_3009495', 'SNP': 'rs73214321', 'p': 0.1952, 'b': -0.0709}, {'UUID': 'PDno23andme_full_gene_notext_6648745', 'SNP': 'rs55884450', 'p': 0.1953, 'b': -0.0506}, {'UUID': 'PDno23andme_full_gene_notext_3423838', 'SNP': 'rs113921485', 'p': 0.1958, 'b': 0.0459}, {'UUID': 'PDno23andme_full_gene_notext_6126668', 'SNP': 'rs113622927', 'p': 0.197, 'b': 0.0457}, {'UUID': 'PDno23andme_full_gene_notext_127373', 'SNP': 'rs6784760', 'p': 0.1971, 'b': -0.0231}, {'UUID': 'PDno23andme_full_gene_notext_4658914', 'SNP': 'rs1948164', 'p': 0.1976, 'b': 0.0292}, {'UUID': 'PDno23andme_full_gene_notext_4605346', 'SNP': 'rs9835599', 'p': 0.1978, 'b': 0.0263}, {'UUID': 'PDno23andme_full_gene_notext_5681764', 'SNP': 'rs820554', 'p': 0.1981, 'b': -0.0681}]",general,"Select, Order By, Similarity Search, Multi-Filter","Effect, GWAS Significance"
-Q50.1293,Q50,Do PTPRD gene mutations increase the risk of Parkinson's disease?,"No, there are no significant mutations in the PTPRD gene associated with an increased risk of Parkinson's disease according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019).","SELECT UUID, SNP, p, b 
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE nearestGene LIKE ""%PTPRD%""
- ORDER BY p
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_6918988', 'SNP': 'rs694209', 'p': 0.0002435, 'b': 0.1003}, {'UUID': 'PDno23andme_full_gene_notext_160474', 'SNP': 'rs616040', 'p': 0.0003056, 'b': 0.0991}, {'UUID': 'PDno23andme_full_gene_notext_1512958', 'SNP': 'rs10116020', 'p': 0.0003165, 'b': -0.137}, {'UUID': 'PDno23andme_full_gene_notext_5859672', 'SNP': 'rs694201', 'p': 0.0003423, 'b': 0.098}, {'UUID': 'PDno23andme_full_gene_notext_6917235', 'SNP': 'rs7039204', 'p': 0.00037, 'b': 0.1147}, {'UUID': 'PDno23andme_full_gene_notext_1249778', 'SNP': 'rs10124277', 'p': 0.000373, 'b': -0.1354}, {'UUID': 'PDno23andme_full_gene_notext_478160', 'SNP': 'rs72704856', 'p': 0.0004038, 'b': 0.2913}, {'UUID': 'PDno23andme_full_gene_notext_6388494', 'SNP': 'rs62534039', 'p': 0.0004043, 'b': -0.1344}, {'UUID': 'PDno23andme_full_gene_notext_4374104', 'SNP': 'rs71507636', 'p': 0.0004563, 'b': 0.1178}, {'UUID': 'PDno23andme_full_gene_notext_6265812', 'SNP': 'rs13286908', 'p': 0.0004563, 'b': -0.1322}, {'UUID': 'PDno23andme_full_gene_notext_3774270', 'SNP': 'rs13292865', 'p': 0.0004799, 'b': -0.1333}, {'UUID': 'PDno23andme_full_gene_notext_5793769', 'SNP': 'rs35441574', 'p': 0.0004826, 'b': -0.1337}, {'UUID': 'PDno23andme_full_gene_notext_6612093', 'SNP': 'rs13292463', 'p': 0.0004867, 'b': 0.1156}, {'UUID': 'PDno23andme_full_gene_notext_6561406', 'SNP': 'rs35777094', 'p': 0.0004903, 'b': -0.1316}, {'UUID': 'PDno23andme_full_gene_notext_7690374', 'SNP': 'rs10115554', 'p': 0.0005126, 'b': -0.1328}, {'UUID': 'PDno23andme_full_gene_notext_6475136', 'SNP': 'rs1407925', 'p': 0.0005422, 'b': 0.0944}, {'UUID': 'PDno23andme_full_gene_notext_1989578', 'SNP': 'rs7863060', 'p': 0.0005567, 'b': -0.141}, {'UUID': 'PDno23andme_full_gene_notext_6970336', 'SNP': 'rs13290896', 'p': 0.0005972, 'b': -0.1308}, {'UUID': 'PDno23andme_full_gene_notext_232903', 'SNP': 'rs12344926', 'p': 0.0006363, 'b': 0.0927}, {'UUID': 'PDno23andme_full_gene_notext_1562523', 'SNP': 'rs10959026', 'p': 0.0006589, 'b': 0.0928}, {'UUID': 'PDno23andme_full_gene_notext_4330670', 'SNP': 'rs16928048', 'p': 0.0006744, 'b': -0.1395}, {'UUID': 'PDno23andme_full_gene_notext_2714173', 'SNP': 'rs1323498', 'p': 0.0006935, 'b': 0.0921}, {'UUID': 'PDno23andme_full_gene_notext_1672762', 'SNP': 'rs62534040', 'p': 0.0007201, 'b': -0.1312}, {'UUID': 'PDno23andme_full_gene_notext_150165', 'SNP': 'rs35929428', 'p': 0.0007249, 'b': -0.129}, {'UUID': 'PDno23andme_full_gene_notext_3964847', 'SNP': 'rs10115201', 'p': 0.0008021, 'b': -0.1376}, {'UUID': 'PDno23andme_full_gene_notext_617772', 'SNP': 'rs6477267', 'p': 0.0008282, 'b': 0.1082}, {'UUID': 'PDno23andme_full_gene_notext_5203060', 'SNP': 'rs13297903', 'p': 0.0008603, 'b': 0.1091}, {'UUID': 'PDno23andme_full_gene_notext_935540', 'SNP': 'rs942158', 'p': 0.0008722, 'b': 0.0904}, {'UUID': 'PDno23andme_full_gene_notext_4817308', 'SNP': 'rs1323592', 'p': 0.001008, 'b': -0.1275}, {'UUID': 'PDno23andme_full_gene_notext_7599291', 'SNP': 'rs34599557', 'p': 0.001012, 'b': -0.1274}, {'UUID': 'PDno23andme_full_gene_notext_1011880', 'SNP': 'rs191360748', 'p': 0.001035, 'b': 0.295}, {'UUID': 'PDno23andme_full_gene_notext_4439663', 'SNP': 'rs617900', 'p': 0.001082, 'b': 0.0954}, {'UUID': 'PDno23andme_full_gene_notext_925090', 'SNP': 'rs1323500', 'p': 0.001248, 'b': 0.0893}, {'UUID': 'PDno23andme_full_gene_notext_3019485', 'SNP': 'rs1544056', 'p': 0.001296, 'b': 0.092}, {'UUID': 'PDno23andme_full_gene_notext_7326010', 'SNP': 'rs117887890', 'p': 0.001327, 'b': 0.2258}, {'UUID': 'PDno23andme_full_gene_notext_3161084', 'SNP': 'rs138131195', 'p': 0.001479, 'b': 0.4982}, {'UUID': 'PDno23andme_full_gene_notext_1083181', 'SNP': 'rs10976856', 'p': 0.001557, 'b': -0.2954}, {'UUID': 'PDno23andme_full_gene_notext_6989660', 'SNP': 'rs62534042', 'p': 0.001744, 'b': -0.1083}, {'UUID': 'PDno23andme_full_gene_notext_5591278', 'SNP': 'rs116949354', 'p': 0.001831, 'b': 0.2191}, {'UUID': 'PDno23andme_full_gene_notext_3958189', 'SNP': 'rs13285375', 'p': 0.001995, 'b': 0.1025}, {'UUID': 'PDno23andme_full_gene_notext_2226233', 'SNP': 'rs10809060', 'p': 0.002353, 'b': 0.0881}, {'UUID': 'PDno23andme_full_gene_notext_4017467', 'SNP': 'rs10959014', 'p': 0.002638, 'b': 0.0833}, {'UUID': 'PDno23andme_full_gene_notext_6731724', 'SNP': 'rs10815842', 'p': 0.00264, 'b': -0.0843}, {'UUID': 'PDno23andme_full_gene_notext_4920380', 'SNP': 'rs16928053', 'p': 0.002702, 'b': -0.1061}, {'UUID': 'PDno23andme_full_gene_notext_5001772', 'SNP': 'rs76108753', 'p': 0.002711, 'b': -0.2729}, {'UUID': 'PDno23andme_full_gene_notext_1956023', 'SNP': 'rs10959015', 'p': 0.002734, 'b': 0.0829}, {'UUID': 'PDno23andme_full_gene_notext_6784956', 'SNP': 'rs12376550', 'p': 0.002789, 'b': -0.2212}, {'UUID': 'PDno23andme_full_gene_notext_5321420', 'SNP': 'rs10976842', 'p': 0.002822, 'b': -0.2718}, {'UUID': 'PDno23andme_full_gene_notext_2375688', 'SNP': 'rs4549838', 'p': 0.002882, 'b': -0.1069}, {'UUID': 'PDno23andme_full_gene_notext_882532', 'SNP': 'rs148858377', 'p': 0.002892, 'b': 0.2077}, {'UUID': 'PDno23andme_full_gene_notext_4488891', 'SNP': 'rs144271132', 'p': 0.00294, 'b': -0.3151}, {'UUID': 'PDno23andme_full_gene_notext_7045357', 'SNP': 'rs12338784', 'p': 0.002983, 'b': 0.205}, {'UUID': 'PDno23andme_full_gene_notext_7641638', 'SNP': 'rs4595181', 'p': 0.002989, 'b': -0.1065}, {'UUID': 'PDno23andme_full_gene_notext_3662642', 'SNP': 'rs1535664', 'p': 0.00299, 'b': 0.0856}, {'UUID': 'PDno23andme_full_gene_notext_7378060', 'SNP': 'rs1323499', 'p': 0.003163, 'b': 0.0852}, {'UUID': 'PDno23andme_full_gene_notext_2835222', 'SNP': 'rs10759050', 'p': 0.003176, 'b': -0.0676}, {'UUID': 'PDno23andme_full_gene_notext_252000', 'SNP': 'rs942159', 'p': 0.003205, 'b': 0.0851}, {'UUID': 'PDno23andme_full_gene_notext_2018225', 'SNP': 'rs12554851', 'p': 0.003253, 'b': 0.2096}, {'UUID': 'PDno23andme_full_gene_notext_6316434', 'SNP': 'rs4740924', 'p': 0.003263, 'b': -0.0861}, {'UUID': 'PDno23andme_full_gene_notext_4507850', 'SNP': 'rs2044361', 'p': 0.003293, 'b': -0.0673}, {'UUID': 'PDno23andme_full_gene_notext_1802339', 'SNP': 'rs5001110', 'p': 0.00334, 'b': 0.0823}, {'UUID': 'PDno23andme_full_gene_notext_2133881', 'SNP': 'rs16928058', 'p': 0.003352, 'b': -0.1034}, {'UUID': 'PDno23andme_full_gene_notext_2309831', 'SNP': 'rs945000', 'p': 0.003354, 'b': -0.2101}, {'UUID': 'PDno23andme_full_gene_notext_4297628', 'SNP': 'rs880634', 'p': 0.00341, 'b': 0.0814}, {'UUID': 'PDno23andme_full_gene_notext_436358', 'SNP': 'rs4495488', 'p': 0.003412, 'b': -0.104}, {'UUID': 'PDno23andme_full_gene_notext_7011457', 'SNP': 'rs4409447', 'p': 0.003423, 'b': -0.1038}, {'UUID': 'PDno23andme_full_gene_notext_1609068', 'SNP': 'rs10756027', 'p': 0.003441, 'b': 0.0836}, {'UUID': 'PDno23andme_full_gene_notext_743934', 'SNP': 'rs10976825', 'p': 0.003468, 'b': -0.2615}, {'UUID': 'PDno23andme_full_gene_notext_3763323', 'SNP': 'rs11999849', 'p': 0.003507, 'b': 0.0709}, {'UUID': 'PDno23andme_full_gene_notext_3775415', 'SNP': 'rs10959502', 'p': 0.003734, 'b': -0.1883}, {'UUID': 'PDno23andme_full_gene_notext_5246253', 'SNP': 'rs10758975', 'p': 0.003798, 'b': -0.0827}, {'UUID': 'PDno23andme_full_gene_notext_454737', 'SNP': 'rs13296910', 'p': 0.003834, 'b': -0.1024}, {'UUID': 'PDno23andme_full_gene_notext_5083864', 'SNP': 'rs10976824', 'p': 0.003872, 'b': -0.2626}, {'UUID': 'PDno23andme_full_gene_notext_1131105', 'SNP': 'rs10976719', 'p': 0.003977, 'b': -0.0839}, {'UUID': 'PDno23andme_full_gene_notext_1632583', 'SNP': 'rs1445213', 'p': 0.003998, 'b': 0.0643}, {'UUID': 'PDno23andme_full_gene_notext_4102299', 'SNP': 'rs13298803', 'p': 0.004242, 'b': -0.1012}, {'UUID': 'PDno23andme_full_gene_notext_6033947', 'SNP': 'rs72708734', 'p': 0.004301, 'b': -0.3048}, {'UUID': 'PDno23andme_full_gene_notext_2064814', 'SNP': 'rs4742594', 'p': 0.004341, 'b': 0.0693}, {'UUID': 'PDno23andme_full_gene_notext_5564052', 'SNP': 'rs4399029', 'p': 0.00469, 'b': 0.0753}, {'UUID': 'PDno23andme_full_gene_notext_3424781', 'SNP': 'rs10815739', 'p': 0.004778, 'b': -0.0824}, {'UUID': 'PDno23andme_full_gene_notext_1929563', 'SNP': 'rs59575925', 'p': 0.004932, 'b': 0.151}, {'UUID': 'PDno23andme_full_gene_notext_7724377', 'SNP': 'rs73419564', 'p': 0.004933, 'b': 0.1479}, {'UUID': 'PDno23andme_full_gene_notext_437648', 'SNP': 'rs144740983', 'p': 0.00496, 'b': 0.2724}, {'UUID': 'PDno23andme_full_gene_notext_2851678', 'SNP': 'rs10756028', 'p': 0.004976, 'b': 0.0792}, {'UUID': 'PDno23andme_full_gene_notext_4265542', 'SNP': 'rs12006331', 'p': 0.005073, 'b': 0.1342}, {'UUID': 'PDno23andme_full_gene_notext_3953027', 'SNP': 'rs78966756', 'p': 0.005275, 'b': -0.1091}, {'UUID': 'PDno23andme_full_gene_notext_151259', 'SNP': 'rs78577609', 'p': 0.005514, 'b': -0.1673}, {'UUID': 'PDno23andme_full_gene_notext_2059813', 'SNP': 'rs117471277', 'p': 0.005601, 'b': -0.1175}, {'UUID': 'PDno23andme_full_gene_notext_5033642', 'SNP': 'rs10977137', 'p': 0.005847, 'b': -0.1155}, {'UUID': 'PDno23andme_full_gene_notext_2539406', 'SNP': 'rs147549924', 'p': 0.005855, 'b': -0.1174}, {'UUID': 'PDno23andme_full_gene_notext_6331219', 'SNP': 'rs75323399', 'p': 0.006075, 'b': -0.1169}, {'UUID': 'PDno23andme_full_gene_notext_5932189', 'SNP': 'rs764310', 'p': 0.006116, 'b': -0.0739}, {'UUID': 'PDno23andme_full_gene_notext_1346333', 'SNP': 'rs4132505', 'p': 0.006187, 'b': 0.0777}, {'UUID': 'PDno23andme_full_gene_notext_4855909', 'SNP': 'rs13291881', 'p': 0.006382, 'b': 0.0637}, {'UUID': 'PDno23andme_full_gene_notext_3327092', 'SNP': 'rs57072794', 'p': 0.006429, 'b': 0.1436}, {'UUID': 'PDno23andme_full_gene_notext_5564101', 'SNP': 'rs10809070', 'p': 0.006431, 'b': 0.0828}, {'UUID': 'PDno23andme_full_gene_notext_4329191', 'SNP': 'rs77916466', 'p': 0.006432, 'b': -0.1162}, {'UUID': 'PDno23andme_full_gene_notext_5607956', 'SNP': 'rs16928072', 'p': 0.00671, 'b': -0.0931}, {'UUID': 'PDno23andme_full_gene_notext_2682608', 'SNP': 'rs2120924', 'p': 0.006793, 'b': 0.0615}, {'UUID': 'PDno23andme_full_gene_notext_379705', 'SNP': 'rs4350033', 'p': 0.006829, 'b': 0.0718}]",general,"Select, Order By, Similarity Search, Multi-Filter","Effect, GWAS Significance"
-Q50.1119,Q50,Do CASQ2 gene mutations increase the risk of Parkinson's disease?,"No, there are no significant mutations in the CASQ2 gene associated with an increased risk of Parkinson's disease according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019).","SELECT UUID, SNP, p, b 
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE nearestGene LIKE ""%CASQ2%""
- ORDER BY p
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_4031209', 'SNP': 'rs76853530', 'p': 0.003204, 'b': -0.2577}, {'UUID': 'PDno23andme_full_gene_notext_1225100', 'SNP': 'rs4483405', 'p': 0.03376, 'b': 0.0412}, {'UUID': 'PDno23andme_full_gene_notext_7346626', 'SNP': 'rs4272626', 'p': 0.03879, 'b': 0.0416}, {'UUID': 'PDno23andme_full_gene_notext_1627809', 'SNP': 'rs4453038', 'p': 0.04154, 'b': 0.041}, {'UUID': 'PDno23andme_full_gene_notext_2254598', 'SNP': 'rs10923504', 'p': 0.04475, 'b': 0.041}, {'UUID': 'PDno23andme_full_gene_notext_7755427', 'SNP': 'rs7520087', 'p': 0.05129, 'b': 0.0377}, {'UUID': 'PDno23andme_full_gene_notext_6781522', 'SNP': 'rs4839488', 'p': 0.05657, 'b': 0.0393}, {'UUID': 'PDno23andme_full_gene_notext_1009647', 'SNP': 'rs4535998', 'p': 0.05978, 'b': 0.0444}, {'UUID': 'PDno23andme_full_gene_notext_1994022', 'SNP': 'rs28730711', 'p': 0.06396, 'b': -0.1047}, {'UUID': 'PDno23andme_full_gene_notext_4528087', 'SNP': 'rs4266885', 'p': 0.06535, 'b': 0.037}, {'UUID': 'PDno23andme_full_gene_notext_1352151', 'SNP': 'rs72701699', 'p': 0.0711, 'b': 0.1093}, {'UUID': 'PDno23andme_full_gene_notext_2444313', 'SNP': 'rs12140397', 'p': 0.07152, 'b': 0.0363}, {'UUID': 'PDno23andme_full_gene_notext_3871757', 'SNP': 'rs72703638', 'p': 0.0717, 'b': 0.1224}, {'UUID': 'PDno23andme_full_gene_notext_281981', 'SNP': 'rs72703604', 'p': 0.07387, 'b': 0.1233}, {'UUID': 'PDno23andme_full_gene_notext_4104187', 'SNP': 'rs10802014', 'p': 0.07914, 'b': 0.0357}, {'UUID': 'PDno23andme_full_gene_notext_5152720', 'SNP': 'rs12759898', 'p': 0.08366, 'b': 0.0681}, {'UUID': 'PDno23andme_full_gene_notext_361604', 'SNP': 'rs13374605', 'p': 0.08369, 'b': 0.1058}, {'UUID': 'PDno23andme_full_gene_notext_2970582', 'SNP': 'rs13374904', 'p': 0.08441, 'b': 0.1055}, {'UUID': 'PDno23andme_full_gene_notext_6043370', 'SNP': 'rs4839044', 'p': 0.08462, 'b': 0.0319}, {'UUID': 'PDno23andme_full_gene_notext_5834506', 'SNP': 'rs11804289', 'p': 0.08935, 'b': 0.1056}, {'UUID': 'PDno23andme_full_gene_notext_188631', 'SNP': 'rs34335710', 'p': 0.08957, 'b': 0.0617}, {'UUID': 'PDno23andme_full_gene_notext_7733815', 'SNP': 'rs4567278', 'p': 0.09276, 'b': 0.051}, {'UUID': 'PDno23andme_full_gene_notext_6440841', 'SNP': 'rs4275458', 'p': 0.0939, 'b': 0.0509}, {'UUID': 'PDno23andme_full_gene_notext_3721123', 'SNP': 'rs6428722', 'p': 0.09506, 'b': 0.0507}, {'UUID': 'PDno23andme_full_gene_notext_5623844', 'SNP': 'rs6428724', 'p': 0.09887, 'b': 0.0501}, {'UUID': 'PDno23andme_full_gene_notext_4526268', 'SNP': 'rs6428719', 'p': 0.1003, 'b': 0.0499}, {'UUID': 'PDno23andme_full_gene_notext_884963', 'SNP': 'rs12117088', 'p': 0.102, 'b': -0.1261}, {'UUID': 'PDno23andme_full_gene_notext_2561972', 'SNP': 'rs72703606', 'p': 0.1041, 'b': 0.1002}, {'UUID': 'PDno23andme_full_gene_notext_64084', 'SNP': 'rs4460638', 'p': 0.1046, 'b': -0.0299}, {'UUID': 'PDno23andme_full_gene_notext_3874196', 'SNP': 'rs34301147', 'p': 0.1065, 'b': 0.0742}, {'UUID': 'PDno23andme_full_gene_notext_7321353', 'SNP': 'rs4596883', 'p': 0.1076, 'b': 0.0343}, {'UUID': 'PDno23andme_full_gene_notext_4037853', 'SNP': 'rs7418954', 'p': 0.1101, 'b': 0.0484}, {'UUID': 'PDno23andme_full_gene_notext_2555491', 'SNP': 'rs10494180', 'p': 0.1108, 'b': 0.0339}, {'UUID': 'PDno23andme_full_gene_notext_627469', 'SNP': 'rs10737728', 'p': 0.1129, 'b': 0.0338}, {'UUID': 'PDno23andme_full_gene_notext_6745306', 'SNP': 'rs6683630', 'p': 0.1137, 'b': 0.0479}, {'UUID': 'PDno23andme_full_gene_notext_3789191', 'SNP': 'rs6697979', 'p': 0.1144, 'b': 0.0478}, {'UUID': 'PDno23andme_full_gene_notext_2854455', 'SNP': 'rs9428096', 'p': 0.1148, 'b': 0.0478}, {'UUID': 'PDno23andme_full_gene_notext_2130959', 'SNP': 'rs3811005', 'p': 0.1151, 'b': 0.0336}, {'UUID': 'PDno23andme_full_gene_notext_4936520', 'SNP': 'rs6428688', 'p': 0.1172, 'b': 0.0334}, {'UUID': 'PDno23andme_full_gene_notext_158557', 'SNP': 'rs6667557', 'p': 0.1176, 'b': 0.0478}, {'UUID': 'PDno23andme_full_gene_notext_5501331', 'SNP': 'rs9428232', 'p': 0.1185, 'b': 0.0473}, {'UUID': 'PDno23andme_full_gene_notext_3208990', 'SNP': 'rs6428687', 'p': 0.1195, 'b': 0.0332}, {'UUID': 'PDno23andme_full_gene_notext_5952866', 'SNP': 'rs57926702', 'p': 0.1211, 'b': 0.0474}, {'UUID': 'PDno23andme_full_gene_notext_4803407', 'SNP': 'rs9428233', 'p': 0.1215, 'b': 0.0469}, {'UUID': 'PDno23andme_full_gene_notext_3213544', 'SNP': 'rs10923234', 'p': 0.1221, 'b': 0.0328}, {'UUID': 'PDno23andme_full_gene_notext_528533', 'SNP': 'rs76462084', 'p': 0.1224, 'b': -0.1147}, {'UUID': 'PDno23andme_full_gene_notext_6478851', 'SNP': 'rs71666765', 'p': 0.1224, 'b': 0.0472}, {'UUID': 'PDno23andme_full_gene_notext_5152674', 'SNP': 'rs78224145', 'p': 0.1232, 'b': 0.0422}, {'UUID': 'PDno23andme_full_gene_notext_7649115', 'SNP': 'rs59374747', 'p': 0.1237, 'b': 0.0929}, {'UUID': 'PDno23andme_full_gene_notext_4694330', 'SNP': 'rs9428236', 'p': 0.1237, 'b': 0.0294}, {'UUID': 'PDno23andme_full_gene_notext_183385', 'SNP': 'rs10754368', 'p': 0.1242, 'b': 0.0315}, {'UUID': 'PDno23andme_full_gene_notext_7041359', 'SNP': 'rs71666766', 'p': 0.1277, 'b': 0.0466}, {'UUID': 'PDno23andme_full_gene_notext_1851812', 'SNP': 'rs60497603', 'p': 0.1281, 'b': 0.0466}, {'UUID': 'PDno23andme_full_gene_notext_7306332', 'SNP': 'rs4612628', 'p': 0.1315, 'b': -0.0278}, {'UUID': 'PDno23andme_full_gene_notext_374192', 'SNP': 'rs36069369', 'p': 0.1324, 'b': 0.0461}, {'UUID': 'PDno23andme_full_gene_notext_2547609', 'SNP': 'rs72703675', 'p': 0.134, 'b': 0.0903}, {'UUID': 'PDno23andme_full_gene_notext_3054098', 'SNP': 'rs35739006', 'p': 0.1353, 'b': 0.0458}, {'UUID': 'PDno23andme_full_gene_notext_2340767', 'SNP': 'rs12736789', 'p': 0.136, 'b': 0.0459}, {'UUID': 'PDno23andme_full_gene_notext_7709080', 'SNP': 'rs4072906', 'p': 0.1376, 'b': 0.045}, {'UUID': 'PDno23andme_full_gene_notext_7588114', 'SNP': 'rs10923449', 'p': 0.1404, 'b': 0.0452}, {'UUID': 'PDno23andme_full_gene_notext_1244254', 'SNP': 'rs11579104', 'p': 0.142, 'b': 0.0447}, {'UUID': 'PDno23andme_full_gene_notext_5548895', 'SNP': 'rs11580099', 'p': 0.1442, 'b': 0.0447}, {'UUID': 'PDno23andme_full_gene_notext_5592433', 'SNP': 'rs2797167', 'p': 0.1454, 'b': 0.0309}, {'UUID': 'PDno23andme_full_gene_notext_3712381', 'SNP': 'rs11580107', 'p': 0.1462, 'b': 0.0445}, {'UUID': 'PDno23andme_full_gene_notext_7253713', 'SNP': 'rs4839045', 'p': 0.1486, 'b': 0.0462}, {'UUID': 'PDno23andme_full_gene_notext_3748241', 'SNP': 'rs4073778', 'p': 0.1497, 'b': 0.0256}, {'UUID': 'PDno23andme_full_gene_notext_4443594', 'SNP': 'rs7554304', 'p': 0.1508, 'b': -0.0929}, {'UUID': 'PDno23andme_full_gene_notext_6893098', 'SNP': 'rs2797181', 'p': 0.1519, 'b': 0.0287}, {'UUID': 'PDno23andme_full_gene_notext_2826542', 'SNP': 'rs112880471', 'p': 0.1524, 'b': 0.0972}, {'UUID': 'PDno23andme_full_gene_notext_7139121', 'SNP': 'rs6677775', 'p': 0.1531, 'b': 0.0284}, {'UUID': 'PDno23andme_full_gene_notext_1542052', 'SNP': 'rs7354918', 'p': 0.1536, 'b': 0.0248}, {'UUID': 'PDno23andme_full_gene_notext_2632950', 'SNP': 'rs4543790', 'p': 0.1552, 'b': -0.0262}, {'UUID': 'PDno23andme_full_gene_notext_5058611', 'SNP': 'rs10923251', 'p': 0.1558, 'b': -0.0262}, {'UUID': 'PDno23andme_full_gene_notext_1261425', 'SNP': 'rs2797179', 'p': 0.1564, 'b': 0.0284}, {'UUID': 'PDno23andme_full_gene_notext_739291', 'SNP': 'rs10923250', 'p': 0.1566, 'b': -0.0261}, {'UUID': 'PDno23andme_full_gene_notext_5673007', 'SNP': 'rs74590485', 'p': 0.1572, 'b': 0.1458}, {'UUID': 'PDno23andme_full_gene_notext_322203', 'SNP': 'rs12031293', 'p': 0.1576, 'b': 0.0304}, {'UUID': 'PDno23andme_full_gene_notext_5828126', 'SNP': 'rs12131360', 'p': 0.1578, 'b': 0.0431}, {'UUID': 'PDno23andme_full_gene_notext_5853639', 'SNP': 'rs2811583', 'p': 0.1579, 'b': 0.0283}, {'UUID': 'PDno23andme_full_gene_notext_3636852', 'SNP': 'rs2811585', 'p': 0.1581, 'b': 0.0283}, {'UUID': 'PDno23andme_full_gene_notext_74494', 'SNP': 'rs4997432', 'p': 0.1586, 'b': 0.0275}, {'UUID': 'PDno23andme_full_gene_notext_39380', 'SNP': 'rs6428747', 'p': 0.1587, 'b': 0.0287}, {'UUID': 'PDno23andme_full_gene_notext_972199', 'SNP': 'rs10923248', 'p': 0.1599, 'b': -0.0259}, {'UUID': 'PDno23andme_full_gene_notext_880193', 'SNP': 'rs10923249', 'p': 0.1606, 'b': -0.0259}, {'UUID': 'PDno23andme_full_gene_notext_1019095', 'SNP': 'rs12034182', 'p': 0.161, 'b': -0.0259}, {'UUID': 'PDno23andme_full_gene_notext_7106053', 'SNP': 'rs7538215', 'p': 0.1615, 'b': -0.091}, {'UUID': 'PDno23andme_full_gene_notext_4821166', 'SNP': 'rs3811003', 'p': 0.1621, 'b': 0.0301}, {'UUID': 'PDno23andme_full_gene_notext_1360039', 'SNP': 'rs10801936', 'p': 0.163, 'b': 0.03}, {'UUID': 'PDno23andme_full_gene_notext_3945768', 'SNP': 'rs9428212', 'p': 0.1668, 'b': 0.0244}, {'UUID': 'PDno23andme_full_gene_notext_1109744', 'SNP': 'rs7523715', 'p': 0.1671, 'b': 0.0273}, {'UUID': 'PDno23andme_full_gene_notext_2240979', 'SNP': 'rs4839477', 'p': 0.1672, 'b': 0.0244}, {'UUID': 'PDno23andme_full_gene_notext_794718', 'SNP': 'rs144373084', 'p': 0.1695, 'b': 0.1561}, {'UUID': 'PDno23andme_full_gene_notext_7189564', 'SNP': 'rs7551746', 'p': 0.1697, 'b': -0.0254}, {'UUID': 'PDno23andme_full_gene_notext_2385322', 'SNP': 'rs4475752', 'p': 0.1702, 'b': -0.0251}, {'UUID': 'PDno23andme_full_gene_notext_479458', 'SNP': 'rs7536370', 'p': 0.1705, 'b': 0.0295}, {'UUID': 'PDno23andme_full_gene_notext_4824636', 'SNP': 'rs10923266', 'p': 0.1706, 'b': 0.0298}, {'UUID': 'PDno23andme_full_gene_notext_6511996', 'SNP': 'rs4423004', 'p': 0.1724, 'b': -0.0252}, {'UUID': 'PDno23andme_full_gene_notext_760924', 'SNP': 'rs140338229', 'p': 0.1726, 'b': -0.126}, {'UUID': 'PDno23andme_full_gene_notext_5933142', 'SNP': 'rs9428214', 'p': 0.1727, 'b': 0.0241}, {'UUID': 'PDno23andme_full_gene_notext_3287813', 'SNP': 'rs9428211', 'p': 0.1735, 'b': 0.0241}]",general,"Select, Order By, Similarity Search, Multi-Filter","Effect, GWAS Significance"
-Q50.585,Q50,Do IGFLR1 gene mutations increase the risk of Parkinson's disease?,"No, there are no significant mutations in the IGFLR1 gene associated with an increased risk of Parkinson's disease according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019).","SELECT UUID, SNP, p, b 
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE nearestGene LIKE ""%IGFLR1%""
- ORDER BY p
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_4558261', 'SNP': 'rs12609803', 'p': 0.1683, 'b': 0.036}, {'UUID': 'PDno23andme_full_gene_notext_7612711', 'SNP': 'rs2242523', 'p': 0.215, 'b': 0.021}, {'UUID': 'PDno23andme_full_gene_notext_3690004', 'SNP': 'rs144495330', 'p': 0.4056, 'b': 0.0565}, {'UUID': 'PDno23andme_full_gene_notext_1566104', 'SNP': 'rs182036503', 'p': 0.4157, 'b': 0.1763}, {'UUID': 'PDno23andme_full_gene_notext_4830679', 'SNP': 'rs77798499', 'p': 0.5626, 'b': 0.0394}, {'UUID': 'PDno23andme_full_gene_notext_3627834', 'SNP': 'rs34562867', 'p': 0.6441, 'b': 0.0133}, {'UUID': 'PDno23andme_full_gene_notext_4330062', 'SNP': 'rs140952221', 'p': 0.7239, 'b': -0.0229}, {'UUID': 'PDno23andme_full_gene_notext_6643078', 'SNP': 'rs12459634', 'p': 0.9538, 'b': 0.0014}, {'UUID': 'PDno23andme_full_gene_notext_7232666', 'SNP': 'rs3848665', 'p': 0.9815, 'b': -0.0005}, {'UUID': 'PDno23andme_full_gene_notext_2060132', 'SNP': 'rs2871921', 'p': 0.9877, 'b': 0.0004}]",general,"Select, Order By, Similarity Search, Multi-Filter","Effect, GWAS Significance"
-Q50.375,Q50,Do TECRL gene mutations increase the risk of Parkinson's disease?,"No, there are no significant mutations in the TECRL gene associated with an increased risk of Parkinson's disease according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019).","SELECT UUID, SNP, p, b 
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE nearestGene LIKE ""%TECRL%""
- ORDER BY p
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_2919413', 'SNP': 'rs116178093', 'p': 0.002704, 'b': 0.1806}, {'UUID': 'PDno23andme_full_gene_notext_4666632', 'SNP': 'rs6839298', 'p': 0.002798, 'b': 0.0533}, {'UUID': 'PDno23andme_full_gene_notext_5531160', 'SNP': 'rs73216062', 'p': 0.004152, 'b': 0.1335}, {'UUID': 'PDno23andme_full_gene_notext_7276358', 'SNP': 'rs7654975', 'p': 0.004179, 'b': 0.0487}, {'UUID': 'PDno23andme_full_gene_notext_1058219', 'SNP': 'rs6551881', 'p': 0.004187, 'b': 0.049}, {'UUID': 'PDno23andme_full_gene_notext_5831092', 'SNP': 'rs10002836', 'p': 0.0042, 'b': 0.0489}, {'UUID': 'PDno23andme_full_gene_notext_4262570', 'SNP': 'rs10025827', 'p': 0.004215, 'b': 0.0489}, {'UUID': 'PDno23andme_full_gene_notext_4175099', 'SNP': 'rs10008224', 'p': 0.004248, 'b': 0.0488}, {'UUID': 'PDno23andme_full_gene_notext_2172853', 'SNP': 'rs4860169', 'p': 0.004294, 'b': 0.0487}, {'UUID': 'PDno23andme_full_gene_notext_74071', 'SNP': 'rs6818012', 'p': 0.004425, 'b': 0.0484}, {'UUID': 'PDno23andme_full_gene_notext_5280479', 'SNP': 'rs12331370', 'p': 0.00443, 'b': 0.0485}, {'UUID': 'PDno23andme_full_gene_notext_663932', 'SNP': 'rs11935400', 'p': 0.004435, 'b': 0.0527}, {'UUID': 'PDno23andme_full_gene_notext_3572148', 'SNP': 'rs4860170', 'p': 0.004503, 'b': 0.0485}, {'UUID': 'PDno23andme_full_gene_notext_5614911', 'SNP': 'rs13113989', 'p': 0.004544, 'b': 0.0531}, {'UUID': 'PDno23andme_full_gene_notext_7449038', 'SNP': 'rs1430511', 'p': 0.004603, 'b': 0.0524}, {'UUID': 'PDno23andme_full_gene_notext_5166603', 'SNP': 'rs9992341', 'p': 0.004812, 'b': 0.0492}, {'UUID': 'PDno23andme_full_gene_notext_3374218', 'SNP': 'rs67522684', 'p': 0.004919, 'b': 0.049}, {'UUID': 'PDno23andme_full_gene_notext_4821716', 'SNP': 'rs28559970', 'p': 0.004989, 'b': 0.0492}, {'UUID': 'PDno23andme_full_gene_notext_5790945', 'SNP': 'rs7696376', 'p': 0.005157, 'b': 0.1307}, {'UUID': 'PDno23andme_full_gene_notext_6972754', 'SNP': 'rs10024718', 'p': 0.005368, 'b': 0.1145}, {'UUID': 'PDno23andme_full_gene_notext_3775429', 'SNP': 'rs10023437', 'p': 0.005884, 'b': 0.0471}, {'UUID': 'PDno23andme_full_gene_notext_3949316', 'SNP': 'rs72647280', 'p': 0.006037, 'b': 0.0796}, {'UUID': 'PDno23andme_full_gene_notext_2962936', 'SNP': 'rs13110201', 'p': 0.006065, 'b': 0.0514}, {'UUID': 'PDno23andme_full_gene_notext_3040008', 'SNP': 'rs9995446', 'p': 0.00623, 'b': 0.3359}, {'UUID': 'PDno23andme_full_gene_notext_123857', 'SNP': 'rs1395744', 'p': 0.00641, 'b': 0.1262}, {'UUID': 'PDno23andme_full_gene_notext_690584', 'SNP': 'rs6551880', 'p': 0.006539, 'b': 0.0681}, {'UUID': 'PDno23andme_full_gene_notext_716171', 'SNP': 'rs6820541', 'p': 0.007219, 'b': 0.0694}, {'UUID': 'PDno23andme_full_gene_notext_3164480', 'SNP': 'rs6823601', 'p': 0.007254, 'b': 0.0694}, {'UUID': 'PDno23andme_full_gene_notext_7107460', 'SNP': 'rs6551879', 'p': 0.007321, 'b': 0.0693}, {'UUID': 'PDno23andme_full_gene_notext_6966116', 'SNP': 'rs6551878', 'p': 0.007323, 'b': 0.0693}, {'UUID': 'PDno23andme_full_gene_notext_6144672', 'SNP': 'rs6551877', 'p': 0.007326, 'b': 0.0693}, {'UUID': 'PDno23andme_full_gene_notext_7573245', 'SNP': 'rs2349111', 'p': 0.007339, 'b': 0.0691}, {'UUID': 'PDno23andme_full_gene_notext_2044659', 'SNP': 'rs6551874', 'p': 0.007374, 'b': 0.05}, {'UUID': 'PDno23andme_full_gene_notext_4958237', 'SNP': 'rs6551873', 'p': 0.007443, 'b': 0.05}, {'UUID': 'PDno23andme_full_gene_notext_1850760', 'SNP': 'rs2349110', 'p': 0.007477, 'b': 0.0692}, {'UUID': 'PDno23andme_full_gene_notext_5675745', 'SNP': 'rs11943564', 'p': 0.007571, 'b': 0.0462}, {'UUID': 'PDno23andme_full_gene_notext_5181409', 'SNP': 'rs1346841', 'p': 0.007658, 'b': 0.05}, {'UUID': 'PDno23andme_full_gene_notext_6566659', 'SNP': 'rs10446805', 'p': 0.007666, 'b': 0.069}, {'UUID': 'PDno23andme_full_gene_notext_4905630', 'SNP': 'rs10866151', 'p': 0.007683, 'b': 0.0477}, {'UUID': 'PDno23andme_full_gene_notext_1083714', 'SNP': 'rs4860631', 'p': 0.007707, 'b': 0.0522}, {'UUID': 'PDno23andme_full_gene_notext_546549', 'SNP': 'rs10446803', 'p': 0.007716, 'b': 0.0689}, {'UUID': 'PDno23andme_full_gene_notext_6830469', 'SNP': 'rs9917946', 'p': 0.007774, 'b': 0.05}, {'UUID': 'PDno23andme_full_gene_notext_5704487', 'SNP': 'rs1346838', 'p': 0.007906, 'b': 0.0475}, {'UUID': 'PDno23andme_full_gene_notext_7310678', 'SNP': 'rs9784543', 'p': 0.007906, 'b': 0.0687}, {'UUID': 'PDno23andme_full_gene_notext_1995665', 'SNP': 'rs7691398', 'p': 0.008013, 'b': 0.0687}, {'UUID': 'PDno23andme_full_gene_notext_2138901', 'SNP': 'rs67714948', 'p': 0.008069, 'b': 0.0686}, {'UUID': 'PDno23andme_full_gene_notext_5867126', 'SNP': 'rs1346839', 'p': 0.008249, 'b': 0.0473}, {'UUID': 'PDno23andme_full_gene_notext_3251161', 'SNP': 'rs6833326', 'p': 0.008314, 'b': 0.0684}, {'UUID': 'PDno23andme_full_gene_notext_7205124', 'SNP': 'rs10866150', 'p': 0.008482, 'b': 0.0471}, {'UUID': 'PDno23andme_full_gene_notext_5604077', 'SNP': 'rs57503605', 'p': 0.008858, 'b': 0.068}, {'UUID': 'PDno23andme_full_gene_notext_3142438', 'SNP': 'rs58267503', 'p': 0.008894, 'b': 0.068}, {'UUID': 'PDno23andme_full_gene_notext_964515', 'SNP': 'rs67686109', 'p': 0.009295, 'b': 0.0677}, {'UUID': 'PDno23andme_full_gene_notext_6772081', 'SNP': 'rs66539552', 'p': 0.009503, 'b': 0.0676}, {'UUID': 'PDno23andme_full_gene_notext_5763850', 'SNP': 'rs67573061', 'p': 0.01004, 'b': 0.0675}, {'UUID': 'PDno23andme_full_gene_notext_3840658', 'SNP': 'rs13113354', 'p': 0.01016, 'b': 0.048}, {'UUID': 'PDno23andme_full_gene_notext_5953768', 'SNP': 'rs115976420', 'p': 0.01026, 'b': -0.1441}, {'UUID': 'PDno23andme_full_gene_notext_589241', 'SNP': 'rs10033140', 'p': 0.01027, 'b': 0.4221}, {'UUID': 'PDno23andme_full_gene_notext_7033810', 'SNP': 'rs4336278', 'p': 0.01038, 'b': 0.0478}, {'UUID': 'PDno23andme_full_gene_notext_6286903', 'SNP': 'rs116830350', 'p': 0.01043, 'b': -0.1755}, {'UUID': 'PDno23andme_full_gene_notext_6816019', 'SNP': 'rs4860174', 'p': 0.01056, 'b': 0.0477}, {'UUID': 'PDno23andme_full_gene_notext_3732122', 'SNP': 'rs76418351', 'p': 0.01069, 'b': 0.145}, {'UUID': 'PDno23andme_full_gene_notext_6975556', 'SNP': 'rs12644089', 'p': 0.01105, 'b': 0.0472}, {'UUID': 'PDno23andme_full_gene_notext_2072519', 'SNP': 'rs75644701', 'p': 0.01133, 'b': 0.1499}, {'UUID': 'PDno23andme_full_gene_notext_4349980', 'SNP': 'rs145499716', 'p': 0.0114, 'b': -0.5516}, {'UUID': 'PDno23andme_full_gene_notext_5595757', 'SNP': 'rs978067', 'p': 0.01189, 'b': 0.0655}, {'UUID': 'PDno23andme_full_gene_notext_3594607', 'SNP': 'rs11932659', 'p': 0.01197, 'b': 0.0655}, {'UUID': 'PDno23andme_full_gene_notext_4643731', 'SNP': 'rs7653995', 'p': 0.01199, 'b': 0.0466}, {'UUID': 'PDno23andme_full_gene_notext_5317385', 'SNP': 'rs1430503', 'p': 0.01211, 'b': 0.0654}, {'UUID': 'PDno23andme_full_gene_notext_4658737', 'SNP': 'rs34073665', 'p': 0.01229, 'b': -0.0559}, {'UUID': 'PDno23andme_full_gene_notext_4678028', 'SNP': 'rs115041940', 'p': 0.01238, 'b': 0.1689}, {'UUID': 'PDno23andme_full_gene_notext_5027159', 'SNP': 'rs2015254', 'p': 0.01248, 'b': 0.0652}, {'UUID': 'PDno23andme_full_gene_notext_1409717', 'SNP': 'rs12648944', 'p': 0.01259, 'b': -0.0555}, {'UUID': 'PDno23andme_full_gene_notext_4763108', 'SNP': 'rs7677334', 'p': 0.01261, 'b': 0.0651}, {'UUID': 'PDno23andme_full_gene_notext_419416', 'SNP': 'rs4402399', 'p': 0.01265, 'b': 0.0467}, {'UUID': 'PDno23andme_full_gene_notext_2923536', 'SNP': 'rs1946560', 'p': 0.01267, 'b': 0.0649}, {'UUID': 'PDno23andme_full_gene_notext_2614433', 'SNP': 'rs4129449', 'p': 0.01275, 'b': 0.0467}, {'UUID': 'PDno23andme_full_gene_notext_5245805', 'SNP': 'rs7674285', 'p': 0.01281, 'b': 0.046}, {'UUID': 'PDno23andme_full_gene_notext_3993481', 'SNP': 'rs1430504', 'p': 0.01321, 'b': 0.0648}, {'UUID': 'PDno23andme_full_gene_notext_4358194', 'SNP': 'rs35408881', 'p': 0.01324, 'b': 0.0648}, {'UUID': 'PDno23andme_full_gene_notext_7426494', 'SNP': 'rs1430505', 'p': 0.01324, 'b': 0.0648}, {'UUID': 'PDno23andme_full_gene_notext_5069037', 'SNP': 'rs13123210', 'p': 0.01335, 'b': 0.0464}, {'UUID': 'PDno23andme_full_gene_notext_5324410', 'SNP': 'rs12650993', 'p': 0.0134, 'b': -0.055}, {'UUID': 'PDno23andme_full_gene_notext_2437721', 'SNP': 'rs2015262', 'p': 0.01342, 'b': 0.0646}, {'UUID': 'PDno23andme_full_gene_notext_4510766', 'SNP': 'rs4399403', 'p': 0.01343, 'b': 0.0736}, {'UUID': 'PDno23andme_full_gene_notext_3242871', 'SNP': 'rs1483716', 'p': 0.01349, 'b': -0.0484}, {'UUID': 'PDno23andme_full_gene_notext_3398552', 'SNP': 'rs12641913', 'p': 0.01357, 'b': 0.1126}, {'UUID': 'PDno23andme_full_gene_notext_3112066', 'SNP': 'rs7655180', 'p': 0.01366, 'b': 0.0463}, {'UUID': 'PDno23andme_full_gene_notext_5267355', 'SNP': 'rs12639640', 'p': 0.01371, 'b': -0.0548}, {'UUID': 'PDno23andme_full_gene_notext_492731', 'SNP': 'rs7435292', 'p': 0.01375, 'b': 0.0464}, {'UUID': 'PDno23andme_full_gene_notext_427193', 'SNP': 'rs7659543', 'p': 0.01399, 'b': 0.0643}, {'UUID': 'PDno23andme_full_gene_notext_4370325', 'SNP': 'rs138291068', 'p': 0.01428, 'b': 0.1416}, {'UUID': 'PDno23andme_full_gene_notext_1025646', 'SNP': 'rs9996258', 'p': 0.0146, 'b': 0.0935}, {'UUID': 'PDno23andme_full_gene_notext_1036865', 'SNP': 'rs72647286', 'p': 0.01481, 'b': 0.0748}, {'UUID': 'PDno23andme_full_gene_notext_6426583', 'SNP': 'rs72647290', 'p': 0.01489, 'b': 0.0748}, {'UUID': 'PDno23andme_full_gene_notext_1736451', 'SNP': 'rs60380988', 'p': 0.0149, 'b': 0.1107}, {'UUID': 'PDno23andme_full_gene_notext_270357', 'SNP': 'rs13141614', 'p': 0.01491, 'b': -0.0544}, {'UUID': 'PDno23andme_full_gene_notext_6128948', 'SNP': 'rs148236985', 'p': 0.0151, 'b': 0.1439}, {'UUID': 'PDno23andme_full_gene_notext_4276713', 'SNP': 'rs58164753', 'p': 0.0152, 'b': 0.0609}, {'UUID': 'PDno23andme_full_gene_notext_6335465', 'SNP': 'rs11940410', 'p': 0.0153, 'b': 0.0744}, {'UUID': 'PDno23andme_full_gene_notext_2518783', 'SNP': 'rs142201122', 'p': 0.01532, 'b': 0.144}]",general,"Select, Order By, Similarity Search, Multi-Filter","Effect, GWAS Significance"
-Q50.276,Q50,Do GATM gene mutations increase the risk of Parkinson's disease?,"No, there are no significant mutations in the GATM gene associated with an increased risk of Parkinson's disease according to the largest European genome-wide meta-analysis of Parkinson's disease (Nalls et al., 2019).","SELECT UUID, SNP, p, b 
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE nearestGene LIKE ""%GATM%""
- ORDER BY p
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_1999767', 'SNP': 'rs68087211', 'p': 0.02333, 'b': 0.0588}, {'UUID': 'PDno23andme_full_gene_notext_6977537', 'SNP': 'rs62025161', 'p': 0.03567, 'b': -0.1583}, {'UUID': 'PDno23andme_full_gene_notext_6050985', 'SNP': 'rs12439938', 'p': 0.05455, 'b': 0.0862}, {'UUID': 'PDno23andme_full_gene_notext_1271778', 'SNP': 'rs74244951', 'p': 0.06196, 'b': 0.0837}, {'UUID': 'PDno23andme_full_gene_notext_7457734', 'SNP': 'rs150353967', 'p': 0.07615, 'b': 0.1156}, {'UUID': 'PDno23andme_full_gene_notext_6696402', 'SNP': 'rs7169818', 'p': 0.07786, 'b': 0.0335}, {'UUID': 'PDno23andme_full_gene_notext_4129239', 'SNP': 'rs2467864', 'p': 0.07802, 'b': 0.0335}, {'UUID': 'PDno23andme_full_gene_notext_4925077', 'SNP': 'rs17618783', 'p': 0.0807, 'b': 0.2077}, {'UUID': 'PDno23andme_full_gene_notext_7591732', 'SNP': 'rs2461702', 'p': 0.08088, 'b': 0.0331}, {'UUID': 'PDno23andme_full_gene_notext_3955749', 'SNP': 'rs2453541', 'p': 0.08241, 'b': 0.033}, {'UUID': 'PDno23andme_full_gene_notext_2048203', 'SNP': 'rs1145091', 'p': 0.08368, 'b': 0.0328}, {'UUID': 'PDno23andme_full_gene_notext_5492417', 'SNP': 'rs1049508', 'p': 0.08424, 'b': 0.0327}, {'UUID': 'PDno23andme_full_gene_notext_2555192', 'SNP': 'rs1153858', 'p': 0.08436, 'b': 0.0327}, {'UUID': 'PDno23andme_full_gene_notext_1171366', 'SNP': 'rs10519021', 'p': 0.08635, 'b': 0.0328}, {'UUID': 'PDno23andme_full_gene_notext_3134883', 'SNP': 'rs1145085', 'p': 0.08747, 'b': 0.0324}, {'UUID': 'PDno23andme_full_gene_notext_278426', 'SNP': 'rs7168414', 'p': 0.08972, 'b': 0.0324}, {'UUID': 'PDno23andme_full_gene_notext_4741677', 'SNP': 'rs7171577', 'p': 0.09052, 'b': 0.0324}, {'UUID': 'PDno23andme_full_gene_notext_6952483', 'SNP': 'rs1153854', 'p': 0.09281, 'b': 0.0319}, {'UUID': 'PDno23andme_full_gene_notext_7040454', 'SNP': 'rs7169587', 'p': 0.09309, 'b': 0.032}, {'UUID': 'PDno23andme_full_gene_notext_5618435', 'SNP': 'rs12591058', 'p': 0.09313, 'b': 0.032}, {'UUID': 'PDno23andme_full_gene_notext_5617244', 'SNP': 'rs7179743', 'p': 0.09319, 'b': 0.0321}, {'UUID': 'PDno23andme_full_gene_notext_7128528', 'SNP': 'rs12593371', 'p': 0.09322, 'b': 0.032}, {'UUID': 'PDno23andme_full_gene_notext_6736799', 'SNP': 'rs4775906', 'p': 0.09326, 'b': 0.0321}, {'UUID': 'PDno23andme_full_gene_notext_4101059', 'SNP': 'rs11852800', 'p': 0.09332, 'b': 0.032}, {'UUID': 'PDno23andme_full_gene_notext_3357069', 'SNP': 'rs7163720', 'p': 0.09342, 'b': 0.032}, {'UUID': 'PDno23andme_full_gene_notext_7003789', 'SNP': 'rs4775907', 'p': 0.09343, 'b': 0.032}, {'UUID': 'PDno23andme_full_gene_notext_399848', 'SNP': 'rs56806728', 'p': 0.09344, 'b': 0.032}, {'UUID': 'PDno23andme_full_gene_notext_4851822', 'SNP': 'rs4775909', 'p': 0.09354, 'b': 0.032}, {'UUID': 'PDno23andme_full_gene_notext_3452350', 'SNP': 'rs11858495', 'p': 0.09405, 'b': 0.032}, {'UUID': 'PDno23andme_full_gene_notext_3043866', 'SNP': 'rs56669689', 'p': 0.09407, 'b': 0.032}, {'UUID': 'PDno23andme_full_gene_notext_5146571', 'SNP': 'rs9783731', 'p': 0.09429, 'b': 0.0319}, {'UUID': 'PDno23andme_full_gene_notext_6847551', 'SNP': 'rs12439274', 'p': 0.09435, 'b': 0.032}, {'UUID': 'PDno23andme_full_gene_notext_3535195', 'SNP': 'rs7171163', 'p': 0.09436, 'b': 0.032}, {'UUID': 'PDno23andme_full_gene_notext_3768612', 'SNP': 'rs113358875', 'p': 0.09452, 'b': 0.032}, {'UUID': 'PDno23andme_full_gene_notext_4054806', 'SNP': 'rs1288775', 'p': 0.09478, 'b': 0.0317}, {'UUID': 'PDno23andme_full_gene_notext_379116', 'SNP': 'rs28605551', 'p': 0.0953, 'b': 0.0318}, {'UUID': 'PDno23andme_full_gene_notext_417140', 'SNP': 'rs16942000', 'p': 0.09537, 'b': 0.0319}, {'UUID': 'PDno23andme_full_gene_notext_7212715', 'SNP': 'rs7183946', 'p': 0.0958, 'b': 0.0319}, {'UUID': 'PDno23andme_full_gene_notext_3151361', 'SNP': 'rs2433611', 'p': 0.09803, 'b': 0.0314}, {'UUID': 'PDno23andme_full_gene_notext_6929847', 'SNP': 'rs7182300', 'p': 0.09822, 'b': 0.0316}, {'UUID': 'PDno23andme_full_gene_notext_1133180', 'SNP': 'rs4774577', 'p': 0.09912, 'b': 0.0315}, {'UUID': 'PDno23andme_full_gene_notext_146091', 'SNP': 'rs61524473', 'p': 0.09914, 'b': 0.0315}, {'UUID': 'PDno23andme_full_gene_notext_2438365', 'SNP': 'rs56850226', 'p': 0.1001, 'b': 0.0315}, {'UUID': 'PDno23andme_full_gene_notext_2986785', 'SNP': 'rs55885762', 'p': 0.1001, 'b': 0.0315}, {'UUID': 'PDno23andme_full_gene_notext_2472088', 'SNP': 'rs4572329', 'p': 0.102, 'b': 0.0312}, {'UUID': 'PDno23andme_full_gene_notext_5773962', 'SNP': 'rs79201669', 'p': 0.1022, 'b': -0.1636}, {'UUID': 'PDno23andme_full_gene_notext_5497941', 'SNP': 'rs4774578', 'p': 0.1025, 'b': 0.0312}, {'UUID': 'PDno23andme_full_gene_notext_2316112', 'SNP': 'rs66714503', 'p': 0.1028, 'b': 0.0312}, {'UUID': 'PDno23andme_full_gene_notext_5699944', 'SNP': 'rs2056493', 'p': 0.1028, 'b': 0.0312}, {'UUID': 'PDno23andme_full_gene_notext_7749227', 'SNP': 'rs10444821', 'p': 0.1029, 'b': 0.0311}, {'UUID': 'PDno23andme_full_gene_notext_2881411', 'SNP': 'rs12593230', 'p': 0.1029, 'b': 0.0312}, {'UUID': 'PDno23andme_full_gene_notext_5246581', 'SNP': 'rs72623915', 'p': 0.103, 'b': 0.0311}, {'UUID': 'PDno23andme_full_gene_notext_6412041', 'SNP': 'rs67831559', 'p': 0.103, 'b': 0.0311}, {'UUID': 'PDno23andme_full_gene_notext_5882891', 'SNP': 'rs4775911', 'p': 0.103, 'b': 0.0311}, {'UUID': 'PDno23andme_full_gene_notext_1677694', 'SNP': 'rs4627277', 'p': 0.1031, 'b': 0.0311}, {'UUID': 'PDno23andme_full_gene_notext_792402', 'SNP': 'rs4271549', 'p': 0.1031, 'b': 0.0311}, {'UUID': 'PDno23andme_full_gene_notext_4056075', 'SNP': 'rs4395020', 'p': 0.1032, 'b': 0.0311}, {'UUID': 'PDno23andme_full_gene_notext_7276684', 'SNP': 'rs4534782', 'p': 0.1032, 'b': 0.0311}, {'UUID': 'PDno23andme_full_gene_notext_7346958', 'SNP': 'rs4625670', 'p': 0.1032, 'b': 0.0311}, {'UUID': 'PDno23andme_full_gene_notext_7408147', 'SNP': 'rs2066090', 'p': 0.1032, 'b': 0.0311}, {'UUID': 'PDno23andme_full_gene_notext_479550', 'SNP': 'rs61365925', 'p': 0.1033, 'b': 0.0311}, {'UUID': 'PDno23andme_full_gene_notext_2950441', 'SNP': 'rs12101539', 'p': 0.1036, 'b': 0.0311}, {'UUID': 'PDno23andme_full_gene_notext_5139498', 'SNP': 'rs11070453', 'p': 0.1039, 'b': 0.0311}, {'UUID': 'PDno23andme_full_gene_notext_1137590', 'SNP': 'rs1049503', 'p': 0.1045, 'b': 0.031}, {'UUID': 'PDno23andme_full_gene_notext_2700675', 'SNP': 'rs12595087', 'p': 0.1049, 'b': 0.0309}, {'UUID': 'PDno23andme_full_gene_notext_1455591', 'SNP': 'rs8032904', 'p': 0.1053, 'b': 0.0309}, {'UUID': 'PDno23andme_full_gene_notext_702095', 'SNP': 'rs3759899', 'p': 0.106, 'b': 0.0308}, {'UUID': 'PDno23andme_full_gene_notext_6693767', 'SNP': 'rs8038342', 'p': 0.1062, 'b': 0.0308}, {'UUID': 'PDno23andme_full_gene_notext_5979062', 'SNP': 'rs4774579', 'p': 0.1063, 'b': 0.0308}, {'UUID': 'PDno23andme_full_gene_notext_4248605', 'SNP': 'rs4774580', 'p': 0.1081, 'b': 0.0307}, {'UUID': 'PDno23andme_full_gene_notext_334544', 'SNP': 'rs1145081', 'p': 0.1089, 'b': 0.0305}, {'UUID': 'PDno23andme_full_gene_notext_7716316', 'SNP': 'rs1145079', 'p': 0.1096, 'b': 0.0305}, {'UUID': 'PDno23andme_full_gene_notext_5590967', 'SNP': 'rs1145078', 'p': 0.1123, 'b': 0.0303}, {'UUID': 'PDno23andme_full_gene_notext_2917864', 'SNP': 'rs10519022', 'p': 0.1155, 'b': 0.0301}, {'UUID': 'PDno23andme_full_gene_notext_292154', 'SNP': 'rs1554521', 'p': 0.1158, 'b': 0.03}, {'UUID': 'PDno23andme_full_gene_notext_1256759', 'SNP': 'rs12594857', 'p': 0.1161, 'b': 0.03}, {'UUID': 'PDno23andme_full_gene_notext_5940362', 'SNP': 'rs1890565', 'p': 0.1166, 'b': 0.03}, {'UUID': 'PDno23andme_full_gene_notext_7076124', 'SNP': 'rs2172874', 'p': 0.1171, 'b': 0.0299}, {'UUID': 'PDno23andme_full_gene_notext_1283216', 'SNP': 'rs1346266', 'p': 0.1196, 'b': 0.0297}, {'UUID': 'PDno23andme_full_gene_notext_1065175', 'SNP': 'rs7494956', 'p': 0.1214, 'b': 0.0296}, {'UUID': 'PDno23andme_full_gene_notext_7046520', 'SNP': 'rs66528868', 'p': 0.1214, 'b': 0.0296}, {'UUID': 'PDno23andme_full_gene_notext_1532383', 'SNP': 'rs12437840', 'p': 0.1217, 'b': 0.0296}, {'UUID': 'PDno23andme_full_gene_notext_6881028', 'SNP': 'rs12437887', 'p': 0.1219, 'b': 0.0296}, {'UUID': 'PDno23andme_full_gene_notext_7082806', 'SNP': 'rs2114501', 'p': 0.122, 'b': 0.0296}, {'UUID': 'PDno23andme_full_gene_notext_2836652', 'SNP': 'rs7164602', 'p': 0.1223, 'b': 0.0296}, {'UUID': 'PDno23andme_full_gene_notext_5817547', 'SNP': 'rs12441971', 'p': 0.1227, 'b': 0.0295}, {'UUID': 'PDno23andme_full_gene_notext_5621378', 'SNP': 'rs7164139', 'p': 0.1236, 'b': 0.0295}, {'UUID': 'PDno23andme_full_gene_notext_6521975', 'SNP': 'rs16942568', 'p': 0.1254, 'b': 0.0293}, {'UUID': 'PDno23andme_full_gene_notext_1949790', 'SNP': 'rs1346268', 'p': 0.1259, 'b': 0.0293}, {'UUID': 'PDno23andme_full_gene_notext_6733481', 'SNP': 'rs67045941', 'p': 0.1278, 'b': 0.0292}, {'UUID': 'PDno23andme_full_gene_notext_7599296', 'SNP': 'rs67744121', 'p': 0.1281, 'b': 0.0291}, {'UUID': 'PDno23andme_full_gene_notext_3700055', 'SNP': 'rs66939267', 'p': 0.1283, 'b': 0.0291}, {'UUID': 'PDno23andme_full_gene_notext_5986791', 'SNP': 'rs67461176', 'p': 0.1289, 'b': 0.0291}, {'UUID': 'PDno23andme_full_gene_notext_6376420', 'SNP': 'rs11070454', 'p': 0.131, 'b': 0.029}, {'UUID': 'PDno23andme_full_gene_notext_5792022', 'SNP': 'rs4775937', 'p': 0.1316, 'b': 0.0289}, {'UUID': 'PDno23andme_full_gene_notext_1805996', 'SNP': 'rs12439575', 'p': 0.1328, 'b': 0.0288}, {'UUID': 'PDno23andme_full_gene_notext_1392507', 'SNP': 'rs7181167', 'p': 0.1341, 'b': 0.0287}, {'UUID': 'PDno23andme_full_gene_notext_3026646', 'SNP': 'rs9788780', 'p': 0.1351, 'b': 0.0287}, {'UUID': 'PDno23andme_full_gene_notext_2183392', 'SNP': 'rs11070457', 'p': 0.1354, 'b': 0.0287}, {'UUID': 'PDno23andme_full_gene_notext_4287257', 'SNP': 'rs11070456', 'p': 0.1361, 'b': 0.0286}]",general,"Select, Order By, Similarity Search, Multi-Filter","Effect, GWAS Significance"
-Q80.305,Q80,What is the patent number associated with Tirzepatide?,"There are 4 patents associated with the drug Tirzepatide; 8734394, 9402957, 9474780 and 11357820.","SELECT DISTINCT UUID, drugName, syns_list, tradeNames_list, patent_no
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%tirzepatide%"" OR LOWER(tradeNames_list) LIKE ""%tirzepatide%"" OR LOWER(syns_list) LIKE ""%tirzepatide%"")
- LIMIT 1000","[{'UUID': 'DrugTargetsIndication121923_text_1045714', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045715', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045716', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045717', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045718', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045719', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045720', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045721', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045722', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045723', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045724', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045725', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045726', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045727', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045728', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045729', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045730', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045731', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045732', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045733', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045734', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045735', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045736', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045737', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045738', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045739', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045740', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045741', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045742', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045743', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045744', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045745', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045746', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045747', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045748', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045749', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045750', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045751', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045752', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045753', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045754', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045755', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045756', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045757', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045758', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045759', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045760', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045761', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045762', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045763', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045764', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045765', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045766', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045767', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045768', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045769', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045770', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045771', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045772', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045773', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045774', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045775', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045776', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045777', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045778', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045779', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045780', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045781', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045782', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045783', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045784', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045785', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045786', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045787', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045788', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045789', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045790', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045791', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045792', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045793', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045794', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045795', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045796', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045797', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045798', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045799', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045800', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045801', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045802', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045803', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045804', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045805', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045806', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045807', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045808', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045809', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045810', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045811', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045812', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045813', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045814', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045815', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045816', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045817', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045818', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045819', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045820', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045821', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045822', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045823', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045824', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045825', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045826', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045827', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045828', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045829', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045830', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045831', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045832', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045833', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045834', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045835', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045836', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045837', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045838', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045839', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045840', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045841', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045842', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045843', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045844', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045845', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045846', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045847', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045848', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '8734394'}, {'UUID': 'DrugTargetsIndication121923_text_1045849', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045850', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045851', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9402957'}, {'UUID': 'DrugTargetsIndication121923_text_1045852', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045853', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045854', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '9474780'}, {'UUID': 'DrugTargetsIndication121923_text_1045855', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045856', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}, {'UUID': 'DrugTargetsIndication121923_text_1045857', 'drugName': 'Tirzepatide', 'syns_list': ""['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']"", 'tradeNames_list': ""['Mounjaro']"", 'patent_no': '11357820'}]",general,"Distinct, Similarity Search",Metadata
-Q80.40,Q80,What is the patent number associated with Dacomitinib?,"There are 4 patents associated with the drug Dacomitinib; 8623883, 10596162, 10603314 and 7772243.","SELECT DISTINCT UUID, drugName, syns_list, tradeNames_list, patent_no
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%dacomitinib%"" OR LOWER(tradeNames_list) LIKE ""%dacomitinib%"" OR LOWER(syns_list) LIKE ""%dacomitinib%"")
- LIMIT 1000","[{'UUID': 'DrugTargetsIndication121923_text_217102', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '8623883'}, {'UUID': 'DrugTargetsIndication121923_text_217103', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '10596162'}, {'UUID': 'DrugTargetsIndication121923_text_217104', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '10603314'}, {'UUID': 'DrugTargetsIndication121923_text_217105', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '7772243'}, {'UUID': 'DrugTargetsIndication121923_text_217106', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '8623883'}, {'UUID': 'DrugTargetsIndication121923_text_217107', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '10596162'}, {'UUID': 'DrugTargetsIndication121923_text_217108', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '10603314'}, {'UUID': 'DrugTargetsIndication121923_text_217109', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '7772243'}, {'UUID': 'DrugTargetsIndication121923_text_217110', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '8623883'}, {'UUID': 'DrugTargetsIndication121923_text_217111', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '10596162'}, {'UUID': 'DrugTargetsIndication121923_text_217112', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '10603314'}, {'UUID': 'DrugTargetsIndication121923_text_217113', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '7772243'}, {'UUID': 'DrugTargetsIndication121923_text_217114', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '8623883'}, {'UUID': 'DrugTargetsIndication121923_text_217115', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '10596162'}, {'UUID': 'DrugTargetsIndication121923_text_217116', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '10603314'}, {'UUID': 'DrugTargetsIndication121923_text_217117', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '7772243'}, {'UUID': 'DrugTargetsIndication121923_text_217118', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '8623883'}, {'UUID': 'DrugTargetsIndication121923_text_217119', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '10596162'}, {'UUID': 'DrugTargetsIndication121923_text_217120', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '10603314'}, {'UUID': 'DrugTargetsIndication121923_text_217121', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '7772243'}, {'UUID': 'DrugTargetsIndication121923_text_217122', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '8623883'}, {'UUID': 'DrugTargetsIndication121923_text_217123', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '10596162'}, {'UUID': 'DrugTargetsIndication121923_text_217124', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '10603314'}, {'UUID': 'DrugTargetsIndication121923_text_217125', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '7772243'}, {'UUID': 'DrugTargetsIndication121923_text_217126', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '8623883'}, {'UUID': 'DrugTargetsIndication121923_text_217127', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '10596162'}, {'UUID': 'DrugTargetsIndication121923_text_217128', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '10603314'}, {'UUID': 'DrugTargetsIndication121923_text_217129', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '7772243'}, {'UUID': 'DrugTargetsIndication121923_text_217130', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '8623883'}, {'UUID': 'DrugTargetsIndication121923_text_217131', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '10596162'}, {'UUID': 'DrugTargetsIndication121923_text_217132', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '10603314'}, {'UUID': 'DrugTargetsIndication121923_text_217133', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '7772243'}, {'UUID': 'DrugTargetsIndication121923_text_217134', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '8623883'}, {'UUID': 'DrugTargetsIndication121923_text_217135', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '10596162'}, {'UUID': 'DrugTargetsIndication121923_text_217136', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '10603314'}, {'UUID': 'DrugTargetsIndication121923_text_217137', 'drugName': 'Dacomitinib', 'syns_list': ""['Dacomitinib', 'Dacomitinib hydrate', 'Dacomitinib monohydratePF-00299804-03', 'Pf-00299804']"", 'tradeNames_list': ""['Vizimpro']"", 'patent_no': '7772243'}]",general,"Distinct, Similarity Search",Metadata
-Q80.342,Q80,What is the patent number associated with Sirolimus?,"There are 4 patents associated with the drug Sirolimus; 8911786, 10206887, 10705070 and 10973806.","SELECT DISTINCT UUID, drugName, syns_list, tradeNames_list, patent_no
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%sirolimus%"" OR LOWER(tradeNames_list) LIKE ""%sirolimus%"" OR LOWER(syns_list) LIKE ""%sirolimus%"")
- LIMIT 1000","[{'UUID': 'DrugTargetsIndication121923_text_1084296', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084297', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084298', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084299', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084300', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084301', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084302', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084303', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084304', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084305', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084306', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084307', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084308', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084309', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084310', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084311', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084312', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084313', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084314', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084315', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084316', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084317', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084318', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084319', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084320', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084321', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084322', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084323', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084324', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084325', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084326', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084327', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084328', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084329', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084330', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084331', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084332', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084333', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084334', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084335', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084336', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084337', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084338', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084339', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084340', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084341', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084342', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084343', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084344', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084345', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084346', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084347', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084348', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084349', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084350', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084351', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084352', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084353', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084354', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084355', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084356', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084357', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084358', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084359', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084360', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084361', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084362', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084363', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084364', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084365', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084366', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084367', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084368', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084369', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084370', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084371', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084372', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084373', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084374', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084375', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084376', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084377', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084378', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084379', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084380', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084381', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084382', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084383', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084384', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084385', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084386', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084387', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084388', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084389', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084390', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084391', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084392', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084393', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084394', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084395', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084396', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084397', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084398', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084399', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084400', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084401', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084402', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084403', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084404', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084405', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084406', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084407', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084408', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084409', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084410', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084411', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084412', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084413', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084414', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084415', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084416', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084417', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084418', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084419', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084420', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084421', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084422', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084423', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084424', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084425', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084426', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084427', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084428', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084429', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084430', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '8911786'}, {'UUID': 'DrugTargetsIndication121923_text_1084431', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084432', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084433', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084434', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084435', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084436', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084437', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084438', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084439', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084440', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084441', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084442', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084443', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084444', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084445', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084446', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084447', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084448', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084449', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084450', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084451', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084452', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084453', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084454', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084455', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084456', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084457', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084458', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084459', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084460', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084461', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084462', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084463', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084464', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084465', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084466', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084467', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084468', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084469', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084470', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084471', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084472', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084473', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084474', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084475', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084476', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084477', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084478', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084479', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084480', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084481', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084482', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084483', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084484', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084485', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084486', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084487', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084488', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084489', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084490', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084491', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084492', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084493', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084494', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084495', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084496', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084497', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084498', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084499', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084500', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084501', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084502', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084503', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084504', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084505', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084506', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084507', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084508', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084509', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084510', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084511', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084512', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084513', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084514', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084515', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084516', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084517', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084518', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084519', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084520', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084521', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084522', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084523', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084524', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084525', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084526', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084527', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084528', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084529', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084530', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084531', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084532', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084533', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084534', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084535', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084536', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084537', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084538', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084539', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084540', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084541', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084542', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084543', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084544', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084545', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084546', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084547', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084548', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084549', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084550', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084551', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084552', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084553', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084554', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084555', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084556', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084557', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084558', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084559', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084560', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084561', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084562', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084563', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084564', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084565', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10206887'}, {'UUID': 'DrugTargetsIndication121923_text_1084566', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084567', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084568', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084569', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084570', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084571', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084572', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084573', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084574', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084575', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084576', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084577', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084578', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084579', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084580', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084581', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084582', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084583', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084584', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084585', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084586', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084587', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084588', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084589', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084590', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084591', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084592', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084593', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084594', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084595', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084596', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084597', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084598', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084599', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084600', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084601', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084602', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084603', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084604', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084605', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084606', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084607', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084608', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084609', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084610', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084611', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084612', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084613', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084614', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084615', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084616', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084617', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084618', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084619', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084620', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084621', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084622', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084623', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084624', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084625', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084626', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084627', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084628', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084629', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084630', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084631', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084632', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084633', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084634', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084635', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084636', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084637', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084638', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084639', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084640', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084641', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084642', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084643', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084644', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084645', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084646', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084647', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084648', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084649', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084650', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084651', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084652', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084653', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084654', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084655', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084656', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084657', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084658', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084659', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084660', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084661', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084662', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084663', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084664', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084665', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084666', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084667', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084668', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084669', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084670', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084671', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084672', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084673', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084674', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084675', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084676', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084677', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084678', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084679', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084680', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084681', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084682', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084683', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084684', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084685', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084686', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084687', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084688', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084689', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084690', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084691', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084692', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084693', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084694', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084695', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084696', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084697', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084698', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084699', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084700', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10705070'}, {'UUID': 'DrugTargetsIndication121923_text_1084701', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084702', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084703', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084704', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084705', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084706', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084707', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084708', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084709', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084710', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084711', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084712', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084713', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084714', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084715', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084716', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084717', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084718', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084719', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084720', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084721', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084722', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084723', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084724', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084725', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084726', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084727', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084728', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084729', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084730', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084731', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084732', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084733', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084734', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084735', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084736', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084737', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084738', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084739', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084740', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084741', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084742', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084743', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084744', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084745', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084746', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084747', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084748', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084749', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084750', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084751', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084752', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084753', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084754', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084755', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084756', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084757', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084758', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084759', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084760', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084761', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084762', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084763', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084764', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084765', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084766', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084767', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084768', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084769', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084770', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084771', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084772', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084773', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084774', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084775', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084776', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084777', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084778', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084779', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084780', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084781', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084782', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084783', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084784', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084785', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084786', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084787', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084788', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084789', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084790', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084791', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084792', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084793', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084794', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084795', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084796', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084797', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084798', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084799', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084800', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084801', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084802', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084803', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084804', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084805', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084806', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084807', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084808', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084809', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084810', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084811', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084812', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084813', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084814', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084815', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084816', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084817', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084818', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084819', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084820', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084821', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084822', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084823', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084824', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084825', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084826', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084827', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084828', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084829', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084830', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084831', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084832', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084833', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084834', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1084835', 'drugName': 'Sirolimus', 'syns_list': ""['AY-22989', 'Fyarro', 'Hyftor', 'L04AA10', 'NSC-226080', 'Npc-12g', 'RapalimusRapamycin', 'SM-88 COMPONENT SIROLIMUS', 'Sirolimus', 'WY-090217']"", 'tradeNames_list': ""['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']"", 'patent_no': '10973806'}, {'UUID': 'DrugTargetsIndication121923_text_1090641', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090642', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090643', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090644', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090645', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090646', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090647', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090648', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090649', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090650', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090651', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090652', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090653', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090654', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090655', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090656', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090657', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090658', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090659', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090660', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090661', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090662', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090663', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090664', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090665', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090666', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090667', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090668', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090669', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090670', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090671', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090672', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090673', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090674', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090675', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090676', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090677', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090678', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090679', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090680', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090681', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090682', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090683', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090684', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090685', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090686', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090687', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090688', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090689', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090690', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090691', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090692', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090693', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090694', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090695', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090696', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090697', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090698', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090699', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090700', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090701', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090702', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090703', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090704', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090705', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090706', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090707', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090708', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090709', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090710', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090711', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090712', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090713', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090714', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090715', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116'}, {'UUID': 'DrugTargetsIndication121923_text_1090716', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090717', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090718', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090719', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090720', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090721', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090722', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090723', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090724', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090725', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090726', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090727', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090728', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090729', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090730', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090731', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090732', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090733', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090734', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090735', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090736', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090737', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090738', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090739', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090740', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090741', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090742', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090743', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090744', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090745', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090746', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090747', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090748', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090749', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090750', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090751', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090752', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090753', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090754', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090755', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090756', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090757', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090758', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090759', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090760', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090761', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090762', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090763', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090764', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090765', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090766', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090767', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090768', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090769', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090770', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090771', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090772', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090773', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090774', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090775', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090776', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090777', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090778', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090779', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090780', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090781', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090782', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090783', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090784', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090785', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090786', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090787', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090788', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090789', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090790', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539'}, {'UUID': 'DrugTargetsIndication121923_text_1090791', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090792', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090793', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090794', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090795', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090796', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090797', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090798', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090799', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090800', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090801', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090802', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090803', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090804', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090805', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090806', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090807', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090808', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090809', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090810', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090811', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090812', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090813', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090814', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090815', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090816', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090817', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090818', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090819', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090820', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090821', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090822', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090823', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090824', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090825', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090826', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090827', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090828', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090829', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090830', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090831', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090832', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090833', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090834', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090835', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090836', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090837', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090838', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090839', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090840', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090841', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090842', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090843', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090844', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090845', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090846', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090847', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090848', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090849', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090850', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090851', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090852', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090853', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090854', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090855', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090856', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090857', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090858', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090859', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090860', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090861', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090862', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090863', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090864', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090865', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700'}, {'UUID': 'DrugTargetsIndication121923_text_1090866', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090867', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090868', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090869', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090870', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090871', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090872', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090873', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090874', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090875', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090876', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090877', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090878', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090879', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090880', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090881', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090882', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090883', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090884', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090885', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090886', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090887', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090888', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090889', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090890', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090891', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090892', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090893', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090894', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090895', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090896', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090897', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090898', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090899', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090900', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090901', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090902', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090903', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090904', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090905', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090906', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090907', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090908', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090909', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090910', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090911', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090912', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090913', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090914', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090915', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090916', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090917', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090918', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090919', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090920', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090921', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090922', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090923', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090924', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090925', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090926', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090927', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090928', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090929', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090930', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090931', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090932', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090933', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090934', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090935', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090936', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090937', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090938', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090939', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090940', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8299116*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090941', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090942', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090943', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090944', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090945', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090946', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090947', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090948', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090949', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090950', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090951', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090952', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090953', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090954', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090955', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090956', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090957', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090958', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090959', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090960', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090961', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090962', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090963', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090964', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090965', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090966', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090967', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090968', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090969', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090970', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090971', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090972', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090973', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090974', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090975', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090976', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090977', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090978', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090979', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090980', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090981', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090982', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090983', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090984', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090985', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090986', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090987', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090988', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090989', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090990', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090991', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090992', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090993', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090994', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090995', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090996', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090997', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090998', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1090999', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091000', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091001', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091002', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091003', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091004', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091005', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091006', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091007', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091008', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091009', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091010', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091011', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091012', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091013', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091014', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091015', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8455539*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091016', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091017', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091018', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091019', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091020', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091021', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091022', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091023', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091024', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091025', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091026', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091027', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091028', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091029', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091030', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091031', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091032', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091033', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091034', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091035', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091036', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091037', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091038', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091039', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091040', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091041', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091042', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091043', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091044', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091045', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091046', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091047', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091048', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091049', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091050', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091051', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091052', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091053', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091054', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091055', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091056', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091057', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091058', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091059', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091060', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091061', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091062', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091063', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091064', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091065', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091066', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091067', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091068', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091069', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091070', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091071', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091072', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091073', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091074', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091075', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091076', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091077', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091078', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091079', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091080', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091081', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091082', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091083', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091084', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091085', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091086', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091087', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091088', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091089', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091090', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8722700*PED'}, {'UUID': 'DrugTargetsIndication121923_text_1091091', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8026276'}, {'UUID': 'DrugTargetsIndication121923_text_1091092', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8026276'}, {'UUID': 'DrugTargetsIndication121923_text_1091093', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8026276'}, {'UUID': 'DrugTargetsIndication121923_text_1091094', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8026276'}, {'UUID': 'DrugTargetsIndication121923_text_1091095', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8026276'}, {'UUID': 'DrugTargetsIndication121923_text_1091096', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8026276'}, {'UUID': 'DrugTargetsIndication121923_text_1091097', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8026276'}, {'UUID': 'DrugTargetsIndication121923_text_1091098', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8026276'}, {'UUID': 'DrugTargetsIndication121923_text_1091099', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8026276'}, {'UUID': 'DrugTargetsIndication121923_text_1091100', 'drugName': 'Temsirolimus', 'syns_list': ""['CCI-779', 'Temsirolimus']"", 'tradeNames_list': ""['Torisel']"", 'patent_no': '8026276'}]",general,"Distinct, Similarity Search",Metadata
-Q80.219,Q80,What is the patent number associated with Sitagliptin?,"There are 6 patents associated with the drug Sitagliptin; 6699871, 7125873, 6699871*PED, 7125873*PED, 7326708 and 7326708*PED.","SELECT DISTINCT UUID, drugName, syns_list, tradeNames_list, patent_no
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%sitagliptin%"" OR LOWER(tradeNames_list) LIKE ""%sitagliptin%"" OR LOWER(syns_list) LIKE ""%sitagliptin%"")
- LIMIT 1000","[{'UUID': 'DrugTargetsIndication121923_text_933038', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933039', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933040', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933041', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933042', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933043', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933044', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933045', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933046', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933047', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933048', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933049', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933050', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933051', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933052', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933053', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933054', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933055', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933056', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933057', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933058', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933059', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933060', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933061', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933062', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933063', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933064', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933065', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933066', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933067', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933068', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933069', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933070', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933071', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933072', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933073', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933074', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933075', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933076', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933077', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933078', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933079', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933080', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933081', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933082', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933083', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933084', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933085', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933086', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933087', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933088', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933089', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933090', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933091', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933092', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933093', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933094', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933095', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933096', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933097', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933098', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933099', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933100', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933101', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933102', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933103', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933104', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933105', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933106', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933107', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933108', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933109', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933110', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933111', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933112', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933113', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933114', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933115', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933116', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933117', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933118', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933119', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933120', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933121', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933122', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933123', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933124', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933125', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933126', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933127', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933128', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933129', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933130', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933131', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933132', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933133', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933134', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933135', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933136', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933137', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933138', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933139', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933140', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933141', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933142', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933143', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933144', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933145', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933146', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933147', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933148', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933149', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933150', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933151', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933152', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933153', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933154', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933155', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933156', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933157', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933158', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933159', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933160', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933161', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933162', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933163', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933164', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933165', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933166', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933167', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933168', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933169', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933170', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933171', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933172', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933173', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933174', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933175', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933176', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933177', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933178', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933179', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933180', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933181', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933182', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933183', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933184', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933185', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933186', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933187', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933188', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933189', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933190', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933191', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933192', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933193', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933194', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933195', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933196', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933197', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933198', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933199', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933200', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933201', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933202', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933203', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933204', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933205', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933206', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933207', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933208', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933209', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933210', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933211', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933212', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933213', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933214', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933215', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933216', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933217', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933218', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933219', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933220', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933221', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933222', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933223', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933224', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933225', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933226', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933227', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933228', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933229', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933230', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933231', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933232', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933233', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933234', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933235', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933236', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933237', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933238', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933239', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933240', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933241', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933242', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933243', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933244', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933245', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933246', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933247', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933248', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933249', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933250', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933251', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933252', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933253', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933254', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933255', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933256', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933257', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933258', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933259', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933260', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933261', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933262', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933263', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933264', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933265', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933266', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933267', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933268', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933269', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933270', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933271', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933272', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933273', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933274', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933275', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933276', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933277', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933278', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933279', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933280', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933281', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933282', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933283', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933284', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933285', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933286', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933287', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933288', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933289', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933290', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933291', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933292', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933293', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933294', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933295', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933296', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933297', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933298', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933299', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933300', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933301', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933302', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933303', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933304', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933305', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933306', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933307', 'drugName': 'Sitagliptin Phosphate', 'syns_list': ""['Glactiv', 'MK-0431', 'MK0431', 'ONO-5435', 'Sitagliptin monophosphateSitagliptin monophosphate anhydrousSitagliptin monophosphate monohydrate', 'Sitagliptin phosphateSitagliptin phosphate anhydrous', 'Sitagliptin phosphate hydrateSitagliptin phosphate monohydrate']"", 'tradeNames_list': ""['Janumet Xr', 'Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933308', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933309', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933310', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933311', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933312', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933313', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933314', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933315', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933316', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933317', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933318', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933319', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933320', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933321', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933322', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933323', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933324', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933325', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933326', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933327', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933328', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933329', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933330', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933331', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933332', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933333', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933334', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933335', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933336', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933337', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933338', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933339', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933340', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933341', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933342', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933343', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933344', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933345', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933346', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933347', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933348', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933349', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933350', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933351', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933352', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933353', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933354', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933355', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933356', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933357', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933358', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933359', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933360', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933361', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933362', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933363', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933364', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933365', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933366', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933367', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933368', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933369', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933370', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933371', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933372', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933373', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933374', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933375', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933376', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933377', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933378', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933379', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933380', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933381', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933382', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933383', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933384', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933385', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933386', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933387', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933388', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933389', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933390', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933391', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933392', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933393', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933394', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933395', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933396', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933397', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933398', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933399', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933400', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933401', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933402', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933403', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933404', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933405', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933406', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933407', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933408', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933409', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933410', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933411', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933412', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933413', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933414', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933415', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933416', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933417', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933418', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933419', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933420', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933421', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933422', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933423', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933424', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933425', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933426', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933427', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933428', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933429', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933430', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933431', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933432', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933433', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933434', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933435', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933436', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933437', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933438', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933439', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933440', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933441', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933442', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933443', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933444', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933445', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933446', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933447', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933448', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933449', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933450', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933451', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933452', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933453', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933454', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933455', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933456', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933457', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933458', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933459', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933460', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933461', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933462', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933463', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933464', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933465', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933466', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933467', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933468', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933469', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933470', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933471', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933472', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933473', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933474', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933475', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933476', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933477', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933478', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933479', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933480', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933481', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933482', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933483', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933484', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933485', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933486', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933487', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933488', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933489', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933490', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933491', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933492', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933493', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933494', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933495', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933496', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933497', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933498', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933499', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933500', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933501', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933502', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933503', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933504', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933505', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933506', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933507', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933508', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933509', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933510', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933511', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933512', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933513', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933514', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933515', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933516', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933517', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933518', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933519', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933520', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933521', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933522', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933523', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933524', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933525', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933526', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933527', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933528', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933529', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933530', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933531', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933532', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933533', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933534', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933535', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933536', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933537', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933538', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933539', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933540', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933541', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933542', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933543', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933544', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933545', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933546', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933547', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933548', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933549', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933550', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933551', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933552', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933553', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933554', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933555', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933556', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933557', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933558', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933559', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933560', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933561', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933562', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933563', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933564', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933565', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933566', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933567', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933568', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933569', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933570', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933571', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933572', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933573', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933574', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933575', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933576', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933577', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933578', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933579', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933580', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933581', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933582', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933583', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933584', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933585', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933586', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933587', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933588', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933589', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933590', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933591', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933592', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933593', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933594', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933595', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933596', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933597', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933598', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933599', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933600', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933601', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933602', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933603', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933604', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933605', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933606', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933607', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933608', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933609', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933610', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933611', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933612', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933613', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933614', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933615', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933616', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933617', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933618', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933619', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933620', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933621', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933622', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933623', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933624', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933625', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933626', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933627', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933628', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933629', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933630', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933631', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933632', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933633', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933634', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933635', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933636', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933637', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933638', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933639', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933640', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933641', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933642', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933643', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933644', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933645', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933646', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933647', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933648', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933649', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933650', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933651', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933652', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933653', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933654', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933655', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933656', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933657', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933658', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933659', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933660', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933661', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933662', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933663', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933664', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933665', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933666', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933667', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933668', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933669', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933670', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933671', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933672', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933673', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933674', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933675', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933676', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933677', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933678', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933679', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933680', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933681', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933682', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933683', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933684', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933685', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933686', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933687', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933688', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933689', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933690', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933691', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933692', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933693', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933694', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933695', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933696', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933697', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933698', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933699', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933700', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933701', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933702', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933703', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933704', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933705', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933706', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871'}, {'UUID': 'DrugTargetsIndication121923_text_933707', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933708', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933709', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933710', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933711', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933712', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933713', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933714', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933715', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933716', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933717', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933718', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933719', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933720', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933721', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933722', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933723', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933724', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933725', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933726', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933727', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933728', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933729', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933730', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933731', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933732', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933733', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933734', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933735', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933736', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933737', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933738', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933739', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933740', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933741', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933742', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933743', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933744', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933745', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933746', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933747', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933748', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933749', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933750', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933751', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933752', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933753', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933754', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933755', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933756', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933757', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933758', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933759', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933760', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933761', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933762', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933763', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933764', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933765', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933766', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933767', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933768', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933769', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933770', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933771', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933772', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933773', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933774', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933775', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933776', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933777', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933778', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933779', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933780', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933781', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933782', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933783', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933784', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933785', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933786', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933787', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933788', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933789', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933790', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873'}, {'UUID': 'DrugTargetsIndication121923_text_933791', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933792', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933793', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933794', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933795', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933796', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933797', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933798', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933799', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933800', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933801', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933802', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933803', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933804', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933805', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933806', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933807', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933808', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933809', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933810', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933811', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '6699871*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933812', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933813', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933814', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933815', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933816', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933817', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933818', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933819', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933820', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933821', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933822', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933823', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933824', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933825', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933826', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933827', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933828', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933829', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933830', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933831', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933832', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7125873*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933833', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933834', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933835', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933836', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933837', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933838', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933839', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933840', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933841', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933842', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933843', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933844', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933845', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933846', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933847', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933848', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933849', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933850', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933851', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933852', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933853', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708'}, {'UUID': 'DrugTargetsIndication121923_text_933854', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933855', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933856', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933857', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933858', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933859', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933860', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933861', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933862', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933863', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933864', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933865', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933866', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933867', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933868', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933869', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933870', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933871', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933872', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933873', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}, {'UUID': 'DrugTargetsIndication121923_text_933874', 'drugName': 'Sitagliptin', 'syns_list': ""['LEZ-763', 'LEZ763', 'MK-0431', 'Sitagliptin']"", 'tradeNames_list': ""['Januvia']"", 'patent_no': '7326708*PED'}]",general,"Distinct, Similarity Search",Metadata
-Q49.1861,Q49,Are there any SMR association signals with the gene AC091132.1 in Progressive supranuclear palsy?,"Yes, there is 1 SNP within AC091132.1 that has a significant SMR association signal in Progressive supranuclear palsy:
-• rs1635291
-    • Cerebellum: Adjusted SMR multi-SNP P-value: 9.49e-10; HEIDI: 1.1310e-04
-","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'PSP' AND Gene = 'AC091132.1' AND p_SMR_multi < 2.95e-6
- ORDER BY p_SMR_multi
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_1714148', 'topRSID': 'rs1635291', 'Disease': 'PSP', 'Gene': 'AC091132.1', 'p_SMR_multi': 9.493124e-10, 'p_HEIDI': 0.0001130954}]",refined,"Select, Order By, Multi-Filter, Threshold",SMR Significance
-Q49.354,Q49,Are there any SMR association signals with the gene RP5-855D21.3 in Amyotrophic Lateral Sclerosis?,"No, there are no SNPs within RP5-855D21.3 that have significant SMR association signals in Amyotrophic Lateral Sclerosis.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'ALS' AND Gene = 'RP5-855D21.3' AND p_SMR_multi < 2.95e-6
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold",SMR Significance
-Q49.1334,Q49,Are there any SMR association signals with the gene MACC1-AS1 in Amyotrophic Lateral Sclerosis?,"No, there are no SNPs within MACC1-AS1 that have significant SMR association signals in Amyotrophic Lateral Sclerosis.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'ALS' AND Gene = 'MACC1-AS1' AND p_SMR_multi < 2.95e-6
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold",SMR Significance
-Q49.906,Q49,Are there any SMR association signals with the gene C17orf96 in Parkinson's Disease?,"No, there are no SNPs within C17orf96 that have significant SMR association signals in Parkinson's Disease.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'PD' AND Gene = 'C17orf96' AND p_SMR_multi < 2.95e-6
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold",SMR Significance
-Q49.1290,Q49,Are there any SMR association signals with the gene GATA2 in Frontotemporal Dementia?,"No, there are no SNPs within GATA2 that have significant SMR association signals in Frontotemporal Dementia.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'FTD' AND Gene = 'GATA2' AND p_SMR_multi < 2.95e-6
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold",SMR Significance
-Q49.1274,Q49,Are there any SMR association signals with the gene ZFYVE27 in Alzheimer's Disease?,"No, there are no SNPs within ZFYVE27 that have significant SMR association signals in Alzheimer's Disease.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'AD' AND Gene = 'ZFYVE27' AND p_SMR_multi < 2.95e-6
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold",SMR Significance
-Q49.939,Q49,Are there any SMR association signals with the gene MYL6B in Progressive supranuclear palsy?,"No, there are no SNPs within MYL6B that have significant SMR association signals in Progressive supranuclear palsy.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'PSP' AND Gene = 'MYL6B' AND p_SMR_multi < 2.95e-6
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold",SMR Significance
-Q49.1732,Q49,Are there any SMR association signals with the gene SUZ12P in Progressive supranuclear palsy?,"No, there are no SNPs within SUZ12P that have significant SMR association signals in Progressive supranuclear palsy.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'PSP' AND Gene = 'SUZ12P' AND p_SMR_multi < 2.95e-6
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold",SMR Significance
-Q49.66,Q49,Are there any SMR association signals with the gene SAA1 in Amyotrophic Lateral Sclerosis?,"No, there are no SNPs within SAA1 that have significant SMR association signals in Amyotrophic Lateral Sclerosis.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'ALS' AND Gene = 'SAA1' AND p_SMR_multi < 2.95e-6
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold",SMR Significance
-Q49.1324,Q49,Are there any SMR association signals with the gene AP000487.5 in Alzheimer's Disease?,"No, there are no SNPs within AP000487.5 that have significant SMR association signals in Alzheimer's Disease.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'AD' AND Gene = 'AP000487.5' AND p_SMR_multi < 2.95e-6
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold",SMR Significance
-Q49.57,Q49,Are there any SMR association signals with the gene GRAMD1A in Parkinson's Disease?,"No, there are no SNPs within GRAMD1A that have significant SMR association signals in Parkinson's Disease.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'PD' AND Gene = 'GRAMD1A' AND p_SMR_multi < 2.95e-6
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold",SMR Significance
-Q49.1293,Q49,Are there any SMR association signals with the gene ZNF691 in Lewy Body Dementia?,"No, there are no SNPs within ZNF691 that have significant SMR association signals in Lewy Body Dementia.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'LBD' AND Gene = 'ZNF691' AND p_SMR_multi < 2.95e-6
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold",SMR Significance
-Q49.1119,Q49,Are there any SMR association signals with the gene RP11-177C12.1 in Frontotemporal Dementia?,"No, there are no SNPs within RP11-177C12.1 that have significant SMR association signals in Frontotemporal Dementia.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'FTD' AND Gene = 'RP11-177C12.1' AND p_SMR_multi < 2.95e-6
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold",SMR Significance
-Q49.585,Q49,Are there any SMR association signals with the gene KLHL7 in Parkinson's Disease?,"Yes, there is 1 SNP within KLHL7 that has a significant SMR association signal in Parkinson's Disease:
-• rs10256996
-    • Whole Blood: Adjusted SMR multi-SNP P-value: 6.94e-08; HEIDI: 3.1787e-04
-","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'PD' AND Gene = 'KLHL7' AND p_SMR_multi < 2.95e-6
- ORDER BY p_SMR_multi
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_1557761', 'topRSID': 'rs10256996', 'Disease': 'PD', 'Gene': 'KLHL7', 'p_SMR_multi': 6.939604e-08, 'p_HEIDI': 0.0003178713}]",refined,"Select, Order By, Multi-Filter, Threshold",SMR Significance
-Q49.375,Q49,Are there any SMR association signals with the gene SGMS1 in Parkinson's Disease?,"No, there are no SNPs within SGMS1 that have significant SMR association signals in Parkinson's Disease.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'PD' AND Gene = 'SGMS1' AND p_SMR_multi < 2.95e-6
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold",SMR Significance
-Q49.276,Q49,Are there any SMR association signals with the gene KCNK1 in Alzheimer's Disease?,"No, there are no SNPs within KCNK1 that have significant SMR association signals in Alzheimer's Disease.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'AD' AND Gene = 'KCNK1' AND p_SMR_multi < 2.95e-6
- ORDER BY p_SMR_multi
- LIMIT 100",[],refined,"Select, Order By, Multi-Filter, Threshold",SMR Significance
-Q2.1861,Q2,What is the allele frequency of the SNP rs11809116 in a Parkinson's Disease study involving a European cohort?,"According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs11809116 has an effect allele T frequency of 0.1549 and non-effect allele C frequency of 0.8451.","SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE SNP = ""rs11809116""
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_7246411', 'SNP': 'rs11809116', 'effect_allele': 'T', 'effect_allele_frequency': 0.1549, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.8451}]",general,"Calculate, Select",Allele Frequency
-Q2.354,Q2,What is the allele frequency of the SNP rs10077515 in a Parkinson's Disease study involving a European cohort?,"According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs10077515 has an effect allele A frequency of 0.1430 and non-effect allele C frequency of 0.8570.","SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE SNP = ""rs10077515""
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_1284203', 'SNP': 'rs10077515', 'effect_allele': 'A', 'effect_allele_frequency': 0.143, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.857}]",general,"Calculate, Select",Allele Frequency
-Q2.1334,Q2,What is the allele frequency of the SNP rs150430303 in a Parkinson's Disease study involving a European cohort?,"According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs150430303 has an effect allele G frequency of 0.0107 and non-effect allele A frequency of 0.9893.","SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE SNP = ""rs150430303""
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_5173230', 'SNP': 'rs150430303', 'effect_allele': 'G', 'effect_allele_frequency': 0.0107, 'non_effect_allele': 'A', 'non_effect_allele_frequency': 0.9893}]",general,"Calculate, Select",Allele Frequency
-Q2.906,Q2,What is the allele frequency of the SNP rs10948725 in a Parkinson's Disease study involving a European cohort?,"According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs10948725 has an effect allele G frequency of 0.4313 and non-effect allele C frequency of 0.5687.","SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE SNP = ""rs10948725""
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_3495017', 'SNP': 'rs10948725', 'effect_allele': 'G', 'effect_allele_frequency': 0.4313, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.5687}]",general,"Calculate, Select",Allele Frequency
-Q2.1290,Q2,What is the allele frequency of the SNP rs79092434 in a Parkinson's Disease study involving a European cohort?,"According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs79092434 has an effect allele A frequency of 0.0507 and non-effect allele G frequency of 0.9493.","SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE SNP = ""rs79092434""
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_5050106', 'SNP': 'rs79092434', 'effect_allele': 'A', 'effect_allele_frequency': 0.0507, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.9493}]",general,"Calculate, Select",Allele Frequency
-Q2.1274,Q2,What is the allele frequency of the SNP rs12402481 in a Parkinson's Disease study involving a European cohort?,"According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs12402481 has an effect allele T frequency of 0.0801 and non-effect allele G frequency of 0.9199.","SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE SNP = ""rs12402481""
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_4978216', 'SNP': 'rs12402481', 'effect_allele': 'T', 'effect_allele_frequency': 0.0801, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.9198999999999999}]",general,"Calculate, Select",Allele Frequency
-Q2.939,Q2,What is the allele frequency of the SNP rs78531275 in a Parkinson's Disease study involving a European cohort?,"According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs78531275 has an effect allele A frequency of 0.0136 and non-effect allele G frequency of 0.9864.","SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE SNP = ""rs78531275""
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_3618636', 'SNP': 'rs78531275', 'effect_allele': 'A', 'effect_allele_frequency': 0.0136, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.9864}]",general,"Calculate, Select",Allele Frequency
-Q2.1732,Q2,What is the allele frequency of the SNP rs141133136 in a Parkinson's Disease study involving a European cohort?,"According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs141133136 has an effect allele G frequency of 0.0164 and non-effect allele C frequency of 0.9836.","SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE SNP = ""rs141133136""
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_6756445', 'SNP': 'rs141133136', 'effect_allele': 'G', 'effect_allele_frequency': 0.0163999999999999, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.9836000000000001}]",general,"Calculate, Select",Allele Frequency
-Q2.66,Q2,What is the allele frequency of the SNP rs28762375 in a Parkinson's Disease study involving a European cohort?,"According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs28762375 has an effect allele C frequency of 0.0011 and non-effect allele T frequency of 0.9989.","SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE SNP = ""rs28762375""
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_257420', 'SNP': 'rs28762375', 'effect_allele': 'C', 'effect_allele_frequency': 0.0010999999999999, 'non_effect_allele': 'T', 'non_effect_allele_frequency': 0.9989000000000001}]",general,"Calculate, Select",Allele Frequency
-Q2.1324,Q2,What is the allele frequency of the SNP rs12964064 in a Parkinson's Disease study involving a European cohort?,"According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs12964064 has an effect allele G frequency of 0.4386 and non-effect allele A frequency of 0.5614.","SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE SNP = ""rs12964064""
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_5152520', 'SNP': 'rs12964064', 'effect_allele': 'G', 'effect_allele_frequency': 0.4386, 'non_effect_allele': 'A', 'non_effect_allele_frequency': 0.5614}]",general,"Calculate, Select",Allele Frequency
-Q2.57,Q2,What is the allele frequency of the SNP rs66839605 in a Parkinson's Disease study involving a European cohort?,"According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs66839605 has an effect allele C frequency of 0.1346 and non-effect allele T frequency of 0.8654.","SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE SNP = ""rs66839605""
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_201998', 'SNP': 'rs66839605', 'effect_allele': 'C', 'effect_allele_frequency': 0.1346, 'non_effect_allele': 'T', 'non_effect_allele_frequency': 0.8654}]",general,"Calculate, Select",Allele Frequency
-Q2.1293,Q2,What is the allele frequency of the SNP rs78983879 in a Parkinson's Disease study involving a European cohort?,"According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs78983879 has an effect allele T frequency of 0.0441 and non-effect allele C frequency of 0.9559.","SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE SNP = ""rs78983879""
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_5056257', 'SNP': 'rs78983879', 'effect_allele': 'T', 'effect_allele_frequency': 0.0441, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.9559}]",general,"Calculate, Select",Allele Frequency
-Q2.1119,Q2,What is the allele frequency of the SNP rs72731583 in a Parkinson's Disease study involving a European cohort?,"According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs72731583 has an effect allele T frequency of 0.0211 and non-effect allele C frequency of 0.9789.","SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE SNP = ""rs72731583""
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_4294323', 'SNP': 'rs72731583', 'effect_allele': 'T', 'effect_allele_frequency': 0.0211, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.9789}]",general,"Calculate, Select",Allele Frequency
-Q2.585,Q2,What is the allele frequency of the SNP rs3098570 in a Parkinson's Disease study involving a European cohort?,"According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs3098570 has an effect allele T frequency of 0.0143 and non-effect allele C frequency of 0.9857.","SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE SNP = ""rs3098570""
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_2201792', 'SNP': 'rs3098570', 'effect_allele': 'T', 'effect_allele_frequency': 0.0143, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.9857}]",general,"Calculate, Select",Allele Frequency
-Q2.375,Q2,What is the allele frequency of the SNP rs6141293 in a Parkinson's Disease study involving a European cohort?,"According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs6141293 has an effect allele C frequency of 0.3684 and non-effect allele T frequency of 0.6316.","SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE SNP = ""rs6141293""
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_1367045', 'SNP': 'rs6141293', 'effect_allele': 'C', 'effect_allele_frequency': 0.3683999999999999, 'non_effect_allele': 'T', 'non_effect_allele_frequency': 0.6316000000000002}]",general,"Calculate, Select",Allele Frequency
-Q2.276,Q2,What is the allele frequency of the SNP rs6538799 in a Parkinson's Disease study involving a European cohort?,"According to the largest European genome-wide meta-analysis of Parkinson's disease from Nalls (2019), single nucleotide polymorphism rs6538799 has an effect allele G frequency of 0.3749 and non-effect allele A frequency of 0.6251.","SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1-freq AS non_effect_allele_frequency
- FROM `card-ai-389220.bio_sql_benchmark.ParkinsonDisease_CompleteGeneData_No23andMe` 
- WHERE SNP = ""rs6538799""
- LIMIT 100","[{'UUID': 'PDno23andme_full_gene_notext_1025478', 'SNP': 'rs6538799', 'effect_allele': 'G', 'effect_allele_frequency': 0.3749, 'non_effect_allele': 'A', 'non_effect_allele_frequency': 0.6251}]",general,"Calculate, Select",Allele Frequency
-Q61.1861,Q61,What is the chemblId of the drug Meclofenamate Sodium?,The chemblId for the drug Meclofenamate Sodium is CHEMBL1562610.,"SELECT UUID, drugName, drugSynonyms_string, tradeNames_string, chemblIdentifier
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%meclofenamate sodium%"" OR LOWER(tradeNames_string) LIKE ""%meclofenamate sodium%"" OR LOWER(drugSynonyms_string) LIKE ""%meclofenamate sodium%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3724', 'drugName': 'Meclofenamate Sodium', 'drugSynonyms_string': 'CL-583.NA SALT, Meclofenamate sodium, Meclofenamate sodium anhydrous, Meclofenamate sodium hydrate, Meclofenamic acid sodium, NSC-757088, Sodium meclofenamate, Sodium meclofenamate monohydrate', 'tradeNames_string': 'Meclodium, Meclofenamate sodium, Meclomen', 'chemblIdentifier': 'CHEMBL1562610'}, {'UUID': 'DrugGeneTargets_v2_3725', 'drugName': 'Meclofenamate Sodium', 'drugSynonyms_string': 'CL-583.NA SALT, Meclofenamate sodium, Meclofenamate sodium anhydrous, Meclofenamate sodium hydrate, Meclofenamic acid sodium, NSC-757088, Sodium meclofenamate, Sodium meclofenamate monohydrate', 'tradeNames_string': 'Meclodium, Meclofenamate sodium, Meclomen', 'chemblIdentifier': 'CHEMBL1562610'}]",general,"Select, Similarity Search",Metadata
-Q61.354,Q61,What is the chemblId of the drug Gemtuzumab?,The chemblId for the drug Gemtuzumab is CHEMBL2108342.,"SELECT UUID, drugName, drugSynonyms_string, tradeNames_string, chemblIdentifier
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%gemtuzumab%"" OR LOWER(tradeNames_string) LIKE ""%gemtuzumab%"" OR LOWER(drugSynonyms_string) LIKE ""%gemtuzumab%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3736', 'drugName': 'Gemtuzumab', 'drugSynonyms_string': 'Gemtuzumab, Hp 67.6', 'tradeNames_string': '', 'chemblIdentifier': 'CHEMBL2108342'}, {'UUID': 'DrugGeneTargets_v2_6112', 'drugName': 'Gemtuzumab Ozogamicin', 'drugSynonyms_string': 'CDP-771, CMA-676, CMC-676, Gemtuzumab ozogamicin, Gemtuzumab ozogamicin recombinant, L01XC05, WAY-CMA-676', 'tradeNames_string': 'Mylotarg', 'chemblIdentifier': 'CHEMBL1201506'}]",general,"Select, Similarity Search",Metadata
-Q61.1334,Q61,What is the chemblId of the drug Cotadutide?,The chemblId for the drug Cotadutide is CHEMBL4297630.,"SELECT UUID, drugName, drugSynonyms_string, tradeNames_string, chemblIdentifier
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%cotadutide%"" OR LOWER(tradeNames_string) LIKE ""%cotadutide%"" OR LOWER(drugSynonyms_string) LIKE ""%cotadutide%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_5839', 'drugName': 'Cotadutide', 'drugSynonyms_string': 'Cotadutide, MEDI-0382, MEDI0382, Medi 0382, Medi0382', 'tradeNames_string': '', 'chemblIdentifier': 'CHEMBL4297630'}, {'UUID': 'DrugGeneTargets_v2_5840', 'drugName': 'Cotadutide', 'drugSynonyms_string': 'Cotadutide, MEDI-0382, MEDI0382, Medi 0382, Medi0382', 'tradeNames_string': '', 'chemblIdentifier': 'CHEMBL4297630'}]",general,"Select, Similarity Search",Metadata
-Q61.906,Q61,What is the chemblId of the drug Fosnetupitant Chloride Hydrochloride?,The chemblId for the drug Fosnetupitant Chloride Hydrochloride is CHEMBL3989919.,"SELECT UUID, drugName, drugSynonyms_string, tradeNames_string, chemblIdentifier
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%fosnetupitant chloride hydrochloride%"" OR LOWER(tradeNames_string) LIKE ""%fosnetupitant chloride hydrochloride%"" OR LOWER(drugSynonyms_string) LIKE ""%fosnetupitant chloride hydrochloride%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_4376', 'drugName': 'Fosnetupitant Chloride Hydrochloride', 'drugSynonyms_string': '08-PNET, Fosnetupitant chloride, Fosnetupitant chloride hydrochloride, Fosnetupitant dihydrochloride', 'tradeNames_string': '', 'chemblIdentifier': 'CHEMBL3989919'}]",general,"Select, Similarity Search",Metadata
-Q61.1290,Q61,What is the chemblId of the drug Am-461?,The chemblId for the drug Am-461 is CHEMBL5095021.,"SELECT UUID, drugName, drugSynonyms_string, tradeNames_string, chemblIdentifier
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%am-461%"" OR LOWER(tradeNames_string) LIKE ""%am-461%"" OR LOWER(drugSynonyms_string) LIKE ""%am-461%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2988', 'drugName': 'Am-461', 'drugSynonyms_string': 'AM461, Am-461', 'tradeNames_string': '', 'chemblIdentifier': 'CHEMBL5095021'}]",general,"Select, Similarity Search",Metadata
-Q61.1274,Q61,What is the chemblId of the drug Ji-101?,The chemblId for the drug Ji-101 is CHEMBL3545155.,"SELECT UUID, drugName, drugSynonyms_string, tradeNames_string, chemblIdentifier
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%ji-101%"" OR LOWER(tradeNames_string) LIKE ""%ji-101%"" OR LOWER(drugSynonyms_string) LIKE ""%ji-101%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_4147', 'drugName': 'Ji-101', 'drugSynonyms_string': 'Angiogenesis inhibitor ji-101, CGI-1842, JI-101, Ji-101', 'tradeNames_string': '', 'chemblIdentifier': 'CHEMBL3545155'}, {'UUID': 'DrugGeneTargets_v2_4148', 'drugName': 'Ji-101', 'drugSynonyms_string': 'Angiogenesis inhibitor ji-101, CGI-1842, JI-101, Ji-101', 'tradeNames_string': '', 'chemblIdentifier': 'CHEMBL3545155'}, {'UUID': 'DrugGeneTargets_v2_4149', 'drugName': 'Ji-101', 'drugSynonyms_string': 'Angiogenesis inhibitor ji-101, CGI-1842, JI-101, Ji-101', 'tradeNames_string': '', 'chemblIdentifier': 'CHEMBL3545155'}]",general,"Select, Similarity Search",Metadata
-Q61.939,Q61,What is the chemblId of the drug Amg553?,The chemblId for the drug Amg553 is CHEMBL4650295.,"SELECT UUID, drugName, drugSynonyms_string, tradeNames_string, chemblIdentifier
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%amg553%"" OR LOWER(tradeNames_string) LIKE ""%amg553%"" OR LOWER(drugSynonyms_string) LIKE ""%amg553%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_5110', 'drugName': 'Amg553', 'drugSynonyms_string': 'AMG553, Amg 553, Amg553', 'tradeNames_string': '', 'chemblIdentifier': 'CHEMBL4650295'}]",general,"Select, Similarity Search",Metadata
-Q61.1732,Q61,What is the chemblId of the drug Antrafenine?,The chemblId for the drug Antrafenine is CHEMBL345524.,"SELECT UUID, drugName, drugSynonyms_string, tradeNames_string, chemblIdentifier
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%antrafenine%"" OR LOWER(tradeNames_string) LIKE ""%antrafenine%"" OR LOWER(drugSynonyms_string) LIKE ""%antrafenine%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3195', 'drugName': 'Antrafenine', 'drugSynonyms_string': 'Antrafenine', 'tradeNames_string': '', 'chemblIdentifier': 'CHEMBL345524'}]",general,"Select, Similarity Search",Metadata
-Q61.66,Q61,What is the chemblId of the drug Trimegestone?,The chemblId for the drug Trimegestone is CHEMBL2104765.,"SELECT UUID, drugName, drugSynonyms_string, tradeNames_string, chemblIdentifier
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%trimegestone%"" OR LOWER(tradeNames_string) LIKE ""%trimegestone%"" OR LOWER(drugSynonyms_string) LIKE ""%trimegestone%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3154', 'drugName': 'Trimegestone', 'drugSynonyms_string': 'RU 27987, RU-27987, Trimegestone', 'tradeNames_string': '', 'chemblIdentifier': 'CHEMBL2104765'}]",general,"Select, Similarity Search",Metadata
-Q61.1324,Q61,What is the chemblId of the drug Telmisartan?,The chemblId for the drug Telmisartan is CHEMBL1017.,"SELECT UUID, drugName, drugSynonyms_string, tradeNames_string, chemblIdentifier
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%telmisartan%"" OR LOWER(tradeNames_string) LIKE ""%telmisartan%"" OR LOWER(drugSynonyms_string) LIKE ""%telmisartan%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3908', 'drugName': 'Telmisartan', 'drugSynonyms_string': 'BIBR 277 SE, BIBR-277, BIBR-277 SE, BIBR-277-SE, BIBR-277SE, C09CA07, Kinzalmono, Pritor, Semintra, Telmisartan, Telmisartan actavis, Telmisartan teva', 'tradeNames_string': 'Micardis, Telmisartan, Tolura', 'chemblIdentifier': 'CHEMBL1017'}]",general,"Select, Similarity Search",Metadata
-Q61.57,Q61,What is the chemblId of the drug Lby-135?,The chemblId for the drug Lby-135 is CHEMBL2109247.,"SELECT UUID, drugName, drugSynonyms_string, tradeNames_string, chemblIdentifier
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%lby-135%"" OR LOWER(tradeNames_string) LIKE ""%lby-135%"" OR LOWER(drugSynonyms_string) LIKE ""%lby-135%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3373', 'drugName': 'Lby-135', 'drugSynonyms_string': 'LBY-135, LBY135, Lby 135', 'tradeNames_string': '', 'chemblIdentifier': 'CHEMBL2109247'}]",general,"Select, Similarity Search",Metadata
-Q61.1293,Q61,What is the chemblId of the drug Mk-2201?,The chemblId for the drug Mk-2201 is CHEMBL3545000.,"SELECT UUID, drugName, drugSynonyms_string, tradeNames_string, chemblIdentifier
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%mk-2201%"" OR LOWER(tradeNames_string) LIKE ""%mk-2201%"" OR LOWER(drugSynonyms_string) LIKE ""%mk-2201%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_1380', 'drugName': 'Mk-2201', 'drugSynonyms_string': 'Mk-2201', 'tradeNames_string': '', 'chemblIdentifier': 'CHEMBL3545000'}]",general,"Select, Similarity Search",Metadata
-Q61.1119,Q61,What is the chemblId of the drug Insulin Zinc Susp Extended Recombinant Human?,The chemblId for the drug Insulin Zinc Susp Extended Recombinant Human is CHEMBL1201641.,"SELECT UUID, drugName, drugSynonyms_string, tradeNames_string, chemblIdentifier
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%insulin zinc susp extended recombinant human%"" OR LOWER(tradeNames_string) LIKE ""%insulin zinc susp extended recombinant human%"" OR LOWER(drugSynonyms_string) LIKE ""%insulin zinc susp extended recombinant human%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_4713', 'drugName': 'Insulin Zinc Susp Extended Recombinant Human', 'drugSynonyms_string': 'Insulin zinc susp extended recombinant human', 'tradeNames_string': 'Humulin u', 'chemblIdentifier': 'CHEMBL1201641'}]",general,"Select, Similarity Search",Metadata
-Q61.585,Q61,What is the chemblId of the drug Emvododstat?,The chemblId for the drug Emvododstat is CHEMBL4650336.,"SELECT UUID, drugName, drugSynonyms_string, tradeNames_string, chemblIdentifier
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%emvododstat%"" OR LOWER(tradeNames_string) LIKE ""%emvododstat%"" OR LOWER(drugSynonyms_string) LIKE ""%emvododstat%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_1774', 'drugName': 'Emvododstat', 'drugSynonyms_string': 'Emvododstat, PTC299, Ptc-299, Ptc299', 'tradeNames_string': '', 'chemblIdentifier': 'CHEMBL4650336'}]",general,"Select, Similarity Search",Metadata
-Q61.375,Q61,What is the chemblId of the drug Alosetron?,The chemblId for the drug Alosetron is CHEMBL1110.,"SELECT UUID, drugName, drugSynonyms_string, tradeNames_string, chemblIdentifier
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%alosetron%"" OR LOWER(tradeNames_string) LIKE ""%alosetron%"" OR LOWER(drugSynonyms_string) LIKE ""%alosetron%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_4889', 'drugName': 'Alosetron', 'drugSynonyms_string': 'A03AE01, Alosetron, Lotronex', 'tradeNames_string': '', 'chemblIdentifier': 'CHEMBL1110'}, {'UUID': 'DrugGeneTargets_v2_5986', 'drugName': 'Alosetron Hydrochloride', 'drugSynonyms_string': 'Alosetron hcl, Alosetron hydrochloride, GR 68755C, GR-68755C, Lotrpnex', 'tradeNames_string': 'Alosetron hydrochloride, Lotronex', 'chemblIdentifier': 'CHEMBL1200885'}]",general,"Select, Similarity Search",Metadata
-Q61.276,Q61,What is the chemblId of the drug Almotriptan?,The chemblId for the drug Almotriptan is CHEMBL1505.,"SELECT UUID, drugName, drugSynonyms_string, tradeNames_string, chemblIdentifier
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%almotriptan%"" OR LOWER(tradeNames_string) LIKE ""%almotriptan%"" OR LOWER(drugSynonyms_string) LIKE ""%almotriptan%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2780', 'drugName': 'Almotriptan', 'drugSynonyms_string': 'Almotriptan, LAS 31416, LAS-31416, NSC-760092', 'tradeNames_string': '', 'chemblIdentifier': 'CHEMBL1505'}, {'UUID': 'DrugGeneTargets_v2_2781', 'drugName': 'Almotriptan', 'drugSynonyms_string': 'Almotriptan, LAS 31416, LAS-31416, NSC-760092', 'tradeNames_string': '', 'chemblIdentifier': 'CHEMBL1505'}, {'UUID': 'DrugGeneTargets_v2_2782', 'drugName': 'Almotriptan', 'drugSynonyms_string': 'Almotriptan, LAS 31416, LAS-31416, NSC-760092', 'tradeNames_string': '', 'chemblIdentifier': 'CHEMBL1505'}, {'UUID': 'DrugGeneTargets_v2_3458', 'drugName': 'Almotriptan Malate', 'drugSynonyms_string': 'Almogran, Almotriptan d,l-hydrogenmalate, Almotriptan malate, Almotriptan maleate, LAS 31416 D,L-MALATE ACID, LAS-31416, LAS-31416 D,L-MALATE ACID, LAS-31416-D,L-MALATE-ACID, PNU-180638E', 'tradeNames_string': 'Almotriptan malate, Axert', 'chemblIdentifier': 'CHEMBL1200521'}, {'UUID': 'DrugGeneTargets_v2_3459', 'drugName': 'Almotriptan Malate', 'drugSynonyms_string': 'Almogran, Almotriptan d,l-hydrogenmalate, Almotriptan malate, Almotriptan maleate, LAS 31416 D,L-MALATE ACID, LAS-31416, LAS-31416 D,L-MALATE ACID, LAS-31416-D,L-MALATE-ACID, PNU-180638E', 'tradeNames_string': 'Almotriptan malate, Axert', 'chemblIdentifier': 'CHEMBL1200521'}, {'UUID': 'DrugGeneTargets_v2_3460', 'drugName': 'Almotriptan Malate', 'drugSynonyms_string': 'Almogran, Almotriptan d,l-hydrogenmalate, Almotriptan malate, Almotriptan maleate, LAS 31416 D,L-MALATE ACID, LAS-31416, LAS-31416 D,L-MALATE ACID, LAS-31416-D,L-MALATE-ACID, PNU-180638E', 'tradeNames_string': 'Almotriptan malate, Axert', 'chemblIdentifier': 'CHEMBL1200521'}]",general,"Select, Similarity Search",Metadata
-Q55.1861,Q55,"Based on Whole Brain meta-analysis mQTL data, what is the top SNP in FAM200B that is associated with Parkinson's Disease (PD), and what is its adjusted SMR p-value?","FAM200B's most significantly associated SNP with Parkinson's Disease in the Whole Brain meta-analysis mQTL is rs6815296, with adjusted SMR multi-SNP P-value of 1.52e-07 and a HEIDI value of 2.1401e-02.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, Omic_tissue, Omic_type
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'PD' AND Gene = 'FAM200B' AND LOWER(Omic_type) LIKE ""%whole brain meta-analysis mqtl%"" AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
- ORDER BY p_SMR_multi
- LIMIT 1","[{'UUID': 'NDD_SMR_genes_all_update_text_431294', 'topRSID': 'rs6815296', 'Disease': 'PD', 'Gene': 'FAM200B', 'p_SMR_multi': 1.524254e-07, 'p_HEIDI': 0.02140065, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL'}]",refined,"Select, Multi-Filter, Similarity Search, Order By, Threshold",Functional Significance
-Q55.354,Q55,"Based on Anterior Cingulate Cortex BA24 eQTL data, what is the top SNP in APOC2 that is associated with Amyotrophic Lateral Sclerosis, and what is its adjusted SMR p-value?",APOC2 has no SNPs significantly associated with Amyotrophic Lateral Sclerosis in the Anterior Cingulate Cortex BA24 eQTL.,"SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, Omic_tissue, Omic_type
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'ALS' AND Gene = 'APOC2' AND LOWER(Omic_type) LIKE ""%anterior cingulate cortex ba24 eqtl%"" AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
- ORDER BY p_SMR_multi
- LIMIT 1",[],refined,"Select, Multi-Filter, Similarity Search, Order By, Threshold",Functional Significance
-Q55.1334,Q55,"Based on Whole Blood eQTL GTEx data, what is the top SNP in INPP5D that is associated with Alzheimer's Disease (AD), and what is its adjusted SMR p-value?","INPP5D's most significantly associated SNP with Alzheimer's Disease in the Whole Blood eQTL GTEx is rs6715767, with adjusted SMR multi-SNP P-value of 1.38e-07 and a HEIDI value of 3.3362e-01.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, Omic_tissue, Omic_type
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'AD' AND Gene = 'INPP5D' AND LOWER(Omic_type) LIKE ""%whole blood eqtl gtex%"" AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
- ORDER BY p_SMR_multi
- LIMIT 1","[{'UUID': 'NDD_SMR_genes_all_update_text_1648149', 'topRSID': 'rs6715767', 'Disease': 'AD', 'Gene': 'INPP5D', 'p_SMR_multi': 1.380763e-07, 'p_HEIDI': 0.3336205, 'Omic_tissue': 'Whole Blood', 'Omic_type': 'Whole Blood eQTL GTEx'}]",refined,"Select, Multi-Filter, Similarity Search, Order By, Threshold",Functional Significance
-Q55.906,Q55,"Based on Frontal Cortex BA9 eQTL data, what is the top SNP in TREM2 that is associated with Lewy Body Dementia, and what is its adjusted SMR p-value?",TREM2 has no SNPs significantly associated with Lewy Body Dementia in the Frontal Cortex BA9 eQTL.,"SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, Omic_tissue, Omic_type
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'LBD' AND Gene = 'TREM2' AND LOWER(Omic_type) LIKE ""%frontal cortex ba9 eqtl%"" AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
- ORDER BY p_SMR_multi
- LIMIT 1",[],refined,"Select, Multi-Filter, Similarity Search, Order By, Threshold",Functional Significance
-Q55.1290,Q55,"Based on Cerebellar Hemisphere eQTL data, what is the top SNP in AC005082.12 that is associated with Progressive supranuclear palsy, and what is its adjusted SMR p-value?",AC005082.12 has no SNPs significantly associated with Progressive supranuclear palsy in the Cerebellar Hemisphere eQTL.,"SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, Omic_tissue, Omic_type
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'PSP' AND Gene = 'AC005082.12' AND LOWER(Omic_type) LIKE ""%cerebellar hemisphere eqtl%"" AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
- ORDER BY p_SMR_multi
- LIMIT 1",[],refined,"Select, Multi-Filter, Similarity Search, Order By, Threshold",Functional Significance
-Q55.1274,Q55,"Based on Cerebellar Hemisphere eQTL data, what is the top SNP in DND1P1 that is associated with Alzheimer's Disease, and what is its adjusted SMR p-value?",DND1P1 has no SNPs significantly associated with Alzheimer's Disease in the Cerebellar Hemisphere eQTL.,"SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, Omic_tissue, Omic_type
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'AD' AND Gene = 'DND1P1' AND LOWER(Omic_type) LIKE ""%cerebellar hemisphere eqtl%"" AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
- ORDER BY p_SMR_multi
- LIMIT 1",[],refined,"Select, Multi-Filter, Similarity Search, Order By, Threshold",Functional Significance
-Q55.939,Q55,"Based on Spinalcord eQTL data, what is the top SNP in DOC2A that is associated with Amyotrophic Lateral Sclerosis, and what is its adjusted SMR p-value?",DOC2A has no SNPs significantly associated with Amyotrophic Lateral Sclerosis in the Spinalcord eQTL.,"SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, Omic_tissue, Omic_type
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'ALS' AND Gene = 'DOC2A' AND LOWER(Omic_type) LIKE ""%spinalcord eqtl%"" AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
- ORDER BY p_SMR_multi
- LIMIT 1",[],refined,"Select, Multi-Filter, Similarity Search, Order By, Threshold",Functional Significance
-Q55.1732,Q55,"Based on Cortex eQTL GTEx data, what is the top SNP in NUPL2 that is associated with Alzheimer's Disease, and what is its adjusted SMR p-value?",NUPL2 has no SNPs significantly associated with Alzheimer's Disease in the Cortex eQTL GTEx.,"SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, Omic_tissue, Omic_type
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'AD' AND Gene = 'NUPL2' AND LOWER(Omic_type) LIKE ""%cortex eqtl gtex%"" AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
- ORDER BY p_SMR_multi
- LIMIT 1",[],refined,"Select, Multi-Filter, Similarity Search, Order By, Threshold",Functional Significance
-Q55.66,Q55,"Based on Amygdala eQTL data, what is the top SNP in SETD1A that is associated with Progressive supranuclear palsy, and what is its adjusted SMR p-value?",SETD1A has no SNPs significantly associated with Progressive supranuclear palsy in the Amygdala eQTL.,"SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, Omic_tissue, Omic_type
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'PSP' AND Gene = 'SETD1A' AND LOWER(Omic_type) LIKE ""%amygdala eqtl%"" AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
- ORDER BY p_SMR_multi
- LIMIT 1",[],refined,"Select, Multi-Filter, Similarity Search, Order By, Threshold",Functional Significance
-Q55.1324,Q55,"Based on Nucleus Accumbens Basal Ganglia data, what is the top SNP in MAPT that is associated with Lewy Body Dementia, and what is its adjusted SMR p-value?",MAPT has no SNPs significantly associated with Lewy Body Dementia in the Nucleus Accumbens Basal Ganglia.,"SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, Omic_tissue, Omic_type
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'LBD' AND Gene = 'MAPT' AND LOWER(Omic_type) LIKE ""%nucleus accumbens basal ganglia%"" AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
- ORDER BY p_SMR_multi
- LIMIT 1",[],refined,"Select, Multi-Filter, Similarity Search, Order By, Threshold",Functional Significance
-Q55.57,Q55,"Based on Cortex eQTL metaBrain data, what is the top SNP in ZNF646 that is associated with Progressive supranuclear palsy, and what is its adjusted SMR p-value?",ZNF646 has no SNPs significantly associated with Progressive supranuclear palsy in the Cortex eQTL metaBrain.,"SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, Omic_tissue, Omic_type
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'PSP' AND Gene = 'ZNF646' AND LOWER(Omic_type) LIKE ""%cortex eqtl metabrain%"" AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
- ORDER BY p_SMR_multi
- LIMIT 1",[],refined,"Select, Multi-Filter, Similarity Search, Order By, Threshold",Functional Significance
-Q55.1293,Q55,"Based on Cortex eQTL GTEx data, what is the top SNP in KANSL1-AS1 that is associated with Lewy Body Dementia, and what is its adjusted SMR p-value?",KANSL1-AS1 has no SNPs significantly associated with Lewy Body Dementia in the Cortex eQTL GTEx.,"SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, Omic_tissue, Omic_type
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'LBD' AND Gene = 'KANSL1-AS1' AND LOWER(Omic_type) LIKE ""%cortex eqtl gtex%"" AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
- ORDER BY p_SMR_multi
- LIMIT 1",[],refined,"Select, Multi-Filter, Similarity Search, Order By, Threshold",Functional Significance
-Q55.1119,Q55,"Based on Liver eQTL data, what is the top SNP in C17orf107 that is associated with Progressive supranuclear palsy, and what is its adjusted SMR p-value?",C17orf107 has no SNPs significantly associated with Progressive supranuclear palsy in the Liver eQTL.,"SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, Omic_tissue, Omic_type
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'PSP' AND Gene = 'C17orf107' AND LOWER(Omic_type) LIKE ""%liver eqtl%"" AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
- ORDER BY p_SMR_multi
- LIMIT 1",[],refined,"Select, Multi-Filter, Similarity Search, Order By, Threshold",Functional Significance
-Q55.585,Q55,"Based on Basal Ganglia eQTL data, what is the top SNP in REXO1 that is associated with Amyotrophic Lateral Sclerosis, and what is its adjusted SMR p-value?",REXO1 has no SNPs significantly associated with Amyotrophic Lateral Sclerosis in the Basal Ganglia eQTL.,"SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, Omic_tissue, Omic_type
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'ALS' AND Gene = 'REXO1' AND LOWER(Omic_type) LIKE ""%basal ganglia eqtl%"" AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
- ORDER BY p_SMR_multi
- LIMIT 1",[],refined,"Select, Multi-Filter, Similarity Search, Order By, Threshold",Functional Significance
-Q55.375,Q55,"Based on Anterior Cingulate Cortex BA24 eQTL data, what is the top SNP in RP11-259G18.3 that is associated with Alzheimer's Disease (AD), and what is its adjusted SMR p-value?","RP11-259G18.3's most significantly associated SNP with Alzheimer's Disease in the Anterior Cingulate Cortex BA24 eQTL is rs199533, with adjusted SMR multi-SNP P-value of 2.10e-06 and a HEIDI value of 8.7716e-01.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, Omic_tissue, Omic_type
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'AD' AND Gene = 'RP11-259G18.3' AND LOWER(Omic_type) LIKE ""%anterior cingulate cortex ba24 eqtl%"" AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
- ORDER BY p_SMR_multi
- LIMIT 1","[{'UUID': 'NDD_SMR_genes_all_update_text_1480161', 'topRSID': 'rs199533', 'Disease': 'AD', 'Gene': 'RP11-259G18.3', 'p_SMR_multi': 2.101674e-06, 'p_HEIDI': 0.8771589, 'Omic_tissue': 'Anterior Cingulate Cortex BA24', 'Omic_type': 'Anterior Cingulate Cortex BA24 eQTL'}]",refined,"Select, Multi-Filter, Similarity Search, Order By, Threshold",Functional Significance
-Q55.276,Q55,"Based on Putamen Basal Ganglia eQTL data, what is the top SNP in NSFP1 that is associated with Progressive supranuclear palsy (PSP), and what is its adjusted SMR p-value?","NSFP1's most significantly associated SNP with Progressive supranuclear palsy in the Putamen Basal Ganglia eQTL is rs17692129, with adjusted SMR multi-SNP P-value of 1.45e-11 and a HEIDI value of 3.9510e-01.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, Omic_tissue, Omic_type
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'Progressive supranuclear palsy (PSP)' AND Gene = 'NSFP1' AND LOWER(Omic_type) LIKE ""%putamen basal ganglia eqtl%"" AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
- ORDER BY p_SMR_multi
- LIMIT 1",[],refined,"Select, Multi-Filter, Similarity Search, Order By, Threshold",Functional Significance
-Q6.1861,Q6,What genes does Aspirin target when it's used to treat angina pectoris?,"Aspirin has not been approved by the FDA as a treatment for angina pectoris, but it is currently undergoing evaluation in clinical trials for this purpose. The proposed gene targets are PTGS2 and PTGS1.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, target, approvedSymbol, approvedName, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%aspirin%"" OR LOWER(tradeNames_list) LIKE ""%aspirin%"" OR LOWER(syns_list) LIKE ""%aspirin%"") AND (LOWER(mesh_heading) LIKE ""%angina pectoris%"" OR LOWER(efo_term) LIKE ""%angina pectoris%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_834379', 'drugName': 'Aspirin', 'tradeNames_list': ""['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']"", 'syns_list': ""['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']"", 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_834850', 'drugName': 'Aspirin', 'tradeNames_list': ""['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']"", 'syns_list': ""['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']"", 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_835007', 'drugName': 'Aspirin', 'tradeNames_list': ""['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']"", 'syns_list': ""['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']"", 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_835164', 'drugName': 'Aspirin', 'tradeNames_list': ""['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']"", 'syns_list': ""['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']"", 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_835478', 'drugName': 'Aspirin', 'tradeNames_list': ""['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']"", 'syns_list': ""['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']"", 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_835635', 'drugName': 'Aspirin', 'tradeNames_list': ""['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']"", 'syns_list': ""['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']"", 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_835792', 'drugName': 'Aspirin', 'tradeNames_list': ""['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']"", 'syns_list': ""['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']"", 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_835949', 'drugName': 'Aspirin', 'tradeNames_list': ""['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']"", 'syns_list': ""['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']"", 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_834693', 'drugName': 'Aspirin', 'tradeNames_list': ""['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']"", 'syns_list': ""['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']"", 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_834065', 'drugName': 'Aspirin', 'tradeNames_list': ""['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']"", 'syns_list': ""['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']"", 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_833751', 'drugName': 'Aspirin', 'tradeNames_list': ""['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']"", 'syns_list': ""['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']"", 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_833594', 'drugName': 'Aspirin', 'tradeNames_list': ""['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']"", 'syns_list': ""['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']"", 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_835321', 'drugName': 'Aspirin', 'tradeNames_list': ""['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']"", 'syns_list': ""['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']"", 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_834536', 'drugName': 'Aspirin', 'tradeNames_list': ""['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']"", 'syns_list': ""['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']"", 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_834222', 'drugName': 'Aspirin', 'tradeNames_list': ""['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']"", 'syns_list': ""['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']"", 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_833908', 'drugName': 'Aspirin', 'tradeNames_list': ""['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']"", 'syns_list': ""['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']"", 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0}]",general,"Distinct, Order By, Similarity Search","Genetic Target, Approval Status"
-Q6.354,Q6,What genes does Copanlisib Hydrochloride target when it's used to treat diffuse large B-cell lymphoma?,"Copanlisib Hydrochloride has not been approved by the FDA as a treatment for diffuse large B-cell lymphoma, but it is currently undergoing evaluation in clinical trials for this purpose. The proposed gene targets are PIK3CD and PIK3CA.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, target, approvedSymbol, approvedName, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%copanlisib hydrochloride%"" OR LOWER(tradeNames_list) LIKE ""%copanlisib hydrochloride%"" OR LOWER(syns_list) LIKE ""%copanlisib hydrochloride%"") AND (LOWER(mesh_heading) LIKE ""%diffuse large b-cell lymphoma%"" OR LOWER(efo_term) LIKE ""%diffuse large b-cell lymphoma%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_858358', 'drugName': 'Copanlisib Hydrochloride', 'tradeNames_list': ""['Aliqopa']"", 'syns_list': ""['BAY 80-6946 DIHYDROCHLORIDE', 'BAY 84-1236', 'BAY-80-6946 DIHYDROCHLORIDEBAY-84-1236', 'Copanlisib dihydrochloride', 'Copanlisib hydrochlorideCopanlisib hydrochloride hydrate']"", 'target': 'ENSG00000121879', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha', 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_858376', 'drugName': 'Copanlisib Hydrochloride', 'tradeNames_list': ""['Aliqopa']"", 'syns_list': ""['BAY 80-6946 DIHYDROCHLORIDE', 'BAY 84-1236', 'BAY-80-6946 DIHYDROCHLORIDEBAY-84-1236', 'Copanlisib dihydrochloride', 'Copanlisib hydrochlorideCopanlisib hydrochloride hydrate']"", 'target': 'ENSG00000121879', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha', 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_858340', 'drugName': 'Copanlisib Hydrochloride', 'tradeNames_list': ""['Aliqopa']"", 'syns_list': ""['BAY 80-6946 DIHYDROCHLORIDE', 'BAY 84-1236', 'BAY-80-6946 DIHYDROCHLORIDEBAY-84-1236', 'Copanlisib dihydrochloride', 'Copanlisib hydrochlorideCopanlisib hydrochloride hydrate']"", 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_858322', 'drugName': 'Copanlisib Hydrochloride', 'tradeNames_list': ""['Aliqopa']"", 'syns_list': ""['BAY 80-6946 DIHYDROCHLORIDE', 'BAY 84-1236', 'BAY-80-6946 DIHYDROCHLORIDEBAY-84-1236', 'Copanlisib dihydrochloride', 'Copanlisib hydrochlorideCopanlisib hydrochloride hydrate']"", 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_858313', 'drugName': 'Copanlisib Hydrochloride', 'tradeNames_list': ""['Aliqopa']"", 'syns_list': ""['BAY 80-6946 DIHYDROCHLORIDE', 'BAY 84-1236', 'BAY-80-6946 DIHYDROCHLORIDEBAY-84-1236', 'Copanlisib dihydrochloride', 'Copanlisib hydrochlorideCopanlisib hydrochloride hydrate']"", 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_858367', 'drugName': 'Copanlisib Hydrochloride', 'tradeNames_list': ""['Aliqopa']"", 'syns_list': ""['BAY 80-6946 DIHYDROCHLORIDE', 'BAY 84-1236', 'BAY-80-6946 DIHYDROCHLORIDEBAY-84-1236', 'Copanlisib dihydrochloride', 'Copanlisib hydrochlorideCopanlisib hydrochloride hydrate']"", 'target': 'ENSG00000121879', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha', 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_858349', 'drugName': 'Copanlisib Hydrochloride', 'tradeNames_list': ""['Aliqopa']"", 'syns_list': ""['BAY 80-6946 DIHYDROCHLORIDE', 'BAY 84-1236', 'BAY-80-6946 DIHYDROCHLORIDEBAY-84-1236', 'Copanlisib dihydrochloride', 'Copanlisib hydrochlorideCopanlisib hydrochloride hydrate']"", 'target': 'ENSG00000121879', 'approvedSymbol': 'PIK3CA', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha', 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_858331', 'drugName': 'Copanlisib Hydrochloride', 'tradeNames_list': ""['Aliqopa']"", 'syns_list': ""['BAY 80-6946 DIHYDROCHLORIDE', 'BAY 84-1236', 'BAY-80-6946 DIHYDROCHLORIDEBAY-84-1236', 'Copanlisib dihydrochloride', 'Copanlisib hydrochlorideCopanlisib hydrochloride hydrate']"", 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'mesh_heading': 'Lymphoma, Large B-Cell, Diffuse', 'efo_term': 'diffuse large B-cell lymphoma', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0}]",general,"Distinct, Order By, Similarity Search","Genetic Target, Approval Status"
-Q6.1334,Q6,What genes does Lidocaine Hydrochloride target when it's used to treat Back pain?,"When used to treat Back pain, the drug Lidocaine Hydrochloride targets the genes SCN1A, SCN5A, SCN4A, SCN7A, SCN2A, SCN9A, SCN3A, SCN11A, SCN8A, and SCN10A.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, target, approvedSymbol, approvedName, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%lidocaine hydrochloride%"" OR LOWER(tradeNames_list) LIKE ""%lidocaine hydrochloride%"" OR LOWER(syns_list) LIKE ""%lidocaine hydrochloride%"") AND (LOWER(mesh_heading) LIKE ""%back pain%"" OR LOWER(efo_term) LIKE ""%back pain%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_637007', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637067', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637087', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637107', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637147', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637167', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637187', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637227', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637247', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637267', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637287', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637327', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637347', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637367', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637387', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637407', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637427', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637447', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637467', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637487', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637507', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637547', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637567', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637587', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637607', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637627', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637667', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637687', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637527', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637207', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637047', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_636967', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_636927', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_636907', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637647', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637307', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637127', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_637027', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_636987', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_636947', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': ""['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']"", 'syns_list': ""['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']"", 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0}]",general,"Distinct, Order By, Similarity Search","Genetic Target, Approval Status"
-Q6.906,Q6,What genes does Prednisone target when it's used to treat acute myeloid leukemia?,"Prednisone has not been approved by the FDA as a treatment for acute myeloid leukemia, but it is currently undergoing evaluation in clinical trials for this purpose. The proposed gene target is NR3C1.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, target, approvedSymbol, approvedName, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%prednisone%"" OR LOWER(tradeNames_list) LIKE ""%prednisone%"" OR LOWER(syns_list) LIKE ""%prednisone%"") AND (LOWER(mesh_heading) LIKE ""%acute myeloid leukemia%"" OR LOWER(efo_term) LIKE ""%acute myeloid leukemia%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_218605', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_219229', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_219437', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_219645', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_220061', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_220269', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_220477', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_220685', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_219021', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_218189', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_217773', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_217565', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_219853', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_218813', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_218397', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_217981', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0}]",general,"Distinct, Order By, Similarity Search","Genetic Target, Approval Status"
-Q6.1290,Q6,What genes does Prednisone target when it's used to treat erythema multiforme?,"When used to treat erythema multiforme, the drug Prednisone targets the gene NR3C1.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, target, approvedSymbol, approvedName, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%prednisone%"" OR LOWER(tradeNames_list) LIKE ""%prednisone%"" OR LOWER(syns_list) LIKE ""%prednisone%"") AND (LOWER(mesh_heading) LIKE ""%erythema multiforme%"" OR LOWER(efo_term) LIKE ""%erythema multiforme%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_218705', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_219329', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_219537', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_219745', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_220161', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_220369', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_220577', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_220785', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_219121', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_218289', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_217873', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_217665', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_219953', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_218913', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_218497', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_218081', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Erythema Multiforme', 'efo_term': 'erythema multiforme', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0}]",general,"Distinct, Order By, Similarity Search","Genetic Target, Approval Status"
-Q6.1274,Q6,What genes does Topotecan Hydrochloride target when it's used to treat gliosarcoma?,"Topotecan Hydrochloride has not been approved by the FDA as a treatment for gliosarcoma, but it is currently undergoing evaluation in clinical trials for this purpose. The proposed gene target is TOP1MT.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, target, approvedSymbol, approvedName, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%topotecan hydrochloride%"" OR LOWER(tradeNames_list) LIKE ""%topotecan hydrochloride%"" OR LOWER(syns_list) LIKE ""%topotecan hydrochloride%"") AND (LOWER(mesh_heading) LIKE ""%gliosarcoma%"" OR LOWER(efo_term) LIKE ""%gliosarcoma%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_1193547', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': ""['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']"", 'syns_list': ""['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']"", 'target': 'ENSG00000184428', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial', 'mesh_heading': 'Gliosarcoma', 'efo_term': 'gliosarcoma', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1193619', 'drugName': 'Topotecan Hydrochloride', 'tradeNames_list': ""['Hycamptin', 'Hycamtin', 'Topotecan', 'Topotecan hydrochloride']"", 'syns_list': ""['Evotopin', 'NSC-759263', 'Nogitecan hydrochloride', 'SK&F S-104864-ASK&F-S-104864A', 'SK-S-104864-A', 'Topotecan (as hydrochloride)Topotecan actavis', 'Topotecan hcl', 'Topotecan hospiraTopotecan hydrochloride', 'Topotecan teva']"", 'target': 'ENSG00000184428', 'approvedSymbol': 'TOP1MT', 'approvedName': 'DNA topoisomerase I mitochondrial', 'mesh_heading': 'Gliosarcoma', 'efo_term': 'gliosarcoma', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 2.0}]",general,"Distinct, Order By, Similarity Search","Genetic Target, Approval Status"
-Q6.939,Q6,What genes does Acetaminophen target when it's used to treat common cold?,"When used to treat common cold, the drug Acetaminophen targets the genes PTGS2, PTGS1, TRPV1, and FAAH.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, target, approvedSymbol, approvedName, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%acetaminophen%"" OR LOWER(tradeNames_list) LIKE ""%acetaminophen%"" OR LOWER(syns_list) LIKE ""%acetaminophen%"") AND (LOWER(mesh_heading) LIKE ""%common cold%"" OR LOWER(efo_term) LIKE ""%common cold%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_829263', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_829578', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_829683', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_829788', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_829998', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_830103', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_830208', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_830418', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_830523', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_830628', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_830733', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_830943', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_831048', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_831153', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_831258', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_831363', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_831468', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_831573', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_831678', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_831783', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_831888', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_832098', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_832203', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_832308', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_832413', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_832518', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_832728', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_832833', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_831993', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_830313', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_829473', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_829053', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_828843', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_828738', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_832623', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_830838', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_829893', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_829368', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_829158', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_828948', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', ""InfadropsInfants\', feverallInjectapap"", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': ""['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']"", 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}]",general,"Distinct, Order By, Similarity Search","Genetic Target, Approval Status"
-Q6.1732,Q6,What genes does Mometasone Furoate target when it's used to treat allergic rhinitis?,"When used to treat allergic rhinitis, the drug Mometasone Furoate targets the gene NR3C1.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, target, approvedSymbol, approvedName, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%mometasone furoate%"" OR LOWER(tradeNames_list) LIKE ""%mometasone furoate%"" OR LOWER(syns_list) LIKE ""%mometasone furoate%"") AND (LOWER(mesh_heading) LIKE ""%allergic rhinitis%"" OR LOWER(efo_term) LIKE ""%allergic rhinitis%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_241938', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_241964', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_241988', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_241989', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_242014', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_242015', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_242016', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_242041', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_242042', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_242066', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_242067', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_242092', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_242093', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_242094', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_242118', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_242119', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_242120', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_242144', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_242145', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_242146', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_242170', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_242172', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_242196', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_242197', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_242198', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_242222', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_242224', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_242171', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_242040', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_241963', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_241936', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_241911', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_241910', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_242223', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_242068', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_241990', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_241962', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_241937', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_241912', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0}]",general,"Distinct, Order By, Similarity Search","Genetic Target, Approval Status"
-Q6.66,Q6,What genes does Cannabidiol target when it's used to treat pain?,"Cannabidiol has not been approved by the FDA as a treatment for pain, but it is currently undergoing evaluation in clinical trials for this purpose. The proposed gene target is CNR1.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, target, approvedSymbol, approvedName, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%cannabidiol%"" OR LOWER(tradeNames_list) LIKE ""%cannabidiol%"" OR LOWER(syns_list) LIKE ""%cannabidiol%"") AND (LOWER(mesh_heading) LIKE ""%pain%"" OR LOWER(efo_term) LIKE ""%pain%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_1074188', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1074261', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1076232', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1075356', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1073458', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1075867', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1073677', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1074918', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1074115', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1076159', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1074699', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1075794', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1075575', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1074480', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1073604', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1073969', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1075721', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1073896', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1074553', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1073531', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1074042', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1075648', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1074334', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1074407', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1075940', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1076305', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1075210', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1075502', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1073823', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1075064', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1075283', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1074626', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1076013', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1074772', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1075137', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1074991', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1073750', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1074845', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1076086', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1075429', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1073385', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Pain', 'efo_term': 'pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_1073493', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1073639', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1073931', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1075683', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1075704', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1074536', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1074755', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1074734', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1073952', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1075756', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1074953', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1074588', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1074515', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1074150', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1074974', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1074171', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1074609', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1074661', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1073660', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1074463', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1074004', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1074223', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1074682', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1075120', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1075631', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1075610', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1074025', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1074244', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1075172', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1075193', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1075464', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1075245', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1075339', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1074077', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1075485', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1075318', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1073441', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1073566', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1073806', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1075558', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1074296', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1075266', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1074317', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1074369', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1075099', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1073785', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1075047', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1075026', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1075391', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1075412', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1073587', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1073858', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1073733', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1074390', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1075537', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1073879', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1074442', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1074807', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1074828', 'drugName': 'Cannabidiol', 'tradeNames_list': ""['Epidiolex']"", 'syns_list': ""['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']"", 'target': 'ENSG00000118432', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1', 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 2.0}]",general,"Distinct, Order By, Similarity Search","Genetic Target, Approval Status"
-Q6.1324,Q6,What genes does Cobimetinib target when it's used to treat breast carcinoma?,"Cobimetinib has not been approved by the FDA as a treatment for breast carcinoma, but it is currently undergoing evaluation in clinical trials for this purpose. The proposed gene targets are MAP2K2 and MAP2K1.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, target, approvedSymbol, approvedName, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%cobimetinib%"" OR LOWER(tradeNames_list) LIKE ""%cobimetinib%"" OR LOWER(syns_list) LIKE ""%cobimetinib%"") AND (LOWER(mesh_heading) LIKE ""%breast carcinoma%"" OR LOWER(efo_term) LIKE ""%breast carcinoma%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_927296', 'drugName': 'Cobimetinib', 'tradeNames_list': ""['Cotellic']"", 'syns_list': ""['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']"", 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_927365', 'drugName': 'Cobimetinib', 'tradeNames_list': ""['Cotellic']"", 'syns_list': ""['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']"", 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_927388', 'drugName': 'Cobimetinib', 'tradeNames_list': ""['Cotellic']"", 'syns_list': ""['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']"", 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_927411', 'drugName': 'Cobimetinib', 'tradeNames_list': ""['Cotellic']"", 'syns_list': ""['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']"", 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_927457', 'drugName': 'Cobimetinib', 'tradeNames_list': ""['Cotellic']"", 'syns_list': ""['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']"", 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_927480', 'drugName': 'Cobimetinib', 'tradeNames_list': ""['Cotellic']"", 'syns_list': ""['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']"", 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_927503', 'drugName': 'Cobimetinib', 'tradeNames_list': ""['Cotellic']"", 'syns_list': ""['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']"", 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_927549', 'drugName': 'Cobimetinib', 'tradeNames_list': ""['Cotellic']"", 'syns_list': ""['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']"", 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_927572', 'drugName': 'Cobimetinib', 'tradeNames_list': ""['Cotellic']"", 'syns_list': ""['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']"", 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_927595', 'drugName': 'Cobimetinib', 'tradeNames_list': ""['Cotellic']"", 'syns_list': ""['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']"", 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_927618', 'drugName': 'Cobimetinib', 'tradeNames_list': ""['Cotellic']"", 'syns_list': ""['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']"", 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_927664', 'drugName': 'Cobimetinib', 'tradeNames_list': ""['Cotellic']"", 'syns_list': ""['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']"", 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_927687', 'drugName': 'Cobimetinib', 'tradeNames_list': ""['Cotellic']"", 'syns_list': ""['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']"", 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_927710', 'drugName': 'Cobimetinib', 'tradeNames_list': ""['Cotellic']"", 'syns_list': ""['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']"", 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_927526', 'drugName': 'Cobimetinib', 'tradeNames_list': ""['Cotellic']"", 'syns_list': ""['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']"", 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_927342', 'drugName': 'Cobimetinib', 'tradeNames_list': ""['Cotellic']"", 'syns_list': ""['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']"", 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_927250', 'drugName': 'Cobimetinib', 'tradeNames_list': ""['Cotellic']"", 'syns_list': ""['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']"", 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_927204', 'drugName': 'Cobimetinib', 'tradeNames_list': ""['Cotellic']"", 'syns_list': ""['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']"", 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_927181', 'drugName': 'Cobimetinib', 'tradeNames_list': ""['Cotellic']"", 'syns_list': ""['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']"", 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_927641', 'drugName': 'Cobimetinib', 'tradeNames_list': ""['Cotellic']"", 'syns_list': ""['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']"", 'target': 'ENSG00000169032', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1', 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_927434', 'drugName': 'Cobimetinib', 'tradeNames_list': ""['Cotellic']"", 'syns_list': ""['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']"", 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_927319', 'drugName': 'Cobimetinib', 'tradeNames_list': ""['Cotellic']"", 'syns_list': ""['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']"", 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_927273', 'drugName': 'Cobimetinib', 'tradeNames_list': ""['Cotellic']"", 'syns_list': ""['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']"", 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_927227', 'drugName': 'Cobimetinib', 'tradeNames_list': ""['Cotellic']"", 'syns_list': ""['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']"", 'target': 'ENSG00000126934', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2', 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0}]",general,"Distinct, Order By, Similarity Search","Genetic Target, Approval Status"
-Q6.57,Q6,What genes does Umbralisib Tosylate target when it's used to treat marginal zone B-cell lymphoma?,"When used to treat marginal zone B-cell lymphoma, the drug Umbralisib Tosylate targets the genes ABL1, PIK3CD, and CSNK1E.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, target, approvedSymbol, approvedName, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%umbralisib tosylate%"" OR LOWER(tradeNames_list) LIKE ""%umbralisib tosylate%"" OR LOWER(syns_list) LIKE ""%umbralisib tosylate%"") AND (LOWER(mesh_heading) LIKE ""%marginal zone b-cell lymphoma%"" OR LOWER(efo_term) LIKE ""%marginal zone b-cell lymphoma%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_744696', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_744741', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_744756', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_744771', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_744801', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_744816', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_744831', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_744861', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_744876', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_744891', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_744906', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_744936', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_744951', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_744966', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_744981', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_744996', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_745011', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_745026', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_745041', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_745056', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_745071', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_745101', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_745116', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_745131', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_745146', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_745161', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_745191', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_745206', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_745221', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_745236', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_745251', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_745266', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_745281', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_745086', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_744846', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_744726', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_744666', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_744636', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_744621', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_745176', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000213923', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_744921', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_744786', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_744711', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_744681', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_744651', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': ""['Ukoniq']"", 'syns_list': ""['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']"", 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0}]",general,"Distinct, Order By, Similarity Search","Genetic Target, Approval Status"
-Q6.1293,Q6,What genes does Aripiprazole target when it's used to treat bipolar I disorder?,"When used to treat bipolar I disorder, the drug Aripiprazole targets the genes DRD2, HTR2A, and HTR1A.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, target, approvedSymbol, approvedName, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%aripiprazole%"" OR LOWER(tradeNames_list) LIKE ""%aripiprazole%"" OR LOWER(syns_list) LIKE ""%aripiprazole%"") AND (LOWER(mesh_heading) LIKE ""%bipolar i disorder%"" OR LOWER(efo_term) LIKE ""%bipolar i disorder%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_158029', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158047', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158053', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158059', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158071', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158077', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158083', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158095', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158101', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158107', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158113', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158125', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158131', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158137', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158143', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158149', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158155', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158161', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158167', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158173', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158179', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158191', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158197', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158203', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158209', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158215', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158227', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158233', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158239', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158245', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158251', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158257', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158263', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158269', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158275', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158281', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158287', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158293', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158299', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158305', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158311', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158317', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158323', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158329', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158335', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158341', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158347', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158353', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158359', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158365', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158371', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158383', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158389', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158395', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158401', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158407', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158413', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158425', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158431', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158437', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158443', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158449', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158455', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158461', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158467', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158473', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158479', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158485', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158491', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158497', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158503', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158509', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158515', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158521', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158527', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158533', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158539', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158545', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158551', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158557', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158563', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158569', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158575', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158581', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158587', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158593', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158377', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158185', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158089', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158041', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158017', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158005', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_157999', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158419', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000102468', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158221', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158119', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158065', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158035', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158023', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_158011', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': ""['Aristada', 'Aristada initio kit']"", 'syns_list': ""['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']"", 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0}]",general,"Distinct, Order By, Similarity Search","Genetic Target, Approval Status"
-Q6.1119,Q6,What genes does Amantadine Hydrochloride target when it's used to treat cerebral atherosclerosis?,"When used to treat cerebral atherosclerosis, the drug Amantadine Hydrochloride targets the genes GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3B, GRIN2C, and GRIN3A.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, target, approvedSymbol, approvedName, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%amantadine hydrochloride%"" OR LOWER(tradeNames_list) LIKE ""%amantadine hydrochloride%"" OR LOWER(syns_list) LIKE ""%amantadine hydrochloride%"") AND (LOWER(mesh_heading) LIKE ""%cerebral atherosclerosis%"" OR LOWER(efo_term) LIKE ""%cerebral atherosclerosis%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_441091', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441133', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441147', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441161', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441189', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441203', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441217', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441245', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441259', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441273', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441287', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441315', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441329', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441343', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441357', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441371', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441385', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441399', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441413', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441427', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441441', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441469', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441483', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441497', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441511', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441525', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441553', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441567', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441581', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441595', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441609', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441623', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441637', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441651', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441665', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441679', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441693', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441707', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441721', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441735', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441749', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441763', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441777', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441791', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441805', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441819', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441833', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441847', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441861', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441875', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441889', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441917', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441931', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441945', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441959', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441973', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441987', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_442015', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_442029', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_442043', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_442057', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_442071', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_442085', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_442099', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_442113', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_442127', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_442141', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_442155', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_442169', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_442183', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_442197', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_442211', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_442225', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_442239', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_442253', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_442267', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_442281', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_442295', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_442309', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_442323', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_442337', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_442351', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_442365', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_442379', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_442393', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_442407', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441903', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441455', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441231', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441119', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441063', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441035', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441021', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_442001', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441539', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441301', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441175', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441105', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441077', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_441049', 'drugName': 'Amantadine Hydrochloride', 'tradeNames_list': ""['Amantadine hydrochloride', 'Gocovri', 'Lysovir', 'Mantadine', 'Osmolex erSymadine', 'Symmetrel']"", 'syns_list': ""['Adamantanamine hydrochloride', 'Amantadine hclAmantadine hydrochloride', 'EXP-105-1', 'Mantadix', 'NSC-83653', 'Osmolex']"", 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'mesh_heading': 'Intracranial Arteriosclerosis', 'efo_term': 'cerebral atherosclerosis', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0}]",general,"Distinct, Order By, Similarity Search","Genetic Target, Approval Status"
-Q6.585,Q6,What genes does Thalidomide target when it's used to treat multiple myeloma?,"When used to treat multiple myeloma, the drug Thalidomide targets the genes CRBN, DDB1, CUL4A, and RBX1.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, target, approvedSymbol, approvedName, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%thalidomide%"" OR LOWER(tradeNames_list) LIKE ""%thalidomide%"" OR LOWER(syns_list) LIKE ""%thalidomide%"") AND (LOWER(mesh_heading) LIKE ""%multiple myeloma%"" OR LOWER(efo_term) LIKE ""%multiple myeloma%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_1105130', 'drugName': 'Thalidomide', 'tradeNames_list': ""['Talidex', 'Thalomid']"", 'syns_list': ""['.alpha.-phthalimidoglutarimide', 'Celgene', 'Contergan', 'Distaval', 'K-17Myrin', 'N-phthalylglutamic acid imide', 'NSC-527179', 'NSC-66847Neurosedyn', 'Pantosediv', 'Pharmion', 'Softenon', 'Thaled', 'ThalidomideThalidomide ']"", 'target': 'ENSG00000167986', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1', 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1105391', 'drugName': 'Thalidomide', 'tradeNames_list': ""['Talidex', 'Thalomid']"", 'syns_list': ""['.alpha.-phthalimidoglutarimide', 'Celgene', 'Contergan', 'Distaval', 'K-17Myrin', 'N-phthalylglutamic acid imide', 'NSC-527179', 'NSC-66847Neurosedyn', 'Pantosediv', 'Pharmion', 'Softenon', 'Thaled', 'ThalidomideThalidomide ']"", 'target': 'ENSG00000139842', 'approvedSymbol': 'CUL4A', 'approvedName': 'cullin 4A', 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1105478', 'drugName': 'Thalidomide', 'tradeNames_list': ""['Talidex', 'Thalomid']"", 'syns_list': ""['.alpha.-phthalimidoglutarimide', 'Celgene', 'Contergan', 'Distaval', 'K-17Myrin', 'N-phthalylglutamic acid imide', 'NSC-527179', 'NSC-66847Neurosedyn', 'Pantosediv', 'Pharmion', 'Softenon', 'Thaled', 'ThalidomideThalidomide ']"", 'target': 'ENSG00000100387', 'approvedSymbol': 'RBX1', 'approvedName': 'ring-box 1', 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1105565', 'drugName': 'Thalidomide', 'tradeNames_list': ""['Talidex', 'Thalomid']"", 'syns_list': ""['.alpha.-phthalimidoglutarimide', 'Celgene', 'Contergan', 'Distaval', 'K-17Myrin', 'N-phthalylglutamic acid imide', 'NSC-527179', 'NSC-66847Neurosedyn', 'Pantosediv', 'Pharmion', 'Softenon', 'Thaled', 'ThalidomideThalidomide ']"", 'target': 'ENSG00000100387', 'approvedSymbol': 'RBX1', 'approvedName': 'ring-box 1', 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1105304', 'drugName': 'Thalidomide', 'tradeNames_list': ""['Talidex', 'Thalomid']"", 'syns_list': ""['.alpha.-phthalimidoglutarimide', 'Celgene', 'Contergan', 'Distaval', 'K-17Myrin', 'N-phthalylglutamic acid imide', 'NSC-527179', 'NSC-66847Neurosedyn', 'Pantosediv', 'Pharmion', 'Softenon', 'Thaled', 'ThalidomideThalidomide ']"", 'target': 'ENSG00000139842', 'approvedSymbol': 'CUL4A', 'approvedName': 'cullin 4A', 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1104956', 'drugName': 'Thalidomide', 'tradeNames_list': ""['Talidex', 'Thalomid']"", 'syns_list': ""['.alpha.-phthalimidoglutarimide', 'Celgene', 'Contergan', 'Distaval', 'K-17Myrin', 'N-phthalylglutamic acid imide', 'NSC-527179', 'NSC-66847Neurosedyn', 'Pantosediv', 'Pharmion', 'Softenon', 'Thaled', 'ThalidomideThalidomide ']"", 'target': 'ENSG00000167986', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1', 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1104782', 'drugName': 'Thalidomide', 'tradeNames_list': ""['Talidex', 'Thalomid']"", 'syns_list': ""['.alpha.-phthalimidoglutarimide', 'Celgene', 'Contergan', 'Distaval', 'K-17Myrin', 'N-phthalylglutamic acid imide', 'NSC-527179', 'NSC-66847Neurosedyn', 'Pantosediv', 'Pharmion', 'Softenon', 'Thaled', 'ThalidomideThalidomide ']"", 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1104695', 'drugName': 'Thalidomide', 'tradeNames_list': ""['Talidex', 'Thalomid']"", 'syns_list': ""['.alpha.-phthalimidoglutarimide', 'Celgene', 'Contergan', 'Distaval', 'K-17Myrin', 'N-phthalylglutamic acid imide', 'NSC-527179', 'NSC-66847Neurosedyn', 'Pantosediv', 'Pharmion', 'Softenon', 'Thaled', 'ThalidomideThalidomide ']"", 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1105652', 'drugName': 'Thalidomide', 'tradeNames_list': ""['Talidex', 'Thalomid']"", 'syns_list': ""['.alpha.-phthalimidoglutarimide', 'Celgene', 'Contergan', 'Distaval', 'K-17Myrin', 'N-phthalylglutamic acid imide', 'NSC-527179', 'NSC-66847Neurosedyn', 'Pantosediv', 'Pharmion', 'Softenon', 'Thaled', 'ThalidomideThalidomide ']"", 'target': 'ENSG00000100387', 'approvedSymbol': 'RBX1', 'approvedName': 'ring-box 1', 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1105217', 'drugName': 'Thalidomide', 'tradeNames_list': ""['Talidex', 'Thalomid']"", 'syns_list': ""['.alpha.-phthalimidoglutarimide', 'Celgene', 'Contergan', 'Distaval', 'K-17Myrin', 'N-phthalylglutamic acid imide', 'NSC-527179', 'NSC-66847Neurosedyn', 'Pantosediv', 'Pharmion', 'Softenon', 'Thaled', 'ThalidomideThalidomide ']"", 'target': 'ENSG00000139842', 'approvedSymbol': 'CUL4A', 'approvedName': 'cullin 4A', 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1105043', 'drugName': 'Thalidomide', 'tradeNames_list': ""['Talidex', 'Thalomid']"", 'syns_list': ""['.alpha.-phthalimidoglutarimide', 'Celgene', 'Contergan', 'Distaval', 'K-17Myrin', 'N-phthalylglutamic acid imide', 'NSC-527179', 'NSC-66847Neurosedyn', 'Pantosediv', 'Pharmion', 'Softenon', 'Thaled', 'ThalidomideThalidomide ']"", 'target': 'ENSG00000167986', 'approvedSymbol': 'DDB1', 'approvedName': 'damage specific DNA binding protein 1', 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1104869', 'drugName': 'Thalidomide', 'tradeNames_list': ""['Talidex', 'Thalomid']"", 'syns_list': ""['.alpha.-phthalimidoglutarimide', 'Celgene', 'Contergan', 'Distaval', 'K-17Myrin', 'N-phthalylglutamic acid imide', 'NSC-527179', 'NSC-66847Neurosedyn', 'Pantosediv', 'Pharmion', 'Softenon', 'Thaled', 'ThalidomideThalidomide ']"", 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'mesh_heading': 'Multiple Myeloma', 'efo_term': 'multiple myeloma', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0}]",general,"Distinct, Order By, Similarity Search","Genetic Target, Approval Status"
-Q6.375,Q6,What genes does Dexamethasone target when it's used to treat metastasis?,"Dexamethasone has not been approved by the FDA as a treatment for metastasis, but it is currently undergoing evaluation in clinical trials for this purpose. The proposed gene target is NR3C1.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, target, approvedSymbol, approvedName, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%dexamethasone%"" OR LOWER(tradeNames_list) LIKE ""%dexamethasone%"" OR LOWER(syns_list) LIKE ""%dexamethasone%"") AND (LOWER(mesh_heading) LIKE ""%metastasis%"" OR LOWER(efo_term) LIKE ""%metastasis%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_230152', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_228442', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_230722', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_228157', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_226162', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_229297', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_231007', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_231292', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_228727', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_227017', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_229012', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_227302', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_227587', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_231577', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_229867', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_231862', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_230437', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_227872', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_229582', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_232147', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_226447', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_226732', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_226403', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0}, {'UUID': 'DrugTargetsIndication121923_text_227828', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0}, {'UUID': 'DrugTargetsIndication121923_text_229538', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0}, {'UUID': 'DrugTargetsIndication121923_text_229253', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0}, {'UUID': 'DrugTargetsIndication121923_text_230393', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0}, {'UUID': 'DrugTargetsIndication121923_text_229823', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0}, {'UUID': 'DrugTargetsIndication121923_text_226973', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0}, {'UUID': 'DrugTargetsIndication121923_text_230108', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0}, {'UUID': 'DrugTargetsIndication121923_text_226118', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0}, {'UUID': 'DrugTargetsIndication121923_text_227258', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0}, {'UUID': 'DrugTargetsIndication121923_text_228398', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0}, {'UUID': 'DrugTargetsIndication121923_text_230678', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0}, {'UUID': 'DrugTargetsIndication121923_text_230963', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0}, {'UUID': 'DrugTargetsIndication121923_text_228683', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0}, {'UUID': 'DrugTargetsIndication121923_text_231248', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0}, {'UUID': 'DrugTargetsIndication121923_text_231533', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0}, {'UUID': 'DrugTargetsIndication121923_text_226688', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0}, {'UUID': 'DrugTargetsIndication121923_text_227543', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0}, {'UUID': 'DrugTargetsIndication121923_text_228968', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0}, {'UUID': 'DrugTargetsIndication121923_text_231818', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0}, {'UUID': 'DrugTargetsIndication121923_text_232103', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0}, {'UUID': 'DrugTargetsIndication121923_text_228113', 'drugName': 'Dexamethasone', 'tradeNames_list': ""['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']"", 'syns_list': ""['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Meningeal Carcinomatosis', 'efo_term': 'leptomeningeal metastasis', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0}]",general,"Distinct, Order By, Similarity Search","Genetic Target, Approval Status"
-Q6.276,Q6,What genes does Metformin Hydrochloride target when it's used to treat ovarian serous cystadenocarcinoma?,"Metformin Hydrochloride has not been approved by the FDA as a treatment for ovarian serous cystadenocarcinoma, but it is currently undergoing evaluation in clinical trials for this purpose. The proposed gene targets are MT-ND6, NDUFA10, NDUFS8, MT-ND4L, NDUFA6, MT-ND1, NDUFB6, NDUFA4, NDUFA11, NDUFB7, MT-ND2, NDUFS2, MT-ND5, NDUFA8, NDUFB5, MT-ND4, MT-ND3, NDUFAB1, NDUFA1, NDUFS4, NDUFB3, NDUFC1, NDUFA2, NDUFS5, NDUFS7, NDUFS6, NDUFB1, NDUFS3, NDUFA3, NDUFB4, NDUFB8, NDUFB2, NDUFA7, NDUFC2, NDUFB10, NDUFV2, NDUFS1, NDUFV1, NDUFV3, NDUFA5, NDUFA9, NDUFAF2, NDUFAF3, NDUFA4L2, NDUFB11, NDUFAF4, NDUFA13, NDUFA12, NDUFAF1, NDUFB9, and GPD2.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, target, approvedSymbol, approvedName, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%metformin hydrochloride%"" OR LOWER(tradeNames_list) LIKE ""%metformin hydrochloride%"" OR LOWER(syns_list) LIKE ""%metformin hydrochloride%"") AND (LOWER(mesh_heading) LIKE ""%ovarian serous cystadenocarcinoma%"" OR LOWER(efo_term) LIKE ""%ovarian serous cystadenocarcinoma%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_1149695', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000198695', 'approvedSymbol': 'MT-ND6', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1149803', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000198695', 'approvedSymbol': 'MT-ND6', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1149839', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000198695', 'approvedSymbol': 'MT-ND6', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1149875', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000198695', 'approvedSymbol': 'MT-ND6', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1149947', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000198695', 'approvedSymbol': 'MT-ND6', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1149983', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000198695', 'approvedSymbol': 'MT-ND6', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1150019', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000198695', 'approvedSymbol': 'MT-ND6', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1150091', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000198695', 'approvedSymbol': 'MT-ND6', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1150127', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000198695', 'approvedSymbol': 'MT-ND6', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1150163', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000198695', 'approvedSymbol': 'MT-ND6', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1150199', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000198695', 'approvedSymbol': 'MT-ND6', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1150271', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000198695', 'approvedSymbol': 'MT-ND6', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1150307', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000198695', 'approvedSymbol': 'MT-ND6', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1150343', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000130414', 'approvedSymbol': 'NDUFA10', 'approvedName': 'NADH:ubiquinone oxidoreductase subunit A10', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1150379', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000130414', 'approvedSymbol': 'NDUFA10', 'approvedName': 'NADH:ubiquinone oxidoreductase subunit A10', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1150415', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000130414', 'approvedSymbol': 'NDUFA10', 'approvedName': 'NADH:ubiquinone oxidoreductase subunit A10', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1150451', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000130414', 'approvedSymbol': 'NDUFA10', 'approvedName': 'NADH:ubiquinone oxidoreductase subunit A10', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1150487', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000130414', 'approvedSymbol': 'NDUFA10', 'approvedName': 'NADH:ubiquinone oxidoreductase subunit A10', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1150523', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000130414', 'approvedSymbol': 'NDUFA10', 'approvedName': 'NADH:ubiquinone oxidoreductase subunit A10', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1150559', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000130414', 'approvedSymbol': 'NDUFA10', 'approvedName': 'NADH:ubiquinone oxidoreductase subunit A10', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1150595', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000130414', 'approvedSymbol': 'NDUFA10', 'approvedName': 'NADH:ubiquinone oxidoreductase subunit A10', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1150667', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000130414', 'approvedSymbol': 'NDUFA10', 'approvedName': 'NADH:ubiquinone oxidoreductase subunit A10', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1150703', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000130414', 'approvedSymbol': 'NDUFA10', 'approvedName': 'NADH:ubiquinone oxidoreductase subunit A10', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1150739', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000130414', 'approvedSymbol': 'NDUFA10', 'approvedName': 'NADH:ubiquinone oxidoreductase subunit A10', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1150775', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000130414', 'approvedSymbol': 'NDUFA10', 'approvedName': 'NADH:ubiquinone oxidoreductase subunit A10', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1150811', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000130414', 'approvedSymbol': 'NDUFA10', 'approvedName': 'NADH:ubiquinone oxidoreductase subunit A10', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1150883', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000130414', 'approvedSymbol': 'NDUFA10', 'approvedName': 'NADH:ubiquinone oxidoreductase subunit A10', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1150919', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000130414', 'approvedSymbol': 'NDUFA10', 'approvedName': 'NADH:ubiquinone oxidoreductase subunit A10', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1150955', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000130414', 'approvedSymbol': 'NDUFA10', 'approvedName': 'NADH:ubiquinone oxidoreductase subunit A10', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1150991', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000130414', 'approvedSymbol': 'NDUFA10', 'approvedName': 'NADH:ubiquinone oxidoreductase subunit A10', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1151027', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000130414', 'approvedSymbol': 'NDUFA10', 'approvedName': 'NADH:ubiquinone oxidoreductase subunit A10', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1151063', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000130414', 'approvedSymbol': 'NDUFA10', 'approvedName': 'NADH:ubiquinone oxidoreductase subunit A10', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1151099', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000130414', 'approvedSymbol': 'NDUFA10', 'approvedName': 'NADH:ubiquinone oxidoreductase subunit A10', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1151135', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000130414', 'approvedSymbol': 'NDUFA10', 'approvedName': 'NADH:ubiquinone oxidoreductase subunit A10', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1151171', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000110717', 'approvedSymbol': 'NDUFS8', 'approvedName': 'NADH:ubiquinone oxidoreductase core subunit S8', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1151207', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000110717', 'approvedSymbol': 'NDUFS8', 'approvedName': 'NADH:ubiquinone oxidoreductase core subunit S8', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1151243', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000110717', 'approvedSymbol': 'NDUFS8', 'approvedName': 'NADH:ubiquinone oxidoreductase core subunit S8', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1151279', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000110717', 'approvedSymbol': 'NDUFS8', 'approvedName': 'NADH:ubiquinone oxidoreductase core subunit S8', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1151315', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000110717', 'approvedSymbol': 'NDUFS8', 'approvedName': 'NADH:ubiquinone oxidoreductase core subunit S8', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1151351', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000110717', 'approvedSymbol': 'NDUFS8', 'approvedName': 'NADH:ubiquinone oxidoreductase core subunit S8', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1151387', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000110717', 'approvedSymbol': 'NDUFS8', 'approvedName': 'NADH:ubiquinone oxidoreductase core subunit S8', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1151423', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000110717', 'approvedSymbol': 'NDUFS8', 'approvedName': 'NADH:ubiquinone oxidoreductase core subunit S8', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1151459', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000110717', 'approvedSymbol': 'NDUFS8', 'approvedName': 'NADH:ubiquinone oxidoreductase core subunit S8', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1151495', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000110717', 'approvedSymbol': 'NDUFS8', 'approvedName': 'NADH:ubiquinone oxidoreductase core subunit S8', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1151531', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000110717', 'approvedSymbol': 'NDUFS8', 'approvedName': 'NADH:ubiquinone oxidoreductase core subunit S8', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1151567', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000110717', 'approvedSymbol': 'NDUFS8', 'approvedName': 'NADH:ubiquinone oxidoreductase core subunit S8', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1151603', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000110717', 'approvedSymbol': 'NDUFS8', 'approvedName': 'NADH:ubiquinone oxidoreductase core subunit S8', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1151639', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000110717', 'approvedSymbol': 'NDUFS8', 'approvedName': 'NADH:ubiquinone oxidoreductase core subunit S8', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1151675', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000110717', 'approvedSymbol': 'NDUFS8', 'approvedName': 'NADH:ubiquinone oxidoreductase core subunit S8', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1151711', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000110717', 'approvedSymbol': 'NDUFS8', 'approvedName': 'NADH:ubiquinone oxidoreductase core subunit S8', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1151747', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000110717', 'approvedSymbol': 'NDUFS8', 'approvedName': 'NADH:ubiquinone oxidoreductase core subunit S8', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1151819', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000110717', 'approvedSymbol': 'NDUFS8', 'approvedName': 'NADH:ubiquinone oxidoreductase core subunit S8', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1151855', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000110717', 'approvedSymbol': 'NDUFS8', 'approvedName': 'NADH:ubiquinone oxidoreductase core subunit S8', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1151891', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000110717', 'approvedSymbol': 'NDUFS8', 'approvedName': 'NADH:ubiquinone oxidoreductase core subunit S8', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1151927', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000110717', 'approvedSymbol': 'NDUFS8', 'approvedName': 'NADH:ubiquinone oxidoreductase core subunit S8', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1151963', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000110717', 'approvedSymbol': 'NDUFS8', 'approvedName': 'NADH:ubiquinone oxidoreductase core subunit S8', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1151999', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000212907', 'approvedSymbol': 'MT-ND4L', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1152071', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000212907', 'approvedSymbol': 'MT-ND4L', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1152107', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000212907', 'approvedSymbol': 'MT-ND4L', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1152143', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000212907', 'approvedSymbol': 'MT-ND4L', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1152179', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000212907', 'approvedSymbol': 'MT-ND4L', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1152215', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000212907', 'approvedSymbol': 'MT-ND4L', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1152251', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000212907', 'approvedSymbol': 'MT-ND4L', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1152287', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000212907', 'approvedSymbol': 'MT-ND4L', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1152323', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000212907', 'approvedSymbol': 'MT-ND4L', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1152359', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000212907', 'approvedSymbol': 'MT-ND4L', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1152395', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000212907', 'approvedSymbol': 'MT-ND4L', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1152431', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000212907', 'approvedSymbol': 'MT-ND4L', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1152467', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000212907', 'approvedSymbol': 'MT-ND4L', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1152503', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000212907', 'approvedSymbol': 'MT-ND4L', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1152539', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000212907', 'approvedSymbol': 'MT-ND4L', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1152575', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000212907', 'approvedSymbol': 'MT-ND4L', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1152611', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000212907', 'approvedSymbol': 'MT-ND4L', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1152647', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000212907', 'approvedSymbol': 'MT-ND4L', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1152683', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000212907', 'approvedSymbol': 'MT-ND4L', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1152719', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000212907', 'approvedSymbol': 'MT-ND4L', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1152755', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000212907', 'approvedSymbol': 'MT-ND4L', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1152791', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000212907', 'approvedSymbol': 'MT-ND4L', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1152827', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000184983', 'approvedSymbol': 'NDUFA6', 'approvedName': 'NADH:ubiquinone oxidoreductase subunit A6', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1152863', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000184983', 'approvedSymbol': 'NDUFA6', 'approvedName': 'NADH:ubiquinone oxidoreductase subunit A6', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1152899', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000184983', 'approvedSymbol': 'NDUFA6', 'approvedName': 'NADH:ubiquinone oxidoreductase subunit A6', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1152935', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000184983', 'approvedSymbol': 'NDUFA6', 'approvedName': 'NADH:ubiquinone oxidoreductase subunit A6', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1152971', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000184983', 'approvedSymbol': 'NDUFA6', 'approvedName': 'NADH:ubiquinone oxidoreductase subunit A6', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1153007', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000184983', 'approvedSymbol': 'NDUFA6', 'approvedName': 'NADH:ubiquinone oxidoreductase subunit A6', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1153043', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000184983', 'approvedSymbol': 'NDUFA6', 'approvedName': 'NADH:ubiquinone oxidoreductase subunit A6', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1153079', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000184983', 'approvedSymbol': 'NDUFA6', 'approvedName': 'NADH:ubiquinone oxidoreductase subunit A6', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1151783', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000110717', 'approvedSymbol': 'NDUFS8', 'approvedName': 'NADH:ubiquinone oxidoreductase core subunit S8', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1150631', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000130414', 'approvedSymbol': 'NDUFA10', 'approvedName': 'NADH:ubiquinone oxidoreductase subunit A10', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1150055', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000198695', 'approvedSymbol': 'MT-ND6', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1149767', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000198695', 'approvedSymbol': 'MT-ND6', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1149623', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000198695', 'approvedSymbol': 'MT-ND6', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1149551', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000198695', 'approvedSymbol': 'MT-ND6', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1149515', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000198695', 'approvedSymbol': 'MT-ND6', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1152035', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000212907', 'approvedSymbol': 'MT-ND4L', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1150847', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000130414', 'approvedSymbol': 'NDUFA10', 'approvedName': 'NADH:ubiquinone oxidoreductase subunit A10', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1150235', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000198695', 'approvedSymbol': 'MT-ND6', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1149911', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000198695', 'approvedSymbol': 'MT-ND6', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1149731', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000198695', 'approvedSymbol': 'MT-ND6', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1149659', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000198695', 'approvedSymbol': 'MT-ND6', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1149587', 'drugName': 'Metformin Hydrochloride', 'tradeNames_list': ""['Bolamyn sr', 'Diagemet xl', 'Fortamet', 'Glucamet 500', 'Glucamet 850Glucient sr', 'Glucophage', 'Glucophage sr', 'Glucophage xr', 'GlumetzaGlyformin', 'Janumet', 'Ledermetin', 'Metabet sr', 'Metformin hydrochlorideMetsol', 'Milform', 'Orabet', 'Riomet', 'Riomet er', 'Sukkarto sr']"", 'syns_list': ""['Apophage', 'Benofomin', 'Diabefagos', 'Diabex', 'EX-404', 'EX404Glucaminol', 'LA-6023', 'Metformin hcl', 'Metformin hydrochlorideNSC-91485', 'Neodipa', 'Siamformet', 'Walaphage']"", 'target': 'ENSG00000198695', 'approvedSymbol': 'MT-ND6', 'approvedName': 'mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6', 'mesh_heading': 'Cystadenoma, Serous', 'efo_term': 'ovarian serous cystadenocarcinoma', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 2.0}]",general,"Distinct, Order By, Similarity Search","Genetic Target, Approval Status"
-Q65.1861,Q65,"What type of molecule is Afacifenacin, and what is its action type?",Afacifenacin is a small molecule drug that acts as an blocker and a antagonist.,"SELECT DISTINCT UUID, drugName, drugSynonyms_string, tradeNames_string, drugMolecularType, drugActionType
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%afacifenacin%"" OR LOWER(tradeNames_string) LIKE ""%afacifenacin%"" OR LOWER(drugSynonyms_string) LIKE ""%afacifenacin%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3100', 'drugName': 'Afacifenacin', 'drugSynonyms_string': 'Afacifenacin, NS-986, Smp-986', 'tradeNames_string': '', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker'}, {'UUID': 'DrugGeneTargets_v2_3101', 'drugName': 'Afacifenacin', 'drugSynonyms_string': 'Afacifenacin, NS-986, Smp-986', 'tradeNames_string': '', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker'}, {'UUID': 'DrugGeneTargets_v2_3102', 'drugName': 'Afacifenacin', 'drugSynonyms_string': 'Afacifenacin, NS-986, Smp-986', 'tradeNames_string': '', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist'}]",general,"Distinct, Similarity Search",Metadata
-Q65.354,Q65,"What type of molecule is Selitrectinib, and what is its action type?",Selitrectinib is a small molecule drug that acts as an inhibitor.,"SELECT DISTINCT UUID, drugName, drugSynonyms_string, tradeNames_string, drugMolecularType, drugActionType
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%selitrectinib%"" OR LOWER(tradeNames_string) LIKE ""%selitrectinib%"" OR LOWER(drugSynonyms_string) LIKE ""%selitrectinib%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_5066', 'drugName': 'Selitrectinib', 'drugSynonyms_string': 'LOXO-195, Loxo-195, Selitrectinib', 'tradeNames_string': '', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor'}]",general,"Distinct, Similarity Search",Metadata
-Q65.1334,Q65,"What type of molecule is Alcuronium, and what is its action type?",Alcuronium is a small molecule drug that acts as an positive allosteric modulator.,"SELECT DISTINCT UUID, drugName, drugSynonyms_string, tradeNames_string, drugMolecularType, drugActionType
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%alcuronium%"" OR LOWER(tradeNames_string) LIKE ""%alcuronium%"" OR LOWER(drugSynonyms_string) LIKE ""%alcuronium%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_4023', 'drugName': 'Alcuronium', 'drugSynonyms_string': ""Alcuronium, Alcuronium cation, Alcuronium ion, Diallylnortoxiferine, N,n'-diallylnortoxiferinium"", 'tradeNames_string': '', 'drugMolecularType': 'Small molecule', 'drugActionType': 'positive allosteric modulator'}]",general,"Distinct, Similarity Search",Metadata
-Q65.906,Q65,"What type of molecule is Cariprazine, and what is its action type?",Cariprazine is a small molecule drug that acts as an modulator.,"SELECT DISTINCT UUID, drugName, drugSynonyms_string, tradeNames_string, drugMolecularType, drugActionType
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%cariprazine%"" OR LOWER(tradeNames_string) LIKE ""%cariprazine%"" OR LOWER(drugSynonyms_string) LIKE ""%cariprazine%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_4947', 'drugName': 'Cariprazine Hydrochloride', 'drugSynonyms_string': 'Cariprazine hcl, Cariprazine hydrochloride, RGH-188 HCL', 'tradeNames_string': 'Vraylar', 'drugMolecularType': 'Small molecule', 'drugActionType': 'modulator'}, {'UUID': 'DrugGeneTargets_v2_4948', 'drugName': 'Cariprazine Hydrochloride', 'drugSynonyms_string': 'Cariprazine hcl, Cariprazine hydrochloride, RGH-188 HCL', 'tradeNames_string': 'Vraylar', 'drugMolecularType': 'Small molecule', 'drugActionType': 'modulator'}, {'UUID': 'DrugGeneTargets_v2_1240', 'drugName': 'Cariprazine', 'drugSynonyms_string': 'Cariprazine, Fri-7000188, GED-129, MP-214, RGH-188', 'tradeNames_string': 'Reagila', 'drugMolecularType': 'Small molecule', 'drugActionType': 'modulator'}, {'UUID': 'DrugGeneTargets_v2_1241', 'drugName': 'Cariprazine', 'drugSynonyms_string': 'Cariprazine, Fri-7000188, GED-129, MP-214, RGH-188', 'tradeNames_string': 'Reagila', 'drugMolecularType': 'Small molecule', 'drugActionType': 'modulator'}]",general,"Distinct, Similarity Search",Metadata
-Q65.1290,Q65,"What type of molecule is Rg-7376, and what is its action type?",Rg-7376 is a small molecule drug that acts as an inhibitor.,"SELECT DISTINCT UUID, drugName, drugSynonyms_string, tradeNames_string, drugMolecularType, drugActionType
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%rg-7376%"" OR LOWER(tradeNames_string) LIKE ""%rg-7376%"" OR LOWER(drugSynonyms_string) LIKE ""%rg-7376%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_4205', 'drugName': 'Rg-7376', 'drugSynonyms_string': 'PLX-5568, Rg-7376', 'tradeNames_string': '', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor'}]",general,"Distinct, Similarity Search",Metadata
-Q65.1274,Q65,"What type of molecule is Idecabtagene Vicleucel, and what is its action type?",Idecabtagene Vicleucel is a gene drug that acts as an binding agent.,"SELECT DISTINCT UUID, drugName, drugSynonyms_string, tradeNames_string, drugMolecularType, drugActionType
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%idecabtagene vicleucel%"" OR LOWER(tradeNames_string) LIKE ""%idecabtagene vicleucel%"" OR LOWER(drugSynonyms_string) LIKE ""%idecabtagene vicleucel%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_5007', 'drugName': 'Idecabtagene Vicleucel', 'drugSynonyms_string': 'Anti-bcma car t cell, BB-2121, Ide-cel, Idecabtagene vicleucel, bb2121', 'tradeNames_string': '', 'drugMolecularType': 'Gene', 'drugActionType': 'binding agent'}]",general,"Distinct, Similarity Search",Metadata
-Q65.939,Q65,"What type of molecule is Ssr180711, and what is its action type?",Ssr180711 is a small molecule drug that acts as an partial agonist.,"SELECT DISTINCT UUID, drugName, drugSynonyms_string, tradeNames_string, drugMolecularType, drugActionType
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%ssr180711%"" OR LOWER(tradeNames_string) LIKE ""%ssr180711%"" OR LOWER(drugSynonyms_string) LIKE ""%ssr180711%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_5403', 'drugName': 'Ssr180711', 'drugSynonyms_string': 'J2.849.107G, SSR-180,711, SSR-180711, SSR180711C, Ssr180711', 'tradeNames_string': '', 'drugMolecularType': 'Small molecule', 'drugActionType': 'partial agonist'}]",general,"Distinct, Similarity Search",Metadata
-Q65.1732,Q65,"What type of molecule is Ensifentrine, and what is its action type?",Ensifentrine is a small molecule drug that acts as an inhibitor.,"SELECT DISTINCT UUID, drugName, drugSynonyms_string, tradeNames_string, drugMolecularType, drugActionType
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%ensifentrine%"" OR LOWER(tradeNames_string) LIKE ""%ensifentrine%"" OR LOWER(drugSynonyms_string) LIKE ""%ensifentrine%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_4823', 'drugName': 'Ensifentrine', 'drugSynonyms_string': 'Ensifentrine, Ls-193,855, Ls-193855, RPL-554, RPL554', 'tradeNames_string': '', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor'}, {'UUID': 'DrugGeneTargets_v2_4824', 'drugName': 'Ensifentrine', 'drugSynonyms_string': 'Ensifentrine, Ls-193,855, Ls-193855, RPL-554, RPL554', 'tradeNames_string': '', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor'}]",general,"Distinct, Similarity Search",Metadata
-Q65.66,Q65,"What type of molecule is Quetiapine Fumarate, and what is its action type?",Quetiapine Fumarate is a small molecule drug that acts as an antagonist.,"SELECT DISTINCT UUID, drugName, drugSynonyms_string, tradeNames_string, drugMolecularType, drugActionType
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%quetiapine fumarate%"" OR LOWER(tradeNames_string) LIKE ""%quetiapine fumarate%"" OR LOWER(drugSynonyms_string) LIKE ""%quetiapine fumarate%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_4441', 'drugName': 'Quetiapine Fumarate', 'drugSynonyms_string': 'FK-947E, FK947E, ICI 204,636, ICI-204636, Quetiapine (as fumarate), Quetiapine fumarate, Quetiapine hemifumarate, Utapine, ZD-5077, ZD5077, ZM 204,636, ZM-204636', 'tradeNames_string': 'Quetiapine fumarate, Seroquel, Seroquel xr', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist'}, {'UUID': 'DrugGeneTargets_v2_4442', 'drugName': 'Quetiapine Fumarate', 'drugSynonyms_string': 'FK-947E, FK947E, ICI 204,636, ICI-204636, Quetiapine (as fumarate), Quetiapine fumarate, Quetiapine hemifumarate, Utapine, ZD-5077, ZD5077, ZM 204,636, ZM-204636', 'tradeNames_string': 'Quetiapine fumarate, Seroquel, Seroquel xr', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist'}, {'UUID': 'DrugGeneTargets_v2_4443', 'drugName': 'Quetiapine Fumarate', 'drugSynonyms_string': 'FK-947E, FK947E, ICI 204,636, ICI-204636, Quetiapine (as fumarate), Quetiapine fumarate, Quetiapine hemifumarate, Utapine, ZD-5077, ZD5077, ZM 204,636, ZM-204636', 'tradeNames_string': 'Quetiapine fumarate, Seroquel, Seroquel xr', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist'}]",general,"Distinct, Similarity Search",Metadata
-Q65.1324,Q65,"What type of molecule is Decoglurant, and what is its action type?",Decoglurant is a small molecule drug that acts as an modulator.,"SELECT DISTINCT UUID, drugName, drugSynonyms_string, tradeNames_string, drugMolecularType, drugActionType
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%decoglurant%"" OR LOWER(tradeNames_string) LIKE ""%decoglurant%"" OR LOWER(drugSynonyms_string) LIKE ""%decoglurant%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_6286', 'drugName': 'Decoglurant', 'drugSynonyms_string': 'Decoglurant, RO-4995819, RO4995819, Rg1578', 'tradeNames_string': '', 'drugMolecularType': 'Small molecule', 'drugActionType': 'modulator'}, {'UUID': 'DrugGeneTargets_v2_6287', 'drugName': 'Decoglurant', 'drugSynonyms_string': 'Decoglurant, RO-4995819, RO4995819, Rg1578', 'tradeNames_string': '', 'drugMolecularType': 'Small molecule', 'drugActionType': 'modulator'}]",general,"Distinct, Similarity Search",Metadata
-Q65.57,Q65,"What type of molecule is Prednisolone Phosphoric Acid, and what is its action type?",Prednisolone Phosphoric Acid is a small molecule drug that acts as an agonist.,"SELECT DISTINCT UUID, drugName, drugSynonyms_string, tradeNames_string, drugMolecularType, drugActionType
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%prednisolone phosphoric acid%"" OR LOWER(tradeNames_string) LIKE ""%prednisolone phosphoric acid%"" OR LOWER(drugSynonyms_string) LIKE ""%prednisolone phosphoric acid%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_5936', 'drugName': 'Prednisolone Phosphoric Acid', 'drugSynonyms_string': 'Prednisolone phosphate, Prednisolone phosphoric acid', 'tradeNames_string': '', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist'}]",general,"Distinct, Similarity Search",Metadata
-Q65.1293,Q65,"What type of molecule is Apilimod, and what is its action type?",Apilimod is a small molecule drug that acts as an inhibitor.,"SELECT DISTINCT UUID, drugName, drugSynonyms_string, tradeNames_string, drugMolecularType, drugActionType
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%apilimod%"" OR LOWER(tradeNames_string) LIKE ""%apilimod%"" OR LOWER(drugSynonyms_string) LIKE ""%apilimod%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_4483', 'drugName': 'Apilimod', 'drugSynonyms_string': 'Apilimod, STA 5326, STA-5326, Sta-5326', 'tradeNames_string': '', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor'}, {'UUID': 'DrugGeneTargets_v2_1384', 'drugName': 'Apilimod Mesylate', 'drugSynonyms_string': 'Apilimod bis-mesylate, Apilimod dimesylate, Apilimod mesilate, Apilimod mesylate, STA 5326 MESYLATE, STA-5326 MESYLATE, Sta 5326 mesilate, Sta 5326 mesylate, Sta-5326 mesilate, Sta-5326 mesylate', 'tradeNames_string': '', 'drugMolecularType': 'Unknown', 'drugActionType': 'inhibitor'}]",general,"Distinct, Similarity Search",Metadata
-Q65.1119,Q65,"What type of molecule is Oxyphenonium Bromide, and what is its action type?",Oxyphenonium Bromide is a small molecule drug that acts as an antagonist.,"SELECT DISTINCT UUID, drugName, drugSynonyms_string, tradeNames_string, drugMolecularType, drugActionType
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%oxyphenonium bromide%"" OR LOWER(tradeNames_string) LIKE ""%oxyphenonium bromide%"" OR LOWER(drugSynonyms_string) LIKE ""%oxyphenonium bromide%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_1163', 'drugName': 'Oxyphenonium Bromide', 'drugSynonyms_string': 'Antrenil, BA-5473, C-5473, NSC-759248, Oxifenon, Oxyfenon, Oxyphenon, Oxyphenonium bromide, Spasmodin, Spasmophen', 'tradeNames_string': 'Antrenyl', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist'}, {'UUID': 'DrugGeneTargets_v2_1164', 'drugName': 'Oxyphenonium Bromide', 'drugSynonyms_string': 'Antrenil, BA-5473, C-5473, NSC-759248, Oxifenon, Oxyfenon, Oxyphenon, Oxyphenonium bromide, Spasmodin, Spasmophen', 'tradeNames_string': 'Antrenyl', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist'}]",general,"Distinct, Similarity Search",Metadata
-Q65.585,Q65,"What type of molecule is Trospium, and what is its action type?",Trospium is a small molecule drug that acts as an antagonist.,"SELECT DISTINCT UUID, drugName, drugSynonyms_string, tradeNames_string, drugMolecularType, drugActionType
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%trospium%"" OR LOWER(tradeNames_string) LIKE ""%trospium%"" OR LOWER(drugSynonyms_string) LIKE ""%trospium%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_6080', 'drugName': 'Trospium', 'drugSynonyms_string': 'Trospium, Trospium cation, Trospium ion', 'tradeNames_string': '', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist'}, {'UUID': 'DrugGeneTargets_v2_6081', 'drugName': 'Trospium', 'drugSynonyms_string': 'Trospium, Trospium cation, Trospium ion', 'tradeNames_string': '', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist'}, {'UUID': 'DrugGeneTargets_v2_4683', 'drugName': 'Trospium Chloride', 'drugSynonyms_string': 'IP-631, IP631, Relaspium, Spasmex, Spasmolyt, Trospium chloride', 'tradeNames_string': 'Flotros, Regurin, Regurin xl, Sanctura, Sanctura xr, Spasmo-lyt, Trospium chloride, Uraplex', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist'}, {'UUID': 'DrugGeneTargets_v2_4684', 'drugName': 'Trospium Chloride', 'drugSynonyms_string': 'IP-631, IP631, Relaspium, Spasmex, Spasmolyt, Trospium chloride', 'tradeNames_string': 'Flotros, Regurin, Regurin xl, Sanctura, Sanctura xr, Spasmo-lyt, Trospium chloride, Uraplex', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist'}]",general,"Distinct, Similarity Search",Metadata
-Q65.375,Q65,"What type of molecule is Rg-1530, and what is its action type?",Rg-1530 is a small molecule drug that acts as an inhibitor.,"SELECT DISTINCT UUID, drugName, drugSynonyms_string, tradeNames_string, drugMolecularType, drugActionType
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%rg-1530%"" OR LOWER(tradeNames_string) LIKE ""%rg-1530%"" OR LOWER(drugSynonyms_string) LIKE ""%rg-1530%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2525', 'drugName': 'Rg-1530', 'drugSynonyms_string': 'R-1530, RG-1530, Rg-1530', 'tradeNames_string': '', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor'}, {'UUID': 'DrugGeneTargets_v2_2526', 'drugName': 'Rg-1530', 'drugSynonyms_string': 'R-1530, RG-1530, Rg-1530', 'tradeNames_string': '', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor'}, {'UUID': 'DrugGeneTargets_v2_2527', 'drugName': 'Rg-1530', 'drugSynonyms_string': 'R-1530, RG-1530, Rg-1530', 'tradeNames_string': '', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor'}, {'UUID': 'DrugGeneTargets_v2_2528', 'drugName': 'Rg-1530', 'drugSynonyms_string': 'R-1530, RG-1530, Rg-1530', 'tradeNames_string': '', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor'}, {'UUID': 'DrugGeneTargets_v2_2529', 'drugName': 'Rg-1530', 'drugSynonyms_string': 'R-1530, RG-1530, Rg-1530', 'tradeNames_string': '', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor'}, {'UUID': 'DrugGeneTargets_v2_2530', 'drugName': 'Rg-1530', 'drugSynonyms_string': 'R-1530, RG-1530, Rg-1530', 'tradeNames_string': '', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor'}, {'UUID': 'DrugGeneTargets_v2_2531', 'drugName': 'Rg-1530', 'drugSynonyms_string': 'R-1530, RG-1530, Rg-1530', 'tradeNames_string': '', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor'}]",general,"Distinct, Similarity Search",Metadata
-Q65.276,Q65,"What type of molecule is Clotiazepam, and what is its action type?",Clotiazepam is a small molecule drug that acts as an positive allosteric modulator.,"SELECT DISTINCT UUID, drugName, drugSynonyms_string, tradeNames_string, drugMolecularType, drugActionType
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%clotiazepam%"" OR LOWER(tradeNames_string) LIKE ""%clotiazepam%"" OR LOWER(drugSynonyms_string) LIKE ""%clotiazepam%"")
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_6147', 'drugName': 'Clotiazepam', 'drugSynonyms_string': 'Clotiazepam', 'tradeNames_string': 'Clozan', 'drugMolecularType': 'Small molecule', 'drugActionType': 'positive allosteric modulator'}]",general,"Distinct, Similarity Search",Metadata
-Q3.1861,Q3,What is the allele frequency of the SNP rs192839900 in an Alzheimer's disease study within a European cohort?,"According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs192839900 has an effect allele A frequency of 0.0089 and non-effect allele G frequency of 0.9911.","SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs192839900'
- LIMIT 1","[{'UUID': 'AD_combo_gene_notext_UUID_19911375', 'SNP': 'rs192839900', 'effect_allele': 'A', 'effect_allele_frequency': 0.0089, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.9911}]",general,"Select, Calculate",Allele Frequency
-Q3.354,Q3,What is the allele frequency of the SNP rs77673442 in an Alzheimer's disease study within a European cohort?,"According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs77673442 has an effect allele C frequency of 0.0519 and non-effect allele G frequency of 0.9481.","SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs77673442'
- LIMIT 1","[{'UUID': 'AD_combo_gene_notext_UUID_3510607', 'SNP': 'rs77673442', 'effect_allele': 'C', 'effect_allele_frequency': 0.0519, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.9480999999999999}]",general,"Select, Calculate",Allele Frequency
-Q3.1334,Q3,What is the allele frequency of the SNP rs11229914 in an Alzheimer's disease study within a European cohort?,"According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs11229914 has an effect allele A frequency of 0.2644 and non-effect allele G frequency of 0.7356.","SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs11229914'
- LIMIT 1","[{'UUID': 'AD_combo_gene_notext_UUID_14135087', 'SNP': 'rs11229914', 'effect_allele': 'A', 'effect_allele_frequency': 0.2644, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.7356}]",general,"Select, Calculate",Allele Frequency
-Q3.906,Q3,What is the allele frequency of the SNP rs150962724 in an Alzheimer's disease study within a European cohort?,"According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs150962724 has an effect allele A frequency of 0.0011 and non-effect allele G frequency of 0.9989.","SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs150962724'
- LIMIT 1","[{'UUID': 'AD_combo_gene_notext_UUID_9725575', 'SNP': 'rs150962724', 'effect_allele': 'A', 'effect_allele_frequency': 0.0011, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.9989}]",general,"Select, Calculate",Allele Frequency
-Q3.1290,Q3,What is the allele frequency of the SNP rs35206234 in an Alzheimer's disease study within a European cohort?,"According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs35206234 has an effect allele G frequency of 0.0719 and non-effect allele T frequency of 0.9281.","SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs35206234'
- LIMIT 1","[{'UUID': 'AD_combo_gene_notext_UUID_13638264', 'SNP': 'rs35206234', 'effect_allele': 'G', 'effect_allele_frequency': 0.0718999999999999, 'non_effect_allele': 'T', 'non_effect_allele_frequency': 0.9281000000000001}]",general,"Select, Calculate",Allele Frequency
-Q3.1274,Q3,What is the allele frequency of the SNP rs114812682 in an Alzheimer's disease study within a European cohort?,"According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs114812682 has an effect allele G frequency of 0.001 and non-effect allele A frequency of 0.999.","SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs114812682'
- LIMIT 1","[{'UUID': 'AD_combo_gene_notext_UUID_13522480', 'SNP': 'rs114812682', 'effect_allele': 'G', 'effect_allele_frequency': 0.001, 'non_effect_allele': 'A', 'non_effect_allele_frequency': 0.999}]",general,"Select, Calculate",Allele Frequency
-Q3.939,Q3,What is the allele frequency of the SNP rs765370428 in an Alzheimer's disease study within a European cohort?,"According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs765370428 has an effect allele T frequency of 0.001 and non-effect allele C frequency of 0.999.","SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs765370428'
- LIMIT 1","[{'UUID': 'AD_combo_gene_notext_UUID_10050935', 'SNP': 'rs765370428', 'effect_allele': 'T', 'effect_allele_frequency': 0.001, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.999}]",general,"Select, Calculate",Allele Frequency
-Q3.1732,Q3,What is the allele frequency of the SNP rs76049581 in an Alzheimer's disease study within a European cohort?,"According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs76049581 has an effect allele C frequency of 0.0028 and non-effect allele T frequency of 0.9972.","SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs76049581'
- LIMIT 1","[{'UUID': 'AD_combo_gene_notext_UUID_18351565', 'SNP': 'rs76049581', 'effect_allele': 'C', 'effect_allele_frequency': 0.0028, 'non_effect_allele': 'T', 'non_effect_allele_frequency': 0.9972}]",general,"Select, Calculate",Allele Frequency
-Q3.66,Q3,What is the allele frequency of the SNP rs263462 in an Alzheimer's disease study within a European cohort?,"According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs263462 has an effect allele A frequency of 0.046 and non-effect allele G frequency of 0.954.","SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs263462'
- LIMIT 1","[{'UUID': 'AD_combo_gene_notext_UUID_645541', 'SNP': 'rs263462', 'effect_allele': 'A', 'effect_allele_frequency': 0.046, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.954}]",general,"Select, Calculate",Allele Frequency
-Q3.1324,Q3,What is the allele frequency of the SNP rs765750437 in an Alzheimer's disease study within a European cohort?,"According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs765750437 has an effect allele A frequency of 0.0003 and non-effect allele G frequency of 0.9997.","SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs765750437'
- LIMIT 1","[{'UUID': 'AD_combo_gene_notext_UUID_14046567', 'SNP': 'rs765750437', 'effect_allele': 'A', 'effect_allele_frequency': 0.0003, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.9997}]",general,"Select, Calculate",Allele Frequency
-Q3.57,Q3,What is the allele frequency of the SNP rs761714536 in an Alzheimer's disease study within a European cohort?,"According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs761714536 has an effect allele A frequency of 0.0005 and non-effect allele T frequency of 0.9995.","SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs761714536'
- LIMIT 1","[{'UUID': 'AD_combo_gene_notext_UUID_591722', 'SNP': 'rs761714536', 'effect_allele': 'A', 'effect_allele_frequency': 0.0005, 'non_effect_allele': 'T', 'non_effect_allele_frequency': 0.9995}]",general,"Select, Calculate",Allele Frequency
-Q3.1293,Q3,What is the allele frequency of the SNP rs11555236 in an Alzheimer's disease study within a European cohort?,"According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs11555236 has an effect allele A frequency of 0.2135 and non-effect allele C frequency of 0.7865.","SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs11555236'
- LIMIT 1","[{'UUID': 'AD_combo_gene_notext_UUID_13676329', 'SNP': 'rs11555236', 'effect_allele': 'A', 'effect_allele_frequency': 0.2135, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.7865}]",general,"Select, Calculate",Allele Frequency
-Q3.1119,Q3,What is the allele frequency of the SNP rs557256176 in an Alzheimer's disease study within a European cohort?,"According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs557256176 has an effect allele G frequency of 0.0018 and non-effect allele A frequency of 0.9982.","SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs557256176'
- LIMIT 1","[{'UUID': 'AD_combo_gene_notext_UUID_11804958', 'SNP': 'rs557256176', 'effect_allele': 'G', 'effect_allele_frequency': 0.0018, 'non_effect_allele': 'A', 'non_effect_allele_frequency': 0.9982}]",general,"Select, Calculate",Allele Frequency
-Q3.585,Q3,What is the allele frequency of the SNP rs59268194 in an Alzheimer's disease study within a European cohort?,"According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs59268194 has an effect allele T frequency of 0.0244 and non-effect allele A frequency of 0.9756.","SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs59268194'
- LIMIT 1","[{'UUID': 'AD_combo_gene_notext_UUID_6006713', 'SNP': 'rs59268194', 'effect_allele': 'T', 'effect_allele_frequency': 0.0243999999999999, 'non_effect_allele': 'A', 'non_effect_allele_frequency': 0.9756000000000001}]",general,"Select, Calculate",Allele Frequency
-Q3.375,Q3,What is the allele frequency of the SNP rs9827879 in an Alzheimer's disease study within a European cohort?,"According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs9827879 has an effect allele A frequency of 0.4811 and non-effect allele G frequency of 0.5189.","SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs9827879'
- LIMIT 1","[{'UUID': 'AD_combo_gene_notext_UUID_3801138', 'SNP': 'rs9827879', 'effect_allele': 'A', 'effect_allele_frequency': 0.4811, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.5188999999999999}]",general,"Select, Calculate",Allele Frequency
-Q3.276,Q3,What is the allele frequency of the SNP rs544720856 in an Alzheimer's disease study within a European cohort?,"According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs544720856 has an effect allele C frequency of 0.0004 and non-effect allele T frequency of 0.9996.","SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID`
- WHERE SNP = 'rs544720856'
- LIMIT 1","[{'UUID': 'AD_combo_gene_notext_UUID_2696770', 'SNP': 'rs544720856', 'effect_allele': 'C', 'effect_allele_frequency': 0.0003999999999999, 'non_effect_allele': 'T', 'non_effect_allele_frequency': 0.9996000000000002}]",general,"Select, Calculate",Allele Frequency
-Q5.567,Q5,Is Triamcinolone Acetonide approved to treat macular retinal edema?,"Triamcinolone Acetonide has not been approved by the FDA as a treatment for macular retinal edema. However, it is currently being evaluated for this purpose and is in clinical trial phase 3.0.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, target, approvedSymbol, approvedName, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%triamcinolone acetonide%"" OR LOWER(tradeNames_list) LIKE ""%triamcinolone acetonide%"" OR LOWER(syns_list) LIKE ""%triamcinolone acetonide%"") AND (LOWER(mesh_heading) LIKE ""%macular retinal edema%"" OR LOWER(efo_term) LIKE ""%macular retinal edema%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_222194', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': ""['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']"", 'syns_list': ""['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Macular Edema', 'efo_term': 'macular retinal edema', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_222324', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': ""['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']"", 'syns_list': ""['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Macular Edema', 'efo_term': 'macular retinal edema', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_222064', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': ""['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']"", 'syns_list': ""['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Macular Edema', 'efo_term': 'macular retinal edema', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_221934', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': ""['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']"", 'syns_list': ""['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Macular Edema', 'efo_term': 'macular retinal edema', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_221869', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': ""['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']"", 'syns_list': ""['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Macular Edema', 'efo_term': 'macular retinal edema', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_222259', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': ""['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']"", 'syns_list': ""['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Macular Edema', 'efo_term': 'macular retinal edema', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_222129', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': ""['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']"", 'syns_list': ""['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Macular Edema', 'efo_term': 'macular retinal edema', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_221999', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': ""['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']"", 'syns_list': ""['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Macular Edema', 'efo_term': 'macular retinal edema', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 3.0}]",general,"Multi-Filter, Similarity Search, Order By, Distinct",Approval Status
-Q5.1102,Q5,Is Aspirin approved to treat osteonecrosis?,"Aspirin has not been approved by the FDA as a treatment for osteonecrosis. However, it is currently being evaluated for this purpose and is in clinical trial phase 3.0.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, target, approvedSymbol, approvedName, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%aspirin%"" OR LOWER(tradeNames_list) LIKE ""%aspirin%"" OR LOWER(syns_list) LIKE ""%aspirin%"") AND (LOWER(mesh_heading) LIKE ""%osteonecrosis%"" OR LOWER(efo_term) LIKE ""%osteonecrosis%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_834382', 'drugName': 'Aspirin', 'tradeNames_list': ""['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']"", 'syns_list': ""['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']"", 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'mesh_heading': 'Osteonecrosis', 'efo_term': 'osteonecrosis', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_834853', 'drugName': 'Aspirin', 'tradeNames_list': ""['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']"", 'syns_list': ""['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']"", 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'mesh_heading': 'Osteonecrosis', 'efo_term': 'osteonecrosis', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_835010', 'drugName': 'Aspirin', 'tradeNames_list': ""['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']"", 'syns_list': ""['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']"", 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'mesh_heading': 'Osteonecrosis', 'efo_term': 'osteonecrosis', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_835167', 'drugName': 'Aspirin', 'tradeNames_list': ""['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']"", 'syns_list': ""['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']"", 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'mesh_heading': 'Osteonecrosis', 'efo_term': 'osteonecrosis', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_835481', 'drugName': 'Aspirin', 'tradeNames_list': ""['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']"", 'syns_list': ""['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']"", 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'mesh_heading': 'Osteonecrosis', 'efo_term': 'osteonecrosis', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_835638', 'drugName': 'Aspirin', 'tradeNames_list': ""['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']"", 'syns_list': ""['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']"", 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'mesh_heading': 'Osteonecrosis', 'efo_term': 'osteonecrosis', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_835795', 'drugName': 'Aspirin', 'tradeNames_list': ""['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']"", 'syns_list': ""['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']"", 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'mesh_heading': 'Osteonecrosis', 'efo_term': 'osteonecrosis', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_835952', 'drugName': 'Aspirin', 'tradeNames_list': ""['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']"", 'syns_list': ""['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']"", 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'mesh_heading': 'Osteonecrosis', 'efo_term': 'osteonecrosis', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_834696', 'drugName': 'Aspirin', 'tradeNames_list': ""['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']"", 'syns_list': ""['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']"", 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'mesh_heading': 'Osteonecrosis', 'efo_term': 'osteonecrosis', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_834068', 'drugName': 'Aspirin', 'tradeNames_list': ""['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']"", 'syns_list': ""['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']"", 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'mesh_heading': 'Osteonecrosis', 'efo_term': 'osteonecrosis', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_833754', 'drugName': 'Aspirin', 'tradeNames_list': ""['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']"", 'syns_list': ""['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']"", 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'mesh_heading': 'Osteonecrosis', 'efo_term': 'osteonecrosis', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_833597', 'drugName': 'Aspirin', 'tradeNames_list': ""['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']"", 'syns_list': ""['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']"", 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'mesh_heading': 'Osteonecrosis', 'efo_term': 'osteonecrosis', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_835324', 'drugName': 'Aspirin', 'tradeNames_list': ""['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']"", 'syns_list': ""['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']"", 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'mesh_heading': 'Osteonecrosis', 'efo_term': 'osteonecrosis', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_834539', 'drugName': 'Aspirin', 'tradeNames_list': ""['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']"", 'syns_list': ""['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']"", 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'mesh_heading': 'Osteonecrosis', 'efo_term': 'osteonecrosis', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_834225', 'drugName': 'Aspirin', 'tradeNames_list': ""['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']"", 'syns_list': ""['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']"", 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'mesh_heading': 'Osteonecrosis', 'efo_term': 'osteonecrosis', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_833911', 'drugName': 'Aspirin', 'tradeNames_list': ""['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']"", 'syns_list': ""['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']"", 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'mesh_heading': 'Osteonecrosis', 'efo_term': 'osteonecrosis', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 3.0}]",general,"Multi-Filter, Similarity Search, Order By, Distinct",Approval Status
-Q5.1474,Q5,Is Obeticholic Acid approved to treat familial partial lipodystrophy?,"Obeticholic Acid has not been approved by the FDA as a treatment for familial partial lipodystrophy. However, it is currently being evaluated for this purpose and is in clinical trial phase 2.0.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, target, approvedSymbol, approvedName, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%obeticholic acid%"" OR LOWER(tradeNames_list) LIKE ""%obeticholic acid%"" OR LOWER(syns_list) LIKE ""%obeticholic acid%"") AND (LOWER(mesh_heading) LIKE ""%familial partial lipodystrophy%"" OR LOWER(efo_term) LIKE ""%familial partial lipodystrophy%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_1104393', 'drugName': 'Obeticholic Acid', 'tradeNames_list': ""['Ocaliva']"", 'syns_list': ""['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']"", 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'mesh_heading': 'Lipodystrophy, Familial Partial', 'efo_term': 'familial partial lipodystrophy', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1104438', 'drugName': 'Obeticholic Acid', 'tradeNames_list': ""['Ocaliva']"", 'syns_list': ""['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']"", 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'mesh_heading': 'Lipodystrophy, Familial Partial', 'efo_term': 'familial partial lipodystrophy', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1104453', 'drugName': 'Obeticholic Acid', 'tradeNames_list': ""['Ocaliva']"", 'syns_list': ""['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']"", 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'mesh_heading': 'Lipodystrophy, Familial Partial', 'efo_term': 'familial partial lipodystrophy', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1104468', 'drugName': 'Obeticholic Acid', 'tradeNames_list': ""['Ocaliva']"", 'syns_list': ""['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']"", 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'mesh_heading': 'Lipodystrophy, Familial Partial', 'efo_term': 'familial partial lipodystrophy', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1104498', 'drugName': 'Obeticholic Acid', 'tradeNames_list': ""['Ocaliva']"", 'syns_list': ""['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']"", 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'mesh_heading': 'Lipodystrophy, Familial Partial', 'efo_term': 'familial partial lipodystrophy', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1104513', 'drugName': 'Obeticholic Acid', 'tradeNames_list': ""['Ocaliva']"", 'syns_list': ""['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']"", 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'mesh_heading': 'Lipodystrophy, Familial Partial', 'efo_term': 'familial partial lipodystrophy', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1104528', 'drugName': 'Obeticholic Acid', 'tradeNames_list': ""['Ocaliva']"", 'syns_list': ""['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']"", 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'mesh_heading': 'Lipodystrophy, Familial Partial', 'efo_term': 'familial partial lipodystrophy', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1104558', 'drugName': 'Obeticholic Acid', 'tradeNames_list': ""['Ocaliva']"", 'syns_list': ""['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']"", 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'mesh_heading': 'Lipodystrophy, Familial Partial', 'efo_term': 'familial partial lipodystrophy', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1104573', 'drugName': 'Obeticholic Acid', 'tradeNames_list': ""['Ocaliva']"", 'syns_list': ""['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']"", 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'mesh_heading': 'Lipodystrophy, Familial Partial', 'efo_term': 'familial partial lipodystrophy', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1104588', 'drugName': 'Obeticholic Acid', 'tradeNames_list': ""['Ocaliva']"", 'syns_list': ""['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']"", 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'mesh_heading': 'Lipodystrophy, Familial Partial', 'efo_term': 'familial partial lipodystrophy', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1104603', 'drugName': 'Obeticholic Acid', 'tradeNames_list': ""['Ocaliva']"", 'syns_list': ""['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']"", 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'mesh_heading': 'Lipodystrophy, Familial Partial', 'efo_term': 'familial partial lipodystrophy', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1104423', 'drugName': 'Obeticholic Acid', 'tradeNames_list': ""['Ocaliva']"", 'syns_list': ""['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']"", 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'mesh_heading': 'Lipodystrophy, Familial Partial', 'efo_term': 'familial partial lipodystrophy', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1104363', 'drugName': 'Obeticholic Acid', 'tradeNames_list': ""['Ocaliva']"", 'syns_list': ""['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']"", 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'mesh_heading': 'Lipodystrophy, Familial Partial', 'efo_term': 'familial partial lipodystrophy', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1104333', 'drugName': 'Obeticholic Acid', 'tradeNames_list': ""['Ocaliva']"", 'syns_list': ""['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']"", 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'mesh_heading': 'Lipodystrophy, Familial Partial', 'efo_term': 'familial partial lipodystrophy', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1104318', 'drugName': 'Obeticholic Acid', 'tradeNames_list': ""['Ocaliva']"", 'syns_list': ""['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']"", 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'mesh_heading': 'Lipodystrophy, Familial Partial', 'efo_term': 'familial partial lipodystrophy', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1104543', 'drugName': 'Obeticholic Acid', 'tradeNames_list': ""['Ocaliva']"", 'syns_list': ""['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']"", 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'mesh_heading': 'Lipodystrophy, Familial Partial', 'efo_term': 'familial partial lipodystrophy', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1104483', 'drugName': 'Obeticholic Acid', 'tradeNames_list': ""['Ocaliva']"", 'syns_list': ""['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']"", 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'mesh_heading': 'Lipodystrophy, Familial Partial', 'efo_term': 'familial partial lipodystrophy', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1104408', 'drugName': 'Obeticholic Acid', 'tradeNames_list': ""['Ocaliva']"", 'syns_list': ""['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']"", 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'mesh_heading': 'Lipodystrophy, Familial Partial', 'efo_term': 'familial partial lipodystrophy', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1104378', 'drugName': 'Obeticholic Acid', 'tradeNames_list': ""['Ocaliva']"", 'syns_list': ""['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']"", 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'mesh_heading': 'Lipodystrophy, Familial Partial', 'efo_term': 'familial partial lipodystrophy', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_1104348', 'drugName': 'Obeticholic Acid', 'tradeNames_list': ""['Ocaliva']"", 'syns_list': ""['6-ecdca', '6-ethylchenodeoxycholic acid', 'DSP-1747', 'INT-747Obeticholic acid']"", 'target': 'ENSG00000012504', 'approvedSymbol': 'NR1H4', 'approvedName': 'nuclear receptor subfamily 1 group H member 4', 'mesh_heading': 'Lipodystrophy, Familial Partial', 'efo_term': 'familial partial lipodystrophy', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0}]",general,"Multi-Filter, Similarity Search, Order By, Distinct",Approval Status
-Q5.1178,Q5,Is Testosterone Enanthate approved to treat Hypogonadotropic hypogonadism?,"Yes, the drug Testosterone Enanthate was approved by the FDA to treat Hypogonadotropic hypogonadism in 1953.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, target, approvedSymbol, approvedName, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%testosterone enanthate%"" OR LOWER(tradeNames_list) LIKE ""%testosterone enanthate%"" OR LOWER(syns_list) LIKE ""%testosterone enanthate%"") AND (LOWER(mesh_heading) LIKE ""%hypogonadotropic hypogonadism%"" OR LOWER(efo_term) LIKE ""%hypogonadotropic hypogonadism%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_921410', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921437', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921446', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921455', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921473', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921482', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921491', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921509', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921518', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921527', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921536', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921554', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921563', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921572', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921581', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921590', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921599', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921608', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921617', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921626', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921635', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921653', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921662', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921671', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921680', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921689', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921707', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921716', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921725', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921734', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921743', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921752', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921761', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921770', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921779', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921788', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921797', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921806', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921815', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921824', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921833', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921842', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921644', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921500', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921428', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921392', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921374', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921365', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921698', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921545', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921464', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921419', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921401', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_921383', 'drugName': 'Testosterone Enanthate', 'tradeNames_list': ""['Delatestryl', 'Primoteston depot', 'Testosterone enanthateXyosted (autoinjector)']"", 'syns_list': ""['Androtardyl', 'NSC-17591', 'Testosterone enantateTestosterone enanthate', 'Testosterone enanthate ciiiTestosterone heptanoate', 'Testosteroni enantas', 'Xyosted']"", 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'mesh_heading': 'Hypogonadism', 'efo_term': 'Hypogonadotropic hypogonadism', 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0}]",general,"Multi-Filter, Similarity Search, Order By, Distinct",Approval Status
-Q5.1010,Q5,Is Fludarabine Phosphate approved to treat osteopetrosis?,"Fludarabine Phosphate has not been approved by the FDA as a treatment for osteopetrosis. However, it is currently being evaluated for this purpose and is in clinical trial phase 2.0.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, target, approvedSymbol, approvedName, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%fludarabine phosphate%"" OR LOWER(tradeNames_list) LIKE ""%fludarabine phosphate%"" OR LOWER(syns_list) LIKE ""%fludarabine phosphate%"") AND (LOWER(mesh_heading) LIKE ""%osteopetrosis%"" OR LOWER(efo_term) LIKE ""%osteopetrosis%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_754595', 'drugName': 'Fludarabine Phosphate', 'tradeNames_list': ""['Fludara', 'Fludarabine phosphate', 'Oforta']"", 'syns_list': '[\'2-f-ara-amp\', \'2-f-araa\', \'2-fluoro ara-a\', \'2-fluorovidarabineFludarabine\', ""Fludarabine 5\'-monophosphateFludarabine monophosphateFludarabine phosphate"", \'Fluradosa\', \'NSC-118218\', \'NSC-118218HNSC-312887\', \'NSC-328002\']', 'target': 'ENSG00000177084', 'approvedSymbol': 'POLE', 'approvedName': 'DNA polymerase epsilon, catalytic subunit', 'mesh_heading': 'Osteopetrosis', 'efo_term': 'osteopetrosis', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_755009', 'drugName': 'Fludarabine Phosphate', 'tradeNames_list': ""['Fludara', 'Fludarabine phosphate', 'Oforta']"", 'syns_list': '[\'2-f-ara-amp\', \'2-f-araa\', \'2-fluoro ara-a\', \'2-fluorovidarabineFludarabine\', ""Fludarabine 5\'-monophosphateFludarabine monophosphateFludarabine phosphate"", \'Fluradosa\', \'NSC-118218\', \'NSC-118218HNSC-312887\', \'NSC-328002\']', 'target': 'ENSG00000146143', 'approvedSymbol': 'PRIM2', 'approvedName': 'DNA primase subunit 2', 'mesh_heading': 'Osteopetrosis', 'efo_term': 'osteopetrosis', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_755147', 'drugName': 'Fludarabine Phosphate', 'tradeNames_list': ""['Fludara', 'Fludarabine phosphate', 'Oforta']"", 'syns_list': '[\'2-f-ara-amp\', \'2-f-araa\', \'2-fluoro ara-a\', \'2-fluorovidarabineFludarabine\', ""Fludarabine 5\'-monophosphateFludarabine monophosphateFludarabine phosphate"", \'Fluradosa\', \'NSC-118218\', \'NSC-118218HNSC-312887\', \'NSC-328002\']', 'target': 'ENSG00000100479', 'approvedSymbol': 'POLE2', 'approvedName': 'DNA polymerase epsilon 2, accessory subunit', 'mesh_heading': 'Osteopetrosis', 'efo_term': 'osteopetrosis', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_755285', 'drugName': 'Fludarabine Phosphate', 'tradeNames_list': ""['Fludara', 'Fludarabine phosphate', 'Oforta']"", 'syns_list': '[\'2-f-ara-amp\', \'2-f-araa\', \'2-fluoro ara-a\', \'2-fluorovidarabineFludarabine\', ""Fludarabine 5\'-monophosphateFludarabine monophosphateFludarabine phosphate"", \'Fluradosa\', \'NSC-118218\', \'NSC-118218HNSC-312887\', \'NSC-328002\']', 'target': 'ENSG00000148229', 'approvedSymbol': 'POLE3', 'approvedName': 'DNA polymerase epsilon 3, accessory subunit', 'mesh_heading': 'Osteopetrosis', 'efo_term': 'osteopetrosis', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_755561', 'drugName': 'Fludarabine Phosphate', 'tradeNames_list': ""['Fludara', 'Fludarabine phosphate', 'Oforta']"", 'syns_list': '[\'2-f-ara-amp\', \'2-f-araa\', \'2-fluoro ara-a\', \'2-fluorovidarabineFludarabine\', ""Fludarabine 5\'-monophosphateFludarabine monophosphateFludarabine phosphate"", \'Fluradosa\', \'NSC-118218\', \'NSC-118218HNSC-312887\', \'NSC-328002\']', 'target': 'ENSG00000048392', 'approvedSymbol': 'RRM2B', 'approvedName': 'ribonucleotide reductase regulatory TP53 inducible subunit M2B', 'mesh_heading': 'Osteopetrosis', 'efo_term': 'osteopetrosis', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_755699', 'drugName': 'Fludarabine Phosphate', 'tradeNames_list': ""['Fludara', 'Fludarabine phosphate', 'Oforta']"", 'syns_list': '[\'2-f-ara-amp\', \'2-f-araa\', \'2-fluoro ara-a\', \'2-fluorovidarabineFludarabine\', ""Fludarabine 5\'-monophosphateFludarabine monophosphateFludarabine phosphate"", \'Fluradosa\', \'NSC-118218\', \'NSC-118218HNSC-312887\', \'NSC-328002\']', 'target': 'ENSG00000171848', 'approvedSymbol': 'RRM2', 'approvedName': 'ribonucleotide reductase regulatory subunit M2', 'mesh_heading': 'Osteopetrosis', 'efo_term': 'osteopetrosis', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_754871', 'drugName': 'Fludarabine Phosphate', 'tradeNames_list': ""['Fludara', 'Fludarabine phosphate', 'Oforta']"", 'syns_list': '[\'2-f-ara-amp\', \'2-f-araa\', \'2-fluoro ara-a\', \'2-fluorovidarabineFludarabine\', ""Fludarabine 5\'-monophosphateFludarabine monophosphateFludarabine phosphate"", \'Fluradosa\', \'NSC-118218\', \'NSC-118218HNSC-312887\', \'NSC-328002\']', 'target': 'ENSG00000198056', 'approvedSymbol': 'PRIM1', 'approvedName': 'DNA primase subunit 1', 'mesh_heading': 'Osteopetrosis', 'efo_term': 'osteopetrosis', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_754319', 'drugName': 'Fludarabine Phosphate', 'tradeNames_list': ""['Fludara', 'Fludarabine phosphate', 'Oforta']"", 'syns_list': '[\'2-f-ara-amp\', \'2-f-araa\', \'2-fluoro ara-a\', \'2-fluorovidarabineFludarabine\', ""Fludarabine 5\'-monophosphateFludarabine monophosphateFludarabine phosphate"", \'Fluradosa\', \'NSC-118218\', \'NSC-118218HNSC-312887\', \'NSC-328002\']', 'target': 'ENSG00000062822', 'approvedSymbol': 'POLD1', 'approvedName': 'DNA polymerase delta 1, catalytic subunit', 'mesh_heading': 'Osteopetrosis', 'efo_term': 'osteopetrosis', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_754043', 'drugName': 'Fludarabine Phosphate', 'tradeNames_list': ""['Fludara', 'Fludarabine phosphate', 'Oforta']"", 'syns_list': '[\'2-f-ara-amp\', \'2-f-araa\', \'2-fluoro ara-a\', \'2-fluorovidarabineFludarabine\', ""Fludarabine 5\'-monophosphateFludarabine monophosphateFludarabine phosphate"", \'Fluradosa\', \'NSC-118218\', \'NSC-118218HNSC-312887\', \'NSC-328002\']', 'target': 'ENSG00000175482', 'approvedSymbol': 'POLD4', 'approvedName': 'DNA polymerase delta 4, accessory subunit', 'mesh_heading': 'Osteopetrosis', 'efo_term': 'osteopetrosis', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_753905', 'drugName': 'Fludarabine Phosphate', 'tradeNames_list': ""['Fludara', 'Fludarabine phosphate', 'Oforta']"", 'syns_list': '[\'2-f-ara-amp\', \'2-f-araa\', \'2-fluoro ara-a\', \'2-fluorovidarabineFludarabine\', ""Fludarabine 5\'-monophosphateFludarabine monophosphateFludarabine phosphate"", \'Fluradosa\', \'NSC-118218\', \'NSC-118218HNSC-312887\', \'NSC-328002\']', 'target': 'ENSG00000101868', 'approvedSymbol': 'POLA1', 'approvedName': 'DNA polymerase alpha 1, catalytic subunit', 'mesh_heading': 'Osteopetrosis', 'efo_term': 'osteopetrosis', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_755423', 'drugName': 'Fludarabine Phosphate', 'tradeNames_list': ""['Fludara', 'Fludarabine phosphate', 'Oforta']"", 'syns_list': '[\'2-f-ara-amp\', \'2-f-araa\', \'2-fluoro ara-a\', \'2-fluorovidarabineFludarabine\', ""Fludarabine 5\'-monophosphateFludarabine monophosphateFludarabine phosphate"", \'Fluradosa\', \'NSC-118218\', \'NSC-118218HNSC-312887\', \'NSC-328002\']', 'target': 'ENSG00000167325', 'approvedSymbol': 'RRM1', 'approvedName': 'ribonucleotide reductase catalytic subunit M1', 'mesh_heading': 'Osteopetrosis', 'efo_term': 'osteopetrosis', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_754733', 'drugName': 'Fludarabine Phosphate', 'tradeNames_list': ""['Fludara', 'Fludarabine phosphate', 'Oforta']"", 'syns_list': '[\'2-f-ara-amp\', \'2-f-araa\', \'2-fluoro ara-a\', \'2-fluorovidarabineFludarabine\', ""Fludarabine 5\'-monophosphateFludarabine monophosphateFludarabine phosphate"", \'Fluradosa\', \'NSC-118218\', \'NSC-118218HNSC-312887\', \'NSC-328002\']', 'target': 'ENSG00000014138', 'approvedSymbol': 'POLA2', 'approvedName': 'DNA polymerase alpha 2, accessory subunit', 'mesh_heading': 'Osteopetrosis', 'efo_term': 'osteopetrosis', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_754457', 'drugName': 'Fludarabine Phosphate', 'tradeNames_list': ""['Fludara', 'Fludarabine phosphate', 'Oforta']"", 'syns_list': '[\'2-f-ara-amp\', \'2-f-araa\', \'2-fluoro ara-a\', \'2-fluorovidarabineFludarabine\', ""Fludarabine 5\'-monophosphateFludarabine monophosphateFludarabine phosphate"", \'Fluradosa\', \'NSC-118218\', \'NSC-118218HNSC-312887\', \'NSC-328002\']', 'target': 'ENSG00000106628', 'approvedSymbol': 'POLD2', 'approvedName': 'DNA polymerase delta 2, accessory subunit', 'mesh_heading': 'Osteopetrosis', 'efo_term': 'osteopetrosis', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_754181', 'drugName': 'Fludarabine Phosphate', 'tradeNames_list': ""['Fludara', 'Fludarabine phosphate', 'Oforta']"", 'syns_list': '[\'2-f-ara-amp\', \'2-f-araa\', \'2-fluoro ara-a\', \'2-fluorovidarabineFludarabine\', ""Fludarabine 5\'-monophosphateFludarabine monophosphateFludarabine phosphate"", \'Fluradosa\', \'NSC-118218\', \'NSC-118218HNSC-312887\', \'NSC-328002\']', 'target': 'ENSG00000077514', 'approvedSymbol': 'POLD3', 'approvedName': 'DNA polymerase delta 3, accessory subunit', 'mesh_heading': 'Osteopetrosis', 'efo_term': 'osteopetrosis', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 2.0}]",general,"Multi-Filter, Similarity Search, Order By, Distinct",Approval Status
-Q5.434,Q5,Is Prednisone approved to treat hematopoietic and lymphoid cell neoplasm?,"Prednisone has not been approved by the FDA as a treatment for hematopoietic and lymphoid cell neoplasm. However, it is currently being evaluated for this purpose and is in clinical trial phase 2.0.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, target, approvedSymbol, approvedName, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%prednisone%"" OR LOWER(tradeNames_list) LIKE ""%prednisone%"" OR LOWER(syns_list) LIKE ""%prednisone%"") AND (LOWER(mesh_heading) LIKE ""%hematopoietic and lymphoid cell neoplasm%"" OR LOWER(efo_term) LIKE ""%hematopoietic and lymphoid cell neoplasm%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_218593', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_219217', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_219425', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_219633', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_220049', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_220257', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_220465', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_220673', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_219009', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_218177', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_217761', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_217553', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_219841', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_218801', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_218385', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_217969', 'drugName': 'Prednisone', 'tradeNames_list': ""['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']"", 'syns_list': ""['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']"", 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'mesh_heading': 'Hematologic Neoplasms', 'efo_term': 'hematopoietic and lymphoid cell neoplasm', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 2.0}]",general,"Multi-Filter, Similarity Search, Order By, Distinct",Approval Status
-Q5.856,Q5,Is Lidocaine approved to treat myofascial pain syndrome?,"Lidocaine has not been approved by the FDA as a treatment for myofascial pain syndrome. However, it is currently being evaluated for this purpose and is in clinical trial phase 2.0.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, target, approvedSymbol, approvedName, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%lidocaine%"" OR LOWER(tradeNames_list) LIKE ""%lidocaine%"" OR LOWER(syns_list) LIKE ""%lidocaine%"") AND (LOWER(mesh_heading) LIKE ""%myofascial pain syndrome%"" OR LOWER(efo_term) LIKE ""%myofascial pain syndrome%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_638300', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_638645', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_638760', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_638875', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_639105', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_639220', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_639335', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_639565', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_639680', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_639795', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_639910', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_640140', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_640255', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_640370', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_640485', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_640600', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_640715', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_640830', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_640945', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_641060', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_641175', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_641405', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_641520', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_641635', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_641750', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_641865', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_642095', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_642210', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_642325', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_642440', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_642555', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_642670', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_642785', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_642900', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_643015', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_643130', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_643245', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_643360', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_643475', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_643590', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_643705', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_643820', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_643935', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_644050', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_644165', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_644280', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_644395', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_644510', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_641290', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_639450', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_638530', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_638070', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_637840', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_637725', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_641980', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_640025', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_638990', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_638415', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_638185', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_637955', 'drugName': 'Lidocaine', 'tradeNames_list': ""['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']"", 'syns_list': ""['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']"", 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0}]",general,"Multi-Filter, Similarity Search, Order By, Distinct",Approval Status
-Q5.1492,Q5,Is Teduglutide approved to treat primary short bowel syndrome?,"Yes, the drug Teduglutide was approved by the FDA to treat primary short bowel syndrome in 2012.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, target, approvedSymbol, approvedName, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%teduglutide%"" OR LOWER(tradeNames_list) LIKE ""%teduglutide%"" OR LOWER(syns_list) LIKE ""%teduglutide%"") AND (LOWER(mesh_heading) LIKE ""%primary short bowel syndrome%"" OR LOWER(efo_term) LIKE ""%primary short bowel syndrome%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_1149494', 'drugName': 'Teduglutide', 'tradeNames_list': ""['Gattex kit']"", 'syns_list': ""['ALX 0600', 'ALX-0600', 'Gattex', 'Revestive', 'TeduglutideTeduglutide (rdna origin)', 'Teduglutide recombinant']"", 'target': 'ENSG00000065325', 'approvedSymbol': 'GLP2R', 'approvedName': 'glucagon like peptide 2 receptor', 'mesh_heading': 'Short Bowel Syndrome', 'efo_term': 'primary short bowel syndrome', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1149458', 'drugName': 'Teduglutide', 'tradeNames_list': ""['Gattex kit']"", 'syns_list': ""['ALX 0600', 'ALX-0600', 'Gattex', 'Revestive', 'TeduglutideTeduglutide (rdna origin)', 'Teduglutide recombinant']"", 'target': 'ENSG00000065325', 'approvedSymbol': 'GLP2R', 'approvedName': 'glucagon like peptide 2 receptor', 'mesh_heading': 'Short Bowel Syndrome', 'efo_term': 'primary short bowel syndrome', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1149449', 'drugName': 'Teduglutide', 'tradeNames_list': ""['Gattex kit']"", 'syns_list': ""['ALX 0600', 'ALX-0600', 'Gattex', 'Revestive', 'TeduglutideTeduglutide (rdna origin)', 'Teduglutide recombinant']"", 'target': 'ENSG00000065325', 'approvedSymbol': 'GLP2R', 'approvedName': 'glucagon like peptide 2 receptor', 'mesh_heading': 'Short Bowel Syndrome', 'efo_term': 'primary short bowel syndrome', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1149476', 'drugName': 'Teduglutide', 'tradeNames_list': ""['Gattex kit']"", 'syns_list': ""['ALX 0600', 'ALX-0600', 'Gattex', 'Revestive', 'TeduglutideTeduglutide (rdna origin)', 'Teduglutide recombinant']"", 'target': 'ENSG00000065325', 'approvedSymbol': 'GLP2R', 'approvedName': 'glucagon like peptide 2 receptor', 'mesh_heading': 'Short Bowel Syndrome', 'efo_term': 'primary short bowel syndrome', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1149485', 'drugName': 'Teduglutide', 'tradeNames_list': ""['Gattex kit']"", 'syns_list': ""['ALX 0600', 'ALX-0600', 'Gattex', 'Revestive', 'TeduglutideTeduglutide (rdna origin)', 'Teduglutide recombinant']"", 'target': 'ENSG00000065325', 'approvedSymbol': 'GLP2R', 'approvedName': 'glucagon like peptide 2 receptor', 'mesh_heading': 'Short Bowel Syndrome', 'efo_term': 'primary short bowel syndrome', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1149467', 'drugName': 'Teduglutide', 'tradeNames_list': ""['Gattex kit']"", 'syns_list': ""['ALX 0600', 'ALX-0600', 'Gattex', 'Revestive', 'TeduglutideTeduglutide (rdna origin)', 'Teduglutide recombinant']"", 'target': 'ENSG00000065325', 'approvedSymbol': 'GLP2R', 'approvedName': 'glucagon like peptide 2 receptor', 'mesh_heading': 'Short Bowel Syndrome', 'efo_term': 'primary short bowel syndrome', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0}]",general,"Multi-Filter, Similarity Search, Order By, Distinct",Approval Status
-Q5.1033,Q5,Is Fentanyl approved to treat Respiratory insufficiency?,"Fentanyl has not been approved by the FDA as a treatment for Respiratory insufficiency. However, it is currently being evaluated for this purpose and is in clinical trial phase 3.0.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, target, approvedSymbol, approvedName, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%fentanyl%"" OR LOWER(tradeNames_list) LIKE ""%fentanyl%"" OR LOWER(syns_list) LIKE ""%fentanyl%"") AND (LOWER(mesh_heading) LIKE ""%respiratory insufficiency%"" OR LOWER(efo_term) LIKE ""%respiratory insufficiency%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_785787', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_785853', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_785863', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_785891', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_785929', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_785939', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_785967', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786005', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786015', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786043', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786053', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786091', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786119', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786129', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786157', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786167', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786195', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786205', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786233', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786243', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786271', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786309', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786319', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786347', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786357', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786385', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786423', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786433', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786461', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786471', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786499', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786509', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786537', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786547', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786575', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786585', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786613', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786623', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786651', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786661', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786689', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786699', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786727', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786737', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786765', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786775', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786803', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786813', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786841', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786851', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786879', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786917', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786927', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786955', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786965', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786993', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_787003', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_787041', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_787069', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_787079', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_787107', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_787117', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_787145', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_787155', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_787183', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_787193', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_787221', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_787231', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_787259', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_787269', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_787297', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_787307', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_787335', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_787345', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_787373', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_787383', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_787411', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_787421', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_787449', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_787459', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_787487', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_787497', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_787525', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_787535', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_787563', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_787573', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786889', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786281', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_785977', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_785825', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_785749', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_785711', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_785701', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_787031', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786395', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_786081', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_785901', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'respiratory depression', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_785815', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_785777', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_785739', 'drugName': 'Fentanyl', 'tradeNames_list': ""['Abstral', 'Actiq', 'Breakyl', 'Duragesic', 'Duragesic-100', 'Duragesic-12Duragesic-25', 'Duragesic-37', 'Duragesic-50', 'Duragesic-75', 'DurogesicDurogesic dtrans', 'Effentora', 'Fencino', 'Fentalis reservoirFentanyl-100', 'Fentanyl-12', 'Fentanyl-25', 'Fentanyl-37', 'Fentanyl-50Fentanyl-62', 'Fentanyl-75', 'Fentanyl-87', 'Fentora', 'Ionsys', 'LeptanalMatrifen', 'Mezolar matrix', 'Mylafent', 'Opiodur', 'Oralet', 'OsmachOsmanil', 'Pecfent', 'Recivit', 'Sublimaze', 'Subsys', 'Tilofyl', 'VictanylYemex']"", 'syns_list': ""['AD 923', 'AD-923', 'Abstral-', 'Durogesic d-trans', 'EN-3267', 'En3267Fendrop', 'Fentanest', 'Fentanyl', 'Fentanyl cii', 'Fentora', 'IDS-NF-001Innovar', 'Ionsys', 'N02AB03', 'Phentanyl', 'R 4263', 'Recuvyra', 'Sublimase']"", 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'mesh_heading': 'Respiratory Insufficiency', 'efo_term': 'Respiratory insufficiency', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0}]",general,"Multi-Filter, Similarity Search, Order By, Distinct",Approval Status
-Q5.1080,Q5,Is Celecoxib approved to treat Hand-foot syndrome?,"Celecoxib has not been approved by the FDA as a treatment for Hand-foot syndrome. However, it is currently being evaluated for this purpose and is in clinical trial phase 3.0.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, target, approvedSymbol, approvedName, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%celecoxib%"" OR LOWER(tradeNames_list) LIKE ""%celecoxib%"" OR LOWER(syns_list) LIKE ""%celecoxib%"") AND (LOWER(mesh_heading) LIKE ""%hand-foot syndrome%"" OR LOWER(efo_term) LIKE ""%hand-foot syndrome%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_833478', 'drugName': 'Celecoxib', 'tradeNames_list': ""['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']"", 'syns_list': ""['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']"", 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'mesh_heading': 'Hand-Foot Syndrome', 'efo_term': 'Hand-foot syndrome', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_833034', 'drugName': 'Celecoxib', 'tradeNames_list': ""['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']"", 'syns_list': ""['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']"", 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'mesh_heading': 'Hand-Foot Syndrome', 'efo_term': 'Hand-foot syndrome', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_832923', 'drugName': 'Celecoxib', 'tradeNames_list': ""['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']"", 'syns_list': ""['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']"", 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'mesh_heading': 'Hand-Foot Syndrome', 'efo_term': 'Hand-foot syndrome', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_833256', 'drugName': 'Celecoxib', 'tradeNames_list': ""['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']"", 'syns_list': ""['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']"", 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'mesh_heading': 'Hand-Foot Syndrome', 'efo_term': 'Hand-foot syndrome', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_833367', 'drugName': 'Celecoxib', 'tradeNames_list': ""['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']"", 'syns_list': ""['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']"", 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'mesh_heading': 'Hand-Foot Syndrome', 'efo_term': 'Hand-foot syndrome', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0}, {'UUID': 'DrugTargetsIndication121923_text_833145', 'drugName': 'Celecoxib', 'tradeNames_list': ""['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']"", 'syns_list': ""['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']"", 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'mesh_heading': 'Hand-Foot Syndrome', 'efo_term': 'Hand-foot syndrome', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0}]",general,"Multi-Filter, Similarity Search, Order By, Distinct",Approval Status
-Q5.1383,Q5,Is Everolimus approved to treat angiomyolipoma?,"Yes, the drug Everolimus was approved by the FDA to treat angiomyolipoma in 2009.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, target, approvedSymbol, approvedName, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%everolimus%"" OR LOWER(tradeNames_list) LIKE ""%everolimus%"" OR LOWER(syns_list) LIKE ""%everolimus%"") AND (LOWER(mesh_heading) LIKE ""%angiomyolipoma%"" OR LOWER(efo_term) LIKE ""%angiomyolipoma%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_1085238', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1085504', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1085508', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1085639', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1085774', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1085778', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1085909', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1086044', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1086048', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1086179', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1086183', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1086318', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1086449', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1086453', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1086584', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1086588', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1086719', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1086723', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1086854', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1086858', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1086989', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1087124', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1087128', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1087259', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1087263', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1087394', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1087529', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1087533', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1087664', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1087668', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1087799', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1087803', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1087934', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1087938', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1088069', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1088073', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1088204', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1088208', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1088339', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1088343', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1088474', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1088478', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1088609', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1088613', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1088744', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1088748', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1088879', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1088883', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1089014', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1089018', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1089149', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1089284', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1089288', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1089419', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1089423', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1089554', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1089558', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1089693', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1089824', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1089828', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1089959', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1089963', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1090094', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1090098', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1090229', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1090233', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1090364', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1090368', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1090499', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1090503', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1090634', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1090638', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1089153', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1086993', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1085913', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1085373', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1085103', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1084968', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1084964', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1089689', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1087398', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1086314', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1085643', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1085369', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1085234', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}, {'UUID': 'DrugTargetsIndication121923_text_1085099', 'drugName': 'Everolimus', 'tradeNames_list': ""['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']"", 'syns_list': ""['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']"", 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0}]",general,"Multi-Filter, Similarity Search, Order By, Distinct",Approval Status
-Q5.783,Q5,Is Epinephrine approved to treat ventricular fibrillation?,"Epinephrine has not been approved by the FDA as a treatment for ventricular fibrillation. However, it is currently being evaluated for this purpose and is in clinical trial phase 2.0.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, target, approvedSymbol, approvedName, mesh_heading, efo_term, yearOfFirstApproval, max_phase_for_ind
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(drugName) LIKE ""%epinephrine%"" OR LOWER(tradeNames_list) LIKE ""%epinephrine%"" OR LOWER(syns_list) LIKE ""%epinephrine%"") AND (LOWER(mesh_heading) LIKE ""%ventricular fibrillation%"" OR LOWER(efo_term) LIKE ""%ventricular fibrillation%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_361064', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_361223', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_361276', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_361329', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_361435', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_361488', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_361541', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_361647', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_361700', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_361753', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_361806', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_361912', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_361965', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_362018', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_362071', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_362124', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_362177', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_362230', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_362283', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_362336', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_362389', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_362495', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_362548', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_362601', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_362654', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_362707', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_362813', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_362866', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_362919', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_362972', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_363025', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_363078', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_363131', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_363184', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_363237', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_363290', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_363343', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_363396', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_363449', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_363502', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_363555', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_363608', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_363661', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_363714', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_363767', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_363820', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_363873', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_363926', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_363979', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_364032', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_364085', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_364191', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_364244', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_364297', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_364350', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_364403', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_364456', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_364562', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_364615', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_364668', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_364721', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_364774', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_364827', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_364880', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_364933', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_364986', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_365039', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_365092', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_365145', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_365198', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_365251', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_365304', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_365357', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_365410', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_365463', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_365516', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_365569', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_365622', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_365675', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_365728', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_365781', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_365834', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_365887', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_365940', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_365993', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_366046', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_364138', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_362442', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_361594', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_361170', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_360958', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_360852', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_360799', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_364509', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_362760', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_361859', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_361382', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_361117', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_361011', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}, {'UUID': 'DrugTargetsIndication121923_text_360905', 'drugName': 'Epinephrine', 'tradeNames_list': ""['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']"", 'syns_list': ""['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']"", 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 2.0}]",general,"Multi-Filter, Similarity Search, Order By, Distinct",Approval Status
-Q34.583,Q34,What are the names of the genes that are targeted by the drug Erlosamide in the treatment of Seizure?,"In the context of Seizure, the drug Erlosamide targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(mesh_heading) LIKE ""%seizure%"" OR LOWER(efo_term) LIKE ""%seizure%"") AND (LOWER(drugName) LIKE ""%erlosamide%"" OR LOWER(tradeNames_list) LIKE ""%erlosamide%"" OR LOWER(syns_list) LIKE ""%erlosamide%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_644716', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_644779', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_644800', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_644821', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_644863', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_644884', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_644905', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_644947', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_644968', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_644989', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_645010', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_645052', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_645073', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_645094', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_645115', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_645136', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_645157', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_645178', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_645199', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_645220', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_645241', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645283', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645304', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645325', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645346', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645367', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645409', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645430', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645451', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645472', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645493', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645514', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645535', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645556', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645577', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645598', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645619', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645640', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645661', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645682', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645703', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645724', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645745', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645766', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645787', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645808', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645829', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645850', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645871', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_645892', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_645913', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_645955', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_645976', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_645997', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_646018', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_646039', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_646060', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_646102', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_646123', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_646144', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_646165', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_646186', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_646207', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_646228', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_646249', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_646270', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_646291', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_646312', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_646333', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_646354', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_646375', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_646396', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_646417', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_646438', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_646459', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_646480', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_646501', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_646522', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_646543', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_646564', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_646585', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_646606', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_646627', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_646648', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_646669', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_646690', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_645934', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_645262', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_644926', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_644758', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_644674', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_644632', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_644611', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_646081', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_645388', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_645031', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_644842', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_644737', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_644695', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_644653', 'drugName': 'Erlosamide', 'tradeNames_list': ""['Lacosamide', 'Vimpat']"", 'syns_list': ""['(r)-lacosamide 1', 'ADD 243037', 'ADD-243037', 'Erlosamide', 'LacosamideLacosamide cv', 'SPM 927', 'SPM-927']"", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}]",general,"Distinct, Multi-Filter, Similarity Search, Order By",Metadata
-Q34.1960,Q34,What are the names of the genes that are targeted by the drug Vorapaxar Sulfate in the treatment of peripheral arterial disease?,"In the context of peripheral arterial disease, the drug Vorapaxar Sulfate targets the gene coagulation factor II thrombin receptor.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(mesh_heading) LIKE ""%peripheral arterial disease%"" OR LOWER(efo_term) LIKE ""%peripheral arterial disease%"") AND (LOWER(drugName) LIKE ""%vorapaxar sulfate%"" OR LOWER(tradeNames_list) LIKE ""%vorapaxar sulfate%"" OR LOWER(syns_list) LIKE ""%vorapaxar sulfate%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_1193356', 'drugName': 'Vorapaxar Sulfate', 'tradeNames_list': ""['Zontivity']"", 'syns_list': ""['SCH 530348', 'SCH-530348', 'Vorapaxar sulfate']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peripheral Arterial Disease', 'efo_term': 'peripheral arterial disease', 'approvedSymbol': 'F2R', 'approvedName': 'coagulation factor II thrombin receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1193360', 'drugName': 'Vorapaxar Sulfate', 'tradeNames_list': ""['Zontivity']"", 'syns_list': ""['SCH 530348', 'SCH-530348', 'Vorapaxar sulfate']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peripheral Arterial Disease', 'efo_term': 'peripheral arterial disease', 'approvedSymbol': 'F2R', 'approvedName': 'coagulation factor II thrombin receptor'}]",general,"Distinct, Multi-Filter, Similarity Search, Order By",Metadata
-Q34.1245,Q34,What are the names of the genes that are targeted by the drug Maraviroc in the treatment of immunodeficiency disease?,"In the context of immunodeficiency disease, the drug Maraviroc targets the gene C-C motif chemokine receptor 5.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(mesh_heading) LIKE ""%immunodeficiency disease%"" OR LOWER(efo_term) LIKE ""%immunodeficiency disease%"") AND (LOWER(drugName) LIKE ""%maraviroc%"" OR LOWER(tradeNames_list) LIKE ""%maraviroc%"" OR LOWER(syns_list) LIKE ""%maraviroc%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_938392', 'drugName': 'Maraviroc', 'tradeNames_list': ""['Celsentri', 'Selzentry']"", 'syns_list': ""['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']"", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autoimmune Diseases', 'efo_term': 'immunodeficiency disease', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938455', 'drugName': 'Maraviroc', 'tradeNames_list': ""['Celsentri', 'Selzentry']"", 'syns_list': ""['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']"", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autoimmune Diseases', 'efo_term': 'immunodeficiency disease', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938476', 'drugName': 'Maraviroc', 'tradeNames_list': ""['Celsentri', 'Selzentry']"", 'syns_list': ""['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']"", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autoimmune Diseases', 'efo_term': 'immunodeficiency disease', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938497', 'drugName': 'Maraviroc', 'tradeNames_list': ""['Celsentri', 'Selzentry']"", 'syns_list': ""['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']"", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autoimmune Diseases', 'efo_term': 'immunodeficiency disease', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938539', 'drugName': 'Maraviroc', 'tradeNames_list': ""['Celsentri', 'Selzentry']"", 'syns_list': ""['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']"", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autoimmune Diseases', 'efo_term': 'immunodeficiency disease', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938560', 'drugName': 'Maraviroc', 'tradeNames_list': ""['Celsentri', 'Selzentry']"", 'syns_list': ""['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']"", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autoimmune Diseases', 'efo_term': 'immunodeficiency disease', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938581', 'drugName': 'Maraviroc', 'tradeNames_list': ""['Celsentri', 'Selzentry']"", 'syns_list': ""['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']"", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autoimmune Diseases', 'efo_term': 'immunodeficiency disease', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938434', 'drugName': 'Maraviroc', 'tradeNames_list': ""['Celsentri', 'Selzentry']"", 'syns_list': ""['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']"", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autoimmune Diseases', 'efo_term': 'immunodeficiency disease', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938350', 'drugName': 'Maraviroc', 'tradeNames_list': ""['Celsentri', 'Selzentry']"", 'syns_list': ""['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']"", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autoimmune Diseases', 'efo_term': 'immunodeficiency disease', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938308', 'drugName': 'Maraviroc', 'tradeNames_list': ""['Celsentri', 'Selzentry']"", 'syns_list': ""['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']"", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autoimmune Diseases', 'efo_term': 'immunodeficiency disease', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938287', 'drugName': 'Maraviroc', 'tradeNames_list': ""['Celsentri', 'Selzentry']"", 'syns_list': ""['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']"", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autoimmune Diseases', 'efo_term': 'immunodeficiency disease', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938518', 'drugName': 'Maraviroc', 'tradeNames_list': ""['Celsentri', 'Selzentry']"", 'syns_list': ""['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']"", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autoimmune Diseases', 'efo_term': 'immunodeficiency disease', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938413', 'drugName': 'Maraviroc', 'tradeNames_list': ""['Celsentri', 'Selzentry']"", 'syns_list': ""['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']"", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autoimmune Diseases', 'efo_term': 'immunodeficiency disease', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938371', 'drugName': 'Maraviroc', 'tradeNames_list': ""['Celsentri', 'Selzentry']"", 'syns_list': ""['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']"", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autoimmune Diseases', 'efo_term': 'immunodeficiency disease', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_938329', 'drugName': 'Maraviroc', 'tradeNames_list': ""['Celsentri', 'Selzentry']"", 'syns_list': ""['Maraviroc', 'Rel-Maraviroc', 'UK-427857', 'Uk-427,857']"", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Autoimmune Diseases', 'efo_term': 'immunodeficiency disease', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5'}]",general,"Distinct, Multi-Filter, Similarity Search, Order By",Metadata
-Q34.1095,Q34,What are the names of the genes that are targeted by the drug Testosterone Undecanoate in the treatment of hypogonadism?,"In the context of hypogonadism, the drug Testosterone Undecanoate targets the gene androgen receptor.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(mesh_heading) LIKE ""%hypogonadism%"" OR LOWER(efo_term) LIKE ""%hypogonadism%"") AND (LOWER(drugName) LIKE ""%testosterone undecanoate%"" OR LOWER(tradeNames_list) LIKE ""%testosterone undecanoate%"" OR LOWER(syns_list) LIKE ""%testosterone undecanoate%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_922002', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922027', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922028', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922040', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922053', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922054', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922066', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922079', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922080', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922092', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922093', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922106', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922118', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922119', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922131', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922132', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922144', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922145', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922157', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922158', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922170', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922183', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922184', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922196', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922197', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922209', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922222', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922223', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922235', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922236', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922248', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922249', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922261', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922262', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922274', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922275', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922287', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922288', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922300', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922301', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922313', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922314', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922326', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922327', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922339', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922340', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922352', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922353', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922365', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922366', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922378', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922391', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922392', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922404', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922405', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922417', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922418', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922431', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922443', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922444', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922456', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922457', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922469', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922470', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922482', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922483', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922495', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922496', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922379', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922171', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922067', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922015', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921989', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921976', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921975', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922430', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922210', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922105', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922041', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadotropic hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922014', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922001', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921988', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': ""['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']"", 'syns_list': ""['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypogonadism', 'efo_term': 'hypogonadism', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}]",general,"Distinct, Multi-Filter, Similarity Search, Order By",Metadata
-Q34.917,Q34,What are the names of the genes that are targeted by the drug Naproxen in the treatment of gastric ulcer?,"In the context of gastric ulcer, the drug Naproxen targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(mesh_heading) LIKE ""%gastric ulcer%"" OR LOWER(efo_term) LIKE ""%gastric ulcer%"") AND (LOWER(drugName) LIKE ""%naproxen%"" OR LOWER(tradeNames_list) LIKE ""%naproxen%"" OR LOWER(syns_list) LIKE ""%naproxen%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_839285', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838383', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839203', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838547', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838465', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838670', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839162', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838711', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839121', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838424', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839531', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839490', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838588', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839613', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838752', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839326', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839244', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838875', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838342', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839367', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838916', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838998', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839039', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839080', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839408', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839572', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839695', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838957', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839449', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838629', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838834', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839654', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838506', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838793', 'drugName': 'Naproxen', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']"", 'syns_list': ""['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838037', 'drugName': 'Naproxen Sodium', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']"", 'syns_list': ""['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']"", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838054', 'drugName': 'Naproxen Sodium', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']"", 'syns_list': ""['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']"", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838088', 'drugName': 'Naproxen Sodium', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']"", 'syns_list': ""['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']"", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838292', 'drugName': 'Naproxen Sodium', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']"", 'syns_list': ""['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']"", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838173', 'drugName': 'Naproxen Sodium', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']"", 'syns_list': ""['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']"", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838105', 'drugName': 'Naproxen Sodium', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']"", 'syns_list': ""['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']"", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838156', 'drugName': 'Naproxen Sodium', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']"", 'syns_list': ""['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']"", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838190', 'drugName': 'Naproxen Sodium', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']"", 'syns_list': ""['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']"", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838207', 'drugName': 'Naproxen Sodium', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']"", 'syns_list': ""['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']"", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838071', 'drugName': 'Naproxen Sodium', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']"", 'syns_list': ""['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']"", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838122', 'drugName': 'Naproxen Sodium', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']"", 'syns_list': ""['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']"", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838224', 'drugName': 'Naproxen Sodium', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']"", 'syns_list': ""['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']"", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838241', 'drugName': 'Naproxen Sodium', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']"", 'syns_list': ""['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']"", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838139', 'drugName': 'Naproxen Sodium', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']"", 'syns_list': ""['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']"", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838258', 'drugName': 'Naproxen Sodium', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']"", 'syns_list': ""['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']"", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838275', 'drugName': 'Naproxen Sodium', 'tradeNames_list': ""['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']"", 'syns_list': ""['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']"", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'gastric ulcer', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}]",general,"Distinct, Multi-Filter, Similarity Search, Order By",Metadata
-Q34.71,Q34,What are the names of the genes that are targeted by the drug Cariprazine Hydrochloride in the treatment of bipolar I disorder?,"In the context of bipolar I disorder, the drug Cariprazine Hydrochloride targets the gene dopamine receptor D2 and dopamine receptor D3.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(mesh_heading) LIKE ""%bipolar i disorder%"" OR LOWER(efo_term) LIKE ""%bipolar i disorder%"") AND (LOWER(drugName) LIKE ""%cariprazine hydrochloride%"" OR LOWER(tradeNames_list) LIKE ""%cariprazine hydrochloride%"" OR LOWER(syns_list) LIKE ""%cariprazine hydrochloride%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_199890', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199899', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199902', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199905', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199911', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199914', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199917', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199923', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199926', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199929', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199932', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199938', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199941', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199944', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199947', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199950', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199953', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199956', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199959', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199962', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199965', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199971', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199974', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199977', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199980', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199983', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199989', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199992', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199995', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199998', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200001', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200004', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200007', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200010', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200013', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200016', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200019', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200022', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200025', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200028', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200031', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200034', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200037', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200040', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200043', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200046', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200049', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200052', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200055', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200058', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200061', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200067', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200070', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200073', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200076', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200064', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199968', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199896', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199884', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199878', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199875', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199920', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199986', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199935', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199908', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199893', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199887', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199881', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': ""['Vraylar']"", 'syns_list': ""['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}]",general,"Distinct, Multi-Filter, Similarity Search, Order By",Metadata
-Q34.430,Q34,What are the names of the genes that are targeted by the drug Selexipag in the treatment of idiopathic and/or familial pulmonary arterial hypertension?,"In the context of idiopathic and/or familial pulmonary arterial hypertension, the drug Selexipag targets the gene prostaglandin I2 receptor.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(mesh_heading) LIKE ""%idiopathic and/or familial pulmonary arterial hypertension%"" OR LOWER(efo_term) LIKE ""%idiopathic and/or familial pulmonary arterial hypertension%"") AND (LOWER(drugName) LIKE ""%selexipag%"" OR LOWER(tradeNames_list) LIKE ""%selexipag%"" OR LOWER(syns_list) LIKE ""%selexipag%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_246145', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246157', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246161', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246165', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246173', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246177', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246181', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246189', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246193', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246197', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246201', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246209', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246213', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246217', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246221', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246225', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246229', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246233', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246237', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246241', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246245', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246253', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246257', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246261', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246265', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246269', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246277', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246281', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246285', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246289', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246293', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246297', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246301', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246305', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246309', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246313', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246317', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246321', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246325', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246329', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246249', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246185', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246153', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246137', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246129', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246125', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246273', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246205', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246169', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246149', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246141', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246133', 'drugName': 'Selexipag', 'tradeNames_list': ""['Uptravi']"", 'syns_list': ""['ACT-293987', 'NS-304', 'Selexipag']"", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}]",general,"Distinct, Multi-Filter, Similarity Search, Order By",Metadata
-Q34.778,Q34,What are the names of the genes that are targeted by the drug Oxymorphone Hydrochloride in the treatment of pain?,"In the context of pain, the drug Oxymorphone Hydrochloride targets the gene opioid receptor mu 1, opioid receptor kappa 1 and opioid receptor delta 1.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(mesh_heading) LIKE ""%pain%"" OR LOWER(efo_term) LIKE ""%pain%"") AND (LOWER(drugName) LIKE ""%oxymorphone hydrochloride%"" OR LOWER(tradeNames_list) LIKE ""%oxymorphone hydrochloride%"" OR LOWER(syns_list) LIKE ""%oxymorphone hydrochloride%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_792215', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792123', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792199', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792130', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792125', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792175', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792134', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792127', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792191', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792138', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792230', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792207', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792142', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792242', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792131', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792171', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792146', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792246', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792133', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792179', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792150', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792135', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792187', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792154', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792225', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792137', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792158', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792233', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792139', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792203', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792162', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792234', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792141', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792211', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792166', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792245', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792143', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792169', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792170', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792243', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792145', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792173', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792174', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792249', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792147', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792177', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792178', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792247', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792149', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792181', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792182', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792151', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792185', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792186', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792222', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792153', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792189', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792227', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792155', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792193', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792194', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792226', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792157', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792197', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792198', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792238', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792159', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792201', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792202', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792231', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792161', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792205', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792206', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792237', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792163', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792209', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792210', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792235', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792165', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792213', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792214', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792250', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792167', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792217', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792218', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792253', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792251', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792239', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792229', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792223', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792221', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792219', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792183', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792190', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792195', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792129', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792241', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792126', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792121', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_792122', 'drugName': 'Oxymorphone Hydrochloride', 'tradeNames_list': ""['Numorphan', 'Opana', 'Opana er', 'Oxymorphone hydrochloride']"", 'syns_list': ""['Oxymorphone hcl', 'Oxymorphone hydrochloride']"", 'yearOfFirstApproval': 1959, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}]",general,"Distinct, Multi-Filter, Similarity Search, Order By",Metadata
-Q34.1622,Q34,What are the names of the genes that are targeted by the drug Dabigatran Etexilate in the treatment of thrombotic disease?,"In the context of thrombotic disease, the drug Dabigatran Etexilate targets the gene coagulation factor II, thrombin.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(mesh_heading) LIKE ""%thrombotic disease%"" OR LOWER(efo_term) LIKE ""%thrombotic disease%"") AND (LOWER(drugName) LIKE ""%dabigatran etexilate%"" OR LOWER(tradeNames_list) LIKE ""%dabigatran etexilate%"" OR LOWER(syns_list) LIKE ""%dabigatran etexilate%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_1092728', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092767', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092780', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092793', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092819', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092832', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092845', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092871', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092884', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092897', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092910', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092936', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092949', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092962', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092975', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092988', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093001', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093014', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093027', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093040', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093053', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093079', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093092', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093105', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093118', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093131', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093157', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093170', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093183', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093196', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093209', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093222', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093235', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093248', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093261', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093274', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093287', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093300', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093313', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093326', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093339', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093352', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093365', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093378', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093391', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093066', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092858', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092754', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092702', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092676', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092663', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093144', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092923', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092806', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092741', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092715', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1092689', 'drugName': 'Dabigatran Etexilate', 'tradeNames_list': ""['Pradaxa']"", 'syns_list': ""['BIBR 1048', 'BIBR 1048 BS RS1', 'BIBR-1048', 'BIBR-1048-BS-RS1Dabigatran etexilate', 'Dabigatran etexilate methanesulfonate']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}]",general,"Distinct, Multi-Filter, Similarity Search, Order By",Metadata
-Q34.1669,Q34,What are the names of the genes that are targeted by the drug Tasimelteon in the treatment of Smith-Magenis syndrome?,"In the context of Smith-Magenis syndrome, the drug Tasimelteon targets the gene melatonin receptor 1A and melatonin receptor 1B.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(mesh_heading) LIKE ""%smith-magenis syndrome%"" OR LOWER(efo_term) LIKE ""%smith-magenis syndrome%"") AND (LOWER(drugName) LIKE ""%tasimelteon%"" OR LOWER(tradeNames_list) LIKE ""%tasimelteon%"" OR LOWER(syns_list) LIKE ""%tasimelteon%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_1094691', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094706', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094707', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094714', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094722', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094723', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094730', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094738', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094739', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094746', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094747', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094755', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094762', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094763', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094770', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094771', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094778', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094779', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094786', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094787', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094794', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094802', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094803', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094810', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094811', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094818', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094826', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094827', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094834', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094835', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094842', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094843', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094850', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094851', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094858', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094859', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094866', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094867', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094874', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094875', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094882', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094883', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094890', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094891', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094898', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094899', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094906', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094907', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094914', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094915', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094922', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094930', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094931', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094938', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094939', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094946', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094947', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094955', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094962', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094963', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094970', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094971', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094978', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094979', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094986', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094987', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094994', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094995', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1095002', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1095003', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1095010', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1095011', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1095018', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1095019', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1095026', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1095027', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1095034', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095035', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095042', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095043', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095050', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095051', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095058', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095059', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095066', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1095067', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1B', 'approvedName': 'melatonin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_1094923', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094795', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094731', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094699', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094683', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094675', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094674', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094954', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094819', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094754', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094715', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Chromosomal anomaly', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094698', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094690', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1094682', 'drugName': 'Tasimelteon', 'tradeNames_list': ""['Hetlioz', 'Hetlioz lq']"", 'syns_list': ""['BMS-214,778', 'BMS-214778', 'Tasimelteon', 'VEC-162']"", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Smith-Magenis Syndrome', 'efo_term': 'Smith-Magenis syndrome', 'approvedSymbol': 'MTNR1A', 'approvedName': 'melatonin receptor 1A'}]",general,"Distinct, Multi-Filter, Similarity Search, Order By",Metadata
-Q34.1262,Q34,What are the names of the genes that are targeted by the drug Progesterone in the treatment of hemorrhage?,"In the context of hemorrhage, the drug Progesterone targets the gene progesterone receptor.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(mesh_heading) LIKE ""%hemorrhage%"" OR LOWER(efo_term) LIKE ""%hemorrhage%"") AND (LOWER(drugName) LIKE ""%progesterone%"" OR LOWER(tradeNames_list) LIKE ""%progesterone%"" OR LOWER(syns_list) LIKE ""%progesterone%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_940054', 'drugName': 'Progesterone', 'tradeNames_list': ""['Crinone', 'Cyclogest', 'Endometrin', 'Gesterol', 'Lutigest', 'MilprosaProchieve', 'Progesta-care', 'Progestasert', 'Progesterone', 'ProgestinPrometrium', 'Regumate', 'Serenity for women', 'Syngestrone', 'Utrogestan']"", 'syns_list': ""['NSC-64377', 'NSC-9704', 'Progesterone', 'Progesterone, micronizedProgesteronum', 'U 3672']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uterine Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940098', 'drugName': 'Progesterone', 'tradeNames_list': ""['Crinone', 'Cyclogest', 'Endometrin', 'Gesterol', 'Lutigest', 'MilprosaProchieve', 'Progesta-care', 'Progestasert', 'Progesterone', 'ProgestinPrometrium', 'Regumate', 'Serenity for women', 'Syngestrone', 'Utrogestan']"", 'syns_list': ""['NSC-64377', 'NSC-9704', 'Progesterone', 'Progesterone, micronizedProgesteronum', 'U 3672']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uterine Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940142', 'drugName': 'Progesterone', 'tradeNames_list': ""['Crinone', 'Cyclogest', 'Endometrin', 'Gesterol', 'Lutigest', 'MilprosaProchieve', 'Progesta-care', 'Progestasert', 'Progesterone', 'ProgestinPrometrium', 'Regumate', 'Serenity for women', 'Syngestrone', 'Utrogestan']"", 'syns_list': ""['NSC-64377', 'NSC-9704', 'Progesterone', 'Progesterone, micronizedProgesteronum', 'U 3672']"", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Uterine Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}]",general,"Distinct, Multi-Filter, Similarity Search, Order By",Metadata
-Q34.1961,Q34,What are the names of the genes that are targeted by the drug Opicapone in the treatment of Parkinson disease?,"In the context of Parkinson disease, the drug Opicapone targets the gene catechol-O-methyltransferase.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(mesh_heading) LIKE ""%parkinson disease%"" OR LOWER(efo_term) LIKE ""%parkinson disease%"") AND (LOWER(drugName) LIKE ""%opicapone%"" OR LOWER(tradeNames_list) LIKE ""%opicapone%"" OR LOWER(syns_list) LIKE ""%opicapone%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_1193366', 'drugName': 'Opicapone', 'tradeNames_list': ""['Ongentys']"", 'syns_list': ""['BIA 9-1067', 'BIA-9-1067', 'BIA-91067', 'Ongentys', 'Opicapone']"", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'COMT', 'approvedName': 'catechol-O-methyltransferase'}, {'UUID': 'DrugTargetsIndication121923_text_1193369', 'drugName': 'Opicapone', 'tradeNames_list': ""['Ongentys']"", 'syns_list': ""['BIA 9-1067', 'BIA-9-1067', 'BIA-91067', 'Ongentys', 'Opicapone']"", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'COMT', 'approvedName': 'catechol-O-methyltransferase'}, {'UUID': 'DrugTargetsIndication121923_text_1193370', 'drugName': 'Opicapone', 'tradeNames_list': ""['Ongentys']"", 'syns_list': ""['BIA 9-1067', 'BIA-9-1067', 'BIA-91067', 'Ongentys', 'Opicapone']"", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'COMT', 'approvedName': 'catechol-O-methyltransferase'}, {'UUID': 'DrugTargetsIndication121923_text_1193371', 'drugName': 'Opicapone', 'tradeNames_list': ""['Ongentys']"", 'syns_list': ""['BIA 9-1067', 'BIA-9-1067', 'BIA-91067', 'Ongentys', 'Opicapone']"", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'COMT', 'approvedName': 'catechol-O-methyltransferase'}, {'UUID': 'DrugTargetsIndication121923_text_1193373', 'drugName': 'Opicapone', 'tradeNames_list': ""['Ongentys']"", 'syns_list': ""['BIA 9-1067', 'BIA-9-1067', 'BIA-91067', 'Ongentys', 'Opicapone']"", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'COMT', 'approvedName': 'catechol-O-methyltransferase'}, {'UUID': 'DrugTargetsIndication121923_text_1193374', 'drugName': 'Opicapone', 'tradeNames_list': ""['Ongentys']"", 'syns_list': ""['BIA 9-1067', 'BIA-9-1067', 'BIA-91067', 'Ongentys', 'Opicapone']"", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'COMT', 'approvedName': 'catechol-O-methyltransferase'}, {'UUID': 'DrugTargetsIndication121923_text_1193375', 'drugName': 'Opicapone', 'tradeNames_list': ""['Ongentys']"", 'syns_list': ""['BIA 9-1067', 'BIA-9-1067', 'BIA-91067', 'Ongentys', 'Opicapone']"", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'COMT', 'approvedName': 'catechol-O-methyltransferase'}, {'UUID': 'DrugTargetsIndication121923_text_1193377', 'drugName': 'Opicapone', 'tradeNames_list': ""['Ongentys']"", 'syns_list': ""['BIA 9-1067', 'BIA-9-1067', 'BIA-91067', 'Ongentys', 'Opicapone']"", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'COMT', 'approvedName': 'catechol-O-methyltransferase'}, {'UUID': 'DrugTargetsIndication121923_text_1193378', 'drugName': 'Opicapone', 'tradeNames_list': ""['Ongentys']"", 'syns_list': ""['BIA 9-1067', 'BIA-9-1067', 'BIA-91067', 'Ongentys', 'Opicapone']"", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'COMT', 'approvedName': 'catechol-O-methyltransferase'}, {'UUID': 'DrugTargetsIndication121923_text_1193379', 'drugName': 'Opicapone', 'tradeNames_list': ""['Ongentys']"", 'syns_list': ""['BIA 9-1067', 'BIA-9-1067', 'BIA-91067', 'Ongentys', 'Opicapone']"", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'COMT', 'approvedName': 'catechol-O-methyltransferase'}, {'UUID': 'DrugTargetsIndication121923_text_1193380', 'drugName': 'Opicapone', 'tradeNames_list': ""['Ongentys']"", 'syns_list': ""['BIA 9-1067', 'BIA-9-1067', 'BIA-91067', 'Ongentys', 'Opicapone']"", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'COMT', 'approvedName': 'catechol-O-methyltransferase'}, {'UUID': 'DrugTargetsIndication121923_text_1193382', 'drugName': 'Opicapone', 'tradeNames_list': ""['Ongentys']"", 'syns_list': ""['BIA 9-1067', 'BIA-9-1067', 'BIA-91067', 'Ongentys', 'Opicapone']"", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'COMT', 'approvedName': 'catechol-O-methyltransferase'}, {'UUID': 'DrugTargetsIndication121923_text_1193376', 'drugName': 'Opicapone', 'tradeNames_list': ""['Ongentys']"", 'syns_list': ""['BIA 9-1067', 'BIA-9-1067', 'BIA-91067', 'Ongentys', 'Opicapone']"", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'COMT', 'approvedName': 'catechol-O-methyltransferase'}, {'UUID': 'DrugTargetsIndication121923_text_1193368', 'drugName': 'Opicapone', 'tradeNames_list': ""['Ongentys']"", 'syns_list': ""['BIA 9-1067', 'BIA-9-1067', 'BIA-91067', 'Ongentys', 'Opicapone']"", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'COMT', 'approvedName': 'catechol-O-methyltransferase'}, {'UUID': 'DrugTargetsIndication121923_text_1193364', 'drugName': 'Opicapone', 'tradeNames_list': ""['Ongentys']"", 'syns_list': ""['BIA 9-1067', 'BIA-9-1067', 'BIA-91067', 'Ongentys', 'Opicapone']"", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'COMT', 'approvedName': 'catechol-O-methyltransferase'}, {'UUID': 'DrugTargetsIndication121923_text_1193362', 'drugName': 'Opicapone', 'tradeNames_list': ""['Ongentys']"", 'syns_list': ""['BIA 9-1067', 'BIA-9-1067', 'BIA-91067', 'Ongentys', 'Opicapone']"", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'COMT', 'approvedName': 'catechol-O-methyltransferase'}, {'UUID': 'DrugTargetsIndication121923_text_1193361', 'drugName': 'Opicapone', 'tradeNames_list': ""['Ongentys']"", 'syns_list': ""['BIA 9-1067', 'BIA-9-1067', 'BIA-91067', 'Ongentys', 'Opicapone']"", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'COMT', 'approvedName': 'catechol-O-methyltransferase'}, {'UUID': 'DrugTargetsIndication121923_text_1193381', 'drugName': 'Opicapone', 'tradeNames_list': ""['Ongentys']"", 'syns_list': ""['BIA 9-1067', 'BIA-9-1067', 'BIA-91067', 'Ongentys', 'Opicapone']"", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'COMT', 'approvedName': 'catechol-O-methyltransferase'}, {'UUID': 'DrugTargetsIndication121923_text_1193372', 'drugName': 'Opicapone', 'tradeNames_list': ""['Ongentys']"", 'syns_list': ""['BIA 9-1067', 'BIA-9-1067', 'BIA-91067', 'Ongentys', 'Opicapone']"", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'COMT', 'approvedName': 'catechol-O-methyltransferase'}, {'UUID': 'DrugTargetsIndication121923_text_1193367', 'drugName': 'Opicapone', 'tradeNames_list': ""['Ongentys']"", 'syns_list': ""['BIA 9-1067', 'BIA-9-1067', 'BIA-91067', 'Ongentys', 'Opicapone']"", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'COMT', 'approvedName': 'catechol-O-methyltransferase'}, {'UUID': 'DrugTargetsIndication121923_text_1193365', 'drugName': 'Opicapone', 'tradeNames_list': ""['Ongentys']"", 'syns_list': ""['BIA 9-1067', 'BIA-9-1067', 'BIA-91067', 'Ongentys', 'Opicapone']"", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'COMT', 'approvedName': 'catechol-O-methyltransferase'}, {'UUID': 'DrugTargetsIndication121923_text_1193363', 'drugName': 'Opicapone', 'tradeNames_list': ""['Ongentys']"", 'syns_list': ""['BIA 9-1067', 'BIA-9-1067', 'BIA-91067', 'Ongentys', 'Opicapone']"", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parkinson Disease', 'efo_term': 'Parkinson disease', 'approvedSymbol': 'COMT', 'approvedName': 'catechol-O-methyltransferase'}]",general,"Distinct, Multi-Filter, Similarity Search, Order By",Metadata
-Q34.384,Q34,What are the names of the genes that are targeted by the drug Mometasone Furoate in the treatment of Nasal polyposis?,"In the context of Nasal polyposis, the drug Mometasone Furoate targets the gene nuclear receptor subfamily 3 group C member 1.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(mesh_heading) LIKE ""%nasal polyposis%"" OR LOWER(efo_term) LIKE ""%nasal polyposis%"") AND (LOWER(drugName) LIKE ""%mometasone furoate%"" OR LOWER(tradeNames_list) LIKE ""%mometasone furoate%"" OR LOWER(syns_list) LIKE ""%mometasone furoate%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_242038', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242116', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242142', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242168', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242220', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242090', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241986', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241934', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241908', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242194', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242064', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242012', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241960', 'drugName': 'Mometasone Furoate', 'tradeNames_list': ""['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']"", 'syns_list': ""['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']"", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}]",general,"Distinct, Multi-Filter, Similarity Search, Order By",Metadata
-Q34.1158,Q34,What are the names of the genes that are targeted by the drug Trametinib in the treatment of cervical cancer?,"Trametinib has not been approved by the FDA as a treatment for cervical cancer, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target names are  mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(mesh_heading) LIKE ""%cervical cancer%"" OR LOWER(efo_term) LIKE ""%cervical cancer%"") AND (LOWER(drugName) LIKE ""%trametinib%"" OR LOWER(tradeNames_list) LIKE ""%trametinib%"" OR LOWER(syns_list) LIKE ""%trametinib%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_928706', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928826', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928866', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928906', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928986', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929026', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929066', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929146', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929186', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929226', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929266', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929346', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929386', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929426', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929466', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929506', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929546', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929586', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929626', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929666', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929706', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929786', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929826', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929866', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929906', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929946', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930026', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930066', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930106', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930146', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930186', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930226', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930266', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930306', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930346', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930386', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930426', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930466', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930506', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930546', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930586', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930626', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930666', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930706', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930746', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930786', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930826', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930866', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930906', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930946', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930986', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931066', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931106', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931146', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931186', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931226', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931266', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931346', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931386', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931426', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931466', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931506', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931546', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931586', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931626', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931666', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931706', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931746', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931786', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931826', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931866', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931906', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931946', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931986', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932026', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932066', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932106', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932146', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932186', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932226', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932266', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932306', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932346', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932386', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932426', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932466', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931026', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929746', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929106', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928786', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928626', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928546', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928506', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_931306', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929986', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929306', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928946', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928746', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928666', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928586', 'drugName': 'Trametinib', 'tradeNames_list': ""['Mekinist']"", 'syns_list': ""['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']"", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Cervical Neoplasms', 'efo_term': 'cervical cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}]",general,"Distinct, Multi-Filter, Similarity Search, Order By",Metadata
-Q34.1447,Q34,What are the names of the genes that are targeted by the drug Liraglutide in the treatment of type 2 diabetes mellitus?,"In the context of type 2 diabetes mellitus, the drug Liraglutide targets the gene glucagon like peptide 1 receptor.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(mesh_heading) LIKE ""%type 2 diabetes mellitus%"" OR LOWER(efo_term) LIKE ""%type 2 diabetes mellitus%"") AND (LOWER(drugName) LIKE ""%liraglutide%"" OR LOWER(tradeNames_list) LIKE ""%liraglutide%"" OR LOWER(syns_list) LIKE ""%liraglutide%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_1044540', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044609', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044632', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044655', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044701', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044724', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044747', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044793', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044816', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044839', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044862', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044908', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044931', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044954', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044977', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045000', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045023', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045046', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045069', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045092', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045115', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045161', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045184', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045207', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045230', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045253', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045299', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045322', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045345', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045368', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045391', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045414', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045437', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045460', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045483', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045506', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045529', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045552', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045575', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045598', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045621', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045644', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045667', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045690', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045713', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045138', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044770', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044586', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044494', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044448', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044425', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045276', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044885', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044678', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044563', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044517', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1044471', 'drugName': 'Liraglutide', 'tradeNames_list': ""['Saxenda', 'Victoza']"", 'syns_list': ""['Liraglutide', 'Liraglutide (rdna origin)', 'Liraglutide recombinantNN-2211', 'NN-9924', 'NN2211', 'NN9924', 'NNC 90-1170', 'NNC-90-1170']"", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}]",general,"Distinct, Multi-Filter, Similarity Search, Order By",Metadata
-Q34.1430,Q34,What are the names of the genes that are targeted by the drug Amlodipine Besylate in the treatment of hypertension?,"In the context of hypertension, the drug Amlodipine Besylate targets the gene calcium voltage-gated channel subunit alpha1 C, calcium voltage-gated channel subunit alpha1 S, calcium voltage-gated channel subunit alpha1 D and calcium voltage-gated channel subunit alpha1 F.","SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
- FROM `card-ai-389220.bio_sql_benchmark.DrugTargets_IndicationsAndTherapeuticUses` 
- WHERE (LOWER(mesh_heading) LIKE ""%hypertension%"" OR LOWER(efo_term) LIKE ""%hypertension%"") AND (LOWER(drugName) LIKE ""%amlodipine besylate%"" OR LOWER(tradeNames_list) LIKE ""%amlodipine besylate%"" OR LOWER(syns_list) LIKE ""%amlodipine besylate%"")
- ORDER BY max_phase_for_ind DESC
- LIMIT 100","[{'UUID': 'DrugTargetsIndication121923_text_1043678', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043902', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043860', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043916', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043776', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043944', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043832', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043706', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043818', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043762', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043958', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043720', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043748', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043664', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043874', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043972', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043930', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043692', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043804', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043888', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043734', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043986', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043790', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043846', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043829', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043843', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043871', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043745', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043661', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043703', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043857', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043717', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043773', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043885', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043787', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043913', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043927', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043899', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1043731', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043801', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043941', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043955', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043689', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043815', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1043969', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043983', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1043675', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043759', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': ""['Amlodipine besylate', 'Norliqva', 'Norvasc']"", 'syns_list': ""['Amlodipine (as besilate)', 'Amlodipine benzenesulfonateAmlodipine besilate', 'Amlodipine besylate', 'Amlor', 'AntacalLodipressin', 'Monopina', 'NSC-758922', 'Norliqva', 'UK-48,340-26UK-48340-26']"", 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Essential Hypertension', 'efo_term': 'essential hypertension', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}]",general,"Distinct, Multi-Filter, Similarity Search, Order By",Metadata
-Q52.1861,Q52,What is the relevance of the gene ZNF728 in Lewy Body Dementia using SMR calculations?,There are no SNPs within ZNF728 that are significant in Lewy Body Dementia.,"SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, b_SMR
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'LBD' AND Gene = 'ZNF728' AND p_SMR_multi < 2.95e-6
- LIMIT 100",[],refined,"Select, Multi-Filter, Threshold",SMR Significance
-Q52.354,Q52,What is the relevance of the gene CHRM3-AS2 in Frontotemporal Dementia using SMR calculations?,There are no SNPs within CHRM3-AS2 that are significant in Frontotemporal Dementia.,"SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, b_SMR
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'FTD' AND Gene = 'CHRM3-AS2' AND p_SMR_multi < 2.95e-6
- LIMIT 100",[],refined,"Select, Multi-Filter, Threshold",SMR Significance
-Q52.1334,Q52,What is the relevance of the gene ARL17A in Alzheimer's Disease using SMR calculations?,"There are 6 SNPs within ARL17A that are significant in Alzheimer's Disease:
-• rs2532233
-    • Cortex: Adjusted SMR multi-SNP P-value: 1.16e-07; HEIDI: -1.00e+04
-• rs58879558
-    • Multi Ancestry Whole Brain: Adjusted SMR multi-SNP P-value: 2.12e-07; HEIDI: 5.5704e-01
-• rs62074125
-    • Whole Blood: Adjusted SMR multi-SNP P-value: 2.60e-07; HEIDI: 5.66e-08
-• rs2696466
-    • Prefrontal Cortex: Adjusted SMR multi-SNP P-value: 9.79e-07; HEIDI: 2.6002e-03
-• rs2732650
-    • Skeletal Muscle: Adjusted SMR multi-SNP P-value: 2.76e-06; HEIDI: -1.00e+04
-• rs17573607
-    • Hypothalamus: Adjusted SMR multi-SNP P-value: 2.93e-06; HEIDI: 4.6477e-01
-","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, b_SMR
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'AD' AND Gene = 'ARL17A' AND p_SMR_multi < 2.95e-6
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_1106834', 'topRSID': 'rs2532233', 'Disease': 'AD', 'Gene': 'ARL17A', 'p_SMR_multi': 1.156287e-07, 'p_HEIDI': -9999.0, 'b_SMR': -0.051123}, {'UUID': 'NDD_SMR_genes_all_update_text_1203023', 'topRSID': 'rs2696466', 'Disease': 'AD', 'Gene': 'ARL17A', 'p_SMR_multi': 9.787664e-07, 'p_HEIDI': 0.002600192, 'b_SMR': -0.1348}, {'UUID': 'NDD_SMR_genes_all_update_text_1291769', 'topRSID': 'rs62074125', 'Disease': 'AD', 'Gene': 'ARL17A', 'p_SMR_multi': 2.553728e-06, 'p_HEIDI': 3.862198e-07, 'b_SMR': 0.0494109}, {'UUID': 'NDD_SMR_genes_all_update_text_1343162', 'topRSID': 'rs2732650', 'Disease': 'AD', 'Gene': 'ARL17A', 'p_SMR_multi': 2.755616e-06, 'p_HEIDI': -9999.0, 'b_SMR': -0.0862851}, {'UUID': 'NDD_SMR_genes_all_update_text_1396753', 'topRSID': 'rs58879558', 'Disease': 'AD', 'Gene': 'ARL17A', 'p_SMR_multi': 2.124628e-07, 'p_HEIDI': 0.5570384, 'b_SMR': -0.0813564}, {'UUID': 'NDD_SMR_genes_all_update_text_1454365', 'topRSID': 'rs17573607', 'Disease': 'AD', 'Gene': 'ARL17A', 'p_SMR_multi': 2.926866e-06, 'p_HEIDI': 0.4647684, 'b_SMR': -0.0523832}, {'UUID': 'NDD_SMR_genes_all_update_text_1502457', 'topRSID': 'rs62074125', 'Disease': 'AD', 'Gene': 'ARL17A', 'p_SMR_multi': 2.59862e-07, 'p_HEIDI': 5.662189e-08, 'b_SMR': 0.0874934}]",refined,"Select, Multi-Filter, Threshold",SMR Significance
-Q52.906,Q52,What is the relevance of the gene RP11-95O2.5 in Alzheimer's Disease using SMR calculations?,There are no SNPs within RP11-95O2.5 that are significant in Alzheimer's Disease.,"SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, b_SMR
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'AD' AND Gene = 'RP11-95O2.5' AND p_SMR_multi < 2.95e-6
- LIMIT 100",[],refined,"Select, Multi-Filter, Threshold",SMR Significance
-Q52.1290,Q52,What is the relevance of the gene ARPC4-TTLL3 in Progressive supranuclear palsy using SMR calculations?,There are no SNPs within ARPC4-TTLL3 that are significant in Progressive supranuclear palsy.,"SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, b_SMR
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'PSP' AND Gene = 'ARPC4-TTLL3' AND p_SMR_multi < 2.95e-6
- LIMIT 100",[],refined,"Select, Multi-Filter, Threshold",SMR Significance
-Q52.1274,Q52,What is the relevance of the gene ERCC2 in Parkinson's Disease using SMR calculations?,There are no SNPs within ERCC2 that are significant in Parkinson's Disease.,"SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, b_SMR
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'PD' AND Gene = 'ERCC2' AND p_SMR_multi < 2.95e-6
- LIMIT 100",[],refined,"Select, Multi-Filter, Threshold",SMR Significance
-Q52.939,Q52,What is the relevance of the gene SFTA2 in Alzheimer's Disease using SMR calculations?,"There are 3 SNPs within SFTA2 that are significant in Alzheimer's Disease:
-• rs2233980
-    • Whole Blood: Adjusted SMR multi-SNP P-value: 4.14e-08; HEIDI: 2.2532e-02
-• rs3132556
-    • Whole Blood: Adjusted SMR multi-SNP P-value: 1.03e-07; HEIDI: 1.3240e-01
-• rs2233974
-    • Whole Blood: Adjusted SMR multi-SNP P-value: 2.04e-07; HEIDI: 1.0480e-01
-","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, b_SMR
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'AD' AND Gene = 'SFTA2' AND p_SMR_multi < 2.95e-6
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_620615', 'topRSID': 'rs2233974', 'Disease': 'AD', 'Gene': 'SFTA2', 'p_SMR_multi': 2.037498e-07, 'p_HEIDI': 0.1048014, 'b_SMR': 0.0132239}, {'UUID': 'NDD_SMR_genes_all_update_text_620616', 'topRSID': 'rs2233980', 'Disease': 'AD', 'Gene': 'SFTA2', 'p_SMR_multi': 4.13716e-08, 'p_HEIDI': 0.02253225, 'b_SMR': 0.00995464}, {'UUID': 'NDD_SMR_genes_all_update_text_620617', 'topRSID': 'rs3132556', 'Disease': 'AD', 'Gene': 'SFTA2', 'p_SMR_multi': 1.025352e-07, 'p_HEIDI': 0.1323954, 'b_SMR': 0.0141394}]",refined,"Select, Multi-Filter, Threshold",SMR Significance
-Q52.1732,Q52,What is the relevance of the gene OR4C3 in Progressive supranuclear palsy using SMR calculations?,There are no SNPs within OR4C3 that are significant in Progressive supranuclear palsy.,"SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, b_SMR
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'PSP' AND Gene = 'OR4C3' AND p_SMR_multi < 2.95e-6
- LIMIT 100",[],refined,"Select, Multi-Filter, Threshold",SMR Significance
-Q52.66,Q52,What is the relevance of the gene RPS26P8 in Alzheimer's Disease using SMR calculations?,"There are 2 SNPs within RPS26P8 that are significant in Alzheimer's Disease:
-• rs2732705
-    • Prefrontal Cortex: Adjusted SMR multi-SNP P-value: 1.84e-06; HEIDI: 4.7832e-02
-• rs55974014
-    • Tibial Nerve: Adjusted SMR multi-SNP P-value: 2.81e-06; HEIDI: -1.00e+04
-","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, b_SMR
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'AD' AND Gene = 'RPS26P8' AND p_SMR_multi < 2.95e-6
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_1203003', 'topRSID': 'rs2732705', 'Disease': 'AD', 'Gene': 'RPS26P8', 'p_SMR_multi': 1.839777e-06, 'p_HEIDI': 0.04783226, 'b_SMR': -0.121657}, {'UUID': 'NDD_SMR_genes_all_update_text_1291756', 'topRSID': 'rs55974014', 'Disease': 'AD', 'Gene': 'RPS26P8', 'p_SMR_multi': 2.810521e-06, 'p_HEIDI': -9999.0, 'b_SMR': -0.0555104}]",refined,"Select, Multi-Filter, Threshold",SMR Significance
-Q52.1324,Q52,What is the relevance of the gene AP006216.11 in Frontotemporal Dementia using SMR calculations?,There are no SNPs within AP006216.11 that are significant in Frontotemporal Dementia.,"SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, b_SMR
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'FTD' AND Gene = 'AP006216.11' AND p_SMR_multi < 2.95e-6
- LIMIT 100",[],refined,"Select, Multi-Filter, Threshold",SMR Significance
-Q52.57,Q52,What is the relevance of the gene SLC6A10P in Alzheimer's Disease using SMR calculations?,There are no SNPs within SLC6A10P that are significant in Alzheimer's Disease.,"SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, b_SMR
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'AD' AND Gene = 'SLC6A10P' AND p_SMR_multi < 2.95e-6
- LIMIT 100",[],refined,"Select, Multi-Filter, Threshold",SMR Significance
-Q52.1293,Q52,What is the relevance of the gene SENP1 in Frontotemporal Dementia using SMR calculations?,There are no SNPs within SENP1 that are significant in Frontotemporal Dementia.,"SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, b_SMR
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'FTD' AND Gene = 'SENP1' AND p_SMR_multi < 2.95e-6
- LIMIT 100",[],refined,"Select, Multi-Filter, Threshold",SMR Significance
-Q52.1119,Q52,What is the relevance of the gene GGCX in Lewy Body Dementia using SMR calculations?,There are no SNPs within GGCX that are significant in Lewy Body Dementia.,"SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, b_SMR
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'LBD' AND Gene = 'GGCX' AND p_SMR_multi < 2.95e-6
- LIMIT 100",[],refined,"Select, Multi-Filter, Threshold",SMR Significance
-Q52.585,Q52,What is the relevance of the gene ITGAX in Alzheimer's Disease using SMR calculations?,"There is 1 SNP within ITGAX that is significant in Alzheimer's Disease:
-• rs11574631
-    • Whole Blood: Adjusted SMR multi-SNP P-value: 3.17e-08; HEIDI: 3.2628e-04
-","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, b_SMR
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'AD' AND Gene = 'ITGAX' AND p_SMR_multi < 2.95e-6
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_1501486', 'topRSID': 'rs11574631', 'Disease': 'AD', 'Gene': 'ITGAX', 'p_SMR_multi': 3.173201e-08, 'p_HEIDI': 0.0003262819, 'b_SMR': 0.0360512}]",refined,"Select, Multi-Filter, Threshold",SMR Significance
-Q52.375,Q52,What is the relevance of the gene C7orf59 in Alzheimer's Disease using SMR calculations?,"There are 2 SNPs within C7orf59 that are significant in Alzheimer's Disease:
-• rs11771139
-    • Whole Blood: Adjusted SMR multi-SNP P-value: 3.98e-13; HEIDI: 8.91e-06
-• rs60458236
-    • Whole Brain: Adjusted SMR multi-SNP P-value: 3.31e-09; HEIDI: 7.86e-06
-","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, b_SMR
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'AD' AND Gene = 'C7orf59' AND p_SMR_multi < 2.95e-6
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_74040', 'topRSID': 'rs60458236', 'Disease': 'AD', 'Gene': 'C7orf59', 'p_SMR_multi': 3.313887e-09, 'p_HEIDI': 7.857328e-06, 'b_SMR': 0.0374152}, {'UUID': 'NDD_SMR_genes_all_update_text_585977', 'topRSID': 'rs11771139', 'Disease': 'AD', 'Gene': 'C7orf59', 'p_SMR_multi': 3.977226e-13, 'p_HEIDI': 8.913888e-06, 'b_SMR': 0.0575781}]",refined,"Select, Multi-Filter, Threshold",SMR Significance
-Q52.276,Q52,What is the relevance of the gene LCN1 in Frontotemporal Dementia using SMR calculations?,There are no SNPs within LCN1 that are significant in Frontotemporal Dementia.,"SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, b_SMR
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'FTD' AND Gene = 'LCN1' AND p_SMR_multi < 2.95e-6
- LIMIT 100",[],refined,"Select, Multi-Filter, Threshold",SMR Significance
-Q63.1861,Q63,What is the maximum clinical trial phase for the drug Nitisinone?,Nitisinone reached phase 4 clinical trials.,"SELECT DISTINCT UUID, drugName, drugSynonyms_string, tradeNames_string, yearOfFirstApproval, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%nitisinone%"" OR LOWER(tradeNames_string) LIKE ""%nitisinone%"" OR LOWER(drugSynonyms_string) LIKE ""%nitisinone%"") 
- ORDER BY maxClinicalTrialPhase desc
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_4714', 'drugName': 'Nitisinone', 'drugSynonyms_string': 'Nitisinone, SC-0735', 'tradeNames_string': 'Nityr, Orfadin', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4}]",general,"Distinct, Similarity Search, Order By",Trial Phase
-Q63.354,Q63,What is the maximum clinical trial phase for the drug Tetrabenazine?,Tetrabenazine reached phase 4 clinical trials.,"SELECT DISTINCT UUID, drugName, drugSynonyms_string, tradeNames_string, yearOfFirstApproval, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%tetrabenazine%"" OR LOWER(tradeNames_string) LIKE ""%tetrabenazine%"" OR LOWER(drugSynonyms_string) LIKE ""%tetrabenazine%"") 
- ORDER BY maxClinicalTrialPhase desc
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3455', 'drugName': 'Tetrabenazine', 'drugSynonyms_string': 'NSC-169886, RO 1-9569, RO-1-9569, RO-19569, Tetrabenazine', 'tradeNames_string': 'Nitoman, Revocon, Tetmodis, Tetrabenazine, Xenazine, Xenazine 25', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1735', 'drugName': 'Dutetrabenazine', 'drugSynonyms_string': 'Deutetrabenazine, Dutetrabenazine, SD-809', 'tradeNames_string': 'Austedo', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4}]",general,"Distinct, Similarity Search, Order By",Trial Phase
-Q63.1334,Q63,What is the maximum clinical trial phase for the drug Lutikizumab?,Lutikizumab reached phase 2 clinical trials.,"SELECT DISTINCT UUID, drugName, drugSynonyms_string, tradeNames_string, yearOfFirstApproval, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%lutikizumab%"" OR LOWER(tradeNames_string) LIKE ""%lutikizumab%"" OR LOWER(drugSynonyms_string) LIKE ""%lutikizumab%"") 
- ORDER BY maxClinicalTrialPhase desc
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_573', 'drugName': 'Lutikizumab', 'drugSynonyms_string': 'A-1234138, ABT-981, Abt-981, Lutikizumab', 'tradeNames_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_574', 'drugName': 'Lutikizumab', 'drugSynonyms_string': 'A-1234138, ABT-981, Abt-981, Lutikizumab', 'tradeNames_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2}]",general,"Distinct, Similarity Search, Order By",Trial Phase
-Q63.906,Q63,What is the maximum clinical trial phase for the drug Dsp-2230?,Dsp-2230 reached phase 1 clinical trials.,"SELECT DISTINCT UUID, drugName, drugSynonyms_string, tradeNames_string, yearOfFirstApproval, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%dsp-2230%"" OR LOWER(tradeNames_string) LIKE ""%dsp-2230%"" OR LOWER(drugSynonyms_string) LIKE ""%dsp-2230%"") 
- ORDER BY maxClinicalTrialPhase desc
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_5488', 'drugName': 'Dsp-2230', 'drugSynonyms_string': 'Dsp-2230', 'tradeNames_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5489', 'drugName': 'Dsp-2230', 'drugSynonyms_string': 'Dsp-2230', 'tradeNames_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1}]",general,"Distinct, Similarity Search, Order By",Trial Phase
-Q63.1290,Q63,What is the maximum clinical trial phase for the drug Theophylline?,Theophylline reached phase 4 clinical trials.,"SELECT DISTINCT UUID, drugName, drugSynonyms_string, tradeNames_string, yearOfFirstApproval, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%theophylline%"" OR LOWER(tradeNames_string) LIKE ""%theophylline%"" OR LOWER(drugSynonyms_string) LIKE ""%theophylline%"") 
- ORDER BY maxClinicalTrialPhase desc
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_5472', 'drugName': 'Aminophylline', 'drugSynonyms_string': 'Aminophylline, Aminophyllinum, Cardophyllin, Linampheta, NSC-7919, Syntophyllin, Theophyllamine, Theophylline ethylenediamine, Theophylline-ethylenediamine', 'tradeNames_string': 'Aminophyllin, Aminophylline, Aminophylline In Sodium Chloride, Aminophylline dye free, Ammophyllin, Amnivent-225 sr, Amnivent-350 sr, Peterphyllin, Phyllocontin, Somophyllin, Somophyllin-df, Truphylline', 'yearOfFirstApproval': 1940, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3799', 'drugName': 'Oxtriphylline', 'drugSynonyms_string': 'Choline theophyllinate, Choline theophylline, Cholinophyllin, NSC-760431, Oxtriphylline, Theocolin', 'tradeNames_string': 'Choledyl, Choledyl sa, Oxtriphylline, Oxtriphylline pediatric, Sabidal', 'yearOfFirstApproval': 1981, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_955', 'drugName': 'Theophylline Sodium Glycinate', 'drugSynonyms_string': 'Bronchoparat, Englate, Glycin theophyllinate, Glytheonate, Panophylline, Theonate sodium, Theophylline sodium glycinate', 'tradeNames_string': 'Asbron, Synophylate', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_956', 'drugName': 'Theophylline Sodium Glycinate', 'drugSynonyms_string': 'Bronchoparat, Englate, Glycin theophyllinate, Glytheonate, Panophylline, Theonate sodium, Theophylline sodium glycinate', 'tradeNames_string': 'Asbron, Synophylate', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2662', 'drugName': 'Theophylline Glycinate', 'drugSynonyms_string': '', 'tradeNames_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2663', 'drugName': 'Theophylline Glycinate', 'drugSynonyms_string': '', 'tradeNames_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2664', 'drugName': 'Theophylline Glycinate', 'drugSynonyms_string': '', 'tradeNames_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3798', 'drugName': 'Oxtriphylline', 'drugSynonyms_string': 'Choline theophyllinate, Choline theophylline, Cholinophyllin, NSC-760431, Oxtriphylline, Theocolin', 'tradeNames_string': 'Choledyl, Choledyl sa, Oxtriphylline, Oxtriphylline pediatric, Sabidal', 'yearOfFirstApproval': 1981, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5470', 'drugName': 'Aminophylline', 'drugSynonyms_string': 'Aminophylline, Aminophyllinum, Cardophyllin, Linampheta, NSC-7919, Syntophyllin, Theophyllamine, Theophylline ethylenediamine, Theophylline-ethylenediamine', 'tradeNames_string': 'Aminophyllin, Aminophylline, Aminophylline In Sodium Chloride, Aminophylline dye free, Ammophyllin, Amnivent-225 sr, Amnivent-350 sr, Peterphyllin, Phyllocontin, Somophyllin, Somophyllin-df, Truphylline', 'yearOfFirstApproval': 1940, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4547', 'drugName': 'Theophylline', 'drugSynonyms_string': 'Dimethylxanthine, Doxophylline metabolite m3, NSC-2066, NSC-757346, Theophylline, Theophylline anhydrous, Theophylline melting point standard, Theophylline monohydrate, Theophylline, anhydrous, Theophylline,anhydrous', 'tradeNames_string': 'Accurbron, Aerolate, Aerolate iii, Aerolate jr, Aerolate sr, Aquaphyllin, Bronkodyl, Duraphyl, Elixicon, Elixomin, Elixophyllin, Elixophyllin sr, Labid, Lanophyllin, Lasma, Nuelin, Nuelin sa, Nuelin sa-250, Pro-vent, Quibron, Quibron-t, Quibron-t/sr, Respbid, Slo-bid, Slo-phyllin, Somophyllin-crt, Somophyllin-t, Sustaire, T-phyl, Theo-24, Theo-dur, Theobid, Theobid jr., Theochron, Theocin, Theoclear l.a.-130, Theoclear l.a.-260, Theoclear-100, Theoclear-200, Theoclear-80, Theograd, Theolair, Theolair-sr, Theolixir, Theophyl, Theophyl-225, Theophyl-sr, Theophylline, Theophylline-sr, Theovent, Uni-dur, Uniphyl, Uniphyllin continus', 'yearOfFirstApproval': 1940, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4546', 'drugName': 'Theophylline', 'drugSynonyms_string': 'Dimethylxanthine, Doxophylline metabolite m3, NSC-2066, NSC-757346, Theophylline, Theophylline anhydrous, Theophylline melting point standard, Theophylline monohydrate, Theophylline, anhydrous, Theophylline,anhydrous', 'tradeNames_string': 'Accurbron, Aerolate, Aerolate iii, Aerolate jr, Aerolate sr, Aquaphyllin, Bronkodyl, Duraphyl, Elixicon, Elixomin, Elixophyllin, Elixophyllin sr, Labid, Lanophyllin, Lasma, Nuelin, Nuelin sa, Nuelin sa-250, Pro-vent, Quibron, Quibron-t, Quibron-t/sr, Respbid, Slo-bid, Slo-phyllin, Somophyllin-crt, Somophyllin-t, Sustaire, T-phyl, Theo-24, Theo-dur, Theobid, Theobid jr., Theochron, Theocin, Theoclear l.a.-130, Theoclear l.a.-260, Theoclear-100, Theoclear-200, Theoclear-80, Theograd, Theolair, Theolair-sr, Theolixir, Theophyl, Theophyl-225, Theophyl-sr, Theophylline, Theophylline-sr, Theovent, Uni-dur, Uniphyl, Uniphyllin continus', 'yearOfFirstApproval': 1940, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_957', 'drugName': 'Theophylline Sodium Glycinate', 'drugSynonyms_string': 'Bronchoparat, Englate, Glycin theophyllinate, Glytheonate, Panophylline, Theonate sodium, Theophylline sodium glycinate', 'tradeNames_string': 'Asbron, Synophylate', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3797', 'drugName': 'Oxtriphylline', 'drugSynonyms_string': 'Choline theophyllinate, Choline theophylline, Cholinophyllin, NSC-760431, Oxtriphylline, Theocolin', 'tradeNames_string': 'Choledyl, Choledyl sa, Oxtriphylline, Oxtriphylline pediatric, Sabidal', 'yearOfFirstApproval': 1981, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5471', 'drugName': 'Aminophylline', 'drugSynonyms_string': 'Aminophylline, Aminophyllinum, Cardophyllin, Linampheta, NSC-7919, Syntophyllin, Theophyllamine, Theophylline ethylenediamine, Theophylline-ethylenediamine', 'tradeNames_string': 'Aminophyllin, Aminophylline, Aminophylline In Sodium Chloride, Aminophylline dye free, Ammophyllin, Amnivent-225 sr, Amnivent-350 sr, Peterphyllin, Phyllocontin, Somophyllin, Somophyllin-df, Truphylline', 'yearOfFirstApproval': 1940, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4548', 'drugName': 'Theophylline', 'drugSynonyms_string': 'Dimethylxanthine, Doxophylline metabolite m3, NSC-2066, NSC-757346, Theophylline, Theophylline anhydrous, Theophylline melting point standard, Theophylline monohydrate, Theophylline, anhydrous, Theophylline,anhydrous', 'tradeNames_string': 'Accurbron, Aerolate, Aerolate iii, Aerolate jr, Aerolate sr, Aquaphyllin, Bronkodyl, Duraphyl, Elixicon, Elixomin, Elixophyllin, Elixophyllin sr, Labid, Lanophyllin, Lasma, Nuelin, Nuelin sa, Nuelin sa-250, Pro-vent, Quibron, Quibron-t, Quibron-t/sr, Respbid, Slo-bid, Slo-phyllin, Somophyllin-crt, Somophyllin-t, Sustaire, T-phyl, Theo-24, Theo-dur, Theobid, Theobid jr., Theochron, Theocin, Theoclear l.a.-130, Theoclear l.a.-260, Theoclear-100, Theoclear-200, Theoclear-80, Theograd, Theolair, Theolair-sr, Theolixir, Theophyl, Theophyl-225, Theophyl-sr, Theophylline, Theophylline-sr, Theovent, Uni-dur, Uniphyl, Uniphyllin continus', 'yearOfFirstApproval': 1940, 'maxClinicalTrialPhase': 4}]",general,"Distinct, Similarity Search, Order By",Trial Phase
-Q63.1274,Q63,What is the maximum clinical trial phase for the drug Anastrozole?,Anastrozole reached phase 4 clinical trials.,"SELECT DISTINCT UUID, drugName, drugSynonyms_string, tradeNames_string, yearOfFirstApproval, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%anastrozole%"" OR LOWER(tradeNames_string) LIKE ""%anastrozole%"" OR LOWER(drugSynonyms_string) LIKE ""%anastrozole%"") 
- ORDER BY maxClinicalTrialPhase desc
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3640', 'drugName': 'Anastrozole', 'drugSynonyms_string': 'Anastrozole, Arimidex, ICI D1033, ICI-D1033, NSC-719344, NSC-759855, Rvg-106400, ZD-1033, ZD1033', 'tradeNames_string': 'Anastrozole, Arimidex, Nastrosa', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4}]",general,"Distinct, Similarity Search, Order By",Trial Phase
-Q63.939,Q63,What is the maximum clinical trial phase for the drug Farglitazar?,Farglitazar reached phase 2 clinical trials.,"SELECT DISTINCT UUID, drugName, drugSynonyms_string, tradeNames_string, yearOfFirstApproval, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%farglitazar%"" OR LOWER(tradeNames_string) LIKE ""%farglitazar%"" OR LOWER(drugSynonyms_string) LIKE ""%farglitazar%"") 
- ORDER BY maxClinicalTrialPhase desc
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_144', 'drugName': 'Farglitazar', 'drugSynonyms_string': 'Farglitazar, G1-262570, GI-262570, GI-262570X, GI262570X, Gi262570', 'tradeNames_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2}]",general,"Distinct, Similarity Search, Order By",Trial Phase
-Q63.1732,Q63,What is the maximum clinical trial phase for the drug Molindone?,Molindone reached phase 4 clinical trials.,"SELECT DISTINCT UUID, drugName, drugSynonyms_string, tradeNames_string, yearOfFirstApproval, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%molindone%"" OR LOWER(tradeNames_string) LIKE ""%molindone%"" OR LOWER(drugSynonyms_string) LIKE ""%molindone%"") 
- ORDER BY maxClinicalTrialPhase desc
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_789', 'drugName': 'Molindone', 'drugSynonyms_string': 'Moban, Molindone, Spn-810', 'tradeNames_string': '', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_788', 'drugName': 'Molindone', 'drugSynonyms_string': 'Moban, Molindone, Spn-810', 'tradeNames_string': '', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3042', 'drugName': 'Molindone Hydrochloride', 'drugSynonyms_string': 'EN-1733A, Molindone hcl, Molindone hydrochloride', 'tradeNames_string': 'Moban, Molindone hydrochloride', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3041', 'drugName': 'Molindone Hydrochloride', 'drugSynonyms_string': 'EN-1733A, Molindone hcl, Molindone hydrochloride', 'tradeNames_string': 'Moban, Molindone hydrochloride', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4}]",general,"Distinct, Similarity Search, Order By",Trial Phase
-Q63.66,Q63,What is the maximum clinical trial phase for the drug Pictilisib?,Pictilisib reached phase 2 clinical trials.,"SELECT DISTINCT UUID, drugName, drugSynonyms_string, tradeNames_string, yearOfFirstApproval, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%pictilisib%"" OR LOWER(tradeNames_string) LIKE ""%pictilisib%"" OR LOWER(drugSynonyms_string) LIKE ""%pictilisib%"") 
- ORDER BY maxClinicalTrialPhase desc
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_33', 'drugName': 'Pictilisib', 'drugSynonyms_string': 'CDC-0941, GDC 0941, GDC-0941, Pictilisib, Pictrelisib, Rg-7321', 'tradeNames_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2}]",general,"Distinct, Similarity Search, Order By",Trial Phase
-Q63.1324,Q63,What is the maximum clinical trial phase for the drug Testosterone Undecanoate?,Testosterone Undecanoate reached phase 4 clinical trials.,"SELECT DISTINCT UUID, drugName, drugSynonyms_string, tradeNames_string, yearOfFirstApproval, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%testosterone undecanoate%"" OR LOWER(tradeNames_string) LIKE ""%testosterone undecanoate%"" OR LOWER(drugSynonyms_string) LIKE ""%testosterone undecanoate%"") 
- ORDER BY maxClinicalTrialPhase desc
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_939', 'drugName': 'Testosterone Undecanoate', 'drugSynonyms_string': 'Kyzatrex, MK-3033, ORG 538, ORG-538, TSX-011, Testosterone 17.beta.-undecylate, Testosterone undecanoate, Testosterone undecylate, Testosterone, undecanoate (ester), Tlando', 'tradeNames_string': 'Andriol, Aveed, Jatenzo, Kyzatrex, Nebido, Restandol, Restandol testocap, Tlando, Undestor', 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4}]",general,"Distinct, Similarity Search, Order By",Trial Phase
-Q63.57,Q63,What is the maximum clinical trial phase for the drug Pentazocine Lactate?,Pentazocine Lactate reached phase 4 clinical trials.,"SELECT DISTINCT UUID, drugName, drugSynonyms_string, tradeNames_string, yearOfFirstApproval, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%pentazocine lactate%"" OR LOWER(tradeNames_string) LIKE ""%pentazocine lactate%"" OR LOWER(drugSynonyms_string) LIKE ""%pentazocine lactate%"") 
- ORDER BY maxClinicalTrialPhase desc
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_652', 'drugName': 'Pentazocine Lactate', 'drugSynonyms_string': 'Pentazocine lactate, Talwin (lactate)', 'tradeNames_string': 'Talwin', 'yearOfFirstApproval': 1967, 'maxClinicalTrialPhase': 4}]",general,"Distinct, Similarity Search, Order By",Trial Phase
-Q63.1293,Q63,What is the maximum clinical trial phase for the drug Ramucirumab?,Ramucirumab reached phase 4 clinical trials.,"SELECT DISTINCT UUID, drugName, drugSynonyms_string, tradeNames_string, yearOfFirstApproval, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%ramucirumab%"" OR LOWER(tradeNames_string) LIKE ""%ramucirumab%"" OR LOWER(drugSynonyms_string) LIKE ""%ramucirumab%"") 
- ORDER BY maxClinicalTrialPhase desc
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_1170', 'drugName': 'Ramucirumab', 'drugSynonyms_string': '1121B, IMC-1121B, LY3009806, Ramucirumab', 'tradeNames_string': 'Cyramza', 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4}]",general,"Distinct, Similarity Search, Order By",Trial Phase
-Q63.1119,Q63,What is the maximum clinical trial phase for the drug Perampanel?,Perampanel reached phase 4 clinical trials.,"SELECT DISTINCT UUID, drugName, drugSynonyms_string, tradeNames_string, yearOfFirstApproval, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%perampanel%"" OR LOWER(tradeNames_string) LIKE ""%perampanel%"" OR LOWER(drugSynonyms_string) LIKE ""%perampanel%"") 
- ORDER BY maxClinicalTrialPhase desc
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2165', 'drugName': 'Perampanel', 'drugSynonyms_string': 'E-2007, E2007, ER-155055-90, Perampanel', 'tradeNames_string': 'Fycompa', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4}]",general,"Distinct, Similarity Search, Order By",Trial Phase
-Q63.585,Q63,What is the maximum clinical trial phase for the drug Icatibant?,Icatibant reached phase 4 clinical trials.,"SELECT DISTINCT UUID, drugName, drugSynonyms_string, tradeNames_string, yearOfFirstApproval, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%icatibant%"" OR LOWER(tradeNames_string) LIKE ""%icatibant%"" OR LOWER(drugSynonyms_string) LIKE ""%icatibant%"") 
- ORDER BY maxClinicalTrialPhase desc
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_226', 'drugName': 'Icatibant Acetate', 'drugSynonyms_string': 'HOE 140, HOE-140, Icatibant acetate', 'tradeNames_string': 'Firazyr', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3024', 'drugName': 'Icatibant', 'drugSynonyms_string': 'HOE-140, Icatibant', 'tradeNames_string': '', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4}]",general,"Distinct, Similarity Search, Order By",Trial Phase
-Q63.375,Q63,What is the maximum clinical trial phase for the drug Farletuzumab?,Farletuzumab reached phase 3 clinical trials.,"SELECT DISTINCT UUID, drugName, drugSynonyms_string, tradeNames_string, yearOfFirstApproval, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%farletuzumab%"" OR LOWER(tradeNames_string) LIKE ""%farletuzumab%"" OR LOWER(drugSynonyms_string) LIKE ""%farletuzumab%"") 
- ORDER BY maxClinicalTrialPhase desc
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_739', 'drugName': 'Farletuzumab', 'drugSynonyms_string': 'Farletuzumab, M3, MORAb-003', 'tradeNames_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3}]",general,"Distinct, Similarity Search, Order By",Trial Phase
-Q63.276,Q63,What is the maximum clinical trial phase for the drug Mt-3724?,Mt-3724 reached phase 2 clinical trials.,"SELECT DISTINCT UUID, drugName, drugSynonyms_string, tradeNames_string, yearOfFirstApproval, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE (LOWER(drugName) LIKE ""%mt-3724%"" OR LOWER(tradeNames_string) LIKE ""%mt-3724%"" OR LOWER(drugSynonyms_string) LIKE ""%mt-3724%"") 
- ORDER BY maxClinicalTrialPhase desc
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_4690', 'drugName': 'Mt-3724', 'drugSynonyms_string': 'Mt-3724', 'tradeNames_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4691', 'drugName': 'Mt-3724', 'drugSynonyms_string': 'Mt-3724', 'tradeNames_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2}]",general,"Distinct, Similarity Search, Order By",Trial Phase
-Q19.56,Q19,Which SNP is most significantly associated with FTD in the Multi Ancestry Whole Brain?,There are no significantly associated SNPs with FTD in the Multi Ancestry Whole Brain.,"SELECT UUID, topRSID, Disease, Omic_tissue, p_SMR_multi, p_HEIDI, A1, A2, Freq, func_sig
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full`
- WHERE Disease = 'FTD' AND LOWER(Omic_tissue) = 'multi ancestry whole brain' AND p_SMR_multi < 2.95e-6 AND p_HEIDI > 0.01
- ORDER BY p_SMR_multi
- LIMIT 1",[],refined,"Select, Multi-Filter, Order By, Threshold",Functional Significance
-Q4.482,Q4,What drugs target the gene FTO?,"There are no approved drugs targeting FTO, but the drug Bisantrene, which potentially targets this gene, is currently undergoing clinical trials.","SELECT DISTINCT UUID, drugName, newLinkedTargets_string, drugIsApproved, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE newLinkedTargets_string LIKE '%FTO %'
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_1486', 'drugName': 'Bisantrene', 'newLinkedTargets_string': 'FTO (ENSG00000140718)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}]",general,"Select, Similarity Search, Order By",Genetic Target
-Q4.77,Q4,What drugs target the gene AR?,"The drugs that target AR are Oxymetholone, Testosterone Cypionate, Testosterone Undecanoate, Testosterone Propionate, Methyltestosterone, Dromostanolone Propionate, Cyproterone Acetate, Bicalutamide, Clascoterone, Oxandrolone, Ethylestrenol, Fluoxymesterone, Nandrolone Phenpropionate, Enzalutamide, Flutamide, Methandrostenolone, Danazol, Darolutamide, Testosterone, Nilutamide, Stanozolol, Nandrolone Decanoate, Testosterone Enanthate, Apalutamide, and Abiraterone.","SELECT DISTINCT UUID, drugName, newLinkedTargets_string, drugIsApproved, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE newLinkedTargets_string LIKE '%AR %'
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_2428', 'drugName': 'Dromostanolone Propionate', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5791', 'drugName': 'Stanozolol', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5601', 'drugName': 'Nilutamide', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3386', 'drugName': 'Oxandrolone', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5959', 'drugName': 'Testosterone Enanthate', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2803', 'drugName': 'Clascoterone', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4704', 'drugName': 'Flutamide', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5106', 'drugName': 'Darolutamide', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_939', 'drugName': 'Testosterone Undecanoate', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_111', 'drugName': 'Oxymetholone', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3566', 'drugName': 'Ethylestrenol', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4917', 'drugName': 'Danazol', 'newLinkedTargets_string': 'AR (ENSG00000169083), PGR (ENSG00000082175)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5308', 'drugName': 'Testosterone', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6320', 'drugName': 'Abiraterone', 'newLinkedTargets_string': 'AR (ENSG00000169083), CYP17A1 (ENSG00000148795), SRD5A1 (ENSG00000145545), SRD5A2 (ENSG00000277893), SRD5A3 (ENSG00000128039)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5812', 'drugName': 'Nandrolone Decanoate', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3801', 'drugName': 'Ceruletide', 'newLinkedTargets_string': 'CCKAR (ENSG00000163394)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2216', 'drugName': 'Methyltestosterone', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2693', 'drugName': 'Sincalide', 'newLinkedTargets_string': 'CCKAR (ENSG00000163394)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2551', 'drugName': 'Cyproterone Acetate', 'newLinkedTargets_string': 'AR (ENSG00000169083), PGR (ENSG00000082175), NR3C1 (ENSG00000113580)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4916', 'drugName': 'Danazol', 'newLinkedTargets_string': 'AR (ENSG00000169083), PGR (ENSG00000082175)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6321', 'drugName': 'Abiraterone', 'newLinkedTargets_string': 'AR (ENSG00000169083), CYP17A1 (ENSG00000148795), SRD5A1 (ENSG00000145545), SRD5A2 (ENSG00000277893), SRD5A3 (ENSG00000128039)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4352', 'drugName': 'Enzalutamide', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6322', 'drugName': 'Abiraterone', 'newLinkedTargets_string': 'AR (ENSG00000169083), CYP17A1 (ENSG00000148795), SRD5A1 (ENSG00000145545), SRD5A2 (ENSG00000277893), SRD5A3 (ENSG00000128039)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4237', 'drugName': 'Nandrolone Phenpropionate', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2550', 'drugName': 'Cyproterone Acetate', 'newLinkedTargets_string': 'AR (ENSG00000169083), PGR (ENSG00000082175), NR3C1 (ENSG00000113580)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2128', 'drugName': 'Testosterone Propionate', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6164', 'drugName': 'Apalutamide', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3461', 'drugName': 'Ceruletide Diethylamine', 'newLinkedTargets_string': 'CCKAR (ENSG00000163394)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4716', 'drugName': 'Methandrostenolone', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2552', 'drugName': 'Cyproterone Acetate', 'newLinkedTargets_string': 'AR (ENSG00000169083), PGR (ENSG00000082175), NR3C1 (ENSG00000113580)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_434', 'drugName': 'Testosterone Cypionate', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5575', 'drugName': 'Proglumide', 'newLinkedTargets_string': 'CCKBR (ENSG00000110148), CCKAR (ENSG00000163394)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3575', 'drugName': 'Fluoxymesterone', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2718', 'drugName': 'Bicalutamide', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5374', 'drugName': 'Dexloxiglumide', 'newLinkedTargets_string': 'CCKAR (ENSG00000163394)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1889', 'drugName': 'Galeterone', 'newLinkedTargets_string': 'AR (ENSG00000169083), CYP17A1 (ENSG00000148795)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1890', 'drugName': 'Galeterone', 'newLinkedTargets_string': 'AR (ENSG00000169083), CYP17A1 (ENSG00000148795)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_6298', 'drugName': 'Gt-0918', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4933', 'drugName': 'Shr3680', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1611', 'drugName': 'Enobosarm', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_6326', 'drugName': 'Vk5211', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_531', 'drugName': 'Seviteronel', 'newLinkedTargets_string': 'AR (ENSG00000169083), CYP17A1 (ENSG00000148795)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2030', 'drugName': 'Ly2452473', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_530', 'drugName': 'Seviteronel', 'newLinkedTargets_string': 'AR (ENSG00000169083), CYP17A1 (ENSG00000148795)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1153', 'drugName': 'Gsk2881078', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1524', 'drugName': 'Cr 1447', 'newLinkedTargets_string': 'ESR2 (ENSG00000140009), AR (ENSG00000169083)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1525', 'drugName': 'Cr 1447', 'newLinkedTargets_string': 'ESR2 (ENSG00000140009), AR (ENSG00000169083)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2827', 'drugName': 'Ce-326597', 'newLinkedTargets_string': 'CCKAR (ENSG00000163394)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3617', 'drugName': 'Mk-0773', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5293', 'drugName': 'Dimethylcurcumin', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_11', 'drugName': 'Azd3514', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1352', 'drugName': 'Apc-100', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1004', 'drugName': 'Glpg0492', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_6017', 'drugName': 'Lgd-2941', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1975', 'drugName': 'He3235', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_3436', 'drugName': 'Gsk2849466', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}]",general,"Select, Similarity Search, Order By",Genetic Target
-Q4.1503,Q4,What drugs target the gene TUBB2B?,"The drugs that target TUBB2B are Polatuzumab Vedotin, Cabazitaxel, Vinflunine, Brentuximab Vedotin, Docetaxel, Belantamab Mafodotin, Paclitaxel, Vinorelbine, Ixabepilone, Enfortumab Vedotin, Eribulin Mesylate, Vincristine Sulfate, Tisotumab Vedotin, Vinblastine, Colchicine, Vincristine, Eribulin, Trastuzumab Emtansine, Vinblastine Sulfate, and Vinorelbine Tartrate.","SELECT DISTINCT UUID, drugName, newLinkedTargets_string, drugIsApproved, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE newLinkedTargets_string LIKE '%TUBB2B %'
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_1084', 'drugName': 'Brentuximab Vedotin', 'newLinkedTargets_string': 'TNFRSF8 (ENSG00000120949), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1872', 'drugName': 'Belantamab Mafodotin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), TNFRSF17 (ENSG00000048462)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4158', 'drugName': 'Tisotumab Vedotin', 'newLinkedTargets_string': 'F3 (ENSG00000117525), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2339', 'drugName': 'Ixabepilone', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_974', 'drugName': 'Vinflunine', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4166', 'drugName': 'Vinblastine', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5756', 'drugName': 'Trastuzumab Emtansine', 'newLinkedTargets_string': 'ERBB2 (ENSG00000141736), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5604', 'drugName': 'Eribulin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2795', 'drugName': 'Enfortumab Vedotin', 'newLinkedTargets_string': 'NECTIN4 (ENSG00000143217), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4743', 'drugName': 'Colchicine', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_560', 'drugName': 'Polatuzumab Vedotin', 'newLinkedTargets_string': 'CD79B (ENSG00000007312), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_561', 'drugName': 'Polatuzumab Vedotin', 'newLinkedTargets_string': 'CD79B (ENSG00000007312), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1085', 'drugName': 'Brentuximab Vedotin', 'newLinkedTargets_string': 'TNFRSF8 (ENSG00000120949), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6261', 'drugName': 'Vinblastine Sulfate', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2794', 'drugName': 'Enfortumab Vedotin', 'newLinkedTargets_string': 'NECTIN4 (ENSG00000143217), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5140', 'drugName': 'Vincristine', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4157', 'drugName': 'Tisotumab Vedotin', 'newLinkedTargets_string': 'F3 (ENSG00000117525), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_762', 'drugName': 'Cabazitaxel', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1267', 'drugName': 'Docetaxel', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3175', 'drugName': 'Eribulin Mesylate', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2177', 'drugName': 'Docetaxel', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2013', 'drugName': 'Paclitaxel', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1871', 'drugName': 'Belantamab Mafodotin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), TNFRSF17 (ENSG00000048462)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5757', 'drugName': 'Trastuzumab Emtansine', 'newLinkedTargets_string': 'ERBB2 (ENSG00000141736), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3353', 'drugName': 'Vincristine Sulfate', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2330', 'drugName': 'Vinorelbine', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6364', 'drugName': 'Vinorelbine Tartrate', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4123', 'drugName': 'Plinabulin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_429', 'drugName': 'Ang1005', 'newLinkedTargets_string': 'LRP1 (ENSG00000123384), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3391', 'drugName': 'Fosbretabulin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1364', 'drugName': 'Ombrabulin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_2595', 'drugName': 'Paclitaxel Poliglumex', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5727', 'drugName': 'Mirvetuximab Soravtansine', 'newLinkedTargets_string': 'FOLR1 (ENSG00000110195), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3781', 'drugName': 'Telisotuzumab Vedotin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), MET (ENSG00000105976)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1224', 'drugName': 'Tusamitamab Ravtansine', 'newLinkedTargets_string': 'CEACAM5 (ENSG00000105388), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1225', 'drugName': 'Tusamitamab Ravtansine', 'newLinkedTargets_string': 'CEACAM5 (ENSG00000105388), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3782', 'drugName': 'Telisotuzumab Vedotin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), MET (ENSG00000105976)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3390', 'drugName': 'Fosbretabulin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_430', 'drugName': 'Ang1005', 'newLinkedTargets_string': 'LRP1 (ENSG00000123384), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4860', 'drugName': 'Patupilone', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5728', 'drugName': 'Mirvetuximab Soravtansine', 'newLinkedTargets_string': 'FOLR1 (ENSG00000110195), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_829', 'drugName': 'Larotaxel', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5370', 'drugName': 'Paclitaxel Docosahexaenoic Acid', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_186', 'drugName': 'Cantuzumab Mertansine', 'newLinkedTargets_string': 'MUC1 (ENSG00000185499), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_187', 'drugName': 'Cantuzumab Mertansine', 'newLinkedTargets_string': 'MUC1 (ENSG00000185499), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5922', 'drugName': 'Indusatumab Vedotin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), GUCY2C (ENSG00000070019)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4294', 'drugName': 'Arx-788', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), ERBB2 (ENSG00000141736)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2981', 'drugName': 'Plocabulin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3189', 'drugName': 'Sagopilone', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5837', 'drugName': 'Soblidotin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4295', 'drugName': 'Arx-788', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), ERBB2 (ENSG00000141736)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4455', 'drugName': 'Ags-16C3F', 'newLinkedTargets_string': 'ENPP3 (ENSG00000154269), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4675', 'drugName': 'Milataxel', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4227', 'drugName': 'Verubulin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4456', 'drugName': 'Ags-16C3F', 'newLinkedTargets_string': 'ENPP3 (ENSG00000154269), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2652', 'drugName': 'Ladiratuzumab Vedotin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), SLC39A6 (ENSG00000141424)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4395', 'drugName': 'Fosbretabulin Tromethamine', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3400', 'drugName': 'Abt-751', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBB3 (ENSG00000258947), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), TUBB8B (ENSG00000173213)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6014', 'drugName': 'Praluzatamab Ravtansine', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), ALCAM (ENSG00000170017)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4590', 'drugName': 'Epothilone D', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5130', 'drugName': 'Fosbretabulin Disodium', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5107', 'drugName': 'T-900607', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5627', 'drugName': 'Bms-275183', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3277', 'drugName': 'Davunetide', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3443', 'drugName': 'Lifastuzumab Vedotin', 'newLinkedTargets_string': 'SLC34A2 (ENSG00000157765), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5974', 'drugName': 'Dolastatin-10', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5923', 'drugName': 'Indusatumab Vedotin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), GUCY2C (ENSG00000070019)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3444', 'drugName': 'Lifastuzumab Vedotin', 'newLinkedTargets_string': 'SLC34A2 (ENSG00000157765), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4739', 'drugName': 'Lexibulin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2653', 'drugName': 'Ladiratuzumab Vedotin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), SLC39A6 (ENSG00000141424)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6314', 'drugName': 'Glembatumumab Vedotin', 'newLinkedTargets_string': 'GPNMB (ENSG00000136235), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5310', 'drugName': 'Kos-1584', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6315', 'drugName': 'Glembatumumab Vedotin', 'newLinkedTargets_string': 'GPNMB (ENSG00000136235), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4544', 'drugName': 'Lorvotuzumab Mertansine', 'newLinkedTargets_string': 'NCAM1 (ENSG00000149294), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4545', 'drugName': 'Lorvotuzumab Mertansine', 'newLinkedTargets_string': 'NCAM1 (ENSG00000149294), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6013', 'drugName': 'Praluzatamab Ravtansine', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), ALCAM (ENSG00000170017)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5238', 'drugName': 'Sofituzumab Vedotin', 'newLinkedTargets_string': 'MUC16 (ENSG00000181143), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5239', 'drugName': 'Sofituzumab Vedotin', 'newLinkedTargets_string': 'MUC16 (ENSG00000181143), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_6096', 'drugName': 'Pinatuzumab Vedotin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), CD22 (ENSG00000012124)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_6097', 'drugName': 'Pinatuzumab Vedotin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), CD22 (ENSG00000012124)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_405', 'drugName': 'Asg-5Me', 'newLinkedTargets_string': 'SLC44A4 (ENSG00000204385), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_752', 'drugName': 'Vandortuzumab Vedotin', 'newLinkedTargets_string': 'STEAP1 (ENSG00000164647), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_831', 'drugName': 'Rg-7841', 'newLinkedTargets_string': 'LY6E (ENSG00000160932), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_753', 'drugName': 'Vandortuzumab Vedotin', 'newLinkedTargets_string': 'STEAP1 (ENSG00000164647), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1646', 'drugName': 'Azintuxizumab Vedotin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), SLAMF7 (ENSG00000026751)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1647', 'drugName': 'Azintuxizumab Vedotin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), SLAMF7 (ENSG00000026751)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_832', 'drugName': 'Rg-7841', 'newLinkedTargets_string': 'LY6E (ENSG00000160932), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1355', 'drugName': 'Pf-06263507', 'newLinkedTargets_string': 'TPBG (ENSG00000146242), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_406', 'drugName': 'Asg-5Me', 'newLinkedTargets_string': 'SLC44A4 (ENSG00000204385), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1356', 'drugName': 'Pf-06263507', 'newLinkedTargets_string': 'TPBG (ENSG00000146242), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_2066', 'drugName': 'Aprutumab Ixadotin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), FGFR2 (ENSG00000066468)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_2067', 'drugName': 'Aprutumab Ixadotin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), FGFR2 (ENSG00000066468)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_641', 'drugName': 'Rg-7600', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), MSLN (ENSG00000102854)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_642', 'drugName': 'Rg-7600', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), MSLN (ENSG00000102854)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5414', 'drugName': 'Rg-7636', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), EDNRB (ENSG00000136160)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5415', 'drugName': 'Rg-7636', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), EDNRB (ENSG00000136160)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5801', 'drugName': 'Enapotamab Vedotin', 'newLinkedTargets_string': 'AXL (ENSG00000167601), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5802', 'drugName': 'Enapotamab Vedotin', 'newLinkedTargets_string': 'AXL (ENSG00000167601), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_6222', 'drugName': 'Bivatuzumab Mertansine', 'newLinkedTargets_string': 'CD44 (ENSG00000026508), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_6223', 'drugName': 'Bivatuzumab Mertansine', 'newLinkedTargets_string': 'CD44 (ENSG00000026508), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}]",general,"Select, Similarity Search, Order By",Genetic Target
-Q4.670,Q4,What drugs target the gene IL12B?,"The drugs that target IL12B are Tildrakizumab, Guselkumab, Ustekinumab, and Risankizumab.","SELECT DISTINCT UUID, drugName, newLinkedTargets_string, drugIsApproved, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE newLinkedTargets_string LIKE '%IL12B %'
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3328', 'drugName': 'Ustekinumab', 'newLinkedTargets_string': 'IL12B (ENSG00000113302), IL23A (ENSG00000110944), IL12A (ENSG00000168811)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6358', 'drugName': 'Risankizumab', 'newLinkedTargets_string': 'IL12B (ENSG00000113302), IL23A (ENSG00000110944)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2147', 'drugName': 'Guselkumab', 'newLinkedTargets_string': 'IL12B (ENSG00000113302), IL23A (ENSG00000110944)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1373', 'drugName': 'Tildrakizumab', 'newLinkedTargets_string': 'IL12B (ENSG00000113302), IL23A (ENSG00000110944)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3327', 'drugName': 'Ustekinumab', 'newLinkedTargets_string': 'IL12B (ENSG00000113302), IL23A (ENSG00000110944), IL12A (ENSG00000168811)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_344', 'drugName': 'Ebdarokimab', 'newLinkedTargets_string': 'IL12B (ENSG00000113302), IL12A (ENSG00000168811), IL23A (ENSG00000110944)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3014', 'drugName': 'Mirikizumab', 'newLinkedTargets_string': 'IL12B (ENSG00000113302), IL23A (ENSG00000110944)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1252', 'drugName': 'Brazikumab', 'newLinkedTargets_string': 'IL12B (ENSG00000113302), IL23A (ENSG00000110944)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1844', 'drugName': 'Briakinumab', 'newLinkedTargets_string': 'IL12B (ENSG00000113302), IL23A (ENSG00000110944), IL12A (ENSG00000168811)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1845', 'drugName': 'Briakinumab', 'newLinkedTargets_string': 'IL12B (ENSG00000113302), IL23A (ENSG00000110944), IL12A (ENSG00000168811)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_345', 'drugName': 'Ebdarokimab', 'newLinkedTargets_string': 'IL12B (ENSG00000113302), IL12A (ENSG00000168811), IL23A (ENSG00000110944)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}]",general,"Select, Similarity Search, Order By",Genetic Target
-Q4.1410,Q4,What drugs target the gene TAAR1?,"There are no approved drugs targeting TAAR1, but the drug Ulotaront, which potentially targets this gene, is currently undergoing clinical trials.","SELECT DISTINCT UUID, drugName, newLinkedTargets_string, drugIsApproved, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE newLinkedTargets_string LIKE '%TAAR1 %'
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3446', 'drugName': 'Ulotaront', 'newLinkedTargets_string': 'HTR1A (ENSG00000178394), TAAR1 (ENSG00000146399)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3447', 'drugName': 'Ulotaront', 'newLinkedTargets_string': 'HTR1A (ENSG00000178394), TAAR1 (ENSG00000146399)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}]",general,"Select, Similarity Search, Order By",Genetic Target
-Q4.1415,Q4,What drugs target the gene TBXA2R?,The drug that targets TBXA2R is Picotamide.,"SELECT DISTINCT UUID, drugName, newLinkedTargets_string, drugIsApproved, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE newLinkedTargets_string LIKE '%TBXA2R %'
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_4430', 'drugName': 'Picotamide', 'newLinkedTargets_string': 'TBXAS1 (ENSG00000059377), TBXA2R (ENSG00000006638)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4429', 'drugName': 'Picotamide', 'newLinkedTargets_string': 'TBXAS1 (ENSG00000059377), TBXA2R (ENSG00000006638)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2143', 'drugName': 'Terutroban', 'newLinkedTargets_string': 'TBXA2R (ENSG00000006638)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_6039', 'drugName': 'Ramatroban', 'newLinkedTargets_string': 'PTGDR2 (ENSG00000183134), TBXA2R (ENSG00000006638)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_979', 'drugName': 'Terbogrel', 'newLinkedTargets_string': 'TBXAS1 (ENSG00000059377), TBXA2R (ENSG00000006638)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_978', 'drugName': 'Terbogrel', 'newLinkedTargets_string': 'TBXAS1 (ENSG00000059377), TBXA2R (ENSG00000006638)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6040', 'drugName': 'Ramatroban', 'newLinkedTargets_string': 'PTGDR2 (ENSG00000183134), TBXA2R (ENSG00000006638)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3144', 'drugName': 'Seratrodast', 'newLinkedTargets_string': 'TBXA2R (ENSG00000006638)', 'drugIsApproved': False, 'maxClinicalTrialPhase': -1}]",general,"Select, Similarity Search, Order By",Genetic Target
-Q4.1090,Q4,What drugs target the gene PLA2G4A?,"There are no approved drugs targeting PLA2G4A, but the drug Giripladib, which potentially targets this gene, is currently undergoing clinical trials.","SELECT DISTINCT UUID, drugName, newLinkedTargets_string, drugIsApproved, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE newLinkedTargets_string LIKE '%PLA2G4A %'
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_3885', 'drugName': 'Giripladib', 'newLinkedTargets_string': 'PLA2G4A (ENSG00000116711)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}]",general,"Select, Similarity Search, Order By",Genetic Target
-Q4.1508,Q4,What drugs target the gene TUBB8?,"The drugs that target TUBB8 are Polatuzumab Vedotin, Cabazitaxel, Vinflunine, Brentuximab Vedotin, Docetaxel, Belantamab Mafodotin, Paclitaxel, Vinorelbine, Ixabepilone, Enfortumab Vedotin, Eribulin Mesylate, Vincristine Sulfate, Tisotumab Vedotin, Vinblastine, Colchicine, Vincristine, Eribulin, Trastuzumab Emtansine, Vinblastine Sulfate, and Vinorelbine Tartrate.","SELECT DISTINCT UUID, drugName, newLinkedTargets_string, drugIsApproved, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE newLinkedTargets_string LIKE '%TUBB8 %'
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_1084', 'drugName': 'Brentuximab Vedotin', 'newLinkedTargets_string': 'TNFRSF8 (ENSG00000120949), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1872', 'drugName': 'Belantamab Mafodotin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), TNFRSF17 (ENSG00000048462)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4158', 'drugName': 'Tisotumab Vedotin', 'newLinkedTargets_string': 'F3 (ENSG00000117525), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2339', 'drugName': 'Ixabepilone', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_974', 'drugName': 'Vinflunine', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4166', 'drugName': 'Vinblastine', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5756', 'drugName': 'Trastuzumab Emtansine', 'newLinkedTargets_string': 'ERBB2 (ENSG00000141736), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5604', 'drugName': 'Eribulin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2795', 'drugName': 'Enfortumab Vedotin', 'newLinkedTargets_string': 'NECTIN4 (ENSG00000143217), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4743', 'drugName': 'Colchicine', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_560', 'drugName': 'Polatuzumab Vedotin', 'newLinkedTargets_string': 'CD79B (ENSG00000007312), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_561', 'drugName': 'Polatuzumab Vedotin', 'newLinkedTargets_string': 'CD79B (ENSG00000007312), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1085', 'drugName': 'Brentuximab Vedotin', 'newLinkedTargets_string': 'TNFRSF8 (ENSG00000120949), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6261', 'drugName': 'Vinblastine Sulfate', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2794', 'drugName': 'Enfortumab Vedotin', 'newLinkedTargets_string': 'NECTIN4 (ENSG00000143217), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5140', 'drugName': 'Vincristine', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4157', 'drugName': 'Tisotumab Vedotin', 'newLinkedTargets_string': 'F3 (ENSG00000117525), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_762', 'drugName': 'Cabazitaxel', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1267', 'drugName': 'Docetaxel', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3175', 'drugName': 'Eribulin Mesylate', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2177', 'drugName': 'Docetaxel', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2013', 'drugName': 'Paclitaxel', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1871', 'drugName': 'Belantamab Mafodotin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), TNFRSF17 (ENSG00000048462)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5757', 'drugName': 'Trastuzumab Emtansine', 'newLinkedTargets_string': 'ERBB2 (ENSG00000141736), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3353', 'drugName': 'Vincristine Sulfate', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2330', 'drugName': 'Vinorelbine', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6364', 'drugName': 'Vinorelbine Tartrate', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4123', 'drugName': 'Plinabulin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_429', 'drugName': 'Ang1005', 'newLinkedTargets_string': 'LRP1 (ENSG00000123384), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3391', 'drugName': 'Fosbretabulin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1364', 'drugName': 'Ombrabulin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_2595', 'drugName': 'Paclitaxel Poliglumex', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5727', 'drugName': 'Mirvetuximab Soravtansine', 'newLinkedTargets_string': 'FOLR1 (ENSG00000110195), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3781', 'drugName': 'Telisotuzumab Vedotin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), MET (ENSG00000105976)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1224', 'drugName': 'Tusamitamab Ravtansine', 'newLinkedTargets_string': 'CEACAM5 (ENSG00000105388), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1225', 'drugName': 'Tusamitamab Ravtansine', 'newLinkedTargets_string': 'CEACAM5 (ENSG00000105388), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3782', 'drugName': 'Telisotuzumab Vedotin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), MET (ENSG00000105976)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3390', 'drugName': 'Fosbretabulin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_430', 'drugName': 'Ang1005', 'newLinkedTargets_string': 'LRP1 (ENSG00000123384), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4860', 'drugName': 'Patupilone', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5728', 'drugName': 'Mirvetuximab Soravtansine', 'newLinkedTargets_string': 'FOLR1 (ENSG00000110195), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_829', 'drugName': 'Larotaxel', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5370', 'drugName': 'Paclitaxel Docosahexaenoic Acid', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_186', 'drugName': 'Cantuzumab Mertansine', 'newLinkedTargets_string': 'MUC1 (ENSG00000185499), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_187', 'drugName': 'Cantuzumab Mertansine', 'newLinkedTargets_string': 'MUC1 (ENSG00000185499), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5922', 'drugName': 'Indusatumab Vedotin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), GUCY2C (ENSG00000070019)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4294', 'drugName': 'Arx-788', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), ERBB2 (ENSG00000141736)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2981', 'drugName': 'Plocabulin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3189', 'drugName': 'Sagopilone', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5837', 'drugName': 'Soblidotin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4295', 'drugName': 'Arx-788', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), ERBB2 (ENSG00000141736)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4455', 'drugName': 'Ags-16C3F', 'newLinkedTargets_string': 'ENPP3 (ENSG00000154269), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4675', 'drugName': 'Milataxel', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4227', 'drugName': 'Verubulin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4456', 'drugName': 'Ags-16C3F', 'newLinkedTargets_string': 'ENPP3 (ENSG00000154269), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2652', 'drugName': 'Ladiratuzumab Vedotin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), SLC39A6 (ENSG00000141424)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4395', 'drugName': 'Fosbretabulin Tromethamine', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3400', 'drugName': 'Abt-751', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBB3 (ENSG00000258947), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), TUBB8B (ENSG00000173213)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6014', 'drugName': 'Praluzatamab Ravtansine', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), ALCAM (ENSG00000170017)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4590', 'drugName': 'Epothilone D', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5130', 'drugName': 'Fosbretabulin Disodium', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5107', 'drugName': 'T-900607', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5627', 'drugName': 'Bms-275183', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3277', 'drugName': 'Davunetide', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3443', 'drugName': 'Lifastuzumab Vedotin', 'newLinkedTargets_string': 'SLC34A2 (ENSG00000157765), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5974', 'drugName': 'Dolastatin-10', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5923', 'drugName': 'Indusatumab Vedotin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), GUCY2C (ENSG00000070019)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3444', 'drugName': 'Lifastuzumab Vedotin', 'newLinkedTargets_string': 'SLC34A2 (ENSG00000157765), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4739', 'drugName': 'Lexibulin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2653', 'drugName': 'Ladiratuzumab Vedotin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), SLC39A6 (ENSG00000141424)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6314', 'drugName': 'Glembatumumab Vedotin', 'newLinkedTargets_string': 'GPNMB (ENSG00000136235), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5310', 'drugName': 'Kos-1584', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6315', 'drugName': 'Glembatumumab Vedotin', 'newLinkedTargets_string': 'GPNMB (ENSG00000136235), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4544', 'drugName': 'Lorvotuzumab Mertansine', 'newLinkedTargets_string': 'NCAM1 (ENSG00000149294), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4545', 'drugName': 'Lorvotuzumab Mertansine', 'newLinkedTargets_string': 'NCAM1 (ENSG00000149294), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6013', 'drugName': 'Praluzatamab Ravtansine', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), ALCAM (ENSG00000170017)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5238', 'drugName': 'Sofituzumab Vedotin', 'newLinkedTargets_string': 'MUC16 (ENSG00000181143), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5239', 'drugName': 'Sofituzumab Vedotin', 'newLinkedTargets_string': 'MUC16 (ENSG00000181143), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_6096', 'drugName': 'Pinatuzumab Vedotin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), CD22 (ENSG00000012124)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_6097', 'drugName': 'Pinatuzumab Vedotin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), CD22 (ENSG00000012124)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_405', 'drugName': 'Asg-5Me', 'newLinkedTargets_string': 'SLC44A4 (ENSG00000204385), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_752', 'drugName': 'Vandortuzumab Vedotin', 'newLinkedTargets_string': 'STEAP1 (ENSG00000164647), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_831', 'drugName': 'Rg-7841', 'newLinkedTargets_string': 'LY6E (ENSG00000160932), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_753', 'drugName': 'Vandortuzumab Vedotin', 'newLinkedTargets_string': 'STEAP1 (ENSG00000164647), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1646', 'drugName': 'Azintuxizumab Vedotin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), SLAMF7 (ENSG00000026751)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1647', 'drugName': 'Azintuxizumab Vedotin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), SLAMF7 (ENSG00000026751)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_832', 'drugName': 'Rg-7841', 'newLinkedTargets_string': 'LY6E (ENSG00000160932), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1355', 'drugName': 'Pf-06263507', 'newLinkedTargets_string': 'TPBG (ENSG00000146242), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_406', 'drugName': 'Asg-5Me', 'newLinkedTargets_string': 'SLC44A4 (ENSG00000204385), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1356', 'drugName': 'Pf-06263507', 'newLinkedTargets_string': 'TPBG (ENSG00000146242), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_2066', 'drugName': 'Aprutumab Ixadotin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), FGFR2 (ENSG00000066468)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_2067', 'drugName': 'Aprutumab Ixadotin', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), FGFR2 (ENSG00000066468)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_641', 'drugName': 'Rg-7600', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), MSLN (ENSG00000102854)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_642', 'drugName': 'Rg-7600', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), MSLN (ENSG00000102854)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5414', 'drugName': 'Rg-7636', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), EDNRB (ENSG00000136160)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5415', 'drugName': 'Rg-7636', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), EDNRB (ENSG00000136160)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5801', 'drugName': 'Enapotamab Vedotin', 'newLinkedTargets_string': 'AXL (ENSG00000167601), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5802', 'drugName': 'Enapotamab Vedotin', 'newLinkedTargets_string': 'AXL (ENSG00000167601), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_6222', 'drugName': 'Bivatuzumab Mertansine', 'newLinkedTargets_string': 'CD44 (ENSG00000026508), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_6223', 'drugName': 'Bivatuzumab Mertansine', 'newLinkedTargets_string': 'CD44 (ENSG00000026508), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}]",general,"Select, Similarity Search, Order By",Genetic Target
-Q4.971,Q4,What drugs target the gene NDUFS5?,The drugs that target NDUFS5 are Metformin and Metformin Hydrochloride.,"SELECT DISTINCT UUID, drugName, newLinkedTargets_string, drugIsApproved, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE newLinkedTargets_string LIKE '%NDUFS5 %'
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_1888', 'drugName': 'Metformin Hydrochloride', 'newLinkedTargets_string': 'GPD2 (ENSG00000115159), MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1887', 'drugName': 'Metformin Hydrochloride', 'newLinkedTargets_string': 'GPD2 (ENSG00000115159), MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1886', 'drugName': 'Metformin', 'newLinkedTargets_string': 'GPD2 (ENSG00000115159), MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1885', 'drugName': 'Metformin', 'newLinkedTargets_string': 'GPD2 (ENSG00000115159), MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3900', 'drugName': 'Me-344', 'newLinkedTargets_string': 'MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_2970', 'drugName': 'Nv-128', 'newLinkedTargets_string': 'MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 1}]",general,"Select, Similarity Search, Order By",Genetic Target
-Q4.1199,Q4,What drugs target the gene PTH1R?,"The drugs that target PTH1R are Parathyroid Hormone, Abaloparatide, Teriparatide, and Teriparatide Acetate.","SELECT DISTINCT UUID, drugName, newLinkedTargets_string, drugIsApproved, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE newLinkedTargets_string LIKE '%PTH1R %'
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_1895', 'drugName': 'Abaloparatide', 'newLinkedTargets_string': 'PTH1R (ENSG00000160801)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2407', 'drugName': 'Teriparatide', 'newLinkedTargets_string': 'PTH1R (ENSG00000160801)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3571', 'drugName': 'Teriparatide Acetate', 'newLinkedTargets_string': 'PTH1R (ENSG00000160801)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_499', 'drugName': 'Parathyroid Hormone', 'newLinkedTargets_string': 'PTH1R (ENSG00000160801)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3861', 'drugName': 'Ostabolin-C', 'newLinkedTargets_string': 'PTH1R (ENSG00000160801)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}]",general,"Select, Similarity Search, Order By",Genetic Target
-Q4.1089,Q4,What drugs target the gene PLA2G2A?,"There are no FDA approved drugs targeting the gene PLA2G2A. However, the following drugs, which potentially target this gene, are currently in various clinical trial stages: Varespladib and Varespladib Methyl.","SELECT DISTINCT UUID, drugName, newLinkedTargets_string, drugIsApproved, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE newLinkedTargets_string LIKE '%PLA2G2A %'
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_6244', 'drugName': 'Varespladib Methyl', 'newLinkedTargets_string': 'PLA2G5 (ENSG00000127472), PLA2G10 (ENSG00000069764), PLA2G2A (ENSG00000188257)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_6246', 'drugName': 'Varespladib Methyl', 'newLinkedTargets_string': 'PLA2G5 (ENSG00000127472), PLA2G10 (ENSG00000069764), PLA2G2A (ENSG00000188257)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_6245', 'drugName': 'Varespladib Methyl', 'newLinkedTargets_string': 'PLA2G5 (ENSG00000127472), PLA2G10 (ENSG00000069764), PLA2G2A (ENSG00000188257)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_794', 'drugName': 'Varespladib', 'newLinkedTargets_string': 'PLA2G2A (ENSG00000188257)', 'drugIsApproved': False, 'maxClinicalTrialPhase': 2}]",general,"Select, Similarity Search, Order By",Genetic Target
-Q4.577,Q4,What drugs target the gene HCN4?,"The drugs that target HCN4 are Ivabradine, Ivabradine Hydrochloride, Dronedarone Hydrochloride, and Dronedarone.","SELECT DISTINCT UUID, drugName, newLinkedTargets_string, drugIsApproved, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE newLinkedTargets_string LIKE '%HCN4 %'
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100","[{'UUID': 'DrugGeneTargets_v2_5384', 'drugName': 'Dronedarone', 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001), KCNJ2 (ENSG00000123700), HCN4 (ENSG00000138622), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3874', 'drugName': 'Dronedarone Hydrochloride', 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001), HCN4 (ENSG00000138622), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), KCNJ2 (ENSG00000123700)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3875', 'drugName': 'Dronedarone Hydrochloride', 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001), HCN4 (ENSG00000138622), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), KCNJ2 (ENSG00000123700)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3873', 'drugName': 'Dronedarone Hydrochloride', 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001), HCN4 (ENSG00000138622), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), KCNJ2 (ENSG00000123700)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1183', 'drugName': 'Ivabradine Hydrochloride', 'newLinkedTargets_string': 'HCN4 (ENSG00000138622)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_32', 'drugName': 'Ivabradine', 'newLinkedTargets_string': 'HCN4 (ENSG00000138622)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5382', 'drugName': 'Dronedarone', 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001), KCNJ2 (ENSG00000123700), HCN4 (ENSG00000138622), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3872', 'drugName': 'Dronedarone Hydrochloride', 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001), HCN4 (ENSG00000138622), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), KCNJ2 (ENSG00000123700)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5383', 'drugName': 'Dronedarone', 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001), KCNJ2 (ENSG00000123700), HCN4 (ENSG00000138622), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5381', 'drugName': 'Dronedarone', 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001), KCNJ2 (ENSG00000123700), HCN4 (ENSG00000138622), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'drugIsApproved': True, 'maxClinicalTrialPhase': 4}]",general,"Select, Similarity Search, Order By",Genetic Target
-Q67.1861,Q67,What is the top-associated SNP of the gene GRIN3B in Cortex eQTL metaBrain omic data for AD and is it functionally significant?,"The top-associated SNP for GRIN3B in Cortex eQTL metaBrain omic data for AD is rs58342790, which has a multi-SNP SMR p-value of 2.31e-08 but is not functionally significant as the association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, Omic_tissue, Omic_type, func_sig
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full` 
- WHERE Gene = ""GRIN3B"" AND Disease = ""AD"" AND LOWER(Omic_type) LIKE ""%cortex eqtl metabrain%""
- ORDER BY p_SMR_multi
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_1107629', 'topRSID': 'rs58342790', 'Disease': 'AD', 'Gene': 'GRIN3B', 'p_SMR_multi': 2.312572e-08, 'p_HEIDI': 3.21611e-06, 'Omic_tissue': 'Cortex', 'Omic_type': 'Cortex eQTL metaBrain', 'func_sig': 'association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium'}]",general,"Select, Similarity Search, Multi-Filter, Order By",Functional Significance
-Q67.354,Q67,What is the top-associated SNP of the gene MMRN1 in Cerebellum eQTL omic data for PD and is it functionally significant?,"The top-associated SNP for MMRN1 in Cerebellum eQTL omic data for PD is rs75329999, which has a multi-SNP SMR p-value of 2.60e-10 but is not functionally significant as the association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, Omic_tissue, Omic_type, func_sig
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full` 
- WHERE Gene = ""MMRN1"" AND Disease = ""PD"" AND LOWER(Omic_type) LIKE ""%cerebellum eqtl%""
- ORDER BY p_SMR_multi
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_19153', 'topRSID': 'rs75329999', 'Disease': 'PD', 'Gene': 'MMRN1', 'p_SMR_multi': 2.596135e-10, 'p_HEIDI': 0.00411219, 'Omic_tissue': 'Cerebellum', 'Omic_type': 'Cerebellum eQTL', 'func_sig': 'association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium'}, {'UUID': 'NDD_SMR_genes_all_update_text_1707457', 'topRSID': 'rs116370523', 'Disease': 'PD', 'Gene': 'MMRN1', 'p_SMR_multi': 9.800664e-06, 'p_HEIDI': 0.008864784, 'Omic_tissue': 'Cerebellum', 'Omic_type': 'Cerebellum eQTL', 'func_sig': 'not functionally significant'}]",general,"Select, Similarity Search, Multi-Filter, Order By",Functional Significance
-Q67.1334,Q67,What is the top-associated SNP of the gene ARFGAP1 in Whole Blood mQTL omic data for PD and is it functionally significant?,"There are no SNPs within the gene ARFGAP1 in Whole Blood mQTL omic data that are significantly associated with PD, indicating that it is not functionally significant.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, Omic_tissue, Omic_type, func_sig
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full` 
- WHERE Gene = ""ARFGAP1"" AND Disease = ""PD"" AND LOWER(Omic_type) LIKE ""%whole blood mqtl%""
- ORDER BY p_SMR_multi
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_1023693', 'topRSID': 'rs2236195', 'Disease': 'PD', 'Gene': 'ARFGAP1', 'p_SMR_multi': 0.4268643, 'p_HEIDI': 0.6046975, 'Omic_tissue': 'Whole Blood', 'Omic_type': 'Whole Blood mQTL', 'func_sig': 'not functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_1023695', 'topRSID': 'rs2236195', 'Disease': 'PD', 'Gene': 'ARFGAP1', 'p_SMR_multi': 0.4493625, 'p_HEIDI': 0.5210566, 'Omic_tissue': 'Whole Blood', 'Omic_type': 'Whole Blood mQTL', 'func_sig': 'not functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_1023694', 'topRSID': 'rs2236195', 'Disease': 'PD', 'Gene': 'ARFGAP1', 'p_SMR_multi': 0.4495859, 'p_HEIDI': 0.3515457, 'Omic_tissue': 'Whole Blood', 'Omic_type': 'Whole Blood mQTL', 'func_sig': 'not functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_1023691', 'topRSID': 'rs6062879', 'Disease': 'PD', 'Gene': 'ARFGAP1', 'p_SMR_multi': 0.8870308, 'p_HEIDI': 0.434525, 'Omic_tissue': 'Whole Blood', 'Omic_type': 'Whole Blood mQTL', 'func_sig': 'not functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_1023692', 'topRSID': 'rs6062879', 'Disease': 'PD', 'Gene': 'ARFGAP1', 'p_SMR_multi': 0.9503302, 'p_HEIDI': 0.5257172, 'Omic_tissue': 'Whole Blood', 'Omic_type': 'Whole Blood mQTL', 'func_sig': 'not functionally significant'}]",general,"Select, Similarity Search, Multi-Filter, Order By",Functional Significance
-Q67.906,Q67,What is the top-associated SNP of the gene CRHR1 in Cortex eQTL metaBrain omic data for PSP and is it functionally significant?,"The top-associated SNP for CRHR1 in Cortex eQTL metaBrain omic data for PSP is rs393152, which has a multi-SNP SMR p-value of 1.15e-20 but is not functionally significant as the association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, Omic_tissue, Omic_type, func_sig
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full` 
- WHERE Gene = ""CRHR1"" AND Disease = ""PSP"" AND LOWER(Omic_type) LIKE ""%cortex eqtl metabrain%""
- ORDER BY p_SMR_multi
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_1154394', 'topRSID': 'rs393152', 'Disease': 'PSP', 'Gene': 'CRHR1', 'p_SMR_multi': 1.1510289999999999e-20, 'p_HEIDI': 2.1426280000000002e-17, 'Omic_tissue': 'Cortex', 'Omic_type': 'Cortex eQTL metaBrain', 'func_sig': 'association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium'}]",general,"Select, Similarity Search, Multi-Filter, Order By",Functional Significance
-Q67.1290,Q67,What is the top-associated SNP of the gene TREML2 in Whole Brain meta-analysis mQTL omic data for AD and is it functionally significant?,"The top-associated SNP for TREML2 in Whole Brain meta-analysis mQTL omic data for AD is rs3800342, which has a multi-SNP SMR p-value of 1.21e-10 but is not functionally significant as the association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, Omic_tissue, Omic_type, func_sig
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full` 
- WHERE Gene = ""TREML2"" AND Disease = ""AD"" AND LOWER(Omic_type) LIKE ""%whole brain meta-analysis mqtl%""
- ORDER BY p_SMR_multi
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_67040', 'topRSID': 'rs3800342', 'Disease': 'AD', 'Gene': 'TREML2', 'p_SMR_multi': 1.208504e-10, 'p_HEIDI': 0.0007742865, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium'}, {'UUID': 'NDD_SMR_genes_all_update_text_67042', 'topRSID': 'rs2006080', 'Disease': 'AD', 'Gene': 'TREML2', 'p_SMR_multi': 2.079623e-06, 'p_HEIDI': 1.158931e-05, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium'}, {'UUID': 'NDD_SMR_genes_all_update_text_67041', 'topRSID': 'rs11752528', 'Disease': 'AD', 'Gene': 'TREML2', 'p_SMR_multi': 0.02320551, 'p_HEIDI': 0.1491954, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'not functionally significant'}]",general,"Select, Similarity Search, Multi-Filter, Order By",Functional Significance
-Q67.1274,Q67,What is the top-associated SNP of the gene FTOP1 in Whole Blood eQTL eQTLgen omic data for AD and is it functionally significant?,"There are no SNPs within the gene FTOP1 in Whole Blood eQTL eQTLgen omic data that are significantly associated with AD, indicating that it is not functionally significant.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, Omic_tissue, Omic_type, func_sig
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full` 
- WHERE Gene = ""FTOP1"" AND Disease = ""AD"" AND LOWER(Omic_type) LIKE ""%whole blood eqtl eqtlgen%""
- ORDER BY p_SMR_multi
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_1491552', 'topRSID': 'rs10193864', 'Disease': 'AD', 'Gene': 'FTOP1', 'p_SMR_multi': 0.2547427, 'p_HEIDI': 0.112348, 'Omic_tissue': 'Whole Blood', 'Omic_type': 'Whole Blood eQTL eQTLgen', 'func_sig': 'not functionally significant'}]",general,"Select, Similarity Search, Multi-Filter, Order By",Functional Significance
-Q67.939,Q67,What is the top-associated SNP of the gene CYP4V2 in Whole Brain meta-analysis mQTL omic data for AD and is it functionally significant?,"There are no SNPs within the gene CYP4V2 in Whole Brain meta-analysis mQTL omic data that are significantly associated with AD, indicating that it is not functionally significant.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, Omic_tissue, Omic_type, func_sig
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full` 
- WHERE Gene = ""CYP4V2"" AND Disease = ""AD"" AND LOWER(Omic_type) LIKE ""%whole brain meta-analysis mqtl%""
- ORDER BY p_SMR_multi
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_57828', 'topRSID': 'rs6552962', 'Disease': 'AD', 'Gene': 'CYP4V2', 'p_SMR_multi': 0.1969403, 'p_HEIDI': 0.2515929, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'not functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_57826', 'topRSID': 'rs4563535', 'Disease': 'AD', 'Gene': 'CYP4V2', 'p_SMR_multi': 0.2380362, 'p_HEIDI': 0.9708892, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'not functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_57825', 'topRSID': 'rs4563535', 'Disease': 'AD', 'Gene': 'CYP4V2', 'p_SMR_multi': 0.3420443, 'p_HEIDI': -9999.0, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'not functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_57824', 'topRSID': 'rs4563535', 'Disease': 'AD', 'Gene': 'CYP4V2', 'p_SMR_multi': 0.343445, 'p_HEIDI': 0.9774929, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'not functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_57831', 'topRSID': 'rs6552962', 'Disease': 'AD', 'Gene': 'CYP4V2', 'p_SMR_multi': 0.3584822, 'p_HEIDI': 0.5407579, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'not functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_57830', 'topRSID': 'rs6552962', 'Disease': 'AD', 'Gene': 'CYP4V2', 'p_SMR_multi': 0.3667319, 'p_HEIDI': 0.5285422, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'not functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_57829', 'topRSID': 'rs6552962', 'Disease': 'AD', 'Gene': 'CYP4V2', 'p_SMR_multi': 0.4139926, 'p_HEIDI': 0.5277075, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'not functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_57827', 'topRSID': 'rs7691348', 'Disease': 'AD', 'Gene': 'CYP4V2', 'p_SMR_multi': 0.706724, 'p_HEIDI': 0.9093638, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'not functionally significant'}]",general,"Select, Similarity Search, Multi-Filter, Order By",Functional Significance
-Q67.1732,Q67,What is the top-associated SNP of the gene ARHGAP27 in Whole Brain meta-analysis mQTL omic data for PD and is it functionally significant?,"The top-associated SNP for ARHGAP27 in Whole Brain meta-analysis mQTL omic data for PD is rs1230106, which has a multi-SNP SMR p-value of 6.21e-07 but is not functionally significant as the association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, Omic_tissue, Omic_type, func_sig
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full` 
- WHERE Gene = ""ARHGAP27"" AND Disease = ""PD"" AND LOWER(Omic_type) LIKE ""%whole brain meta-analysis mqtl%""
- ORDER BY p_SMR_multi
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_491057', 'topRSID': 'rs62065376', 'Disease': 'PD', 'Gene': 'ARHGAP27', 'p_SMR_multi': 1.134698e-11, 'p_HEIDI': 0.3072466, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_491055', 'topRSID': 'rs62064637', 'Disease': 'PD', 'Gene': 'ARHGAP27', 'p_SMR_multi': 1.191891e-10, 'p_HEIDI': 0.01724892, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_491070', 'topRSID': 'rs62064641', 'Disease': 'PD', 'Gene': 'ARHGAP27', 'p_SMR_multi': 1.443951e-09, 'p_HEIDI': 0.005539955, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium'}, {'UUID': 'NDD_SMR_genes_all_update_text_491054', 'topRSID': 'rs56220387', 'Disease': 'PD', 'Gene': 'ARHGAP27', 'p_SMR_multi': 1.596535e-09, 'p_HEIDI': 1.122701e-05, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium'}, {'UUID': 'NDD_SMR_genes_all_update_text_491068', 'topRSID': 'rs62065379', 'Disease': 'PD', 'Gene': 'ARHGAP27', 'p_SMR_multi': 2.278676e-09, 'p_HEIDI': 0.001470994, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium'}, {'UUID': 'NDD_SMR_genes_all_update_text_491065', 'topRSID': 'rs62064641', 'Disease': 'PD', 'Gene': 'ARHGAP27', 'p_SMR_multi': 7.657835e-09, 'p_HEIDI': 1.372586e-05, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium'}, {'UUID': 'NDD_SMR_genes_all_update_text_491067', 'topRSID': 'rs113575082', 'Disease': 'PD', 'Gene': 'ARHGAP27', 'p_SMR_multi': 8.045148e-09, 'p_HEIDI': 0.002087863, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium'}, {'UUID': 'NDD_SMR_genes_all_update_text_491051', 'topRSID': 'rs56220387', 'Disease': 'PD', 'Gene': 'ARHGAP27', 'p_SMR_multi': 2.559485e-08, 'p_HEIDI': 1.279532e-08, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium'}, {'UUID': 'NDD_SMR_genes_all_update_text_491053', 'topRSID': 'rs56220387', 'Disease': 'PD', 'Gene': 'ARHGAP27', 'p_SMR_multi': 2.570105e-08, 'p_HEIDI': 4.804364e-06, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium'}, {'UUID': 'NDD_SMR_genes_all_update_text_491052', 'topRSID': 'rs56220387', 'Disease': 'PD', 'Gene': 'ARHGAP27', 'p_SMR_multi': 4.284958e-08, 'p_HEIDI': 0.000939369, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium'}, {'UUID': 'NDD_SMR_genes_all_update_text_491050', 'topRSID': 'rs56220387', 'Disease': 'PD', 'Gene': 'ARHGAP27', 'p_SMR_multi': 2.040238e-07, 'p_HEIDI': 1.429269e-06, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium'}, {'UUID': 'NDD_SMR_genes_all_update_text_491066', 'topRSID': 'rs62065379', 'Disease': 'PD', 'Gene': 'ARHGAP27', 'p_SMR_multi': 2.157062e-07, 'p_HEIDI': 0.0008073726, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium'}, {'UUID': 'NDD_SMR_genes_all_update_text_491060', 'topRSID': 'rs1059504', 'Disease': 'PD', 'Gene': 'ARHGAP27', 'p_SMR_multi': 3.154594e-07, 'p_HEIDI': 1.250028e-05, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium'}, {'UUID': 'NDD_SMR_genes_all_update_text_491069', 'topRSID': 'rs62064641', 'Disease': 'PD', 'Gene': 'ARHGAP27', 'p_SMR_multi': 3.983043e-07, 'p_HEIDI': 2.672757e-05, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium'}, {'UUID': 'NDD_SMR_genes_all_update_text_491059', 'topRSID': 'rs1230106', 'Disease': 'PD', 'Gene': 'ARHGAP27', 'p_SMR_multi': 4.521334e-07, 'p_HEIDI': 2.109317e-05, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium'}, {'UUID': 'NDD_SMR_genes_all_update_text_491071', 'topRSID': 'rs1230106', 'Disease': 'PD', 'Gene': 'ARHGAP27', 'p_SMR_multi': 6.20697e-07, 'p_HEIDI': 0.003741494, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium'}, {'UUID': 'NDD_SMR_genes_all_update_text_491048', 'topRSID': 'rs62064597', 'Disease': 'PD', 'Gene': 'ARHGAP27', 'p_SMR_multi': 7.33942e-07, 'p_HEIDI': 0.0008400544, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium'}, {'UUID': 'NDD_SMR_genes_all_update_text_491064', 'topRSID': 'rs62065379', 'Disease': 'PD', 'Gene': 'ARHGAP27', 'p_SMR_multi': 8.092345e-07, 'p_HEIDI': 0.0004670534, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium'}, {'UUID': 'NDD_SMR_genes_all_update_text_491072', 'topRSID': 'rs1230106', 'Disease': 'PD', 'Gene': 'ARHGAP27', 'p_SMR_multi': 1.118825e-06, 'p_HEIDI': 0.01578108, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_491062', 'topRSID': 'rs1230106', 'Disease': 'PD', 'Gene': 'ARHGAP27', 'p_SMR_multi': 1.59529e-06, 'p_HEIDI': 3.927617e-06, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium'}, {'UUID': 'NDD_SMR_genes_all_update_text_491056', 'topRSID': 'rs56212100', 'Disease': 'PD', 'Gene': 'ARHGAP27', 'p_SMR_multi': 2.231037e-06, 'p_HEIDI': -9999.0, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium'}, {'UUID': 'NDD_SMR_genes_all_update_text_491063', 'topRSID': 'rs35327136', 'Disease': 'PD', 'Gene': 'ARHGAP27', 'p_SMR_multi': 3.613189e-06, 'p_HEIDI': 1.211223e-05, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'not functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_491061', 'topRSID': 'rs1230085', 'Disease': 'PD', 'Gene': 'ARHGAP27', 'p_SMR_multi': 0.0004309626, 'p_HEIDI': -9999.0, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'not functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_491058', 'topRSID': 'rs1230106', 'Disease': 'PD', 'Gene': 'ARHGAP27', 'p_SMR_multi': 0.0004910843, 'p_HEIDI': 1.483704e-06, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'not functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_491049', 'topRSID': 'rs1230096', 'Disease': 'PD', 'Gene': 'ARHGAP27', 'p_SMR_multi': 0.005543902, 'p_HEIDI': 3.403872e-05, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'not functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_491073', 'topRSID': 'rs1230084', 'Disease': 'PD', 'Gene': 'ARHGAP27', 'p_SMR_multi': 0.2191889, 'p_HEIDI': 0.002558024, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'not functionally significant'}]",general,"Select, Similarity Search, Multi-Filter, Order By",Functional Significance
-Q67.66,Q67,What is the top-associated SNP of the gene LRRC37A in Tibial Nerve eQTL omic data for PD and is it functionally significant?,"The top-associated SNP for LRRC37A in Tibial Nerve eQTL omic data for PD is rs3874943, which has a multi-SNP SMR p-value of 1.43e-11 but is not functionally significant as the association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, Omic_tissue, Omic_type, func_sig
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full` 
- WHERE Gene = ""LRRC37A"" AND Disease = ""PD"" AND LOWER(Omic_type) LIKE ""%tibial nerve eqtl%""
- ORDER BY p_SMR_multi
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_1328939', 'topRSID': 'rs3874943', 'Disease': 'PD', 'Gene': 'LRRC37A', 'p_SMR_multi': 1.429027e-11, 'p_HEIDI': 9.436828e-06, 'Omic_tissue': 'Tibial Nerve', 'Omic_type': 'Tibial Nerve eQTL', 'func_sig': 'association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium'}]",general,"Select, Similarity Search, Multi-Filter, Order By",Functional Significance
-Q67.1324,Q67,What is the top-associated SNP of the gene CRHR1 in Whole Blood mQTL omic data for AD and is it functionally significant?,"The top-associated SNP for CRHR1 in Whole Blood mQTL omic data for AD is rs113790915, which has a multi-SNP SMR p-value of 1.08e-06 and a HEIDI of 0.02, indicating that it is functionally significant.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, Omic_tissue, Omic_type, func_sig
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full` 
- WHERE Gene = ""CRHR1"" AND Disease = ""AD"" AND LOWER(Omic_type) LIKE ""%whole blood mqtl%""
- ORDER BY p_SMR_multi
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_591172', 'topRSID': 'rs17689882', 'Disease': 'AD', 'Gene': 'CRHR1', 'p_SMR_multi': 3.894906e-07, 'p_HEIDI': 0.008599073, 'Omic_tissue': 'Whole Blood', 'Omic_type': 'Whole Blood mQTL', 'func_sig': 'association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium'}, {'UUID': 'NDD_SMR_genes_all_update_text_591169', 'topRSID': 'rs113790915', 'Disease': 'AD', 'Gene': 'CRHR1', 'p_SMR_multi': 7.455325e-07, 'p_HEIDI': 0.1832888, 'Omic_tissue': 'Whole Blood', 'Omic_type': 'Whole Blood mQTL', 'func_sig': 'functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_591171', 'topRSID': 'rs62062279', 'Disease': 'AD', 'Gene': 'CRHR1', 'p_SMR_multi': 8.830123e-07, 'p_HEIDI': 0.01147118, 'Omic_tissue': 'Whole Blood', 'Omic_type': 'Whole Blood mQTL', 'func_sig': 'functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_591170', 'topRSID': 'rs113790915', 'Disease': 'AD', 'Gene': 'CRHR1', 'p_SMR_multi': 1.075968e-06, 'p_HEIDI': 0.01605031, 'Omic_tissue': 'Whole Blood', 'Omic_type': 'Whole Blood mQTL', 'func_sig': 'functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_591175', 'topRSID': 'rs62057073', 'Disease': 'AD', 'Gene': 'CRHR1', 'p_SMR_multi': 7.58103e-06, 'p_HEIDI': 0.05422487, 'Omic_tissue': 'Whole Blood', 'Omic_type': 'Whole Blood mQTL', 'func_sig': 'not functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_591178', 'topRSID': 'rs12944712', 'Disease': 'AD', 'Gene': 'CRHR1', 'p_SMR_multi': 1.245446e-05, 'p_HEIDI': 0.0002199247, 'Omic_tissue': 'Whole Blood', 'Omic_type': 'Whole Blood mQTL', 'func_sig': 'not functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_591177', 'topRSID': 'rs111273167', 'Disease': 'AD', 'Gene': 'CRHR1', 'p_SMR_multi': 4.45353e-05, 'p_HEIDI': 0.001178519, 'Omic_tissue': 'Whole Blood', 'Omic_type': 'Whole Blood mQTL', 'func_sig': 'not functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_591173', 'topRSID': 'rs199499', 'Disease': 'AD', 'Gene': 'CRHR1', 'p_SMR_multi': 9.226908e-05, 'p_HEIDI': 0.2730911, 'Omic_tissue': 'Whole Blood', 'Omic_type': 'Whole Blood mQTL', 'func_sig': 'not functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_591179', 'topRSID': 'rs17763104', 'Disease': 'AD', 'Gene': 'CRHR1', 'p_SMR_multi': 0.03093689, 'p_HEIDI': 0.07751756, 'Omic_tissue': 'Whole Blood', 'Omic_type': 'Whole Blood mQTL', 'func_sig': 'not functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_591174', 'topRSID': 'rs151314932', 'Disease': 'AD', 'Gene': 'CRHR1', 'p_SMR_multi': 0.06012737, 'p_HEIDI': -9999.0, 'Omic_tissue': 'Whole Blood', 'Omic_type': 'Whole Blood mQTL', 'func_sig': 'not functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_591176', 'topRSID': 'rs12944712', 'Disease': 'AD', 'Gene': 'CRHR1', 'p_SMR_multi': 0.08507669, 'p_HEIDI': 0.0002662194, 'Omic_tissue': 'Whole Blood', 'Omic_type': 'Whole Blood mQTL', 'func_sig': 'not functionally significant'}]",general,"Select, Similarity Search, Multi-Filter, Order By",Functional Significance
-Q67.57,Q67,What is the top-associated SNP of the gene DGKQ in Prefrontal Cortex eQTL omic data for PD and is it functionally significant?,"The top-associated SNP for DGKQ in Prefrontal Cortex eQTL omic data for PD is rs6814642, which has a multi-SNP SMR p-value of 1.42e-09 but is not functionally significant as the association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, Omic_tissue, Omic_type, func_sig
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full` 
- WHERE Gene = ""DGKQ"" AND Disease = ""PD"" AND LOWER(Omic_type) LIKE ""%prefrontal cortex eqtl%""
- ORDER BY p_SMR_multi
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_1236185', 'topRSID': 'rs6814642', 'Disease': 'PD', 'Gene': 'DGKQ', 'p_SMR_multi': 1.423406e-09, 'p_HEIDI': 1.355011e-12, 'Omic_tissue': 'Prefrontal Cortex', 'Omic_type': 'Prefrontal Cortex eQTL', 'func_sig': 'association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium'}]",general,"Select, Similarity Search, Multi-Filter, Order By",Functional Significance
-Q67.1293,Q67,What is the top-associated SNP of the gene TMEM175 in Whole Brain meta-analysis mQTL omic data for PD and is it functionally significant?,"The top-associated SNP for TMEM175 in Whole Brain meta-analysis mQTL omic data for PD is rs6848199, which has a multi-SNP SMR p-value of 1.17e-09 and a HEIDI of 0.26, indicating that it is functionally significant.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, Omic_tissue, Omic_type, func_sig
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full` 
- WHERE Gene = ""TMEM175"" AND Disease = ""PD"" AND LOWER(Omic_type) LIKE ""%whole brain meta-analysis mqtl%""
- ORDER BY p_SMR_multi
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_429841', 'topRSID': 'rs10008187', 'Disease': 'PD', 'Gene': 'TMEM175', 'p_SMR_multi': 4.414637e-10, 'p_HEIDI': 0.4333231, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_429843', 'topRSID': 'rs10008187', 'Disease': 'PD', 'Gene': 'TMEM175', 'p_SMR_multi': 6.686346e-10, 'p_HEIDI': 0.3099254, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_429842', 'topRSID': 'rs6848199', 'Disease': 'PD', 'Gene': 'TMEM175', 'p_SMR_multi': 1.173192e-09, 'p_HEIDI': 0.2607437, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_429844', 'topRSID': 'rs10008187', 'Disease': 'PD', 'Gene': 'TMEM175', 'p_SMR_multi': 1.397854e-09, 'p_HEIDI': 0.2163939, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_429848', 'topRSID': 'rs17783233', 'Disease': 'PD', 'Gene': 'TMEM175', 'p_SMR_multi': 6.678886e-07, 'p_HEIDI': 0.005727583, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium'}, {'UUID': 'NDD_SMR_genes_all_update_text_429845', 'topRSID': 'rs2290403', 'Disease': 'PD', 'Gene': 'TMEM175', 'p_SMR_multi': 9.382849e-07, 'p_HEIDI': 8.056445e-08, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium'}, {'UUID': 'NDD_SMR_genes_all_update_text_429846', 'topRSID': 'rs6842808', 'Disease': 'PD', 'Gene': 'TMEM175', 'p_SMR_multi': 2.308662e-06, 'p_HEIDI': 1.344941e-05, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium'}, {'UUID': 'NDD_SMR_genes_all_update_text_429839', 'topRSID': 'rs11729289', 'Disease': 'PD', 'Gene': 'TMEM175', 'p_SMR_multi': 2.360771e-06, 'p_HEIDI': 1.131187e-11, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium'}, {'UUID': 'NDD_SMR_genes_all_update_text_429847', 'topRSID': 'rs11730111', 'Disease': 'PD', 'Gene': 'TMEM175', 'p_SMR_multi': 7.018157e-06, 'p_HEIDI': 2.756563e-05, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'not functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_429840', 'topRSID': 'rs935965', 'Disease': 'PD', 'Gene': 'TMEM175', 'p_SMR_multi': 0.03003756, 'p_HEIDI': 0.0231481, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain meta-analysis mQTL', 'func_sig': 'not functionally significant'}]",general,"Select, Similarity Search, Multi-Filter, Order By",Functional Significance
-Q67.1119,Q67,What is the top-associated SNP of the gene RP11-259G18.3 in Whole Brain eQTL omic data for PSP and is it functionally significant?,"The top-associated SNP for RP11-259G18.3 in Whole Brain eQTL omic data for PSP is rs169201, which has a multi-SNP SMR p-value of 1.77e-17 but is not functionally significant as the association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, Omic_tissue, Omic_type, func_sig
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full` 
- WHERE Gene = ""RP11-259G18.3"" AND Disease = ""PSP"" AND LOWER(Omic_type) LIKE ""%whole brain eqtl%""
- ORDER BY p_SMR_multi
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_1646046', 'topRSID': 'rs169201', 'Disease': 'PSP', 'Gene': 'RP11-259G18.3', 'p_SMR_multi': 1.769883e-17, 'p_HEIDI': 0.0004513712, 'Omic_tissue': 'Whole Brain', 'Omic_type': 'Whole Brain eQTL', 'func_sig': 'association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium'}]",general,"Select, Similarity Search, Multi-Filter, Order By",Functional Significance
-Q67.585,Q67,What is the top-associated SNP of the gene FBXO7 in Whole Blood mQTL omic data for PSP and is it functionally significant?,"There are no SNPs within the gene FBXO7 in Whole Blood mQTL omic data that are significantly associated with PSP, indicating that it is not functionally significant.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, Omic_tissue, Omic_type, func_sig
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full` 
- WHERE Gene = ""FBXO7"" AND Disease = ""PSP"" AND LOWER(Omic_type) LIKE ""%whole blood mqtl%""
- ORDER BY p_SMR_multi
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_1055269', 'topRSID': 'rs11107', 'Disease': 'PSP', 'Gene': 'FBXO7', 'p_SMR_multi': 0.5331562, 'p_HEIDI': 0.197172, 'Omic_tissue': 'Whole Blood', 'Omic_type': 'Whole Blood mQTL', 'func_sig': 'not functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_1055271', 'topRSID': 'rs4820080', 'Disease': 'PSP', 'Gene': 'FBXO7', 'p_SMR_multi': 0.5550014, 'p_HEIDI': -9999.0, 'Omic_tissue': 'Whole Blood', 'Omic_type': 'Whole Blood mQTL', 'func_sig': 'not functionally significant'}, {'UUID': 'NDD_SMR_genes_all_update_text_1055270', 'topRSID': 'rs5749450', 'Disease': 'PSP', 'Gene': 'FBXO7', 'p_SMR_multi': 0.7051218, 'p_HEIDI': 0.4414362, 'Omic_tissue': 'Whole Blood', 'Omic_type': 'Whole Blood mQTL', 'func_sig': 'not functionally significant'}]",general,"Select, Similarity Search, Multi-Filter, Order By",Functional Significance
-Q67.375,Q67,What is the top-associated SNP of the gene FRAT1 in Whole Blood eQTL eQTLgen omic data for PSP and is it functionally significant?,"There are no SNPs within the gene FRAT1 in Whole Blood eQTL eQTLgen omic data that are significantly associated with PSP, indicating that it is not functionally significant.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, Omic_tissue, Omic_type, func_sig
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full` 
- WHERE Gene = ""FRAT1"" AND Disease = ""PSP"" AND LOWER(Omic_type) LIKE ""%whole blood eqtl eqtlgen%""
- ORDER BY p_SMR_multi
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_1575070', 'topRSID': 'rs2297988', 'Disease': 'PSP', 'Gene': 'FRAT1', 'p_SMR_multi': 0.1834924, 'p_HEIDI': 0.1005794, 'Omic_tissue': 'Whole Blood', 'Omic_type': 'Whole Blood eQTL eQTLgen', 'func_sig': 'not functionally significant'}]",general,"Select, Similarity Search, Multi-Filter, Order By",Functional Significance
-Q67.276,Q67,What is the top-associated SNP of the gene TSPAN14 in Whole Blood eQTL eQTLgen omic data for AD and is it functionally significant?,"The top-associated SNP for TSPAN14 in Whole Blood eQTL eQTLgen omic data for AD is rs12260962, which has a multi-SNP SMR p-value of 1.46e-06 but is not functionally significant as the association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium.","SELECT UUID, topRSID, Disease, Gene, p_SMR_multi, p_HEIDI, Omic_tissue, Omic_type, func_sig
- FROM `card-ai-389220.bio_sql_benchmark.NeurodegenerativeDiseases_SMR_Genes_Full` 
- WHERE Gene = ""TSPAN14"" AND Disease = ""AD"" AND LOWER(Omic_type) LIKE ""%whole blood eqtl eqtlgen%""
- ORDER BY p_SMR_multi
- LIMIT 100","[{'UUID': 'NDD_SMR_genes_all_update_text_1497629', 'topRSID': 'rs12260962', 'Disease': 'AD', 'Gene': 'TSPAN14', 'p_SMR_multi': 1.463233e-06, 'p_HEIDI': 3.336469e-06, 'Omic_tissue': 'Whole Blood', 'Omic_type': 'Whole Blood eQTL eQTLgen', 'func_sig': 'association meets significance threshold but shows signs of linkage/ Linkage Disequilibrium'}]",general,"Select, Similarity Search, Multi-Filter, Order By",Functional Significance
-Q35.1861,Q35,Is the SNP rs992204 significant in AD?,"No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs992204 has a p-value of 6.77e-01 and therefore is not significant in AD.","SELECT UUID, SNP, p, b
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID` 
- WHERE SNP = 'rs992204'
- ORDER BY p
- LIMIT 1","[{'UUID': 'AD_combo_gene_notext_UUID_7469151', 'SNP': 'rs992204', 'p': 0.6772, 'b': 0.0034}]",general,"Select, Order By",GWAS Significance
-Q35.354,Q35,Is the SNP rs117252809 significant in AD?,"Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs117252809 has a p-value of 6.55e-20 and therefore is significant in AD.","SELECT UUID, SNP, p, b
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID` 
- WHERE SNP = 'rs117252809'
- ORDER BY p
- LIMIT 1","[{'UUID': 'AD_combo_gene_notext_UUID_19978840', 'SNP': 'rs117252809', 'p': 6.549e-20, 'b': 0.8418}]",general,"Select, Order By",GWAS Significance
-Q35.1334,Q35,Is the SNP rs34075676 significant in AD?,"No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs34075676 has a p-value of 2.79e-01 and therefore is not significant in AD.","SELECT UUID, SNP, p, b
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID` 
- WHERE SNP = 'rs34075676'
- ORDER BY p
- LIMIT 1","[{'UUID': 'AD_combo_gene_notext_UUID_10534616', 'SNP': 'rs34075676', 'p': 0.279, 'b': 0.0131}]",general,"Select, Order By",GWAS Significance
-Q35.906,Q35,Is the SNP rs36195148 significant in AD?,"Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs36195148 has a p-value of 6.70e-12 and therefore is significant in AD.","SELECT UUID, SNP, p, b
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID` 
- WHERE SNP = 'rs36195148'
- ORDER BY p
- LIMIT 1","[{'UUID': 'AD_combo_gene_notext_UUID_3417938', 'SNP': 'rs36195148', 'p': 6.7e-12, 'b': 0.0573}]",general,"Select, Order By",GWAS Significance
-Q35.1290,Q35,Is the SNP rs72633503 significant in AD?,"No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs72633503 has a p-value of 5.89e-01 and therefore is not significant in AD.","SELECT UUID, SNP, p, b
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID` 
- WHERE SNP = 'rs72633503'
- ORDER BY p
- LIMIT 1","[{'UUID': 'AD_combo_gene_notext_UUID_16271607', 'SNP': 'rs72633503', 'p': 0.5893, 'b': -0.0049}]",general,"Select, Order By",GWAS Significance
-Q35.1274,Q35,Is the SNP rs532050787 significant in AD?,"No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs532050787 has a p-value of 9.98e-01 and therefore is not significant in AD.","SELECT UUID, SNP, p, b
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID` 
- WHERE SNP = 'rs532050787'
- ORDER BY p
- LIMIT 1","[{'UUID': 'AD_combo_gene_notext_UUID_13164787', 'SNP': 'rs532050787', 'p': 0.9982, 'b': -0.0004}]",general,"Select, Order By",GWAS Significance
-Q35.939,Q35,Is the SNP rs283809 significant in AD?,"Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs283809 has a p-value of 3.26e-56 and therefore is significant in AD.","SELECT UUID, SNP, p, b
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID` 
- WHERE SNP = 'rs283809'
- ORDER BY p
- LIMIT 1","[{'UUID': 'AD_combo_gene_notext_UUID_19974330', 'SNP': 'rs283809', 'p': 3.262e-56, 'b': -0.3594}]",general,"Select, Order By",GWAS Significance
-Q35.1732,Q35,Is the SNP rs112707917 significant in AD?,"No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs112707917 has a p-value of 6.63e-01 and therefore is not significant in AD.","SELECT UUID, SNP, p, b
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID` 
- WHERE SNP = 'rs112707917'
- ORDER BY p
- LIMIT 1","[{'UUID': 'AD_combo_gene_notext_UUID_5537337', 'SNP': 'rs112707917', 'p': 0.6629, 'b': 0.1441}]",general,"Select, Order By",GWAS Significance
-Q35.66,Q35,Is the SNP rs12741203 significant in AD?,"Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs12741203 has a p-value of 2.46e-08 and therefore is significant in AD.","SELECT UUID, SNP, p, b
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID` 
- WHERE SNP = 'rs12741203'
- ORDER BY p
- LIMIT 1","[{'UUID': 'AD_combo_gene_notext_UUID_992349', 'SNP': 'rs12741203', 'p': 2.457e-08, 'b': 0.0492}]",general,"Select, Order By",GWAS Significance
-Q35.1324,Q35,Is the SNP rs146420298 significant in AD?,"No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs146420298 has a p-value of 4.63e-02 and therefore is not significant in AD.","SELECT UUID, SNP, p, b
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID` 
- WHERE SNP = 'rs146420298'
- ORDER BY p
- LIMIT 1","[{'UUID': 'AD_combo_gene_notext_UUID_6116867', 'SNP': 'rs146420298', 'p': 0.04627, 'b': -0.2794}]",general,"Select, Order By",GWAS Significance
-Q35.57,Q35,Is the SNP rs140009180 significant in AD?,"Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs140009180 has a p-value of 2.73e-10 and therefore is significant in AD.","SELECT UUID, SNP, p, b
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID` 
- WHERE SNP = 'rs140009180'
- ORDER BY p
- LIMIT 1","[{'UUID': 'AD_combo_gene_notext_UUID_3418004', 'SNP': 'rs140009180', 'p': 2.734e-10, 'b': -0.0519}]",general,"Select, Order By",GWAS Significance
-Q35.1293,Q35,Is the SNP rs555987053 significant in AD?,"No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs555987053 has a p-value of 9.81e-01 and therefore is not significant in AD.","SELECT UUID, SNP, p, b
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID` 
- WHERE SNP = 'rs555987053'
- ORDER BY p
- LIMIT 1","[{'UUID': 'AD_combo_gene_notext_UUID_10992680', 'SNP': 'rs555987053', 'p': 0.9806, 'b': 0.0026}]",general,"Select, Order By",GWAS Significance
-Q35.1119,Q35,Is the SNP rs72820277 significant in AD?,"No, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs72820277 has a p-value of 5.37e-01 and therefore is not significant in AD.","SELECT UUID, SNP, p, b
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID` 
- WHERE SNP = 'rs72820277'
- ORDER BY p
- LIMIT 1","[{'UUID': 'AD_combo_gene_notext_UUID_13479434', 'SNP': 'rs72820277', 'p': 0.5374, 'b': 0.0287}]",general,"Select, Order By",GWAS Significance
-Q35.585,Q35,Is the SNP rs4803806 significant in AD?,"Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs4803806 has a p-value of 1.36e-22 and therefore is significant in AD.","SELECT UUID, SNP, p, b
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID` 
- WHERE SNP = 'rs4803806'
- ORDER BY p
- LIMIT 1","[{'UUID': 'AD_combo_gene_notext_UUID_19976804', 'SNP': 'rs4803806', 'p': 1.362e-22, 'b': 0.1157}]",general,"Select, Order By",GWAS Significance
-Q35.375,Q35,Is the SNP rs2927488 significant in AD?,"Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs2927488 has a p-value of 5.95e-15 and therefore is significant in AD.","SELECT UUID, SNP, p, b
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID` 
- WHERE SNP = 'rs2927488'
- ORDER BY p
- LIMIT 1","[{'UUID': 'AD_combo_gene_notext_UUID_19973034', 'SNP': 'rs2927488', 'p': 5.952e-15, 'b': -0.0816}]",general,"Select, Order By",GWAS Significance
-Q35.276,Q35,Is the SNP rs146217697 significant in AD?,"Yes, according to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), the SNP rs146217697 has a p-value of 1.30e-08 and therefore is significant in AD.","SELECT UUID, SNP, p, b
- FROM `card-ai-389220.bio_sql_benchmark.AlzheimerDisease_CombinedGeneData_UUID` 
- WHERE SNP = 'rs146217697'
- ORDER BY p
- LIMIT 1","[{'UUID': 'AD_combo_gene_notext_UUID_19972593', 'SNP': 'rs146217697', 'p': 1.303e-08, 'b': -0.2409}]",general,"Select, Order By",GWAS Significance
-Q1.482,Q1,Is FTO a druggable gene?,"There are currently no approved drugs targeting FTO, but there is 1 drug in a clinical trial indicating that it may be a druggable gene.","SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE newLinkedTargets_string LIKE ""%FTO %""
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100
-","[{'UUID': 'DrugGeneTargets_v2_1486', 'drugName': 'Bisantrene', 'drugIsApproved': False, 'newLinkedTargets_string': 'FTO (ENSG00000140718)', 'maxClinicalTrialPhase': 3}]",general,"Similarity Search, Order By, Distinct","Approval Status, Genetic Target"
-Q1.77,Q1,Is AR a druggable gene?,"There are currently 25 approved drugs which target AR, indicating that it is a druggable gene.","SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE newLinkedTargets_string LIKE ""%AR %""
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100
-","[{'UUID': 'DrugGeneTargets_v2_2428', 'drugName': 'Dromostanolone Propionate', 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5791', 'drugName': 'Stanozolol', 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5601', 'drugName': 'Nilutamide', 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3386', 'drugName': 'Oxandrolone', 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5959', 'drugName': 'Testosterone Enanthate', 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2803', 'drugName': 'Clascoterone', 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4704', 'drugName': 'Flutamide', 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5106', 'drugName': 'Darolutamide', 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_939', 'drugName': 'Testosterone Undecanoate', 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_111', 'drugName': 'Oxymetholone', 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3566', 'drugName': 'Ethylestrenol', 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4917', 'drugName': 'Danazol', 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083), PGR (ENSG00000082175)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5308', 'drugName': 'Testosterone', 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6320', 'drugName': 'Abiraterone', 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083), CYP17A1 (ENSG00000148795), SRD5A1 (ENSG00000145545), SRD5A2 (ENSG00000277893), SRD5A3 (ENSG00000128039)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5812', 'drugName': 'Nandrolone Decanoate', 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3801', 'drugName': 'Ceruletide', 'drugIsApproved': True, 'newLinkedTargets_string': 'CCKAR (ENSG00000163394)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2216', 'drugName': 'Methyltestosterone', 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2693', 'drugName': 'Sincalide', 'drugIsApproved': True, 'newLinkedTargets_string': 'CCKAR (ENSG00000163394)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2551', 'drugName': 'Cyproterone Acetate', 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083), PGR (ENSG00000082175), NR3C1 (ENSG00000113580)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4916', 'drugName': 'Danazol', 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083), PGR (ENSG00000082175)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6321', 'drugName': 'Abiraterone', 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083), CYP17A1 (ENSG00000148795), SRD5A1 (ENSG00000145545), SRD5A2 (ENSG00000277893), SRD5A3 (ENSG00000128039)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4352', 'drugName': 'Enzalutamide', 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6322', 'drugName': 'Abiraterone', 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083), CYP17A1 (ENSG00000148795), SRD5A1 (ENSG00000145545), SRD5A2 (ENSG00000277893), SRD5A3 (ENSG00000128039)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4237', 'drugName': 'Nandrolone Phenpropionate', 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2550', 'drugName': 'Cyproterone Acetate', 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083), PGR (ENSG00000082175), NR3C1 (ENSG00000113580)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2128', 'drugName': 'Testosterone Propionate', 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6164', 'drugName': 'Apalutamide', 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3461', 'drugName': 'Ceruletide Diethylamine', 'drugIsApproved': True, 'newLinkedTargets_string': 'CCKAR (ENSG00000163394)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4716', 'drugName': 'Methandrostenolone', 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2552', 'drugName': 'Cyproterone Acetate', 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083), PGR (ENSG00000082175), NR3C1 (ENSG00000113580)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_434', 'drugName': 'Testosterone Cypionate', 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5575', 'drugName': 'Proglumide', 'drugIsApproved': True, 'newLinkedTargets_string': 'CCKBR (ENSG00000110148), CCKAR (ENSG00000163394)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3575', 'drugName': 'Fluoxymesterone', 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2718', 'drugName': 'Bicalutamide', 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5374', 'drugName': 'Dexloxiglumide', 'drugIsApproved': False, 'newLinkedTargets_string': 'CCKAR (ENSG00000163394)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1889', 'drugName': 'Galeterone', 'drugIsApproved': False, 'newLinkedTargets_string': 'AR (ENSG00000169083), CYP17A1 (ENSG00000148795)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1890', 'drugName': 'Galeterone', 'drugIsApproved': False, 'newLinkedTargets_string': 'AR (ENSG00000169083), CYP17A1 (ENSG00000148795)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_6298', 'drugName': 'Gt-0918', 'drugIsApproved': False, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4933', 'drugName': 'Shr3680', 'drugIsApproved': False, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1611', 'drugName': 'Enobosarm', 'drugIsApproved': False, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_6326', 'drugName': 'Vk5211', 'drugIsApproved': False, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_531', 'drugName': 'Seviteronel', 'drugIsApproved': False, 'newLinkedTargets_string': 'AR (ENSG00000169083), CYP17A1 (ENSG00000148795)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2030', 'drugName': 'Ly2452473', 'drugIsApproved': False, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_530', 'drugName': 'Seviteronel', 'drugIsApproved': False, 'newLinkedTargets_string': 'AR (ENSG00000169083), CYP17A1 (ENSG00000148795)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1153', 'drugName': 'Gsk2881078', 'drugIsApproved': False, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1524', 'drugName': 'Cr 1447', 'drugIsApproved': False, 'newLinkedTargets_string': 'ESR2 (ENSG00000140009), AR (ENSG00000169083)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_1525', 'drugName': 'Cr 1447', 'drugIsApproved': False, 'newLinkedTargets_string': 'ESR2 (ENSG00000140009), AR (ENSG00000169083)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2827', 'drugName': 'Ce-326597', 'drugIsApproved': False, 'newLinkedTargets_string': 'CCKAR (ENSG00000163394)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3617', 'drugName': 'Mk-0773', 'drugIsApproved': False, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5293', 'drugName': 'Dimethylcurcumin', 'drugIsApproved': False, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_11', 'drugName': 'Azd3514', 'drugIsApproved': False, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1352', 'drugName': 'Apc-100', 'drugIsApproved': False, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1004', 'drugName': 'Glpg0492', 'drugIsApproved': False, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_6017', 'drugName': 'Lgd-2941', 'drugIsApproved': False, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1975', 'drugName': 'He3235', 'drugIsApproved': False, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_3436', 'drugName': 'Gsk2849466', 'drugIsApproved': False, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 1}]",general,"Similarity Search, Order By, Distinct","Approval Status, Genetic Target"
-Q1.1503,Q1,Is TUBB2B a druggable gene?,"There are currently 20 approved drugs which target TUBB2B, indicating that it is a druggable gene.","SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE newLinkedTargets_string LIKE ""%TUBB2B %""
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100
-","[{'UUID': 'DrugGeneTargets_v2_1084', 'drugName': 'Brentuximab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'TNFRSF8 (ENSG00000120949), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1872', 'drugName': 'Belantamab Mafodotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), TNFRSF17 (ENSG00000048462)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4158', 'drugName': 'Tisotumab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'F3 (ENSG00000117525), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2339', 'drugName': 'Ixabepilone', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_974', 'drugName': 'Vinflunine', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4166', 'drugName': 'Vinblastine', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5756', 'drugName': 'Trastuzumab Emtansine', 'drugIsApproved': True, 'newLinkedTargets_string': 'ERBB2 (ENSG00000141736), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5604', 'drugName': 'Eribulin', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2795', 'drugName': 'Enfortumab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'NECTIN4 (ENSG00000143217), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4743', 'drugName': 'Colchicine', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_560', 'drugName': 'Polatuzumab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'CD79B (ENSG00000007312), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_561', 'drugName': 'Polatuzumab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'CD79B (ENSG00000007312), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1085', 'drugName': 'Brentuximab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'TNFRSF8 (ENSG00000120949), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6261', 'drugName': 'Vinblastine Sulfate', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2794', 'drugName': 'Enfortumab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'NECTIN4 (ENSG00000143217), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5140', 'drugName': 'Vincristine', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4157', 'drugName': 'Tisotumab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'F3 (ENSG00000117525), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_762', 'drugName': 'Cabazitaxel', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1267', 'drugName': 'Docetaxel', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3175', 'drugName': 'Eribulin Mesylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2177', 'drugName': 'Docetaxel', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2013', 'drugName': 'Paclitaxel', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1871', 'drugName': 'Belantamab Mafodotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), TNFRSF17 (ENSG00000048462)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5757', 'drugName': 'Trastuzumab Emtansine', 'drugIsApproved': True, 'newLinkedTargets_string': 'ERBB2 (ENSG00000141736), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3353', 'drugName': 'Vincristine Sulfate', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2330', 'drugName': 'Vinorelbine', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6364', 'drugName': 'Vinorelbine Tartrate', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4123', 'drugName': 'Plinabulin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_429', 'drugName': 'Ang1005', 'drugIsApproved': False, 'newLinkedTargets_string': 'LRP1 (ENSG00000123384), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3391', 'drugName': 'Fosbretabulin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1364', 'drugName': 'Ombrabulin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_2595', 'drugName': 'Paclitaxel Poliglumex', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5727', 'drugName': 'Mirvetuximab Soravtansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'FOLR1 (ENSG00000110195), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3781', 'drugName': 'Telisotuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), MET (ENSG00000105976)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1224', 'drugName': 'Tusamitamab Ravtansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'CEACAM5 (ENSG00000105388), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1225', 'drugName': 'Tusamitamab Ravtansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'CEACAM5 (ENSG00000105388), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3782', 'drugName': 'Telisotuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), MET (ENSG00000105976)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3390', 'drugName': 'Fosbretabulin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_430', 'drugName': 'Ang1005', 'drugIsApproved': False, 'newLinkedTargets_string': 'LRP1 (ENSG00000123384), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4860', 'drugName': 'Patupilone', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5728', 'drugName': 'Mirvetuximab Soravtansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'FOLR1 (ENSG00000110195), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_829', 'drugName': 'Larotaxel', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5370', 'drugName': 'Paclitaxel Docosahexaenoic Acid', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_186', 'drugName': 'Cantuzumab Mertansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'MUC1 (ENSG00000185499), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_187', 'drugName': 'Cantuzumab Mertansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'MUC1 (ENSG00000185499), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5922', 'drugName': 'Indusatumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), GUCY2C (ENSG00000070019)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4294', 'drugName': 'Arx-788', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), ERBB2 (ENSG00000141736)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2981', 'drugName': 'Plocabulin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3189', 'drugName': 'Sagopilone', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5837', 'drugName': 'Soblidotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4295', 'drugName': 'Arx-788', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), ERBB2 (ENSG00000141736)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4455', 'drugName': 'Ags-16C3F', 'drugIsApproved': False, 'newLinkedTargets_string': 'ENPP3 (ENSG00000154269), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4675', 'drugName': 'Milataxel', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4227', 'drugName': 'Verubulin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4456', 'drugName': 'Ags-16C3F', 'drugIsApproved': False, 'newLinkedTargets_string': 'ENPP3 (ENSG00000154269), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2652', 'drugName': 'Ladiratuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), SLC39A6 (ENSG00000141424)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4395', 'drugName': 'Fosbretabulin Tromethamine', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3400', 'drugName': 'Abt-751', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBB3 (ENSG00000258947), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), TUBB8B (ENSG00000173213)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6014', 'drugName': 'Praluzatamab Ravtansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), ALCAM (ENSG00000170017)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4590', 'drugName': 'Epothilone D', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5130', 'drugName': 'Fosbretabulin Disodium', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5107', 'drugName': 'T-900607', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5627', 'drugName': 'Bms-275183', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3277', 'drugName': 'Davunetide', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3443', 'drugName': 'Lifastuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC34A2 (ENSG00000157765), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5974', 'drugName': 'Dolastatin-10', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5923', 'drugName': 'Indusatumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), GUCY2C (ENSG00000070019)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3444', 'drugName': 'Lifastuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC34A2 (ENSG00000157765), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4739', 'drugName': 'Lexibulin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2653', 'drugName': 'Ladiratuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), SLC39A6 (ENSG00000141424)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6314', 'drugName': 'Glembatumumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'GPNMB (ENSG00000136235), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5310', 'drugName': 'Kos-1584', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6315', 'drugName': 'Glembatumumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'GPNMB (ENSG00000136235), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4544', 'drugName': 'Lorvotuzumab Mertansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'NCAM1 (ENSG00000149294), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4545', 'drugName': 'Lorvotuzumab Mertansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'NCAM1 (ENSG00000149294), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6013', 'drugName': 'Praluzatamab Ravtansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), ALCAM (ENSG00000170017)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5238', 'drugName': 'Sofituzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'MUC16 (ENSG00000181143), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5239', 'drugName': 'Sofituzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'MUC16 (ENSG00000181143), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_6096', 'drugName': 'Pinatuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), CD22 (ENSG00000012124)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_6097', 'drugName': 'Pinatuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), CD22 (ENSG00000012124)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_405', 'drugName': 'Asg-5Me', 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC44A4 (ENSG00000204385), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_752', 'drugName': 'Vandortuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'STEAP1 (ENSG00000164647), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_831', 'drugName': 'Rg-7841', 'drugIsApproved': False, 'newLinkedTargets_string': 'LY6E (ENSG00000160932), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_753', 'drugName': 'Vandortuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'STEAP1 (ENSG00000164647), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1646', 'drugName': 'Azintuxizumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), SLAMF7 (ENSG00000026751)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1647', 'drugName': 'Azintuxizumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), SLAMF7 (ENSG00000026751)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_832', 'drugName': 'Rg-7841', 'drugIsApproved': False, 'newLinkedTargets_string': 'LY6E (ENSG00000160932), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1355', 'drugName': 'Pf-06263507', 'drugIsApproved': False, 'newLinkedTargets_string': 'TPBG (ENSG00000146242), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_406', 'drugName': 'Asg-5Me', 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC44A4 (ENSG00000204385), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1356', 'drugName': 'Pf-06263507', 'drugIsApproved': False, 'newLinkedTargets_string': 'TPBG (ENSG00000146242), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_2066', 'drugName': 'Aprutumab Ixadotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_2067', 'drugName': 'Aprutumab Ixadotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_641', 'drugName': 'Rg-7600', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), MSLN (ENSG00000102854)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_642', 'drugName': 'Rg-7600', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), MSLN (ENSG00000102854)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5414', 'drugName': 'Rg-7636', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), EDNRB (ENSG00000136160)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5415', 'drugName': 'Rg-7636', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), EDNRB (ENSG00000136160)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5801', 'drugName': 'Enapotamab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'AXL (ENSG00000167601), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5802', 'drugName': 'Enapotamab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'AXL (ENSG00000167601), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_6222', 'drugName': 'Bivatuzumab Mertansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'CD44 (ENSG00000026508), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_6223', 'drugName': 'Bivatuzumab Mertansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'CD44 (ENSG00000026508), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}]",general,"Similarity Search, Order By, Distinct","Approval Status, Genetic Target"
-Q1.670,Q1,Is IL12B a druggable gene?,"There are currently 4 approved drugs which target IL12B, indicating that it is a druggable gene.","SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE newLinkedTargets_string LIKE ""%IL12B %""
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100
-","[{'UUID': 'DrugGeneTargets_v2_3328', 'drugName': 'Ustekinumab', 'drugIsApproved': True, 'newLinkedTargets_string': 'IL12B (ENSG00000113302), IL23A (ENSG00000110944), IL12A (ENSG00000168811)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6358', 'drugName': 'Risankizumab', 'drugIsApproved': True, 'newLinkedTargets_string': 'IL12B (ENSG00000113302), IL23A (ENSG00000110944)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2147', 'drugName': 'Guselkumab', 'drugIsApproved': True, 'newLinkedTargets_string': 'IL12B (ENSG00000113302), IL23A (ENSG00000110944)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1373', 'drugName': 'Tildrakizumab', 'drugIsApproved': True, 'newLinkedTargets_string': 'IL12B (ENSG00000113302), IL23A (ENSG00000110944)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3327', 'drugName': 'Ustekinumab', 'drugIsApproved': True, 'newLinkedTargets_string': 'IL12B (ENSG00000113302), IL23A (ENSG00000110944), IL12A (ENSG00000168811)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_344', 'drugName': 'Ebdarokimab', 'drugIsApproved': False, 'newLinkedTargets_string': 'IL12B (ENSG00000113302), IL12A (ENSG00000168811), IL23A (ENSG00000110944)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3014', 'drugName': 'Mirikizumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'IL12B (ENSG00000113302), IL23A (ENSG00000110944)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1252', 'drugName': 'Brazikumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'IL12B (ENSG00000113302), IL23A (ENSG00000110944)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1844', 'drugName': 'Briakinumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'IL12B (ENSG00000113302), IL23A (ENSG00000110944), IL12A (ENSG00000168811)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1845', 'drugName': 'Briakinumab', 'drugIsApproved': False, 'newLinkedTargets_string': 'IL12B (ENSG00000113302), IL23A (ENSG00000110944), IL12A (ENSG00000168811)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_345', 'drugName': 'Ebdarokimab', 'drugIsApproved': False, 'newLinkedTargets_string': 'IL12B (ENSG00000113302), IL12A (ENSG00000168811), IL23A (ENSG00000110944)', 'maxClinicalTrialPhase': 3}]",general,"Similarity Search, Order By, Distinct","Approval Status, Genetic Target"
-Q1.1410,Q1,Is TAAR1 a druggable gene?,"There are currently no approved drugs targeting TAAR1, but there is 1 drug in a clinical trial indicating that it may be a druggable gene.","SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE newLinkedTargets_string LIKE ""%TAAR1 %""
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100
-","[{'UUID': 'DrugGeneTargets_v2_3446', 'drugName': 'Ulotaront', 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR1A (ENSG00000178394), TAAR1 (ENSG00000146399)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3447', 'drugName': 'Ulotaront', 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR1A (ENSG00000178394), TAAR1 (ENSG00000146399)', 'maxClinicalTrialPhase': 3}]",general,"Similarity Search, Order By, Distinct","Approval Status, Genetic Target"
-Q1.1415,Q1,Is TBXA2R a druggable gene?,"There is 1 drug, Picotamide, that targets TBXA2R, indicating that it is a druggable gene.","SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE newLinkedTargets_string LIKE ""%TBXA2R %""
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100
-","[{'UUID': 'DrugGeneTargets_v2_4430', 'drugName': 'Picotamide', 'drugIsApproved': True, 'newLinkedTargets_string': 'TBXAS1 (ENSG00000059377), TBXA2R (ENSG00000006638)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4429', 'drugName': 'Picotamide', 'drugIsApproved': True, 'newLinkedTargets_string': 'TBXAS1 (ENSG00000059377), TBXA2R (ENSG00000006638)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2143', 'drugName': 'Terutroban', 'drugIsApproved': False, 'newLinkedTargets_string': 'TBXA2R (ENSG00000006638)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_6039', 'drugName': 'Ramatroban', 'drugIsApproved': False, 'newLinkedTargets_string': 'PTGDR2 (ENSG00000183134), TBXA2R (ENSG00000006638)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_979', 'drugName': 'Terbogrel', 'drugIsApproved': False, 'newLinkedTargets_string': 'TBXAS1 (ENSG00000059377), TBXA2R (ENSG00000006638)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_978', 'drugName': 'Terbogrel', 'drugIsApproved': False, 'newLinkedTargets_string': 'TBXAS1 (ENSG00000059377), TBXA2R (ENSG00000006638)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6040', 'drugName': 'Ramatroban', 'drugIsApproved': False, 'newLinkedTargets_string': 'PTGDR2 (ENSG00000183134), TBXA2R (ENSG00000006638)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3144', 'drugName': 'Seratrodast', 'drugIsApproved': False, 'newLinkedTargets_string': 'TBXA2R (ENSG00000006638)', 'maxClinicalTrialPhase': -1}]",general,"Similarity Search, Order By, Distinct","Approval Status, Genetic Target"
-Q1.1090,Q1,Is PLA2G4A a druggable gene?,"There are currently no approved drugs targeting PLA2G4A, but there is 1 drug in a clinical trial indicating that it may be a druggable gene.","SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE newLinkedTargets_string LIKE ""%PLA2G4A %""
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100
-","[{'UUID': 'DrugGeneTargets_v2_3885', 'drugName': 'Giripladib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PLA2G4A (ENSG00000116711)', 'maxClinicalTrialPhase': 2}]",general,"Similarity Search, Order By, Distinct","Approval Status, Genetic Target"
-Q1.1508,Q1,Is TUBB8 a druggable gene?,"There are currently 20 approved drugs which target TUBB8, indicating that it is a druggable gene.","SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE newLinkedTargets_string LIKE ""%TUBB8 %""
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100
-","[{'UUID': 'DrugGeneTargets_v2_1084', 'drugName': 'Brentuximab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'TNFRSF8 (ENSG00000120949), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1872', 'drugName': 'Belantamab Mafodotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), TNFRSF17 (ENSG00000048462)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4158', 'drugName': 'Tisotumab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'F3 (ENSG00000117525), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2339', 'drugName': 'Ixabepilone', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_974', 'drugName': 'Vinflunine', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4166', 'drugName': 'Vinblastine', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5756', 'drugName': 'Trastuzumab Emtansine', 'drugIsApproved': True, 'newLinkedTargets_string': 'ERBB2 (ENSG00000141736), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5604', 'drugName': 'Eribulin', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2795', 'drugName': 'Enfortumab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'NECTIN4 (ENSG00000143217), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4743', 'drugName': 'Colchicine', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_560', 'drugName': 'Polatuzumab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'CD79B (ENSG00000007312), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_561', 'drugName': 'Polatuzumab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'CD79B (ENSG00000007312), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1085', 'drugName': 'Brentuximab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'TNFRSF8 (ENSG00000120949), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6261', 'drugName': 'Vinblastine Sulfate', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2794', 'drugName': 'Enfortumab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'NECTIN4 (ENSG00000143217), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5140', 'drugName': 'Vincristine', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4157', 'drugName': 'Tisotumab Vedotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'F3 (ENSG00000117525), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_762', 'drugName': 'Cabazitaxel', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1267', 'drugName': 'Docetaxel', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3175', 'drugName': 'Eribulin Mesylate', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2177', 'drugName': 'Docetaxel', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2013', 'drugName': 'Paclitaxel', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1871', 'drugName': 'Belantamab Mafodotin', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), TNFRSF17 (ENSG00000048462)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5757', 'drugName': 'Trastuzumab Emtansine', 'drugIsApproved': True, 'newLinkedTargets_string': 'ERBB2 (ENSG00000141736), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3353', 'drugName': 'Vincristine Sulfate', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2330', 'drugName': 'Vinorelbine', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_6364', 'drugName': 'Vinorelbine Tartrate', 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_4123', 'drugName': 'Plinabulin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_429', 'drugName': 'Ang1005', 'drugIsApproved': False, 'newLinkedTargets_string': 'LRP1 (ENSG00000123384), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3391', 'drugName': 'Fosbretabulin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1364', 'drugName': 'Ombrabulin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_2595', 'drugName': 'Paclitaxel Poliglumex', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5727', 'drugName': 'Mirvetuximab Soravtansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'FOLR1 (ENSG00000110195), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3781', 'drugName': 'Telisotuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), MET (ENSG00000105976)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1224', 'drugName': 'Tusamitamab Ravtansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'CEACAM5 (ENSG00000105388), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_1225', 'drugName': 'Tusamitamab Ravtansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'CEACAM5 (ENSG00000105388), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3782', 'drugName': 'Telisotuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), MET (ENSG00000105976)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_3390', 'drugName': 'Fosbretabulin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_430', 'drugName': 'Ang1005', 'drugIsApproved': False, 'newLinkedTargets_string': 'LRP1 (ENSG00000123384), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_4860', 'drugName': 'Patupilone', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5728', 'drugName': 'Mirvetuximab Soravtansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'FOLR1 (ENSG00000110195), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_829', 'drugName': 'Larotaxel', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_5370', 'drugName': 'Paclitaxel Docosahexaenoic Acid', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_186', 'drugName': 'Cantuzumab Mertansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'MUC1 (ENSG00000185499), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_187', 'drugName': 'Cantuzumab Mertansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'MUC1 (ENSG00000185499), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5922', 'drugName': 'Indusatumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), GUCY2C (ENSG00000070019)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4294', 'drugName': 'Arx-788', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), ERBB2 (ENSG00000141736)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2981', 'drugName': 'Plocabulin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3189', 'drugName': 'Sagopilone', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5837', 'drugName': 'Soblidotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4295', 'drugName': 'Arx-788', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), ERBB2 (ENSG00000141736)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4455', 'drugName': 'Ags-16C3F', 'drugIsApproved': False, 'newLinkedTargets_string': 'ENPP3 (ENSG00000154269), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4675', 'drugName': 'Milataxel', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4227', 'drugName': 'Verubulin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4456', 'drugName': 'Ags-16C3F', 'drugIsApproved': False, 'newLinkedTargets_string': 'ENPP3 (ENSG00000154269), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2652', 'drugName': 'Ladiratuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), SLC39A6 (ENSG00000141424)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4395', 'drugName': 'Fosbretabulin Tromethamine', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3400', 'drugName': 'Abt-751', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBB3 (ENSG00000258947), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), TUBB8B (ENSG00000173213)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6014', 'drugName': 'Praluzatamab Ravtansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), ALCAM (ENSG00000170017)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4590', 'drugName': 'Epothilone D', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5130', 'drugName': 'Fosbretabulin Disodium', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5107', 'drugName': 'T-900607', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5627', 'drugName': 'Bms-275183', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3277', 'drugName': 'Davunetide', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3443', 'drugName': 'Lifastuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC34A2 (ENSG00000157765), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5974', 'drugName': 'Dolastatin-10', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5923', 'drugName': 'Indusatumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), GUCY2C (ENSG00000070019)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_3444', 'drugName': 'Lifastuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC34A2 (ENSG00000157765), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4739', 'drugName': 'Lexibulin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_2653', 'drugName': 'Ladiratuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), SLC39A6 (ENSG00000141424)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6314', 'drugName': 'Glembatumumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'GPNMB (ENSG00000136235), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5310', 'drugName': 'Kos-1584', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6315', 'drugName': 'Glembatumumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'GPNMB (ENSG00000136235), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4544', 'drugName': 'Lorvotuzumab Mertansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'NCAM1 (ENSG00000149294), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_4545', 'drugName': 'Lorvotuzumab Mertansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'NCAM1 (ENSG00000149294), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_6013', 'drugName': 'Praluzatamab Ravtansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), ALCAM (ENSG00000170017)', 'maxClinicalTrialPhase': 2}, {'UUID': 'DrugGeneTargets_v2_5238', 'drugName': 'Sofituzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'MUC16 (ENSG00000181143), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5239', 'drugName': 'Sofituzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'MUC16 (ENSG00000181143), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_6096', 'drugName': 'Pinatuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), CD22 (ENSG00000012124)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_6097', 'drugName': 'Pinatuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), CD22 (ENSG00000012124)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_405', 'drugName': 'Asg-5Me', 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC44A4 (ENSG00000204385), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_752', 'drugName': 'Vandortuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'STEAP1 (ENSG00000164647), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_831', 'drugName': 'Rg-7841', 'drugIsApproved': False, 'newLinkedTargets_string': 'LY6E (ENSG00000160932), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_753', 'drugName': 'Vandortuzumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'STEAP1 (ENSG00000164647), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1646', 'drugName': 'Azintuxizumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), SLAMF7 (ENSG00000026751)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1647', 'drugName': 'Azintuxizumab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), SLAMF7 (ENSG00000026751)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_832', 'drugName': 'Rg-7841', 'drugIsApproved': False, 'newLinkedTargets_string': 'LY6E (ENSG00000160932), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1355', 'drugName': 'Pf-06263507', 'drugIsApproved': False, 'newLinkedTargets_string': 'TPBG (ENSG00000146242), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_406', 'drugName': 'Asg-5Me', 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC44A4 (ENSG00000204385), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_1356', 'drugName': 'Pf-06263507', 'drugIsApproved': False, 'newLinkedTargets_string': 'TPBG (ENSG00000146242), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_2066', 'drugName': 'Aprutumab Ixadotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_2067', 'drugName': 'Aprutumab Ixadotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_641', 'drugName': 'Rg-7600', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), MSLN (ENSG00000102854)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_642', 'drugName': 'Rg-7600', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), MSLN (ENSG00000102854)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5414', 'drugName': 'Rg-7636', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), EDNRB (ENSG00000136160)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5415', 'drugName': 'Rg-7636', 'drugIsApproved': False, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), EDNRB (ENSG00000136160)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5801', 'drugName': 'Enapotamab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'AXL (ENSG00000167601), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_5802', 'drugName': 'Enapotamab Vedotin', 'drugIsApproved': False, 'newLinkedTargets_string': 'AXL (ENSG00000167601), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_6222', 'drugName': 'Bivatuzumab Mertansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'CD44 (ENSG00000026508), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_6223', 'drugName': 'Bivatuzumab Mertansine', 'drugIsApproved': False, 'newLinkedTargets_string': 'CD44 (ENSG00000026508), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 1}]",general,"Similarity Search, Order By, Distinct","Approval Status, Genetic Target"
-Q1.971,Q1,Is NDUFS5 a druggable gene?,"There are currently 2 approved drugs which target NDUFS5, indicating that it is a druggable gene.","SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE newLinkedTargets_string LIKE ""%NDUFS5 %""
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100
-","[{'UUID': 'DrugGeneTargets_v2_1888', 'drugName': 'Metformin Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'GPD2 (ENSG00000115159), MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1887', 'drugName': 'Metformin Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'GPD2 (ENSG00000115159), MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1886', 'drugName': 'Metformin', 'drugIsApproved': True, 'newLinkedTargets_string': 'GPD2 (ENSG00000115159), MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1885', 'drugName': 'Metformin', 'drugIsApproved': True, 'newLinkedTargets_string': 'GPD2 (ENSG00000115159), MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3900', 'drugName': 'Me-344', 'drugIsApproved': False, 'newLinkedTargets_string': 'MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'maxClinicalTrialPhase': 1}, {'UUID': 'DrugGeneTargets_v2_2970', 'drugName': 'Nv-128', 'drugIsApproved': False, 'newLinkedTargets_string': 'MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'maxClinicalTrialPhase': 1}]",general,"Similarity Search, Order By, Distinct","Approval Status, Genetic Target"
-Q1.1199,Q1,Is PTH1R a druggable gene?,"There are currently 4 approved drugs which target PTH1R, indicating that it is a druggable gene.","SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE newLinkedTargets_string LIKE ""%PTH1R %""
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100
-","[{'UUID': 'DrugGeneTargets_v2_1895', 'drugName': 'Abaloparatide', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTH1R (ENSG00000160801)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_2407', 'drugName': 'Teriparatide', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTH1R (ENSG00000160801)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3571', 'drugName': 'Teriparatide Acetate', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTH1R (ENSG00000160801)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_499', 'drugName': 'Parathyroid Hormone', 'drugIsApproved': True, 'newLinkedTargets_string': 'PTH1R (ENSG00000160801)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3861', 'drugName': 'Ostabolin-C', 'drugIsApproved': False, 'newLinkedTargets_string': 'PTH1R (ENSG00000160801)', 'maxClinicalTrialPhase': 2}]",general,"Similarity Search, Order By, Distinct","Approval Status, Genetic Target"
-Q1.1089,Q1,Is PLA2G2A a druggable gene?,"There are currently no approved drugs targeting PLA2G2A, but there are 2 drugs in clinical trials indicating that it may be a druggable gene.","SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE newLinkedTargets_string LIKE ""%PLA2G2A %""
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100
-","[{'UUID': 'DrugGeneTargets_v2_6244', 'drugName': 'Varespladib Methyl', 'drugIsApproved': False, 'newLinkedTargets_string': 'PLA2G5 (ENSG00000127472), PLA2G10 (ENSG00000069764), PLA2G2A (ENSG00000188257)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_6246', 'drugName': 'Varespladib Methyl', 'drugIsApproved': False, 'newLinkedTargets_string': 'PLA2G5 (ENSG00000127472), PLA2G10 (ENSG00000069764), PLA2G2A (ENSG00000188257)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_6245', 'drugName': 'Varespladib Methyl', 'drugIsApproved': False, 'newLinkedTargets_string': 'PLA2G5 (ENSG00000127472), PLA2G10 (ENSG00000069764), PLA2G2A (ENSG00000188257)', 'maxClinicalTrialPhase': 3}, {'UUID': 'DrugGeneTargets_v2_794', 'drugName': 'Varespladib', 'drugIsApproved': False, 'newLinkedTargets_string': 'PLA2G2A (ENSG00000188257)', 'maxClinicalTrialPhase': 2}]",general,"Similarity Search, Order By, Distinct","Approval Status, Genetic Target"
-Q1.577,Q1,Is HCN4 a druggable gene?,"There are currently 4 approved drugs which target HCN4, indicating that it is a druggable gene.","SELECT DISTINCT UUID, drugName, drugIsApproved, newLinkedTargets_string, maxClinicalTrialPhase
- FROM `card-ai-389220.bio_sql_benchmark.DrugGeneTargets_ComprehensiveAnnotations_updated`
- WHERE newLinkedTargets_string LIKE ""%HCN4 %""
- ORDER BY maxClinicalTrialPhase DESC
- LIMIT 100
-","[{'UUID': 'DrugGeneTargets_v2_5384', 'drugName': 'Dronedarone', 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001), KCNJ2 (ENSG00000123700), HCN4 (ENSG00000138622), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3874', 'drugName': 'Dronedarone Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001), HCN4 (ENSG00000138622), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), KCNJ2 (ENSG00000123700)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3875', 'drugName': 'Dronedarone Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001), HCN4 (ENSG00000138622), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), KCNJ2 (ENSG00000123700)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3873', 'drugName': 'Dronedarone Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001), HCN4 (ENSG00000138622), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), KCNJ2 (ENSG00000123700)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_1183', 'drugName': 'Ivabradine Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'HCN4 (ENSG00000138622)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_32', 'drugName': 'Ivabradine', 'drugIsApproved': True, 'newLinkedTargets_string': 'HCN4 (ENSG00000138622)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5382', 'drugName': 'Dronedarone', 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001), KCNJ2 (ENSG00000123700), HCN4 (ENSG00000138622), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_3872', 'drugName': 'Dronedarone Hydrochloride', 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001), HCN4 (ENSG00000138622), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), KCNJ2 (ENSG00000123700)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5383', 'drugName': 'Dronedarone', 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001), KCNJ2 (ENSG00000123700), HCN4 (ENSG00000138622), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'maxClinicalTrialPhase': 4}, {'UUID': 'DrugGeneTargets_v2_5381', 'drugName': 'Dronedarone', 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001), KCNJ2 (ENSG00000123700), HCN4 (ENSG00000138622), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'maxClinicalTrialPhase': 4}]",general,"Similarity Search, Order By, Distinct","Approval Status, Genetic Target"